{"title": "PDF", "author": "PDF", "url": "https://www.inmunologia.org/images/site/revista/JULIO-SEPTIEMBRE-2022/Suplemento_SEI_MontadoV1.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "www.inmunologia.org\nPublicaci\u00f3n oficial de la Sociedad Espa\u00f1ola de Inmunolog\u00edaVolumen 41 \u2022 Suplemento 1 \u2022 2022Publicaci\u00f3n trimestral en l\u00ednea de la Sociedad Espa\u00f1ola de Inmunolog\u00eda.\nISSN (digital): 0213-9626  www.inmunologia.org  \nISBN - 978-84-09-44168-6\nCoordinaci\u00f3n General:  Rafael Sirera\nCoordinaci\u00f3n Secciones:  Rafael Sirera (Panorama)\n Daniel Pleguezuelo (Cl\u00ednica)\n Pedro Roda (Investigaci\u00f3n)\n Alfredo Corell (Divulgaci\u00f3n)\n Pascual Mart\u00ednez (Docencia)\nComit\u00e9 editorial:  Carmen C\u00e1mara  Carmen Mart\u00edn\n Javier Carbone  Fernando Fari\u00f1as\n Manuel Muro  Jes\u00fas S\u00e1nchez\n Silvia S\u00e1nchez-Ram\u00f3n  David Sancho\n Sandra Pascual  Jorge Laborda\nSecretar\u00eda T\u00e9cnica SEI:  Calle Castell\u00f3,128 7\u00aa planta.  \n28006 Madrid (SPAIN)Para futuras colaboraciones:\n1. Descarga las instrucciones a los autores aqu\u00ed.\n2. Puedes contactar directamente con los coordinadores \npulsando en el enlace en su nombre al inicio de cada  \nsecci\u00f3n o subsecci\u00f3n. 3. Para comentarios, sugerencias o informaci\u00f3n sobre  \nc\u00f3mo anunciarse, contacta con la Secretar\u00eda T\u00e9cnica  \naqu\u00ed.\nLa responsabilidad del contenido de las colaboraciones\npublicadas en la revista Inmunolog\u00eda corresponder\u00e1 a sus\nautores, quienes autorizan la reproducci\u00f3n de sus art\u00edculos\ne im\u00e1genes a la SEI exclusivamente para esta revista.\nLa SEI no hace necesariamente suyas las opiniones o los\ncriterios expresados por sus colaboradores.\n\u00a9 Sociedad Espa\u00f1ola de Inmunolog\u00eda, 2020\nReservados todos los derechos. El contenido de la presente\npublicaci\u00f3n no puede ser reproducido, ni transmitido por\nning\u00fan procedimiento electr\u00f3nico o mec\u00e1nico, incluyendo\nfotocopia, grabaci\u00f3n magn\u00e9tica, ni registrado por ning\u00fan\nsistema de recuperaci\u00f3n de informaci\u00f3n, en ninguna forma,\nni por ning\u00fan medio, sin la previa autorizaci\u00f3n por escrito\ndel titular de los derechos de explotaci\u00f3n de la misma.\nCon el patrocinio de:\n3\u00cdndice\nComit\u00e9s  4\nBienvenida  6\nPrograma\nJueves 22  7\nViernes 23  21\nS\u00e1bado 24  40\nExposici\u00f3n comer cial 43\nInformaci\u00f3n general  44\nPatrocinadores  46 Patrocinadores 46\nLibro de abstracts 474COMIT\u00c9 ORGANIZADOR LOCAL\nPresidente:\nJose M\u00aa Garc\u00eda Ruiz de Morales\nVicepresidente:\n\u00a0Sara M\u00aa Calleja Antolin\nSecretario:\n\u00a0Juan Martin Garc\u00eda-Sancho\nVocales:\nIgnacio Rodr\u00edguez Barbosa\nM\u00aa Luisa del Rio Gonz\u00e1lez\nAna N\u00fa\u00f1ez Garn\u00e9s\nCarmen Luz Avenda\u00f1o Monje\nJuan Garc\u00eda Herrero\nRonald Colindres\nCOMIT\u00c9 CIENT\u00cdFICO\nAfrica Gonz\u00e1lez Fern\u00e1ndez (Vigo)\nAlvaro Prada I\u00f1urrategui (San Sebastian)\nLuis Fern\u00e1ndez Pereira (C\u00e1ceres)\nJavier Cid Fern\u00e1ndez (A Coru\u00f1a)\nRicardo Rojo Amigo (A Coru\u00f1a)\nJuana Gil Herrera (Madrid)\nAlfredo Corell Almuzara (Valladolid)\nEduardo Arranz Sanz (Valladolid)\nDavid Bernardo Ordiz (Valladolid)\nLourdes Mozo Avellaneda (Oviedo)\nJaime Pons de Ves (Palma de Mallorca)\nM\u00aa Rosa Juli\u00e1 Benique (Palma de Mallorca)\nJuan E. Vi\u00f1uela (Santiago))\nMarcos L\u00f3pez Hoyos (Santander)\nEva Martinez Caceres (Barcelona)\nCarmen C\u00e1mara Hijon (Madrid)\nFrancisco Manuel Marco de la Calle (Alicante)\nJordi Cano Ochando (Madrid)\nJorge Carrillo Molina (Barcelona)\nMar\u00eda Montoya Gonz\u00e1lez (Madrid)\nM\u00aa Carmen Martin Alonso (Valladolid)\nIvelise Barrios del Pino (Santa Cruz de Tenerife)\nManuel Hern\u00e1ndez Gonz\u00e1lez (Barcelona)\nFrancisco Boix Giner (Salamanca)\n\u00a0Estanislao Nistal Millan (Madrid)5COMIT\u00c9 DE HONOR\nPRESIDENTE\nS.M. el Rey Don Felipe VI\nMIEMBROS DEL COMIT\u00c9\nExcma Sra. D\u00aa Carolina Darias San Sebasti\u00e1n\nMinistra de Sanidad\nExcmo. Sr. D. Alejandro V\u00e1zquez Ramos\nConsejero de Sanidad de la Junta de Castilla y Le\u00f3n\nIlmo Sr. D. Eduardo Mor\u00e1n Pacios\nPresidente de la Diputaci\u00f3n de Le\u00f3n\nIlmo. Sr D. Jos\u00e9 Antonio Diez Diaz\nAlcalde de Le\u00f3n\nSr. Rector Magn\u00ed\ufb01co D. Juan Francisco Garc\u00eda Mar\u00edn.\nRector de la Universidad de Le\u00f3n\nD. Alfonso Rodr\u00edguez- Hevia\nDirector Gerente del Complejo Asistencial Universitario de Le\u00f3n\nJUNTA DIRECTIVA\nPresidente\nMarcos L\u00f3pez Hoyos\nVicepresidenta\nEva Mart\u00ednez C\u00e1ceres\nSecretaria\nCarmen C\u00e1mara Hij\u00f3n\nTesorero\nJordi Cano Ochando\nVocales\nFrancisco Manuel Marco de la Calle\nJorge Carrillo Molina\nMar\u00eda Montoya Gonz\u00e1lez\nM\u00aa Carmen Mart\u00edn Alonso\nYvelise Barrios del Pino\nManuel Hern\u00e1ndez Gonz\u00e1lez\nFrancisco Boix Giner6Carta de Bienvenida\nEstimados compa\u00f1eros:\nTras casi dos a\u00f1os en los que la pandemia Covid-19 ha reducido al m\u00ednimo \nlas interacciones personales, estamos esperanzados en que esta situaci\u00f3n \npueda ser \ufb01nalmente revertida por efecto de las vacunas. Esto nos permitir\u00e1 \npoder reunirnos de nuevo para debatir y disfrutar presencialmente de la \nInmunolog\u00eda en el marco del 43 Congreso de la Sociedad Espa\u00f1ola de \nInmunolog\u00eda, que se celebrar\u00e1 en Le\u00f3n en Septiembre de 2022. Durante \neste tiempo hemos constatado que, si adem\u00e1s incorporamos contenidos \nvirtuales, podremos contar con ponentes de alta calidad que de otra manera \nser\u00eda dif\u00edcil que pudiesen desplazarse hasta aqu\u00ed.\nCon ese objetivo estamos trabajando con ilusi\u00f3n para organizar un congreso \nde \u201creencuentro\u201d en el que abordemos las novedades en investigaci\u00f3n \ny asistenciales de nuestra disciplina, haciendo especial hincapi\u00e9 en la \ninvestigaci\u00f3n traslacional y en la inmunoterapia. Para ello, contaremos \ncon la presencia de cient\u00ed\ufb01cos y expertos en las diferentes materias que \ngaranticen un contenido de m\u00e1xima actualidad y calidad cient\u00ed\ufb01ca.\nEstamos seguros que nuestra ciudad, con su encanto y tradici\u00f3n cultural, \nproporcionar\u00e1 un entorno agradable en el que retomar los contactos \npersonales, aprender, compartir y dise\u00f1ar nuevos proyectos de colaboraci\u00f3n.\nEn breve, a trav\u00e9s de la p\u00e1gina web de la SEI, dispondr\u00e9is de informaci\u00f3n \ndetallada sobre el programa cient\u00ed\ufb01co, inscripciones, env\u00edo de comunicaciones, \nbecas, premios y toda la informaci\u00f3n referente al congreso.\nUn afectuoso saludo,\nJose M. Garc\u00eda Ruiz de Morales\nPresidente del Comit\u00e9 OrganizadorMarcos L\u00f3pez-Hoyos\nPresidente de la SEI\n7PROGRAMA\nD\u00cdA 1 JUEVES 22 DE SEPTIEMBRE\n08:00-08:30    Recogida de credenciales y documentaci\u00f3n congreso\n08:30-10:00    PLENARIA 1 COVID 19  \nSALA PALACIO\nModeradores: \nMar\u00eda Montoya Gonz\u00e1lez . Centro de Investigaci\u00f3n Margarita Salas, \nCSIC, Madrid\nMarcos L\u00f3pez Hoyos . Inmunolog\u00eda, Hospital Marqu\u00e9s de Valdecilla, \nSantander\nPonentes: \n Tim Thomson . Instituto Biolog\u00eda Molecular de Barcelona (IBMB-CSIC)\n\u201cThe in\ufb02ammosome in COVID-19: a platform for the discovery of \nin\ufb02ammosome inhibitors\u201d \n Jos\u00e9 G\u00f3mez Rial . Inmunolog\u00eda, Hospital Universitario Santiago de \nCompostela\n\u201cCOVID-19:\u00bfNecesitamos un booster (actualizado)?\u201d\n10:00-11:00    SESI\u00d3N 1 TRASPLANTE\nSALA PALACIO\nModeradores: \nFrancisco Boix Giner . Centro de Transfusi\u00f3n, Hospital General \nUniversitario de Valencia\nMar\u00eda Luisa del R\u00edo Gonz\u00e1lez . Departamento Sanidad Animal, \nUniversidad de Le\u00f3n\nPonentes:\n Rafael Correa Rocha . Instituto de Investigaci\u00f3n Sanitaria Gregorio \nMara\u00f1\u00f3n, Madrid\n\u201cA new approach to prevent graft rejection employing a celular \ntherapy with Treg obtained from thymic tissue. Preliminary results of \nthe \u201c\ufb01rst-in- human\u201d clinical trial\u201d\n Jordi Cano Ochando . Mount Sinai School of Medicine, New York, USA\n\u201cTrained immunity in organ transplantation\u201d810:00-11:00    SESI\u00d3N 2 EUROPEAN IN VITRO DIAGNOSTIC REGULATION\nSALA PALAC\u00cdN 1\nModeradores:\nM\u00aa Carmen Martin Alonso . Centro de Hemoterapia y Hemodonaci\u00f3n, \nValladolid\nLourdes Mozo Avellaneda . Inmunolog\u00eda, Hospital Universitario Central \nde Asturias\nPonentes:\n Isabel de la Villa . Departamento de Sanidad, Entidad Nacional \nAcreditaci\u00f3n (ENAC), Madrid\n\u201cIn vitro diagnostic medical devices regulation. View from the Spanish \naccreditation Agency-ENAC\u201d \n Manuel Hern\u00e1ndez Gonz\u00e1lez . Hospital Universitari Vall d\u2019Hebron, \nBarcelona\n\u201cIn vitro diagnostic regulation: impact for clinical immunology\u201d\n Brice Ezzouaouy . Beckman-Coulter, Marsella, Francia\n\u201cIn vitro diagnostic regulation: perspective from a manufacturer. \nPartnering for a smooth transition\u201d\n10:00-11:00    SESI\u00d3N 3 C\u00c9LULAS DEL SISTEMA INMUNE\nSALA PALAC\u00cdN 2\nModeradores: \nJuan E. Vi\u00f1uela Rold\u00e1n . Inmunolog\u00eda, Complejo Hospitalario \nUniversitario de Santiago de Compostela\nJorge Carrillo Molina . Instituto de Investigaci\u00f3n IrsiCaixa, Barcelona\nPonentes:\n Miguel L\u00f3pez-Botet . Instituto Hospital del Mar de Investigaciones \nM\u00e9dicas, Barcelona\n\u201cAdaptive NK cell response to human cytomegalovirus: facts and \nopen issues\u201d\n Luis Gra\u00e7a . Instituto de Medicina Molecular, Lisboa, Portugal\n\u201cRegulation of antibody production: from cells to populations\u201d\n11:00-11:30    INAUGURACI\u00d3N CON AUTORIDADES\nSALA PALACIO\n11:30-12:00    PAUSA CAF\u00c9912:00-13:00    PLENARIA 2 TRASPLANTE\nSALA PALACIO\nModeradores: \nJose I. Rodr\u00edguez Barbosa . \u00c1rea de Inmunolog\u00eda, Universidad de Le\u00f3n\nJordi Cano Ochando . Mount Sinai School of Medicine, New York\nPonentes:\n Megan Sykes . Columbia Center for Translational Immunology, New \nYork, USA\n\u201cCombined TCR and RNA sequencing to monitor activities of donor-\nreactive T cells in human transplant recipients\u201d\n13:00-14:00    SIMPOSIO BECKMAN COULTER \u201cAPLICACI\u00d3N DE LA CITOMETR\u00cdA DE FLUJO EN ESTUDIOS\nSALA PALACIO   FUNCIONALES DE LOS ERRORES INNATOS DE LA INMUNIDAD\u201d\nModerador:\nCarmen P\u00e9rez Robles. Especialista de Aplicaciones en Citometr\u00eda de \nFlujo, Beckman Coulter\nPonentes:\n Dra. Luc\u00eda del Pino Molina. Servicio de Inmunolog\u00eda, CIBERER U767, \nHospital La Paz de Madrid\n\u201cImportancia de la estandarizaci\u00f3n multiplataforma en citometr\u00eda de \n\ufb02ujo\u201d\n Jose Antonio Delgado Garc\u00eda.  PhD, Especialista de Aplicaciones en \nCitometr\u00eda de Flujo, Beckman Coulter\n\u201cEUROFLOW STANDARIZATION FOR 8C APPROACHES BECKMAN \nCOULTER DxFLEX INSTRUMENTS \u201d\n13:00-14:00   SIMPOSIO DIAGN\u00d3STICA LONGWOOD \u201cSEGUIMIENTO EN TRASPLANTE ALOG\u00c9NICO\u201d\nSALA PALAC\u00cdN 1\nModerador: \nJes\u00fas Onta\u00f1\u00f3n Rodr\u00edguez . Jefe Inmunolog\u00eda Hospital. Universitario \nAlbacete\nPonentes:\n Dr. Marcelo Fern\u00e1ndez Vi\u00f1a . PhD Professor, Department of Pathology, \nStanford University Disease Pro\ufb01ling Laboratory, California. \n\u201cIncompatibilidad de ep\u00edtopos en trasplante de \u00f3rgano s\u00f3lido\u201d\n Dr. Miguel Alcoceba.  Departamento de Hematolog\u00eda, Hospital \nUniversitario de Salamanca\nValidaci\u00f3n del kit de AlloSeq HCT para seguimiento de precursores \nhematopoy\u00e9ticos.1013:00-14:00   SIMPOSIO HYRIS \u201cDESARROLLO DE UN TEST DIAGN\u00d3STICO DE PCR PARA LA MONITORIZACI\u00d3N\nSALA PALAC\u00cdN 2   DE LA INMUNIDAD CELULAR VIRAL\u201d\nModerador:  \nJordi Cano Ochando. Mount Sinai School of Medicine,New York\nPonente:\n Matteo Audano, PhD. Product Specialist, Hyris SRL\n14:00-15:00   VISITA P\u00d3STER\nHALL EXPOSICI\u00d3N\nPantalla 1.  Inmunolog\u00eda B\u00e1sica. (P-001 \u2013 P-016)\nModeradores:\n\u00c1frica Gonz\u00e1lez Fern\u00e1ndez.  CINBIO, Universidad de Vigo\nAlfredo Corell Almuzara. Facultativo Especialista De Inmunolog\u00eda. \nCatedr\u00e1tico de Inmunolog\u00eda. Universidad de Valladolid\nPantalla 2.  Inmunidad innata (P-017 \u2013 P-033)\nModeradores:\nDavid Bernardo Ordiz. Instituto de Biomedicina y Gen\u00e9tica, CSIC, \nValladolid\nJordi Cano Ochando. Mount Sinai School of Medicine, New York\nPantalla 3.  Inmunode\ufb01ciencias: primarias y secundarias (P-034 \u2013 \nP-065)\nModeradores:\nCarmen C\u00e1mara Hij\u00f3n. \u00a0Inmunolog\u00eda, Hospital Universitario La Paz, \nMadrid\nLuis Fern\u00e1ndez Pereira. \u00a0Inmunolog\u00eda, Hospital San Pedro de \nAlc\u00e1ntara, C\u00e1ceres\nPantalla 4.  Miscel\u00e1nea (In\ufb02amaci\u00f3n - Inmunidad anti-tumoral- Alergias \ny reacciones de hipersensibilidad) (P-066 \u2013 P-076 / P-122 \u2013 P-134)\nModeradores:\nJaume Pons de Ves. Inmunolog\u00eda Hospital Universitario Son Espases, \nPalma de Mallorca\nYvelise Barrios del Pino. Inmunolog\u00eda, Hospital Universitario de \nCanarias\nPantalla 5.  Inmunoterapia (I) (P-077 \u2013 P-099)\nModeradores:\nRafael Sirera. Departamento de Biolog\u00eda Celular. Universidad \nPolit\u00e9cnica de Valencia.\nSara Mar\u00eda Calleja Antol\u00edn. Inmunolog\u00eda, Complejo Hospitalario \nUniversitario de Le\u00f3n11Pantalla 6.  Inmunoterapia (II) (P-100 \u2013 P-120)\nModeradores:\nRafael Sirera. Departamento de Biolog\u00eda Celular. Universidad \nPolit\u00e9cnica de Valencia.\nSara Mar\u00eda Calleja Antol\u00edn. Inmunolog\u00eda, Complejo Hospitalario \nUniversitario de Le\u00f3n\n15:00-16:00    COMUNICACIONES ORALES 2. Inmunodeficiencias: primarias y secundarias\nSALA PALACIO\nModeradores:\nCarmen C\u00e1mara Hij\u00f3n. Inmunolog\u00eda, Hospital Universitario La Paz, Madrid\nLuis Fern\u00e1ndez Pereira. Inmunolog\u00eda, Hospital San Pedro de Alc\u00e1ntara, \nC\u00e1ceres \nCO-07\nDISSECTING THE EFFECT OF A NOVEL HYPOMORPHIC IL2RB  \nMUTATION ON IMMUNE DYSREGULATION\nOlivia Bailey1, Berenice Cabrera-Martinez1, Josselyn Garcia-Perez2, \nRyan Baxter1, Isabel Fernandez1, Mary Jo Foster1, Laurant Gapin1, Ross \nKedl1, Elena Hsieh1.\n1University of Colorado Anschutz Medical Campus, Colorado; \n2Cellcarta, Brussels.\nCO-08\nA TRUNCATED P.Y153X CD247 (TCR \u0396) V ARIANT IS STABLE AND FORMS \nPOTENTIALL Y PATHOGENIC CD247 HETERODIMERS IN HETEROZYGOSIS \nRebeca F Megino1, Ana V Marin1, Julia Fernandez-Boraita1, Diego J \nJimenez1, Alejandro C Briones1, Marta Herrero-Alonso1, Daniel Chacon-\nArguedas1, Elena Garcia-Mart\u00ednez2, Elena Seoane-Reula2, Carmen \nRodriguez-Sainz2, Jose R Regueiro1.\n1Department of Immunology, Ophthalmology and ENT, Complutense \nUniversity School of Medicine and 12 de Octubre Health Research Institute \n(i+12), Madrid; 2Gregorio Mara\u00f1\u00f3n Health Research Institute, Madrid.\nCO-09\nCORRECTING APDS2 SYNDROME-CAUSED MUTATION FOR FUTURE \nGENE AND CELL THERAPIES\nIrene Romayor1, Marta Ingl\u00e9s-Ferr\u00e1ndiz1, Myriam Martin-Inaraja1, Lara \nHerrera1, Silvia Santos2, Miguel \u00c1ngel Vesga2, Jose Ram\u00f3n Pineda3, Juan \nAnguita4, Luis M Allende5, Luis I Gonzalez-Granado5, Cristina Eguizabal1.\n1Instituto de Investigaci\u00f3n Sanitaria Biocruces Bizkaia, Barakaldo; \n2Centro Vasco de Transfusi\u00f3n y Tejidos Humanos, Galdakao; \n3Universidad del Pa\u00eds Vasco (UPV/EHU), Leioa; 4CIC Biogune, Derio; \n5Hospital Universitario 12 de Octubre, Madrid.12CO-10\nHETEROZYGOUS NONSENSE CD247 MUTATIONS SHOW \nPOTENTIALLY PATHOGENIC DOMINANT-NEGATIVE FEATURES \nAFFECTING TCR EXPRESSION AND FUNCTION\nAlejandro C Briones1, Rebeca F Megino1, Ana V Marin1, Daniel Chac\u00f3n-\nArguedas1, Rebeca Chaparro1, Carmen Rodr\u00edguez-Sainz2, Elena \nSeoane-Reula2, Paloma Sanchez-Mateos3, Hugh T Reyburn4, Sarah \nHenrickson5, Jose R Regueiro1, Paula P Cardenas1.\n1Department of Immunology, Ophthalmology and ENT, Complutense \nUniversity School of Medicine and 12 de Octubre Health Research \nInstitute (i+12), Madrid; 2Inmuno-Alergia Infantil. Unidad de \nInmunode\ufb01ciencias HGU Gregorio Mara\u00f1\u00f3n, Madrid; 3Instituto de \nInvestigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM). Laboratorio \nde Inmuno-Oncolog\u00eda., Madrid; 4Department of Immunology and \nOncology, National Centre for Biotechnology, CNB-CSIC, Madrid; \n5Division of Allergy and Immunology, Children\u2019s Hospital of \nPhiladelphia., Philadelphia.\nCO-11\nCANDIDIASIS MUCOCUT\u00c1NEA CR\u00d3NICA POR GANANCIA DE \nFUNCI\u00d3N DE STAT1: EXPERIENCIA DEL HOSPITAL UNIVERSITARIO \nLA PAZ\nLaura Miguel Berenguel , Ricardo Cuesta Mart\u00edn De La C\u00e1mara, Andrea \nGonz\u00e1lez Torbay, Elisabet Matas P\u00e9rez, \u00c1ngel Robles Marhuenda, \nMar\u00eda Bravo Garc\u00eda-Morato, Carla Gianelli, Carmen C\u00e1mara Hij\u00f3n, \nEduardo L\u00f3pez Granados, Rebeca Rodr\u00edguez Pena.\nHospital Universitario La Paz, Madrid.\nCO-12\nSOMATIC GENETIC RESCUE CORRELATING WITH CLINICAL \nIMPROVEMENT IN A PATIENT WITH TNFRSF9  (CD137/4-1BB) \nDEFICIENCY\nRoger Colobran1, Marina Garcia-Prat2, Alba Parra-Mart\u00ednez2, Clara \nFranco-Jarava1, Daniel \u00c1lvarez De La Sierra1, Aina Aguil\u00f3-Cucurull1, \nJacques G. Riviere2, Andrea Martin-Nalda2, Pere Soler-Palacin2, Ferran \nCasals3, Laia Alsina4, Montserrat Torrent5, Laura Batlle-Mas\u00f32.\n1Translational Immunology Research Group, Vall d\u2019Hebron Research \nInstitute (VHIR). Servei d\u2019Immunologia, Servei de Gen\u00e8tica, \nHospital Universitari Vall d\u2019Hebron (HUVH), Barcelona; 2Infection in \nImmunocompromised Pediatric Patients, Vall d\u2019Hebron Research \nInstitute (VHIR). Unitat de Patologia Infecciosa i Immunode\ufb01ci\u00e8ncies \nde Pediatria, Hospital Universitari Vall d\u2019Hebron (HUVH), Barcelona; \n3Department of Genetics, Microbiology and Statistics, Universitat \nde Barcelona (UB), Barcelona; 4Clinical Immunology and Primary \nImmunode\ufb01ciencies Unit, Pediatric Allergy and Clinical Immunology \nDepartment, Hospital Sant Joan de D\u00e9u, Barcelona; 5Paediatric \nHematopoietic Transplant Unit, Hospital Santa Creu i Sant Pau, \nBarcelona.1315:00-16:00    COMUNICACIONES ORALES 1. Inmunolog\u00eda B\u00e1sica\nSALA PALAC\u00cdN 1\nModeradores:\n\u00c1frica Gonz\u00e1lez Fern\u00e1ndez . CINBIO, Universidad de Vigo\nAlfredo Corell Almuzara.  Facultativo Especialista De Inmunolog\u00eda. \nCatedr\u00e1tico de Inmunolog\u00eda. Universidad de Valladolid\nCO-01\nGENOMEWIDE ANALYSIS OF AID TARGET SPECIFICITY IN HUMAN \nMEMORY B CELLS\n\u00c1lvaro Serrano Navarro1, \u00c1ngel Francisco \u00c1lvarez Prado2, F\u00e1tima   \nS\u00e1nchez Cabo1, Almudena R. Ramiro1.\n1CNIC, Madrid; 2Ludwig Institute for Cancer Research, Lausanne.\nCO-02\nRESIDENT MEMORY CD8 T CELLS TRIGGER PDC INFILTRATION \nAND MATURATION IN THE SKIN\nElena Hern\u00e1ndez Garc\u00eda1, Francisco Javier Cueto Rodr\u00edguez2, Ana \nRedondo Urzainqui1, Sof\u00eda Chayeb Khouili3, Salvador Iborra Mart\u00edn1.\n1Universidad Complutense de Madrid, Madrid; 2IdiPAZ - Instituto de \nInvestigaci\u00f3n Hospital Universitario La Paz, Madrid; 3Centro Nacional \nde Investigaciones Cardiovasculares (CNIC), Madrid.\nCO-03\nPHOSPHATASES OF REGENERATING LIVER (PRLS) AS REGULATORS \nOF ACTIN POLYMERIZATION BALANCE THROUGH THE WDR1/\nCOFILIN/CORONIN COMPLEX IN T LYMPHOCYTES.\n\u00d3scar Aguilar Sope\u00f1a1, Mat\u00edas Estar\u00e1s Hermosel2, Patricia Castro S\u00e1nchez3, \nCarlos Carrasco Padilla1, Sergio Alegre G\u00f3mez1, Pedro Roda Navarro1.\n1Facultad de Medicina. Universidad Complutense de Madrid. Departamento \nde inmunolog\u00eda, Madrid; 2Institute of Molecular Pathology Biomarkers. \nUniversity of Extremadura., C\u00e1ceres; 3Institute of Immunology and \nInfection Research. University of Edinburgh, Edinburgh.\nCO-04\nCHARACTERIZATION OF EXTRACELLULAR VESICLES SECRETED \nBY THYMIC REGULATORY T CELLS (THYTREG-EVS)\nMarta Fern\u00e1ndez Castillo1, Roc\u00edo L\u00f3pez Esteban1, Ver\u00f3nica Astrid \nP\u00e9rez Fern\u00e1ndez2, Elena Bl\u00e1zquez L\u00f3pez3, Javier Vaquero Mart\u00edn3, \nRafael Correa Rocha1, Marjorie Pion2.\n1Laboratorio de Inmuno-Regulaci\u00f3n, Instituto de Investigaci\u00f3n Sanitaria \nGregorio Mara\u00f1\u00f3n, Madrid; 2Grupo de Inmuno-Regulaci\u00f3n Avanzada, \nInstituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, Madrid; \n3Laboratorio de Investigaci\u00f3n en Hepatolog\u00eda y Gastroenterolog\u00eda, \nInstituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, Madrid.14CO-05\nHUMAN INTESTINAL CD103+SIRP \u03b1+ CONVENTIONAL DENDRITIC \nCELLS FROM PATIENTS WITH CROHN\u00b4S DISEASE PRIME IL-17+ \nT-CELLS\nElisa Arribas Rodr\u00edguez1, Carolina Gonz\u00e1lez De Castro1, Aida Fiz \nL\u00f3pez1, \u00c1ngel De Prado Santos1, Luis Fern\u00e1ndez Salazar2, Jes\u00fas \nBarrio Andr\u00e9s3, Sandra Izquierdo2, Javier Garc\u00eda Alonso3, Beatriz De \nAndr\u00e9s2, Jos\u00e9 Mar\u00eda Garc\u00eda Abril3, Alejandro Romero2, Javier S\u00e1nchez \nGonz\u00e1lez3, Jos\u00e9 Antonio Garrote Adrados1, Eduardo Arranz Sanz1, \nDavid Bernardo Ordiz1.\n1Instituto de Biolog\u00eda y Gen\u00e9tica Molecular, Valladolid; 2Hospital \nCl\u00ednico Universitario de Valladolid, Valladolid; 3Hospital Universitario \nRio Hortega, Valladolid.\nCO-06\nFOLDING OF NEWLY SYNTHESIZED PROTEINS REGULATES JURKAT \nT CELL METABOLISM AND INTERCELLULAR COMMUNICATION\nAmelia Rojas G\u00f3mez1, Sara Garc\u00eda Dosil1, Francisco Javier Chich\u00f3n2, \nNieves Fern\u00e1ndez-Gallego1, Alessia Ferrarini1, Enrique Calvo1, Diego \nCalzada Fraile1, Silvia Requena3, Joaquin Oton4, \u00c1lvaro Serrano1, \nRoc\u00edo Tarifa1, Montserrat Arroyo3, Andrea Sorrentino4, Eva Pereiro4, \nJes\u00fas V\u00e1zquez1, Jose Mar\u00eda Valpuesta2, Francisco S\u00e1nchez Madrid3, \nNoa Mart\u00edn C\u00f3freces3.\n1CNIC, Madrid; 2CNB, Madrid; 3Hospital Universitario de La Princesa, \nMadrid; 4ALBA Synchrotron Light Source, Barcelona .\n15:00-16:00    COMUNICACIONES ORALES 3. Inmunidad innata\nSALA PALAC\u00cdN 2\nModeradores: \nJordi Cano Ochando . Mount Sinai School of Medicine, New York\nDavid Bernardo Ordiz . Instituto de Biomedicina y Gen\u00e9tica, CSIC, Valladolid\nCO-13\nCYTOTOXIC NKG2DHI NK CELLS ACTIVATED BY CD1C+ DENDRITIC \nCELLS CONTRIBUTE TO PRIMARY SJ\u00d6GREN SYNDROME PATHOLOGY\nIldefonso S\u00e1nchez Cerrillo1, Marta Calvet Mirabent1, Ana Triguero \nMartinez1, Diego Calzada Fraile2, Cristina Delgado Ar\u00e9valo1, Mariel \nValdivia1, Marta Ram\u00edrez2, Enrique V\u00e1zquez De Luis2, Alberto Bengur\u00eda \nFilippini2, Roberto Moreno2, Mar\u00eda Magdalena Adrados De Llano1, \nHortensia De La Fuente Flores1, Ilya Tsukalov1, Emilia Roy Vallejo1, \nAlmudena Ramiro2, Salvador Iborra2, Francisco S\u00e1nchez Madrid1, Ana \nDopazo2, Isidoro Gonzalez1, Santos Casta\u00f1eda1, Enrique Mart\u00edn Gayo3.\n1Hospital Universitario La Princesa, Madrid; 2Centro Nacional de \nInvestigaciones Cardiovasculares, Madrid; 3Universidad Aut\u00f3noma de \nMadrid, Madrid.15CO-14\nNON-REDUNDANT ROLE OF NF-KB AND INFLAMMASOME \nSENSORS DRIVING PATHOGENIC DIFFERENTIATION AND \nACTIVATION OF MONOCYTES IN RESPONSE TO DISTINCT SARS-\nCOV-2 COMPONENTS\nIlya Tsukalov1, Ildefonso S\u00e1nchez Cerillo2, Olga Rajas3, Elena Avalos3, \nGorane Iturricastillo3, Mar\u00eda Jos\u00e9 Buz\u00f3n4, Maritxell Genesc\u00e04, Laura \nEsparcia2, Olga Popova2, Cristina Delgado Arevalo2, Marta Calvet \nMirabent2, Hortensia De La Fuente2, Noa Mart\u00edn C\u00f3freces2, Ignacio \nDe Los Santos2, Ceclia Mu\u00f1oz Calleja2, Arantzazu Alfranca2, Mar\u00eda \nJos\u00e9 Calzada2, Isidoro Gonz\u00e1lez Alvaro5, Julio Ancochea3, Francisco \nS\u00e1nchez Madrid2, Enrique Mart\u00edn Gayo2.\n1Universidad Aut\u00f3noma de Madrid, Madrid; 2Servicio de Inmunolog\u00eda, \nHospital Universitario de La Princesa, Madrid; 3Servicio de Neumolog\u00eda, \nHospital Universitario de La Princesa, Madrid; 4Val d\u2019Hebron Institut de \nRecerca, Barcelona; 5Servicio de Reumatolog\u00eda, Hospital Universitario \nde La Princesa, Madrid.\nCO-15\nGM-CSF PROGRAMS HEMATOPOIETIC STEM AND PROGENITOR \nCELLS DURING CANDIDA ALBICANS  VACCINATION FOR \nPROTECTION AGAINST REINFECTION\nCristina Bono , Paula Guerrero, Ana Erades, Mar\u00eda Luisa Gil, Alberto \nY\u00e1\u00f1ez.\nUniversitat de Val\u00e8ncia, Burjassot.\nCO-16\nREGULATION OF MACROPHAGE FUNCTION BY AN IFNAR-ISG15-\nMITOCHONDRIAL AXIS\nGillian Dunphy,  Irene Ad\u00e1n Barrientos, Irene Fern\u00e1ndez Delgado, \nCarolina Villarroya Beltri, Andrea Curtabbi, Ignacio Heras Murillo, Aitor \nJarit Cabanillas, Miguel S\u00e1nchez \u00c1lvarez, Miguel \u00c1ngel Del Pozo, Jos\u00e9 \nAntonio Enr\u00edquez, Francisco S\u00e1nchez Madrid, David Sancho.\nCentro Nacional de Investigaciones Cardiovasculares, Madrid.\nCO-17\nDIRECT TLR2 SIGNALING THROUGH MTOR AND TBK1 INDUCES C/\nEBP\u03b2 AND IRF7-DEPENDENT MACROPHAGE DIFFERENTIATION IN \nHEMATOPOIETIC STEM AND PROGENITOR CELLS \nCristina Bono, Pa Ula Guerrero, Ana Erades, Alberto Y\u00e1\u00f1ez, Mar\u00eda \nLuisa Gil .\nUniversitat de Val\u00e8ncia, Burjasot.16CO-18\nOXYGEN-INDEPENDENT REGULATION OF HIF-1 \u03b1 IN ILC3S \nAMELIORATES THE INFLAMMATION OF C. RODENTIUM-INDUCED \nCOLITIS\nAna Valle-Noguera1, Mar\u00eda Jos\u00e9 G\u00f3mez-S\u00e1nchez1, Anne Ochoa-\nRamos1, Patricia Yag\u00fce Fern\u00e1ndez2, Blanca Soler Palacios3, Virginia \nZorita4, Berta Braposo Ponce5, Jos\u00e9 Mar\u00eda Gonz\u00e1lez-Granado6, Juli\u00e1n \nAragon\u00e9s7, Aranzazu Cruz-Adalia1.\n1Universidad Complutense de Madrid, Madrid; 2Centro de \nInvestigaciones Biol\u00f3gicas Margarita Salas, Madrid; 3Centro Nacional \nDe Biotecnolog\u00eda, Madrid; 4Centro Nacional de Investigaciones \nCardiovasculares, Madrid; 5Centro de Biolog\u00eda Molecular Severo \nOchoa, Madrid; 6instituto de Investigaci\u00f3n Sanitaria Hospital 12 de \nOctubre, Madrid; 7Hospital Santa Cristina, Fundaci\u00f3n de Investigaci\u00f3n \nHospital de la Princesa, Madrid\n16:00-17:00   COMUNICACIONES ORALES 4. Inmunoterapia\nSALA PALACIO\nModeradores:\nRafael Sirera.  Departamento de Biolog\u00eda Celular. Universidad \nPolit\u00e9cnica de Valencia.\nSara Mar\u00eda Calleja Antol\u00edn.  Inmunolog\u00eda, Complejo Hospitalario \nUniversitario de Le\u00f3n\nCO-19\nANTIBODY AND T-CELL MEDIATED IMMUNE RESPONSES \nINDUCED BY CD19 CHIMERIC ANTIGEN RECEPTOR (ARI-0001) IN \nRELAPSED/REFRACTORY PATIENTS WITH CD19 POSITIVE B-CELL \nMALIGNANCIES\nAriadna Bartol\u00f3 - Ibars1, Europa Azucena Gonz\u00e1lez-Navarro2, \nNela Klein - Gonz\u00e1lez3, Berta Casanovas-Albert\u00ed3, Valent\u00edn Ortiz- \nMaldonado2, Montserrat Torrebadell4, Marta Espa\u00f1ol-Rego2, Maria \nCastell\u00e02, Daniel Ben\u00edtez2, Raquel Cabez\u00f3n2, Jordi Esteve2, Jordi \nYag\u00fce2, Mariona Pascal2, \u00c1lvaro Urbano-Ispizua2, Susana Rives4, Julio \nDelgado2, Manel Juan2.\n1Fundaci\u00f3 Cl\u00ednic per la Recerca Biom\u00e8dica, Barcelona; 2Hospital Cl\u00ednic \nde Barcelona, Barcelona; 3Instituto de Investigaciones Biom\u00e9dicas \nAugust Pi i Sunyer, Barcelona; 4Hospital Sant Joan de D\u00e9u, Barcelona .17CO-20\nPROGRESS TOWARDS A PATIENT-SPECIFIC MONOCLONAL \nANTIBODY IN S\u00c9ZARY SYNDROME\nMarta Herrero Alonso1, Ana V. Mar\u00edn Mar\u00edn1, Rebeca Fernandez \nMegino1, Daniel Chac\u00f3n Argueras1, Marcos Vi\u00f1uela Mart\u00edn2, Jose Luis \nSubiza3, Jose R Regueiro1.\n1Department of Immunology, Ophthalmology and ENT, Complutense \nUniversity School of Medicine and 12 de Octubre Health Research \nInstitute (i+12), Madrid; 2Clinical Immunology-Experimental and \nSurgery Department, Hospital Cl\u00ednico Universitario San Carlos, Madrid; \n3Inmunotek, Alcal\u00e1 de Henares.\nCO-21\nIDENTIFYING SARS-COV-2 \u2018MEMORY\u2019 NK CELLS FROM COVID-19 \nCONVALESCENT DONORS FOR ADOPTIVE CELL THERAPY \n(RELEASE)\nLara Herrera1, Myriam Martin-Inaraja1, Silvia Santos1, Marta Ingl\u00e9s-\nFerr\u00e1ndiz1, Aida Azkarate1, Maria Bur\u00f3n1, Miguel \u00c1ngel P\u00e9rez-Vaquero1, \nMiguel \u00c1ngel Vesga1, Jose Luis Vicario2, Bernat Soria3, Carlos Solano4, \nRaquel De Paz5, Antonio Marcos5, Cristina Ferreras6, Antonio P\u00e9rez-\nM\u00e1rtinez6, Cristina Eguizabal1.\n1CVTTH-IIS Biocruces-Bizkaia, Galdakao; 2Centro de Transfusi\u00f3n de la \nComunidad de Madrid, Madrid; 3ISABIAL, Alicante; 4Hospital Cl\u00ednico \nUniversitario de Valencia, Valencia; 5Hospital la Paz, Madrid; 6Hospital \nla Paz-Idipaz, Madrid.\nCO-22\nDEVELOPING CAR-NK CELLS ON NK-92 CELLS STABLY \nTRANSFECTED WITH CD16\nDavid Giraldos , Chantal Reina, Nuria Sancho, Isabel Marzo, Javier \nNaval, Alberto Anel.\nUniversidad de Zaragoza, Zaragoza.\nCO-23\nNEXT GENERATION OF TUMOR IMMUNOTHERAPIES BASED IN \nBACTERIA-TRAINED LYMPHOCYTES\nRaquel Garc\u00eda Ferreras, Lara Del Campo Mil\u00e1n, Almudena M\u00e9ndez \nP\u00e9rez, Esteban Veiga Chac\u00f3n .\nCentro Nacional de Biotecnolog\u00eda (CNB, CSIC), Madrid.\nCO-24\nDEVELOPMENT OF NEW TOLEROGENIC PEPTIDE-BASED VACCINE \nFOR RHEUMATOID ARTHRITIS\nLaura Romero Castillo1, VIlma Urbonaviciute1, Bingze Xu2, Rikard \nHolmdahl2.\n1Karolinska Institutet, Estocolomo; 2Karolinska Institutet, Estocolmo.1816:00-17:00   REUNI\u00d3N DE GRUPO DE EMBAJADORES GESEI\nSALA LOUNGE\nModerador: \nIsabel Cortegano Jimeno.  Laboratorio de Inmunobiolog\u00eda Centro \nNacional de Microbiolog\u00eda - Instituto de Salud Carlos III, Madrid\n16:00-18:00   REUNI\u00d3N TALLER IQ\nSALA PALAC\u00cdN 1\nModeradores: \nEsther Moga Naranjo . Hospital de la Santa Creu i Sant Pau, Barcelona\nManuel Hern\u00e1ndez Gonz\u00e1lez . Inmunolog\u00eda, Hospital Vall d\u00b4Hebron, Barcelona\n16:00-18:00   REUNI\u00d3N TALLER GETHIT\nSALA PALAC\u00cdN 2\nModeradores:  \nJes\u00fas Onta\u00f1\u00f3n Rodr\u00edguez . Jefe Inmunolog\u00eda Hospital Universitario \nAlbacete\nFrancisco Boix Giner . Centro de Transfusi\u00f3n, Hospital General \nUniversitario de Valencia\nPonentes:\n Dr. Marcelo Fern\u00e1ndez-Vi\u00f1a. Profesor Pathology, Stanford University\n\u201cActualizaci\u00f3n de la de\ufb01nici\u00f3n de las especi\ufb01cidades HLA a nivel \nserol\u00f3gico\u201d\n Dr. Francisco Boix Giner. Inmun\u00f3logo. Centro Transfusiones Valencia\n\u201cEvaluaci\u00f3n del bene\ufb01cio diagn\u00f3stico del ADN libre de c\u00e9lulas \nderivado de donante (dd-cfDNA) para el trasplante renal\u201d.\n Dr. Juan Torres Canizales.  Centro de diagn\u00f3stico Biom\u00e9dico (CDB). \nServicio Inmunolog\u00eda. H. Clinic Barcelona\n\u201cResultado de la encuesta sobre la prueba cruzada por citometr\u00eda de \n\ufb02ujo en el contexto del trasplante de \u00f3rganos s\u00f3lidos \u201c\n17:00-18:00   COMUNICACIONES ORALES 5. Miscel\u00e1nea (Inflamaci\u00f3n/Alergias y reacciones de\nSALA LOUNGE   hipersensibilidad/ Inmunidad anti-tumoral)\nModeradores: \nJaume Pons de Ves.  Inmunolog\u00eda Hospital Universitario Son Espases, \nPalma de Mallorca\nYvelise Barrios del Pino . Inmunolog\u00eda, Hospital Universitario de Canarias19CO-25\nSPECIFIC CELLULAR REGULATION OF LAMIN A/C IN IMMUNE AND \nSTROMA CELLS AS A THERAPEUTIC TARGET FOR INFLAMMATORY \nBOWEL DISEASE\nRaquel G\u00f3mez Bris1, Beatriz Herrero Fern\u00e1ndez1, H\u00e9ctor S\u00e1nchez Mart\u00ednez2, \nSara Moran De Bustos2, Irene Moreno Aperribay2, Marta Amor\u00f3s3, Alberto \nDel Monte3, Vicente Andr\u00e9s3, Gabriel Criado2, Alicia Usategui2, Jose Luis \nPablos Alvarez2, \u00c1ngela Saez4, Jos\u00e9 Mar\u00eda Gonz\u00e1lez Granado2.\n1Universidad Aut\u00f3noma de Madrid, Madrid; 2Instituto de Investigaci\u00f3n \nHospital 12 de Octubre (imas12), Madrid; 3Centro Nacional de \nInvestigaciones Cardiovasculares (CNIC), Madrid; 4Universidad \nFrancisco de Vitoria (UFV), Madrid .\nCO-26\nFINDING IMMUNOLOGICAL DIFFERENCES TO HELP DIAGNOSIS \nAND EARLY TREATMENT OF KAWASAKI DISEASE AND MIS-C \n(MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN)\nRebeca Kennedy-Batalla1, Elisa Fern\u00e1ndez-Cooke2, Javier Aracil-\nSantos3, Jes\u00fas Saavedra4, Alberto Garc\u00eda-Salido5, Manuel Jos\u00e9 \nG\u00f3mez6, Teresa Albendea-G\u00f3mez7, Beatriz Escobar7, Miguel \u00c1ngel \nCano-Nieto1, Sof\u00eda Mesa8, Jose Antonio Ruiz-Dom\u00ednguez9, Felipe \nGonz\u00e1lez4, Silvia Mart\u00edn-Puig7, Rafael Correa-Rocha1.\n1Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM), Madrid; \n2Unidad de Infectolog\u00eda Pedi\u00e1trica. Hospital Universitario 12 de Octubre, \nMadrid; 3Enfermedades Infecciosas Pedi\u00e1tricas. Hospital Universitario La \nPaz, Madrid; 4Pediatr\u00eda. Hospital Universitario Gregorio Mara\u00f1\u00f3n, Madrid; \n5Fundaci\u00f3n de Investigaci\u00f3n Biom\u00e9dica Hospital Infantil Universitario \nNi\u00f1o Jes\u00fas, Madrid; 6Unidad de Bioinform\u00e1tica. Centro Nacional de \nInvestigaciones Cardiovasculares (CNIC), Madrid; 7Centro Nacional de \nInvestigaciones Cardiovasculares (CNIC), Madrid; 8Unidad de Urgencias \nde Pediatr\u00eda. Hospital Universitario 12 de Octubre, Madrid; 9Servicio de \nUrgencias Pedi\u00e1tricas. Hospital Universitario La Paz, Madrid.\nCO-27\nPD-1 SE EXPRESA EN GR\u00c1NULOS CITOT\u00d3XICOS DE LAS C\u00c9LULAS \nNK Y SE MOVILIZA R\u00c1PIDAMENTE A LA MEMBRANA CELULAR \nTRAS EL RECONOCIMIENTO DE UNA C\u00c9LULA TUMORAL\nCecilia Pesini1, Sandra Hidalgo1, Maykel Arias1, Llipsy Santiago1, \nYurena Aguilar2, Marta Ocariz-D\u00edez3, Dolores Isla3, Pilar Lanuza1, M \nJos\u00e9 Agust\u00edn2, Ariel Ramirez1, Juli\u00e1n Pardo1.\n1Instituto de Investigaci\u00f3n Sanitaria de Arag\u00f3n, Zaragoza; 2Hospital \nUniversitario Miguel Servet, Zaragoza; 3Hospital Cl\u00ednico Univesitario \nLozano Blesa, Zaragoza. \nCO-28\nDEFICIENCY OF SHP1 IN MYELOID CELLS PROMOTES TUMOR GROWTH.\nMiguel Gal\u00e1n1, Elena Hern\u00e1ndez-Garc\u00eda2, Francisco J Cueto1, Ana \nRedondo-Urzainqui2, Stefanie K. Wculek1, Ignacio Heras-Murillo1, \nSalvador Iborra2, David Sancho1.\n1Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, \nSpain., Madrid; 2Department of Immunology, Ophthalmology and ENT. School \nof Medicine, Universidad Complutense de Madrid, 28040, Spain., Madrid.20CO-29\nBACTERIA EXPRESSING TUMOR ANTIGENS CAN TRAIN CD4+ \nLYMPHOCYTES FOR AN EFFECTIVE AND SPECIFIC ANTITUMOR \nIMMUNOTHERAPY\nLara Del Campo Mil\u00e1n1, Raquel Garc\u00eda-Ferreras1, Almudena M\u00e9ndez-\nP\u00e9rez2, Maria Jose G\u00f3mez-S\u00e1nchez3, Esteban Veiga2.\n1Centro Nacional de Biotecnolog\u00eda, Madrid; 2Centro Nacional de \nBiotecnolog\u00eda-CSIC, Madrid; 3Departamento de Inmunolog\u00eda, Facultad \nde Medicina, Universidad Complutense de Madrid, Madrid.\n17:00-18:00   SESI\u00d3N 4 MUJERES EN LA CIENCIA\nSALA PALACIO\nModeradores: \nM\u00aa Rosa Juli\u00e1 Benique . \u00a0Inmunolog\u00eda, Hospital Universitario Son \nEspases, Palma de Mallorca \nMar\u00eda Montoya Gonz\u00e1lez . Centro de Investigaci\u00f3n Margarita Salas, \nCSIC, Madrid\nPonentes:\n Mar\u00eda Mayan . Instituto de Investigaci\u00f3n Biom\u00e9dica, A Coru\u00f1a\n\u201cHow much are women disadvantaged in science?. The gender data\u201d\n Ana Fern\u00e1ndez Sesma . Icahn School of Medicine, New York, USA\n18:00-19:00   PLENARIA 3 METABOLISMO E INFLAMACI\u00d3N\nSALA PALACIO\nModeradores: \nJos\u00e9 Mar\u00eda Garc\u00eda Ruiz de Morales . Inmunolog\u00eda, Complejo \nHospitalario Universitario de Le\u00f3n\nJuan E. Vi\u00f1uela Rold\u00e1n . Inmunolog\u00eda, Complejo Hospitalario \nUniversitario de Santiago de Compostela\nPonentes:\n Ruslan Medzhitov . Yale School of Medicine, Connecticut ,USA\n\u201cMetabolism and In\ufb02ammation\u201d\n19:00-20:00   SIMPOSIO GSK \u201cINMUNOLOG\u00cdA Y VACUNACI\u00d3N DEL ADULTO\u201d\nSALA PALACIO\nPonentes:\n \u00c1frica Gonz\u00e1lez Fern\u00e1ndez , CINBIO (Centro de Investigaciones \nBiom\u00e9dicas), Universidad de Vigo\n V\u00edctor del Campo P\u00e9rez , Servicio de Medicina Preventiva del Complexo \nHospitalario Universitario de Vigo21D\u00cdA 2 VIERNES 23 DE SEPTIEMBRE\n08:30-09:30    PLENARIA 4 RESPUESTA INMUNE INNATA EN LUPUS\nSALA PALACIO\nModeradores: \nMarcos L\u00f3pez Hoyos.  Inmunolog\u00eda, Hospital Marqu\u00e9s de Valdecilla, \nSantander\nMar\u00eda Mittelbrunn.  Centro de Biolog\u00eda Molecular Severo Ochoa, CSIC, \nMadrid\nPonente: \n Carola Garc\u00eda de Vinuesa.  Francis Crick Institute, Londres, Reino Unido\n\u201cInnate immune responses en systemic lupus erythematosus\u201d\n09:30-10:30 \u00a0  PLENARIA 5 ONE HEALTH\nSALA PALACIO\nModeradores: \n\u00c1frica Gonz\u00e1lez Fern\u00e1ndez . CINBIO, Universidad de Vigo\nSara Mar\u00eda Calleja Antol\u00edn . Inmunolog\u00eda, Complejo Hospitalario \nUniversitario de Le\u00f3n \nPonente:\n Mar\u00eda Neira . Departamento de Salud P\u00fablica y Ambiente, Organizaci\u00f3n \nMundial de la Salud, Ginebra, Suiza\n\u201cOne health\u201d\n10:30-11:30   SESI\u00d3N 5 INMUNOTERAPIA EN C\u00c1NCER\nSALA PALACIO\nModeradores: \nRafael Sirera.  Departamento de Biolog\u00eda Celular, Universidad \nPolit\u00e9cnica de Valencia\nMar\u00eda May\u00e1n . Instituto de Investigaci\u00f3n Biom\u00e9dica, A Coru\u00f1a  \nPonentes:\n Ignacio Melero Bermejo . Centro de Investigaci\u00f3n M\u00e9dica Aplicada, \nUniversidad de Navarra\n\u201cIL 8 and neutrophil extracellular traps (NET) as a part of the wrong \nin\ufb02ammation in tumors\u201d\n Manel Juan Otero . Servicio de Inmunolog\u00eda, Hospital Clinic, Barcelona\n\u201cTreating patients with ATMPs from a public hospital: our experience \nwith the ARI program in Barcelona\u201d 2210:30-11:30   SESI\u00d3N 6 INMUNODEFICIENCIAS PRIMARIAS\nSALA PALAC\u00cdN 1\nModeradores: \nCarmen C\u00e1mara Hij\u00f3n . Inmunolog\u00eda, Hospital Universitario La Paz, \nMadrid\nOscar de la Calle Mart\u00edn . Inmunolog\u00eda, Hospital de la Santa Creu i San \nPau, Barcelona\nPonentes:\n Roger Colobran Oriol. Servicio de Inmunolog\u00eda, Hospital Vall d\u00b4Hebron, \nBarcelona\n Mar\u00eda Bravo Garc\u00eda-Morato.  Servicio de Inmunolog\u00eda, Hospital La Paz, \nMadrid\n\u201cCurrent and future challenges in genetic diagnosis of primary \nimmunode\ufb01ciencies. Expect the unexpected\u201d\n10:30-11:30   SESI\u00d3N 7 MICROBIOMA Y ENFERMEDAD\nSALA PALAC\u00cdN 2\nModeradores: \nSara Mar\u00eda Calleja Antol\u00edn . Inmunolog\u00eda, Complejo Hospitalario \nUniversitario de Le\u00f3n\nDavid Bernardo Ordiz.  Instituto de Biomedicina y Gen\u00e9tica, CSIC, \nValladolid \nPonentes:\n Rachel Caspi . National Eye Institute, NIH, Bethesda, Maryland, USA\n\u201cMicrobiota in uveitis\u201d\n Roger Paredes . Instituto Investigaci\u00f3n IrsiCAIXA, Hospital Germans \nTrias I Pujol, Barcelona\n10:30-11:30   ASAMBLEA DE USUARIOS DEL PROGRAMA GECLID\nSALA LOUNGE \nModerador: \nM\u00aa Carmen Mart\u00edn Alonso . Centro de Hemoterapia y Hemodonaci\u00f3n, \nValladolid\n11:30-12:00    PAUSA CAF\u00c92312:00-13:00   PLENARIA 6 ENVEJECIMIENTO E INFLAMAC I\u00d3N\nSALA PALACIO\nModeradores: \nJos\u00e9 Mar\u00eda Garc\u00eda Ruiz de Morales . Inmunolog\u00eda, Complejo \nHospitalario Universitario de Le\u00f3n\n\u00c1frica Gonz\u00e1lez Fern\u00e1ndez . CINBIO, Universidad de Vigo  \nPonentes:\n Mar\u00eda Mittelbrunn.  Centro de Biolog\u00eda Molecular Severo Ochoa (CSIC), \nMadrid\n\u201cImmunometabolism at the crosroad between in\ufb02ammation and \naging\u201d\n Santiago Moreno . Servicio de Enfermedades Infecciosas, Hospital \nRam\u00f3n y Cajal, Madrid\n\u201cIn\ufb02ammation and immunsenescence in HIV infected patients\u201d\n13:00-14:00   SIMPOSIO HEALTHINCODE \u201cNUEVOS AVANCES EN LA GEN\u00c9TICA APLICADA A\nSALA PALACIO   INMUNODEFICIENCIAS PRIMARIAS\u201d\nModeradora:\nYvelise Barrios del Pino. M\u00e9dico. Especialista en Inmunolog\u00eda. Vocal \nde la Junta Directiva de la Sociedad Espa\u00f1ola de Inmunolog\u00eda\nPonentes:\n Jean-Laurent Casanova . St. Giles Laboratory of Human Genetics of \nInfectious Diseases, The Rockefeller University, New York\n Carlos Rodr\u00edguez-Gallego . Servicio de Inmunolog\u00eda, Hospital \nUniversitario Dr. Negr\u00edn, Las Palmas de Gran Canaria\n13:00-14:00   SIMPOSIO BD \u201cMOLECULAR CYTOMETRY: KEY TOOL FOR EXPANDING OUR KNOWLEDGE OF\nSALA PALAC\u00cdN 1   IMMUNOLOGY. CITOMETR\u00cdA MOLECULAR: HERRAMIENTA CLAVE PARA AMPLIAR NUESTROS \nCONOCIMIENTOS EN INMUNOLOG\u00cdA\u201d\nModeradora: \nGemma Coma Bravo.  PhD, Marketing Manager BDB Iberia. BD Life \nSciences- Biosciences\nPonente:\n Werner Rodr\u00edguez Acebo . Senior Single Cell Solution Architect South \nEurope. BD Life Sciences- Biosciences2413:00-14:00   SIMPOSIO GRIFOLS \u201cNUEVAS TENDENCIAS EN LA MONITORIZACI\u00d3N TERAP\u00c9UTICA DE\nSALA PALAC\u00cdN 2  F\u00c1RMACOS BIOL\u00d3GICOS: MEJORAS EN EL FLUJO DE TRABAJO DEL LABORATORIO Y EN LA \nOPTIMIZACI\u00d3N DE LAS TERAPIAS BIOL\u00d3GICAS\u201d\nModeradora:\nDra. Dora Pascual Salcedo.  Independent Consultant in Clinical \nPractice\nPonentes:\n Dr. V\u00edctor Manuel Navas. Secci\u00f3n de Gastroenterolog\u00eda y Nutrici\u00f3n \nInfantil. Hospital Reg. Univ. de M\u00e1laga\n Ainhoa Ruiz Del Agua, PhD, Especialista de Desarrollo de Producto, \nProgenika Grifols\n14:00-14:30   VISITA P\u00d3STER\nHALL EXPOSICI\u00d3N\nPantalla 1. Autoinmunidad (I) (P-135 \u2013 P-158)\nModeradores:\nLourdes Mozo Avellaneda. Inmunolog\u00eda, Hospital Universitario \nCentral de Asturias\nRicardo Rojo Amigo. Inmunolog\u00eda, Complejo Hospitalario Universitario \nde A Coru\u00f1a\nPantalla 2.  Autoinmunidad (II) (P-159 \u2013 P-181)\nLourdes Mozo Avellaneda. Inmunolog\u00eda, Hospital Universitario \nCentral de Asturias\nRicardo Rojo Amigo. Inmunolog\u00eda, Complejo Hospitalario Universitario \nde A Coru\u00f1a\nPantalla 3.  Inmunogen\u00e9tica (P-182 \u2013 P-203)\nManuel Muro Amador.  Inmunolog\u00eda, Hospital Cl\u00ednico Universitario \nVirgen Arrixaca, El Palmar, Murcia\n\u00d3scar de la Calle Mart\u00edn.  Inmunolog\u00eda, Hospital de la Santa Creu i San \nPau, Barcelona\nPantalla 4. Trasplante (P-204 \u2013 P-229)\nFrancisco Boix Giner.  Centro de Transfusi\u00f3n, Hospital General \nUniversitario de Valencia\nJos\u00e9 ignacio Rodr\u00edguez Barbosa.  \u00c1rea de Inmunolog\u00eda, Universidad \nde Le\u00f3n25Pantalla 5.  Inmunidad frente a las infecciones (P-230 \u2013 P-260)\nEstanislao Nistal Vill\u00e1n.  Ciencias Farmac\u00e9uticas y de la Salud. \nUniversidad CEU San Pablo. Madrid\nManuel Hern\u00e1ndez Gonz\u00e1lez.  Inmunolog\u00eda, Hospital Vall d\u00b4Hebron, \nBarcelona\nPantalla 6. Vacunas (P-261 \u2013 P-274)\nJorge Carrillo Molina.  Instituto de Investigaci\u00f3n IrsiCaixa, Barcelona\nMar\u00eda Montoya Gonz\u00e1lez.  Centro de Investigaci\u00f3n Margarita Salas, \nCSIC, Madrid\n14:30-15:30   SESI\u00d3N 8 INMUNIDAD EN MUCOSAS\nSALA PALACIO\nModeradores: \nDavid Bernardo Ordiz.  Instituto de Biomedicina y Gen\u00e9tica, \nUniversidad de Valladolid\nManuel Hern\u00e1ndez Gonz\u00e1lez.  Inmunolog\u00eda, Hospital Vall d\u00b4Hebron, \nBarcelona \nPonente:\n William W. Agace . Mucosal Immunology Section, Lund University, \nLund, Suecia  \n\u201cExploring intestinal dendritic cell heterogeneity and function \u201c\n14:30-15:30   REUNI\u00d3N GJSEI\nSALA PALAC\u00cdN 1\nModerador: \nCarlos \u00c1vila Nieto . Grupo de Inmunolog\u00eda (IGG). Institut de Recerca \nde la Sida (IrsiCaixa), Badalona  \n14:30-15:30   COMUNICACIONES ORALES 6. Autoinmunidad\nSALA PALAC\u00cdN 2\nModeradores: \nLourdes Mozo Avellaneda.  Inmunolog\u00eda, Inmunolog\u00eda, Hospital \nUniversitario Central de Asturias\nRicardo Rojo Amigo.  Inmunolog\u00eda, Complejo Hospitalario Universitario \nde A Coru\u00f1a26CO-31\nDIFFERENTIAL EFFECTS OF ANTI-TNF \u03b1\u00a0AND ANTI- \u03b14\u03b27 DRUGS \nON CIRCULATING DENDRITIC CELLS MIGRATORY CAPACITY IN \nINFLAMMATORY BOWEL DISEASE\nIrene Soleto1, Samuel Fern\u00e1ndez-Tom\u00e92, Irene Mora-Gutierrez3, \nMontserrat Baldan-Martin1, Cristina Ramirez1, Cecilio Santander1, \nJose Andr\u00e9s Moreno-Monteagudo1, Maria Jos\u00e9 Casanova1, Fernando \nCasals1, Sergio Casabona1, Irene Becerro1, Maria Chaparro1, David \nBernardo4, Javier P. Gisbert1.\n1Gastroenterology Unit, Hospital Universitario de La Princesa and \nInstituto de Investigaci\u00f3n Sanitaria Princesa (IIS-Princesa), Centro \nde Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y \nDigestivas (CIBERehd), Madrid; 2Departamento de Nutrici\u00f3n y Ciencia \nde los Alimentos, Facultad de Farmacia, Universidad Complutense de \nMadrid, Madrid; 3Biobanco del sistema de salud de Arag\u00f3n, Zaragoza; \n4Mucosal Immunology Lab, Unidad de Exclencia Instituto de Biolog\u00eda \ny Gen\u00e9tica Molecular (IBGM, Universidad de Valladolid-CISC),Centro \nde Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedadmes Infecciones \n(CIBERINFEC), Valladolid.\nCO-32\nCIRCULATING IMMUNE-COMPLEXES OF IGG/IGM BOUND TO B2-\nGLYCOPROTEIN-I ASSOCIATED WITH COMPLEMENT CONSUMPTION \nAND THROMBOCYTOPENIA IN ANTIPHOSPHOLIPID SYNDROME\nLaura Naranjo1, Ljudmila Stojanovich2, Aleksandra Djokovic3, Laura \nAndreoli4, Angela Tincani4, Maria Ma \u015bli\u0144ska5, Savino Sciascia6, Maria \nInfantino7, Sara Garcinu\u00f1o1, Kinga Kostyra-Grabczak5, Mariangela \nManfredi7, Francesca Regola4, Natasa Stanisavljevic2, Milomir \nMilanovic2, Jovica Saponjski8, Dario Roccatello6, Irene Cecchi6, \nMassimo Radin6, Maurizio Benucci9, Daniel Pleguezuelo1, Manuel \nSerrano1, Yehuda Shoenfeld10, Antonio Serrano1.\n1Immunology Department, Hospital Universitario 12 de Octubre, \nMadrid; 2Internal Medicine, University Hospital Center Bezanijska \nKosa, Belgrado; 3Cardiology Department, University Hospital Center \nBezanijska Kosa, Belgrado; 4Unit of Rheumatology and Clinical \nImmunology, ASST Spedali Civili, Brescia; 5Early Arthritis Clinic, \nNational Institute of Geriatrics, Rheumatology and Rehabilitation, \nVarsovia; 6Nephrology and Dialysis Unit (ERK-net Member), Center of \nResearch of Immunopathology and Rare Diseases, San Giovanni Bosco \nHospital, Tur\u00edn; 7Immunology and Allergy Laboratory, San Giovanni di \nDio Hospital, Florencia; 8Cardiology Department, University Clinical \nCenter of Serbia, Belgrado; 9Rheumatology Unit, San Giovanni di Dio \nHospital, Florencia; 10Ariel University, Ariel, Israel; Zabludowicz Center \nfor Autoimmune Diseases, She ba Medical Center, Tel-Hashomer.27CO-33\nLOS NIVELES DE IGM FRENTE A FOSFATIDILCOLINA EN SUERO \nPREDICEN LA RESPUESTA AL TRATAMIENTO CON NATALIZUMAB \nE INTERFER\u00d3N- \u03b2\nMaria Cruz S\u00e1daba Argaiz1, Esther Escudero Lirola1, Cristina Sebal \nNeira1, Elena Urcelay Garc\u00eda2, Rafael Arroyo G\u00f3nzalez3, Mar\u00eda Angel \nGarc\u00eda Mart\u00ednez2, Francisco J Quintana4, Roberto \u00c1lvarez Lafuente2, \n\u00darsula Mu\u00f1oz Mor\u00f3n1.\n1Universidad San Pablo CEU, Madrid; 2Hospital Cl\u00ednico San Carlos, \nMadrid; 3Hospital Universitario Quir\u00f3nsalud, Madrid; 4Ann Romney \nCenter for Neurologic Diseases. Brigham and Women\u2019s Hospital. \nHarvard Medical School, Boston.\nCO-34\nCHARACTERIZATION OF THE INTERACTION OF THE AUTOIMMUNE \nREGULATOR (AIRE) WITH THE E3-UBIQUITIN LIGASES SIAH1 AND \nSIAH2\nAdri\u00e1n Tirado Herranz1, Alba Pastor Moreno2, Mar\u00eda Area Navarro2, \nMiguel Marcilla3, Alberto Paradela3, I\u00f1aki \u00c1lvarez2.\n1Hospital Cl\u00ednic / Institut de Biotecnologia i Biomedicina, Barcelona; \n2Institut de Biotecnologia i Biomedicina, Cerdanyola del Vall\u00e8s; 3Centro \nNacional de Biotecnolog\u00eda, Madrid.\nCO-35\nTHYROID FOLLICULAR CELLS CAN MODULATE T CELL \nFUNCTION AND PHENOTYPE IN MIXED AUTOLOGOUS CULTURES; \nIMPLICATIONS FOR THYROID AUTOIMMUNE DISEASES\nDaniel \u00c1lvarez De La Sierra1, Aroa G\u00f3mez2, Irene Bello2, Carmela \nIglesias2, Anna Petit3, \u00d3scar Gonz\u00e1lez2, Pablo Moreno3, Carlos Zaf\u00f3n2, \nRicardo Pujol2.\n1Vall d\u2019Hebron Research Institute (VHIR), Barcelona; 2Hospital \nUniversitario Vall d\u2019Hebron (HUVH), Barcelona; 3Hospital Universitario \nde Bellvitge (HUB), Barcelona.\nCO-36\nROLE OF POLYREACTIVE AUTOANTIBODIES IN SJ\u00d6GREN\u2019S \nSYNDROME\nRebeca Guti\u00e9rrez-C\u00f3zar , Manuel S\u00e1ez Moya, Joan Pu\u00f1et-Ortiz, Ana \nAngulo, Pablo Engel.\nUniversidad de Barcelona, Barcelona.2814:30-15:30   COMUNICACIONES ORALES 7. Inmunogen\u00e9tica\nSALA LOUNGE\nModeradores:  \nOscar de la Calle Mart\u00edn.  Inmunolog\u00eda, Hospital de la Santa Creu i San \nPau, Barcelona\nManuel Muro Amador.  Inmunolog\u00eda, Hospital Cl\u00ednico Universitario \nVirgen Arrixaca, El Palmar, Murcia\nCO-37\nUNDERSTANDING THE ETIOLOGY OF INTESTINAL IMMUNE \nDYSREGULATION IN A NOVEL LCK VARIANT \u2013 OF HUMAN AND MOUSE\nVictor Lui1, Manfred Hoenig2, Klaus Schwarz2, Elena Hsieh1.\n1University of Colorado Anschutz Medical Campus, Colorado; \n2University Medical Center Ulm, Ulm.\nCO-38\nNUEVAS APROXIMACIONES EN EL DIAGN\u00d3STICO GEN\u00c9TICO \nDE INMUNODEFICIENCIAS PRIMARIAS: DESARROLLO DE UNA \nESTRATEGIA DE AN\u00c1LISIS PARA LA EVALUACI\u00d3N DE VARIANTES \nDE DOSIS G\u00c9NICA MEDIANTE NGS\nElisabet Matas P\u00e9rez , Andrea Gonz\u00e1lez Torbay, Maria \u00c1ngeles Mori \n\u00c1lvarez, Carmen Rodr\u00edguez Jim\u00e9nez, Ricardo Cuesta Mart\u00edn De La \nC\u00e1mara, Laura Miguel Berenguel, Carla Gianelli, Carmen C\u00e1mara \nHij\u00f3n, Rebeca Rodr\u00edguez Pena, Eduardo L\u00f3pez Granados, \u00c1ngela Del \nPozo Mate, Mar\u00eda Bravo Garc\u00eda-Morato.\nHospital Universitario La Paz, Madrid.\nCO-39\nMITOCHONDRIAL COMPLEX I REGULATES ANTIGEN CROSS-\nPRESENTATION IN DENDRITIC CELLS\nElena Priego1, Michel Enamorado2, Annalaura Mastrangelo1, Sarai \nMart\u00ednez-Cano1, Pablo Rodr\u00edguez-Silvestre3, Johan Garaude4, Eduardo \nBalsa5, Patrycja Kozik3, Salvador Iborra6, David Sancho1.\n1CNIC, Madrid; 2National Institute of Allergy and Infectious Diseases, \nBethesda; 3MRC Laboratory of Molecular Biology, Cambridge; 4Institut \nnational de la sant\u00e9 et de la recherche m\u00e9dicale, Bordeaux; 5Centro de \nBiolog\u00eda Molecular Severo Ochoa, Madrid; 6Universidad Complutense \nde Madrid, Madrid.\nCO-40\nASOCIACI\u00d3N DE LOS NONAP\u00c9PTIDOS PRESENTADOS POR HLA-E \nCON LA ENFERMEDAD DE BEH\u00c7ET\n\u00c1ngel Luis Casta\u00f1o N\u00fa\u00f1ez1, Marco Antonio Montes Cano2, Jos\u00e9 Ra\u00fal \nGarc\u00eda Lozano2, Raquel Mu\u00f1oz Garc\u00eda2, Carmen Morales Garc\u00eda2, Alicia \nJurado Orozco2, Mar\u00eda Francisca Gonz\u00e1lez Escribano2.\n1Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid; 2Hospital \nUniversitario Virgen del Roc\u00edo, Sevilla.29CO-41\nHEK293F CELL LINE SHOWS DIFFERENT ANTIGEN PRESENTATION \nFEATURES THAN HEK293\nAlba Pastor Moreno1, Mar\u00eda Dolores Area Navarro1, Erika Scholz1, \nAdri\u00e1n Tirado Herranz1, Miguel Marcilla2, Francesc Canals3, Manel \nJuan4, I\u00f1aki \u00c1lvarez1.\n1Immunology Unit, Department of Cell Biology, Physiology, and \nImmunology and Institut de Biotecnologia i Biomedicina, Universitat \nAut\u00f2noma de Barcelona, Bellaterra; 2Proteomics Unit, Spanish \nNational Biotechnology Centre, Madrid; 3Proteomics Laboratory, \nVall d\u2019Hebron Institute of Oncology (VHIO), Universitat Aut\u00f2noma \nde Barcelona, Barcelona; 4Servei d\u2019Immunologia, Hospital Cl\u00ednic de \nBarcelona, IDIBAPS, Universitat de Barcelona, Barcelona.\nCO-42\nHLA-G EN UVE\u00cdTIS: MENOS ES M\u00c1S\nMarta Molina Alejandre1, Christian Vaquero Yuste1, Ignacio Juarez1, \nMarina Bego\u00f1a Gorro\u00f1o Echebarria2, Elisa Mar\u00eda Molanes L\u00f3pez3, \nFabio Suarez Trujillo1, Carmen Rodriguez Sainz4, Eduardo Fern\u00e1ndez \nCruz4, Antonio Arnaiz Villena1, Jos\u00e9 Manuel Mart\u00edn Villa1.\n1Dpto. de Inmunolog\u00eda, Oftalmolog\u00eda Y ORL. Facultad de Medicina. \nUniversidad Complutense de Madrid, Madrid; 2Servicio de \nOftalmolog\u00eda. Hospital Universitario Pr\u00edncipe de Asturias, Alcal\u00e1 de \nHenares; 3Dpto. de Estad\u00edstica e Investigaci\u00f3n Operativa. Facultad de \nMedicina. Universidad Complutense de Madrid, Madrid; 4Instituto de \nInvestigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, Madrid.\n15:30-17:30   REUNI\u00d3N TALLER AI\nSALA PALACIO\nModerador:  \nM\u00aa Luisa Vargas P\u00e9rez.  Servicio de Inmunolog\u00eda y Gen\u00e9tica. Hospital \nUniversitario de Badajoz\n15:30-16:30   REUNI\u00d3N AEH\nSALA PALAC\u00cdN 1\nModerador: \nJaume Pons de Ves. Inmunolog\u00eda Hospital Universitario Son Espases, \nPalma de Mallorca3015:30-16:30   COMUNICACIONES ORALES 8. Inmunidad frente a las infecciones\nSALA PALAC\u00cdN 2\nModeradores:  \nEstanislao Nistal Vill\u00e1n . Ciencias Farmac\u00e9uticas y de la Salud. \nUniversidad CEU San Pablo. Madrid\nManuel Hern\u00e1ndez Gonz\u00e1lez . Inmunolog\u00eda, Hospital Vall d\u00b4Hebron, \nBarcelona\nCO-43\nS PROTEIN VACCINE-INDUCED IMMUNE IMPRINTING REDUCES N \nPROTEIN ANTIBODY RESPONSE IN SARS-COV-2 INFECTION\nJuan Francisco Delgado De La Poza1, M\u00f3nica Vidal1, Maria Carmen \nMoya2, Mateu Espasa3, Antonio Casabella3, Manel Seda2, Rosa Mar\u00eda \nSerrano2, Pilar Pe\u00f1a2.\n1Immunology Unit, Laboratory Service. Parc Taul\u00ed Hospital Universitari. \nInstitut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT). Universitat \nAut\u00f2noma de Barcelona, Departament de Medicina., Sabadell; \n2Occupational Health Department. Parc Taul\u00ed Hospital Universitari. \nInstitut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT). Universitat \nAut\u00f2noma de Barcelona., Sabadell; 3Microbiology Unit, Laboratory \nService. Parc Taul\u00ed Hospital Universitari. Institut d\u2019Investigaci\u00f3 i \nInnovaci\u00f3 Parc Taul\u00ed (I3PT). Universitat Aut\u00f2noma de Barcelona. \nSabadell. Spain., Sabadell.\nCO-44\nA DIFFERENTIAL SIGNATURE OF CIRCULATING MIRNAS AND \nCYTOKINES BETWEEN COVID-19 AND COMMUNITY-ACQUIRED \nPNEUMONIA UNCOVERS NOVEL PHYSIOPATHOLOGICAL \nMECHANISMS OF COVID-19\nPedro Mart\u00ednez Fleta , Paula Vera Tom\u00e9, Mar\u00eda Jim\u00e9nez Fern\u00e1ndez, \nSilvia Requena, Emilia Roy Vallejo, Ancor Sanz Garc\u00eda, Marta Lozano \nPrieto, Celia L\u00f3pez Sanz, Alicia Vara, \u00c1ngel Lancho S\u00e1nchez, Enrique \nMart\u00edn Gayo, Cecilia Mu\u00f1oz Calleja, Arantzazu Alfranca, Isidoro \nGonz\u00e1lez \u00c1lvaro, Jos\u00e9 Mar\u00eda Galv\u00e1n Rom\u00e1n, Javier Aspa, Hortensia \nDe La Fuente, Francisco S\u00e1nchez Madrid.\nHU de la Princesa, Madrid.\nCO-45\nEXTRACELLULAR VESICLES FROM LISTERIA MONOCYTOGENES-\nINFECTED DENDRITIC CELLS ALERT THE INNATE IMMUNE \nRESPONSE\nRa\u00fal Izquierdo Serrano1, Irene Fern\u00e1ndez Delgado2, Olga Moreno \nGonzalo1, Enrique Mart\u00edn Gayo2, Diego Calzada Fraile1, Inmaculada \nJorge1, Emilio Camafeita1, Francisco S\u00e1nchez Madrid2.\n1Centro Nacional Investigaciones Cardiovasculares (CNIC) Carlos III, \nMadrid; 2Instituto Investigaci\u00f3n Sanitaria Hospital Universitario La \nPrincesa (IIS-HUP)-Universidad Aut\u00f3noma de Madrid (UAM), Madrid.31CO-46\nKIR-LIGAND  POLYMORPHISM IMPROVED A MORTALITY \nPREDICTION MODEL INCLUDING CLINICAL DATA OF KNOWN \nCOMORBIDITY IN PATIENTS WITH SARS-COV-2 INFECTION\nJairo Eduardo Ni\u00f1o Ram\u00edrez , Maria Nieves Gutierrez Zu\ufb01aurre, Miguel \nMarcos, Mr Bartol S\u00e1nchez, Roc\u00edo Eiros, Miguel Alcoceba Sanchez, Mar\u00eda \nGarc\u00eda Alvarez, Pilar T erradillos S\u00e1nchez, Daniel Presa, Juan Luis Mu\u00f1oz, A \nL\u00f3pez Bern\u00fas, E L\u00f3pez S\u00e1nchez, D Gonz\u00e1lez Calle, Pedro L S\u00e1nchez, Olga \nComp\u00e1n Fern\u00e1ndez, Marcos Gonz\u00e1lez, Ram\u00f3n Garc\u00eda Sanz, Francisco Boix.\nHospital Universitario de Salamanca, Salamanca.\nCO-47\nDIFFERENTIAL EXPRESSION OF CHEMOKINE RECEPTORS IN \nSARS-COV2- SPECIFIC CD4+ T LYMPHOCYTES\nLaura Esparcia , Angel Lancho, Noelia Ropero, Enrique Mart\u00edn, Noa \nMartin, Francisco S\u00e1nchez Madrid, Arantzazu Alfranca.\nServicio de Inmunolog\u00eda, Hospital de la Princesa, Madrid.\nCO-48\nNATURAL KILLER CELL DEGRANULATION: A DETERMINANT \nFACTOR IN COVID-19 EVOLUTION\nSara Garcinu\u00f1o , Francisco Javier Gil Etayo, Esther Mancebo, Marta \nLopez Nevado, Antonio Lalueza, Raquel Diaz Sim\u00f3n, Daniel Enrique \nPleguezuelo, Manuel Serrano, \u00d3scar Cabrera Marante, Luis M Allende, \nEstela Paz Artal, Antonio Serrano.\nHospital Universitario 12 de Octubre, Madrid.\n15:30-17:30   REUNI\u00d3N DE GRUPO DE CITOMETR\u00cdA (GECIT)\nSALA LOUNGE\nModeradores:  \nJordi Cano Ochando . Mount Sinai School of Medicine, New York\nDaniel Lozano Ojalvo . Assistant Professor. Deparment of Dermatology. \nMount Sinai Hospital, New York\n16:30-17:30   REUNI\u00d3N GEIT\nSALA PALAC\u00cdN 1\nModerador: \nBel\u00e9n Blanco Durango.  Unidad de Inmunoterapia del C\u00e1ncer. Hospital \n12 de Octubre, Madrid\nPonentes:\n Manel Juan. Servicio de Immunolog\u00eda. CBD-Hospital Cl\u00ednic, Barcelona.\n\u201cMonitorizaci\u00f3n anal\u00edtica de CAR-T: para qu\u00e9 y por qu\u00e9 debe hacerse \npor los inmun\u00f3logos de cada centro\u201d\n Elena S\u00e1nchez Zapardiel.  Unidad de Inmunolog\u00eda. Hospital \nUniversitario La Paz-IdiPAZ, Madrid.\n\u201cMonitorizaci\u00f3n CAR-T: recomendaciones de consenso desde la \nperspectiva del inmun\u00f3logo\u201d3216:30-17:30   COMUNICACIONES ORALES 9. Trasplante\nSALA PLAC\u00cdN 2\nModeradores:  \nFrancisco Boix Giner . Centro de Transfusi\u00f3n, Hospital General \nUniversitario de Valencia\nJos\u00e9 Ignacio Rodr\u00edguez Barbosa . \u00c1rea de Inmunolog\u00eda, Universidad \nde Le\u00f3n\nCO-49\nTHE IMPACT OF CD160 DEFICIENCY ON ALLOREACTIVE CD8 T \nCELL RESPONSES AND ALLOGRAFT \u00a0REJECTION\nJose-Ignacio Rodriguez Barbosa , Maria Luisa Del Rio Gonzalez.\nSection of Immunobiology, University of Leon, Leon\nCO-50\nNK CELL TRANSCRIPTOME AND PHENOTYPICAL CHANGES \nAFTER AUTOLOGOUS HSCT: TRANSIENT EXPANSION OF A CD9+ \nDECIDUAL-LIKE NK CELL SUBSET.\nGabirel Astarloa-Pando1, Ane Orrantia1, I\u00f1igo Terr\u00e9n1, Ainhoa Amarilla-\nIrusta1, Silvia P\u00e9rez-Fernandez1, Itziar Astigarraga1, Juan J. Mateos-\nMaz\u00f3n1, Juan C. Garc\u00eda-Ruiz1, Marta Ri\u00f1\u00f3n1, Carmen Gonz\u00e1lez2, Alasne \nUranga2, Jos\u00e9 J. Uriz2, Mercedes Rey2, Tom\u00e1s Carrascosa3, Enrique \nV\u00e1zquez-De Luis4, Sergio Callejas4, Ana Quintas4, Ana Dopazo4, Olatz \nZenarruzabeitia1, Francisco Borrego1.\n1Biocruces Bizkaia Health Research Institute \u2013 Cruces University \nHospital, Barakaldo; 2Biodonostia Health Research Institute \u2013 Donostia \nUniversity Hospital, Donostia; 3Biocruces Bizkaia Health Research \nInstitute \u2013 Galdakao-Usansolo Hospital, Galdakao; 4Centro Nacional \nde Investigaciones Cardiovasculares (CNIC), Madrid.\nCO-51\nINMUNIDAD ENTRENADA EN PACIENTES CON ENFERMEDAD \nRENAL CR\u00d3NICA AVANZADA (ERCA) Y EN RECEPTORES DE \nTRASPLANTE RENAL (RTR): NANOINMUNOTERAPIA PARA SU \nMODULACI\u00d3N\nMarta Chivite Lacaba1, Cecilia Gonz\u00e1lez Cuadrado1, Marcos J Berges \nBuxeda2, Patricia Almendro V\u00e1zquez1, Jara Caro Espada3, Esther \nGonz\u00e1lez3, Alberto Utrero Rico4, Roc\u00edo Laguna Goya3, Esther Mancebo \nSierra3, Amado Andr\u00e9s3, Jordi Ochando2, Estela Paz Artal3.\n1Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica Hospital 12 de Octubre, \nMadrid; 2Centro Nacional de Microbiolog\u00eda, Instituto de Salud Carlos \nIII, Madrid; 3Hospital 12 de Octubre, Madrid; 4Icahn School of Medicine \nat Mount Sinai, Nueva York.33CO-52\nCOMPARISON OF IMMUNE RECONSTITUTION BETWEEN POST-\nTRANSPLANT CYCLOPHOSPHAMIDE AND CONVENTIONAL \nGRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN ALLOGENEIC \nHEMATOPOIETIC STEM CELL TRANSPLANTATION\nJennifer Bola\u00f1os G\u00f3mez1, Martha G\u00f3mez Hernando2, Jose Luis Caro1, \nCarles Serra1, Eduard Palou1, Mar\u00eda Queralt Salas2, Alexandra Pedraza2, \nMonserrat Rovira2, Carmen Mart\u00ednez Mu\u00f1oz2, Juan Torres Canizales1.\n1Transplant Immunology Section, Immunology Department, \nHospital Cl\u00ednic de Barcelona, Barcelona; 2Hematopoietic Stem Cell \nTransplantation Unit, Hematology Department, Hospital Cl\u00ednic de \nBarcelona, IDIBAPS, Barcelona.\nCO-53\nEVALUACI\u00d3N DEL PERFIL DE SENSIBILIDAD A F\u00c1RMACOS \nINMUNOSUPRESORES EN PACIENTES CON TRASPLANTE RENAL, \nMEDIANTE EL ENSAYO IMMUNOBIOGRAM\u00ae (IMBG) Y MARCADORES \nDE ACTIVACI\u00d3N LINFOCITARIA\nCecilia Gonz\u00e1lez Cuadrado1, Marta Chivite Lacaba1, Patricia Almendro \nV\u00e1zquez1, Alvaro Ortega2, Teresa Diez2, Isabel Potero2, Amado Andr\u00e9s3, \nJulio Pascual3, Estela Paz Artal3, Esther Mancebo Sierra3.\n1Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica Hospital 12 octubre, \nMadrid; 2Biohope Scienti\ufb01c Solutions for Human Health SL, Tres \nCantos; 3Hospital Universitario 12 de Octubre, Madrid.\nCO-54\nMODULATION OF THE INNATE IMMUNE RESPONSE IN \nTRASPLANTATION BY TARGETED DELIVERY OF MYCOPHENOLIC \nACID BY MUSSEL-INSPIRED NANOPARTICLES\nCelia Nieto Jim\u00e9nez1, Milena A. Vega Moreno2, Eva M. Mart\u00edn Del \nValle2, Mar\u00eda Luisa Del R\u00edo3, Jos\u00e9 Ignacio Rodr\u00edguez Barbosa1.\n1Section of Transplant Immunobiology and Immunotherapy, Institute \nof Molecular Biology, Genomics and Proteomics, University of Leon, \nLe\u00f3n; 2Chemical Engineering Department, Faculty of Chemical \nSciences, University of Salamanca, Salamanca; 3Section of Transplant \nImmunobiology and Immunotherapy, Institute of Molecular Biology, \nGenomics and Proteomics, University of Leon, Salamanca.\n17:30-18:30   COMUNICACIONES ORALES 10. Vacunas\nSALA LOUNGE\nModeradores: \nJorge Carrillo Molina . Instituto de Investigaci\u00f3n IrsiCaixa, Barcelona\nMar\u00eda Montoya Gonz\u00e1lez . Centro de Investigaci\u00f3n Margarita Salas, \nCSIC, Madrid34CO-55\nMESOPOROUS SILICON MICROPARTICLES (MSMPS) ENHANCE \nCELLULAR AND HUMORAL IMMUNE RESPONSE TO SARS-COV-2\nAna L\u00f3pez G\u00f3mez1, Irene Real Ar\u00e9valo1, Elsa Mayol Hornero1, Ignacio \nJu\u00e1rez1, Beatriz Mart\u00edn Adrados1, Raquel Gonz\u00e1lez Garc\u00eda1, Ra\u00fal Mart\u00edn \nPalma2, Eduardo Mart\u00ednez Naves1, Manuel G\u00f3mez Del Moral3.\n1Universidad Complutense de Madrid, Departamento de inmunolog\u00eda, \nFacultad de Medicina, Madrid; 2Universidad Aut\u00f3noma de Madrid, \nDepartamento de F\u00edsica Aplicada, Facultad de Ciencias, Madrid; \n3Universidad Complutense de Madrid, Departamento de Biolog\u00eda \nCelular, Facultad de Medicina, Madrid.\nCO-56\nPREDICTIVE FACTORS OF THE MAGNITUDE AND LOSS OF ANTI-S \nANTIBODY TITERS AFTER TWO DOSES OF BNT162B2 VACCINE IN \nOLDER PEOPLE: AN EIGHT MONTHS FOLLOW-UP\nMar\u00eda Del Mar Pozo Balado1, \u00c1ngel Bulnes Ramos1, Vanesa Garrido \nRodr\u00edguez1, Israel Olivas Fern\u00e1ndez1, Carmen Lozano2, Ana Isabel \n\u00c1lvarez R\u00edos2, Berta Gonz\u00e1lez Gonz\u00e1lez2, Jos\u00e9 Manuel Lara2, Isabel \nMaldonado Calzado2, Encarnaci\u00f3n S\u00e1nchez Bejarano2, Juan Antonio \nSantamar\u00eda3, Mar\u00eda Francisca Gonz\u00e1lez Escribano2, Manuel Leal4, \nYolanda M. Pacheco1.\n1Instituto de Biomedicina de Sevilla, HUVR, Sevilla; 2Hospital \nUniversitario Virgen del Roc\u00edo, Sevilla; 3Residencia Hogar de la Santa \nCaridad, Sevilla; 4Hospital Viamed Santa \u00c1ngela de la Cruz/Hogar \nResidencia de la Santa Caridad, Sevilla.\nCO-57\nINMUNOTERAPIA INDUCIDA POR LA VACUNA MV130 EN UN \nMODELO EXPERIMENTAL DE NEUMON\u00cdA NEUMOC\u00d3CICA\nAlejandro Arrabal Sierra1, Mercedes Rodr\u00edguez1, Carolina Ru\u00edz1, \nM. Carmen Prado2, Isabel Cortegano1, Laura Conejero3, Mar\u00eda Jos\u00e9 \nFerrandiz4, Adela G. De La Campa4, Jos\u00e9 Luis Subiza3, Mar\u00eda Luisa \nGaspar1, Bel\u00e9n De Andr\u00e9s1\n1Laboratorio de Inmunobiolog\u00eda - Centro Nacional de Microbiolog\u00eda - \nInstituto de Salud Carlos III, Majadahonda; 2Unidad de Citometr\u00eda de \nFlujo - Centro Nacional de Microbiolog\u00eda - Instituto de Salud Carlos \nIII, Majadahonda; 3Inmunotek, Alcal\u00e1 de Henares; 4Laboratorio de \nGen\u00e9tica Bacteriana - Centro Nacional de Microbiolog\u00eda - Instituto de \nSalud Carlos III, Majadahonda35CO-58\nCELLULAR AND HUMORAL RESPONSES FOLLOW-UP FOR 8 \nMONTHS AFTER VACCINATION WITH MRNA-BASED ANTI-SARS-\nCOV-2 VACCINES\nSergio Gil Manso1, Diego Carbonell2, Ver\u00f3nica Astrid P\u00e9rez Fern\u00e1ndez1, \nRoc\u00edo L\u00f3pez Esteban3, Roberto Alonso4, Patricia Mu\u00f1oz4, Jordi Cano5, \nIgnacio S\u00e1nchez-Arcilla Conejo6, Jose Mar\u00eda Bell\u00f3n7, Rafael Correa \nRocha3, Marjorie Pion1.\n1Grupo de Inmuno-Regulaci\u00f3n Avanzanda, IiSGM, HGUGM, Madrid; \n2Servicio de Hematolog\u00eda, HGUGM, Madrid; 3Laboratorio de Inmuno-\nRegulaci\u00f3n, IiSGM, HGUGM, Madrid; 4Servicio de Microbiolog\u00eda Cl\u00ednica \ny Enfermedades Infecciosas, HGUGM, Madrid; 5Precision Immunology \nInstitute, Icahn School of Medicine at Mount Sinai, Nueva York; 6Servicio \nde Prevenci\u00f3n de Riesgos Laborales, HGUGM, Madrid; 7Servicio de \nBioestad\u00edstica, IiSGM, HGUGM, Madrid.\nCO-59\nDIFFERENCES BETWEEN B-CELL SUBPOPULATIONS AND \nNEUTRALIZING ANTIBODIES FOLLOWING BNT162B2 (PFIZER-\nBIONTECH) VACCINE IN PERSONS WITH AND WITHOUT HISTORY \nINFECTION OF SARS-COV-2\nJos\u00e9 Javier Morales N\u00fa\u00f1ez1, Sa\u00fal Alberto D\u00edaz P\u00e9rez1, Mariel Garc\u00eda \nChagoll\u00e1n1, Jos\u00e9 Francisco Mu\u00f1oz Valle1, Paola Carolina Torres \nHern\u00e1ndez1, Sara\u00ed Citlalic Rodr\u00edguez Reyes1, Guillermo Santoscoy \nAscencio2, Jos\u00e9 Julio Sierra Garc\u00eda De Quevedo2, Jorge Hern\u00e1ndez \nBello1.\n1Universidad de Guadalajara - Centro Universitario de Ciencias de la \nSalud, Guadalajara; 2Unidad de Patolog\u00eda Clinica - UPC, Guadalajara.\nCO-60\nMYCOPHENOLATE & MTOR INHIBITORS TREATMENT AFFECTS \nTHE RESPONSE TO MRNA-1273 VACCINATION IN PATIENTS WITH \nRENAL TRANSPLANTATION\nIgnacio Ju\u00e1rez1, Isabel P\u00e9rez-Flores2, Ana L\u00f3pez-G\u00f3mez3, Raquel \nGonz\u00e1lez-Garc\u00eda3, Bel\u00e9n Peix-Jim\u00e9nez2, Manuel G\u00f3mez Del Moral4, \nAna S\u00e1nchez-Fructuoso2, Eduardo Mart\u00ednez-Naves3.\n1Dpto. De Inmunolog\u00eda, Oftalmolog\u00eda y ORL, Facultad de Medicina, \nUniversidad Complutense De Madrid, Madrid; 2Servicio de Nefrolog\u00eda, \nHospital Cl\u00ednico San Carlos, Madrid; 3Dpto. De Inmunolog\u00eda, \nOftalmolog\u00eda y ORL, Facultad de Medicina, Universidad Complutense \nDe Madrid., Madrid; 4Dpto. De Biolog\u00eda Celular, Facultad de Medicina, \nUniversidad Complutense De M adrid., Madrid.3617:30-19:00   SESI\u00d3N 9 NUEVAS TERAPIAS EN DM I\nSALA PALACIO\nModerador: \nSara Mar\u00eda Calleja Antol\u00edn.  Inmunolog\u00eda, Complejo Hospitalario \nUniversitario de Le\u00f3n\nRicardo Rojo Amigo . Inmunolog\u00eda, Complejo Hospitalario Universitario \nde A Coru\u00f1a\nPonentes:\n Francisco Le\u00f3n. ProventionBio, New Jersey, USA\n\u201cTargeting the autoimmmune origins of type 1 diabetes\u201d\n Mattias von Herrath. La Jolla Institute for Immunology, California, USA\n\u201cInduction-maintenance combination therapies for type1 diabetes\u201d\n Pieter Rottiers . Precigen Actobio, Ghent, B\u00e9lgica\n17:30-19:00   CASOS CL\u00cdNICOS AI\nSALA PALAC\u00cdN 1\nModeradores:\nM\u00aa Luisa Vargas P\u00e9rez. Servicio de Inmunolog\u00eda y Gen\u00e9tica. Hospital \nUniversitario de Badajoz\nYvelise Barrios del Pino.  Inmunolog\u00eda, Hospital Universitario de Canarias\nCCAI-01\nPERSISTENCIA A LARGO PLAZO DE AC ANTIGLIADINA DEAMINADA \nIGG EN UNA PACIENTE CON APARICI\u00d3N DE NOVO DE D\u00c9FICIT \nSELECTIVO DE IGA POST DIAGN\u00d3STICO DE CEL\u00cdAQU\u00cdA.\nAntonino Cavallo , Paulina Vasquez, Mildred Fabiola Villegas Siles, \nAndrea Ferranti, Esther Vergara Prieto, Luis Miguel Fern\u00e1ndez Pereira.\nHospital San Pedro de Alc\u00e1ntara, C\u00e1ceres\nCCAI-02\nDESARROLLO DE NEUROMIELITIS \u00d3PTICA EN PACIENTE CON \nMIASTENIA GRAVIS Y TIMECTOM\u00cdA\nBeatriz Rioseras De Bustos , Roc\u00edo L\u00f3pez Mart\u00ednez, Raquel Monta\u00f1a \nRodr\u00edguez, Manuel Amorin D\u00edaz, Walter Javier Villafani Echazu, \nLourdes Mozo Avellaned1.\nHosptial Universitario Centras de Asturias (HUCA), Oviedo\nCCAI-03\nENCEFALITIS ANTI-R-NMDA POST VACUNA SARS-COV-2 \u00a0\nRosana Gonz\u00e1lez L\u00f3pez , Carmen Botella Mart\u00ednez, Victor Jim\u00e9nez Coll, \nCarlos S\u00e1nchez Rodr\u00edguez, Pedro Mart\u00ednez Garc\u00eda, Manuel Muro Amador.\nHospital Cl\u00ednico Universitario Virgen de la Arrixaca, Murcia37CCAI-04\nANTICUERPOS DE ISOTIPO IGA ANTI-MEMBRANA BASAL \nGLOMERULAR POST-TRASPLANTE RENAL EN PACIENTE CON \nS\u00cdNDROME DE ALPORT \nMarina Segura Guerrero1, Carles Saus Sarrias1, Roberto Gozalbo \nRovira2, Mar\u00eda Lu\u00edsa Vargas P\u00e9rez3, Juan Bautista Saus Mas2, Mar\u00eda \nRosa Juli\u00e0 Benique.\nHospital Universitario Son Espases. Instituto de Investigaci\u00f3n \nSanitaria Illes Balears (IdISBa)1; Facultad de medicina y Odontolog\u00eda. \nUniversidad de Valencia, Valencia2; Complejo Hospitalario Universitario \nde Badajoz, Badajoz3\nCCAI-05\nHETEROGENEIDAD CL\u00cdNICA EN EL S\u00cdNDROME POLIGLANDULAR \nAUTOINMUNE DE TIPO 1, M\u00c1S ALL\u00c1 DEL DEFECTO MONOG\u00c9NICO\nElisabet Matas P\u00e9rez , Laura Miguel Berenguel, Andrea Gonz\u00e1lez \nTorbay, Mar\u00eda Bravo Garc\u00eda Morato, Pilar Nozal Aranda, Rebeca \nRodr\u00edguez Pena.\nHospital Universitario La Paz, Madrid\nCCAI-06\nANTICUERPOS ANTI-SRP EN UNA PACIENTE CON ESCLEROSIS \nSIT\u00c9MICA, CIRROSIS BILIAR PRIMARIA Y SIN SIGNOS DE MIOPAT\u00cdA \nINFLAMATORIA. \nRoberto Pariente Rodr\u00edguez, Elena Manterola Navarro, Carlota Garc\u00eda-\nHoz Jim\u00e9nez, Jes\u00fas Loarce Martos, Ana\u00eds Mariscal Rodr\u00edguez, Miren \nGarbi\u00f1e Roy Ari\u00f1o.\nHospital Universitario Ram\u00f3n y Cajal, Madrid\nCCAI-07\nS\u00cdNDROME DE COTARD (DELIRIO NIHILISTA) COMO DEBUT DE \nENCEFALITIS AUTOINMUNE\nAntonio Trujillo Aguilera , Raquel Bernardo Serrano, Ana Mar\u00eda Navas \nRomo, Roc\u00edo Aguado, Sara Cantis\u00e1n, Aurora Jurado Roger.\nHospital Universitario Reina Sof\u00eda, C\u00f3rdoba\n17:30-19:00   CASOS CL\u00cdNICOS ID\nSALA PALAC\u00cdN 2\nModeradores: \nCarmen C\u00e1mara Hij\u00f3n . Inmunolog\u00eda, Hospital Universitario La Paz, \nMadrid\nJuana Gil Herrera .\u00a0Inmunolog\u00eda, Hospital Universitario Gregorio \nMara\u00f1\u00f3n, Madrid38CCID-01\nDIAGN\u00d3STICO DE S\u00cdNDROME DE DELECI\u00d3N 22Q11 EN EDAD ADULTA\nLaura Miguel Berenguel , Ricardo Cuesta Mart\u00edn De La C\u00e1mara, \nAndrea Gonz\u00e1lez Torbay, Elisabet Matas P\u00e9rez, Mar\u00eda Bravo Garc\u00eda-\nMorato, Carmen C\u00e1mara Hij\u00f3n.\nHospital Universitario, La Paz, Madrid\nCCID-02\nDEFICIENCIA DE TAP1 EN PACIENTE CON INMUNODEFICIENCIA Y \nLESIONES GRANULOMATOSAS CUT\u00c1NEAS CR\u00d3NICAS\nAurora Fern\u00e1ndez Galv\u00e1n1, Mar Llamas Velasco1, Javier Fraga1, Daniel \nArroyo S\u00e1nchez2, Oscar Cabrera Marante2, Luis M Allende2.\nHospital la Princesa, Madrid1; Hospital 12 de Octubre, Madrid2 \nCCID-03\nSINDROME DE VEXAS. UN NUEVO INVITADO EN LAS \nENFEMREDADES INFLAMATORIAS.\nAna Lucia Jimenez1, Ernesto Tovar1, Mariano Andres1, Anna Mensa2, \nJuan Arostegui2, Francisco M. Marco1.\nHospital General Universitario de Alicante Dr. Balmis, Alicante1; \nHospital Clinic de Barcelona, Barcelona2.\nCCID-04\nALOTRASPLANTE DE DONANTE NO-EMPARENTADO COMO \nTRATAMIENTO EXITOSO EN UN CASO DE INMUNODEFICIENCIA \nPRIMARIA POR S\u00cdNDROME DE WISKOTT-ALDRICH CON \nDISREGULACI\u00d3N INMUNE\nAntonio Costa Anzola , Antonio Trujillo, Juan Molina, Ana Navas, \nAurora Jurado.\nHospital Universitario Reina Sof\u00eda, C\u00f3rdoba.\nCCID-05\nNEUTROPENIA CONG\u00c9NITA POR DEFICIENCIA DEL RECEPTOR DE \nG-CSF\nCarmen Morales Garc\u00eda1, Alicia Jurado Orozco1, Pilar Ortiz Aljaro1, \nAntonia Rodriguez Villa2, Jos\u00e9 Manuel Lucena Soto1.\nHospital Universitario Virgen del Roc\u00edo, Sevilla1; Hospital Universitario \nReina Sof\u00eda, C\u00f3rdoba2.\nCCID-06\nA PROP\u00d3SITO DE UN CASO FAMILIAR DE S\u00cdNDROME DE HIPER-\nIGE CON NIVELES NORMALES DE IGE\nElisabet Matas P\u00e9rez , Andrea Gonz\u00e1lez Torbay, Ricardo Cuesta Mart\u00edn \nDe La C\u00e1mara, Teresa Del Rosal Rabes, Mar\u00eda Bravo Garc\u00eda-Morato, \nCarmen C\u00e1mara Hij\u00f3n.\nHospital Universitario La Paz, Madrid39CCID-07\nD\u00c9FICIT AUTOS\u00d3MICO RECESIVO PARCIAL DEL RECEPTOR \nDEL\u00a0IFN-\u03b3:\u00a0EFECTO FUNDADOR EN ISLAS CANARIAS \nRaquel Mu\u00f1oz Garc\u00eda1, Carmen Morales Garc\u00eda1, Ana Reyes Dom\u00ednguez \nAcosta2, Maria Del Pino Santana Falc\u00f3n2, Inmaculada Zorio Reyes2, \nCarlos Rodriguez Gallego2.\nHospital Universitario Virgen del Roc\u00edo, Sevilla1; Hospital Universitario \nDoctor Negrin, Las Palmas de Gran Canaria2.\n19:00-20:00   ASAMBLEA GENERAL SEI\nSALA PALACIO\nModerador: \nCarmen C\u00e1mara Hij\u00f3n . Inmunolog\u00eda, Hospital Universitario La Paz, \nMadrid40D\u00cdA 3 S\u00c1BADO 24 DE SEPTIEMBRE\n08:15-09:15    PLENARIA 7 CAR-T E N AUTOINMUNIDAD\nSALA PALACIO\nModeradores:  \nLuis Fern\u00e1ndez Pereira . Inmunolog\u00eda, Hospital San Pedro de Alc\u00e1ntara, \nC\u00e1ceres\nEva Mart\u00ednez C\u00e1ceres . Inmunolog\u00eda, Hospital Germans Trias, Barcelona\nPonentes:\n George Schett. Friedrich Alexander University Erlangen-Nuremberg & \nUniversit\u00e4tsklinikum, Alemania\n\u201cCAR-T in systemic lupus erythematosus\u201d\n09:15-10:15   PLENARIA 8 CELIACA\nSALA PALACIO\nModeradores: \nEduardo Arranz Sanz . Instituto de Biomedicina y Gen\u00e9tica, Universidad \nde Valladolid\nLuis Fern\u00e1ndez Pereira . Inmunolog\u00eda, Hospital San Pedro de Alc\u00e1ntara, \nC\u00e1ceres\nPonente:\n Detlef Schuppan. Institute of Translational Immunology, Johannes \nGutenberg University Medical Center, Mainz, Alemania\n\u201cSick with wheat: celiac disease, type 2 allergy and ATT sensitivity\u201d\n10:15-10:30    PAUSA CAF\u00c9\n10:30-11:30    SIMPOSIO PATROCINADO \u201cACTUALIZACI\u00d3N EN LA FISIOPATOLOG\u00cdA Y EL TRATAMIENTO DEL\nSALA PALACIO   ANGIOEDEMA HEREDITARIO\u201d4110:30-11:30   SIMPOSIO DIAGN\u00d3STICA LONGWOOD  \u201c EL PODER TERAP\u00c9UTICO DE CAR-T, CAR-NK \nSALA PALAC\u00cdN 2   \u201dGENiCAR\u201d. EL FUTURO DE LA TERAPIA CELULAR PARA EL TRATAMIENTO DEL C\u00c1NCER\u201d\nModerador: \nFrancisco Boix Giner . Facultativo Especialista en Inmunolog\u00eda, \nHospital General Universitario de Valencia\nPonente:\n Dr. Alejandro Madrigal, MD PhD FRCP FRCPath DSc HonDSci FMedSci. \nProfessor of Haematology, UCL Cancer Institute\n11:30-13:00   SESI\u00d3N 10 NEUROINFLAMACI\u00d3N\nSALA PALACIO\nModeradores: \nEva Mart\u00ednez C\u00e1ceres . Inmunolog\u00eda, Hospital Germans Trias, Barcelona\n\u00c1lvaro Prada I\u00f1urrategui . Inmunolog\u00eda, Hospital Universitario de Donostia\nPonentes:\n Juan Carlos G\u00f3mez Esteban . Servicio de Neurolog\u00eda, Hospital Cruces, \nBilbao.\n\u201cAutoimmune dysautonomias\u201d\n M. Villar . Servicio de Inmunolog\u00eda, Hospital Ram\u00f3n y Cajal, Madrid.\n\u201cEffects of B -cell depletion in multiple sclerosis. Immunological and \nclinical aspects\u201d\n \u00c1lvaro Prada I\u00f1urrategui . Servicio de Inmunolog\u00eda, Hospital \nUniversitario Donostia, San Sebastian\n\u201cAnti NMO and anti MOG antibodies in NMOSD and MOGAD\u201d\n11:30-13:00   SESI\u00d3N 11 INFLAMACI\u00d3N TH2\nSALA PALAC\u00cdN 1\nModeradores: \nJaume Pons de Ves . Inmunolog\u00eda, Hospital Universitario Son Espases, \nPalma de Mallorca\nYvelise Barrios del Pino . Inmunolog\u00eda, Hospital Universitario de Canarias\nPonentes:\n Ana Gim\u00e9nez-Arnau . Servicio de Dermatolog\u00eda, Hospital del Mar, \nBarcelona \n\u201c Urticaria cr\u00f3nica: bases patog\u00e9nicas y estrategias terap\u00e9uticas:\u201d\n Mar\u00eda Luisa Baeza . Servicio de Alergolog\u00eda, Hospital Gregorio Mara\u00f1\u00f3n, \nMadrid\n\u201cAnaphylaxis\u201d4211:30-13:00   SESI\u00d3N 12 DIVULGACI\u00d3N/INMUNOMEDIATICOS\nSALA PALAC\u00cdN 2\nModeradores: \nRafael Sirera . Departamento de Biolog\u00eda Celular, Universidad \nPolit\u00e9cnica de Valencia\nLourdes Mozo Avellaneda . Inmunolog\u00eda, Hospital Universitario Central \nde Asturias  \nPonente:\n Alfredo Corell Almuzara . Departamento de Pediatr\u00eda e Inmunolog\u00eda, \nUniversidad de Valladolid\n \u00c1frica Gonz\u00e1lez Fern\u00e1ndez . CINBIO, Universidad de Vigo\n Carmen C\u00e1mara Hij\u00f3n . Servicio de Inmunolog\u00eda, Hospital Universitario \nLa Paz, Madrid\n13:00-14:30    PLENARIA 9 SINDROMES HEMOFAGOC\u00cdTICOS\nSALA PALACIO\nModeradores: \nJuana Gil Herrera . Inmunolog\u00eda, Hospital Universitario Gregorio \nMara\u00f1\u00f3n, Madrid\nOscar de la Calle Mart\u00edn . Inmunolog\u00eda, Hospital de la Santa Creu i San \nPau, Barcelona\nPonentes:\n Michael Jordan . Cincinnati Children\u00b4s Hospital Medical Center, Ohio, \nUSA\n\u201cPrimary Hemophagocytic Lymphohistiocytosis: Updates on \nPathogenesis and Treatment\u201d\n Jan Inge Henter . Karolinska University Hospital, Stockholm, Suecia\n\u201cUpdate on secondary hemophagocytic syndromes\u201d\n14:30-15:00    ACTO FIN CONGRESO Y ENTREGA DE PREMIOS\nSALA PALACIO\n15:00   COMIDA CLAUSURA CONGRESO43EXPOSICI\u00d3N COMERCIAL\n44INFORMACI\u00d3N GENERAL\nSEDE DEL CONGRESO\nPalacio de Congresos y Exposiciones de Le\u00f3n\nCalle G\u00f3mez Salazar, 24009 Le\u00f3n\nLe\u00f3n, Espa\u00f1a\nORGANIZA\nSOCIEDAD ESPA\u00d1OLA DE INMUNOLOGIA\nCalle Castell\u00f3 128, 7\u00ba, 28006 Madrid \nTel. +34 913836000\nEmail: secretaria@inmunologia.org\nSECRETAR\u00cdA T\u00c9CNICA\nGRUPO PAC\u00cdFICO\nCalle Castell\u00f3,128 7\u00aa planta\n28006 Madrid (SPAIN)\nTel. +34 913 836 000 \u2013 ext 5121\nFax. +34 913 023 926\nEmail: sei2022@paci\ufb01co-meetings.com\nHORARIO DE SECRETAR\u00cdA\n Jueves 22 de septiembre: de 08:00h a 20:00h\n Viernes 23 de septiembre:  de 08:00h a 20:00h\n S\u00e1bado 24 de septiembre:  de 08:00h a 15:00h\nENTREGA DE DOCUMENTACI\u00d3N\nLa retirada de documentaci\u00f3n se efectuar \u00e1 mediante la presentaci\u00f3n del bono de \ncon\ufb01rmaci\u00f3n de su inscripci\u00f3n en horario de secretar\u00eda.\nLa documentaci\u00f3n se entregar \u00e1 exclusivamente al titular de la misma.\nNUEVAS INSCRIPCIONES\nSe aceptar\u00e1n nuevas inscripciones en horario de secretar\u00eda, de acuerdo a las cuotas \nestablecidas.45CERTIFICADOS DE ASISTENCIA\nLos certi\ufb01cados se entregar\u00e1n ONLINE,  a partir del martes 27 de septiembre  (una vez \n\ufb01nalizado.\nel congreso), a trav\u00e9s del enlace que se publicar \u00e1 en la web www.sei2022.com\nDISTINTIVO\nCon la documentaci\u00f3n se entregar \u00e1 un distintivo personalizado, que deber\u00e1 llevar visible \ndurante todo el congreso.\nSu presentaci\u00f3n es imprescindible para la entrada a las salas y exposici\u00f3n comercial para \nsu control.\nENTREGA DE PRESENTACIONES Y PRUEBAS AUDIOVISUALES\nHabr\u00e1 un espacio habilitado donde podr\u00e1n entregar el soporte de su presentaci\u00f3n, para \nser luego proyectada directamente en la sala correspondiente, debiendo entregarla con \ntiempo su\ufb01ciente, y como m\u00ednimo, dos horas antes del inicio de su sesi\u00f3n, o en el caf\u00e9 \no almuerzo anterior . Una vez empezada la sesi\u00f3n podr\u00e1n entregar su presentaci\u00f3n al \nt\u00e9cnico de sala, pero no se podr\u00e1 probar en pantalla.\nLas presentaciones de PowerPoint que incluyen video deben incluir tambi\u00e9n el software y \nCodex correspondientes para su visualizaci\u00f3n din\u00e1mica. Recuerde que los videos necesitan \nun tiempo m\u00ednimo para su descarga por lo que se ruega especialmente que todas las \npresentaciones con video se entreguen con la debida antelaci\u00f3n. Por favor, informe al \nt\u00e9cnico en el momento de su carga y compruebe que se visualiza correctamente.\nEXPOSICI \u00d3N COMERCIAL\nPalacio de Congresos de Exposiciones de Le\u00f3n\nIDIOMA  \nLas sesiones ser\u00e1n en espa\u00f1ol o ingl\u00e9s, no habr\u00e1 traducci\u00f3n simult\u00e1nea.  \nSEGURO\nEl Comit\u00e9 Organizador del presente Congreso declina toda responsabilidad en caso de \naccidentes, enfermedad, p\u00e9rdida o da\u00f1o de los objetos personales que puedan ocurrir \ndurante la celebraci\u00f3n del Congreso o pre y pos viaje. Se recomienda a los asistentes que \ntengan contratados los seguros que consideren oportunos.46PATROCINADORES\npatrocinador platinum\npatrocinador oro\npatrocinador plata\npatrocinador bronce\npatrocinador general\n \n  \n 43 CONGRESO DE LA SOCIEDAD ESPA\u00d1OLA DE INMUNOLOG\u00cdA  COMUNICACIONES ORALES  Sesi\u00f3n Comunicaciones Orales 1. Inmunolog\u00eda B\u00e1sica  CO-01  GENOMEWIDE ANALYSIS OF AID TARGET SPECIFICITY IN HUMAN MEMORY B CELLS  Serrano Navarro, \u00c1lvaro1; \u00c1lvarez Prado, \u00c1nfel Francisco2; S\u00e1nchez Cabo, F\u00e1tima1; R. Ramiro, Almudena1.  1CNIC, Madrid; 2Ludwig Institute for Cancer Research.Lausanne, Suiza  After antigen recognition mature B lymphocytes can undergo immunoglobulin (Igs) secondary diversification in germinal centers (GCs) through somatic hypermutation (SHM) and class switch recombination (CSR). SHM introduces point mutations in the variable regions of Igs and can generate higher affinity antibodies, while CSR exchanges the constant region of Igs to allow the expression of alternate isotypes. Both SHM and CSR are initiated by Activation Induced Deaminase (AID) through the deamination of C on Ig DNA, thus generating a U:G mismatch that is repaired by different mechanisms. However, AID activity is not exclusively restricted to Ig loci; instead, it can target other regions, known as off-targets, leading to mutations and chromosome translocations with oncogenic potential. The mechanisms underlying the specificity of AID activity are not well understood. To address this question, we have evaluated AID activity in human memory B cells, which generally are GC experienced, using a DNA capture protocol coupled with UMI-based high throughput sequencing. We sequenced more than 20.000 regions in the genome, accounting for 12.6Mb, which cover the first exon of all described coding genes. Error corrected sequencing (ECS) method reduced the technical error below 1/10.000 mut/bp threshold. We were able to identify 49 off-target candidate regions in two donors and found that switched memory B cells have a higher mutational load at off-targets than unswichted memory B cells. Off-targets harboured on average 1.28e-4 mutations/bp, which had a distinct mutational footprint found by de-novo extraction of mutational signatures. In addition, we found that the identified off-targets are among the top expressed genes in the GC B cells. Thus, our data reveal for the first time an unbiased set of AID off-targets in normal human B cells. The potential impact of these mutations on lymphoma development is currently under investigation.   \n  \nCO-03  PHOSPHATASES OF REGENERATING LIVER (PRLS) AS REGULATORS OF ACTIN POLYMERIZATION BALANCE THROUGH THE WDR1/COFILIN/CORONIN COMPLEX IN T LYMPHOCYTES.  Aguilar Sope\u00f1a, \u00d3scar1; Estar\u00e1s Hermosel, Mat\u00edas2; Castro S\u00e1nchez, Patricia3; Carrasco Padilla, Carlos1; Alegre G\u00f3mez, Sergio1; Roda Navarro, Pedro1.  1Facultad de Medicina. Universidad Complutense de Madrid. Departamento de Inmunolog\u00eda; 2Institute of Molecular Pathology Biomarkers. University of Extremadura.; 3Institute of Immunology and Infection Research. University of Edinburgh.  PRLs group (PRL-1, 2 and 3) is formed by three highly-homolog proteins that belong to dual specificity phosphatases family. Their role in lymphocytes is mainly unknown, despite having similar expression to other phosphatases which are important in their function. We have previously reported that PRLs are relevant in the effector function and activation of T lymphocytes, regarding interleukin secretion and immune synapse architecture. However, there are still many questions to answer about PRLs and the mechanism by which they are regulating lymphocytes activity. We thought that identifying substrates of PRLs could help in our task, since there is a lack of knowledge about that in the bibliography. To do so, we develop a proteomic assay of an immunoprecipitation of GFP-PRL-1 in activated Jurkat cells. Interestingly, the three proteins of the complex WDR1/cofilin/coronin had high scores. This complex is a regulator of the actin polymerization process, which is crucial to T lymphocyte biology. As a consequence, we tried to evaluate the possible interaction between PRLs and WDR1, because it has been described an immunodeficiency due to WDR1 mutations. Our data in both HEK and Jurkat cells confirmed that PRLs, either overexpressed or at endogenous levels, interacted with WDR1. This interaction is dependent on the farnesylation state of PRLs in their C-terminal motif, since a mutant GFP-PRL-1 protein in this motif and an inhibitor of farnesyl transferase disrupted the interaction. Additionally, confocal microscopy assays in activated Jurkat cells through TCR stimulation demonstrated how WDR1 is polarized to the immune synapse and let us to define its distribution compared to F-actin and PRL-1/2. Lastly, we performed immunoprecipitation assays with \u03b2-actin in Jurkat cells in which PRL-1/2 appeared to be with the actin filament alongside WDR1. All together, we propose that PRLs affects several aspects of T lymphocytes biology by regulating actin filament dynamics.   \n  \n                          \n \n  \nCO-04  CHARACTERIZATION OF EXTRACELLULAR VESICLES SECRETED BY THYMIC REGULATORY T CELLS (THYTREG-EVS)  Fern\u00e1ndez Castillo, Marta1; L\u00f3pez Esteban, Roc\u00edo1; P\u00e9rez Fern\u00e1ndez, Ver\u00f3nica Astrid2; Bl\u00e1zquez L\u00f3pez, Elena3; Vaquero Mart\u00edn, Javier3; Correa Rocha, Rafael1; Pion, Marjorie2.  1Laboratorio de Inmuno-Regulaci\u00f3n, Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, Madrid; 2Grupo de Inmuno-Regulaci\u00f3n Avanzada, Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, Madrid; 3Laboratorio de Investigaci\u00f3n en Hepatolog\u00eda y Gastroenterolog\u00eda, Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, Madrid.  Introduction Regulatory T cells (Tregs) are currently used in therapy and, in most cases, are obtained from peripheral blood. However, a different cellular profile is observed by using the human thymus as a novel Treg source. These cells (thyTreg cells) seem to manifest more suitable features for therapy than peripheral Treg cells, such as purity, suppressive capacity, stability, and cell numbers without extensive proliferation.  Extracellular vesicles (EVs) constitute an important cell-communicating mechanism that has been broadly studied during the last years. In immunology, regulatory EVs from mesenchymal or Treg cells are thought to be pivotal in maintaining the immune homeostasis. Therefore, EVs are thoroughly studied as a potential treatment for a great variety of diseases. For that, EVs show characteristics that make them an interesting alternative to cell therapies:  \u2022 A small size allowing a wider distribution, reaching more tissues. \u2022 There is no risk of differentiation, modification and proliferation because of their lack of nucleus. \u2022 More feasible storage and stability. The current project lies in understanding EVs-derived thyTreg (thyTreg-EVs), their properties and characteristics.   Materials and Methods Firstly, thyTreg cells were purified from human thymuses and later cultured and activated. EVs were obtained from the conditioned media by different isolation methods such as Immunocapture, Ultrafiltration and Size Exclusion Chromatography and further characterized by Western Blot and Nanoparticle Tracking Analysis.  Results EVs from thyTreg cells were characterized by the presence of EV-enriched proteins (CD9 and  \n  \nTSG101) by Western Blot. Size distribution was also studied, observing two main EVs subpopulations, one of which proved to be small EV-like (30-150 nm). These findings show that thyTreg-EVs with a good purity grade can be isolated from this source, opening new possibilities regarding EV therapy.  \n                                   \n \n  \nCO-05  HUMAN INTESTINAL CD103+SIRP\u0391+ CONVENTIONAL DENDRITIC CELLS FROM PATIENTS WITH CROHN\u00b4S DISEASE PRIME IL-17+ T-CELLS.  Arribas Rodr\u00edguez, Elisa1; Gonz\u00e1lez De Castro, Carolina1; Fiz L\u00f3pez, Aida1; De Prado Santos, \u00c1ngel1; Fern\u00e1ndez Salazar, Luis2; Barrio Andr\u00e9s, Jes\u00fas3; Izquierdo, Sandra2; Garc\u00eda Alonso, Javier3; De Andr\u00e9s, Beatriz2; Garc\u00eda Abril, Jos\u00e9 Mar\u00eda3; Romero, Alejandro2; S\u00e1nchez Gonz\u00e1lez, Javier3; Garrote Adrados, Jos\u00e9 Antonio1; Arranz Sanz, Eduardo1; Bernardo Ordiz, David1.  1Instituto de Biolog\u00eda y Gen\u00e9tica Molecular, Valladolid; 2Hospital Cl\u00ednico Universitario de Valladolid; 3Hospital Universitario Rio Hortega, Valladolid.  Human intestinal conventional dendritic cells (cDC) maintain the balance between immunity and tolerance. However, their specific function in patients with Crohn\u00b4s disease (CD) is scarce. Hence, we hereby decided to assess their phenotype in inflamed and non-inflamed tissue from patients with CD referred to non-inflamed controls.  Tissue resections from patients with ileocolonic CD and controls (healthy tissue from proximal colonic cancer patients) were obtained, being subsequently enzymatically digested. Total intestinal cDC were identified within singlet viable leukocytes as CD14-CD64-HLA-DR+CD11c+. Three cDC subsets were sorted based on the expression of CD103 and SIRP\u03b1+ (CD103-SIRP\u03b1+; CD103+SIRP\u03b1+; CD103+SIRP\u03b1-) while total macrophages were sorted as CD14+CD64+HLA-DR+. cDC subsets and macrophages were further cultured with allogeneic CD4+ na\u00efve T-cells to assess their Th1, Th17 and Treg phenotype.  All 3 intestinal cDC subsets from controls stimulated na\u00efve T-cells as opposed to intestinal macrophages. Indeed, cDC stimulated T-cells produced IL-10 and co-expressed FoxP3, being this capacity increased in both CD103+ subsets. Moreover, all three ileal cDC subsets stimulated T-cells more efficiently than their paired colonic counterparts, although the acquired T-cell profile did not differ among tissues. None of the cDC subsets, however, induced the expression of IFN\u03b3 or IL-17. Referred to CD patients, all three colonic cDC subsets were more stimulatory than their counterparts from control tissue, while CD103+SIRP\u03b1+ cDC from inflamed ileum primed the generation of IL-17+ responding T-cells.  We have demonstrated that all human intestinal cDC prime the generation of Tregs, being this capacity increased in CD103+ cDC. Indeed, ileal cDC were more stimulatory than their paired colonic counterparts, suggesting an increased capacity of the ileum to generate Tregs.  \n  \nNevertheless, this processed was dysregulated in the inflamed tissue from patients with CD were CD103+SIRP\u03b1+ cDC seem to have been reprogramed by the tissue microenvironment to prime the generation of Th17 T-cells hence driving disease progression.                                               \n  \nSesi\u00f3n Comunicaciones Orales 2. Inmunodeficiencias: primarias y secundarias   CO-07  DISSECTING THE EFFECT OF A NOVEL HYPOMORPHIC IL2RB MUTATION ON IMMUNE DYSREGULATION  Bailey, Olivia1; Cabrera-Martinez, Berenice1; Garcia-Perez, Josselyn2; Baxter, Ryan1; Fernandez, Isabel1; Foster, Mary Jo1; Gapin, Laurant1; Kedl, Ross1; Hsieh, Elena1.  1University of Colorado Anschutz Medical Campus, Colorado, USA; 2Cellcarta.Brussels, Belgium  Human inborn errors of immunity (IEIs) are a class of genetic disorders caused by monogenic germline mutations that impair the function of the encoded protein. We recently described a novel IEI due to an IL2RB homozygous mutation (p.Pro222_Gln225Del) in two siblings who suffered from multi-organ autoimmunity and CMV susceptibility. This mutation resulted in decreased cell surface protein expression and increased serum IL-2/15 levels, with concomitant increased baseline STAT5 phosphorylation (pSTAT5) but poor pSTAT5 response to IL-2 and IL-15 stimulation. Counterintuitively, this IL-2R\u03b2 hypomorphic mutation led to an expansion of memory CD8+ T and immature CD56bright NK cells, which express the highest levels of IL-2R\u03b2 and require IL-2/15 signaling for survival and differentiation. Yet, their maturation and function appeared impaired, suggesting that both intrinsic (hypomorphic receptor) and extrinsic (serum cytokine milieu) mechanisms were at play. To further interrogate these receptor instrinsic/extrinsic mechanisms we developed a mouse model that harbors the homolog mutation (Il2rbMut/Mut). Notably, when mutant bone marrow cells reconstituted a WT host, serum IL-2/15 levels and IL-2Rb protein surface expression partially normalized, though IL-2/15-induced signaling remained hypofunctional. Additionally, the dysregulated mutant IL-2Rb-driven CD8+ T cell immunophenotype normalized but the NK phenotype did not. These data highlight the asymmetrical effect that a partial IL-2Rb defect has on CD8 T and NK cell IL-2/15-dependent signaling and downstream cellular processes. These results imply that strategies to modify serum IL-2/15 levels may serve as a therapeutic approach to treating IL-2/15 signaling defects.            \n  \nCO-08  A TRUNCATED P.Y153X CD247 (TCR\u0396) VARIANT IS STABLE AND FORMS POTENTIALLY PATHOGENIC CD247 HETERODIMERS IN HETEROZYGOSIS   Fern\u00e1ndez Megino, Rebeca1; Marin, Ana V1; Fernandez-Boraita, Julia1; Jimenez, Diego J1; Briones, Alejandro C1; Herrero-Alonso, Marta1; Chacon-Arguedas, Daniel1; Garcia-Mart\u00ednez, Elena2; Seoane-Reula, Elena2; Rodriguez-Sainz, Carmen2; Regueiro, Jose R1.  1Department of Immunology, Ophthalmology and ENT, Complutense University School of Medicine and 12 de Octubre Health Research Institute (i+12), Madrid; 2Gregorio Mara\u00f1\u00f3n Health Research Institute, Madrid.  The T-cell receptor (TCR) consists of a variable heterodimer, two invariant CD3 heterodimers and a single invariant homodimer (TCR\u03b6/CD247). CD247 is essential for TCR expression and signaling through its three ITAMs (immunoreceptor tyrosine\u2010based activation motifs). Thus, homozygous null mutations in CD247 (\u2013/\u2013) are associated with primary immunodeficiency, but carriers (+/\u2013) show no clinical features despite decreased surface TCR levels. Such cases help to understand human TCR biology. We studied an 8-year-old female with chronic refractory immune thrombocytopenia associated with CMV primo-infection. The patient inherited a hitherto undescribed heterozygous mutation in CD247 (c.459C>A, p.Y153X) predicted to truncate the third ITAM. The carrier but asymptomatic mother had high IgE and RF, past episodes of lymphopenia and recurrent canker sores. Our aim was to stablish a cell model to recapitulate p.Y153X carrier T cells and analyze if it may affect TCR expression, structure and/or function with pathogenic relevance.  PBMC were immortalized using HTLV-1. Extra and intracellular TCR/CD3/CD247 phenotype was performed and compared between immortalized and primary CD4+ T cells by flow cytometry. Western blot was used to analyze CD247 proteins.  HTLV-1 T-cell lines fully recapitulated the CD247 phenotype of p.Y153X carrier primary T cells, showing normal surface TCR levels, in contrast to +/\u2013 T cells. Western blot analyses showed a normal-sized CD247 protein (14.5 kDa), but also a smaller 14.3 kDa band, likely p.Y153X, giving rise to three CD247 dimer forms: two dominant dimers (a normal homodimer and a normal/p.Y153X heterodimer) and a minor p.Y153X homodimer.  We have thus developed a reliable cell model to further study TCR assembly and function in this case and shown that p.Y153X is stable and may form frequent variant surface TCR ensembles that could be the involved in the patient`s pathology, in contrast to null mutation carriers who build only normal CD247 dimers.  \n  \nCO-09  CORRECTING APDS2 SYNDROME-CAUSED MUTATION FOR FUTURE GENE AND CELL THERAPIES  Romayor, Irene1; Ingl\u00e9s-Ferr\u00e1ndiz, Marta1; Martin-Inaraja, Myriam1; Herrera, Lara1; Santos, Silvia2; Vesga, Miguel \u00c1ngel2; Pineda, Jose Ram\u00f3n3; Anguita, Juan4; Allende, Luis M5; Gonzalez-Granado, Luis I5; Eguizabal, Cristina1.  1Instituto de Investigaci\u00f3n Sanitaria Biocruces Bizkaia; 2Centro Vasco de Transfusi\u00f3n y Tejidos Humanos; 3Universidad del Pa\u00eds Vasco (UPV/EHU); 4CIC Biogune, Derio; 5Hospital Universitario 12 de Octubre, Madrid.  APDS2 syndrome is a genetic disorder classified as a primary immunodeficiency and caused by mutations in PIK3R1 gene. Such alteration results in a dysfunctional immune system, affecting NK cells among others. Giving the lack of specialized non-toxic long-term treatments against APDS2 syndrome, we aim to develop novel strategies to uncover effective specific-therapies directed to APDS2 patients by correcting the mutation in their own cells. For this purpose, we use the CRISPR/Cas9 molecular tool to edit the genome of an APDS2-derived iPS cell line recently generated in our laboratory. According to the characteristics of the iPS cells, we utilize nucleofection as the transfection method for CRISPR/Cas9 complex internalization, which supplies a less aggressive and more reproducible gene editing technology. Finally, we use corrected APDS2-derived iPS to differentiate them into hematopoietic stem cells expressing the CD34+ marker. These hematopoietic progenitors could be also differentiated into the different types of blood cells, including NK cells. To this extent, we will be able to obtain not only normal NK cells, but also a personal source of healthy transfusable components from the APDS2 patient. As a whole, our work represents an innovative therapy that will improve current treatments, providing an exceptional and powerful tool to study APDS2 syndrome as well as personalized gene and cell therapy. Moreover, our findings could be extrapolated to the research of similar pathologies, facilitating the development of advanced targeted gene and cell therapies.                 \n  \nCO-10  HETEROZYGOUS NONSENSE CD247 MUTATIONS SHOW POTENTIALLY PATHOGENIC DOMINANT-NEGATIVE FEATURES AFFECTING TCR EXPRESSION AND FUNCTION    Briones, Alejandro C1; Megino, Rebeca F1; Marin, Ana V1; Chac\u00f3n-Arguedas, Daniel1; Chaparro, Rebeca1; Rodr\u00edguez-Sainz, Carmen2; Seoane-Reula, Elena2; Sanchez-Mateos, Paloma3; Reyburn, Hugh T4; Henrickson, Sarah5; Regueiro, Jose R1; Cardenas, Paula P1.  1Department of Immunology, Ophthalmology and ENT, Complutense University School of Medicine and 12 de Octubre Health Research Institute (i+12, Madrid); 2Inmuno-Alergia Infantil. Unidad de Inmunodeficiencias HGU Gregorio Mara\u00f1\u00f3n, Madrid; 3Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM). Laboratorio de Inmuno-Oncolog\u00eda, Madrid; 4Department of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid; 5Division of Allergy and Immunology, Children's Hospital of Philadelphia, USA.  The TCR has a single invariant homodimer (TCR\u03b6/CD247) that is essential for expression and signaling through its three ITAMs (immunoreceptor tyrosine\u2010based activation motifs). Thus, homozygous null mutations in CD247 are associated with immunodeficiency, but +/\u2013 carriers show no clinical features despite decreased surface CD3 (50% vs normal). It is unclear if carriers of CD247 variants show dominant-negative effects. We analyzed the impact of heterozygous CD247 mutations in patients with signs of immunodeficiency or autoimmunity. A 6-month-old boy with recurrent infections carried a CD247 mutation (p.Q101X) predicted to ablate the last two ITAMs. Primary T cells showed a moderate reduction of surface CD3 expression (85%, with UCHT1 MoAb) but a severe reduction of intracellular CD247 (20% with H146, an ITAM3-specific MoAb). A second patient with the same mutation, a 50-year-old woman with autoimmune alopecia, showed a similar reduction in CD3 (70%) but normal iCD247 expression (90%) and increased (400%) or normal induction of activation markers CD69 and CD25 in response to anti-CD3/CD28, respectively.  To evaluate Q101X impact in TCR expression and function, Jurkat cells (JK) and CRISPR/Cas9-edited CD247-deficient JK (ZKO), were lentivirally transduced with plasmids carrying normal CD247 or mutations ablating three (Q70X, associated to immunodeficiency), two (Q101X), or one (Q142X, ClinVar-reported) ITAM, to compare Q101X with more (Q70X) or potentially less (Q142X) severe variants. Transduction of the mutations into ZKO could not restore normal surface CD3 expression (11%, 22% and 61%, respectively), whereas in JK they reduced it (9%, 18% and 38%), and both effects occurred in an ITAM number-dependent fashion. All six transfectants showed similarly reduced CD69 induction (25-50%). Our results suggest that variant homodimers lacking ITAMs are defective for normal TCR assembly and may exert a dominant-negative effect in normal TCR expression and signaling which, in turn, may cause disease, as shown for Q70X and Q101X.    \n  \nCO-11  CANDIDIASIS MUCOCUT\u00c1NEA CR\u00d3NICA POR GANANCIA DE FUNCI\u00d3N DE STAT1: EXPERIENCIA DEL HOSPITAL UNIVERSITARIO LA PAZ  Miguel Berenguel, Laura; Cuesta Mart\u00edn De La C\u00e1mara, Ricardo; Gonz\u00e1lez Torbay, Andrea; Matas P\u00e9rez, Elisabet; Robles Marhuenda, \u00c1ngel; Bravo Garc\u00eda-Morato, Mar\u00eda; Gianelli, Carla; C\u00e1mara Hij\u00f3n, Carmen; L\u00f3pez Granados, Eduardo; Rodr\u00edguez Pena, Rebeca.  Hospital Universitario La Paz, Madrid.  El s\u00edndrome de ganancia de funci\u00f3n de STAT1 (STAT1 GOF) es una enfermedad gen\u00e9tica con penetrancia completa y expresividad cl\u00ednica muy variable, siendo la candidiasis mucocut\u00e1nea cr\u00f3nica (CMC) el fenotipo cl\u00e1sico y la presentaci\u00f3n cl\u00ednica m\u00e1s com\u00fan, frecuentemente asociada a infecciones no f\u00fangicas, distintas formas de autoinmunidad y procesos inflamatorios.  Se realiza un estudio retrospectivo de 6 pacientes de edades comprendidas entre 20 meses y 77 a\u00f1os, estudiados en el Hospital Universitario La Paz entre los a\u00f1os 2015 y 2022. Se revisan las caracter\u00edsticas epidemiol\u00f3gicas, presentaci\u00f3n cl\u00ednica y tratamientos, as\u00ed como los hallazgos inmunol\u00f3gicos y gen\u00e9ticos.  A nivel cl\u00ednico, todos los individuos presentaron candidiasis y la mitad sufri\u00f3 infecciones bacterianas de repetici\u00f3n del tracto respiratorio, dos de ellos con bronquiectasias. Las manifestaciones autoinmunes fueron variadas, desarrollando hidrosadenitis supurativa (2/6), enfermedad de Addison (1/6), hipotiroidismo autoinmune (1/6) y trombopenia autoinmune (1/6). Respecto a los tratamientos, todos han recibido antif\u00fangicos y antimicrobianos, una paciente requiere gammaglobulina inespec\u00edfica peri\u00f3dica, corticoides y metotrexato, y un paciente recibe baricitinib. Lo m\u00e1s caracter\u00edstico del estudio inmunol\u00f3gico fue la disminuci\u00f3n de linfocitos Th17 y aumento de Th1, que se observ\u00f3 en el 100% de los pacientes estudiados, as\u00ed como linfopenia en 5/6. En cuanto al estudio gen\u00e9tico, se detectaron variantes en el gen STAT1 en todos los pacientes. Mediante el ensayo de fosforilaci\u00f3n de pSTAT1, pudimos catalogarlas como variantes generadoras de ganancia de funci\u00f3n.  El s\u00edndrome STAT1 GOF es una entidad cl\u00ednica a considerar ante un paciente con candidiasis de inicio temprano, infecciones bacterianas del tracto respiratorio, manifestaciones de autoinmunidad y citopenia Th17. En nuestra experiencia, el ensayo de fosforilaci\u00f3n tiene una gran utilidad para validar el estudio gen\u00e9tico. Los tratamientos con inhibidores de la v\u00eda JAK/STAT suponen una nueva opci\u00f3n terap\u00e9utica, principalmente en pacientes con inflamaci\u00f3n y/o autoinmunidad.   \n  \nCO-12  SOMATIC GENETIC RESCUE CORRELATING WITH CLINICAL IMPROVEMENT IN A PATIENT WITH TNFRSF9 (CD137/4-1BB) DEFICIENCY.  Colobran, Roger1; Garcia-Prat, Marina2; Parra-Mart\u00ednez, Alba2; Franco-Jarava, Clara1; \u00c1lvarez De La Sierra, Daniel1; Aguil\u00f3-Cucurull, Aina1; Riviere, Jacques G.2; Martin-Nalda, Andrea2; Soler-Palacin, Pere2; Casals, Ferran3; Alsina, Laia4; Torrent, Montserrat5; Batlle-Mas\u00f3, Laura2.  1Translational Immunology Research Group, Vall d'Hebron Research Institute (VHIR). Servei d'Immunologia, Servei de Gen\u00e8tica, Hospital Universitari Vall d'Hebron (HUVH), Barcelona; 2Infection in Immunocompromised Pediatric Patients, Vall d\u2019Hebron Research Institute (VHIR). Unitat de Patologia Infecciosa i Immunodefici\u00e8ncies de Pediatria, Hospital Universitari Vall d\u2019Hebron (HUVH), Barcelona; 3Department of Genetics, Microbiology and Statistics, Universitat de Barcelona (UB); 4Clinical Immunology and Primary Immunodeficiencies Unit, Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de D\u00e9u, Barcelona; 5Paediatric Hematopoietic Transplant Unit, Hospital Santa Creu i Sant Pau, Barcelona.  Reversion mosaicism is a naturally occurring event involving spontaneous correction of a pathogenic mutation in somatic cells. TNFRSF9 (CD137/4-1BB) deficiency is a recently described inborn error of immunity (IEI) characterized by lymphocytic defects with early-onset Epstein-Barr virus (EBV)-associated lymphoma. We report a patient who at 12 years of age developed a severe EBV-associated hemophagocytic lymphohistiocytosis episode. No genetic defects were found at that time, and she underwent HSCT from an HLA identical brother with good engraftment. In the following 8 years the patient could not control the EBV, with recurrent reactivations, lymphoproliferation and EBV-associated smooth muscle tumor. Then, the patient experienced a spontaneous decrease in EBV viral load. Using wole exome sequencing (WES) we identified a novel homozygous stop-gain variant in TNFRSF9. Strikingly, the HSCT donor was also homozygous but without overt clinical symptoms (incomplete penetrance). The presence of small, unexpected peaks in Sanger sequencing of blood samples lead us to suspect a possible somatic reversion event. Using deep amplicon sequencing (a next generation sequencing approach) we confirmed the presence of two independent somatic reversion events: a second-site mutation in the same codon (leading from a STOP codon to a missense variant) and a \u201cback mutation\u201d (leading from a STOP codon to the wild-type sequencing). The revertants were specifically located at CD8-T cells (absent in neutrophils, B cells and CD4-T cells), the main cell type involved in EBV control. Single-cell RNA sequencing experiments in purified CD8 T cells are ongoing. We report the first case of reversion mosaicism in CD137 deficiency associated with clinical improvement, which may point the way to gene therapy strategies in this IEI.    \n  \nSesi\u00f3n Comunicaciones Orales 3. Inmunidad innata  CO-13  CYTOTOXIC NKG2DHI NK CELLS ACTIVATED BY CD1C+ DENDRITIC CELLS CONTRIBUTE TO PRIMARY SJ\u00d6GREN SYNDROME PATHOLOGY   S\u00e1nchez Cerrillo, Ildefonso1; Calvet Mirabent, Marta1; Triguero Martinez, Ana1; Calzada Fraile, Diego2; Delgado Ar\u00e9valo, Cristina1; Valdivia, Mariel1; Ram\u00edrez, Marta2; V\u00e1zquez De Luis, Enrique2; Bengur\u00eda Filippini, Alberto2; Moreno, Roberto2; Adrados De Llano, Mar\u00eda Magdalena1; De La Fuente Flores, Hortensia1; Tsukalov, Ilya1; Roy Vallejo, Emilia1; Ramiro, Almudena2; Iborra, Salvador2; S\u00e1nchez Madrid, Francisco1; Dopazo, Ana2; Gonzalez, Isidoro1; Casta\u00f1eda, Santos1; Mart\u00edn Gayo, Enrique3.  1Hospital Universitario La Princesa, Madrid; 2Centro Nacional de Investigaciones Cardiovasculares, Madrid; 3Universidad Aut\u00f3noma de Madrid.  Sj\u00f6gren syndrome (pSS) is characterized by pathogenic Th17 adaptative immune responses in salivary glands (SG) but the contribution of innate natural killer (NK) and dendritic cells (DC) to the pathology remains unclear.   PBMCs from 38 pSS patients and 42 healthy donors were used for phenotypical analysis by FACS. Function of NK cells from these individuals was tested by co-culture with target K562 cells. CD1c+ cDC from pSS were characterized by RNA-seq analysis and by functional co-culture assays with autologous NK cells. Expression of ligands for NK cell receptors on cDC was analyzed basally and after stimulation with poly I:C in the presence of siRNAs specific for RIG-I/DDX60. Finally, influence of NK cell enrichment in pathogenic adaptative Th17 cells in the SG and impact of anti-NK1.1-depleting antibody was determined in a mouse SS model.   Enriched proportions of transitional CD16+ CD56hi NK cells characterized by increased expression of NKG2D (p<0.0001), IFNg and TNFa (p=0.01) and high cytotoxic activity were found in pSS. In addition, we detected significantly basal higher expression (p<0.0001) of the activating NKG2D ligand MICab on CD1c+ cDC from pSS, which exhibited transcriptional signatures enriched on RIG-I/DDX60 and IFN target genes. Such CD1c+ cDC phenotype was associated with higher ability to activate cytotoxic NK cells ex vivo. Importantly, expression of MICab was efficiently induced on cDCs from pSS after stimulation with poly I:C and was dependent on RIG-I, DDX60. Importantly, transitional NK cells NKG2Dhi and CD1c+ cDC expressing higher levels of NKG2D ligand were also detected in vivo in the SG of mice injected with poly I:C and NK cell depletion was associated with reduced levels of IL-17 cells in this tissue.    \n  \nOur study suggests and active role of NK cells during pSS pathology and provides novel mechanisms of activation mediated by DC that could represent future therapeutic targets.                                                      \n  \nCO-14  NON-REDUNDANT ROLE OF NF-KB AND INFLAMMASOME SENSORS DRIVING PATHOGENIC DIFFERENTIATION AND ACTIVATION OF MONOCYTES IN RESPONSE TO DISTINCT SARS-COV-2 COMPONENTS  Tsukalov, Ilya1; S\u00e1nchez Cerillo, Ildefonso2; Rajas, Olga3; Avalos, Elena3; Iturricastillo, Gorane3; Buz\u00f3n, Mar\u00eda Jos\u00e94; Genesc\u00e0, Maritxell4; Esparcia, Laura2; Popova, Olga2; Delgado Arevalo, Cristina2; Calvet Mirabent, Marta2; De La Fuente, Hortensia2; Mart\u00edn C\u00f3freces, Noa2; De Los Santos, Ignacio2; Mu\u00f1oz Calleja, Ceclia2; Alfranca, Arantzazu2; Calzada, Mar\u00eda Jos\u00e92; Gonz\u00e1lez Alvaro, Isidoro5; Ancochea, Julio3; S\u00e1nchez Madrid, Francisco2; Mart\u00edn Gayo, Enrique2.  1Universidad Aut\u00f3noma de Madrid; 2Servicio de Inmunolog\u00eda, Hospital Universitario de La Princesa, Madrid; 3Servicio de Neumolog\u00eda, Hospital Universitario de La Princesa, Madrid; 4Val d'Hebron Institut de Recerca, Barcelona; 5Servicio de Reumatolog\u00eda, Hospital Universitario de La Princesa, Madrid.  Background: Inflammatory CD16+CD14+ transitional and CD16HiCD14lo non-classical monocytes (Mo) associate with severe COVID-19. Previous studies suggest that Mo exposed to SARS-CoV-2 Spike protein might induce the activation of the inflammasome. However, specific innate sensors mediating the activation or differentiation of Mo in response to different SARS-CoV-2 components remain poorly characterized. Methods: Mo from healthy donors (n=15) were stimulated with SARS-CoV-2 peptide pools of Spike protein-1 (S1), Receptor Binding Protein (RBD), Nucleocapsid protein (NP). Differentiation of Mo subsets and activation were assessed by FACS analysis of CD14, CD16, CD40 and CD86 and IL-1 b was evaluated in culture supernatants. Experiments were sometimes performed in the presence of specific inhibitors for NF-kB/Caspase1 (Parthenolide), NLRP3 (MCC950), caspase 1,5,9 (Z-WEHD-FMK) or siRNAs targeting NLRP3, NLRP1, NLRC4. Bronchoalveolar lavage (BAL;n=13) paired blood samples (n=8) from severe COVID-19 patients were included in some experiments. Finally, functionality of Mo stimulated with SARS-CoV-2 components was analyzed by in vitro co-cultures with isolated allogenic T cells from healthy donors. Pathogenic CD4+ T cells were identified by expression of IL-4, IL-17, IFN-g. Results: SARS-CoV-2 S1 but not NP and RBD induced Mo differentiation into transitional and non-classical subsets, however all components induced IL1-b secretion. Interestingly, differentiation of Mo from peripheral blood and COVID-19 BAL into these subsets was observed exclusively in response to S1 and was dependent on NF-kB activation, while the NLRP3 inflammasome was required for the induction of CD86+ classical Mo in response to S1. In contrast, NLRC4 and NLRP3 regulated CD86 upregulation in Mo after stimulation with RBD and NP. Such activation/differentiation patterns were associated with differential abilities  \n  \nof Mo primed with S1, RBD and NP to induce pathogenic IFNg+IL-4+ CD4+ T-cells in vitro. Conclusion: Distinct SARS-CoV-2 components differentially mediate activation, subset generation and functional activity of Mo and could represent new targets against COVID-19 pathology.                                                 \n  \nCO-15  GM-CSF PROGRAMS HEMATOPOIETIC STEM AND PROGENITOR CELLS DURING CANDIDA ALBICANS VACCINATION FOR PROTECTION AGAINST REINFECTION  Bono Tapp, Cristina; Guerrero, Paula; Erades, Ana; Gil, Mar\u00eda Luisa; Y\u00e1\u00f1ez, Alberto.  Universitat de Val\u00e8ncia.  Trained immunity is defined as the adaptation of the innate immune system to mount a faster and greater response against a secondary challenge. We previously demonstrated that this concept can be applied not only to mature myeloid cells, but also to hematopoietic stem and progenitor cells (HSPCs), making them important players in fighting against infection.  In this work, we have studied the mechanisms that drive trained immunity in HSPCs during a primary infection with a low-virulence, non-germinative strain of Candida albicans (PCA2) that causes a mild infection and confers protection from a lethal reinfection with a virulent C. albicans strain.  In order to characterize transcriptomic changes in specific HSPC subsets during the PCA2 infection, we performed scRNA-seq of Lin\u2013 c-Kit+ cells isolated from the bone marrow of non-infected mice, the bone marrow of 24-h PCA2-infected mice, the bone marrow and spleen of 7-day PCA2-infected mice, and the bone marrow and spleen of mice reinfected with a virulent strain of C. albicans for 24 h. These analyses showed changes in biological pathways involved in the generation of trained immunity, in the activation of an emergency myelopoiesis response, and in immune cell responses against infections, such as regulation of cytokine production. In fact, we found that, upon reinfection, HSPCs are trained to produce greater amounts of proinflammatory cytokines. In addition, by performing adoptive transfer experiments, we showed that PCA2-trained HSPCs contribute to protection against reinfection. Finally, blocking GM-CSF demonstrated its involvement in HSPC training and in the protection induced by PCA2 infection. Overall, these findings reveal a fundamental role for HSPCs in the protective response provided by trained immunity. Mechanistically, autocrine GM-CSF activation of HSPCs is responsible for the trained phenotype and essential for the PCA2-induced protection.  Funding: RTI2018-093426-B-100 (Ministerio de Ciencia, Innovaci\u00f3n y Universidades, Spain and European Fund for Regional Development).    \n  \n CO-16  REGULATION OF MACROPHAGE FUNCTION BY AN IFNAR-ISG15-MITOCHONDRIAL AXIS  Dunphy, Gillian; Ad\u00e1n Barrientos, Irene; Fern\u00e1ndez Delgado, Irene; Villarroya Beltri, Carolina; Curtabbi, Andrea; Heras Murillo, Ignacio; Jarit Cabanillas, Aitor; S\u00e1nchez \u00c1lvarez, Miguel; Del Pozo, Miguel \u00c1ngel; Antonio Enr\u00edquez, Jos\u00e9; S\u00e1nchez Madrid, Francisco; Sancho, David.  Centro Nacional de Investigaciones Cardiovasculares, Madrid.  Type I Interferons (IFN-I) are multi-functional cytokines required for the initiation, but also the resolution, of many immune responses. IFN-I bind to their receptor (IFNAR) leading to activation of IFN Stimulated Genes (ISGs) and immune modulation. Upon stimulation of bone marrow-derived macrophages with STING/MAVS agonists, which strongly induce IFN-I, we observed a decrease in mitochondrial membrane potential (MMP). The decrease in MMP was also observed with recombinant IFN-I but not with other pattern recognition receptor agonists. This effect of IFN-I relied on IFNAR signalling and the ubiquitin-like protein ISG15, which has been previously been found to modify several mitochondrial proteins. One effect of the IFN-I induced decrease in MMP was an increase in efferocytosis by BMDMs and peritoneal macrophages, dependent on ISG15. In vivo, ISG15-deficient mice showed decreased clearance of apoptotic thymocytes upon dexamethasone administration, indicating decreased efferocytosis. Decreased MMP also lead to activation of the mitochondrial protease OMA1 and the induction of mitochondrial fission, decreasing the contact sites between the mitochondria and the Endoplasmic Reticulum, signalling hubs known as Mitochondrial Associated Membranes (MAMs). Preventing mitochondrial fission or the decrease in MAMs, using ISG15-deficient or OMA1-deficient cells, enhanced ISG induction upon IFN-I stimulation without affecting the primary response to STING stimulation. These data indicate that IFNAR-ISG15 signalling can modulate key macrophage functions, promoting the resolution of inflammation.                \n  \nCO-17  DIRECT TLR2 SIGNALING THROUGH MTOR AND TBK1 INDUCES C/EBP\u0392 AND IRF7-DEPENDENT MACROPHAGE DIFFERENTIATION IN HEMATOPOIETIC STEM AND PROGENITOR CELLS    Bono, Cristina; Guerrero, Paula; Erades, Ana; Y\u00e1\u00f1ez, Alberto; Gil, Mar\u00eda Luisa.  Universitat de Val\u00e8ncia, Burjasot.  During an infection, hematopoiesis is altered to increase the output of mature myeloid cells to fight off the pathogen. Despite convincing evidence that hematopoietic stem and progenitor cells (HSPCs) can sense pathogens directly, more mechanistic studies are needed to reveal whether pattern recognition receptor (PRR) signaling initiates myeloid development directly, or indirectly through the production of cytokines by HSPCs that can act in an autocrine/paracrine manner, or by a combination of both direct and indirect mechanisms. In this study, we have used an in vitro model of murine HSPCs to study myeloid differentiation in response to the TLR2 ligand Pam3CSK4 and showed that, besides indirect mechanisms, TLR2 stimulation of HSPCs promotes myelopoiesis directly by initiating a MyD88-dependent signaling. This direct differentiation program involves a combined activation of the transcription factors PU.1, C/EBP\u03b2 and IRF7 driven by TBK1 and PI3K/mTOR. Notably, downstream of MyD88, the activated TBK1 kinase can activate mTOR directly and IRF7 induction is mediated by both TBK1 and mTOR. TLR2 signaling also induces NF-\u03baB dependent IL-6 production that may further induce indirect myeloid differentiation. Our results have identified the direct signaling pathways and the transcription factors involved in macrophage development from HSPCs in response to TLR2 engagement, a critical process to trigger a rapid immune response during infection. This study defines the mechanism by which direct macrophage differentiation is induce upon microbial sensing by HSPCs. Understanding the biology of emergency myelopoiesis induced by TLRs may aid in devising new therapeutic strategies to treat infections and hematologic diseases. TLR2-activated pathways could be targeted to boost innate immune replenishment during infection and to induce the terminal differentiation of myeloid leukemic cells. Funding: RTI2018-093426-B-100 (Ministerio de Ciencia, Innovaci\u00f3n y Universidades, Spain and European Fund for Regional Development).          \n  \nCO-18  OXYGEN-INDEPENDENT REGULATION OF HIF-1\u0391 IN ILC3S AMELIORATES THE INFLAMMATION OF C. RODENTIUM-INDUCED COLITIS  Valle-Noguera, Ana1; G\u00f3mez-S\u00e1nchez, Mar\u00eda Jos\u00e91; Ochoa-Ramos, Anne1; Yag\u00fce Fern\u00e1ndez, Patricia2; Soler Palacios, Blanca3; Zorita, Virginia4; Braposo Ponce, Berta5; Gonz\u00e1lez-Granado, Jos\u00e9 Mar\u00eda6; Aragon\u00e9s, Juli\u00e1n7; Cruz-Adalia, Aranzazu1.  1Universidad Complutense de Madrid, Madrid; 2Centro de Investigaciones Biol\u00f3gicas Margarita Salas, Madrid; 3Centro Nacional De Biotecnolog\u00eda, Madrid; 4Centro Nacional de Investigaciones Cardiovasculares, Madrid; 5Centro de Biolog\u00eda Molecular Severo Ochoa, Madrid; 6Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre, Madrid; 7Hospital Santa Cristina, Fundaci\u00f3n de Investigaci\u00f3n Hospital de la Princesa, Madrid.  Innate lymphoid cells type 3 (ILC3) are tissue-resident immune cells that are fundamental in maintaining mucosal integrity and protecting against extracellular infections, particularly in the gut. ILC3s primarily act by secreting IL-22 and IL-17, but the cellular and molecular processes that control them need to be better characterized. This is especially significant when it comes to understanding colitis, which is defined by an imbalance in the connection between the host, their microbiota, and immune system. According to a new research, hypoxia can modulate the activity of intestinal ILC3s via stabilizing hypoxia-inducible factor (HIF-1 a a) in a post-translational manner. This molecular mechanism, however, needs further validation in vivo using more specific transgenic knock out mice to evaluate its functional significance during the development of infectious colitis. In this research, we identified a new molecular pathway that modulates HIF-1a transcriptionally in ILC3s after Citrobacter rodentium infection. We assessed the response to this infection in novel transgenic mice designed for specific HIF-1\u03b1 gene inactivation in ILC3s (RAG-1KO HIF-1afl/fl RortCre). Mice showed a more severe colitis after C. rodentium infection than control mice due to the inability to upregulate IL-22. Moreover, colon explants from these transgenic mice revealed that IL-18, produced most likely by the activation of Toll Like Receptors, is the cytokine responsible for the IL-22 secretion through HIF-1a in ILC3s. Importantly, sorted ILC3s activated ex vivo with IL-18 and IL-23 induced the transcription of HIF-1a and IL-22, but not IL-17. Our findings show for the first time that C. rodentium can modulate transcriptionally HIF-1a in ILC3s, promoting the secretion of IL-22 upon IL-18 stimulation, opening up new research pathways in the field of infectious colitis and the molecular regulation of these cells.   \n  \n                                 \n \n  \nSesi\u00f3n Comunicaciones Orales 4. Inmunoterapia   CO-19  ANTIBODY AND T-CELL MEDIATED IMMUNE RESPONSES INDUCED BY CD19 CHIMERIC ANTIGEN RECEPTOR (ARI-0001) IN RELAPSED/REFRACTORY PATIENTS WITH CD19 POSITIVE B-CELL MALIGNANCIES  Bartol\u00f3 - Ibars, Ariadna1; Gonz\u00e1lez-Navarro, Europa Azucena2; Klein - Gonz\u00e1lez, Nela3; Casanovas-Albert\u00ed, Berta3; Ortiz- Maldonado, Valent\u00edn2; Torrebadell, Montserrat4; Espa\u00f1ol-Rego, Marta2; Castell\u00e0, Maria2; Ben\u00edtez, Daniel2; Cabez\u00f3n, Raquel2; Esteve, Jordi2; Yag\u00fce, Jordi2; Pascal, Mariona2; Urbano-Ispizua, \u00c1lvaro2; Rives, Susana4; Delgado, Julio2; Juan, Manel2.  1Fundaci\u00f3 Cl\u00ednic per la Recerca Biom\u00e8dica, Barcelona; 2Hospital Cl\u00ednic de Barcelona, Barcelona; 3Instituto de Investigaciones Biom\u00e9dicas August Pi i Sunyer, Barcelona; 4Hospital Sant Joan de D\u00e9u, Barcelona.  Background: ARI-0001 cells express a second-generation CAR that combines the anti-CD19 single-chain variable fragment (scFv) originated from A3B1, a murine monoclonal antibody, conjugated with the transmembrane and co-stimulatory domains. The Spanish Agency of Medicine has approved under hospital exemption this treatment for patients with actue lymphoblastic leukemia (ALL) older than 25 of age.  Although the efficacy and safety has been demonstrated, it has been poorly investigated the relevance of the immunogenicity induced by CAR-T19 cells.  Methods: Regarding humoral response, the detection of human anti-murine antibodies (HAMA) in patients' sera was assessed by a cell-based fluorescence assay. Afterwards, a cytotoxicity assay was performed to study the effect of HAMA on the CART-cell function. To study the cellular response, possible HLA-specific CAR19 immunogenic peptides were predicted in silico. These peptides were used to assess the presence of reactive T cells (peptide specific) in patients.  Results: Twenty out of 47 patients (42.5%) tested positive for the presence of anti-CAR antibodies after a year of the first or second infusion. Despite the fact that 42.5% had anti-CAR antibodies, only some of these patients' HAMA positive had neutralizing effect on ARI-0001 cells in vitro. Concerning cellular immune response, a set of 103 prioritized immunogenic peptides specific for HLA patients derived from scFv and CAR19 domains (68 HLA-I peptides and 35 HLA-II peptides) were chosen for assessing the T-cell activation. It has been observed a T-cell activation (IFNg secretion).   \n  \nConclusions: These data suggest that our CAR19 induces humoral and cellular immune responses. On the one hand, anti-CAR antibodies had been detected in 42,5% of patients. Moreover, these antibodies had a neutralizing effect on ARI-0001 cells. On the other hand, it has been detected reactive T-cell against HLA-specific CAR19 peptides. Thus, immunogenicity induced by ARI-0001 cells could be clinically important, specially before considering a second infusion.                                              \n  \nCO-20  PROGRESS TOWARDS A PATIENT-SPECIFIC MONOCLONAL ANTIBODY IN S\u00c9ZARY SYNDROME Herrero Alonso, Marta1; Mar\u00edn Mar\u00edn, Ana V.1; Fernandez Megino, Rebeca1; Chac\u00f3n Argueras, Daniel1; Vi\u00f1uela Mart\u00edn, Marcos2; Subiza, Jose Luis3; Regueiro, Jose R1.  1Department of Immunology, Ophthalmology and ENT, Complutense University School of Medicine and 12 de Octubre Health Research Institute (i+12), Madrid; 2Clinical Immunology-Experimental and Surgery Department, Hospital Cl\u00ednico Universitario San Carlos, Madrid; 3Inmunotek, Alcal\u00e1 de Henares.  S\u00e9zary Syndrome (SS) is an aggressive ultra-rare leukemic form of cutaneous T-cell lymphoma characterized by circulating malignant CD4 T lymphocytes (SS cells). Patients with SS have poor prognosis and current treatments show high rates of relapse. Thus, there is an unmet need for an efficient treatment. SS cells have unique clonal potentially targetable surface epitopes, including its TCR, which we aim to generate specific mouse monoclonal antibodies (mAbs) against SS cells.  SS patient primary sorted SS (tumoral) and non-SS (healthy) T cells using CD4 and PD-1 were expanded in vitro using different immortalization procedures, such as exposure to HTLV-I, HVS or irradiated allogeneic feeder cells (PBMC and EBV-B cells from different donors). Non-SS cells were stained with deep red cell tracker and mixed 1:1 with SS cells for mAb reactivity screening by flow cytometry. Mice were immunized with SS cells and Ab producing hybridomas were generated by fusion of splenic mice with immortal myeloma cells (SP2)  We showed that in vitro expanded SS cell lines recapitulate the clonal malignant TCR by PCR and Western blot. Regarding mAbs, a total of 203 hybridomas were obtained after fusion and two hybridomas (M5F8 and M9A9) consistently recognized immortalized SS slightly better than non-SS T cells, in comparison to an anti-CD3 hybridoma (Leu-4) as positive control. We are currently cloning the hybridomas and characterizing their specificity.  In conclusion, we have generated two mAbs specific for SS cells that could become patient-specific reagents to treat SS.       \n  \nCO-21  IDENTIFYING SARS-COV-2 'MEMORY' NK CELLS FROM COVID-19 CONVALESCENT DONORS FOR ADOPTIVE CELL THERAPY (RELEASE)  Herrera, Lara1; Martin-Inaraja, Myriam1; Santos, Silvia1; Ingl\u00e9s-Ferr\u00e1ndiz, Marta1; Azkarate, Aida1; Bur\u00f3n, Maria1; P\u00e9rez-Vaquero, Miguel \u00c1ngel1; Vesga, Miguel \u00c1ngel1; Vicario, Jose Luis2; Soria, Bernat3; Solano, Carlos4; De Paz, Raquel5; Marcos, Antonio5; Ferreras, Cristina6; P\u00e9rez-M\u00e1rtinez, Antonio6; Eguizabal, Cristina1.  1CVTTH-IIS Biocruces-Bizkaia, Galdakao; 2Centro de Transfusi\u00f3n de la Comunidad de Madrid, Madrid; 3ISABIAL, Alicante; 4Hospital Cl\u00ednico Universitario de Valencia, Valencia; 5Hospital la Paz, Madrid; 6Hospital la Paz-Idipaz, Madrid.  COVID-19 disease is the manifestation of syndrome coronavirus 2 (SARS-CoV-2) infection, which is causing a worldwide pandemic. This disease can lead to multiple and different symptoms, being lymphopenia associated with severity one of the most persistent. Natural killer cells (NK cells) are part of the innate immune system, and play a key role fighting against virus-infected cells. Unlike T lymphocytes, NK cells are not known for their specific memory population. Nevertheless, studies regarding NK cell population in other viral infections, such as cytomegalovirus, have shown specific memory population of these cells. These NK cells are particularly re-activated when facing viral-specific peptides. In this study, we determined the phenotype of NK cells after COVID-19 and the main characteristic of SARS-CoV-2-specific-like NK population in the blood of convalescent donors. CD57+ NKG2C+ phenotype in SARS-CoV-2 convalescent donors indicates the presence of 'memory'/activated NK cells as it has been shown for cytomegalovirus infections. Moreover, this \u201cmemory\u201d population responds to the presence of SARS-CoV-2 peptides. Although the existence of this population is donor dependent, its expression may be crucial for the specific response against SARS-CoV-2. As a result, it gives us a tool for selecting the best donors to produce off-the-shelf living drug for cell therapy to treat COVID-19 patients under the RELEASE clinical trial (NCT04578210). NK cells from selected donors\u2019 have been isolated, frozen and storage. NK cell arm of RELEASE phase 1 clinical trial has been initiated in several patients.               \n  \nCO-22  DEVELOPING CAR-NK CELLS ON NK-92 CELLS STABLY TRANSFECTED WITH CD16  Giraldos, David; Reina, Chantal; Sancho, Nuria; Marzo, Isabel; Naval, Javier; Anel, Alberto.  Universidad de Zaragoza, Zaragoza.  Natural Killer (NK) cells are a promising adoptive cellular therapy against cancer due to their ability to lyse infected or transformed cells in an antigen\u2010independent manner. Human allogenic NK cells produced from healthy donor peripheral blood cells should be expanded and activated with specific feeder cell and cytokines to become a viable treatment, generating expanded NK cells (eNK). Previous results from our research group showed a moderate cytotoxicity effect of eNK cells over several Multiple Myeloma (MM) cell lines, which could be increased combining the eNK cells with the anti\u2010CD38 monoclonal antibody Daratumumab, approved for use in MM patients. However, there\u2019s often a noteworthy variability between each series of experiments because of the donor\u2019s genetic background. To avoid that variability, we chose the highly cytotoxic cell line NK\u201092 as a more stable model. However, NK\u201092 cells are unable to induce Antibody Dependent Cell Cytotoxicity (ADCC) since these cells do not express CD16. We transduced NK\u201092 cells with the high affinity CD16 variant and a fluorescent reporter using lentiviral supernatant. The new cell line obtained, NK\u201092\u2010CD16, showed more cytotoxicity alone and especially in combination with Daratumumab than both parental cells and eNK cells. In order to maximize their cytotoxic potential and clinical use, we decided to transfect these NK\u201092\u2010CD16 cells with an anti\u2010SLAMF7 chimeric antigen receptor (CAR). Although CAR expression and stability has been achieved, CAR-NK-92-CD16 cells did not display greater cytotoxicity than NK-92-CD16 at least in vitro, although they could have a better targeting potential in vivo. In addition, since NK-92 cells should be irradiated for its clinical use, we also checked if irradiation impaired their functionality.                 \n  \nCO-24  DEVELOPMENT OF NEW TOLEROGENIC PEPTIDE-BASED VACCINE FOR RHEUMATOID ARTHRITIS  Romero Castillo, Laura1; Urbonaviciute, Vilma1; Xu, Bingze2; Holmdahl, Rikard2.  1Karolinska Institutet, Estocolomo; 2Karolinska Institutet, Estocolmo.  Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease, characterized by inflammation of peripheral joints and bone destruction due to synovial tissue infiltration with immune cells, secretion of proinflammatory cytokines, and matrix metalloproteinases. Interestingly, around the onset of the disease, autoantibodies against citrullinated proteins cross-react with joint proteins, such as type II collagen (Col2). Currently, the medical treatment of established RA is the neutralization of inflammatory mediators such as TNF\u03b1. However, these treatments remain problematic, largely because of their lack of immune specificity and side-effects. Hence, there is a need for the development of more specific, safer, and more effective therapeutic interventions targeting the initiating immune mechanisms. The genetic association of RA with certain MHC class II (MHCII) alleles indicate T cells as central players and, consequently, an important target for therapeutic intervention in the disease. We suggest a tolerogenic peptide-based vaccination as a new therapeutic option for the prevention of RA and, possibly, treatment of early/established disease. In this sense, we have previously shown that modulation of Col2-reactive T cells by vaccination with soluble mouse MHCII molecules in complex with the glycosylated Col2 peptide 259-273 efficiently prevents collagen-induced arthritis (CIA), as well as also therapeutically cures the disease. Our current focus is to develop vaccines based on human MHCII molecules, improve them and investigating the mechanism of the vaccine induce tolerance, through our unique humanized mouse strains that will provide new opportunities to develop an effective vaccine against RA in humans.  \n  \n                               \n \n  \nSesi\u00f3n Comunicaciones Orales 5. Miscel\u00e1nea (Inflamaci\u00f3n / Alergias y reacciones de hipersensibilidad / Inmunidad anti-tumoral)  CO-25  SPECIFIC CELLULAR REGULATION OF LAMIN A/C IN IMMUNE AND STROMA CELLS AS A THERAPEUTIC TARGET FOR INFLAMMATORY BOWEL DISEASE  G\u00f3mez Bris, Raquel1; Herrero Fern\u00e1ndez, Beatriz1; S\u00e1nchez Mart\u00ednez, H\u00e9ctor2; Moran De Bustos, Sara2; Moreno Aperribay, Irene2; Amor\u00f3s, Marta3; Del Monte, Alberto3; Andr\u00e9s, Vicente3; Criado, Gabriel2; Usategui, Alicia2; Pablos Alvarez, Jose Luis2; Saez, \u00c1ngela4; Gonz\u00e1lez Granado, Jos\u00e9 Mar\u00eda2.  1Universidad Aut\u00f3noma de Madrid, Madrid; 2Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12), Madrid; 3Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid; 4Universidad Francisco de Vitoria (UFV), Madrid.  The maintenance of intestinal homeostasis is crucial to prevent the development of inflammatory bowel disease (IBD). It has been shown that gut homeostasis strictly depends on the interplay between several cell types including immune and non-immune cells. However, the mechanism of action of intestinal homeostasis-regulating cells remains largely unknown. Here, we explore the specific role of several of these immune cells and stroma cells by regulating the levels of lamin A/C, a structural, epigenetic, and transcriptional regulator, in a mouse model of IBD with dextran sulfate sodium salt (DSS). DSS-colitis development was measured in mice that lack of lamin A/C (Lmna-/-) in all immune cells (Vav1-Cre), T cells (CD4-Cre), some myeloid cells (LysM-Cre), and stroma cells (Col1a2-Cre) or in mice overexpressing lamin A/C in T cells (Lmna++/++ CD4-Cre). Mice were exposed to one or two cycles of DSS to preferably stimulate innate or adaptive immunity, respectively. Our experiments show that, in comparison to wild-type mice (Lmna+/+), the absence of lamin A/C in T cells, in myeloid cells, or stroma cells upon one dose of DSS protects from colitis. The protection appears to be more accentuated when mice that lack lamin A/C in T cells are exposed to two doses of DSS, hence, highlighting the key role of lamin A/C in the adaptive immunity in colitis. In accordance, lamin A/C overexpression in T cells provokes much more colitis upon two doses of DSS.  The lack of lamin A/C in all immune cells protects from colitis upon one or two doses of DSS. In conclusion, lamin A/C levels in immune cells and stroma cells seems to be important in colitis evolution: its absence protects against colitis while its overexpression worsen the disease, converting lamin A/C regulation in certain immune cells in a potential therapeutic target.    \n  \nCO-26  FINDING IMMUNOLOGICAL DIFFERENCES TO HELP DIAGNOSIS AND EARLY TREATMENT OF KAWASAKI DISEASE AND MIS-C (MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN)  Kennedy-Batalla, Rebeca1; Fern\u00e1ndez-Cooke, Elisa2; Aracil-Santos, Javier3; Saavedra, Jes\u00fas4; Garc\u00eda-Salido, Alberto5; G\u00f3mez, Manuel Jos\u00e96; Albendea-G\u00f3mez, Teresa7; Escobar, Beatriz7; Cano-Nieto, Miguel \u00c1ngel1; Mesa, Sof\u00eda8; Ruiz-Dom\u00ednguez, Jose Antonio9; Gonz\u00e1lez, Felipe4; Mart\u00edn-Puig, Silvia7; Correa-Rocha, Rafael1.  1Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM), Madrid; 2Unidad de Infectolog\u00eda Pedi\u00e1trica. Hospital Universitario 12 de Octubre, Madrid; 3Enfermedades Infecciosas Pedi\u00e1tricas. Hospital Universitario La Paz, Madrid; 4Pediatr\u00eda. Hospital Universitario Gregorio Mara\u00f1\u00f3n, Madrid; 5Fundaci\u00f3n de Investigaci\u00f3n Biom\u00e9dica Hospital Infantil Universitario Ni\u00f1o Jes\u00fas, Madrid; 6Unidad de Bioinform\u00e1tica. Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid; 7Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid; 8Unidad de Urgencias de Pediatr\u00eda. Hospital Universitario 12 de Octubre, Madrid; 9Servicio de Urgencias Pedi\u00e1tricas. Hospital Universitario La Paz, Madrid.  The recent COVID-19 pandemic was first thought to spare children from health deprivation caused by infection with SARS-CoV-2. However, soon a new syndrome resembling Kawasaki Disease (KD) was reported: Multisystem Inflammatory Syndrome in Children (MIS-C). The aim of this study is to provide new biomarkers for both diseases in order to facilitate diagnosis and reduce the time-lapse until treatment is provided \u2013 which will reduce the risk of developing severe cardiovascular complications. An extensive immune system characterization by flow cytometry and serum protein characterization by a multiplex technology (Olink) was performed from fresh blood samples of patients with acute MIS-C (n=19) and KD (n=10). For protein characterization we also analysed recovery samples for these groups (n=19 and n=8, respectively). Besides the already described lymphopenia in MIS-C, we found additional significant immune differences in both groups. Although lymphocyte numbers (cells/ml) were lower in MIS-C, percentages of activated T-CD4+ and T-CD8+ cells were higher compared to KD. Moreover, when comparing activated T cells in MIS-C and KD individually, regulatory T cells (Treg) showed the highest levels. These data suggest a stronger response of T cells in MIS-C, and higher Treg activity in both groups, which could reflect the response to the excessive inflammation. Ratios previously described in other inflammatory conditions were evaluated: MIS-C showed higher neutrophil/lymphocyte and Th17/Treg ratios than KD, suggesting higher inflammatory conditions in this group. In addition, monocyte and dendritic cells (DCs) numbers were decreased in MIS-C relative to KD. Parallel to these inflammatory cellular profiles, we identified increased levels of inflammatory cytokines in plasma of patients during the acute phase of the disease compared to recovery samples. Moreover, IL-6, which is one of the main  \n  \ncytokines involved in cytokine storm in adult COVID-19, was higher in MIS-C suggesting, again, stronger inflammatory conditions in this pathology compared to KD.                                                      \n  \nCO-27  PD-1 SE EXPRESA EN GR\u00c1NULOS CITOT\u00d3XICOS DE LAS C\u00c9LULAS NK Y SE MOVILIZA R\u00c1PIDAMENTE A LA MEMBRANA CELULAR TRAS EL RECONOCIMIENTO DE UNA C\u00c9LULA TUMORAL  Pesini, Cecilia1; Hidalgo, Sandra1; Arias, Maykel1; Santiago, Llipsy1; Aguilar, Yurena2; Ocariz-D\u00edez, Maitane3; Isla, Dolores4; Lanuza, Pilar1; Agust\u00edn, M Jos\u00e92; G\u00e1lvez, Eva5; Ramirez, Ariel1; Pardo, Juli\u00e1n1.  1Instituto de Investigaci\u00f3n Sanitaria de Arag\u00f3n, Zaragoza; 2Hospital Universitario Miguel Servet, Zaragoza; 3Hospital Cl\u00ednico Univesitario Lozano Blesa, Zaragoza; 4Hospital Cl\u00ednico Universitario Lozano Blesa, Zaragoza; 5CSIC - Instituto de Carboqu\u00edmica (ICB), Zaragoza.  La contribuci\u00f3n de PD-1 a la regulaci\u00f3n de la actividad de las c\u00e9lulas NK es un tema controvertido, con resultados ambiguos en cuanto a su expresi\u00f3n y papel en la modulaci\u00f3n de su actividad anti-tumoral. Nuestro estudio presenta nuevas evidencias sobre el mecanismo implicado en la regulaci\u00f3n de la expresi\u00f3n de PD-1 en la membrana de las c\u00e9lulas NK y sus consecuencias funcionales durante la eliminaci\u00f3n de c\u00e9lulas tumorales. A diferencia de las c\u00e9lulas NK de pacientes con c\u00e1ncer, las de donantes sanos no expresan PD-1 en la membrana celular. Sin embargo, al incubar estas \u00faltimas con c\u00e9lulas tumorales, aumenta la expresi\u00f3n de PD-1 en membrana, al mismo tiempo que se produce la movilizaci\u00f3n de CD107a a la superficie. Este hallazgo sugiere la movilizaci\u00f3n de PD-1 a la membrana celular durante la degranulaci\u00f3n de las c\u00e9lulas NK tras el contacto con c\u00e9lulas diana. De hecho, observamos presencia de PD-1 citos\u00f3lico en c\u00e9lulas NK reci\u00e9n aisladas de donantes sanos, y que este colocaliza con CD107a y granzima B, indicando que PD-1 se expresa en los gr\u00e1nulos citot\u00f3xicos y se moviliza a la membrana tras el reconocimiento de la c\u00e9lula diana. La movilizaci\u00f3n de PD-1 a la membrana reduce significativamente la actividad antitumoral de las c\u00e9lulas NK frente a c\u00e9lulas tumorales que expresan PD-L1 in vitro e in vivo, revirti\u00e9ndose parcialmente con anticuerpos bloqueantes de PD-1. Estos resultados indican que c\u00e9lulas NK de individuos sanos expresan PD-1 asociado a gr\u00e1nulos citot\u00f3xicos, moviliz\u00e1ndose r\u00e1pidamente a la membrana celular despu\u00e9s de la interacci\u00f3n con las c\u00e9lulas diana tumorales. Este nuevo hallazgo ayuda a comprender c\u00f3mo se regula la expresi\u00f3n de PD-1 en la membrana de las c\u00e9lulas NK y las consecuencias funcionales durante la eliminaci\u00f3n de las c\u00e9lulas tumorales, lo que ayudar\u00e1 a dise\u00f1ar inmunoterapias contra el c\u00e1ncer basadas en c\u00e9lulas NK m\u00e1s           \n  \nCO-28  DEFICIENCY OF SHP1 IN MYELOID CELLS PROMOTES TUMOR GROWTH.    Gal\u00e1n, Miguel1; Hern\u00e1ndez-Garc\u00eda, Elena2; J Cueto, Francisco1; Redondo-Urzainqui, Ana2; K. Wculek, Stefanie1; Heras-Murillo, Ignacio1; Iborra, Salvador2; Sancho, David1.  1Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain., Madrid; 2Department of Immunology, Ophthalmology and ENT. School of Medicine, Universidad Complutense de Madrid, 28040, Spain., Madrid.  Introduction:  Tyrosine kinases and phosphatases mediate the phosphorylation state of proteins and control cell homeostasis. Although the phosphoprotein tyrosine phosphatase SHP1 acts as an immune checkpoint in CD8+T cells, its pharmacological inhibition has no effect against tumor development in clinical trials, suggesting that SHP1 may play opposing roles in different cells in the tumor microenvironment. Here we assessed the effect of depleting SHP1 in CD11c+ cells in the anti-tumoral response. Methods:  We subcutaneously inoculated different tumors in CD11cCre SHP1flox mice (CD11c\u2206SHP1). Tumor growth was assessed and immune infiltrates were analysed by flow cytometry. To dissect the specific role of SHP1 in conventional type 1 (cDC1s) and type 2 (cDC2) dendritic cells, we adoptively transferred cDC1s or cDC2s from WT or CD11c\u2206SHP1 mice loaded with tumour lysates containing OVA to WT mice. Then, lymph node cells were restimulated with OVA257-264 or OVA323-339 peptides to reveal the CD8 and CD4 OVA-specific T cell response, respectively. Also, we depleted macrophages by clodronate liposome injection into WT or SHP1KO mice, and monitored the effect in tumor growth.  Results:  B16 tumors grew similarly in WT and CD11c\u2206SHP1 mice, but the immune cell infiltrates were reduced in CD11c\u2206SHP1 mice. Cancer-bearing CD11c\u2206SHP1 mice showed an impaired rejection of highly immunogenic tumours and a deficient response to PD1 blockade immunotherapy of MC38 tumors, compared with WT mice. However, vaccination with SHP-1-deficient cDCs induced normal or even increased cross-priming of OVA-specific IFN-\u03b3+ CD8+ T cells. Notably, depletion of macrophages with clodronate-liposomes reverted the deficient rejection of MC38 tumors treated with anti-PD1 in CD11c\u2206SHP1 mice. Conclusion:  Our results show that SHP1 depletion in CD11c+ cells impairs anti-tumor immunity and suggest that CD11c+ macrophages, rather than cDCs, are responsible for this effect   \n  \nCO-29  BACTERIA EXPRESSING TUMOR ANTIGENS CAN TRAIN CD4+ LYMPHOCYTES FOR AN EFFECTIVE AND SPECIFIC ANTITUMOR IMMUNOTHERAPY    Del Campo Mil\u00e1n, Lara1; Rom\u00e1n Camacho, Eduardo1; Garc\u00eda-Ferreras, Raquel2; M\u00e9ndez-P\u00e9rez, Almudena1; G\u00f3mez-S\u00e1nchez, Maria Jose3; Veiga, Esteban1.  1Centro Nacional de Biotecnolog\u00eda-CSIC, Madrid; 2Centro Nacional de Biotecnolog\u00eda, Madrid; 3Departamento de Inmunolog\u00eda, Facultad de Medicina, Universidad Complutense de Madrid, Madrid.  Transphagocytosis has been described by our group as a mechanism by which conventional CD4+ T lymphocytes can capture and kill bacteria from previously infected dendritic cells. Bacteria capture \u201ctrains\u201d CD4+ T cells (from now on bacteria trained T cells; BacT) that acquired novel abilities as antigen presenting cells. BacT cross-present bacterial antigens to na\u00efve CD8+ T cells, triggering a potent and specific cytotoxic response, with great perspectives for being furtherly used as a cancer immunotherapeutic resource 1,2. In the present work we aimed to evaluate the efficacy of BacT cell immunotherapy in a model of mouse melanoma. We genetically engineered different strains of recombinant Listeria Monocytogenes (L.) by using the integrative plasmid vector pPL2, to express antigens from B16-F10 mouse melanoma, or OVA. Hence, Listeria-TRP2 express TRP2, a well-known antigen expressed in murine and human melanomas 3. Listeria-NeoAg express a tandem of 5 previously described immunoactive neoantigens 4. Listeria-OVA was also used as a tumor non-specific control. Melanoma tumors were implanted by subcutaneous injection of 400K B16-F10 cells per mouse. Tumor growth was monitored daily for 13 days post inoculation. Mice were weighed every two days and inspected for health, ulcers, and survival every day. Animals that met humane end point criteria were euthanized and the deaths recorded for the survival curve analysis. Mouse spleen na\u00efve CD4+ cells were isolated and trained with either Listeria-OVA, Listeria-TRP2 or Listeria-NeoAg. BacT CD4+ cells, were then isolated by density gradient centrifugation and freezed until intravenous injection once the tumor has been formed (around day 6 after tumor implantation). Treatment with either bactT-TRP2, bacT-NeoAg or a mixture of both, significantly retarded tumor growth compared with bactT-OVA group, and extended lifespan by 26%.         \n  \nSesi\u00f3n Comunicaciones Orales 6. Autoinmunidad  CO-31  DIFFERENTIAL EFFECTS OF ANTI-TNF\u0391 AND ANTI-\u03914\u03927 DRUGS ON CIRCULATING DENDRITIC CELLS MIGRATORY CAPACITY IN INFLAMMATORY BOWEL DISEASE   Soleto, Irene1; Fern\u00e1ndez-Tom\u00e9, Samuel2; Mora-Gutierrez, Irene3; Baldan-Martin, Montserrat1; Ramirez, Cristina1; Santander, Cecilio1; Moreno-Monteagudo, Jose Andr\u00e9s1; Casanova, Maria Jos\u00e91; Casals, Fernando1; Casabona, Sergio1; Becerro, Irene1; Chaparro, Maria1; Bernardo, David4; P. Gisbert, Javier1.  1Gastroenterology Unit, Hospital Universitario de La Princesa and Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS-Princesa), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Madrid; 2Departamento de Nutrici\u00f3n y Ciencia de los Alimentos, Facultad de Farmacia, Universidad Complutense de Madrid, Madrid; 3Biobanco del sistema de salud de Arag\u00f3n, Zaragoza; 4Mucosal Immunology Lab, Unidad de Exclencia Instituto de Biolog\u00eda y Gen\u00e9tica Molecular (IBGM, Universidad de Valladolid-CISC),Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedadmes Infecciones (CIBERINFEC),, Valladolid.  Inflammatory bowel disease (IBD) is a and chronic disorder that includes ulcerative colitis (UC) and Crohn\u2019s disease (CD). Both diseases show an uncontrolled intestinal immune response that generate tissue inflammation. Dendritic cells (DC) are antigen presenting cells that play a key role in the tolerogenic maintenance of the gastrointestinal mucosa. It has been reported that DC are recruited by intestinal mucosa in a CCR2 dependent manner and in IBD patients, this recruitment is more prominent than in healthy controls (HC), but the specific migration mechanism is still unknown. Here we study if anti-TNF\u03b1 and anti-\u03b14\u03b27 drugs modify the GI mucosa recruitment capacity of DC in the same manner. For that Peripheral blood mononuclear cells were obtained from 15 patients per group (HC, UC and CD active and quiescent). Then, the expression of homing markers and the circulating DC migratory capacity toward CCL2, CCL25 and MadCam1 from the different study groups were determined. Then, cells were cultured in presence of anti-TNF\u03b1 or anti-\u03b14\u03b27, hence assessing the differential effect of biological drugs (if any) over the DC subset in the different groups. Our data reveal that cDC2 (CD1c+) express more surface markers than other DC, the expression of CCR9 within this subset was expanded in both quiescent groups and integrin \u03b27 was modulated by anti-\u03b14\u03b27. CCL2 showed a clear chemoattract effect but it was not modulated by biological drugs. Anti-TNF increased the migratory capacities in almost all groups. So, we described for the first time a cDC2 subset as a potential diagnostic marker in IBD. DC from IBD patients express a different migration pattern than HC, being the expression of these molecules modulated by anti-\u03b14\u03b27. CCR9 seem to elicit a protective function over IBD. The CCR2/CCL2 recruitment mechanism is not modulated by biological drugs. Keywords: biological drugs; inflammatory bowel disease; dendritic cells.    \n  \nCO-32  CIRCULATING IMMUNE-COMPLEXES OF IGG/IGM BOUND TO B2-GLYCOPROTEIN-I ASSOCIATED WITH COMPLEMENT CONSUMPTION AND THROMBOCYTOPENIA IN ANTIPHOSPHOLIPID SYNDROME.  Naranjo, Laura1; Stojanovich, Ljudmila2; Djokovic, Aleksandra3; Andreoli, Laura4; Tincani, Angela4; Ma\u015bli\u0144ska, Maria5; Sciascia, Savino6; Infantino, Maria7; Garcinu\u00f1o, Sara1; Kostyra-Grabczak, Kinga5; Manfredi, Mariangela7; Regola, Francesca4; Stanisavljevic, Natasa2; Milanovic, Milomir2; Saponjski, Jovica8; Roccatello, Dario6; Cecchi, Irene6; Radin, Massimo6; Benucci, Maurizio9; Pleguezuelo, Daniel1; Serrano, Manuel1; Shoenfeld, Yehuda10; Serrano, Antonio1.  1Immunology Department, Hospital Universitario 12 de Octubre, Madrid; 2Internal Medicine, University Hospital Center Bezanijska Kosa, Belgrado; 3Cardiology Department, University Hospital Center Bezanijska Kosa, Belgrado; 4Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili, Brescia; 5Early Arthritis Clinic, National Institute of Geriatrics, Rheumatology and Rehabilitation, Varsovia; 6Nephrology and Dialysis Unit (ERK-net Member), Center of Research of Immunopathology and Rare Diseases, San Giovanni Bosco Hospital, Tur\u00edn; 7Immunology and Allergy Laboratory, San Giovanni di Dio Hospital, Florencia; 8Cardiology Department, University Clinical Center of Serbia, Belgrado; 9Rheumatology Unit, San Giovanni di Dio Hospital, Florencia; 10Ariel University, Ariel, Israel; Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer.  Background.  Antiphospholipid syndrome (APS) is a multisystemic autoimmune disorder characterized by thrombotic events and/or gestational morbidity in patients with antiphospholipid antibodies (aPL). In a previous single-center study, APS-related clinical manifestations that were not included in the classification criteria (livedo reticularis, thrombocytopenia, leukopenia) were associated with the presence of circulating immune-complexes (CIC) formed by beta-2-glycoprotein-I (B2GP1) and anti-B2GP1 antibodies (B2-CIC). We have performed a multicenter study on APS features associated with the presence of B2-CIC.  Methods.  A multicenter, cross-sectional and observational study was conducted on 303 patients recruited from six European hospitals who fulfilled APS classification criteria. Prevalence of B2-CIC (IgG/IgM isotypes) and its association with clinical manifestations and biomarkers related to the disease activity were evaluated.   Results.  B2-CIC prevalence in APS patients was 39.3%. B2-CIC-positive patients with thrombotic APS presented a higher incidence of thrombocytopenia (OR: 2.32, p=0.007), heart valve thickening and dysfunction (OR: 9.06, p=0.015) and triple aPL positivity (OR: 1.83, p=0.027), as well as lower levels of C3, C4 and platelets (p-values: <0.001, <0.001 and 0.001) compared to B2-CIC- \n  \nnegative patients. B2-CIC of IgM isotype were significantly more prevalent in gestational than thrombotic APS.  Conclusions.  Patients with thrombotic events and positive for B2-CIC had lower platelet count and complement levels than those who were negative, suggesting a greater degree of platelet activation. B2-CIC could be a possible biomarker of disease activity in APS patients.                                              \n  \nCO-33  LOS NIVELES DE IGM FRENTE A FOSFATIDILCOLINA EN SUERO PREDICEN LA RESPUESTA AL TRATAMIENTO CON NATALIZUMAB E INTERFER\u00d3N-\u0392    S\u00e1daba Argaiz, Maria Cruz1; Escudero Lirola, Esther1; Sebal Neira, Cristina1; Urcelay Garc\u00eda, Elena2; Arroyo G\u00f3nzalez, Rafael3; Garc\u00eda Mart\u00ednez, Mar\u00eda Angel2; Quintana, Francisco J4; \u00c1lvarez Lafuente, Roberto2; Mu\u00f1oz Mor\u00f3n, \u00darsula1.  1Universidad San Pablo CEU, Madrid; 2Hospital Cl\u00ednico San Carlos, Madrid; 3Hospital Universitario Quir\u00f3nsalud, Madrid; 4Ann Romney Center for Neurologic Diseases. Brigham and Women's Hospital. Harvard Medical School, Boston.  Antecedentes: Hemos desarrollado un ELISA ultrasensible que ha demostrado que el 90% de los pacientes con esclerosis m\u00faltiple (EM) presentan IgM frente a fosfatidilcolina en suero (IgMPCs), siendo la t\u00e9cnica m\u00e1s sensible para el diagn\u00f3stico de la enfermedad. Los pacientes con EM son tratados con inmunosupresores, pero en un porcentaje considerable el tratamiento no es efectivo.  Objetivo: Analizar el papel de los anticuerpos IgMPCs como biomarcador de respuesta al tratamiento. Materiales: Muestras pareadas de suero de 95 pacientes con EM obtenidas antes y despu\u00e9s de 6 meses de tratamiento. Los pacientes fueron clasificados en respondedores, si no hab\u00eda nuevos brotes ni aumento de la discapacidad, y en no respondedores cuando no se cumpl\u00edan esos criterios. Resultados: Los niveles de IgMPC en suero antes de comenzar el tratamiento con natalizumab fueron significativamente mayores en los pacientes que posteriormente respond\u00edan a este f\u00e1rmaco (0.618\u00b10.065) que en los que no respond\u00edan al mismo (0.327\u00b10.054; p=0.020). El 93% de los pacientes en cuartil 4 respond\u00edan al tratamiento con natalizumab. Los niveles de IgMPC en suero aumentaban despu\u00e9s de seis meses de tratamiento con interferon-\u03b2 en los pacientes que no respond\u00edan a este f\u00e1rmaco (23.72% \u00b1 15.95%), por el contrario, los pacientes que respond\u00edan a interfer\u00f3n-\u03b2 mostraron un descenso significativo de la concentraci\u00f3n de IgMPC en suero (-26.63 \u00b1 8.95; p=0.007). Un 84,6% de los pacientes que respond\u00edan al tratamiento con interferon-beta mostraron disminuci\u00f3n de estos anticuerpos. En s\u00f3lo un 27,3% de los pacientes que no respond\u00edan al tratamiento se observ\u00f3 disminuci\u00f3n de IgMPC en suero. Conclusiones: Los niveles de IgMPC antes de comenzar el tratamiento son un biomarcador de respuesta al natalizumab y el descenso de los niveles de IgMPC tras seis meses de tratamiento son un biomarcador de respuesta al interfer\u00f3n-\u03b2      \n  \nCO-34  CHARACTERIZATION OF THE INTERACTION OF THE AUTOIMMUNE REGULATOR (AIRE) WITH THE E3-UBIQUITIN LIGASES SIAH1 AND SIAH2     Tirado Herranz, Adri\u00e1n1; Pastor Moreno, Alba2; Area Navarro, Mar\u00eda2; Marcilla, Miguel3; Paradela, Alberto3; \u00c1lvarez, I\u00f1aki2.  1Hospital Cl\u00ednic / Institut de Biotecnologia i Biomedicina, Barcelona; 2Institut de Biotecnologia i Biomedicina, Cerdanyola del Vall\u00e8s; 3Centro Nacional de Biotecnolog\u00eda, Madrid.  The Central Tolerance is a process based on the elimination of autoreactive thymocytes in the thymus. To generate a non-reactive T cell repertoire is necessary the expression of, ideally, the whole proteome of the organism by the medullary thymic epithelial cells (mTECs). The Autoimmune Regulator (AIRE) is expressed in mTECs. It leads the ectopic expression of a wide set of tissue restricted antigens (TRAs) to avoid the eggression of potentially autoreactive T cells to the peripheral tissues and thus produce autoimmune responses. AIRE is a multi-domain protein has been involved in different activities: regulation of the expression machinery, RNA processing, maturation and differentiation of mTECs, apoptosis and cell cycle regulation. AIRE also acts reading epigenetics marks, leading to the expression of specific genes. Previous findings of our group showed differences in the proteome between WT and AIRE-transfected epithelial cells. AIRE-transfected cells showed increased levels of pro-apoptotic proteins and chaperones and lower amounts of some cytoskeleton-interacting proteins. One increased protein was Calcyclin-binding protein/SIAH1 interacting protein (CACYBP/SIP), an adaptor protein involved in ubiquitination. The Seven in Absentia Homologue (SIAH) E3-ubiquitin ligase family is involved in proteasome-mediated degradation. It contains 2 active members, SIAH1 and SIAH2, that have shared and specific targets. SIAH1 is expressed in response to genotoxic damage or apoptotic signals, while SIAH2 is increased under hypoxia conditions. SIAH-interacting proteins contain a consensus motif (PxAxVxP) present in CACYBP/SIP and AIRE. These data suggest that AIRE interacts with SIAH through this motif. Here, we studied the impact of AIRE transfection on the proteome of HEK-293 cells. The results confirmed the increase of CACYBP/SIP in HEK-293. AIRE interacts with both active members of SIAH through the so-called SIAH1-interacting motif. This interaction may define a new role for AIRE as a member of a degradation complex including SIAH, or may describe an AIRE-degradation pathway.        \n  \nCO-35  THYROID FOLLICULAR CELLS CAN MODULATE T CELL FUNCTION AND PHENOTYPE IN MIXED AUTOLOGOUS CULTURES; IMPLICATIONS FOR THYROID AUTOIMMUNE DISEASES  \u00c1lvarez De La Sierra, Daniel1; G\u00f3mez, Aroa2; Bello, Irene2; Iglesias, Carmela2; Petit, Anna3; Gonz\u00e1lez, \u00d3scar2; Moreno, Pablo3; Zaf\u00f3n, Carlos2; Pujol, Ricardo2.  1Vall d'Hebron Research Institute (VHIR), Barcelona; 2Hospital Universitario Vall d'Hebron (HUVH), Barcelona; 3Hospital Universitario de Bellvitge (HUB), Barcelona.  PD-L1 expression by parenchymal cells have been proposed as an important mechanism of peripheral tolerance that is utilized by neoplastic cells to escape anti-tumoral immune response, this being under intense investigation; however, but much less attention has been paid to its role in common autoimmune diseases.  PD-L1 expression by thyroid follicular cells (TFCs) in glands from patients with Hashimoto Thyroiditis (HT) and Graves\u2019 disease (GD) was previously reported by our group. Similar findings were simultaneously reported in islet beta cells from human and mouse diabetic pancreas. Interestingly, PD-L1 expression by TFC from autoimmune glands is, however, much less intense that HLA class II \u201cectopic\u201d expression in autoimmune glands in vivo, but arises spontaneously in TFC as plated in culture and is increased by IFN-gamma, this pointing to PD-L1 in vivo inhibition. In order to better understand PD-L1 expression regulation, autologous mixed TFC-PBMC cultures have been set using samples from Graves` disease and multinodular goiter (MNG) patients, and cadaveric organ donors. In this setting, TFCs have been shown to suppress CD3/CD28 induced T cell proliferation at different culture ratios. Additional experiments using transwell demonstrated that the observed effect was contact dependant. Unexpectedly, T cell proliferation inhibition produced by TFCs was not mediated by PD-L1/PD-1 axis signaling, as treatment of mixed cultures with Nivolumab, a blocking antibody against PD-1, had no effect on T cell proliferation.  In order to identify possible immunecheckpoint ligands and other mediators expressed by TFCs or other parenchymatous thyroid cells, single cell RNA-seq (scRNA-seq) was performed on 5 GD and 4 MNG thyroid patients previously depleted of CD45+ cells. Additional negative immunecheckpoints has been identified in TFCs from GD and MNG thyroids, including IDO1, CD276 (B7-H3), PVR or NECTIN2. Further experiments must be done to assess their role in the regulation of immune responses when expressed by TFCs.       \n  \nCO-36  ROLE OF POLYREACTIVE AUTOANTIBODIES IN SJ\u00d6GREN'S SYNDROME  Guti\u00e9rrez-C\u00f3zar, Rebeca; S\u00e1ez Moya, Manuel; Pu\u00f1et-Ortiz, Joan; Angulo, Ana; Engel, Pablo.  Universidad de Barcelona, Barcelona.  Sj\u00f6gren\u2019s syndrome (SjS) is a chronic autoimmune disease that primarily affects exocrine glands and is characterized by the presence of anti-nuclear antibodies such as anti-dsDNA and anti-Ro52. Our analysis of the B cell repertoire of NOD.H-2h4 mice, which spontaneously develop a SjS-like disease, showed that these mice presented higher frequencies of autoreactive/polyreactive B cell clones that increase with age, as compared to B6 mice (WT-type) mice. No loss of polyreactivity was observed upon antibody class switching to IgG or somatic mutation. Moreover, strikingly, all anti-Ro52 IgG autoantibodies were polyreactive. We hypothesize that these polyreactive antibodies may play a pathogenic role. We further analyzed if anti-Ro52 antibodies were able to accelerate the disease process using a mouse model of SjS. Anti-Ro52 mouse monoclonal antibodies were injected in autoimmune MRL/lpr mice infected with mouse cytomegalovirus. Our results show that they induced increased levels of autoantibodies and salivary gland tissue damage. In conclusion, polyreactive antibodies against Ro52 induce pathogenic phenomena in susceptible mice indicting a role of these antibodies in the pathogenesis of SjS disease.                   \n  \nSesi\u00f3n Comunicaciones Orales 7. Inmunogen\u00e9tica  CO-37  UNDERSTANDING THE ETIOLOGY OF INTESTINAL IMMUNE DYSREGULATION IN A NOVEL LCK VARIANT \u2013 OF HUMAN AND MOUSE  Lui, Victor1; Hoenig, Manfred2; Schwarz, Klaus2; Hsieh, Elena1.  1University of Colorado Anschutz Medical Campus, Colorado; 2University Medical Center Ulm, Ulm.  Partial T cell defect primary immunodeficiency disorders (PIDD) are a heterogeneous group of genetic disorders characterized by incomplete reduction of T cell number and/or function. Unlike severe T cell immunodeficiencies, partial T immunodeficiencies are commonly associated with hyper-immune dysregulation, including autoimmunity and inflammatory complications. Lymphocyte cell-specific protein-tyrosine kinase (LCK) is a Src family tyrosine kinase that initiates T cell receptor (TCR) signaling. Given its role in TCR signal transduction, LCK is critical to T cell development and function.  Here we report the clinical and immunological phenotypes of a novel LCK variant which results in partial T cell defects and immune dysregulation.  A novel homozygous mutation in LCK (p.Pro440Ser, LCK P440S) was identified in two siblings who were born to consanguineous parents, presenting with recurrent viral and fungal infections, and early-onset pulmonary and gastrointestinal inflammatory complications. The immunological phenotype included T lymphopenia, impaired vaccine responses, and increased CD21lo B cells. The LCK P440S mutation results in decreased protein expression and defective TCR signaling. To address questions pertaining to T cell development and immune dysregulation, a mouse model harboring the murine homolog of this mutation was created (Lck mut mouse).  The Lck mut mouse demonstrated impaired thymocyte development with concomitant T cell lymphopenia, decreased regulatory T cells, and spontaneously developed colitis, recapitulating the human phenotype. While Lck knock-out (KO) mice replicate the T cell aberrations in Lck mut mice, Lck KO mice do not develop colitis, suggesting that partial loss of Lck function drives colitis. Our findings explain the abnormal immune system development in the human P440S patients, help advance our understanding of gastrointestinal inflammation in the context of perturbed T cell development/function arising from defective TCR signaling and establish a model system with which to develop therapies against monogenic gastrointestinal inflammation.   \n  \n CO-38  NUEVAS APROXIMACIONES EN EL DIAGN\u00d3STICO GEN\u00c9TICO DE INMUNODEFICIENCIAS PRIMARIAS: DESARROLLO DE UNA ESTRATEGIA DE AN\u00c1LISIS PARA LA EVALUACI\u00d3N DE VARIANTES DE DOSIS G\u00c9NICA MEDIANTE NGS  Matas P\u00e9rez, Elisabet; Gonz\u00e1lez Torbay, Andrea; Mori \u00c1lvarez, Maria \u00c1ngeles; Rodr\u00edguez Jim\u00e9nez, Carmen; Cuesta Mart\u00edn De La C\u00e1mara, Ricardo; Miguel Berenguel, Laura; Gianelli, Carla; C\u00e1mara Hij\u00f3n, Carmen; Rodr\u00edguez Pena, Rebeca; L\u00f3pez Granados, Eduardo; Del Pozo Mate, \u00c1ngela; Bravo Garc\u00eda-Morato, Mar\u00eda.  Hospital Universitario La Paz, Madrid.  Introducci\u00f3n: Los avances metodol\u00f3gicos en el campo de la gen\u00e9tica han permitido la descripci\u00f3n de nuevas entidades cl\u00ednicas y la ampliaci\u00f3n de fenotipos en otras ya conocidas. El siguiente reto diagn\u00f3stico consiste en la detecci\u00f3n de variantes de dosis g\u00e9nica que, hasta el momento, solo pueden ser evaluadas mediante t\u00e9cnicas cuantitativas.  Los objetivos de este trabajo son mostrar el desarrollo de una estrategia de filtrado para el an\u00e1lisis de variantes de dosis g\u00e9nica mediante NGS utilizando el programa VarSeq y comparar su sensibilidad con la estrategia de rutina y con las t\u00e9cnicas gold standard.   M\u00e9todos: Para establecer la estrategia de filtrado mediante VarSeq se recopilaron 25 muestras con deleciones conocidas, que fueron usadas para definir los par\u00e1metros del filtrado. Las 25 deleciones hab\u00edan sido detectadas por MLPA, array-CGH y/o PCR de puntos de corte. Todas ellas fueron evaluadas por la nueva estrategia dise\u00f1ada para VarSeq como por la estrategia de rutina, basada en los softwares XHMM y LACONv.  Resultados: Para el an\u00e1lisis por VarSeq se establecieron 4 grupos de filtrado atendiendo al n\u00famero de exones implicados (uno o m\u00e1s) y a la cigosidad de la deleci\u00f3n (homo/hetero-cigosis). Los par\u00e1metros de filtrado seleccionados fueron CNV-State, #Samples, #Target, Avg-Ratio y Avg-Z-Score. En la evaluaci\u00f3n de 25 muestras con deleciones conocidas, el an\u00e1lisis con VarSeq present\u00f3 mayor sensibilidad que la estrategia de rutina (95,5% vs 63,6%). Tres deleciones no fueron detectadas mediante la herramienta VarSeq, dos por encontrarse en una regi\u00f3n no capturada. Se observ\u00f3 una buena correlaci\u00f3n con las t\u00e9cnicas gold standard (Fig.1).   \n  \n Conclusiones: El an\u00e1lisis de variantes de dosis g\u00e9nica usando VarSeq mejor\u00f3 la sensibilidad de la estrategia de rutina. Su principal limitaci\u00f3n es que \u00fanicamente permite la evaluaci\u00f3n de variantes en regiones capturadas. La secuenciaci\u00f3n masiva podr\u00eda ser incorporada como una herramienta de screening de variantes de dosis g\u00e9nica pr\u00f3ximamente.  \n                         \n \n  \nCO-39  MITOCHONDRIAL COMPLEX I REGULATES ANTIGEN CROSS-PRESENTATION IN DENDRITIC CELLS  Priego, Elena1; Enamorado, Michel2; Mastrangelo, Annalaura1; Mart\u00ednez-Cano, Sarai1; Rodr\u00edguez-Silvestre, Pablo3; Garaude, Johan4; Balsa, Eduardo5; Kozik, Patrycja3; Iborra, Salvador6; Sancho, David1.  1CNIC, Madrid; 2National Institute of Allergy and Infectious Diseases, Bethesda; 3MRC Laboratory of Molecular Biology, Cambridge; 4Institut national de la sant\u00e9 et de la recherche m\u00e9dicale, Bordeaux; 5Centro de Biolog\u00eda Molecular Severo Ochoa, Madrid; 6Universidad Complutense de Madrid, Madrid.  Mitochondrial metabolism regulates the inflammatory responses induced by dendritic cells. However, how the individual mitochondrial complexes impact the immunobiology of the dendritic cells remain largely unknown. Using a mouse model deficient for mitochondrial complex I in dendritic cells, we found an impairment of antigen cross-presentation but not direct presentation. The reduced ability to cross-present antigens to CD8 T cells was not associated with perturbations in cytokine production or phagocytosis. Notably, complex I deficiency induced a reduction in oxidative phosphorylation without compromising the mitochondrial membrane potential or extracellular acidification. Mechanistically, the reduction in lipid peroxidation decreases antigen leakage out of the phagosome, limiting antigen availability for cross-presentation. Together, this work reveals how the individual mitochondrial complex activity is repurposed to shape dendritic cell immunobiology and opens new approaches to target dendritic cells in vaccine development and other immunotherapies.  \n  \n \n                              \n \n  \nCO-40  ASOCIACI\u00d3N DE LOS NONAP\u00c9PTIDOS PRESENTADOS POR HLA-E CON LA ENFERMEDAD DE BEH\u00c7ET    Casta\u00f1o N\u00fa\u00f1ez, \u00c1ngel Luis1; Montes Cano, Marco Antonio2; Garc\u00eda Lozano, Jos\u00e9 Ra\u00fal2; Mu\u00f1oz Garc\u00eda, Raquel2; Morales Garc\u00eda, Carmen2; Jurado Orozco, Alicia2; Gonz\u00e1lez Escribano, Mar\u00eda Francisca2.  1Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid; 2Hospital Universitario Virgen del Roc\u00edo, Sevilla.  Introducci\u00f3n Las mol\u00e9culas HLA clase I tienen una asociaci\u00f3n bien establecida con la enfermedad de Beh\u00e7et (EB), aunque la causa de esta asociaci\u00f3n es desconocida. HLA-E presenta un polimorfismo limitado que podr\u00eda calificarse de dim\u00f3rfico, ya que los alelos m\u00e1s comunes, HLA-E*01:01 y *01:03, representan el 99% del total. Las mol\u00e9culas HLA-E presentan un conjunto limitado de p\u00e9ptidos los cuales son nonap\u00e9ptidos derivados de la secuencia l\u00edder de las mol\u00e9culas HLA-I cl\u00e1sicas.  Objetivo Estudiar la relaci\u00f3n entre el dimorfismo al\u00e9lico de HLA-E y el conjunto de nonap\u00e9ptidos que presenta esta mol\u00e9cula con la predisposici\u00f3n a la EB.  Material y m\u00e9todos El estudio de alelos HLA-E incluy\u00f3 273 pacientes y 273 controles. Para el genotipado se utiliz\u00f3 PCR en tiempo real con sondas Taqman. El estudio de p\u00e9ptidos incluy\u00f3 a 435 pacientes y 444 controles previamente genotipados en HLA-I por PCR-SSOP, codificando muestras de acuerdo con sus secuencias de p\u00e9ptido l\u00edder HLA-A, B y C.    C\u00f3digo  P\u00e9ptido  HLA 1 VMAPRTLLL  A*01,*03,*11,*29,*30,*31,*32,*33,*36; C*02,*15  2 VMAPRTLVL  A*02,*23,*24,*25,*26,*66,*69  5 VMAPRTVLL  B*07,*08,*14,*38,*39,*42,*48  6 VTAPRTLLL  B*13,*18,*27,*37,*40,*44,*47*54,*55,*56  7 VTAPRTVLL  B*15,*35,*40,*41,*45,*46,*49,*50,*51,*52,*53,*57,*58  8 VMAPRTLIL  C*01,*03,*04,*05,*06,*08,*12,*14,*16  9 VMAPRALLL  C*07,*18    \n  \nResultados No hubo diferencias en la distribuci\u00f3n de los alelos HLA-E*01:01 y *01:03 entre pacientes y controles (*01:01: 0,54 frente a 0,52; *01:03: 0,46 frente a 0,48). El an\u00e1lisis univariante de los p\u00e9ptidos l\u00edder revel\u00f3 asociaci\u00f3n de riesgo con los p\u00e9ptidos 2 y 7, y de protecci\u00f3n con el p\u00e9ptido 5. En el an\u00e1lisis multivariante, la asociaci\u00f3n de riesgo con el p\u00e9ptido 2 se mantuvo incluso despu\u00e9s de condicionar con B51 (p<0,05, OR=1,47, 95%CI 1.05-2.06).  Conclusi\u00f3n El nonap\u00e9ptido VMAPRTLVL puede explicar la asociaci\u00f3n con la predisposici\u00f3n a padecer EB descrita en la regi\u00f3n HLA-A. La uni\u00f3n de este p\u00e9ptido a mol\u00e9culas HLA-E podr\u00eda modificar la expresi\u00f3n en la superficie de estas mol\u00e9culas e influir en la regulaci\u00f3n de la actividad citot\u00f3xica.                                      \n  \nCO-41  HEK293F CELL LINE SHOWS DIFFERENT ANTIGEN PRESENTATION FEATURES THAN HEK293  Pastor Moreno, Alba1; Area Navarro, Mar\u00eda Dolores1; Scholz, Erika1; Tirado Herranz, Adri\u00e1n1; Marcilla, Miguel2; Canals, Francesc3; Juan, Manel4; \u00c1lvarez, I\u00f1aki1.  1Immunology Unit, Department of Cell Biology, Physiology, and Immunology and Institut de Biotecnologia i Biomedicina, Universitat Aut\u00f2noma de Barcelona, Bellaterra; 2Proteomics Unit, Spanish National Biotechnology Centre, Madrid; 3Proteomics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Universitat Aut\u00f2noma de Barcelona, Barcelona; 4Servei d\u2019Immunologia, Hospital Cl\u00ednic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona.  HEK-293 is a cell line of human embryonic kidney origin with several variants deriving from these. Cells of one of these variants, known as HEK-293F, grow in suspension rather than being adherent cells, which is the case of HEK-293 cells. This is an advantage when there is a need of high number of cells in culture. Both cell lines have been used as equivalent.  We planned to use HEK-293F cells to express different variants of the SARS-CoV-2 Spike protein and to find HLA-I ligands derived from them in the corresponding immunopeptidomes. To confirm that HEK-293F and HEK-293 cells present similar HLA-I peptide repertoires, these peptidomes were purified from non-transfected cells and analyzed by mass spectrometry. The resulting peptidomes showed that there was a lack of HLA-A*03:01 ligands among the peptides from HEK293F cells, while the peptidome from HEK-293 cells contained HLA-A*03:01 peptide ligands. The analysis of the HLA-I allotypes at the cell surface confirmed that there is no expression of HLA-A*03:01 molecules in the cell membrane of HEK-293F cells. The transcriptional expression of the different HLA-I alleles presented in HEK-293 and HEK-293F was studied by qPCR. Results showed that mRNAs corresponding to HLA-A3 were detected, but the ratio HLA-A3/HLA-A2 was lower in HEK-293F cells, partially explaining the absence of HLA-A*03:01.  Some Spike-derived peptides have the features to be ligands of HLA-A*03:01, but they would be lost in HEK-293F cells.  In conclusion, HEK-293F do not have the same antigen presentation features than the parental HEK-293.      \n  \nCO-42  HLA-G EN UVE\u00cdTIS: MENOS ES M\u00c1S  Molina Alejandre, Marta1; Vaquero Yuste, Christian1; Juarez, Ignacio1; Gorro\u00f1o Echebarria, Marina Bego\u00f1a2; Molanes L\u00f3pez, Elisa Mar\u00eda3; Suarez Trujillo, Fabio1; Rodriguez Sainz, Carmen4; Fern\u00e1ndez Cruz, Eduardo4; Arnaiz Villena, Antonio1; Mart\u00edn Villa, Jos\u00e9 Manuel1.  1Dpto. de Inmunolog\u00eda, Oftalmolog\u00eda Y ORL. Facultad de Medicina. Universidad Complutense de Madrid, Madrid; 2Servicio de Oftalmolog\u00eda. Hospital Universitario Pr\u00edncipe de Asturias, Alcal\u00e1 de Henares; 3Dpto. de Estad\u00edstica e Investigaci\u00f3n Operativa. Facultad de Medicina. Universidad Complutense de Madrid, Madrid; 4Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, Madrid.  HLA-G es un gen HLA de clase I no cl\u00e1sico que codifica una mol\u00e9cula con propiedades tolerog\u00e9nicas. Su expresi\u00f3n est\u00e1 regulada, en parte, por algunos polimorfismos de la regi\u00f3n 3\u2019UTR del gen: 14bp INS/DEL, +3142C/G, +3187A/G y +3196C/G. Altos niveles de HLA-G se han correlacionado con algunos tipos de c\u00e1ncer, mientras que bajos niveles se han asociado con el riesgo a desarrollar enfermedades inflamatorias, como la uve\u00edtis. Los polimorfismos de la regi\u00f3n 3\u2019UTR y los haplotipos que forman fueron analizados en una cohorte de 149 pacientes espa\u00f1oles con uve\u00edtis idiop\u00e1tica, caracterizada por inflamaci\u00f3n de la \u00favea. Los pacientes fueron clasificados seg\u00fan criterios anat\u00f3micos (anterior, intermedia y posterior), y se compararon con 117 controles de la misma nacionalidad, para establecer una correlaci\u00f3n entre los polimorfismos y el riesgo de desarrollar uve\u00edtis.  Se obtuvieron muestras de saliva de pacientes procedentes del Servicio de Oftalmolog\u00eda del Hospital Universitario Pr\u00edncipe de Asturias (Alcal\u00e1 de Henares \u2013 Madrid) y de voluntarios sanos. Se extrajo DNA gen\u00f3mico, y se analizaron los polimorfismos mediante PCR, PCR-RFLP y secuenciaci\u00f3n de Sanger. Los datos obtenidos fueron analizados utilizando SNPStats y GraphPad Prism.  No se observaron diferencias significativas entre pacientes y controles al analizar la frecuencia de cada uno de los polimorfismos de forma individual. Sin embargo, estos polimorfismos se encuentran en desequilibrio de ligamiento, formando distintos haplotipos (D\u2019<1, p<0,05). El an\u00e1lisis de haplotipos mostr\u00f3 que el haplotipo HLA-G UTR-2, asociado a bajos niveles de HLA-G, estaba aumentado de forma significativa en pacientes en comparaci\u00f3n con los controles (29,2% vs 22,4%; OR IC (95%) = 2,1 (1,1-4,2); p = 0,037).  Estos resultados sugieren que los mecanismos que conducen a la inflamaci\u00f3n ocular en la uve\u00edtis idiop\u00e1tica est\u00e1n asociados a una baja expresi\u00f3n de HLA-G, y establecen el haplotipo UTR-2 como un nuevo marcador gen\u00e9tico de susceptibilidad a la enfermedad.  \n  \n                                      \n \n  \nSesi\u00f3n Comunicaciones Orales 8. Inmunidad frente a las infecciones  CO-43  S PROTEIN VACCINE-INDUCED IMMUNE IMPRINTING REDUCES N PROTEIN ANTIBODY RESPONSE IN SARS-COV-2 INFECTION  Delgado De La Poza, Juan Francisco1; Vidal, M\u00f3nica1; Moya, Maria Carmen2; Espasa, Mateu3; Casabella, Antonio3; Seda, Manel2; Serrano, Rosa Mar\u00eda2; Pe\u00f1a, Pilar2.  1Immunology Unit, Laboratory Service. Parc Taul\u00ed Hospital Universitari. Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT). Universitat Aut\u00f2noma de Barcelona, Departament de Medicina., Sabadell; 2Occupational Health Department. Parc Taul\u00ed Hospital Universitari. Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT). Universitat Aut\u00f2noma de Barcelona., Sabadell; 3Microbiology Unit, Laboratory Service. Parc Taul\u00ed Hospital Universitari. Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT). Universitat Aut\u00f2noma de Barcelona. Sabadell. Spain., Sabadell.  Immune imprinting or original antigenic sin (OAS) refers to the immune system's preference to activate existing memory cells when an individual encounters a new but closely related antigen rather than stimulate de novo responses to the new epitopes. According to OAS, in a second entry of the same virus, the secondary response can inhibit a primary response against new epitope antigens if the virus partially modifies its antigen.  The present study analyzes whether the memory antibody B cell response generated by mRNA vaccines against S protein can inhibit the primary antibody immune response to other SARS-CoV-2 antigens, such as nucleocapsid (N) protein. Therefore, antibody response against N protein in both healthcare workers (HCWs) infected by SARS-CoV-2 after vaccination (n=51) and non-vaccinated HCWs (n=188) was analyzed and compared.  All HCWs in the vaccinated group after infection have increased antibody titers against S protein (> 34 fold-change, p<0.001). The increase in antibody titers against the S protein observed is mainly due to the memory response induced by vaccination. Subsequently, we have analyzed the N protein antibody response in HCWs from the vaccinated group and from the non-vaccinated group to evaluate the influence of the S protein memory antibody response in another SARS-CoV-2 antigen. N protein response is greater in the HCWs from the non-vaccinated group compared to the vaccinated group: 12.2 (IQR 4.2-32.0) versus 5.7 (IQR 2.3-15.2) AU/mL, respectively. This 2.1 fold-change between groups was statistically significant, p=0.005.  Further studies are needed to elucidate whether this reduced response could also occur with the new epitopes on S protein generated by SARS-CoV-2 variants. This phenomenon should be  \n  \ntaken into account in the development of vaccines against these new variants.   In conclusion, our results show that the vaccine-induced immune imprinting against the S protein partially inhibits the response against N protein after SARS-CoV-2 infection.                                                   \n  \nCO-44  A DIFFERENTIAL SIGNATURE OF CIRCULATING MIRNAS AND CYTOKINES BETWEEN COVID-19 AND COMMUNITY-ACQUIRED PNEUMONIA UNCOVERS NOVEL PHYSIOPATHOLOGICAL MECHANISMS OF COVID-19  Mart\u00ednez Fleta, Pedro; Vera Tom\u00e9, Paula; Jim\u00e9nez Fern\u00e1ndez, Mar\u00eda; Requena, Silvia; Roy Vallejo, Emilia; Sanz Garc\u00eda, Ancor; Lozano Prieto, Marta; L\u00f3pez Sanz, Celia; Vara, Alicia; Lancho S\u00e1nchez, \u00c1ngel; Mart\u00edn Gayo, Enrique; Mu\u00f1oz Calleja, Cecilia; Alfranca, Arantzazu; Gonz\u00e1lez \u00c1lvaro, Isidoro; Galv\u00e1n Rom\u00e1n, Jos\u00e9 Mar\u00eda; Aspa, Javier; De La Fuente, Hortensia; S\u00e1nchez Madrid, Francisco.  HU de la Princesa, Madrid.  Despite enormous efforts to understand underlying etiopathogenic mechanisms of COVID-19, many of them remain elusive. The study of miRNAs as master regulators of gene expression could reveal new insights into the pathophysiology of this disease. miRNA profile was evaluated with RT-qPCR panels comprising 179 miRNAs commonly found in human plasma. The screening cohort consisted of 38 COVID-19 and 9 community-acquired pneumonia patients. Validation assays were carried out in a second cohort of 85 COVID-19 and 24 community-acquired pneumonia patients by customised PCR panels. Targets of differentially expressed microRNAs were identified via miRTarBase. Cytokines and soluble factors were measured by ELISA. Fifteen dysregulated miRNAs between COVID-19 and community-acquired pneumonia patients were detected. Additionally, multivariate analysis displayed a combination of 4 miRNAs (miR-106b-5p, miR-221-3p, miR-25-3p and miR-30a-5p) that significantly discriminated between both pathologies. The study of target molecules identified a differential plasma proteins signature between COVID-19 and community-acquired pneumonia that included EGFR, CXCL12 and IL-10. Significant differences were also detected in plasma levels of CXCL12, IL-17, TIMP-2 and IL-21R between mild and severe COVID-19 patients.  This differential profile of plasma microRNAs and soluble factors in COVID-19 versus community-acquired pneumonia highlights the implication of inflammatory pathways and vascular related processes during the clinical course of COVID-19. These findings provide new insights into the etiopathological mechanisms underlying COVID-19.  \n  \n           \n \n  \nCO-46  KIR-LIGAND POLYMORPHISM IMPROVED A MORTALITY PREDICTION MODEL INCLUDING CLINICAL DATA OF KNOWN COMORBIDITY IN PATIENTS WITH SARS-COV-2 INFECTION    Ni\u00f1o Ram\u00edrez, Jairo Eduardo; Gutierrez Zufiaurre, Maria Nieves; Marcos, Miguel; Bartol S\u00e1nchez, Mr; Eiros, Roc\u00edo; Alcoceba Sanchez, Miguel; Garc\u00eda Alvarez, Mar\u00eda; Terradillos S\u00e1nchez, Pilar; Presa, Daniel; Mu\u00f1oz, Juan Luis; L\u00f3pez Bern\u00fas, A; L\u00f3pez S\u00e1nchez, E; Gonz\u00e1lez Calle, D; S\u00e1nchez, Pedro L; Comp\u00e1n Fern\u00e1ndez, Olga; Gonz\u00e1lez, Marcos; Garc\u00eda Sanz, Ram\u00f3n; Boix, Francisco.  Hospital Universitario de Salamanca, Salamanca.  Background:  Natural Killer (NK) cells play an important role controlling the course of infections as key modulators of both innate and adaptive immune responses against viruses. Their cytotoxic activity is modulated by a series of membrane-bound receptors such as the immunoglobulin-like receptors (KIR) that trigger activating or inhibitory signals.  Aim:  The present study focused on analysing the impact of the KIR-ligand (A*03/*11, -Bw4, -Bw6, -C1, -C2) polymorphism with mortality in patients infected with SARS-CoV-2 from the University Hospital of Salamanca (n=459).  Material and methods:  Patients were grouped according to their clinical severity criteria. KIR typing of infected and healthy controls (n=667) was performed by PCR-SSOP (LIFECODES kit, Immucor\u00ae). KIR frequencies, haplotypes, centromeric and telomeric motifs, and functional combinations with ligands was calculated using IBM SPSS Statistics 26. Two predictive models were developed using the Hosmer-Lemeshow multivariate logistic regression and sensitivity and specificity from both were compared with the ROC curve analysis. A p-value <0.05 was considered statistically significant.  Results:  Mortality was the end-point of this study. The first model (M1) included hypertension, age, sex, diabetes, C-reactive protein, dyslipidemia, smoking, ferritin, and fibrinogen as clinical variable of known comorbidity in COVID-19 (AUC=0.854, p<0.0001), whereas in the second model (M2) KIR-ligand polymorphism was additionally added (AUC=0.972, p<0.0001). KIR2DL2/C1, KIR2DS2/C1 and KIR2DS3/C1 significantly impacted the progression of  \n  \npatients to a more severe infection. KIR2DL2/C1 [OR=15.2 (95% CI 1.5-147), P= 0.018] showed the strongest association with mortality in our cohort of patients.  Discussion and Conclusion:  When KIR was included into the model, it increased its sensitivity predicting a more severe infection. We believe that inclusion of KIR genotype along with clinical data in patients with COVID-19 could improve their clinical stratification, allowing a more personalised therapeutical approach. These preliminary results should be validated in multicentre studies to ascertain the model\u2019s powerfulness predicting mortality.  \n                 \n \n  \nCO-47  DIFFERENTIAL EXPRESSION OF CHEMOKINE RECEPTORS IN SARS-COV2- SPECIFIC CD4+ T LYMPHOCYTES.    Esparcia, Laura; Lancho, Angel; Ropero, Noelia; Mart\u00edn, Enrique; Martin, Noa; S\u00e1nchez Madrid, Francisco; Alfranca, Arantzazu.  Servicio de Inmunolog\u00eda, Hospital de la Princesa, Madrid.  Chemokine receptors regulate immune cell migration in many situations, including autoimmune conditions, inflammation and infectious diseases. GWAS studies have identified several genetic loci, including those for CCR9 and CXCR6, associated with worse prognosis in COVID-19 infection.  There are few studies about chemokine receptor expression in SARS CoV-2 specific immune cells, so it is very relevant to analyze this issue in deep.  Using activation-induced marker assays (AIM) we detected an increase in CCR9 and CXCR6 expression in cells activated with different pools of SARS-CoV 2 peptides. Furthermore, when cells were activated with staphylococcal enterotoxin B (SEB) (positive control), CXCR6 expression also increased but, on the contrary, CCR9 expression decreased. Chemokine receptor expression didn\u2019t change when cells were activated with actin-derived peptide pools (negative control). AIM assays with CMV peptides showed similar results as with SARS-CoV-2 peptides.  In order to rule out a general activation-dependent effect on chemokine receptor expression, we used SARS-CoV-2 class II tetramers to select specific CD4+ cells (tetramer+ cells); and found that this population selectively express higher levels of CCR9 than non-specific CD4+ lymphocytes (tetramer-).  CD4+ functional profile was assessed through the analysis of IFNg, TNFa, IL-17 and IL-4 by flow cytometry, both in tetramer+/tetramer- cells, and in CCR9+/CCR9- tetramer+ populations. Overall, cytokine profile was similar in the populations analyzed, with the exception of IL-4 and IL-17, whose levels were higher in SARS-CoV-2 specific cells. In addition, CCR9+ tetramer+ CD4+ lymphocytes showed increased frequency of IFNg+TNFa double positive cells.  In summary, there is an enrichment of CCR9+ expression in the specific SARS-CoV 2 CD4+ population, which show a pro-inflammatory profile.     \n  \nCO-48  NATURAL KILLER CELL DEGRANULATION: A DETERMINANT FACTOR IN COVID-19 EVOLUTION  Garcinu\u00f1o, Sara; Gil Etayo, Francisco Javier; Mancebo, Esther; Lopez Nevado, Marta; Lalueza, Antonio; Diaz Sim\u00f3n, Raquel; Pleguezuelo, Daniel Enrique; Serrano, Manuel; Cabrera Marante, \u00d3scar; Allende, Luis M; Paz Artal, Estela; Serrano, Antonio.  Hospital Universitario 12 de Octubre, Madrid.  Background:  NK-degranulation plays an important role in the cytotoxic activity of the innate immunity in the clearance of intracellular infections and is an important factor in the outcome of the disease. This work has studied NK-degranulation and innate immunological profile and functionality in COVID-19 patients and its association with the illness severity.  Methods:  A prospective observational study enrolling a final number of 99 COVID-19 patients was conducted. Patients were grouped according to hospital requirements and severity. Innate immunity cells subpopulations and functionality were analyzed by flow cytometry and the measurement of extracellular granzyme A and B was assessed by ELISA.  Results:  The profile and functionality of innate immunity cells differs between healthy controls and severe patients, CD56dim NK cells being increased and MAIT cells and NK-degranulation rates decreased in COVID-19 subjects. High degranulation rates were observed in non-severe patients and in healthy controls compared to severe patients. Evaluation of the extracellular granzymes showed that benign forms of the disease had a higher GranzymeA/GranzymeB ratio than those with complex forms of the disease. In a multivariate analysis, degranulation capacity resulted a protective factor against severe forms of the disease (OR: 0.86), whereas permanent expression of NKG2D in NKT cells was an independent risk factor (OR: 3.81), all of this with an AUC: 0.84.  Conclusion:  An early and efficient degranulation functionality of the innate immune cells at the early stages of the infection could be used as a tool to identify patients who will have a better evolution.  In addition, the examination of granzyme ratio in some infection diseases could be used as a potent prognostic biomarker.    \n  \nSesi\u00f3n Comunicaciones Orales 9. Trasplante  CO-49  THE IMPACT OF CD160 DEFICIENCY ON ALLOREACTIVE CD8 T CELL RESPONSES AND ALLOGRAFT REJECTION  Rodriguez Barbosa, Jose-Ignacio; Del Rio Gonzalez, Maria Luisa.  University of Leon, Leon.  CD160 is a member of the immunoglobulin superfamily with a pattern of expression mainly restricted to cytotoxic cells. To assess the functional relevance of the HVEM/ CD160 signaling pathway in allogeneic cytotoxic responses, exon 2 of the CD160 gene was targeted by CRISPR/Cas9 to generate CD160 deficient mice. Next, we evaluated the impact of CD160 deficiency in the course of an alloreactive response. To that aim, parental donor WT (wild-type) or CD160 KO (knock-out) T cells were intravenously adoptively transferred into non-irradiated semiallogeneic F1 recipients. In this setting, donor alloreactive CD160 KO CD4 T cells and CD8 T cells clonally expanded less vigorously than in WT T cell counterparts. This differential proliferative response rate at the early phase of T cell expansion influenced the course of CD8 T cell differentiation and the composition of the effector T cell pool that led to a significant decreased of the memory precursor effector cells (MPECs) / short-lived effector cells (SLECs) ratio in CD160 KO CD8 T cells compared to WT CD8 T cells. Despite these differences in T cell proliferation and differentiation, allogeneic MHC class I mismatched (bm1) skin allograft survival in CD160 KO recipients was comparable to that of WT recipients. However, the administration of CTLA-4.Ig showed an enhanced survival trend of bm1 skin allografts in CD160 KO with respect to WT recipients. Finally, CD160 deficient NK cells were as proficient as CD160 WT NK cells in rejecting allogeneic cellular allografts or MHC class I deficient tumor cells. CD160 may represent a CD28 alternative costimulatory molecule for the modulation of allogeneic CD8 T cell responses either in combination with costimulation blockade or by direct targeting of alloreactive CD8 T cells that upregulate CD160 expression in response to alloantigen stimulation        \n  \n CO-50  NK CELL TRANSCRIPTOME AND PHENOTYPICAL CHANGES AFTER AUTOLOGOUS HSCT: TRANSIENT EXPANSION OF A CD9+ DECIDUAL-LIKE NK CELL SUBSET.    Astarloa-Pando, Gabirel1; Orrantia, Ane1; Terr\u00e9n, I\u00f1igo1; Amarilla-Irusta, Ainhoa1; P\u00e9rez-Fernandez, Silvia1; Astigarraga, Itziar1; Mateos-Maz\u00f3n, Juan J.1; Garc\u00eda-Ruiz, Juan C.1; Ri\u00f1\u00f3n, Marta1; Gonz\u00e1lez, Carmen2; Uranga, Alasne2; Uriz, Jos\u00e9 J.2; Rey, Mercedes2; Carrascosa, Tom\u00e1s3; V\u00e1zquez-De Luis, Enrique4; Callejas, Sergio4; Quintas, Ana4; Dopazo, Ana4; Zenarruzabeitia, Olatz1; Borrego, Francisco1.  1Biocruces Bizkaia Health Research Institute \u2013 Cruces University Hospital, Barakaldo; 2Biodonostia Health Research Institute \u2013 Donostia University Hospital, Donostia; 3Biocruces Bizkaia Health Research Institute \u2013 Galdakao-Usansolo Hospital, Galdakao; 4Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid.  Rationale and objective:  Autologous hematopoietic stem cell transplantation (autoHSCT) is a worldwide-established treatment option for a diverse group of hematological malignancies, including multiple myeloma (MM), and for solid tumors in pediatric patients. Natural killer (NK) cells are the first lymphocyte subset to recover during immune reconstitution after transplantation. The aim of this project was to study NK cells reconstitution after autoHSCT to uncover changes in the NK cell repertoire. Patients and methods: Peripheral blood mononuclear cells from adult MM patients and pediatric patients with different solid tumors that underwent autoHSCT were studied by multiparametric flow cytometry. Samples collected before and after autoHSCT over one-year period were analyzed from each patient. Samples from MM patients were used to investigate the NK cell transcriptome using RNA-seq. Functional assays were performed to determine NK cell effector functions.   Results:  In adult patients, we found that the phenotype and gene expression profile of circulating NK cells changed shortly after autoHSCT. RNA-seq analysis revealed that several biological processes, including DNA replication and the mevalonate pathway, were enriched. In addition, we also observed that following autoHSCT, NK cells acquired a CD9+ decidual-like gene expression profile. CD9+ decidual-like NK cells exhibited lower degranulation besides higher granzyme B and perforin expression than CD9- NK cells.  RNA-seq results were validated by flow cytometry in the cohort of pediatric patients. They  \n  \nshowed altered NK cell markers repertoire following autoHSCT, characterized among others, by an expansion of the decidual-like NK cells.  Conclusion:  Transcriptome and phenotype of NK cells significantly changed after autoHSCT. There is a higher expression of markers associated with decidual-like NK cells, such as CD9. CD9+ decidual-like NK cells exhibit different effector functions.                                             \n  \n CO-51  INMUNIDAD ENTRENADA EN PACIENTES CON ENFERMEDAD RENAL CR\u00d3NICA AVANZADA (ERCA) Y EN RECEPTORES DE TRASPLANTE RENAL (RTR): NANOINMUNOTERAPIA PARA SU MODULACI\u00d3N  Chivite Lacaba, Marta1; Gonz\u00e1lez Cuadrado, Cecilia1; Berges Buxeda, Marcos J2; Almendro V\u00e1zquez, Patricia1; Caro Espada, Jara3; Gonz\u00e1lez, Esther3; Utrero Rico, Alberto4; Laguna Goya, Roc\u00edo3; Mancebo Sierra, Esther3; Andr\u00e9s, Amado3; Ochando, Jordi2; Paz Artal, Estela3.  1Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica Hospital 12 de Octubre, Madrid; 2Centro Nacional de Microbiolog\u00eda, Instituto de Salud Carlos III, Madrid; 3Hospital 12 de Octubre, Madrid; 4Icahn School of Medicine at Mount Sinai, Nueva York.  Introducci\u00f3n:  La respuesta inmune aumentada que se produce en c\u00e9lulas del sistema inmune innato sometidas a segundos est\u00edmulos es conocida como inmunidad entrenada (IE). La terapia renal sustitutiva (hemodi\u00e1lisis o di\u00e1lisis peritoneal) y/o el trasplante podr\u00edan tener un efecto de entrenamiento que podr\u00eda obstaculizar la tolerancia del trasplante. La modulaci\u00f3n de la IE mediante nanoinmunoterapia podr\u00eda mejorar la supervivencia y funcionalidad del injerto.   Objetivos:  (1) Identificar IE en pacientes dializados o RTR. (2) Evaluar IE en monocitos humanos  y en la l\u00ednea monocitaria THP-1 in vitro y analizar la eficacia de nanopart\u00edculas lipoprot\u00e9icas unidas a rapamicina (mTORi-HDL) para su posible uso en modulaci\u00f3n terap\u00e9utica de la IE.   Metodolog\u00eda:  En monocitos de pacientes dializados y RTR, tras activar con LPS, se estudiaron marcadores de inflamaci\u00f3n sugerentes de IE. La inducci\u00f3n de IE in vitro se realiz\u00f3 en monocitos circulantes de controles sanos (CS) y c\u00e9lulas THP-1 diferenciadas a macr\u00f3fagos con PMA, que se cultivaron con \u03b2-glucano (1er est\u00edmulo) y con LPS (2\u00ba est\u00edmulo), y se trataron con mTORi-HDL.   Resultados:  El trasplante no parece inducir IE, ya que monocitos de RTR no mostraron un aumento de TNF\u03b1 en relaci\u00f3n al pre-trasplante. En pacientes dializados se observ\u00f3 mayor producci\u00f3n de TNF\u03b1 en monocitos de forma proporcional al tiempo en di\u00e1lisis, en comparaci\u00f3n con los no dializados. En monocitos de CS cultivados en condiciones de entrenamiento se detect\u00f3 un tama\u00f1o celular superior, mayor expresi\u00f3n de CCR2 y CD86 y mayor producci\u00f3n de TNF\u03b1, que se redujo significativamente con mTORi-HDL de forma dosis-dependiente. El cultivo con \u03b2- \n  \nglucano (1er. est\u00edmulo) y LPS (2do. est\u00edmulo) entrenaba a los macr\u00f3fagos THP-1 asoci\u00e1ndose a una mayor producci\u00f3n de IL6 y TNF\u03b1.   Conclusiones:  La di\u00e1lisis podr\u00eda inducir IE. La nanoterapia con mTORi-HDL inhibe la inducci\u00f3n de IE in vitro en monocitos humanos.                                                \n  \nCO-52  COMPARISON OF IMMUNE RECONSTITUTION BETWEEN POST-TRANSPLANT CYCLOPHOSPHAMIDE AND CONVENTIONAL GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION   Bola\u00f1os G\u00f3mez, Jennifer1; G\u00f3mez Hernando, Martha2; Caro, Jose Luis1; Serra, Carles1; Palou, Eduard1; Queralt Salas, Mar\u00eda2; Pedraza, Alexandra2; Rovira, Monserrat2; Mart\u00ednez Mu\u00f1oz, Carmen2; Torres Canizales, Juan1.  1Transplant Immunology Section, Immunology Department, Hospital Cl\u00ednic de Barcelona, Barcelona; 2Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Hospital Cl\u00ednic de Barcelona, IDIBAPS, Barcelona.  Introduction:  Graft versus host disease (GVHD) is every day less frequent in patients with allogeneic hematopoietic cell transplantation (allo-HCT) due to prophylaxis regiment applied. Post-transplantation high-dose cyclophosphamide (PTCy) is being increasingly used for GVHD prophylaxis across various donor types. However, immune reconstitution (IR) comparison with conventional GVHD prophylaxis has not been well studied. The aim of this study is to determine how PTCy influence IR after allo-HCT and its potential impact on clinical outcomes.  Materials and methods:  100 adult diagnosed with malignant haematological diseases, treated with allo-HCT from 2018-2020 were included. Dynamics of absolute lymphocytes (ALC), monocytes cell counts (MNC), CD3+, CD8+, CD4+ were collected, and overall survival (OS), relapse, non-relapse mortality (NRM), acute and chronic GVHD were analysed during the first year after transplant.   Results:  PTCy was used in 67 patients. Main differences in the patterns of immune cell dynamics between groups were detected in the first 100 days post-transplantation (Figure 1, A and B). Patients who received PTCy had low persistent ALC at day +45 (131vs.371cells/\u00b5L, p<0.001), d+70 (447vs.641cells/\u00b5L, p<0.001), and d+90 (570vs.817 cells/\u00b5L, p>0.05), respectively. PTCy treated patients had less chronic GVHD (23%vs.45%, p=0.039) and better 1 year OS (71%vs.55%, p=0.05) without difference in the cumulated incidence of NRM or relapse (Figure1,C). Preliminary analysis showed an increase in ALC at d+30 with more NRM and. On the other hand decreased MNC at d+70 was related to lower NRM and decreased MNC at day+90 to better OS. There were no differences in CD3, CD4 or CD8 at 6, 12 and 24 months between the groups.   \n  \n Conclusions:  PTCy as GVHD prophylaxis influences peripheral lymphocyte expansion, favouring lower allorecognition, which manifests as less GVHD disease and better clinical outcomes. Analysis of early IR could provide useful information for post-transplant immunosuppressive treatment or adaptive cell therapy to optimize clinical outcomes. \n                    \n \n  \nCO-53  EVALUACI\u00d3N DEL PERFIL DE SENSIBILIDAD A F\u00c1RMACOS INMUNOSUPRESORES EN PACIENTES CON TRASPLANTE RENAL, MEDIANTE EL ENSAYO IMMUNOBIOGRAM\u00ae (IMBG) Y MARCADORES DE ACTIVACI\u00d3N LINFOCITARIA.  Gonz\u00e1lez Cuadrado, Cecilia1; Chivite Lacaba, Marta1; Almendro V\u00e1zquez, Patricia1; Ortega, Alvaro2; Diez, Teresa2; Potero, Isabel2; Andr\u00e9s, Amado3; Pascual, Julio3; Paz Artal, Estela3; Mancebo Sierra, Esther3.  1Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica Hospital 12 octubre, Madrid; 2Biohope Scientific Solutions for Human Health SL, Tres Cantos; 3Hospital Universitario 12 de Octubre, Madrid.  Introducci\u00f3n:  Immunobiogram\u00ae es un nuevo inmunoensayo farmacodin\u00e1mico in vitro que determina la sensibilidad del paciente a diferentes inmunosupresores.  Objetivos:  Analizar en trasplantados renales (TR) el IMBG y correlacionar los datos obtenidos del IMBG frente tacrolimus con marcadores de activaci\u00f3n linfocitaria medidos por citometr\u00eda de flujo (CF).  Metodolog\u00eda:  Reclutamos 30 pacientes TR estables (>1 a\u00f1o post-trasplante). En el IMBG, PBMCs aisladas y activadas con anti-CD3/CD28, se dispensan sobre hidrogeles con gradientes de concentraci\u00f3n de everolimus, tacrolimus, micofenolato o metilpednisolona. Por fluorimetr\u00eda se eval\u00faa la inhibici\u00f3n de la activaci\u00f3n linfocitaria en el gradiente, obteni\u00e9ndose par\u00e1metros de m\u00e1xima respuesta inhibitoria (RiMax) e ID25, 50, 75 (distancia al inmunosupresor donde la actividad celular es del 75%, 50% y 25%, respectivamente), valores altos determinan alta sensibilidad al inmunosupresor. Por CF se analizan los marcadores de activaci\u00f3n linfocitaria (IL-2, IFN-\u03b3), en PBMCs estimuladas con PMA/Ionomiciona, tras el tratamiento in vitro con tacrolimus.  Resultados:  En nuestra cohorte, el 13% y 26% de los pacientes resultaron poco sensibles a tacrolimus y micofenolato (en el punto de RiMax), respectivamente. La metilprednisolona fue el inmunosupresor con mayor tasa de sensibilidad con solo 1 paciente (3%) con baja inhibici\u00f3n en el punto de RiMax y valores de ID25/50/75 m\u00e1s altos que el resto de inmunosupresores. La sensibilidad a tacrolimus, everolimus y metilprednisolona correlacion\u00f3 positivamente. El tratamiento con tacrolimus disminuy\u00f3 significativamente el porcentaje de linfocitos  \n  \nCD4+IL2+, IFN\u03b3+ e IL2+IFN\u03b3+ (p<0.01), evaluado por CF. La correlaci\u00f3n entre los par\u00e1metros del IMBG y el fold change de la producci\u00f3n de IL-2 e IFN-\u03b3 tras el tratamiento con tacrolimus fue variable.  Conclusiones:  Es posible cuantificar la sensibilidad de cada paciente a la terapia inmunosupresora mediante el IMBG y la CF. El IMBG parece recapitular mejor la sensibilidad global de cada paciente a tacrolimus en comparaci\u00f3n con la citometr\u00eda de flujo.                                           \n  \nCO-54  MODULATION OF THE INNATE IMMUNE RESPONSE IN TRASPLANTATION BY TARGETED DELIVERY OF MYCOPHENOLIC ACID BY MUSSEL-INSPIRED NANOPARTICLES  Nieto Jim\u00e9nez, Celia1; Vega Moreno, Milena A.2; Mart\u00edn Del Valle, Eva M.2; Del R\u00edo, Mar\u00eda Luisa3; Rodr\u00edguez Barbosa, Jos\u00e9 Ignacio1.  1Section of Transplant Immunobiology and Immunotherapy, Institute of Molecular Biology, Genomics and Proteomics, University of Leon, Le\u00f3n; 2Chemical Engineering Department, Faculty of Chemical Sciences, University of Salamanca, Salamanca; 3Section of Transplant Immunobiology and Immunotherapy, Institute of Molecular Biology, Genomics and Proteomics, University of Leon, Salamanca.  Today, effective prevention of acute transplant rejection is possible thanks to the development of efficacious immunosuppressive agents (IAs). However, prevention of transplant rejection in the long-term is more complicated because IAs must be chronically administered, causing undesirable side effects that may lead to the gradual deterioration of the transplanted organ.  In this scenario, the novel use of targeted polydopamine nanoparticles (PDA NPs) transporting mycophenolic acid (MPA) has been assessed with the purpose of improving the efficacy while reducing the side effects of MPA. Taking advantage of the observation that myeloid innate cells avidly uptake foreign NPs, these phagocytic cells were targeted with 190 nm-in size PDA NPs, which were synthesized, characterized, and loaded with MPA (12-18 \u00b5g/mg NP) and an anti-CD11b receptor antibody (11-12 \u00b5g/mg NP).  According to our findings, MPA release profile from the developed nanosystem was sustained overtime and pH-dependent, which could be of interest as it may prevent early MPA release from PDA NPs in the systemic circulation. Besides, as demonstrated by confocal microscopy, NP uptake by myeloid cells (specifically by a mouse macrophage cell line (J774.A1)) was enhanced by the incorporation of the anti-CD11b antibody to the PDA NPs. Moreover, conjugated PDA NPs reduced in vitro the viability of J774.A1 cells and primary peritoneal macrophages in a dose-dependent manner (to 26.5-2% after 72h exposure).   Finally, in vivo, intraperitoneal administration of safe doses of both, naked and loaded PDA NPs, increased the absolute number of T cells, B1 and B2 cells, and granulocytes in this cavity, thus promoting an inflammation process that could enhance phagocytic cell targeting.  Thereby, based on these preliminary results, ongoing work is being performed to further evaluate the immunosuppressive activity of the developed nanosystem, which could represent  \n  \nan innovative tool to modulate the innate immune response for the prevention of allograft rejection.                                               \n  \nSesi\u00f3n Comunicaciones Orales 10. Vacunas  CO-55  MESOPOROUS SILICON MICROPARTICLES (MSMPS) ENHANCE CELLULAR AND HUMORAL IMMUNE RESPONSE TO SARS-COV-2   L\u00f3pez G\u00f3mez, Ana1; Real Ar\u00e9valo, Irene1; Mayol Hornero, Elsa1; Ju\u00e1rez, Ignacio1; Mart\u00edn Adrados, Beatriz1; Gonz\u00e1lez Garc\u00eda, Raquel1; Mart\u00edn Palma, Ra\u00fal2; Mart\u00ednez Naves, Eduardo1; G\u00f3mez Del Moral, Manuel3.  1Universidad Complutense de Madrid, Departamento de inmunolog\u00eda, Facultad de Medicina, Madrid; 2Universidad Aut\u00f3noma de Madrid, Departamento de F\u00edsica Aplicada, Facultad de Ciencias, Madrid; 3Universidad Complutense de Madrid, Departamento de Biolog\u00eda Celular, Facultad de Medicina, Madrid.  Objectives Mesoporous silicon Microparticles (MSMPs) show a high immunostimulatory capacity, which makes them potential adjuvants. The high transmissibility and mortality of Covid-19 have led to the development of different vaccines. Even though, the vaccine challenge is still present and research to find new adjuvants is essential. This project studies the immunostimulatory capacity of MSMPs against SARS-CoV-2 on human PBMCs and BALB/c mice. Methods Activation of human PBMCs was analyzed after stimulation with and without MSMPs conjugated with a pool of Spike-peptides, measured as IFN\u03b3 production by flow cytometry (FCM). The humoral and cellular immune response was analyzed in Spike (RBD) SARS-CoV-2 immunized mice, with and without MSMPs. Humoral response (IgG, IgG1, IgG2a) and neutralizing (ACE2-RBD) antibodies was studied by competitive ELISA assay and cellular response was measured as IFN\u03b3 production and memory B cells (CD19+ CD27+ CD138-) phenotyping in splenocytes by FCM In addition, we study how MSMPs stimulate innate immune cells such as neutrophils, dendritic cells and macrophages in human and mice. Results. In vitro we observed that IFN\u03b3 production is higher in PBMCs stimulated with MSMPs-Spike-peptides (6.36 p\u02c20.05) and this increase is greater when PBMCs are co-cultured with dendritic cells, previously stimulated with MSMPs- Spike-peptides (16.2 p\u02c20.05). In vivo, we observed that MSMPs-Spike immunized mice show a greater humoral response IgG, IgG1 and IgG2a (8.12; 2.71; 3.98 p\u02c20.05) than mice immunized exclusively with Spike (0.71;  \n  \n0.89; 1.55 p\u02c20.05). Also, we observed higher neutralization (70% p\u02c20.05) and a higher correlation (=0.067 p\u02c20.0001) between IgG and neutralizing antibodies in MSMPs-Spike mice. In addition, these mice have a better cellular response and a higher percentage of memory B cells. Conclusion. The results show that MSMPs, conjugated with spike, can generate a better humoral and cellular response than isolated antigen. This suggests that MSMPs could be used as adjuvants.    \n               \n \n  \nCO-56  PREDICTIVE FACTORS OF THE MAGNITUDE AND LOSS OF ANTI-S ANTIBODY TITERS AFTER TWO DOSES OF BNT162B2 VACCINE IN OLDER PEOPLE: AN EIGHT MONTHS FOLLOW-UP    Pozo Balado, Mar\u00eda Del Mar1; Bulnes Ramos, \u00c1ngel1; Garrido Rodr\u00edguez, Vanesa1; Olivas Fern\u00e1ndez, Israel1; Lozano, Carmen2; \u00c1lvarez R\u00edos, Ana Isabel2; Gonz\u00e1lez Gonz\u00e1lez, Berta2; Lara, Jos\u00e9 Manuel2; Maldonado Calzado, Isabel2; S\u00e1nchez Bejarano, Encarnaci\u00f3n2; Santamar\u00eda, Juan Antonio3; Gonz\u00e1lez Escribano, Mar\u00eda Francisca2; Leal, Manuel4; Pacheco, Yolanda M.1.  1Instituto de Biomedicina de Sevilla, HUVR, Sevilla; 2Hospital Universitario Virgen del Roc\u00edo, Sevilla; 3Residencia Hogar de la Santa Caridad, Sevilla; 4Hospital Viamed Santa \u00c1ngela de la Cruz/Hogar Residencia de la Santa Caridad, Sevilla.   Older adults achieve lower antibody titers than younger populations after Covid-19 vaccination, showing a marked waning of humoral immunity over time, likely due to immunosenescence.  We aimede to identify age-related factors potentially associated to the magnitude of the response to the Covid-19 vaccine in older people, as well as predictive factors of the loss of anti-S antibody titers after the second dose of vaccine.   Residents and health workers from the \u201cSanta Caridad Elderly Home\u201d receiving two doses of BNT162b2 were recruited (n=143). Blood samples were collected one month (T1) after the second dose, and four and eight months later (T4 and T8, respectively). IgG-antibodies against trimeric SARS-CoV-2 Spike protein were quantified by chemiluminescence (LIAISON\u00aeSARS-CoV-2 TrimericS IgG), considering seroconversion \u226533.8 BAU/mL. At T1, inflammatory markers and immune cellular subsets were determined by standard procedures. We also quantified telomere relative length (TRL) and ratio \u03b4/\u03b2 TREC on peripheral mononuclear cells by digital PCR and serum \u03b11-thymosin levels by ELISA.  Participants were subdivided into three groups: Young <50 years-old (n=41) (38[30-44]; 24.4% men), Middle-Age 50-65 years (n=31) (61[54-64]; 55.8% men) and Elderly \u226565 years (n=71) (77[71-82]; 100% men). Although all participants seroconverted at T1, antibody titers were significantly lower in Elderly than in Young (Figure 1A). Age, homocysteine, \u03b2-2 microglobulin, D-dimers, and percentages of NK cells negatively correlated with anti-S titers at T1, while CD3, CD4, CD8, B cells, lymphocytes and \u03b4/\u03b2 TREC positively correlated (Fig.1B). Elderly also experienced a significantly higher decrease at short-term (T1-T4) (percentage of loss 75[67-82] vs. 69[59-72] respectively; p=0.011) (Fig.1C). Levels of \u03b11-thymosin negatively  \n  \ncorrelated with the loss of anti-S titers at both short- and long-term (Fig.1B).   Vaccination protocols including \u03b11-thymosin as adjuvant could improve the durability of the humoral response to the Covid-19 vaccine in older people, possibly increasing the time between booster doses \n        \n \n  \nCO-57  INMUNOTERAPIA INDUCIDA POR LA VACUNA MV130 EN UN MODELO EXPERIMENTAL DE NEUMON\u00cdA NEUMOC\u00d3CICA  Arrabal Sierra, Alejandro1; Rodr\u00edguez, Mercedes1; Ru\u00edz, Carolina1; Prado, M. Carmen2; Cortegano, Isabel1; Conejero, Laura3; Ferrandiz, Mar\u00eda Jos\u00e94; G. De La Campa, Adela4; Subiza, Jos\u00e9 Luis3; Gaspar, Mar\u00eda Luisa1; De Andr\u00e9s, Bel\u00e9n1.  1Laboratorio de Inmunobiolog\u00eda - Centro Nacional de Microbiolog\u00eda - Instituto de Salud Carlos III, Majadahonda; 2Unidad de Citometr\u00eda de Flujo - Centro Nacional de Microbiolog\u00eda - Instituto de Salud Carlos III, Majadahonda; 3Inmunotek, Alcal\u00e1 de Henares; 4Laboratorio de Gen\u00e9tica Bacteriana - Centro Nacional de Microbiolog\u00eda - Instituto de Salud Carlos III, Majadahonda.  Streptococcus pneumoniae (SPN) causa infecciones respiratorias con una creciente resistencia a antibi\u00f3ticos. Existen varias vacunas antineumoc\u00f3cicas aunque su efectividad es nula frente a serotipos no incluidos en su formulaci\u00f3n. El objetivo de este estudio ha sido la respuesta inmunitaria y protecci\u00f3n que genera la vacuna bacteriana de mucosas MV130 (Inmunotek) en un modelo experimental de rat\u00f3n. MV130 induce inmunidad entrenada y est\u00e1 compuesta por una mezcla de bacterias enteras inactivadas que incluye un 60% de SPN de 9 serotipos distintos (1, 3, 5, 6B, 9V, 14, 19F, 20, 23F).  Ratones C57BL6/J recibieron tres dosis de MV130 durante dos semanas intranasalmente y tras una semana de descanso, se infectaron con una dosis sub\u00f3ptima de SPN serotipo 3. A los tres d\u00edas se sacrificaron y analizaron los pulmones para cuantificar y fenotipar diferentes poblaciones inmunitarias y el contenido de citoquinas. Los animales tratados con MV130 e infectados con SPN: a) sobreviven m\u00e1s (curvas de Kaplan-Meier, p<0,01); b) pierden menos peso; c) presentan un incremento en el reclutamiento de neutr\u00f3filos y de monocitos cl\u00e1sicos respecto a no cl\u00e1sicos (ratios de 2,2 en MV130 y de 1,1 en no tratados); d) tienen una mayor proporci\u00f3n de c\u00e9lulas dendr\u00edticas derivadas de monocitos respecto a macr\u00f3fagos derivados de monocitos (ratios de 3,7 en MV130 y 1,6 en no tratados); e) hay una mayor concentraci\u00f3n de quimioquinas y citoquinas: CXCL1, CCL2 e IFN\u03b3 y menores niveles de IL1\u03b2 y TNF\u03b1 en los pulmones de los animales vacunados e infectados, comparado con los controles infectados, favoreciendo el reclutamiento temprano de las c\u00e9lulas mieloides en el pulm\u00f3n e induciendo una respuesta inflamatoria moderada. Resultados similares se han obtenido con MV130X, que carece del serotipo 3 de SPN. En conclusi\u00f3n, los resultados demuestran que MV130 induce una respuesta inmunitaria innata controlada y protege frente a SPN de forma serotipo independiente.       \n  \nCO-58  CELLULAR AND HUMORAL RESPONSES FOLLOW-UP FOR 8 MONTHS AFTER VACCINATION WITH MRNA-BASED ANTI-SARS-COV-2 VACCINES  Gil Manso, Sergio1; Carbonell, Diego2; P\u00e9rez Fern\u00e1ndez, Ver\u00f3nica Astrid1; L\u00f3pez Esteban, Roc\u00edo3; Alonso, Roberto4; Mu\u00f1oz, Patricia4; Cano, Jordi5; S\u00e1nchez-Arcilla Conejo, Ignacio6; Bell\u00f3n, Jose Mar\u00eda7; Correa Rocha, Rafael3; Pion, Marjorie1.  1Grupo de Inmuno-Regulaci\u00f3n Avanzanda, IiSGM, HGUGM, Madrid; 2Servicio de Hematolog\u00eda, HGUGM, Madrid; 3Laboratorio de Inmuno-Regulaci\u00f3n, IiSGM, HGUGM, Madrid; 4Servicio de Microbiolog\u00eda Cl\u00ednica y Enfermedades Infecciosas, HGUGM, Madrid; 5Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, Nueva York; 6Servicio de Prevenci\u00f3n de Riesgos Laborales, HGUGM, Madrid; 7Servicio de Bioestad\u00edstica, IiSGM, HGUGM, Madrid.  Because there is no specific treatment against COVID-19, vaccination against SARS-CoV-2 has become the main method of reducing mortality and severity of the disease. mRNA-based vaccines have emerged as a new type of preparation, used for the first time worldwide against SARS-CoV-2. Since they are a novel type of vaccine, several questions have been raised about their efficacy and their ability to confer immunity against the novel coronavirus. For this reason, this work aims to study the evolution of the specific anti-SARS-CoV-2 cellular and humoral responses conferred by the two mRNA vaccines after the first two doses and potential factors that may be implicated in these responses. On days 30 and 240 after the 2nd dose of both vaccines, the anti-S antibodies in plasma were evaluated from 82 volunteers vaccinated with BNT162b2 (BioNTech/Pfizer) and 68 vaccinated with mRNA-1273 (Moderna). IgG Anti-S were measured directly in the plasma, while peripheral blood was stimulated with a mixture of peptides encompassing the entire SARS-CoV-2 protein Spike sequence to measure the cellular-specific memory response. Then, the inflammatory cytokines\u2019 levels (IFN-\u03b3, IL-10, IL-2, and IL-4) were measured after 16 hours post-stimulation, corresponding to the level of cellular response. Stratifying the volunteers by age (< or \u2265 48 years old) and gender, differences between vaccines were observed mainly in women under 48 and men over 48 years old. Therefore, this work could help understand the evolution of the specific immune response over time post-vaccination, and identify potential cohort groups where a specific vaccination strategy could be applied to confer maximum immunity.           \n  \nCO-59  DIFFERENCES BETWEEN B-CELL SUBPOPULATIONS AND NEUTRALIZING ANTIBODIES FOLLOWING BNT162B2 (PFIZER-BIONTECH) VACCINE IN PERSONS WITH AND WITHOUT HISTORY INFECTION OF SARS-COV-2  Morales N\u00fa\u00f1ez, Jos\u00e9 Javier1; D\u00edaz P\u00e9rez, Sa\u00fal Alberto1; Garc\u00eda Chagoll\u00e1n, Mariel1; Mu\u00f1oz Valle, Jos\u00e9 Francisco1; Torres Hern\u00e1ndez, Paola Carolina1; Rodr\u00edguez Reyes, Sara\u00ed Citlalic1; Santoscoy Ascencio, Guillermo2; Sierra Garc\u00eda De Quevedo, Jos\u00e9 Julio2; Hern\u00e1ndez Bello, Jorge1.  1Universidad de Guadalajara - Centro Universitario de Ciencias de la Salud, Guadalajara; 2Unidad de Patolog\u00eda Clinica - UPC, Guadalajara.  Background:  The immunological mechanisms of immunization of novel COVID-19 vaccines still have specific questions, one of which is related to humoral immunity. The production of neutralizing antibodies is a parameter to measure the effectiveness of a vaccine, and the B cells are the origin of their production.   Objective:  To determine the dynamics of the subpopulations of B lymphocytes in response to the BTN162b2 mRNA vaccine (Pfizer-BioNTech) in persons with and without a history of COVID-19.   Methods:  Thirty-nine immunized persons (22 with prior COVID-19 and 17 without prior COVID-19) and ten subjects not vaccinated against SARS-CoV-2 (control group) were included. B cell subpopulations (transitional, mature, na\u00efve, memory, and plasmablasts) and neutralizing antibody levels were analyzed and quantified by flow cytometry and ELISA, respectively.   Results:  The dynamics of the B cells subpopulations after vaccination showed the following pattern: the percentage of transitional B cells was higher in the prior COVID-19 group (p < 0.05), whereas virgin B cells were more prevalent in the group without prior COVID-19 (p < 0.05), mature B cells predominated in both vaccinated groups (p < 0.01), and memory B cells and plasmablasts were higher in the not vaccinated group (p < 0.05).   Conclusions:  BNT162b2 vaccine induces changes in B cell subpopulations, especially generating plasma cells and producing neutralizing antibodies against SARS-CoV-2. However, the previous  \n  \ninfection with SARS-CoV-2 does not alter the dynamics of these subpopulations significantly but induces more rapid and optimal antibody production.  Keywords: B cell, BNT162b2, SARS-CoV-2, Immunophenotype, Vaccine  \n                          \n \n  \nCO-60  MYCOPHENOLATE & MTOR INHIBITORS TREATMENT AFFECTS THE RESPONSE TO MRNA-1273 VACCINATION IN PATIENTS WITH RENAL TRANSPLANTATION    Ju\u00e1rez, Ignacio1; P\u00e9rez-Flores, Isabel2; L\u00f3pez-G\u00f3mez, Ana3; Gonz\u00e1lez-Garc\u00eda, Raquel3; Peix-Jim\u00e9nez, Bel\u00e9n2; G\u00f3mez Del Moral, Manuel4; S\u00e1nchez-Fructuoso, Ana2; Mart\u00ednez-Naves, Eduardo3.  1Dpto. De Inmunolog\u00eda, Oftalmolog\u00eda y ORL, Facultad de Medicina, Universidad Complutense De Madrid, Madrid; 2Servicio de Nefrolog\u00eda, Hospital Cl\u00ednico San Carlos, Madrid; 3Dpto. De Inmunolog\u00eda, Oftalmolog\u00eda y ORL, Facultad de Medicina, Universidad Complutense De Madrid., Madrid; 4Dpto. De Biolog\u00eda Celular, Facultad de Medicina, Universidad Complutense De Madrid., Madrid.  Immunocompromised patients have an increased risk of developing severe COVID disease, as well as a tendency to suboptimal responses to vaccines. Patients undergoing kidney transplantation have pharmacological immunosuppression, limiting their potential response to vaccination, being one of the groups at a higher risk.  Objectives To study the cellular and humoral response to SARS-CoV-2 after mRNA-1273 (Moderna-Biotech) vaccination in a cohort of kidney transplant patients. Material and methods. We recruited 221 patients from the Hospital Cl\u00ednico San Carlos (Madrid). Blood was obtained prior to vaccination and at 3 time-points after the administration of the different doses. Anti-RBD IgG and the neutralization capacity of the sera was analyzed by ELISA. Cellular response (CD4 and CD8 T-cells) against Spike-protein peptides was analyzed by flow cytometry.  Results Kidney transplant (KT) patients have lower CD8 (64.5%) and CD4 (58.3%) T-cell response-rates after three doses compared to controls (90.5% and 80.9%, respectively, p<0.001). KT patients have lower humoral response-rates (56% after 2nd-dose and 75% after 3rd-dose, N=149) after vaccination compared to controls (p<0.001). IgG production is lower in KT patients, with a delay in antibody production after the second dose. Anti-RBD IgG antibody titers were correlated to the neutralizing capacity of the sera (p<0.0001, R-square=0.27).  Mycophenolate(MMF)-treatment reduces the response-rate to vaccination (50% vs 82% after 2nd-dose and 72% vs 89% after 3rd-dose, compared to non-MMF-treated patients). mTOR inhibitors(imTOR)-treatment increases the response-rate (85% vs 46% after 2nd-dose and 95%  \n  \nvs 68% after 3rd-dose, compared to non-imTOR-treated KT patients). imTOR-treated patients have a higher neutralization capacity after three doses.  Conclusions The response-rate of mRNA-1273 vaccine in KT patients is lower compared to the general population. MMF treatment deeply reduces the humoral response of patients, whereas imTOR-treatment may recover the effect of pharmacological immunosuppression in these patients. Administration of an additional dose to patients lacking response might be necessary.                               \n  \nPOSTERS  Sesi\u00f3n Poster. Inmunolog\u00eda B\u00e1sica. Pantalla 1   P-001  PTP4A2 GENE PERTURBATION BY CRISPR-CAS9 GENOME EDITING AFFECTS IS ASSEMBLY AND INTERLEUKIN-2 SECRETION IN JURKAT CD4+ T CELLS.  Carrasco Padilla, Carlos1; Aguilar Sope\u00f1a, \u00d3scar1; Alegre G\u00f3mez, Sergio1; Fern\u00e1ndez Boraita, Julia1; Torres Ruiz, Ra\u00fal2; Rodr\u00edguez Perales, Sandra2; Roda Navarro, Pedro1.  1Department of Immunology, Ophthalmology and ENT, School of Medicine, Universidad Complutense de Madrid and 12 de Octubre Health Research Institute (imas12), Madrid; 2Molecular Cytogenetics and Genome Editing Unit, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO),, Madrid.  Phosphatases of regenerating liver (PRLs; PRL-1, PRL-2 and PRL-3 encoded by PTP4A1, PTP4A2 and PTP4A3 genes) are dual-specificity phosphatases (DSPs) with an important role in cancer. To further studied the role of these DSPs in T cell activation, IS assembly and effector function, CRISPR/Cas9 genome editing was here employed to make knockouts (KO) of PRL-1 and PRL-2 encoding genes. The loss of PRL-1 and PRL-2 in KO cells was corroborated by Western blot, in which a compensation of the expression between these two phosphatases was uncovered. We then characterized the antigen-induced activation and effector function of KO and control JK cells by measuring the early activation marker CD69 and the overnight secretion of IL-2 in response to decreasing concentrations of superantigen. PRL-1 and PRL-2 deficiency resulted in a reduced expression of IL-2, however, only PRL-2 deficiency caused increased expression levels of CD69 at the cell surface. The IS assembly was then investigated in PRL-2 KO cells interacting with superantigen loaded Raji B cells. An increased filamentous (F)-actin polarization and a smaller central F-actin clearance was found at the IS of PRL-2 KO cells in comparison to control cells. This phenotype was accompanied by a higher localization of CD3\u025b-containing microclusters at the F-actin rich peripheral area of the IS. We propose that PRL-2 is critical for earlier events of T cell activation and IS assembly and can compensate the loss of PRL-1 at this step. PRL-1, however, seems to be also critical for IL-2 production suggesting that different molecular mechanisms are controlled by these PRLs during early and late activation events. Thus, the presented data contribute more evidences supporting a regulatory role of PRLs in T cell immune responses. Further research in this line will help us to understand the role of these DSPs in healthy and cancer-related T cell biology.   \n  \n    \n \n  \nP-002  TCR CROSSTALK WITH SURFACE COMPLEMENT REGULATORS (CREG) IN \u0391\u0392 T LYMPHOCYTES  Chacon-Arguedas, Daniel; Est\u00e9vez, Iv\u00e1n B.; Fern\u00e1ndez-Boraita, Julia; Tortajada, Agustin; Marin, Ana V.; Regueiro, Jos\u00e9 R.  Universidad Complutense de Madrid, Madrid.  The B cell receptor (BCR) and complement receptors such as CR2 (CD21) crosstalk when engaged by C3-opsonized antigen by reducing BCR activation threshold. We are exploring similar interactions in T cells by genetic analyses. Here we studied HTVL-1-immortalized \u03b1\u03b2 CD4+ T cell lines, either normal or with different defects in TCR invariant chains (CD247+/\u2013, CD247\u2013/\u2013, CD3D\u0394Ex2/\u0394Ex2) derived from patients with such mutations, which caused increasing TCR signaling deficiency. Cells were phenotyped for CR (CR1, CR2, CR3, CR4, C5aR1, C3aR) and Creg (CD46, CD55, CD59), stimulated with Dynabeads\u00ae T-Activator CD3/CD28 for 24h and analyzed for induction of CR and Creg by flow cytometry. CD69 was used as positive surface stimulation control. PMA+ionomycin for 24 h was used as a TCR-independent stimulus. The basal CR/Creg phenotype was similar in the different T cell lines (CR1\u2014CR2\u2014CR3+CR4\u2014C5aR1\u2014C3aR\u2014CD46+CD55+CD59+CD69+). After TCR engagement, normal T cells showed increased levels of only CD46, CD55, CD59 and CD69, suggesting crosstalk between the TCR and all CReg expressed. CD247+/\u2013 T cells also induced CD69 expression, but, in contrast, did not induce any Creg, supporting TCR-dependence of expressed CReg induction. CD247\u2013/\u2013 and CD3D\u0394ex2/\u0394ex2 T cells were unable to induce CD69 or Creg. PMA+Ionomycin stimulation showed that normal, CD247+/\u2013 and CD247\u2013/\u2013, but not CD3D\u0394ex2/\u0394ex2, T cells, were capable of TCR-independent CD69, CD55 and CD59 induction. Therefore, our data provide evidence of specific TCR-to-CReg signaling which is dependent on TCR signaling capacity by genetic analyses, suggesting that T cells may receive CReg-dependent information of extracellular complement levels after antigen engagement.               \n  \nP-004  A CASE OF CD157 NEGATIVE NON-PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WITH THE CLONE SY11B   S\u00e1nchez Redondo, David; Aguilar Criado, Marta; Bravo Le\u00f3n, Gloria; S\u00e1nchez Gutierrez, Mar\u00eda Eugenia; Carbonell P\u00e9rez, Jos\u00e9 Mar\u00eda; Alcal\u00e1 Pe\u00f1a, Mar\u00eda Inmaculada; Melero Ruiz, Josefa.  Hospital Universitario de Badajoz, Badajoz.  Paroxysmal nocturnal hemoglobinuria (PNH) is caused by somatic mutations in the PIGA gene (Xp22.1), which encodes a protein involved in the biosynthesis of the glycosylphosphatidylinositol (GPI) anchor. When a patient lacks GPI and suffers from PNH, some proteins are not correctly anchored to the membrane, such as CD55 or CD59, (which are involved in the regulation of hemolysis due to complement), that inactive complement activation avoiding hemolysis, or CD157 (BST1 gene), which is a useful flow cytometric marker.  It has been described that monoclonal antibody anti-CD157 clone SY11B5, used in (the) routine clinical practice, fails to detect the single nucleotide polymorphism (SNP) of BST1 (p.Arg145Gln). Furthermore, other factors can cause false negatives, such as interference of certain drugs with monoclonal antibodies anti-CD157.  We present a patient with suspected PNH, that had a false negative result in a flow cytometry test using the monoclonal antibody anti-CD157 clone SY11B5. This result was confirmed subsequently with a new blood sample. Then, another clone of anti-CD157 antibody, called RF3, was used, being the flow test positive for the expression of CD157 in the surface of monocytes and neutrophils. The explanation for this phenomenon is that RF3 (recognize also) also recognizes the SNP p.Arg145Gln of the gene BST1. The presence of the former SNP was confirmed by Sanger sequencing.  These types of cases highlight the importance of having different monoclonal antibodies directed against the same marker (CD157 in our case). This could be important to explain discordant results in immunological and hematological tests performed by flow cytometry.       \n  \nP-005  GERMINAL CENTER B CELL SELECTION MECHANISMS CANNOT BE STUDIED USING AS READOUT THE KINETICS OF ANTIBODY-ANTIGEN INTERACTIONS IN SOLUTION   Faro, Jose1; Garc\u00eda, Miguel2; Castro, Mario2.  1Universidade de Vigo, Vigo; 2Instituto de Investigaci\u00f3n Tecnol\u00f3gica-Universidad Pontificia Comillas, Madrid.  Antigens (Ag) form complexes with antibodies (Ab) and complement (C\u2019) fragments. These complexes bind to Fc and C\u2019 receptors on the membrane of follicular dendritic cells (FDC), forming on them depots of complexes where Ag is maintained intact for months. Follicular B cells bind cognate Ag through BCRs during B cell-FDC interactions. Therefore, in contrast to Ab-Ag interactions, which take place with at least one component in solution and hence in 3 dimensional (3D) conditions, BCR-Ag interactions take place in 2D conditions. Importantly, it has been shown recently that the effective kinetics of BCR-Ag 2D binding cannot be predicted from Ab-Ag 3D kinetics due to qualitative differences in translational and rotational diffusion processes in 3D vs 2D conditions. Similarly to TCRs, BCRs bound to membrane-tethered Ags are submitted to shear and tensile forces of the order of 10-20 pN. These forces affect in an unpredictable and substantial way the mean bond duration (inverse of the koff rate constant). Moreover, two different BCRs specific for the same Ag may respond to force with very different increments of their intrinsic koff rates. Therefore, the 2D kinetics of BCR-Ag interactions under zero force is also an inadequate proxy for BCR-Ag interactions under naturally generated forces. Last, the shear forces generated during an immunological synapse formation act on BCR-Ag bonds laterally and, hence, differently than the pulling or tensile forces generated during the B-cell synapse retraction into an endosomal vesicle, which act normal to the cell membrane. This introduces an additional layer of complexity into the effective 2D kinetics of BCR-Ag interactions, in which BCR-Ag bonds are submitted to two different, consecutive force regimes. All of the above indicates that the paradigm of effective kinetic rates of Ab-Ag 3D interactions is totally inadequate to help uncover any B-cell selective mechanism in germinal centers.          \n  \nP-006  INVOLVEMENT OF TYROSINE KINASE TYK2 IN THE ESTABLISHMENT AND FUNCTION OF SPLENIC B CELLS  Delgado Wicke, Pablo1; Bodega Mayor, Irene2; Gaspar, Mar\u00eda Luisa2; De Andr\u00e9s, Bel\u00e9n2; Fern\u00e1ndez Ruiz, Elena1.  1Hospital Universitario de La Princesa, Madrid; 2Instituto de Salud Carlos III, Madrid.  TYK2 is a member of the JAK family class of kinases that is responsible for mediating the response to IL-12, IL-23 and type I interferon (IFN). As a consequence, certain alterations in this kinase have been related to an increased susceptibility to viral and encapsulated bacterial infections, as well as hematological malignancies. Our group has previously described a significantly reduced expression of TYK2 in a cohort of patients with B-cell acute lymphoblastic leukemia, accompanied, in some cases, by the presence of loss-of-function variants. These data suggest that alterations in this gene may be involved in the appearance or development of this neoplasm.  Our working hypothesis consists of studying the role of Tyk2 in the splenic B cell subpopulations. Using a Tyk2-deficient mouse model, we analyzed the effect of Tyk2 loss on: 1) the establishment of B cells; 2) the gene expression profile of these subpopulations in homeostasis; and 3) the response of B cells to different Tlr-dependent stimuli. Flow cytometry studies determined that splenic B cell distribution was altered showing a decrease in marginal zone (MZ) B cells in Tyk2-/-. RNA-seq transcriptome studies in sorted B-cell subpopulations (MZ and follicular splenic B cells) identified several genes whose expression was altered, such as type I IFN pathway genes and a marked decrease in Tlr7 receptor expression. In addition, B-cell culture assays showed that Tyk2-/-B cells proliferated and differentiated into plasmablasts to a lesser extent than WT B cells in the presence of different Tlr stimuli (TLR7/8-CL097, TLR7-Imiquimod). Analysis of culture supernatants revealed a significant reduction of immunoglobulins and cytokines secreted by Tyk2-/-B cells (ELISA and CBA techniques). Taken together, these data demonstrate the involvement of Tyk2 in the establishment of mouse marginal zone B lymphocytes and in the functionality of splenic B cells.             \n  \nP-007  SECRETOME FROM PORCINE CARDIOSPHERE-DERIVED CELLS REPROGRAMS PORCINE M1 MACROPHAGES TOWARD A MORE ANGIOGENIC AND ANTI-INFLAMMATORY PROFILE IN VITRO.    Pulido Fresneda, Maria1; De Pedro Mu\u00f1oz, Maria De Los Angeles1; Alvarez Perez, Veronica1; Sanchez Margallo, Francisco Miguel1; Garcia Casado, Javier2; Lopez Nieto, Esther1.  1Centro de Cirug\u00eda de Minima Invasi\u00f3n Jes\u00fas Us\u00f3n, C\u00e1ceres;2Universidad de Extremadura, C\u00e1ceres;  Activated macrophages are usually divided into M1 (pro-inflammatory profile) and M2 (anti-inflammatory profile), depending on the expression of surface markers and cytokine secretion. Both are related to inflammatory diseases such as myocardial infarction (MI), being key in both the initial inflammatory response and subsequent wound healing. Cardiosphere-derived cells (CDCs) delivery has been suggested as a promising therapeutic approach for inflammatory diseases, as they appear to improve the inflammatory environment by modulating M1/M2 polarization. Pigs are widely used as animal models in the field of cardiovascular diseases due to their similarity to the human heart. Therefore, we improved the therapeutic potential of CDCs by priming them with IFN\u03b3 and TNF\u03b1 and evaluated the effect of their secretome (S-CDCs*) on macrophage polarization in vitro. Porcine macrophages were isolated from the peripheral blood of healthy pigs and polarized to M1 by adding hGM-CSF to the medium. On day 7 of culture, surface receptor expression and cytokine expression were measured by flow cytometry and qPCR in response to 24 hours of stimulation with LPS + IFN and treatment with S-CDCs*. M1-polarized macrophages with hGM-CSF and stimulated with LPS + IFNg, and M2-polarized macrophages with hM-CSF and stimulated with IL-4 were used as controls. After treatment with S-CDCs*, there was an increase in the expression of anti-inflammatory genes such as Arg-1 and IL-10 and a decrease in the proinflammatory gene TNFa, as well as an increase in the expression of VEFGa and MMP9, both related to neovascularization. In conclusion, administration of S-CDCs* may have a beneficial effect on both the inflammatory and reparative phases of AMI.           \n  \nP-009  LA EXPRESI\u00d3N DE TRAF1 EN LINFOCITOS T CAUSA LA EXPANSI\u00d3N DE TIMOCITOS Y PREVIENE LA INVOLUCI\u00d3N T\u00cdMICA SIN ALTERAR EL N\u00daMERO DE LINFOCITOS T PERIF\u00c9RICOS   P\u00e9rez-Chac\u00f3n, Gema1; Barbero-Casc\u00f3n, Miguel2; Acosta-Iborra, Barbara2; Garc\u00eda-Le\u00f3n, Mar\u00eda Jes\u00fas3; Toribio, Maria L4; Zapata, Juan Manuel2.  1Centro Nacional de Oncolog\u00eda, Madrid; 2Instituto de Investigaciones Biom\u00e9dicas \"Alberto Sols\" (CSIC-UAM), Madrid; 3Centre de Recherche en Biomedecine de Strasbourg, Strasbourg; 4Centro de Biolog\u00eda Molecular \"Severo Ochoa\", Madrid.  TRAF1 es el \u00fanico miembro de la familia TRAF sin dominio RING y, consecuentemente, sin actividad E3-ubiquitina-ligasa. TRAF1 no se expresa en linfocitos T en reposo, pero se induce tras activaci\u00f3n, pudiendo regular a distintos TNFRs. Hemos generado 2 l\u00edneas de ratones transg\u00e9nicos (CBA-TRAF1-T y FvbN-TRAF1-T) que sobreexpresan TRAF1 espec\u00edficamente en linfocitos T. Los niveles de expresi\u00f3n del TRAF1 transg\u00e9nico son similares a los de TRAF1 en linfocitos T activados y pueden considerarse fisiol\u00f3gicos. La expresi\u00f3n de TRAF1 causa un aumento del tama\u00f1o del timo ya observable al mes de edad que correlaciona con un aumento de la celularidad. Adem\u00e1s, en ratones TRAF1-T de edad superior a 7 meses el timo no se atrofia y presenta un tama\u00f1o superior al de los ratones j\u00f3venes TRAF1-T en ambas l\u00edneas de ratones debido a la acumulaci\u00f3n de timocitos. Esta acumulaci\u00f3n no altera los porcentajes de las poblaciones t\u00edmicas CD4+CD8+, CD4+CD8- y CD4-CD8+. Sin embargo, el n\u00famero de linfocitos T en el bazo de los ratones salvajes y TRAF1-T permanece similar en ratones de 2 a 14 meses de edad.   Un an\u00e1lisis transcript\u00f3mico diferencial en timocitos de ratones CBA-TRAF1-T y salvajes demostr\u00f3 que el FGF-10 (un factor de crecimiento del epitelio t\u00edmico) se encontraba sobreexpresado (~9 veces) en los timocitos TRAF1-T, diferencias que fueron a\u00fan mayores en an\u00e1lisis por QPCR. Estudios inmunohistoqu\u00edmicos mostraron que mientras que los timos de ratones salvajes de 1 a\u00f1o de edad eran atr\u00f3ficos, los de los ratones TRAF1-T no mostraban evidencias de atrofia y ten\u00edan \u00e1reas corticales y medulares engrandecidas y un epitelio t\u00edmico cortical con mayor densidad y con morfolog\u00eda alterada.  Estos resultados sugieren que la sobreexpresi\u00f3n de FGF10 mediada por TRAF1 en timocitos potenciar\u00eda el crecimiento del epitelio t\u00edmico que, a su vez, permitir\u00eda la acumulaci\u00f3n de timocitos y prevendr\u00eda la involuci\u00f3n del timo.       \n  \nP-010  ACUTE HYPOXIA EFFECT ON MENSTRUAL BLOOD-DERIVED MESENCHYMAL STROMAL CELLS (MENSCS) IMMUNOMODULATORY RESPONSE   De Pedro, Mar\u00eda De Los \u00c1ngeles1; Pulido, Mar\u00eda1; \u00c1lvarez, Ver\u00f3nica1; S\u00e1nchez-Margallo, Francisco Miguel1; G Casado, Javier2; L\u00f3pez, Esther1.  1Jes\u00fas Us\u00f3n Minimally Invasive Surgery Centre, C\u00e1ceres; 2Immunology Unit, University of Extremadura, C\u00e1ceres.  Menstrual blood-derived mesenchymal stromal cells (MenSCs) are a new source of stromal cells that stand out for being easy to isolate non-invasively, having a high rate of proliferation, and without ethical concerns. Currently, their therapeutic use is arousing interest due to their immunomodulatory and regenerative properties. New strategies are being developed in order to increase the likelihood of successful therapies. The aim of this work was to expose MenSCs to severe hypoxia to determine possible beneficial changes in their immunomodulatory properties. For that, five primary MenSCs cultures under basal condition or after 48h of incubation at acute hypoxia (0.1-1%) were compared in terms of surface receptors and gene expression. A total of 21 surface markers related to migration, cell adhesion, and immune response were analyzed by flow cytometry, and their gene expression profile (25 genes) was examined by qPCR. In addition, the secretion of two immunomodulatory molecules (IDO-1 and TGF-\u03b2) was determined by ELISA. Our results showed positive alterations in the expression of surface markers such as a significant increase in CD274, CD279, and other cell adhesion markers which enhance the MenSC immunomodulatory properties. The gene ontology (GO) analysis of the differences in the gene expression profile between the studied conditions showed an enrichment in the immune and inflammatory response GO categories. However, the migration capacity seems to be diminished. Moreover, an increase in IDO-1 and TGF-\u03b2 expression was also detected under severe hypoxia. For all of this, short exposure of MenSCs to acute hypoxia should be considered as a method to modulate the immune response in patients treated with MenSCs.                 \n  \nP-011  MULTIPLE MIELOMA IGD. A REPORT OF 13 CASES.   Just Balerdi, Mar\u00eda Bego\u00f1a; T\u00e9llez P\u00e9rez, Raquel; Garc\u00eda Cabello, Ana; Calabia Gonz\u00e1lez, Olalla; Casta\u00f1o N\u00fa\u00f1ez, \u00c1ngel Luis; Santiago \u00c1lvarez, Jose Luis.  Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid.   Introduction: Multiple Mieloma (MM)  IgD  is a rare entity, it represents only 2% of MM. It is more often found in men and, compared with other isotypes, it associates a more aggressive development and lower survival (Revised International Staging System, (R-ISS III). Nowadays there are few cohorts described, probably because it is an underdiagnosed entity, since serum IgD levels are very low (0.7-13 mg/dL) and routine immunofixations (IF) do not include IgD, making it difficult to identify monoclonal IgD proteins.  Methods:  Our review includes 13 patients of MM IgD identified in our laboratory from 2016 to 2022. Serum and urine IF (Hydrasys 2\u00ae, Sebia) and proteinograms (Capillarys\u00ae, Sebia) were made in all of them, as well as immunoglobulin (G, A , M, D and E) and light chain quantification (Optilite\u00ae, Binding Site).  Results:  12 out of 13 patients were men with a mean age of 66 years (range 47-75) and only one presented kappa-type IgD MM. Mean IgD quantification was 689 mg/dL (range 9-2162) and Lambda Free Light Chain 913 mg/L (5.7-26.3) with anemia in 46% and hypercalcaemia in 2 of them. The mean concentration of the monoclonal component was 0.47 g/dL at diagnosis, showing all of them an altered ratio Kappa/Lambda. High rates of B2- microglobulin was found in 55% of the patients. Only one case did not present Bence Jones (BJ) and bone involvement was found in 31% and kidney involvement in 76.9%. Use of free Kappa and Lambda antiserum help us to discard free light chain MM.  Discussion: IF with specific antiserum against IgD and IgD quantification are tests that must be included to avoid misdiagnoses of MM IgD diagnoses.   \n  \nP-012  EFFECT OF MESENCHYMAL STEM CELL CONDITIONED MEDIA (MSC-CM) ON THE EXPRESSION OF KILLER-CELL IMMUNOGLOBULIN-LIKE RECEPTORS (KIR) KIR3DL1, KIR2DS4 Y KIR2DL2/DL3 OF PERIPHERAL BLOOD NK CELLS.    Mart\u00ednez-Peinado, Pascual; Bidah, Najoua; Pascual-Garc\u00eda, Sandra; L\u00f3pez-Ja\u00e9n, Ana Bel\u00e9n; Baeza-Morales, Andr\u00e9s; Medina-Garc\u00eda, Miguel; Sempere-Ortells, Jos\u00e9 Miguel.  Universidad de Alicante, Alicante.  Introduction:  Mesenchymal stem cells (MSC) are a broadly used population in cell therapy for their ability to modulate the immune system responses. MSCs and their conditioned media (CM) can decrease the degranulation of NK cells among these responses, but there are only a few studies focusing on the modulation of Killer-cell immunoglobulin-like receptors (KIR) expression. Here we describe the effect of MSC-CM on the expression of Killer-cell immunoglobulin-like receptors (KIR) KIR3DL1, KIR2DS4 y KIR2DL2/DL3 of peripheral blood NK cells.  Materials and Methods:  First, CM were obtained from MSC cultures in 25 cm^2 flasks with different cell numbers (50000 (CM1), 100000 (CM2) and 200000 (CM3)) for 3 days in a volume of 5 ml of DMEM. Afterwards, PBMCs were isolated with Ficoll-Hypaque and cultured in 96-well plates at a final concentration of 10^6 cells/ml in a final volume of 200 uL of RPMI, supplemented with different concentrations of CM (10%, 25% and 50%) with and without PHA for 4 days at 37\u00b0C. After culture, PBMC were labeled with monoclonal antibodies (anti CD16/56, anti-KIR3DL1, anti-KIR2DS4 and anti-KIR2DL2/DL3) and analyzed by flow cytometry.  Results:  First, PHA caused an increase in the expression of the three analyzed markers in all cases. Regarding the effect of the different concentrations of CM, to a greater or lesser extent, the three markers followed the same pattern, increasing their expression for concentrations 10% and 25%, but decreasing for concentrations of 50%, observing an hormetic effect. No differences were observed between the different conditioned media (CM1, CM2 and CM3).  Conclusions:  MSC-derived conditioned medium increased the expression of KIR receptors KIR3DL1, KIR2DS4 and KIR2DL2/DL3 at low concentrations (10% and 25%) but decreased their expression at higher concentrations (50%).  \n  \n P-013  A MOUSE MODEL WITH PI3 KINASE P110\u0391 INACTIVATION IN T CELLS. EFFECTS ON THE DEVELOPMENT OF FUNCTIONAL SUBPOPULATIONS.   Briones, Alejandro C1; Montes-Casado, Mar\u00eda2; Villa-G\u00f3mez, Cristina2; Guti\u00e9rrez-Huerta, Pedro2; Collado-Garc\u00eda, Silvia2; Ramiro-Montalb\u00e1n, Victoria2; Garc\u00eda, Raquel3; Ortega, Sagrario3; Barbacid, Mariano3; Rojo, Jos\u00e9 Mar\u00eda4; Portol\u00e9s P\u00e9rez, Pilar5.  1Centro Nac. Microbiolog\u00eda, Insto. Salud Carlos III; Dept. Immunology, Complutense Univ. Sch. Medicine; i+12 Research Institute, Madrid; 2Centro Nacional de Microbiolog\u00eda, ISCIII, Majadahonda - Madrid; 3Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), Madrid; 4Centro de Investigaciones Biol\u00f3gicas, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), Madrid; 5Centro Nacional de Microbiolog\u00eda, Instituto de Salud Carlos III; y CSIC (Presidencia), Majadahonda - Madrid.  The enzymes phosphatidyl-inositol-3 kinases (PI3K) regulate essential cellular processes such as metabolism, activation, proliferation, motility, angiogenesis, inflammation and carcinogenesis. However, the specific involvement of certain catalytic Class I PI3K isoforms is poorly understood in immune processes. P110\u03b1 is an ubiquitous catalytic isoform in body cells, with involvement in ICOS-mediated signals and a high rate of mutation in cancer. To study the role of p110\u03b1 in T lymphocytes, we have developed a new mouse model with functional inactivation of p110\u03b1 (Kinase dead) in T lymphocytes (p110\u03b1KD-T) linked to the Cre-lox system. P110\u03b1KD-T mice show an increase in the number of cells in the thymus and spleen with a slight decrease in the proportion of single positive CD4+ in the thymus and naive CD8+ T (CD44low CD62Lhigh) in the spleen. No differences in \"in vitro\" proliferation or IFN\u03b3 production were observed in CD4+ cultures stimulated with antiCD3\u00b1antiCD28 or \u00b1antiICOS; nor in the \"in vitro\" differentiation of Th1 or Th17 subpopulations. However, \"in vitro\" differentiation of follicular Th subpopulations (Tfh) showed a lower yield of Tfh cell number and IL-21 production in p110\u03b1KD-T cultures versus control. \"In vitro\" ICOS-induced cell elongation assays showed defects in this response in Tfh-KD cells. Control Tfh cells showed inhibition of this elongation response in the presence of p110\u03b1(A66)- or p110\u03b4(IC87114)-inhibitor. These results demonstrate, by genetic modification (p110\u03b1KD-T) and specific inhibition, the involvement of both p110\u03b1 and \u03b4 catalytic chains in the elongation response mediated by ICOS in Tfh cells. Additional \"in vitro\" and \"in vivo\" tests will make it possible to characterize the effect produced by the inactivation of p110\u03b1 in T lymphocytes in this mouse model.      \n  \nP-014  BEYOND THE BIOMARKER: IMMUNOLOGIC AND METABOLIC PHENOTYPING OF THE MIR-721 KO MICE   Ruiz Fern\u00e1ndez, Ignacio; S\u00e1nchez D\u00edaz, Raquel; Martin, Pilar.  CNIC, Madrid.  MicroRNAs (miRNAs) are small non-coding RNAs, which act as negative regulators of the gene expression at a post-transcriptional level. The focus of this study is mmu-miR-721, which was first described in mouse embryonic nervous tissue but is also related to other processes due to the activity of some of its target genes: Meox2, a negative regulator of angiogenesis; Ppargamma, a regulator of insulin metabolism; and Nos2, an enzyme involved in nitric oxide metabolism. In our laboratory, this miRNA has been found to be related to the biology of Th17 lymphocytes, which synthesise it during autoimmune myocarditis. To study the role of this miRNA and its mechanisms of action, we have generated the mmu-miR-721 knockout mouse. Hence, our objective is the immunological and metabolic characterisation of this strain. The immunologic profiling of the mmu-miR-721 KO strain revealed a hypercellular thymus with an aberrant intrathymic T cell selection process, compared to WT mice measured by FACS. Particularly, intermediate thymocytes were enriched, while resultant CD4+ and CD8+ T cells were reduced, suggesting an arrest in the negative selection. This is in line with decreased Th17 responses observed in the model of myocarditis. Furthermore, the metabolic phenotyping revealed an increased abdominal fat weight and lipidic plasma levels in adult miR-721 KO female mice, compared to WT. Nevertheless, this phenotype is not observed in pre-fertile females nor males. Moreover, male KO mice even present lower body weight and decreased abdominal fact when compared to WT littermates. This sex-dependant differences and the change upon fertility in this strain suggest miR-721 is involved in the sex hormone homeostasis. These data make the miR-721 KO model a powerful tool to understand the role of this molecule in the development of the immune cells, as well as to illustrate the influence that lymphocytes can have in the lipidic metabolism.        \n  \n P-015  EVALUATION OF DIFFERENT PRESERVATION METHODS FOR CEREBROSPINAL FLUID MONONUCLEAR CELLS.    Fern\u00e1ndez-Velasco, Jos\u00e9 Ignacio; Villarrubia Migall\u00f3n, Noelia; Villar Guimerans, Luisa Mar\u00eda.  Hospital Universitario Ram\u00f3n y Cajal, Madrid.  Background:  Characterization of changes in the different cerebrospinal fluid (CSF) leukocyte subsets in multiple sclerosis patients receiving a particular treatment often need to be done in a reduced number or reference laboratories. Thus, working with fresh cells is not always possible and cell preservation has to be done.  Objective:  To study two different methods of cell preservation to compare them with fresh cells.  Methods:  Eight patients diagnosed with different neurological diseases at Ram\u00f3n y Cajal University Hospital (Madrid, Spain). CSF samples were always obtained for clinical purposes. CSF cells obtained from Fresh, TransFix and Frozen methods were analyzed by flow cytometry, using BD FACSDiva Software V.8.0. Statistical analyses were made using GraphPad Prism 8.0 software. Friedman ANOVA test for paired data was used to compare results obtained in fresh and preserved samples. Post-hoc analysis were done to evaluate differences between groups.  Results:  Statistical differences in absolute numbers of total mononuclear cells obtained in Fresh and preserved CSF samples were found (p=0.0024), due to lower counts found in Frozen samples compared to Fresh ones (p<0.01). No differences were found between total mononuclear cell numbers obtained in TransFix compared to Fresh samples. However, we found a relative increase in B cell percentages in Frozen samples compared to TransFix and Fresh ones (p=0.0003) and a clear decrease in the percentages of CD4+ T cells in CSF Frozen samples compared to the other two conditions (p=0.018).  Conclusions:  Cryopreservation of CSF mononuclear cells induced a significant reduction in absolute CSF cell numbers that affected mainly to CD4+ T cells. A relative increase of B cells was probably due  \n  \nto CD4+ T cell reduction. These changes were not observed in transfixed cells. These results show that TransFix method could be useful for studying CSF leukocyte subpopulations by flow cytometry up to two days after lumbar puncture.                                                    \n  \nP-016  DESIGN AND VALIDATION OF NOVEL FLOW CYTOMETRY PANELS TO ANALYZE A COMPREHENSIVE RANGE OF PERIPHERAL IMMUNE CELLS IN C57BL/6J MICE.  Barco-Tejada, Ainara1; L\u00f3pez-Esteban, Roc\u00edo2; Pion, Marjorie2; Correa-Rocha, Rafael2; Desco, Manuel1; Cuss\u00f3, Lorena2.  1Universidad Carlos III de Madrid, Legan\u00e9s; 2Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, Madrid.  Introduction:  Flow cytometry is a widely used technique to diagnose several immune-related diseases in humans in peripheral blood (PB). However, in murine models, it presents several limitations, such as the meager amount of PB available, narrow variety of commercial antibodies and fluorochromes and high inter-subject variability in immune populations. We have defined novel cytometry panels to analyze extensively immune cell populations in mice from 100uL of blood. The panles have been tested in lipopolysaccharide (LPS) lung inflammation model.  M&M:  Twelve C57BL/6J mice were randomized into two groups: LPS, (n=6) undergoing intratraqueal inoculation of LPS (5mg/kg) in 100 \u00b5L of saline; and control (n=6). Fresh blood was collected from the maxillary venous sinus on day 1 pre-inoculation, and days 1 and 3 post-inoculation (p.i). Whole blood was labeled with 27 antibodies distributed in two panels, and acquired in a 16 channels Flow Cytometer.  Peripheral populations were assessed overtime, overlapping innate and adaptive immune subsets.    Results:  LPS-induced inflammation was rapidly observed at day 1 p.i, by an increase of granulocytes frequency and numbers, correlated with the mice's weight loss. Interestingly, a decline in the pro-inflammatory Th1 and NK subsets was observed in the same group. Rare cellular populations have shown high variability, likely due to very low cells/\u00b5L.  Conclusions:  Our panels allowed us to analyze most physiological peripheral immune cellular subsets from a minimal amount of whole blood and can permit us to detect immune changes due to rapid inflammation induction. This longitudinal study could help in determining the best timing for future experimental designs, using minimal blood and with a minimal impact on the animal status, avoiding unnecessary animal sacrifices and thus, reducing sample size.   \n  \n \n \n \n  \nSesi\u00f3n Poster. Inmunidad Innata. Pantalla 2  P-018  LACK OF TYPE 1 CONVENTIONAL DENDRITIC CELLS REDUCES ADIPOKINE PRODUCTION IN ADIPOSE TISSUE   Cook, Emma1; Hern\u00e1ndez Garc\u00eda, Elena1; Cueto, Francisco2; Redondo Urzainqui, Ana1; Sancho, David2; Iborra, Salvador1.  1Department of Immunology, Ophthalmology and ENT. School of Medicine, Universidad Complutense de Madrid, Madrid; 2Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid.  Our group has previously seen that type 1 conventional dendritic cells (cDC1) are necessary for a healthy adipose tissue. Batf3KO mice, lacking cDC1, become obese with age. On the other hand, mice that have more dendritic cells do not gain as much weight when put on a high fat diet as their control counterparts. The latter effect is lost in Batf3KO mice. To understand the mechanisms by which cDC1 are able to decrease white adipose tissue weight we looked at the production of adipokines in Batf3KO mice. Batf3KO mice have a reduced production of adiponectin, leptin and Fgf21. These hormones are important regulators of satiety and can explain why young Batf3KO mice eat more than WT mice. Forcefully increasing the energy expenditure in these mice is able to counteract age-induced obesity and promotes adiponectin production by the adipose tissue. However, Fgf21 production is still lower in Batf3KO mice compared to WT mice. Fgf21 is also implicated in the preference for sweet foods. Young Batf3ko mice have a disrupted eating pattern, waking during the resting period to feed. On a ketogenic diet, with very low concentrations of carbohydrate, Batf3KO mice correct this behaviour. Fgf21 has previously been shown to be required in order to survive LPS-induced endotoxemia. Batf3KO mice, producing less Fgf21, have reduced survival rates in this model. In conclusion, mice lacking cDC1 have a disrupted adipokine production that affects their eating habits and their weight gain, but also affects their response to a sterile inflammatory response.              \n  \nP-019  CANDIDA ALBICANS PCA2 INFECTION PROGRAMS HEMATOPOIETIC STEM AND PROGENITOR CELLS IN THE BONE MARROW AND MOBILIZES THEM TO THE SPLEEN.     Guerrero, Paula; Bono Tapp, Cristina; Erades, Ana; Gil, Mar\u00eda Luisa; Y\u00e1\u00f1ez, Alberto.  Universidad de Valencia, Burjasot.  Hematopoietic stem and progenitor cells (HSPCs) are increasingly being appreciated to be important players in the fight against infection. In this study, we show that a mild infection with the low-virulent strain of Candida albicans PCA2, expands and reprograms HSPCs early during infection and mobilize them transiently to the spleen to produce trained macrophages.  HSPC populations in the bone marrow and the spleen were analyzed by flow cytometry during infection. Bone marrow LKS+ (Lin\u2013 c-Kit+ Sca-1+) cells expand progressively in response to the PCA2 infection, with a general increase in all MPP (multipotent progenitors) populations. In the spleen, a significant increase in LKS+ cells and all MPPs is observed at day 7 post-infection. To find out whether infection recruits HSPCs to the spleen or expands them from the few residing in the spleen, we used two different adoptive transfer models. By transferring HSPCs from uninfected mice to PCA2 infected mice, we demonstrate that infection enhances the ability of the spleen to recruit bone marrow HSPCs. Moreover, adoptive transfer of HSPCs from PCA2 infected mice into uninfected mice shows an increased ability of HSPCs from infected mice to home the spleen. Furthermore, we assessed the ability of ex-vivo HSPC-derived macrophages to produce proinflammatory cytokines at different time points post-infection. We found that bone marrow HSPCs are programed to produce trained macrophages early during infection (day 3), while day 7 HSPCs produce macrophages with an unaltered or tolerized phenotype. Interestingly, splenic HSPCs from 7-day PCA2-infected mice produce trained macrophages. Taken together, these data show that C. albicans PCA2 infection expands and reprograms HSPCs early in the bone marrow and mobilize them to the spleen to produce trained macrophages to fight against infection. This work was supported by grant RTI2018-093426-B-100 (Ministerio de Ciencia, Innovaci\u00f3n y Universidades, Spain and European Fund for Regional Development).           \n  \nP-020  MITOCHONDRIAL DYNAMICS OF HUMAN CYTOKINE-INDUCED MEMORY-LIKE NK CELLS  Terr\u00e9n, I\u00f1igo1; Amarilla-Irusta, Ainhoa1; Astarloa-Pando, Gabirel1; Orrantia, Ane1; Zenarruzabeitia, Olatz1; Scorrano, Luca2; Borrego, Francisco3.  1Immunopathology Group, Biocruces Bizkaia Health Research Institute, Barakaldo; 2Department of Biology, University of Padova / Veneto Institute of Molecular Medicine, Padova; 3Immunopathology Group, Biocruces Bizkaia Health Research Institute / Ikerbasque, Basque Foundation for Science, Barakaldo.  Natural Killer (NK) cells represent a valuable tool in cancer immunotherapy, and mitochondria represent an attractive target that could further improve current therapeutic strategies. Indeed, recent findings suggested that NK cell-based immunotherapies could be successfully combined with mitochondrial-targeting strategies. A promising therapy for cancer patients is based on the adoptive transfer of IL-12/15/18-stimulated NK cells, also known as cytokine-induced memory-like (CIML) NK cells. In this work, we focused on the mitochondrial changes that happen in human CIML NK cells both after stimulation with IL-12, IL-15 and IL-18, and after a resting period. We have studied mitochondrial fitness by measuring changes in mitochondrial membrane potential and accumulation of mitochondrial reactive oxygen species. Additionally, we measured the autophagic and mitophagic activity of CIML NK cells. To understand the relevance of these results, we have analyzed changes in cell viability through different experimental approaches. Additionally, we studied mitochondrial dynamics by measuring the expression of mitochondrial shaping proteins and analyzing mitochondrial morphology. Altogether, our results suggest that CIML NK cells could progressively accumulate dysfunctional mitochondria, which can induce cell death and ultimately curtail the success of therapies based on the adoptive transfer of CIML NK cells.                  \n  \nP-021  THE GSK3B-MAFB AXIS CONTROLS THE PRO-FIBROTIC GENE PROFILE OF PATHOGENIC MONOCYTE-DERIVED MACROPHAGES IN SEVERE COVID-19   Sim\u00f3n Fuentes, Miriam1; R\u00edos, Israel1; Muller, Ittai B2; Anta, Laura3; Herrero, Cristina1; Alonso, B\u00e1rbara1; Lasala, F\u00e1tima4; Labiod, Nuria4; Luczkowiak, Joanna4; Jansen, Gerrit2; Delgado, Rafael4; Colmenares, Maria5; Puig-Kr\u00f6ger, Amaya6; Vega, Miguel A1; Corb\u00ed, \u00c1ngel L1; Dom\u00ednguez-Soto, \u00c1ngeles1.  1Centro de Investigaciones Biol\u00f3gicas Margarita Salas (CSIC), Madrid; 2Amsterdam University Medical Center, Amsterdam; 3Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela; 4Instituto de Investigaci\u00f3n Hospital Universitario 12 de Octubre (imas12), Universidad Complutense School of Medicine, Madrid; 5Myeloid Cell Laboratory, Centro de Investigaciones Biol\u00f3gicas, CSIC, Madrid; 6Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, Madrid.  Macrophages are responsible for orchestrating the immune response. They are fundamental effectors of the innate immune system and connect it to the acquired immune system. Macrophages are involved in a wide range of processes. They can stimulate and resolve inflammatory responses but are also involved in tissue development and homeostasis. Their functional diversity is reflected by the huge spectrum of polarization states acquired by macrophages in response to cues from the tissue environment. Of note, macrophage malfunction can give rise to clinically relevant pathologies such as tumors, COVID-19, and autoimmune and inflammatory disorders. Macrophages can acquire a wide spectrum of activation states, although two opposite extremes of the spectrum have been defined for simplicity. Pro-inflammatory macrophages appear in the presence of IFN\u03b3 or GM-CSF, they express high levels of co-stimulatory molecules, and produce pro-inflammatory cytokines. On the other hand, IL-4 or M-CSF prompt the acquisition of an anti-inflammatory functional profile in macrophages, in which they secrete anti-inflammatory cytokines. The study of the transcriptional signature of anti-inflammatory macrophages, and their responses towards pathogenic stimuli constitutes the central axis of this work. MAF and MAFB are two transcription factors that mediate tissue development, regulate immune responses, and are required for the acquisition and maintenance of the transcriptional and functional profile of anti-inflammatory human macrophages. We have identified MAF-dependent genes (such as FOLR2), MAFB-dependent genes (such as IL10), and MAF/MAFB-dependent genes (such as IGF or CD163). In addition, GSK3\u03b2 has been stablished as a major regulator of the MAFB-dependent transcriptome. Furthermore, a direct link between GSK3\u03b2, MAFB-dependent genes and the transcriptional profile of pathogenic alveolar macrophages genes in severe COVID-19 has been found. Besides, we have identified macrophage effector functionalities that are differently regulated by MAFB and MAF, namely the production of  \n  \nmonocyte-recruiting chemokines and the ability to stimulate T lymphocyte proliferation.                                                        \n  \nP-022  DIFFERENTIAL ENGRAFTMENT OF  A20 PD-L1 WT AND PD-L1 KO LEUKEMIA CELLS IN SEMIALLOGENEIC RECIPIENTS IN THE CONTEXT OF PD-L1/PD-1 INTERACTION AND NK MEDIATED HYBRID RESISTANCE  Del R\u00edo Gonzalez, Mar\u00eda Luisa1; P\u00e9rez Sim\u00f3n, Jos\u00e9 Antonio2; Rodr\u00edguez Barbosa, Jos\u00e9 Ignacio1.  1Universidad de Le\u00f3n, Le\u00f3n; 2Hospital Universitario de Sevilla, Sevilla.  The contribution of NK cells to tumor rejection in the context of PD-L1/PD-1 blockade is a matter of intense debate. To elucidate the role of PD-L1 expression on tumor cells and the functional consequences of engaging PD-1 receptor on cytotoxic cells, PD-L1 expression was genetically inactivated and WT or PD-L1 deficient parental tumor cells were adoptively transferred intravenously into F1 recipients. The engraftment of PD-L1 deficient A20 tumor cells in spleen and liver of F1 recipients was impaired compared with A20 PD-L1 WT tumor counterparts. To elucidate the mechanism responsible for this differential tumor engraftment and determine the relevance of the role of PD-L1 / PD-1 pathway in the interplay tumor cells / NK cells, a short-term competitive tumor implantation assay in the peritoneal cavity of semiallogeneic F1 recipients was designed. The results presented herein showed that NK cells killed target tumor cells with similar efficiency regardless of PD-L1 expression, whereas PD-L1 expression on A20 tumor cells conferred a significant tumor protection against rejection by CD8 T cells confirming the role of the co-inhibitory receptor PD-1 in the modulation of their cytotoxic activity. In summary, PD-L1 expression on A20 leukemia tumor cells modulates CD8 T cell-mediated responses to tumor-specific antigens, but does not contribute to inhibit NK cell-mediated hybrid resistance, which correlates with the inability to detect PD-1 expression on NK cells neither under steady-state conditions nor under inflammatory conditions.                   \n  \nP-023  SIDT1 IS REQUIRED FOR IFN-I RESPONSES TO NUCLEIC ACIDS BY ENDOSOMAL TOLL-LIKE RECEPTORS IN PLASMACYTOID DENDRITIC CELLS, AND MEDIATES THE PATHOGENESIS OF IFN-MEDIATED DISEASES   Morell Hita, Mar\u00eda1; Varela Hern\u00e1ndez, Nieves1; Castillejo-L\u00f3pez, Casimiro1; Coppard, C\u00e9line1; Luque, Mar\u00eda Jos\u00e91; Wu, Ying-Yu2; Mart\u00edn-Morales, Natividad3; P\u00e9rez-C\u00f3zar, Francisco1; Blanco, Alfonso4; G\u00f3mez-Hern\u00e1ndez, Gonzalo1; Kumar, Ramesh2; O'valle, Francisco3; Alarc\u00f3n-Riquelme, Marta Eugenia1; Mara\u00f1\u00f3n Lizana, Concepci\u00f3n1.  1Centro GENYO, Granada; 2Oklahoma Research Foundation, Oklahoma City; 3Universidad de Granada, Granada; 4Universidad de C\u00f3rdoba, C\u00f3rdoba.  Type I IFN (IFN-I) is involved in the pathogenesis of autoimmune and autoinflammatory diseases such as psoriasis and lupus. SIDT1 is an ER-resident protein expressed in the lymphoid lineage, and involved in anti-viral IFN-I responses in vivo, through an unclear mechanism. Herein we have dissected the role of SIDT1 in the natural IFN-producing cells, the plasmacytoid dendritic cells (pDC). The function of SIDT1 in pDC was determined by silencing its expression in human primary pDC and in GEN2.2 cell line. SIDT1 role in vivo was assessed using the imiquimod-induced psoriasis model and the TLR7.tg lupus model crossed with SIDT1-deficient mice (sidt1-/-).  Silencing of SIDT1 in primary human pDC and GEN2.2 cells led to a blockade of the IFN-I response after stimulation of TLR7 and TLR9, without affecting the pro-inflammatory responses or upregulation of maturation markers. We found that SIDT1 migrates from the ER to the endosomal and lysosomal compartments together with TLR9 after CpG stimulation. Thus, SIDT1 participates in the access of the TLR9-CpG complexes to lysosome-related vesicles, and therefore mediates the activation of TBK1 and the nuclear migration of IRF7, but not of NF-kB. sidt1-/- mice showed a significant decrease in severity parameters of the imiquimod-induced acute psoriasis-like and spontaneous TLR7.tg lupus models, associated with a decrease in the production of IFN-I and IFN-dependent chemokines.  Our findings indicate that SIDT1 is at the cross-road between the IFN-I and the proinflammatory pathways and constitutes a promising drug target for autoinflammatory diseases mediated by IFN-I responses.            \n  \nP-024  RESIDUAL VIRAL REPLICATION AND BACTERIAL TRANSLOCATION MAY DIFFERENTIALLY REGULATE LIGANDS FOR CHECKPOINT RECEPTORS ON MYELOID CELLS FROM PEOPLE LIVING WITH HIV-1   Calvet Mirabent, Marta1; S\u00e1nchez Cerrillo, Ildefonso1; Tsukalov, Ilya2; Popova, Olga1; De Los Santos, Ignacio1; Sanz, Jes\u00fas1; Garc\u00eda Fraile, Lucio1; De La Fuente, Hortensia1; S\u00e1nchez Madrid, Francisco1; Mu\u00f1oz Fern\u00e1ndez, Mar\u00eda \u00c1ngeles3; Alfranca, Arantzazu1; Mart\u00edn Gayo, Enrique1.  1Hospital Universitario de La Princesa, Madrid; 2Universidad Aut\u00f3noma de Madrid, Madrid; 3Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid.  Dendritic cell-based immunotherapies are a promising tool against HIV-1 infection to increase activation and antiviral function of CD8+ T cells. However, differential expression of checkpoint inhibitory receptors (CIR) in CD8+ T cells from people living with HIV (PLWH) limit their ability to respond to stimulation. Whether distinct chronic inflammatory processes differentially regulate the potential of myeloid cells remains understudied. Myeloid cells from HIV-negative (HC; n=13) and PLWH (n=6) were exposed to Pathogen-Associated Molecular Patterns (PAMP) mimicking bacterial translocation (LPS and Flagellin) or viral replication (CL097, Poly I:C and HIV-1 Gag peptides). Expression of CD64, CD40, ligands for CIR (PDL1, CD155 and Galectin-9), and IL1\u03b2 levels were analyzed by flow cytometry, qPCR and ELISA. Viral PAMPS preferentially induced higher levels of PDL1 and CD155 expression on myeloid cells more significantly in PLWH than HC. Interestingly, Poly I:C and CL097 induced both protein and mRNA levels of CD155 and PDL1, while HIV-1 Gag exclusively induced an increase of protein levels of these molecules. In contrast, LPS and flagellin were not able to induce protein expression of these ligands both in HC and PLWH. In contrast, Galectin-9 expression, ligand of TIM3, was significantly reduced by Gag peptides and Poly I:C specifically in Mo from PLWH and not in HC, suggesting negative regulation of Galectin-9 expression by viremia specifically in PLWH but not in not-infected individuals and negatively correlating with CD155 expression. Such trained state correlated with higher expression and secretion of IL1\u03b2 at baseline and after viral PAMP stimulation, and with the induction of CD64+ CD40+ cells in Mo from PLWH compared to cells from HC. In conclusion, residual viral replication rather than bacterial translocation, induce phenotypic changes on myeloid cells from PLWH that may potentiate CD8+ T cell dysfunctionality, underlying the need to introduce modulation of myeloid cells for effective HIV immunotherapies.   \n  \nP-025  FH DESIALILATION ALTERS COMPLEMENT REGULATION ON CELLULAR SURFACES, AND COULD CONTRIBUTE TO ATYPICAL HAEMOLYTIC URAEMIC SYNDROME.   Corvillo, Fernando1; Gonz\u00e1lez S\u00e1nchez, Laura1; G\u00f3mez Delgado, Irene2; M\u00e1rquez Tirado, B\u00e1rbara3; Goicoechea De Jorge, Elena3; S\u00e1nchez-Corral G\u00f3mez, Pilar1.  1Complement Research Group, Hospital La Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Center for Biomedical Network Research on Rare Diseases (CIBERER), Madrid; 2Complement Research Group, Hospital La Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid; 3Department of Immunology, Complutense University and Research Institute Hospital 12 de Octubre (imas12), Madrid.  Introduction The plasma glycoprotein Factor H (FH) is essential to prevent autologous damage by the Complement system. FH mutations or autoantibodies favour disease conditions such as the Haemolytic Uraemic Syndrome (aHUS), where microvascular endothelial cells are injured by the host Complement. We recently observed transient desialylation of FH in aHUS patients with Streptococcus Pneumoniae infections, and proposed that desialilated FH could contribute to disease pathogenesis.   Objectives To explore the role of FH sialic acids on its capacity to control Complement activation on different cellular surfaces.  Methods Desialilated FH (dFH) was generated \u201cin vitro\u201d with C. perfringens neuraminidase. The binding of FH and dFH to C3b deposited on a surface was tested by a competition assay using fluorescently labelled-FH (FHA488) on opsonized sheep erythrocytes (ShE). The ability of FH/dFH to regulate complement was assayed on Human Microvascular Endothelial Cells (HMEC-1), which were incubated with normal human serum (NHS) or with an aHUS serum carrying the FHW1183L mutation, and with increasing amounts of exogenous FH/dFH. C3b deposition on the endothelial cells was then analyzed by immunofluorescence using a FITC-conjugated anti-human C3c antibody, and quantified with ImageJ Software.  Results Experiments on ShE showed a decreased capacity of dFH compared with native FH to compete the binding of FHA488 to the opsonized erythrocyte surface, suggesting that dFH has a lower affinity to interact with C3b on a surface.  \n  \nThe experiments with HMEC-1 cells revealed that native FH decreased C3b deposition in a dose-dependent manner, while dFH barely show inhibitory activity. These findings were observed when using the NHS or the aHUS serum as a source for C3b.  Conclusions We conclude that removal of FH sialic acids alters its capacity to efficiently control complement activation on cellular surfaces, although additional experiments will be required to determine the precise mechanism.                                           \n  \nP-026  AN\u00c1LISIS FUNCIONAL Y PERFIL DE EXPRESI\u00d3N DE RECEPTORES ACTIVADORES E INHIBIDORES EN C\u00c9LULAS NK TIPO-MEMORIA INDUCIDAS POR IL-12/IL-15/IL-18  L\u00f3pez Sejas, Nelson; S\u00e1nchez Hern\u00e1ndez, Eva; Gonz\u00e1lez S\u00e1nchez, Marina; Carreira Santos, Sof\u00eda; Casado, Javier G.; Tarazona, Raquel.  Unidad de Inmunolog\u00eda, Departamento de Fisiolog\u00eda, Facultad de Veterinaria, Universidad de Extremadura, C\u00e1ceres.  Las c\u00e9lulas NK son un componente principal de la inmunidad innata, con capacidad para lisar c\u00e9lulas infectadas o transformadas a trav\u00e9s de una respuesta r\u00e1pida y robusta que ha sido objeto de intensos estudios en los \u00faltimos a\u00f1os. Uno de ellos es la generaci\u00f3n de subpoblaciones de c\u00e9lulas NK con caracter\u00edsticas similares a memoria inducidas por citoquinas, denominadas c\u00e9lulas NK CIML (cytokine-induced memory-like). En este trabajo, describimos los cambios en el fenotipo y funci\u00f3n de las c\u00e9lulas NK CIML generadas por la preactivaci\u00f3n con las citoquinas IL-12, IL-15 e IL-18 en comparaci\u00f3n con c\u00e9lulas NK control cultivadas en presencia de IL-15.  A las 16 horas de preactivaci\u00f3n con citoquinas, se observ\u00f3 un aumento de la expresi\u00f3n de los receptores NKG2A, CD25, y CD69 y un descenso del receptor CD16 en las c\u00e9lulas NK CIML con respecto a las c\u00e9lulas NK control, diferencias que se mantuvieron a los 7 d\u00edas de cultivo a excepci\u00f3n de CD69. Los receptores activadores DNAM-1, NKp30, y NKp46 aumentaron en c\u00e9lulas NK CIML respecto al control, tanto a los 7 como a los 14 d\u00edas. En cuanto a la expresi\u00f3n de los receptores inhibidores PAN-KIR y TIGIT disminuyeron en las c\u00e9lulas NK CIML. El an\u00e1lisis funcional revel\u00f3, en el d\u00eda 7, un aumento de la degranulaci\u00f3n de las c\u00e9lulas NK CIML en respuesta a las c\u00e9lulas diana K562 y MaMel-56.  Tanto el TNF-\u03b1 como el IFN-\u03b3 presentaron niveles bajos de expresi\u00f3n a los d\u00edas 7 y 14.  En conclusi\u00f3n, los resultados muestran que las c\u00e9lulas NK CIML presentan un potencial citot\u00f3xico mayor probablemente debido al aumento de los receptores activadores lo que sugiere profundos cambios en t\u00e9rminos transcript\u00f3micos, prote\u00f3micos, metabol\u00f3micos o epigen\u00e9ticos que deben ser analizados para la optimizaci\u00f3n de los protocolos de expansi\u00f3n de las c\u00e9lulas NK CIML para su uso en inmunoterapia adoptiva.            \n  \nP-027  CARDIAC MACROPHAGE-DERIVED CIRCULATING MIRNAS AFTER ACUTE MYOCARDIAL INFARCTION  Mart\u00edn Aguado, Laura; Blanco Dom\u00ednguez, Rafael; N\u00fa\u00f1ez, Vanessa; Ricote, Mercedes; Mart\u00edn, Pilar.  Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid.  Objectives The aim of this work is the identification of specific circulating miRNAs of cardiac macrophages after acute myocardial infarction (AMI). Material and Methods An analysis was performed by means of a miRNA-microarray in cardiac pro-inflammatory macrophages and a small RNAseq in plasma, from different mouse models after AMI and myocarditis - as control of non-ischemic cardiomyopathy -. Next, the miRNAs of interest were validated by qPCR in mouse macrophages and plasma after AMI. To assess the expression of these miRNAs in circulation and within extracellular vesicles, ex-vivo cultures of cardiac macrophages isolated from mice after AMI were made. Finally, a translational study was carried out in swine model and in patients, for the validation of these miRNAs in cardiac macrophages after AMI (small-RNAseq) and plasma (qPCR), respectively. Results We have identified miR-185-5p, miR-222-3p and miR-1306-3p as miRNAs specific to cardiac pro-inflammatory macrophages after ischemic cardiomyopathy. These miRNAs, secreted into the circulation within extracellular vesicles, are specific to AMI and are not expressed in others non-ischemic cardiomyopathies such as myocarditis. The murine miRNAs miR-185-5p, miR-222-3p, and miR-1306-3p are conserved and expressed in cardiac macrophages and plasma, from swine and human, respectively. These miRNAs are involved in the regulation of processes such as inflammation, metabolism, and circadian cycles. Conclusions In this study we have identified a signature of miRNAs: miR-185-5p, miR-222-3p and miR-1306- 3p, which are specifically expressed in pro-inflammatory macrophages and are secreted into plasma within extracellular vesicles after AMI. These miRNAs are conserved in swine model and in AMI patients. Our work suggests that the expression of these miRNAs in circulation could be a tool to study the pro-inflammatory state in myocardium during AMI. Funding  Ministerio de Educaci\u00f3n y Formaci\u00f3n Profesional (FPU19/03941); Ministerio de Econom\u00eda y Competitividad (RTI2018-095928-B-I00); Comunidad de Madrid (S2017/BMD-3684); Instituto  \n  \nde Salud Carlos III (PI19/00545).                                                       \n  \nP-028  OVERLAP CASE BETWEEN ACQUIRED ANGIOEDEMA AND SJ\u00d6GREN SYNDROME SUCCESSFULLY TREATED   Costa Anzola, Antonio; Saiz, Vanessa; Navas, Ana; Bernardo, Raquel; Carmen, Moreno; Jurado, Aurora.  Hospital Universitario Reina Sofia, C\u00f3rdoba.  Background.  Acquired angioedema is a life-threatening non-common disorder whose clinical presentation is characterized by recurrent episodes of edema and gastrointestinal symptoms. Sj\u00f6gren syndrome is an autoimmune disease with a clinical presentation of ocular and oral dryness and salivary gland swelling, which commonly overlaps with other diseases. We aimed to describe the algorithm followed to diagnose an overlap case between acquired angioedema and Sj\u00f6gren syndrome. Material and Methods.  A 62-year-old female with no medical history of interest consulted Allergology Department with 15 days of daily facial edema distributed in eyelids and lips but no other skin lesions or systemic symptoms. In every episode, the patient needed to attend emergency room and was treated with corticoids iv and antihistaminic with temporary response and no need of hospitalization. Laboratory tests were performed, including hemogram, skin prick test, complement, immunoglobulin and autoantibody detection. Results.  Blood analyses revealed low levels of C1INH 10 mg/dL [41-95], C1q 6,00 mg/dL [21,0-38,0], C3 51,80 mg/dL [75,00-120,00] and C4 8,21 mg/dL [12,00-50,00]. Acquired angioedema was diagnosed and treatment was initiated with intravenous C1-inhibitor weekly. During the followed-up, the patient referred partial improvement, but joint pain with metacarpal inflammation appeared in the absence of dry syndrome. Under these new symptoms, autoimmunity tests were performed, reporting positive anti-nuclear antibodies at 1/640 title with homogeneous pattern (AC-1) by indirect immunofluorescence and anti-SSA/Ro 8 U/L (<7,0) and anti-SSB/La antibodies 9 U/L (<7,0). Sj\u00f6gren syndrome was diagnosed after the result of a minor salivary gland biopsy, and treatment was initiated with hydroxychloroquine and low corticoid dose. After 3-weeks of the treatment onset, the patient was asymptomatic with no new episodes of angioedema until now. Conclusion.  Physicians must know the atypical presentation of a possible overlap between a complement disease and autoimmune disease, its correlation with analytical findings and its remission with  \n  \nspecific treatment.                                                       \n  \nP-029  LAMIN A/C IN ANTIGEN PRESENTING CELLS AND ITS ROLE IN INFLAMMATORY BOWEL DISEASE.  Herrero Fern\u00e1ndez, Beatriz1; G\u00f3mez Bris, Raquel1; Zorita, Virginia2; S\u00e1nchez Mart\u00ednez, H\u00e9ctor3; S\u00e1ez, \u00c1ngela4; Arribas, Silvia Magdalena1; Gonz\u00e1lez Granado, Jos\u00e9 Mar\u00eda3.  1Universidad Aut\u00f3noma de Madrid, Madrid; 2Centro Nacional de Investigaciones Cardiovasculare, Madrid; 3Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12), Madrid; 4Universidad Francisco de Vitoria (UFV), Madrid.  The intermediate filament, lamin A/C, is in the nuclear envelope. Antigen presenting cells (APCs) stimulate na\u00efve T cells, triggering T cell activation and adaptive immune responses. Several pathological processes are linked to abnormal APC function altering the subsequence T cell-mediated response. Lamin A/C in CD4+ T cells enhances T cell activation and differentiation towards Th1 phenotype but its role in APC has not been defined. Inflammatory bowel disease (IBD) is a heterogeneous state of chronic intestinal inflammation of unknown causes. IBD has been linked to genetic and environmental factors, microbiota dysbiosis, innate and adaptive immunity exacerbation and epithelial intestinal barrier disfunction. IBD pathogenesis is classically associated to gut accumulation of proinflammatory Th1 and Th17 cells while insufficient Tregs suppression. Our objective is to analyze the role of lamin A/C in APC capacity to trigger adaptive immune responses in IBD. To achieve this, we studied a mouse lacking lamin A/C (Lmna-/-) in the myeloid compartment (LysM) as a model DSS induced-IBD, and analyzed GM-CSF bone marrow derived-DCs (BM-DCs) from these mice for in vitro studies.   In vitro, Lmna-/- GM-CSF BM-DCs showed less production of proinflammatory cytokines mRNA. Lmna-/- GM-CSF BMDCs showed a diminished capacity to form conjugates with na\u00efve CD4+ T cells and to promote CD4+ T cells activation and proliferation compared to WT BM-DCs. Lmna-/- BM-DCs induced less Th1 differentiation as observed by a decrease in Th1-specific transcription factor T-bet and IFN\u03b3 production in CD4+ T cells when compared to WT BM-DCs. The adoptive transfer of Lmna-/- BMDC to WT mice before the treatment with DSS ameliorates colitis induction when compared to WT GMSCF-BMDC transfer.  In conclusion, the absence of lamin A/C in APCs protects from IBD maybe by a reduction in proinflammatory cytokine production and by the decrease of Th1-mediated response.       \n  \nP-030  ELABORACI\u00d3N DE P\u00cdLDORAS FORMATIVAS POR ALUMNADO DE CIENCIAS DE LA SALUD, DE FORMA MULTIDISCIPLINAR Y COLABORATIVA.   Y\u00e1\u00f1ez Boyer, Alberto; Corch\u00f3n Arreche, Silvia; Mart\u00ednez Sabater, Antonio; Bono Tapp, Cristina; Gil Herrero, M. Luisa; Merelles Tormo, Antoni.  Universitat De Val\u00e8ncia, Valencia.  En el presente proyecto hemos planteado un proceso de actualizaci\u00f3n e innovaci\u00f3n docente basado en el uso del microaprendizaje entre profesorado y alumnado de la asignatura Inmunolog\u00eda e Inmunopatolog\u00eda (IEI) del grado de Bioqu\u00edmica y Ciencias Biom\u00e9dicas (BCB) y de varias asignaturas del grado de Enfermer\u00eda de la Universitat de Val\u00e8ncia.  La asignatura IEI contempla una pr\u00e1ctica de laboratorio en la que se analiza la capacidad fagoc\u00edtica y microbicida de leucocitos de sangre humana. Esta es una oportunidad para el alumnado del grado de BCB de manipular una muestra real, tal y como se desarrollar\u00eda en un laboratorio de hospital. La manipulaci\u00f3n de estas muestras requiere una serie de medidas de bioseguridad, as\u00ed como estar preparado para actuar ante alguna contingencia que pudiera producirse en el momento de la extracci\u00f3n. El alumnado del grado de Enfermer\u00eda posee los conocimientos necesarios en cuanto a las pr\u00e1cticas en bioseguridad para la extracci\u00f3n y manipulaci\u00f3n de muestras humanas, pero no est\u00e1n tan familiarizados con la metodolog\u00eda y las t\u00e9cnicas de algunos ensayos que se llevan a cabo en los laboratorios cl\u00ednicos. El alumnado de ambos grados interaccion\u00f3 durante las pr\u00e1cticas (en la extracci\u00f3n y en la pr\u00e1ctica posterior) y se generaron p\u00edldoras formativas en forma de v\u00eddeos cortos de cinco minutos, como herramienta educativa y como resultado del aprendizaje colaborativo interdisciplinar. El material generado se ofreci\u00f3 al alumnado de ambos grados junto con una encuesta de opini\u00f3n y valoraci\u00f3n. Los resultados de las encuestas fueron positivos en cuanto al nivel de conocimientos transmitidos, la utilidad y la calidad de los v\u00eddeos. Este proyecto ha iniciado una colaboraci\u00f3n interdepartamental en innovaci\u00f3n docente y ha generado objetos de microaprendizaje que pretenden completar la formaci\u00f3n del alumnado y generar cohesi\u00f3n entre diferentes disciplinas afines. Proyecto de innovaci\u00f3n docente UV-SFPIE_PID-1638203, Universitat de Val\u00e8ncia.          \n  \nP-031  LOCALIZACI\u00d3N SUBCELULAR DE TRIPARTITE MOTIF (TRIM)-37 EN RESPUESTA A LPS E INTERFER\u00d3N E IDENTIFICACI\u00d3N DE LOS COMPONENTES DE SU SIGNALOSOMA  Barbero Casc\u00f3n, Miguel1; Franzka, Patricia1; De Andr\u00e9s, Andrea1; Aldea, Marcos2; Perez-Chac\u00f3n, Gema3; Zapata, Juan Manuel1.  1Instituto de Investigaciones Biom\u00e9dicas \"Alberto Sols\" (CSIC-UAM), Madrid; 2Facultad de Medicina, Universidad CEU San Pablo, Madrid; 3Centro Nacional de Oncolog\u00eda, Madrid.  Cada vez existen m\u00e1s evidencias del papel de determinadas especies componentes de la microbiota en la regulaci\u00f3n de determinados procesos oncog\u00e9nicos. En este trabajo, hemos estudiado en distintas l\u00edneas tumorales y no tumorales el efecto del lipopolisac\u00e1rido (LPS) y del interfer\u00f3n (IFN)-\u03b3 en la localizaci\u00f3n subcelular de TRIM37, una E3 ubiquitina ligasa que contiene un dominio TRAF. En el citosol de c\u00e9lulas HepG2 (y en otros tipos celulares) TRIM37 se asocia a peroxisomas (colocaliza con la catalasa). En respuesta a IFN\u03b3 se induce la expresi\u00f3n de las prote\u00ednas NMI e IFP35, las cuales colocalizan con TRIM37 en los peroxisomas. Sin embargo, en otros tipos celulares, como PC3 y EA.hy926, TRIM37 se encuentra preferentemente en el n\u00facleo, donde colocaliza parcialmente con los cuerpos nucleares PML (PML-NBs). En respuesta a IFN\u03b3, el n\u00famero de PML-NBs aumenta, as\u00ed como su colocalizaci\u00f3n con TRIM37. En PC3 y EA.hy926, NMI e IFP35 tambi\u00e9n se inducen con IFN\u03b3, pero mientras que NMI se moviliza al n\u00facleo y colocaliza con TRIM37 en los PML-NBs, IFP35 permanece mayoritariamente en el citosol y no colocaliza en los PML-NBs. Cuando las c\u00e9lulas PC3 y EA.hy926 se tratan con LPS, se observa tambi\u00e9n la inducci\u00f3n de NMI e IFP35 y colocalizaciones similares a las anteriores, pero con una cin\u00e9tica diferente. As\u00ed, se observa que TRIM37 y PML-NBs colocalizan en el n\u00facleo antes de la inducci\u00f3n de la expresi\u00f3n y la movilizaci\u00f3n al n\u00facleo de NMI. Estos resultados indican que TRIM37 es un componente de los PML-NBs, a los que m\u00e1s tarde se asociar\u00eda NMI. Tambi\u00e9n sugiere que TRIM37, una ubiquitina ligasa con un dominio hom\u00f3logo a la histona deacetilasa-1 (aunque su funcionalidad no ha sido comprobada), podr\u00eda ser un componente regulador de la actividad transcripcional de PML y participar en la regulaci\u00f3n de PML por los receptores de reconocimiento de patrones.           \n  \nP-032  AN\u00c1LISIS DE GENES DE LA RUTA DE LA AUTOFAGIA EN ENFERMEDAD DE BEH\u00c7ET   Mu\u00f1oz Garc\u00eda, Raquel; Ortiz Aljaro, Pilar; Lozano Garc\u00eda, Jose Raul; Gonz\u00e1lez Escribano, Maria Francisca.  Hospital Universitario Virgen del Roc\u00edo, Sevilla.  Introducci\u00f3n:   La Enfermedad de Behcet (BD) es una vasculitis sist\u00e9mica. Inmunol\u00f3gicamente se considera una enfermedad de patr\u00f3n mixto, en cuya predisposici\u00f3n influyen desajustes en ambas ramas del sistema inmunitario. Adem\u00e1s de su relaci\u00f3n bien establecida con HLA-B51, se ha descrito asociaci\u00f3n de la enfermedda con genes relacionados con el sistema inmunitario innato como los del inflamasoma. Independientemente de otras funciones, la autofagia es un proceso que regula la inflamaci\u00f3n, de heho, se ha descrito asociaci\u00f3n entre genes relacionados con la autofagia y la predisposici\u00f3n a enfermedades con componente inflamatorio como la enfermedad de Crohn. Objetivo: Investigar la posible asociaci\u00f3n de la ruta de la autofagia con susceptibilidad a BD. Materiales y m\u00e9todos:  Genotipado mediante secuenciaci\u00f3n masiva del exoma de 17 genes relacionados con autofagia: ULK1, ATG13, RB1CC1, ATG101, PI3KC3, BECN1, ATG14, PIK3R4, NRBF2, RUBCN, UVRAG, WIPI1, WIPI2, ATG2A, ATG2B, ATG16L1, ATG5, ATG12, ATG3, ATG4A, ATG4B, ATG4D, ATG7 y ATG10. El estudio incluye una cohorte de 58 pacientes con BD. Las frecuencias al\u00e9licas de la poblaci\u00f3n control se obtuvieron de la poblaci\u00f3n IBS del proyecto 1000 genoma que incluye 107 controles. Las frecuencias al\u00e9licas en pacientes y controles se compararon mediante la prueba \u03c7\u00b2. Resultados:  Se identificaron una media de 25 variantes por muestra. Se detect\u00f3 diferente distribuci\u00f3n al\u00e9lica de la variante c.4147C>G (rs3759601), p.Gln1383Glu en el gen ATG2B en pacientes y controles (MAF G 0.32 en pacientes Vs. 0.42 en controles p=0.03, OR=0.59, 95% IC=0,36-0,96).  Conclusiones:  La autofagia y concretamente, variantes en el gen ATG2B pueden estar relacionada con la predisposici\u00f3n a desarrollar BD.      \n  \nP-033  LA INMUNIDAD CELULAR: \u00bfLA GRAN OLVIDADA EN LA PANDEMIA DE COVID-19?  L\u00f3pez Corbal\u00e1n, Juan Carlos1; Segu\u00ed Ripoll, Jos\u00e9 Miguel2.  1Subdelegacion del Gobierno en Alicante/ Centro Vacunas, Alicante; 2Hospital San Juan Alicante, Alicante.  La pandemia de SARS CoV2 a d\u00eda de hoy, seg\u00fan el Jonhs Hopkins ha producido m\u00e1s de 535   millones de casos y cerca de 6,3 millones de muertes. Cifras que seguramente ser\u00e1n inferiores a las reales. Tras los primeros meses de incertidumbre y preocupaci\u00f3n, quiz\u00e1s los medios de comunicaci\u00f3n han influido en mirar \u00fanica y exclusivamente a la inmunidad humoral quiz\u00e1s de forma obsesiva sobre el \u201cnivel protector de anticuerpos neutralizantes\u201d y quiz\u00e1s olvidando a la inmunidad celular, las c\u00e9lulas T de memoria. A d\u00eda de hoy quiz\u00e1s no hay una cifra cuantitativa que pudi\u00e9ramos considerar como \u201cde seguridad\u201d de anticuerpos y que en la g\u00e9nesis de la Tras la infecci\u00f3n, las c\u00e9lulas T se diferencian en una poblaci\u00f3n heterog\u00e9nea de c\u00e9lulas T efectoras que pueden mediar en la eliminaci\u00f3n del pat\u00f3geno, aparece un subconjunto de estas c\u00e9lulas T efectoras posee la capacidad de sobrevivir a largo plazo y madurar hasta convertirse en c\u00e9lulas T de memoria que pueden proporcionar inmunidad a largo plazo.  Creemos que las t\u00e9cnicas de medici\u00f3n y contaje de c\u00e9lulas T son caras y complicadas, pero nos ayudar\u00edan a comprender las se\u00f1ales que regulan el desarrollo de las c\u00e9lulas T de memoria es crucial para dise\u00f1ar vacunas capaces de provocar una inmunidad basada en c\u00e9lulas T. Las c\u00e9lulas T CD4(+) son esenciales para la formaci\u00f3n de c\u00e9lulas T de memoria protectoras CD8(+) tras una infecci\u00f3n o inmunizaci\u00f3n. Sin embargo, hasta hace poco, no estaban claros los mecanismos por los que las c\u00e9lulas T CD4(+) act\u00faan para favorecer el desarrollo de c\u00e9lulas T CD8(+) de memoria tras la infecci\u00f3n.            \n  \nSesi\u00f3n Poster. Inmunodeficiencias: primarias y secundarias.  P-034  DIAGN\u00d3STICO DE DEFICIENCIA DE NFKB2 A RA\u00cdZ DE INFECCI\u00d3N GRAVE POR COVID-19 Morales Garc\u00eda, Carmen; Mu\u00f1oz Garc\u00eda, Raquel; Ortiz Aljaro, Pilar; Olbrich, Peter; Neth, Olaf; Lucena Soto, Jose Manuel.  Hospital Universitario Virgen del Roc\u00edo, Sevilla.  Var\u00f3n de 4 a\u00f1os sin antecedentes familiares, con dos episodios de ingreso en la Unidad de Cuidados Intensivos: un primer ingreso a los 2 a\u00f1os por meningoencefalitis por enterovirus y un segundo ingreso un a\u00f1o despu\u00e9s por una neumon\u00eda causada por sobreinfecci\u00f3n bacteriana en el contexto de gripe A. En los siguientes a\u00f1os el paciente estuvo en seguimiento por la unidad de neurolog\u00eda por un trastorno del lenguaje y sufri\u00f3 diversas infecciones de las v\u00edas respiratorias altas que no requirieron ingreso hospitalario.  En enero de 2022 ingresa por infecci\u00f3n por COVID-19 con neumon\u00eda con caracter\u00edsticas de etiolog\u00eda bacteriana. Al inicio present\u00f3 una evoluci\u00f3n cl\u00ednica favorable pero el sexto d\u00eda reapareci\u00f3 la fiebre acompa\u00f1ada de un marcado aumento de los reactantes de fase aguda y una bajada de la saturaci\u00f3n de ox\u00edgeno al 93-94% que precis\u00f3 del inicio de oxigenoterapia. El estudio inmunol\u00f3gico revel\u00f3 una hipogammaglobulinemia pronunciada acompa\u00f1ada de niveles bajos de c\u00e9lulas NK y elevados de CD25 soluble.  Material y m\u00e9todos: Secuenciaci\u00f3n del exoma con an\u00e1lisis dirigido de 461 genes asociados a Errores Cong\u00e9nitos del Sistema Inmunol\u00f3gico. La secuenciaci\u00f3n se realiz\u00f3 utilizando la plataforma NextSeq 500 Sequencing System (Illumina). Para el an\u00e1lisis bioinform\u00e1tico se utiliz\u00f3 la plataforma SOPHiA DDM. Resultados: Se detect\u00f3 una variante gen\u00e9tica en el gen NFKB2 (c.2554delC) en heterocigosis, no descrita previamente. Esta deleci\u00f3n de un nucle\u00f3tido implica el cambio de la pauta de lectura y la aparici\u00f3n de un cod\u00f3n de parada prematuro. Se valora, por tanto, como patog\u00e9nica. Se utiliz\u00f3 la secuenciaci\u00f3n Sanger para confirmar el resultado y realizar el estudio familiar, el cual revel\u00f3 el car\u00e1cter de novo de la mutaci\u00f3n. Conclusiones: En base a la mutaci\u00f3n presentada, la cl\u00ednica y los datos inmunol\u00f3gicos (hipogammaglobulinemia); el paciente fue diagnosticado de deficiencia de NFKB2, de herencia  \n  \nautos\u00f3mica dominante y adscrita a la Inmunodeficiencia Com\u00fan Variable.                                                      \n  \nP-035  NOVEL GERMLINE TET2 MUTATIONS IN TWO UNRELATED PATIENTS WITH AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME-LIKE PHENOTYPE AND HEMATOLOGIC MALIGNANCY  L\u00f3pez-Nevado, Marta1; Ortiz-Mart\u00edn, Javier2; Serrano, Cristina3; P\u00e9rez-Saez, Mar\u00eda A4; L\u00f3pez-Lorenzo, Jos\u00e9 L4; Gil-Etayo, Francisco J1; Rodr\u00edguez-Fr\u00edas, Edgar1; Cabrera-Marante, Oscar1; Morales-P\u00e9rez, Pablo1; Rodr\u00edguez-Pinilla, Mar\u00eda S5; Manso, Rebeca5; Salgado-S\u00e1nchez, Roc\u00edo N4; Cerd\u00e1-Montagud, Ana4; Quesada-Espinosa, Juan F6; G\u00f3mez-Rodr\u00edguez, Mar\u00eda J6; Paz-Artal, Estela1; Mu\u00f1oz-Calleja, Cecilia7; Arranz-S\u00e1ez, Reyes2; Allende, Luis M1.  1Immunology Department, University Hospital 12 de Octubre, Madrid; 2Hematology Department, University Hospital La Princesa, Madrid; 3Immunology Department, University Hospital Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid; 4Hematology Department, University Hospital Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid; 5Pathology Department, Research Institute Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid; 6Genetics Department, University Hospital 12 de Octubre, Madrid; 7Immunology Department, University Hospital La Princesa, Madrid.  Somatic mutations in the ten-eleven translocation methylcytosine dioxygenase 2 gene (TET2) have been associated to hematologic malignancies. More recently, biallelic and monoallelic germinal mutations conferring susceptibility to lymphoid and myeloid cancer have been described. We report two unrelated autoimmune lymphoproliferative syndrome-like patients who presented with T-cell lymphoma associated to novel germinal biallelic or monoallelic mutations in the TET2 gene. Both patients presented a history of chronic lymphoproliferation with lymphadenopathies and splenomegaly, cytopenias and immune dysregulation. We identified the first compound heterozygous patient for TET2 mutations (P1) and the first ALPS-like patient with a monoallelic TET2 mutation (P2). P1 had the most severe form of autosomal recessive disease due to TET2 loss of function resulting in absent TET2 expression and profound increase in DNA methylation. The immunophenotype showed some alterations in innate and adaptive immune system as inverted myeloid/plasmacytoid dendritic cells ratio, elevated terminally differentiated effector memory CD8 T-cells re-expressing CD45RA (CD8 TEMRA), regulatory T-cells and Th2 circulating follicular T-cells. According to the ALPS-like suspicion, double negative T-cells, vitamin B12 and IL-10 were elevated. Interestingly, the healthy brother of P1 carried one of the TET2 mutations and presented some biomarkers of immune dysregulation, such as elevated IL-10 levels, decreased HDL levels, inverted mDCs/pDCs ratio, expanded CD8 TEMRA and increased DNA methylation in isolated CD8 subpopulations. P2 presented a later debut of the disease, with less severe immune alteration. According to ALPS-like suspicion, she showed elevated vitamin B12, hypergammaglobulinemia and decreased HDL levels. Therefore, novel molecular defects in TET2 confirm and expand both clinical and immunological phenotype, contributing to the better  \n  \nknowledge of the bridge between cancer and immunity.                                                       \n  \nP-036  DEVELOPMENT OF ARTIFICIAL THYMIC ORGANOIDS AS A MODEL OF T-LYMPHOCYTE DIFFERENTIATION TO STUDY T-CELL IMMUNODEFICIENCIES  Cela Rodr\u00edguez, Carmela1; Gonz\u00e1lez Garc\u00eda, Sara1; Alcain S\u00e1nchez, Juan1; Garc\u00eda Torres, Enrique2; Arias Dachary, Francisco Javier3; Boni, Lorenzo2; Pastor Senovilla, \u00c1ngela3; Gonz\u00e1lez Granados, Luis Ignacio3; Toribio Garc\u00eda, Mar\u00eda Luisa1.  1Centro de Biolog\u00eda Molecular Severo Ochoa (CSIC-UAM), Madrid; 2Cirug\u00eda Card\u00edaca Infantil. Instituto Pedi\u00e1trico del Coraz\u00f3n. Hospital Universitario 12 de Octubre, Madrid; 3Instituto de Investigaci\u00f3n Hospital 12 de Octubre (i+12). Hospital Universitario 12 de Octubre, Madrid.  Introduction  Next Generation Sequencing has greatly improved the diagnosis of genetic defects underlying different types of immunodeficiencies.  However, T-cell lymphopenia can originate from hematopoietic stem cell-extrinsic defects associated with the thymus microenvironment, for which alternative diagnostic methods are required. Identification of the patient's specific T-cell differentiation blockage can help to characterize disease severity and guide diagnosis and treatment. To this end, in vitro T-cell differentiation systems based on artificial thymic organoids (ATOs) have been developed.  Objectives 1.Generation and functional validation of ATOs for the differentiation of human early thymic progenitors (ETP) and hematopoietic stem cells from umbilical cord blood (CB) into mature T lymphocytes. 2.Application of ATOs to study T-cell differentiation from hematopoietic progenitors of patients with T lymphopenia in order to determine their maturational defect.  M&M: CD34+ progenitors were obtained by immunomagnetic selection from thymus and CB from healthy donors, or from peripheral blood of immunodeficient patients. ATOs generated with the stromal cell line MS5 transduced with Notch ligand DLL4 (MS5-hDLL4) were seeded with CD34+ progenitors and cultured in vitro for 6-12 weeks in the presence of IL-7 and Flt3-L. T-cell differentiation was analyzed by flow cytometry.  Results: We provide evidence of the reliability of the ATO system for supporting the differentiation of human hematopoietic progenitors along the sequential intrathymic maturing stages and their  \n  \nefficient generation of mature T lymphocytes. Comparative studies using CD34+ progenitors from patients with severe combined immunodeficiency (SCID) revealed specific developmental defects at particular T-cell maturation stages.  Conclusions: ATOs allow to study T-cell maturation of patients with T -lymphopenia of unknown origin and to determine whether their defect relies on intrinsic alterations of hematopoietic progenitors or extrinsic cues due to thymic microenvironment defects. Therefore, ATOs represent a useful tool for diagnosis and treatment orientation of immunodeficient patients, opening a new door toward personalized medicine.     \n                  \n \n  \nP-037  ANTICUERPOS ANTI-SARS-COV-2 EN PACIENTES CON INMUNODEFICIENCIAS PRIMARIAS TRATADOS CON INMUNOGLOBULINAS  Egu\u00eda, Jorge1; Caballero, M\u00aa Araceli2; Cos, M\u00aa Lourdes2; Grau, Santiago2; Mellibovsky, Leonardo2; Villegas, Eduardo1; Blasco, Fabiola2; Lemus, Ana2; Crespo, Marta2; Padilla, Eduardo1; Gimeno, Ram\u00f3n2.  1Laboratori de Refer\u00e8ncia de Catalunya (dibi), El Prat de Llobregat; 2Hospital del Mar, Barcelona.  Introducci\u00f3n: La pandemia de la COVID-19 ha originado una alta comorbilidad en pacientes con inmunodeficiencias primarias, contrarrestada con las vacunas frente al SARS-CoV-2.  Objetivos: Se determin\u00f3 la respuesta inmune vacunal en 19 pacientes con d\u00e9ficit primario de anticuerpos (DPA), 15 de ellos tratados con inmunoglobulinas (Igs) de sustituci\u00f3n.  Material y m\u00e9todos: La respuesta humoral se evalu\u00f3 mediante la determinaci\u00f3n de anticuerpos anti-spike (AAS) y anti-nucleoc\u00e1pside (AAN) y la respuesta celular mediante el ensayo de liberaci\u00f3n de interfer\u00f3n gamma. Ambas respuestas se evaluaron antes de la vacuna y al mes de la segunda dosis y los resultados se compararon con los obtenidos en un grupo de 50 individuos sanos.  Resultados: Los valores medios de ASS fueron de 170 [20-800] AU/mL y 734 [532-1149] AU/mL en pacientes y controles, respectivamente. Se detect\u00f3 respuesta celular en el 58% de los pacientes. El 44% de los pacientes ten\u00edan AAN prevacunales, sin evidencias de haber pasado la enfermedad, por lo que se analizaron diferentes lotes de Igs administradas, objetiv\u00e1ndose la presencia de AAN.   Conclusiones: Se demostr\u00f3 una menor respuesta humoral y celular en pacientes con DPA tras la vacunaci\u00f3n, en comparaci\u00f3n con los controles. Se constat\u00f3 la presencia de AAN en las Igs administradas y su transferencia a los pacientes con DPA, pudiendo proporcionar un nivel adicional de protecci\u00f3n frente al SARS-CoV-2.       \n  \n   Niveles de AAN en lotes de Igs administradas  Lote Producto  Muestras  AAN (positivo > 1.0) 1  Flebogamma  1 Negativo  0.25 2 Flebogamma  1 Positivo  1.69 3 Flebogamma  1 Positivo  5.72 4 Flebogamma 1 Positivo 1.77 5 Flebogamma  1 Positivo  14.02 +/ - 0.55 6 Flebogamma  1 Positivo  3.85 +/ - 0.06 7 Flebogamma  1 Positivo  13.60  8 HyQvia  1 Positivo  6.06 +/ - 0.13 9 Plangamma  1 Negativo  0.24 +/ - 0.12 10 Plangamma  1 Positivo  57.70  11 Plangamma  1 Positivo  58.80  12 Flebogamma  1 Positivo  5.59                                  \n  \nP-038  IMMUNE RECONSTITUTION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A PATIENT WITH AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME-LIKE PHENOTYPE DUE TO ADA2 DEFICIENCY   L\u00f3pez -Nevado, Marta1; L\u00f3pez-Godino, Oriana2; Fern\u00e1ndez-L\u00f3pez, \u00c1ngel3; Quesada-Espinosa, Juan F4; Delmiro, Aitor5; Allende, Luis M1.  1Immunology department, University Hospital 12 De Octubre, Madrid; 2Hematology Department. University Hospital Morales Mesegu\u00e9, Murcia; 3Hematology Department, Hospital HLA La Vega, Murcia; 4Genetics Department, University Hospital 12 de Octubre, Madrid; 5UDisGen, University Hospital 12 de Octubre, Madrid.  Adenosine deaminase 2 deficiency (DADA2) is an autosomal recessive auto-inflammatory disorder that presents in some cases with benign lymphoproliferation and cytopenias mimicking an autoimmune lymphoproliferative syndrome-like (ALPS-like) phenotype. Here we described an ALPS-like 40-year-old man with DADA2 who underwent hematopoietic stem cell transplantation (HSCT). The patient presented lymphadenopathies and splenomegaly with no history of infections in childhood. Biopsy of lymph node was consistent with an EBV-associated Hodking lymphoma (HL). After treatment, he achieved complete remission. He presented persistent splenomegaly and cytopenias, so screening for ALPS was indicated. Immunologic evaluation revealed T lymphopenia, decreased levels of na\u00efve, increased TEMRA and activated CD8 T-cells, B lymphopenia, low levels of class-switched memory B-cells and elevation of transitional and CD21low B-cells. ALPS-biomarkers were normal except to elevated vitamin B12. Molecular studies revealed a previously unreported homozygous variant in ADA2 (c.1348G>C; p.Gly450Arg) that lead to a deficient ADA2 enzymatic activity. He was candidate for an autologous HSCT from her healthy carrier sister as haploidentical donor. Complete quimerism was presented since day +28 but immune reconstitution 2 months after transplant was partial, with severely decreased na\u00efve and increased activated effector T-cells. Elevation of transitional B-cells suggesting an immature B compartment was also observed. Six months after transplant, an improvement was observed but not achieving total reconstitution. ADA2 enzymatic activity was already recovered at 2 months post-transplant. Nowadays, he has no history of graft versus host disease and/or complications after transplant. In conclusion, allogeneic HSCT was successfully performed in the patient reported here, without significant toxicity and it rescued ADA2 functional activity with complete remission of the associated HL in the reevaluation after HSCT.       \n  \nP-039  TRATAMIENTO DE INMUNODEFICIENCIAS: PRODUCCI\u00d3N DE MEDICAMENTOS HEMODERIVADOS EN UNA COMUNIDAD   Mart\u00edn, M Carmen; Gonzalez, M Isabel; Santamar\u00eda, Jennifer; Y\u00e1\u00f1ez, Marta; Blanco-Peris, Lydia.  Centro de Hemoterapia y Hemodonaci\u00f3n de Castilla y Le\u00f3n, Valladolid.  El \u00fanico tratamiento disponible para muchas inmunodeficiencias: la gammaglobulina, se obtiene exclusivamente del plasma de origen humano. Estos enfermos requerir\u00e1n generalmente tratamiento de por vida y no es posible fabricar o producir gammaglobulinas, si no es a partir de plasma procedente de donantes. Los datos analizados en el presente estudio se han obtenido de las bases de datos de nuestro centro de trasfusi\u00f3n (n\u00famero de donantes y litros plasma), los registros de la industria fraccionadora (hemoderivados obtenidos) y el informe anual de actividad de centros y servicios de trasfusi\u00f3n (consumo de hemoderivados en nuestra comunidad). En los \u00faltimos 5 a\u00f1os se ha obtenido una media de 25.095 L/a\u00f1o (23.824-26.367) de plasma (IC95%) procedentes de un m\u00ednimo de 41.825 donaciones. Por cada af\u00e9resis se obtienen 600 mL de plasma, mientras que de una donaci\u00f3n de sangre total, solo se consiguen unos 200 mL. Desde 2017 se han obtenido 125.477 L totales de plasma, a partir de los cuales se han fraccionado 513.870 g de gammaglobulina (4.09 g/L de plasma) y 3.162.120 g de alb\u00famina. Aunque la cantidad es variable, un paciente adulto podr\u00eda necesitar unos 300 g de gammaglobulina al a\u00f1o, as\u00ed que las donaciones de plasma estar\u00edan permitiendo tratar m\u00e1s de 300 casos cada a\u00f1o: cada uno de ellos requerir\u00eda unas 125 donaciones de plasma anuales. Con los medicamentos obtenidos de la industria fraccionadora se han cubierto el 46.1% de las necesidades de gammaglobulina de la comunidad, sin que este porcentaje de cobertura disminuyera con la pandemia, ni durante las campa\u00f1as de plasma convaleciente. El Centro de Hemoterapia y Hemodonaci\u00f3n de nuestra comunidad es l\u00edder en Espa\u00f1a en cuanto a litros de plasma donados por habitante pero, dado el elevado n\u00famero de donaciones necesarias para tratar cada caso de inmunodeficiencias, es necesario continuar fomentando los programas de donaci\u00f3n de plasma.     \n  \n                                  \n \n  \nP-040  MANEJO Y DETECCI\u00d3N PRECOZ DE REACCI\u00d3N ADVERSA GRAVE A GAMMAGLOBULINA INTRAVENOSA: EL PAPEL DE LA ENFERMER\u00cdA ESPECIALIZADA   Escobar Palaz\u00f3n, Mar\u00eda \u00c1ngeles; D\u00edaz Luna, Mercedes; Balastegui Mart\u00edn, H\u00e9ctor; Moncayo Mu\u00f1oz, Ana Paulina; Carbone Campoverde, Javier; Gil Herrera, Juana; Fern\u00e1ndez Cruz, Eduardo.  HGU Gregorio Mara\u00f1on, Madrid.  El TRALI (acr\u00f3nimo de transfusion related acute lung injury o reacci\u00f3n aguda pulmonar en relaci\u00f3n a transfusi\u00f3n) es una complicaci\u00f3n rara tras uso de gammaglobulinas IV (GGIV). Presentamos el caso cl\u00ednico de un var\u00f3n de 86 a\u00f1os con Inmunodeficiencia Variable Com\u00fan (IDVC), hiperesplenismo secundario y trombopenia asociada, en tratamiento sustitutivo con GGIV 10% a dosis de 20g cada 4 semanas. Durante una de sus infusiones mensuales en Hospital de D\u00eda de Inmunolog\u00eda, desarroll\u00f3 un cuadro cl\u00ednico de sensaci\u00f3n dist\u00e9rmica, disnea y desaturaci\u00f3n de O2 de hasta 82%, con cifras tensionales y frecuencia cardiaca normales. La infusi\u00f3n se detuvo y se traslad\u00f3 al paciente al Servicio de Urgencias. En ning\u00fan momento present\u00f3 sintomatolog\u00eda cut\u00e1nea ni gastrointestinal, dolor tor\u00e1cico o p\u00e9rdida de consciencia, descart\u00e1ndose anafilaxia. En una radiograf\u00eda de t\u00f3rax se objetivaban m\u00faltiples opacidades bilaterales en campos medios con sospecha de infecci\u00f3n respiratoria COVID-19, por lo que se realiz\u00f3 PCR para SARS-CoV2, resultando negativa. Anal\u00edticamente presentaba leucocitosis con linfopenia asociada, con elevaci\u00f3n de reactantes de fase aguda (PCR y fibrin\u00f3geno) as\u00ed como de d\u00edmero D. La evaluaci\u00f3n reuni\u00f3 criterios cl\u00ednicos y anal\u00edticos de TRALI. Tras an\u00e1lisis del lote administrado de GGIV, as\u00ed como suero del paciente en el Centro de Transfusiones, se detectaron anticuerpos IgG antiHNA 1a, 1b, 1c, 3a y 3b en el preparado utilizado. Tras este episodio, se decidi\u00f3 cambiar la terapia de reemplazo de GGIV a gammaglobulina subcut\u00e1nea (GGSC) facilitada, prescribi\u00e9ndose a dosis de 20g cada 4 semanas. El paciente fue entrenado por parte de enfermer\u00eda especializada en el hospital de d\u00eda para el aprendizaje de la autoadministraci\u00f3n de la GGSC en domicilio. Actualmente, ha acumulado varias sesiones de terapia sin complicaciones. Como conclusi\u00f3n, hay que estar atentos ante esta posible complicaci\u00f3n grave del uso de GGIV.  En caso de TRALI una opci\u00f3n es la terapia con GGSC facilitada.          \n  \nP-041  ALTERNATIVAS TERAP\u00c9UTICAS EN PACIENTE CON MUTACION EN STAT1 Y CANDIDIASIS MUCOCUT\u00c1NEA CR\u00d3NICA   Di Natale, Marisa; Balastegui, Hector; Garcia-Mart\u00ednez, Elena; Fernandez-Cruz, Eduardo; Rodr\u00edguez-Sainz, Carmen.  Hospital General Universitario Gregorio Mara\u00f1on, Madrid.  Introducci\u00f3n La prote\u00edna STAT1 (Signal Transducer and Activator of Transcription 1) media la expresi\u00f3n de una gran variedad de genes importantes en la respuesta a pat\u00f3genos. Presentaci\u00f3n del Caso Mujer de 37 a\u00f1os en seguimiento por la Unidad de Inmunolog\u00eda Cl\u00ednica del Hospital Universitario Gregorio Mara\u00f1\u00f3n y con diagn\u00f3stico de candidiasis mucocut\u00e1nea cr\u00f3nica (CMC) de predominio orofar\u00edngeo con debut a los 8 meses. Ingresos por m\u00faltiples cuadro de candidiasis esof\u00e1gica severa y con resistencia a numerosas l\u00edneas de tratamiento, incluido antif\u00fangicos.  Inicio tratamiento con autovacuna de mucosas Candida al 100% en 2015 con mejor\u00eda de los cuadros llegando a desaparecer las lesiones y con empeoramiento cl\u00ednico tras las temporadas de suspensi\u00f3n. En el estudio inmunol\u00f3gico se objetiva defecto de IgG4, linfopenia B e hipocomplementemia C3. Adem\u00e1s de anticuerpos de celiaqu\u00eda positivos sin asociar cl\u00ednica gastrointestinal.  M\u00e9todos Se aisl\u00f3 DNA gen\u00f3mico a partir de sangre perif\u00e9rica de la paciente y se ha procedi\u00f3 a la construcci\u00f3n de una librer\u00eda enriquecida en 200 genes relacionados con la respuesta inmune.  Resultados En el an\u00e1lisis inmunogen\u00e9tico, se identifica una mutaci\u00f3n missense patog\u00e9nica de ganancia de funci\u00f3n en heterocigosis en STAT1: p.Cys174Arg compatible con el diagn\u00f3stico molecular de CMC.  Conclusiones El diagn\u00f3stico molecular de la paciente abre la posibilidad de nuevas alternativas terap\u00e9uticas entre las que destacan los inhibidores de JAK1/JAK2. No obstante, estos tratamientos llevan consigo una serie de riesgos y la recurrencia de los s\u00edntomas tras su interrupci\u00f3n. La paciente tuvo una buena respuesta con la autovacuna de mucosas con composici\u00f3n Candida al 100%. Por todo ello, y como consecuencia de tratarse de un tratamiento m\u00e1s inocuo, deber\u00eda contemplarse dentro del arsenal terap\u00e9utico de la paciente. Se hipotetiza que la autovacuna podr\u00eda asociarse a cambios epigen\u00e9ticos o metab\u00f3licos englobados dentro del concepto \u201cinmunidad entrenada\u201d a  \n  \nnivel del sistema inmune innato de mucosas.                                                       \n  \nP-042  EXPLORING POTENTIAL MOLECULAR MECHANISMS OF B CELL DEREGULATION IN SECONDARY ANTIBODY DEFICIENCIES.    Soto Serrano, Yolanda1; Marty, Jaime1; Gianelli, Carla2; C\u00e1mara, Carmen2; Rodr\u00edguez Pena, Rebeca3; Mart\u00ednez Feito, Ana4; Plasencia, Chamaida5; L\u00f3pez Granados, Eduardo3; Del Pino Molina, Luc\u00eda3.  1Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ)., Madrid; 2Department of Clinical Immunology, La Paz University Hospital.Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ)., Madrid; 3Department of Clinical Immunology, La Paz University Hospital.Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ). Center for Biomedical Network Research on Rare Diseases (CIBERER U767)., Madrid; 4Department of Clinical Immunology, La Paz University Hospital, Madrid, Spain, Madrid; 5Rheumatology, La Paz University Hospital, Madrid, Spain., Madrid.  Background:  Secondary antibody deficiencies (SADs) are becoming more prevalent as increasing numbers of patients are treated for autoimmune diseases or cancer with diverse B-cell targeted therapies (BCTT), in particular Rituximab. Here, we report the major immunological characteristics of a large cohort of SADs patients after BCTT. B cell recovery upon treatment discontinuation is quite heterogeneous.   Methods:  We conducted a retrospective study of a cohort of 90 patients with SAD upon Rituximab treatment, referred to our clinic between 2006 and 2021. Clinical, epidemiologic and general laboratory data were collected from clinical records. Initially, we analysed the integrity of NFkB activation and Ca2+ upregulation upon BCR stimulation in replenished na\u00efve B cells several years after B cell targeted therapy by intracellular flow cytometry.  Results:  In our cohort 62% of patients were treated with Rituximab due to a hemato-oncologic process, and 38% of them for autoimmune conditions. 37% were males and 63% were females, with a median age at diagnosis of 57 years. Immunological assessment include immunoglobulin levels, specific antibodies, major lymphocyte subpopulations and detailed B cell phenotype: reduced total B cell numbers or severely decreased percentages of memory B cells are observed in most patients.  Preliminary results revealed conserved IKBA degradation and induced Ca2+ levels upon several stimuli in recovered na\u00efve B cells from patients with secondary hypogammaglobulinemia.    \n  \nConclusion:  Broad heterogeneity in the reconstitution of the B-cell compartment is observed in patients treated with Rituximab. Our preliminary results do not suggest a grossly impaired activating response in na\u00efve B cells that re-emerged in peripheral blood after B cell depletion. A better physiological understanding of the impact of this therapy on the replenished B-cell compartment is mandatory. This will aid in the individual prognosis and clinical management of secondary antibody deficiency in patients.                                              \n  \nP-043  KINETICS OF T CELL IMMUNE RESPONSES ELICITED AFTER THREE MRNA COVID-19 VACCINE DOSES IN PREDOMINANTLY ANTIBODY-DEFICIENT INDIVIDUALS  Ainsua Enrich, Erola1; Pedre\u00f1o Lopez, N\u00faria1; Brake, Carmen2; \u00c1vila-Nieto, Carlos1; Rodriguez De La Concepci\u00f3n, Maria Luisa1; Pradenas, Edwards1; Trinit\u00e9, Benjamin1; Marfil, Silvia1; Miranda, Cristina3; Gonz\u00e1lez, Sandra3; Toledo, Ruth3; Font, Marta3; Benet, Susana3; Escrib\u00e0, Tuixent1; Jimenez-Moyano, Esther1; Pe\u00f1a, Ruth1; Cede\u00f1o, Samandhy1; G. Prado, Julia1; Mothe, Beatriz1; Brander, Christian1; Izquierdo-Useros, Nuria1; Vergara-Alert, Julia4; Segal\u00e9s, Joaquim4; Massanella, Marta1; Benitez, Rosa Mar\u00eda2; Romero, Alba2; Molina-Morant, Daniel2; Blanco, Juli\u00e01; Clotet, Bonaventura1; Mateu, Lourdes2; Pedro-Botet, Mar\u00eda Luisa2; Carrillo, Jorge1.  1IrsiCaixa AIDS Resesarch Institute, Badalona; 2Infectious Diseases Department, Germans Trias i Pujol Hospital, Badalona; 3Fight AIDS Foundation, Badalona; 4IRTA. Programa de Sanitat Animal. Centre de Recerca en Sanitat Animal (CReSA), Universitat Aut\u00f2noma de Barcelona, Bellaterra, Bellaterra.  Mass vaccination campaigns reduced COVID-19 incidence and severity. Recently, an additional dose has been recommended, particularly to those individuals that remain vulnerable. Here, we evaluated the cellular responses developed in Predominantly Antibody-Deficiency (PAD) individuals after three mRNA-1273 vaccine doses. Our PAD cohort includes 23 SARS-CoV-2-na\u00efve individuals grouped as follows: Unclassified Primary Antibody-Deficiency (unPAD, n=9); Common Variable Immunodeficiency (CVID, n=12); Combined Immunodeficiency (CID, n=1) and Thymoma with Immunodeficiency (TID, n=1). Ten SARS-CoV-2 na\u00efve healthy controls (HCs) were also included, matched by sex and age. PAD and HC groups were immunized at week 0 (w0) and w4. PAD individuals received an additional dose at w24. Cellular responses were evaluated by IFN-\u03b3 ELISpot and flow cytometry. UnPAD and CVID groups showed lower levels of Spike-specific IFN-g-producing T-cells compared to HCs, even after the third vaccine boost. However, the frequency of Spike-specific CD4+ T-cells after two vaccine doses (determined by the frequency of activation-induced markers) was similar between PAD patients and HCs. The third vaccine dose did not increase the frequency of these cells in PAD individuals. Anti-Spike CD8+ T-cell responses were comparable between unPAD and HCs. However, we observed reduced levels of these cells in CVID individuals, that still remained lower after the third immunization. CID and TID patients developed cellular responses after two immunizations.  In conclusion, we show that PAD individuals and HCs developed comparable frequency of Spike-specific CD4+ T cells responses after mRNA-1273 vaccination. However, CVID individuals showed reduced levels of CD8+ T-cell responses compared to unPAD and HCs. Despite that, PAD individuals showed reduced levels of IFN-\u03b3-producing T-cells. Interestingly, we reported that the third vaccine dose had little effect on boosting T-cells responses. mRNA- \n  \n1273 vaccine-induced immune responses in PAD individuals are heterogeneous, depend on the type and degree of antibody-deficiency, and should be immunomonitored to define a personalized vaccination strategy.                                                   \n  \nP-044  CHARACTERIZATION OF VACCINE-INDUCED HUMORAL RESPONSES ELICITED AFTER THREE MRNA COVID-19 DOSES IN PATIENTS WITH PREDOMINANTLY ANTIBODY-DEFICIENCIES   Pedre\u00f1o Lopez, Nuria1; Ainsua Enrich, Erola1; Bracke, Carmen2; Avila Nieto, Carlos1; Rodriguez De La Concepcion, Maria Luisa1; Pradenas, Edwards1; Trinite, Benjamin1; Marfil, Silvia1; Miranda, Cristina3; Gonzalez, Sandra3; Toledo, Ruth3; Font, Marta3; Benet, Susana3; Escrib\u00e0, Tuixent1; Jimenez Moyano, Esther1; Pe\u00f1a, Ruth1; Cede\u00f1o, Samandhy1; Garcia Prado, Julia1; Mothe, Beatriz1; Brander, Christian1; Izquierdo Useros, Nuria1; Vergara Alert, Julia4; Segales, Joaquim4; Massanella, Marta1; Benitez, Rosa Maria2; Romero, Alba2; Molina Morant, Daniel2; Blanco, Juli\u00e01; Clotet, Bonaventura1; Mateu, Lourdes2; Pedro Botet, Maria Luisa2; Carrillo, Jorge1.  1Institut de Recerca de la Sida, Badalona; 2Hospital Germans Trias i Pujol, Badalona; 3Fundaci\u00f3 Lluita contra la Sida, Badalona; 4Centre Recerca en Sanitat Animal, Bellaterra.  Mass vaccination has reduced incidence and severity of COVID-19 illness. However, little is known about how three COVID-19 vaccine doses work in patients with predominantly antibody-deficiencies (PAD). In this study, we characterized the humoral responses developed in SARS-CoV-2-uninfected PAD individuals (n=23) after mRNA-1273 vaccination.  We identified that patients with unclassified primary antibody-deficiencies (unPAD, n=9) developed comparable levels of binding antibodies after only two COVID-19 mRNA vaccine doses compared to healthy controls (HCs, n=10). Conversely, common variable immunodeficiency (CVID, n=12) patients showed lower levels of Spike-specific binding antibodies after two doses. After an additional dose, this group was able to reach similar levels to those elicited in HCs. We then characterized the breadth and potency of the neutralizing antibodies developed by our cohort of PAD patients against the original SARS-CoV-2 Wuhan strain, Delta and Omicron variants of concern. Again, while CVID patients elicited significantly lower titers against all three strains than the HCs, unPAD individuals were able to mount similar neutralizing responses against these strains. The third administration boosted these responses only in unPAD individuals. Last, we determined Spike-specific IgG avidity of our PAD cohort. Overall, we observed a gradual increase overtime in PAD and HC groups. Combined immunodeficiency (CID, n=1) and thymoma with immunodeficiency (TID, n=1) patients were not able to mount antigen-specific humoral responses after two immunizations. However, CID individual developed binding and neutralizing antibody titers against Wuhan and Delta after the third vaccine dose. Thus, mRNA-1273-induced humoral responses in PAD individuals are heterogeneous, depend on the type and degree of antibody-deficiency, and should be immunomonitored to define a personalized vaccination strategy.    \n  \nP-046  RELACI\u00d3N ENTRE LAS SUBPOBLACIONES DE MEMORIA Y NA\u00cfVE EN LA RESPUESTA A LA VACUNACI\u00d3N FRENTE AL SARS-COV-2 EN PACIENTES CON INSUFICIENCIA RENAL CR\u00d3NICA    Garc\u00eda Torre, Alejandra1; Bueno Garc\u00eda, Eva1; Sanz Garc\u00eda, Clara2; Vidau, Pedro2; L\u00f3pez Mart\u00ednez, Roc\u00edo3; Rioseras, Beatriz3; P\u00e9rez Iglesias, Patricia4; Moro Garc\u00eda, Marco Antonio3; Alonso Arias, Rebeca3.  1Instituto de Investigaci\u00f3n Sanitaria de Asturias (ISPA), Oviedo; 2Servicio de Nefrolog\u00eda Hospital Universitario Central de Asturias (HUCA), Oviedo; 3Hospital Universitario Central de Asturias (HUCA), Oviedo; 4Pediatr\u00eda Hospital Universitario San Agust\u00edn, Avil\u00e9s.  Los pacientes con Insuficiencia Renal Cr\u00f3nica (IRC) se caracterizan por un proceso de inmunosenescencia que incluye una disminuci\u00f3n en sus valores absolutos de linfocitos T na\u00efve, lo cual puede suponer una respuesta reducida o defectuosa frente a nuevas vacunas o pat\u00f3genos. En este trabajo estudiamos la capacidad de respuesta inmune a la vacunaci\u00f3n frente al SARS-CoV-2, as\u00ed como la posible relaci\u00f3n entre dicha respuesta y los niveles de linfocitos T CD4+ y CD8+ de memoria y na\u00efve en pacientes con IRC. Se reclutaron 40 pacientes con IRC y 40 controles sanos con la misma media de edad (68 a\u00f1os). La proporci\u00f3n de las subpoblaciones de linfocitos T CD4+ y CD8+ se determin\u00f3 mediante marcajes superficiales de sangre perif\u00e9rica evaluados por citometr\u00eda de flujo. La respuesta de memoria generada por los linfocitos T frente a la vacuna del SARS-CoV-2 fue determinada mediante ELISpots espec\u00edficos para IFN-\u03b3. Para ello, se aislaron c\u00e9lulas mononucleares de sangre perif\u00e9rica y se cultivaron en presencia de un pool de p\u00e9ptidos de las prote\u00ednas S1 y S2. Encontramos una menor respuesta frente a la vacuna en los pacientes con IR (mediana=60 c\u00e9lulas x 106 PBMCs, RI: 1528 c\u00e9lulas x 106 PBMCs) que en el grupo control (mediana=280 c\u00e9lulas x 106 PBMCs, RI: 1656 c\u00e9lulas x 106 PBMCs) (p=0,001). Adem\u00e1s, hallamos una correlaci\u00f3n negativa entre la respuesta celular frente a la vacuna y los linfocitos CD4+CD28null y CD8+CD28null (p<0,05). Finalmente, tanto los linfocitos T CD4+ na\u00efve, incluyendo los CD4+CD31+, como los CD8+ na\u00efve se correlacionaron positivamente con la respuesta a la vacuna frente al SARS-CoV-2 (p<0,05). Estos resultados sugieren que la proporci\u00f3n de linfocitos T na\u00efve es clave para desarrollar una buena respuesta frente a nuevas vacunas y que un alto grado de diferenciaci\u00f3n de los linfocitos T puede influir en una peor respuesta en pacientes con IRC.       \n  \nP-047  VACUNACI\u00d3N FRENTE A SARS-COV-2 EN PACIENTES CON INMUNODEFICIENCIA VARIABLE COM\u00daN: INMUNOGENICIDAD Y REPERCUSI\u00d3N CL\u00cdNICA  Arroyo S\u00e1nchez, Daniel; Cabrera Marante, Oscar; Almendro V\u00e1zquez, Patricia; Pleguezuelo, Daniel Enrique; Paz Artal, Estela.  Hospital 12 de Octubre, Madrid.  Objetivo La inmunodeficiencia variable com\u00fan (IDVC) produce hipogammaglobulinemia y/o un defecto a la hora de producir anticuerpos frente ant\u00edgenos T dependientes e independientes. Buscamos estudiar en una cohorte de pacientes con IDVC de forma prospectiva la inmunogenicidad producida por las vacunas anti-SARS-CoV-2 y su relaci\u00f3n con la protecci\u00f3n frente a COVID-19.  M\u00e9todos Mediante t\u00e9cnica ELISA y Fluorospot, se determin\u00f3 la producci\u00f3n de anticuerpos anti-S1 y la respuesta de c\u00e9lulas T IFN-\u03b3 espec\u00edficas de S1 respectivamente de una cohorte de 18 pacientes de IDVC. Se compararon con los datos de 50 controles sanos. Se realiz\u00f3 un seguimiento durante un a\u00f1o en el que se registraron las infecciones por COVID-19 confirmadas por PCR y el curso de la enfermedad. Resultados Observamos que la presencia de respuesta humoral y celular fue m\u00e1s lenta en pacientes con IDVC en comparaci\u00f3n con los controles. Tras la segunda dosis, los pacientes mejoraron su tasa de respuesta vacunal, tanto a nivel humoral como celular (83% ambas), pero segu\u00edan por debajo de los niveles de la poblaci\u00f3n sana (100% y 98% respectivamente), as\u00ed como en intensidad.  Con respecto al seguimiento cl\u00ednico, 7 padecieron COVID-19 tras la vacunaci\u00f3n. De esos, 6 pacientes presentaron un curso cl\u00ednico leve y 1 grave. De los 6 pacientes que presentaron un curso leve de la enfermedad (no requirieron hospitalizaci\u00f3n), 5 presentaban respuesta humoral y celular y 1 presentaba exclusivamente respuesta humoral. La paciente con COVID-19 grave requiri\u00f3 de hospitalizaci\u00f3n durante 22 d\u00edas, aporte oxig\u00e9nico y corticoterapia. No hab\u00eda respondido ni a nivel humoral ni celular. Conclusi\u00f3n Una respuesta adecuada a la vacunaci\u00f3n contra SARS-CoV-2 se asoci\u00f3 a menor riesgo de padecer COVID-19 grave comparado con quien no ha respondido a la vacunaci\u00f3n. Se requiere m\u00e1s investigaci\u00f3n para comprender si la respuesta a la vacunaci\u00f3n en pacientes con IDCV es  \n  \nsuficientemente protectora.                                                        \n  \nP-048  THE ROLE OF THE DIFFERENT CD3\u0393 DOMAINS IN TCR EXPRESSION AND SIGNALING  Marin, Ana V.1; Megino, Rebeca F.1; Herrero-Alonso, Marta1; Garcillan, Beatriz1; Guardo, Alberto C.1; Perez-Flores, Veronica1; Juraske, Claudia2; Idstein, Vicent2; Martin-Fernandez, Jose M.1; Geisler, Carsten3; Schamel, Wolfgang W. A.2; Regueiro, Jose R.1.  1Department of Immunology, Ophthalmology and ENT, Complutense University School of Medicine and 12 de Octubre Health Research Institute (imas12), Madrid; 2Department of Immunology, Faculty of Biology, University of Freiburg, Freiburg; 3The LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Faculty of Health and Medical Sciences, Copenhagen.  The CD3 subunits of the T-cell antigen receptor (TCR) play a central role in regulation of surface TCR expression levels. Humans who lack CD3g (g\u2014) show reduced surface TCR expression levels and abolished phorbol ester (PMA)-induced TCR down-regulation. The response to PMA is mediated by a di-leucine motif in the intracellular (IC) domain of CD3\u03b3. However, the molecular cause of the reduced TCR surface expression in g\u2014 lymphocytes is still not known. Our aim was to understand the roles of CD3 chains domains in TCR surface expression and function. Retroviral vectors carrying wild type CD3\u03b3 or CD3d or the following chimeras (EC-extracellular, TM-transmembrane and IC):  dECgTMgIC (dgg for short), ggd, gdd and gg- were expressed in g\u2014 primary or Jurkat (JGN) T cells. Basal surface TCR expression, PMA-induced TCR down-regulation and TCR-dependent functional events (induction of CD69, IL-2 or TNF\u03b1) were measured by flow cytometry. Expression of ggg, ggd, gdd or gg- in JGN demonstrated that cell surface TCR levels were dependent on the EC domain of CD3g, which could not be replaced by that of CD3d. In JGN and primary g\u2014 T cells, the tested chimeras confirmed that the response to PMA maps to the IC domain of CD3g. In JGN cells all chimeric TCRs were signalling competent. However, an IC domain at CD3g was required for TCR-dependent CD69, IL-2 or TNF-\u03b1 induction. Our data confirm that TCR surface exportation depends on the CD3g EC domain, while PMA-induced TCR down-modulation and TCR-dependent CD69, IL-2 and TNF-\u03b1 induction depends on the CD3g IC domain.          \n  \nP-049  FACTORES ASOCIADOS A LA DISMINUCI\u00d3N DE LINFOCITOS T NA\u00cfVE EN PACIENTES CON INSUFICIENCIA CARIDACA CR\u00d3NICA   Garc\u00eda Torre, Alejandra1; Bueno Garc\u00eda, Eva1; L\u00f3pez Mart\u00ednez, Roc\u00edo2; Rioseras, Beatriz2; D\u00edaz Molina, Beatriz2; Moro Garc\u00eda, Marco3; Alonso Arias, Rebeca3.  1Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), Oviedo; 2Hospital Universitario Central de Asturias (HUCA), Oviedo; 3HUCA/ISPA, Oviedo.  Los pacientes con Insuficiencia Card\u00edaca Cr\u00f3nica (ICC) presentan niveles disminuidos de linfocitos T na\u00efve (N), adem\u00e1s de niveles incrementados de memoria (M) y un elevado estatus inflamatorio asociado a la infecci\u00f3n cr\u00f3nica por CMV. Analizamos el posible efecto de la inflamaci\u00f3n sist\u00e9mica sobre los niveles de linfocitos T N y su capacidad intr\u00ednseca de proliferaci\u00f3n homeost\u00e1tica en respuesta a la IL-7. Se reclutaron 40 pacientes con ICC (edad media=55 a\u00f1os). Los niveles de citocinas proinflamatorias s\u00e9ricas IL-1\u03b2, IL-6, TNF, IFN, IL-12p70 e IL-17A se determinaron mediante tecnolog\u00eda xMAP de Luminex y los niveles de anticuerpos anti-CMV se cuantificaron por ELISA. Las subpoblaciones de linfocitos CD4+ y CD8+ se evaluaron mediante citometr\u00eda de flujo en sangre perif\u00e9rica y c\u00e9lulas mononucleares aisladas de sangre perif\u00e9rica se cultivaron en presencia de IL-7 para cuantificar la respuesta proliferativa (Ki67). La capacidad proliferativa en respuesta a la IL-7 se encontr\u00f3 conservada en los linfocitos T N de los pacientes con ICC. La proliferaci\u00f3n fue significativamente m\u00e1s elevada en los linfocitos CD4+M que en los CD4+N (p=0,03). Sin embargo, los linfocitos CD8+N proliferaron m\u00e1s que los CD8+M en presencia de IL-7 (p=0,04). En cuanto a las citocinas, se encontr\u00f3 correlaci\u00f3n negativa entre los valores absolutos de los linfocitos T CD4+N y CD8+N y los niveles s\u00e9ricos de las citocinas IL-1\u03b2, IL-6, TNF e IL-17A (p<0,05). Sin embargo, al realizar un an\u00e1lisis de regresi\u00f3n lineal solo se encontr\u00f3 correlaci\u00f3n entre la IL-1 \u03b2 y los linfocitos CD4+N (p=0,01). Finalmente, los valores absolutos de CD8+N correlacionaron negativamente con el t\u00edtulo de anticuerpos anti-CMV (p<0,05). Nuestros resultados sugieren que, aunque la capacidad proliferativa de los linfocitos T N est\u00e1 conservada, el estatus inflamatorio de los pacientes con ICC as\u00ed como su historia de infecci\u00f3n por CMV condicionan los niveles de estas subpoblaciones.         \n  \nP-050  NEW CRITERIA FOR A MORE ACCURATE DIAGNOSIS OF LATE-ONSET COMBINED IMMUNODEFICIENCY BASED ON AGE-REFERENCE NA\u00cfVE CD4+ T-CELLS VALUES   Torres-Valle, Alba1; P\u00e9rez-Andr\u00e9s, Mart\u00edn2; De Arriba, Sonia3; Arag\u00f3n, Larraitz4; Serrano, Cristina5; Silva, Susana L.6; Subira, Dolores7; Ruiz Mercado, Marta8; Marcos, Miguel9; In\u00e9s, Sandra9; Martins, Catarina10; Albarr\u00e1n, Beatriz11; Barez, Abelardo12; Hurtado, Guillermina13; Neirinck, Janna14; Arenas-Caro, Pedro Pablo15; Madruga, Ignacio9; Mart\u00edn, Alejandro16; Bastida, Jos\u00e9 Mar\u00eda16; D\u00e1vila, Ignacio17; Contreras-Sanfeliciano, Teresa18; Jara, Mar\u00eda2; Prieto, Carlos19; Bonroy, Carolien20; Sousa, Ana E.6; Prada, \u00c1lvaro15; Van Dongen, Jacques J. M.21; Orfao, Alberto2.  1Department of Medicine, Cancer Research Centre (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS), University of Salamanca (USAL), Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), number CB16/12/00400,  Instituto de Salud Carlos III, Madrid; 2Department of Medicine, Cancer Research Centre (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS), University of Salamanca (USAL), Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), number CB16/12/00400, Instituto de Salud Carlos III, Madrid; 3Servicio de Pediatr\u00eda, Hospital Universitario de Salamanca, Salamanca; 4Immunology Department, Donostia University Hospital, Osakidetza Basque Health Service, San Sebasti\u00e1n; 5Servicio de Inmunolog\u00eda, Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid; 6Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa; 7Flow Cytometry Unit, Department of Hematology, Hospital Universitario Guadalajara, Guadalajara; 8Hospital Costa del Sol, Hematologia y Hemoterapia, Marbella; 9Servicio de Medicina Interna, Hospital Universitario de Salamanca, Salamanca; 10NOVA Medical School/Faculdade de Ci\u00eancias M\u00e9dicas Universidade Nova de Lisboa, Lisboa; 11Hematology, Complejo Asistencial Universitario de Palencia, Palencia; 12Department of Hematology, Complejo Asistencial de \u00c1vila, \u00c1vila; 13Servicio de Hematolog\u00eda, Complejo Hospitalario de Navarra, Pamplona; 14Department of Laboratory Medicine, Ghent University Hospital; Department of Diagnostic Sciences, Ghent University, Ghent; 15Immunology Department, Donostia University Hospital, Osakidetza Basque Health Service, San Sebasti\u00e1n, San Sebasti\u00e1n; 16Servicio de Hematolog\u00eda, Hospital Universitario de Salamanca, Institute for Biomedical Research of Salamanca, Salamanca, Spain; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC) number CB/16/12/00233, Instituto de salud Carlos III, Madrid; 17Servicio de Alergia, Hospital Universitario de Salamanca, Institute for Biomedical Research of Salamanca, Biomedical and Diagnosis Science Department, University of Salamanca, Salamanca; 18Servicio de Bioqu\u00edmica Cl\u00ednica, Hospital Universitario de Salamanca, Salamanca; 19Bioinformatics service (NUCLEUS), University of Salamanca, Salamanca; 20Department of Laboratory Medicine, Ghent University Hospital; Department of Diagnostic Sciences, Ghent University, Ghent, Belgium, Ghent; 21Department of Medicine, Cancer Research Centre, Cytometry Service, University of Salamanca, Institute of Biomedical Research of Salamanca, Salamanca; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), number CB16/12/00400, Instituto de Salud Carlos III, Madrid; Department of Immunology, Leiden University Medical Center, Leiden.  Background and aims Several reports demonstrate that a subset of common variable immunodeficiency (CVID) patients actually suffers from a more severe disease, called late-onset combined  \n  \nimmunodeficiency (LOCID). Na\u00efve CD4+ T-cell counts have been proposed as the most powerful parameter for LOCID diagnosis. However, previously proposed classifications did not include age-related reference ranges for absolute counts. Methods 97 CVID patients from eleven hospitals were studied by flow cytometry. Absolute na\u00efve CD4+ T-cell counts were normalized against the lower limit of normality (LLN) obtained from 262 healthy donors (4-9y:359; 10-17y:249; 18-39y:127; 40-59y:112 and >60y:31 cells/\u00b5L). This new criterion was compared to the DEFI (<20 na\u00efve CD4+T-cells/\u00b5L) and Freiburg (<10% na\u00efve CD4+ T-cells) classifications. Results A higher frequency of CVID patients was identified as LOCID with the new criteria (30%), compared to the DEFI (19%) and Freiburg (24%) classifications (p<0.001). The age-based criteria was particularly efficient to identify LOCID patients, among the 18-39y CVID patients (33% vs. 15% vs. 24%; p<0.01) and the 40-59y age-group (43% vs. 26% and 29%; p<0.001). In addition, the age-reference criteria discriminated a higher percentage of patients presenting with non-infectious complications typically associated with LOCID (autoimmune cytopenias, enteropathy and granulomas), compared to patients with normal na\u00efve CD4+ T-cell counts (83% vs. 46% of patients; p=0.001), as compared to the DEFI (78% vs. 52%; p=0.06) and Freiburg (78% vs. 50%; p=0.03) classifications. Furthermore, the presence of reduced na\u00efve CD4+ T-cell counts was also associated with higher rates of other complications, including organomegalies (83% vs. 47%, p=0.001; 83% vs. 52%, p=0.02; 87% vs. 49%, p=0.001) and lymphadenopathies (57% vs. 23%, p=0.002; 59% vs. 27%, p=0.02; 64% vs. 24%, p=0.001). Conclusions Age-matched reference values for the identification of decreased na\u00efve CD4+ T-cell counts in CVID patients, results in a more accurate diagnosis of LOCID and identifies patients with severe clinical phenotypes.                 \n  \nP-051  IMMUNE CELL PROFILE ANALYSIS IN FIVE PATIENTS WITH GOOD'S SYNDROME    Torres-Valle, Alba1; P\u00e9rez-Andr\u00e9s, Mart\u00edn2; Arag\u00f3n, Larraitz3; Serrano, Cristina4; Marcos, Miguel5; Arenas-Caro, Pedro Pablo3; Bonroy, Carolien6; De Arriba, Sonia7; Neirinck, Jana6; Prada, \u00c1lvaro8; Van Dongen, Jacques J.m.9; Orfao, Alberto10.  1Department of Medicine, Cancer Research Centre (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS), University of Salamanca (USAL), Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), number CB16/12/00400,  Instituto de Salud Carlos III, Madrid, Salamanca; 21Department of Medicine, Cancer Research Centre (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS), University of Salamanca (USAL), Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), number CB16/12/00400, Instituto de Salud Carlos III, Madrid, Spain., Salamanca; 3Immunology Department, Donostia University Hospital, Osakidetza Basque Health Service, San Sebasti\u00e1n; 4Servicio de Inmunolog\u00eda, Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid; 5Servicio de Medicina Interna, Hospital Universitario de Salamanca, Salamanca; 6Department of Laboratory Medicine, Ghent University Hospital; Department of Diagnostic Sciences, Ghent University, Ghent; 7Servicio de Pediatr\u00eda, Hospital Universitario de Salamanca, Salamanca; 8Immunology Department, Donostia University Hospital, Osakidetza Basque Health Service, San Sebastian; 9Department of Medicine, Cancer Research Centre, Cytometry Service, University of Salamanca, Institute of Biomedical Research of Salamanca; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), number CB16/12/00400, Instituto de Salud Carlos III; Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden; 10Department of Medicine, Cancer Research Centre (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS), University of Salamanca (USAL), Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), number CB16/12/00400, Instituto de Salud Carlos III, Madrid, Spain., Salamanca.  Background and Aims Classically, Good\u2019s syndrome (GS) was defined as a rare association of thymoma and hypogammaglobulinemia, suggesting that it might be a subset of Common Variable Immunodeficiency. However, the knowledge of the disease is hampered by the incomplete and inconsistent reports about the disease due to low prevalence of the disease (1.5 cases per million). A more detailed dissection of the immune cells in a significant set of patients would contribute to understand the pathophysiology of the disease.  Methods Up to 350 immune subpopulations were analyzed in five GS patients (53-72 years) from 3 different hospitals and 39 age-matched controls using next-generation flow cytometry.  Results All patients consistently presented with lack of B-cells (<0.02 cells/\u03bcL). In addition, alterations  \n  \nwere also found in other immune subsets including significantly reduced count of total CD4+ T-cells, NK-cells, eosinophils, CD141+ and plasmacytoid dendritic cells (DCs) (p\u22640.05), as compared to age-matched controls. Decreased of total CD4+ T-cell counts was due to reduced numbers of na\u00efve cells and, in addition, lower Treg, TFH, Th2, Th17, Th22, Th1/Th17 and Th1/Th2 cells (p\u22640.01). However, number of Th1 cells was not different from age-matched controls (p>0.05). Interestingly, counts of na\u00efve CD8+ and TCRgd+ T-cells were normal, meanwhile total CD8+ and TCRgd+ T-cells were statistically significant increased (p\u22640.01) due to statistically significant expanded effector memory CD8+ T-cells and terminally differentiated CD8+ and TCRgd+ T-cells (p\u22640.01). All the other immune subsets analyzed were within the normal range.  Conclusions In addition to the lack of B-cells, a complex profile of alterations was observed in GS patients including but an also large spectrum of defects in the adaptative (CD4+ T-cells) and innate cells (NK-cells, eosinophils, DCs). In contrast, the cytotoxic response was observed, including normal counts of CD8+ and TCRgd+ T-cells, and Th1 CD4+ T-cells.                                \n  \nP-052  CD4+ T-CELL COMPARTMENT ALTERATIONS ARE ASSOCIATED WITH CLINICAL COMPLICATIONS IN LOCID AND CVID PATIENTS   Torres-Valle, Alba1; P\u00e9rez-Andr\u00e9s, Martin2; De Arriba, Sonia3; Aragon, Larraitz4; Serrano, Cristina5; Silva, Susana L.6; Subir\u00e1, Dolores7; Ruiz Mercado, Marta8; Marcos, Miguel9; In\u00e9s, Sandra9; Martins, Catarina10; Albarr\u00e1n, Beatriz11; Barez, Abelardo12; Hurtado, Guillermina13; Neirinck, Jana14; Arenas-Caro, Pedro Pablo4; Madruga, Ignacio9; Mart\u00edn, Alejandro15; Bastida, Jos\u00e9 Mar\u00eda15; D\u00e1vila, Ignacio16; Contreras-Sanfeliciano, Teresa17; Jara, Mar\u00eda2; Prieto, Carlos18; Bonroy, Carolien14; Sousa, Ana E.6; Prada, \u00c1lvaro4; Van Dongen, Jacques J. M.19; Orfao, Alberto2.  1Department of Medicine, Cancer Research Centre (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS), University of Salamanca (USAL), Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), number CB16/12/00400,  Instituto de Salud Carlos III, Madrid; 2Department of Medicine, Cancer Research Centre (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS), University of Salamanca (USAL), Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), number CB16/12/00400, Instituto de Salud Carlos III, Madrid; 3Servicio de Pediatr\u00eda, Hospital Universitario de Salamanca, Salamanca; 4Immunology Department, Donostia University Hospital, Osakidetza Basque Health Service, San Sebasti\u00e1n; 5Servicio de Inmunolog\u00eda, Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid; 6Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa; 7Flow Cytometry Unit, Department of Hematology, Hospital Universitario de Guadalajara, Guadalajara; 8Hospital Costa del Sol, Hematologia y Hemoterapia, Marbella; 9Servicio de Medicina Interna, Hospital Universitario de Salamanca, Salamanca; 10NOVA Medical School/Faculdade de Ci\u00eancias M\u00e9dicas Universidade Nova de Lisboa, Lisboa; 11Hematology, Complejo Asistencial Universitario de Palencia, Palencia; 12Department of Hematology, Complejo Asistencial de \u00c1vila, \u00c1vila; 13Servicio de Hematolog\u00eda, Complejo Hospitalario de Navarra, Pamplona; 14Department of Laboratory Medicine, Ghent University Hospital; Department of Diagnostic Sciences, Ghent University, Ghent; 15Servicio de Hematolog\u00eda, Hospital Universitario de Salamanca, Institute for Biomedical Research of Salamanca, Salamanca, Spain; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC) number CB/16/12/00233, Instituto de salud Carlos III, Madrid; 16Servicio de Alergia, Hospital Universitario de Salamanca, Institute for Biomedical Research of Salamanca, Biomedical and Diagnosis Science Department, University of Salamanca (USAL), Salamanca; 17Servicio de Bioqu\u00edmica Cl\u00ednica, Hospital Universitario de Salamanca, Salamanca; 18Bioinformatics service (NUCLEUS), University of Salamanca, Salamanca; 19Department of Medicine, Cancer Research Centre, Cytometry Service, University of Salamanca, Institute of Biomedical Research of Salamanca, Salamanca; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), number CB16/12/00400, Instituto de Salud Carlos III, Madrid; Department of Immunology, Leiden University Medical Center, Leiden.  Background and aims Alterations in the CD4+ T-cell compartment in common variable immunodeficiency (CIVD) patients have been reported earlier. However, most studies did not report on patients with a na\u00efve CD4+ T-cell defect who met the criteria for late-onset combined immunodeficiency (LOCID).   \n  \nMethods CD4+T-cell subsets were analyzed in 48 CVID and 19 LOCID patients, in parallel to 156 healthy donors (4-88 years) using in depth EuroFlow-based flow cytometry methods.  Results Higher frequencies of decreased T-cell subset counts were observed in LOCID vs. CVID patients, including Treg (84% vs. 60% of patients; p=0.09), Th2 (100% vs. 52%; p<0.001), Th17 (95% vs. 48%, p<0.001), and Th1/Th2 (63% vs. 33%; p=0.03), as compared to age-reference values. However, in both LOCID and CVID, decreased TFH (11% and 2%), Th1 (21% and 21%) and Th1/Th17 (16% and 15%) (p>0.05) counts were found in only a few patients. Multivariate analysis based on all age-matched CD4+ T-cell compartments,  showed two subgroups of LOCID cases presenting with clearly distinct clinical phenotypes: those with higher Th1 counts presented with a greater frequency of autoimmune cytopenias (89% vs. 19%; p=0.003) and interstitial lung disease (78% vs. 9%; p=0.003), together with lower percentage of non-respiratory infections (57% vs. 100%; p=0.03). Three subgroups of patients (CVID1, CVID2, and CVID3) were identified within those CVID cases without a T-cell production defect, based on Th1 and TFH cells, and a significantly higher frequency of autoimmune cytopenia (63% vs. 9% vs. 22%; p\u22640.05) was observed in CVID cases with higher Th1 counts.   Conclusions LOCID patients show more severe T-cell defects (Treg, Th2, Th17 and Th1/Th2) than CVID patients. Increased counts of Th1 CD4+T-cells in blood, is strongly associated with the presence of autoimmune cytopenias in both LOCID and CVID cases, together with interstitial lung disease in LOCID (but not CVID) patients.                    \n  \nP-053  DEMOGRAF\u00cdA DE LA INMUNODEFICIENCIA COM\u00daN VARIABLE EN LA REGI\u00d3N DE MURCIA.  S\u00e1nchez Rodr\u00edguez, Carlos; Jim\u00e9nez Coll, V\u00edctor; Soto Ram\u00edrez, Mar\u00eda Fernanda; G\u00f3nzalez L\u00f3pez, Rosana; Fern\u00e1ndez Gonz\u00e1lez, Marina; Botella Mart\u00ednez, Carmen; Gali\u00e1n Meg\u00edas, Jose Antonio; Muro Amador, Manuel; Novoa Bol\u00edvar, Erika.  Hospital Cl\u00ednico universitario Virgen de La Arrixaca IMIB, Murcia.  La IDCV (Inmunodeficiencia Variable Com\u00fan) incluye un grupo heterog\u00e9neo de pacientes mayores de 4 a\u00f1os, con manifestaciones cl\u00ednicas variables desde infecciones graves y recurrentes por pat\u00f3genos comunes y oportunistas con compromiso de los tractos respiratorio y gastrointestinal, en cuyo contexto se establece el diagn\u00f3stico de hipogammaglobulinemia, deficiente producci\u00f3n de anticuerpos, y recuentos variables precursores B en sangre perif\u00e9rica. La variabilidad cl\u00ednica e inmunol\u00f3gica de la enfermedad es tal, que pueden solaparse enfermedades inmunomediadas, fen\u00f3menos de linfoproliferaci\u00f3n, desregulaci\u00f3n inmune, complicaciones infecciosas y algunas neoplasias.   La prevalencia estimada es de 1 por cada 25.000 habitantes, afectando por igual ambos sexos. La regi\u00f3n de Murcia con una poblaci\u00f3n total de 1.518.486 habitantes (INE 2021), tiene actualmente 41 pacientes con IDCV entre los 9 a los 71 a\u00f1os (edad al diagn\u00f3stico), derivados de las 9 \u00e1reas de salud de la Regi\u00f3n a la Consulta de Inmunolog\u00eda del Hospital Virgen de la Arrixaca y sometidos a cribado inmunol\u00f3gico mediante los criterios ESID, seguimiento, diagn\u00f3stico y manejo multidisciplinar.   La manifestaci\u00f3n cl\u00ednica m\u00e1s prevalente al deb\u00fat han sido las infecciones respiratorias, bronquiectasias (H. influenzae y S. Neumoniae), y la diarrea recurrente (C. jejuni, C. difficile, Giardia lambdia) edad de consulta 20 a 45 a\u00f1os.   Se detectaron 2 pacientes con autoinmunidad al debut, y progresi\u00f3n a linfomas, portadores de la Variante p.Ile87Asn en el gen TNFRSF13B.  Dos hermanos adultos al debut con PTI (P\u00farpura Trombocitop\u00e9nica idiop\u00e1tica), portadores p.Met860Asnfs*5 heterocigosis en NFKB1.      \n  \n             \n \n  \nP-054  EVOLUTIONARY DYNAMICS OF SOMATIC PATHOGENIC VARIANTS IN ALPS: IMPLICATIONS FOR DIAGNOSTICS.  Colobran, Roger1; Franco-Jarava, Clara1; Garcia-Prat, Marina2; Aguil\u00f3-Cucurull, Aina1; Velasco, Pablo3; Rivi\u00e8re, Jacques G.2; Mart\u00edn Nalda, Andrea4; Mart\u00ednez-Gallo, M\u00f3nica1; Soler-Palac\u00edn, Pere2; Batlle-Mas\u00f3, Laura2.  1Translational Immunology Research Group, Vall d'Hebron Research Institute (VHIR). Servei d'Immunologia, Servei de Gen\u00e8tica, Hospital Universitari Vall d'Hebron (HUVH), Barcelona; 2Infection in Immunocompromised Pediatric Patients, Vall d\u2019Hebron Research Institute (VHIR). Unitat de Patologia Infecciosa i Immunodefici\u00e8ncies de Pediatria, Hospital Universitari Vall d\u2019Hebron (HUVH), Barcelona; 3Department of Pediatric Hematology and Oncology, Hospital Universitari Vall d'Hebron, Barcelona; 4Pediatric Infectius Diseases and Immunodeficiencies Unit, Hospital universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Universitat Aut\u00f2noma de Barcelona, Barcelona.  Autoimmune lymphoproliferative syndrome (ALPS) is an early-onset disorder presenting with lymphadenopathy, autoimmunity, hepatosplenomegaly, and elevated double-negative alpha-beta T cells (DNT). ALPS is mostly associated with genetic variants in the FAS gene, which can be somatic in up to 20% of the cases. Here, we present a patient with early-onset ALPS in whom we identified a somatic pathogenic insertion at the FAS gene (c.718_719insGTCG) using Sanger sequencing on a CD3 enriched sample (although the variant was not detected in whole blood using this method). Moreover, we extended the study by exploring the evolutionary dynamics of this somatic variant with NGS. For that, we used blood samples obtained before and during the treatment with immunosuppressive drugs, over five years. By using deep amplicon sequencing (DAS, coverage 20,000-30,000x) we were able to detect the variant in all samples with a variant allele frequency (VAF) ranging from 7% (in pre-treatment samples) to 0.5% (in samples during treatment). The VAF evolution was significantly correlated to the DNT population frequency (Pearson\u2019s R: 0.98), concordant with the preferent location of the FAS somatic variants in this population. Additionally, in one of the samples with DNT values within the expected range (0.89%), we performed DAS on DNA from whole blood and purified CD3 cells (using RosetteSep\u2122). When comparing the results, we showed that the VAF of the somatic variant was doubled in CD3 cells (1.6% versus 0.68% in blood). Taken together, our results evidence that i) somatic genetic variants in FAS can be detected and studied with DAS; ii) evolutionary dynamics of somatic variants can be studied in peripheral blood samples regardless of the normalization of the DNT population frequency (<2%); and iii) DAS experiments, combined with an appropriate bioinformatic approach, successfully detect somatic variants in ALPS patients even in samples obtained after several years under treatment.   \n  \nP-055  DESCRIPCI\u00d3N DE DOS NUEVAS MUTACIONES EN EL GEN WAS   Franco Leyva, Teresa1; Mart\u00ednez Mart\u00ednez, Laura1; Boera Carnicero, Gemma1; Mateus Medina, Eder2; Badell, Isabel1; De La Torre, Ronny3; De La Calle Mart\u00edn, \u00d3scar1.  1Hospital de la Santa Creu i Sant Pau, Barcelona; 2Institut de Recerca - Hospital de la Santa Creu i Sant Pau, Barcelona; 3Universidad Central del Ecuador. Jeffrey Modell Foundation Centers Network, Quito.  Las alteraciones en el gen WAS dan lugar a 3 entidades cl\u00ednicas bien diferenciadas: el s\u00edndrome de Wiskott-Aldrich (WAS), la trombocitopenia ligada al X (XLT) y la neutropenia ligada al X (XLN). El WAS est\u00e1 causado por mutaciones que implican una p\u00e9rdida completa de la funci\u00f3n de la prote\u00edna WASp; la XLT por alteraciones que dan una p\u00e9rdida parcial de su funcionalidad; y la XLN por mutaciones que implican una ganancia de funci\u00f3n de WASp. El primer caso que presentamos es un ni\u00f1o hispanoamericano de 2 a\u00f1os que desde el nacimiento present\u00f3 la tr\u00edada cl\u00e1sica de WAS: trombocitopenia microtromboc\u00edtica, eczema e infecciones recurrentes. La secuenciaci\u00f3n de WAS revel\u00f3 una deleci\u00f3n en el ex\u00f3n 2 (c.176del) que provocaba un desplazamiento en la pauta de lectura originando un cod\u00f3n Stop 17 amino\u00e1cidos despu\u00e9s (p.Pro59Leufs*17). Se trata de una mutaci\u00f3n no descrita que implica seguro una p\u00e9rdida de funci\u00f3n ya que la prote\u00edna se reduce a tan solo 57 amino\u00e1cidos. El segundo caso es un ni\u00f1o cauc\u00e1sico de 11 a\u00f1os que present\u00f3 neutropenia desde el nacimiento, inicialmente orientada como aloinmune. Tras descartar otros defectos centrales de neutropenia, se estableci\u00f3 la sospecha diagn\u00f3stica de XLN. El estudio del ex\u00f3n 9 del gen WAS revel\u00f3 una mutaci\u00f3n missense (c.895G>A, p.G299R) no descrita previamente, pero en una posici\u00f3n muy pr\u00f3xima a las ya asociadas a XLN. Los estudios de viabilidad, migraci\u00f3n, fagocitosis y capacidad oxidativa en los neutr\u00f3filos del paciente realizados hasta la fecha parecen indicar que se trata de una mutaci\u00f3n que implica una ganancia de funci\u00f3n de WASp. La madre es portadora de la mutaci\u00f3n y presenta un fenotipo parcial de XLN. Como conclusi\u00f3n, hemos identificado dos nuevas mutaciones del gen WAS: una compatible con WAS y otra en la regi\u00f3n asociada a XLN que parece dar lugar a una ganancia de funci\u00f3n            \n  \nP-056  A CHARACTERIZATION OF CHRONIC CAMPYLOBACTER INFECTION IN COMMON VARIABLE IMMUNODEFICIENCY PATIENTS.   Roa-Bautista, Adriel1; Gonz\u00e1lez L\u00f3pez, Elena1; Ocejo Vinjals, Gonzalo1; Brown, Li-An2; Tadros, Susan3; Burns, Siobhan4; Godbole, Gauri5; Lowe, David4.  1Hospital Universitario Marqu\u00e9s de Valdecilla., Santander; 2University College of London Hospital, London; 3Royal Free Hospital, London; 4Institute of immunity and transplantation, University College of London, London; 5Gastrointestinal Bacteria Reference Unit, Health Security Agent., London.  Background Campylobacter infection usually causes a self-limited clinical illness lasting 5-7 days, resolving without antimicrobial treatment in immunocompetent subjects. However, an inadequate immune response can lead to a prolonged and severe disease requiring antibiotics and more aggressive therapeutic approaches. Methods A retrospective cohort of 17 common variable immunodeficiency (CVID) patients with Campylobacter infection and 109 CVID controls attending the Immunology clinic at the Royal Free Hospital was assessed. Immunological, clinical and microbiological parameters were measured. Patients were treated according to a novel algorithm for Campylobacter in antibody deficient patients.  Results Immunological parameters: Flow cytometry evaluation of peripheral B lymphocytes demonstrated a lower long-term average CD19+ count with a higher proportion of CD21LOWCD38LOW B cells in Campylobacter patients versus controls. Furthermore, a reduction in CD4+ T cell and NK cell counts over time was observed in Campylobacter patients.  Treatment response: Patients were treated according to our novel algorithm. Clinical improvement and bacterial clearance were obtained after a median of 21 and 169 days for acute Campylobacter (ACP) and chronic Campylobacter (CCP) infections respectively. Ten received first-line of treatment [Azithromycin or Chloramphenicol], four second-line [Neomycin], and three received third-line [Tigecycline, Chloramphenicol and Ertapenem (one received Gentamicin due to resistance to carbapenems)].   Conclusions Our study highlights immunological and clinical characteristics of recurrent Campylobacter  \n  \ninfections in patients with CVID.  Our treatment algorithm was successful and should be evaluated in a larger cohort.    \n                                      \n \n  \nP-057  EVALUACI\u00d3N DE LA INMUNIZACI\u00d3N CON TYPHIM VI EN EL DIAGN\u00d3STICO DE INMUNODEFICIENCIA SECUNDARIA EN S\u00cdNDROMES LINFOPROLIFERATIVOS B   Peixoto Rodr\u00edguez, Alejandro; Bailey Maldonado, Rodrigo; Mayol, Elsa; Ochoa-Grull\u00f3n, Juliana; Ramiro Ponce, Vanessa; De La Fuente Mu\u00f1oz, Eduardo; Villegas, \u00c1ngela; Mansilla, Maril\u00f3; P\u00e9rez L\u00f3pez, Cristina; Pe\u00f1a Cortijo, Ascensi\u00f3n; Mateo Morales, Marta; Anguita Mandley, Eduardo; Jim\u00e9nez Garc\u00eda, Carlos; Bola\u00f1os, Estefan\u00eda; \u00cd\u00f1igo, Bel\u00e9n; Medina, Fiorella; Rodr\u00edguez De La Pe\u00f1a, Antonia; Fern\u00e1ndez Arquero, Miguel; Gonz\u00e1lez Fern\u00e1ndez, Ata\u00falfo; Benavente Cuesta, Celina; S\u00e1nchez Ram\u00f3n, Silvia.  Hospital Cl\u00ednico San Carlos, Madrid.  Los s\u00edndromes linfoproliferativos B (SLPB) se asocian a una inmunodeficiencia secundaria (SID) caracterizada por hipogammaglobulinemia o d\u00e9ficit de producci\u00f3n de anticuerpos e infecciones graves y recurrentes, siendo la causa m\u00e1s importante de morbilidad en estos pacientes. El objetivo principal del estudio fue determinar la utilidad de la respuesta frente al ant\u00edgeno polisac\u00e1rido puro de Salmonella Typhi (Thyphim Vi) en el diagn\u00f3stico y tratamiento de SID, determinando los rangos de respuesta normal en pacientes con SLPB.  Se estudi\u00f3 un total de 84 pacientes con SLPB, de los cuales 34 con infecciones recurrentes o graves, 20 sin infecciones recurrentes o graves y 30 controles sanos. En funci\u00f3n del SLPB se han reclutado 16 pacientes con leucemia linfoc\u00edtica cr\u00f3nica (LLC), 37 pacientes con linfomas no Hodgkin (LNH) y 11 pacientes con gammapat\u00eda monoclonal de significado incierto (GMSI), en los cuales se compararon los niveles de anticuerpos prevacunales y postvacunales.  Hubo niveles significativamente menores de respuesta a Typhim Vi en los pacientes con LLC, LNH, MGUS respecto a sanos (p<0.001, p<0,001 y p=0,005, respectivamente). En la respuesta frente a neumococo, los pacientes con LLC y LNH fueron significativamente menores que los controles sanos (p=0,003 y p=0,001, respectivamente), sin diferencias entre el grupo GMSI y sanos. La respuesta a la vacunaci\u00f3n con Typhim Vi permiti\u00f3 la identificaci\u00f3n de crecimiento tumoral en pacientes en etapas pre-malignas, como lo es la GMSI.  La vacunaci\u00f3n con polisac\u00e1rido puro Typhim Vi permite diferenciar individuos sanos de pacientes con SLPB, adem\u00e1s de presentar la capacidad de discriminar pacientes con GMSI con infecciones recurrentes o graves, por lo que podr\u00eda utilizarse como test funcional predictivo de infecciones, adem\u00e1s del crecimiento tumoral y progresi\u00f3n de la etapa pre-maligna. El uso  \n  \ncombinado de las tres vacunas (Typhim Vi, neumococo y toxoide tet\u00e1nico) puede aportar un mayor conocimiento de la situaci\u00f3n inmunol\u00f3gica del paciente.                                                     \n  \nP-058  DESCRIPCI\u00d3N DE 3 NUEVAS VARIANTES MONOG\u00c9NICAS EN EL GEN IRF2BP2 EN COHORTE DE PACIENTES CON INMUNODEFICIENCIA COM\u00daN VARIABLE  Lucena, Jos\u00e9 Manuel; Ortiz, Pilar; Jurado, Alicia.  Hospital Universitario Virgen del Roc\u00edo, Sevilla.  La inmunodeficiencia com\u00fan variable (IDCV) es la inmunodeficiencia primaria que con m\u00e1s frecuencia encontramos en la pr\u00e1ctica cl\u00ednica. Cl\u00ednicamente se define como la presencia de infecciones recurrentes y una reducci\u00f3n en suero de IgG (al menos 2 desviaciones est\u00e1ndar por debajo de los valores de referencia para la edad) y al menos otra de las inmunoglobulinas (IgA o IgM) y una reducci\u00f3n o ausencia de producci\u00f3n de anticuerpos. La cl\u00ednica que presentan estos pacientes es variada, incluyendo infecciones pulmonares, bacterianas sist\u00e9micas y complicaciones gastrointestinales. Aproximadamente el 5% de los casos son familiares, y la mayor disponibilidad de tecnolog\u00eda de secuenciaci\u00f3n masiva ha permitido la identificaci\u00f3n de un n\u00famero creciente de genes asociados a IDCV. Uno de estos genes es IRF2BP2, cuya variante en heterocigosis (herencia autos\u00f3mica dominante) estaba presente en 3 miembros de una familia. A trav\u00e9s de estudios de secuenciaci\u00f3n masiva, identificamos 3 nuevas variantes gen\u00f3micas en heterocigosis del gen de IRF2BP2, no descritas previamente, en pacientes con cl\u00ednica compatible de IDCV. Las variantes son:  \u2022 p.Cys37Phe: Mujer de 57 a\u00f1os de edad con infecciones respiratorias de repetici\u00f3n y s\u00edndrome bronquiect\u00e1sico.  \u2022 p.Pro25Leu: Mujer de 55 a\u00f1os con bronquitis a repetici\u00f3n. \u2022 p.E253Cfs*8: Mujer de 46 a\u00f1os con cl\u00ednica de infecciones recurrentes ORL y respiratorias, candidiasis esof\u00e1gica/vaginal, enfermedad de Crohn y artritis seronegativa. A falta de los estudios funcionales que valoren la patogenicidad y estudios familiares para analizar su penetrancia, hemos encontramos nuevas variantes heterocig\u00f3ticas de IRF2BP2, lo que nos lleva a concluir que mutaciones monoal\u00e9licas en IRF2BP2 pueden causar IDCV monog\u00e9nica con diferentes manifestaciones cl\u00ednicas e inicio de s\u00edntomas, apoyando lo que se ha descrito recientemente en la literatura.     \n  \nP-059  EFECTOS DE LAS GAMMAGLOBULINAS POLICLONALES SOBRE LAS POBLACIONES MIELOIDES CIRCULANTES. ESTUDIO BIRTH   Peixoto Rodr\u00edguez, Alejandro; Bola\u00f1os, Estefan\u00eda; Ramiro Ponce, Vanessa; Mayol, Elsa; Bailey Maldonado, Rodrigo; Ochoa-Gru\u00f1\u00f3n, Juliana; Jimenez Garc\u00eda, Carlos; Rodr\u00edguez De La Pe\u00f1a, Antonia; De La Fuente, Eduardo; Villegas, \u00c1ngela; Mansilla, Maril\u00f3; Perez Lopez, Cristina; Pe\u00f1a Cortijo, Ascensi\u00f3n; Mateo Morales, Marta; Anguita Mandley, Eduardo; Fern\u00e1ndez-Arquero, Miguel; Benavente Cuesta, Celina; S\u00e1nchez-Ram\u00f3n, Silvia.  Hospital Cl\u00ednico San Carlos, Madrid.  Los pacientes afectos de s\u00edndromes linfoproliferativos B (SLPB), en concreto, mieloma m\u00faltiple (MM) y leucemia linfoc\u00edtica cr\u00f3nica (LLC), presentan habitualmente un d\u00e9ficit de producci\u00f3n de anticuerpos y/o hipogammaglobulinemia que les hace susceptibles a infecciones recurrentes o graves, estando indicada la terapia de remplazo de inmunoglobulinas TRIg. Hasta la fecha no existen estudios sobre el uso de TRIg sobre la evoluci\u00f3n del SLPB ni biomarcadores de seguimiento de la inmunodeficiencia secundaria (SID). Se ha demostrado que la TRIg induce una reprogramaci\u00f3n de los macr\u00f3fagos hacia un estado m\u00e1s pro-inflamatorio, lo que podr\u00eda frenar procesos infecciosos recurrentes. Se ha estudiado un total de 16 pacientes (4 pacientes con LLC, 11 con linfoma no Hodking (LNH) y 1 paciente con gammapatia monoclonal de significado incierto (MGUS). El desarrollo experimental constar\u00e1 de cuatro procesos anal\u00edticos por cada paciente, en primer lugar al inicio del TRig, posteriormente a los siete d\u00edas, a los seis meses y por \u00faltimo, transcurrido un a\u00f1o. En 16 pacientes estudiados, se observ\u00f3 un aumento significativo de la poblaci\u00f3n de M-MDSCs tras la infusi\u00f3n de IgIV a las 6 horas (13,37\u00b113,17 vs 26,62\u00b116.52; p= 0,008). Adem\u00e1s, en 3 de ellos se mantuvo este aumento a los siete d\u00edas. Tambi\u00e9n se ha observado una disminuci\u00f3n significativa de los monocitos intermedios (13,60\u00b110,63 vs 8,07\u00b114,08; p=0,008 y no cl\u00e1sicos (4,53\u00b12.46 vs 1,79\u00b12.72; p=0.001). Asimismo, se aprecia que este tratamiento produce un cambio de fenotipo hacia M2 mediante la disminuci\u00f3n de citoquinas antinflamatorias (CXCL10 e IL-10) y aumento de las proinflamatorias (IL-12 y TNF-alfa). Conclusiones: Nuestros datos preliminares sugieren que la infusi\u00f3n de IVIg induce un efecto proinflamatorio mediante la reprogramaci\u00f3n de macr\u00f3fagos hacia el fenotipo M2 permitiendo una reducci\u00f3n de las infecciones y de la progresi\u00f3n tumoral. Pero tambi\u00e9n tienen efecto antiinflamatorio mediante la expansi\u00f3n de MDSCs circulantes y la disminuci\u00f3n de monocitos proinflamatorios.     \n  \nP-060  NEW STAT3 GAIN-OF-FUNCTION MUTATION (P.MET162ARG) IN A PAEDIATRIC PATIENT   Pol Pol, Elisabet1; Segura Guerrero, Marina1; Ramakers, Jan1; Carreras, Carmen2; Vogel, Tiphanie3; Lucena, Jose Manuel4; Ferrer Balaguer, Joana Maria1; Mart\u00ednez Pomar, Natalia1.  1Hospital Universitario Son Espases. Instituto de Investigaci\u00f3n Sanitaria Illes Balears (IdISBa), Palma de Mallorca; 2Hospital Universitario la Fe, Valencia; 3Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston; 4Hospital Universitario Virgen del Roc\u00edo, Sevilla.  Gain of function mutations in STAT3 (signal transducer and activator of transcription 3) gene cause \u201cinfantile-onset multisystem autoimmune disease-1\u201d. Insulin dependent diabetes mellitus, autoimmune enteropathy or coeliac diseases are the most common manifestations together with hematologic autoimmune alterations. Patients usually are of short stature and present non-specific dermatitis. We present a 2 years old boy admitted at 18 days of age with respiratory syncytial virus bronchiolitis that required PICU admission. At 6 weeks of age he presented severe Salmonella and Rotavirus acute gastroenteritis (AGE) accompanied by dehydration again requiring admission to Paediatric Intensive Care Unit (PICU). Episodes of AGE caused several hospital admissions in the first months of live. He presented failure to thrive and atopic eczema well controlled with topical treatment in the second year of live. Laboratory findings included normal percentage and absolute values of lymphocyte subpopulations CD3, CD4, CD8, CD19 and NK cells with a slight decrease of switch memory (CD27+ IgD-) B cells and a decrease of serum IgG (440 mg/dl). He had a normal response to Streptococcus pneumoniae, Haemophilus influenzae, tetanus and hepatitis B virus vaccination. The genetic study identified a non-previously described heterozigous \u201cde novo\u201d variant in STAT3 gene (p.Met162Arg;c.485T>G). \u201cIn vitro\u201d functional characterization by STAT3 luciferase studies revealed an increase in STAT3 activity in cells transfected of M162R mutant STAT3 plasmid. Due to the heterogeneous manifestation of the disease and the progressive onset of symptoms, genetic study is essential for the early diagnosis and follows up of \u201cinfantile-onset multisystem autoimmune disease-1\u201d     \n  \n                             \n \n  \nP-061  DIAGN\u00d3STICO NEONATAL EN SCID DEBIDO A CD3 DELTA EN POBLACI\u00d3N AUT\u00d3CTONA DE MANAB\u00cd (ECUADOR): PUESTA A PUNTO Y PROPUESTA.  Garc\u00eda-Ram\u00f3n, Diana1; Seco Hidalgo, Victor1; Mart\u00ednez Mart\u00ednez, Laura2; Calder\u00f3n Espinosa, Evelyn1; Franco Leyva, Teresa2; Cede\u00f1o, Richard3; Gonz\u00e1lez-Andrade, Fabricio4; De La Calle Mart\u00edn, Oscar2.  1School of Medicine. Universidad Internacional del Ecuador, Quito; 2Hospital de Sant Pau, Barcelona; 3Solca Manab\u00ed Hospital, Portoviejo; 4Faculty of Medical Sciences. Universidad Central del Ecuador, Quito.  Debido a su sintomatolog\u00eda poco espec\u00edfica, las Inmunodeficiencias Severas Combinadas (SCID) constituyen un grupo de enfermedades subdiagnosticadas. Diferentes estudios moleculares van ampliando el conocimiento y la capacidad de detecci\u00f3n de las mismas, incluyendo el estudio perinatal de la prueba del tal\u00f3n. Una de ellas es el SCID asociado a CD3-Delta (CD3D). Esta enfermedad ha sido asociada a 3 variantes al\u00e9licas, todas con herencia autos\u00f3mica recesiva, diagnostic\u00e1ndose un total de 11 casos: 7 relacionados con la mutaci\u00f3n R68X, 1 con la mutaci\u00f3n C93X y 4 relacionados con IVS2DSG-A+5. En los dos primeros tipos de mutaci\u00f3n todos los casos refieren consanguinidad, mientras que la \u00faltima variante al\u00e9lica se ha descrito en pacientes no consangu\u00edneos de etnia precolombina, procedentes de una \u00fanica regi\u00f3n, Manab\u00ed. Con el objetivo de determinar la frecuencia de la mutaci\u00f3n IVS2DSG-A+5, hemos llevado a cabo un muestreo sobre 396 individuos sanos originarios de esta zona de la costa ecuatoriana. A partir de sangre perif\u00e9rica recolectada en papeles FTA se realiz\u00f3 la extracci\u00f3n de ADN total que fue sometido a un ensayo de genotipificaci\u00f3n mediante PCR en tiempo real utilizando sondas TaqMan\u00ae capaces de detectar el SNP asociado a esta mutaci\u00f3n (rs730880296). Para validar esta metodolog\u00eda, 50 de las muestras fueron tambi\u00e9n analizadas mediante RFLP y secuenciaci\u00f3n. Como controles se utilizaron 1000 muestras de individuos sanos de otras regiones de Ecuador, incluyendo diferentes or\u00edgenes \u00e9tnicos, familiares portadores de pacientes con SCID debido a CD3-Delta y los mismos pacientes. Los resultados del ensayo de genotipificaci\u00f3n mostraron un total de 18 individuos heterocigotos (porcentaje de portadores = 4,55 %), obteniendo una frecuencia del alelo mutado de 2,27. La elevada frecuencia de dicha mutaci\u00f3n en la regi\u00f3n de Manab\u00ed indica la necesidad de un diagn\u00f3stico poblacional espec\u00edfico basado en la detecci\u00f3n de esta variante mediante la prueba del tal\u00f3n.        \n  \nP-062  INSUFICIENCIA DE SUBCLASE IGG2 E INFECCI\u00d3N BACTERIANA. UNA NUEVA MANERA DE IDENTIFICAR EL RIESGO DE INFECCI\u00d3N.   Mej\u00eda Gonz\u00e1lez, Mar\u00eda Alejandra1; D\u00edaz Luna, Mar\u00eda De Las Mercedes1; Moncayo Mu\u00f1oz, Ana Paulina1; Alonso Armend\u00e1riz, Rocio2; Navarro Caspistegui, Joaqu\u00edn1; Fern\u00e1ndez-Cruz P\u00e9rez, Eduardo1; Carbone Campoverde, Javier1.  1Servicio de Inmunolog\u00eda, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid; 2Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, Madrid.  El rol de la subclase IgG2 para el control de infecciones bacterianas es bien reconocido. Se utiliza el punto de corte establecido por el laboratorio como nivel definitorio de deficiencia de IgG2. La hip\u00f3tesis de este estudio es que los pacientes que desarrollan infecciones bacterianas tienen menores concentraciones s\u00e9ricas de IgG2 siendo posible identificar un punto de corte de asociaci\u00f3n que entra dentro del rango considerado como normal que podr\u00eda definirse como insuficiencia. En un estudio retrospectivo se incluyeron 223 pacientes con infecciones bacterianas y 117 sin antecedente de infecci\u00f3n bacteriana, con distintas patolog\u00edas de base inmunol\u00f3gica (controles). Se define infecci\u00f3n bacteriana a la presencia de 3 o m\u00e1s procesos infecciosos anuales tratados con antibioterapia o al menos un ingreso hospitalario por infecci\u00f3n bacteriana. Se recogi\u00f3 informaci\u00f3n de los siguientes par\u00e1metros: IgG, IgA, IgM, subclases IgG, C3, C4, anticuerpos basales anti-polisac\u00e1rido de neumococo, recuentos absolutos de subpoblaciones linfocitarias. Los niveles de IgG2 se testaron mediante turbidimetr\u00eda, analizador Optilite\u00ae. En la comparaci\u00f3n de medias entre grupos se detect\u00f3 un nivel significativamente m\u00e1s bajo de IgG total (999.8 vs 1124.9 mg/dL, p=0.016) a expensas de la subclase IgG2 (2.79 vs 3.61 g/L, p<0.001). El nivel basal de anticuerpos anti-polisac\u00e1rido de neumococo fue significativamente m\u00e1s bajo en los pacientes con infecciones bacterianas (7.28 vs 8.91 mg/dL, p=0.0022). No se detectaron diferencias significativas en los otros par\u00e1metros estudiados. Utilizando los niveles normales del reactivo (1,47-6,29g/L) y curvas ROC se definieron los siguientes valores: IgG2 < 1.47 g/L deficiencia; 1.47-3.7 insuficiencia; > 3.71 suficiencia. Los niveles de insuficiencia se asociaron significativamente al riesgo de infecci\u00f3n bacteriana (p<0.001).  Concluimos que es posible identificar un nivel de insuficiencia de IgG2 como factor de riesgo de infecci\u00f3n bacteriana. Si se validan estos resultados en un estudio multic\u00e9ntrico, podr\u00edan identificar pacientes en riesgo inmunol\u00f3gico.       \n  \nP-063  SINDROME DE KABUKI: UN DIAGNOSTICO QUE NO DEBES IGNORAR  Fusi Velarde, Cinthya; Bravo Gonzalez, Maikel; Jimenez Portillo, Ana Lucia; Mora Diaz, Sergio; Marco De La Calle, Francisco Manuel.  Hospital General Universitario de Alicante Dr. Balmis, Alicante.  Caso 1. Mujer de 51 a\u00f1os con antecedente de panhipogammaglobulinemia, luxaci\u00f3n cong\u00e9nita de caderas bilateral, sordera neurosensorial, diarrea cr\u00f3nica por criptosporidium, enfermedad pulmonar intersticial linfocitica granulomatosa compatible (biopsia pulmonar), gastritis cr\u00f3nica atr\u00f3fica, hiperplasia nodular linfoide ileal, hipertransaminasemia a estudio, pancitopenia a estudio, diabetes mellitus tipo 2. A los 40 a\u00f1os tras estudio inmunol\u00f3gico completo se diagnostica de Inmunodeficiencia Variable Com\u00fan (IDVC) y se inicia tratamiento sustitutivo con inmunoglobulinas.  Caso 2. Mujer de 51 a\u00f1os con antecedente de hipogamaglobulinemia, retraso psicomotor, glaucoma, hipoacusia conductiva bilateral, hipotiroidismo primario, pancitopenia, arteria subclavia derecha aberrante, enfermedad pulmonar intersticial linfoc\u00edtica granulomatosa e hipertransaminasemia. Se realiz\u00f3 estudio inmunol\u00f3gico que revelo una deficiencia de producci\u00f3n de anticuerpos y alteraciones compatibles con IDVC.  Ambos casos se caracterizaban por una combinaci\u00f3n de manifestaciones cl\u00ednicas similares y rasgos faciales caracter\u00edsticos (Figura 1), por lo que se realiz\u00f3 estudio gen\u00e9tico dirigido para descartar s\u00edndrome de Kabuki. En el Caso 1 se detecta la variante c.13884dupC en el gen KMT2D en heterocigosis (NGS-MiSeq, Agilent) y en el Caso 2 se identifica la variante probablemente patog\u00e9nica c.1613del en el gen KMT2D en heterocigosis (Next Seq 500, Agilent).     Nuestros casos muestran que el Sindrome de Kabuki (SK) (OMIM 147920 y 300867) es una forma de IDVC monog\u00e9nica, potencialmente grave (con elevada frecuencia de complicaciones no infecciosas), que debemos sospechar ante la presencia rasgos faciales caracter\u00edsticos (fisuras palpebrales largas con eversi\u00f3n del tercio lateral del p\u00e1rpado inferior, cejas arqueadas y anchas con muescas o escasez en el tercio lateral, columela corta con punta nasal deprimida, orejas grandes, prominentes o ahuecadas y dermatoglifos fetales persistentes ) y alteraciones cl\u00ednicas compatibles.   \n  \n                                   \n \n  \nP-064  FENOTIPO HIPER IG-E LIKE ASOCIADO A MUTACION HETEROCIGOTA COMPUESTAS DE LA FOSFOGLUCOMUTASA 3 (PGM3) EN GEMELOS MONOCIG\u00d3TICOS   Jim\u00e9nez Portillo, Ana Luc\u00eda; Bravo Gonz\u00e1lez, Maikel; Fusi Velarde, Cinthya; Mora D\u00edaz, Sergio; Marco De La Calle, Francisco M.  Hospital General Universitario de Alicante Dr. Balmis, Alicante.  La deficiencia de fosfoglucomutasa 3 (PGM3) (Inmunodeficiencia 23, OMIM: 615816) es trastorno cong\u00e9nito raro de la glicosilaci\u00f3n que puede llevar a los pacientes a un s\u00edndrome de hiper-IgE (HIES).  La PGM3 es una enzima responsable de la conversi\u00f3n de N-acetil-glucosamina (GlcNAc)-6-fosfato en GlcNAc-1-fosfato, esta conversi\u00f3n es necesaria para la producci\u00f3n de uridina difosfato (UDP)-GlcNAc, que es un sustrato com\u00fan de m\u00faltiples v\u00edas de glicosilaci\u00f3n y es un precursor esencial de la glicosilaci\u00f3n. Nuestro objetivo es caracterizar el fenotipo cl\u00ednico, el perfil inmunol\u00f3gico y el resultado gen\u00e9tico de unos gemelos monocig\u00f3ticos de 37 a\u00f1os con deficiencia de PGM3. Seleccionamos el gemelo con la presentaci\u00f3n cl\u00ednica m\u00e1s grave como caso \u00edndice, realizando una secuenciaci\u00f3n del exoma completo. La secuenciaci\u00f3n Sanger de PGM 3 se realiz\u00f3 en el otro gemelo y en ambos padres.  Los pacientes fueron estudiados con un panel de pruebas inmunol\u00f3gicas que inclu\u00edan la detecci\u00f3n de poblaciones TH17, estudio de lectinas por citometr\u00eda de flujo (L-PHA) y otras pruebas orientadas al HIES. Ambos gemelos presentaban rasgos faciales dism\u00f3rficos, micrognatia, enfermedad at\u00f3pica severa, abscesos cut\u00e1neos recurrentes, e infecciones respiratorias severas (virales y bacterianas) y deterioro cognitivo de diferente grado de severidad. La secuenciaci\u00f3n del exoma identific\u00f3 una variante heterocigota compuesta de PGM3 c.1438_1442del y c.1475C>T.  La secuenciaci\u00f3n Sanger de PGM3 realizada al otro gemelo, identific\u00f3 la misma variante gen\u00e9tica. Cada uno de los progenitores era portador de una de las variantes confirmando el patr\u00f3n de herencia.  El an\u00e1lisis de L-PHA de las c\u00e9lulas mononucleares de la sangre perif\u00e9rica mostr\u00f3 una menor uni\u00f3n de la lectina en comparaci\u00f3n con los controles sanos. Ambos pacientes mostraron una mayor expresi\u00f3n de la poblaci\u00f3n Th17. Nuestros pacientes presentan un s\u00edndrome similar al de Job, consideramos que la mutaci\u00f3n del gen PGM3 debe ser considerada entre los posibles diagn\u00f3sticos en individuos con HIES.      \n  \nP-065  FALTA DE ESTANDARIZACI\u00d3N EN LA CUANTIFICACI\u00d3N DE LA IGG Y DE SUS SUBCLASES  Mora D\u00edaz, Sergio; Bravo Gonz\u00e1lez, Maikel; Jim\u00e9nez Portillo, Ana; Marco De La Calle, Francisco Manuel; Fusi Velarde, Cinthia Mavel.  Hos\u00ectal General Dr. Balmis, Alicante.  La IgG es dominante en el suero y existen cuatro subclases (IgGSc) cuya abundancia, funciones y afinidad var\u00edan dependiendo de la edad. Pueden existir desequilibrios particularmente en inmunodeficiencias primarias. Los ensayos comerciales para su cuantifiaci\u00f3n utilizan los calibradores ERM-DA470k y Sanquin-M1590. En nuestro laboratorio observamos diferencias en la suma de IgGSc y la IgG. Se compar\u00f3 la suma de IgGSc e IgG, as\u00ed como la IgG y IgGSc cuantificadas usando ambos calibradores. La IgG y IgGSc se cuantificaron en 185 muestras de suero siguiendo las instrucciones del fabricante:  -IgG (OSAS15) y IgGSc (OQXI09, OQXK09, OPAV03, OPAU03) usando Sanquin-M1590 en el autoanalizador BNII (Siemens). -IgG (NK009.OPT) y IgGSc (NK006.OPT, NK007.OPT, LK008.OPT, NK004.OPT) usando ERM-DA470k en el autoanalizador Optilite (Binding Site). Se descartaron los valores at\u00edpcos con fines estad\u00edsticos. Se determin\u00f3 la correlaci\u00f3n lineal (Test Pearson) y compararon la IgG con la suma de IgGSc para cada calibrador, as\u00ed como los valores de IgG y IgGSc entre calibradores (T Student de muestras pareadas). Los valores de IgG fueron similares a la suma de IgGSc con Sanquin-M1590 (p=0,223), pero significativamente distintos con ERM-DA470k (IC 95% IgG-suma IgGSc= 20,4 a 43,0; p<0.001). Existi\u00f3 correlaci\u00f3n lineal entre la IgG y IgGSc entre ambos calibradores (p<0,001). Pero la cuantificaci\u00f3n de IgG fue diferente entre calibadores (IC 95% IgG Sanquin-M1590 - IgG ERM-DA470k= -88,4 a -15,2; p=0.006). Las IgGSc fueron distinas entre calibradores (IgG1: IC 95% Sanquin-M1590 - ERM-DA470k= 80,4 a 113,7; p<0,001; IgG2: IC 95% Sanquin-M1590 - ERM-DA470k= -75,4 a -50,8; p<0,001; IgG3: IC 95% Sanquin-M1590 - ERM-DA470k= -39,0 a -32,3; p<0,001; IgG4: IC 95% Sanquin-M1590 - ERM-DA470k= 7,1 a 12,5; p<0,001). Es necesaria la estandarizaci\u00f3n de la cuantificaci\u00f3n de IgG y IgGSc, pues su cuantificaci\u00f3n es diferente entre calibradores. La suma de IgGSc s\u00f3lo fue similar a la IgG determinadas con el calibrador Sanquin-M1590.    \n  \n Sesi\u00f3n Poster. Miscel\u00e1nea. (Inflamaci\u00f3n / Alergias y reacciones de hipersensibilidad / Inmunidad anti-tumoral). Pantalla 4  P-066  ANGIOPOIETIN-LIKE PROTEIN 2 LEVELS AS A MARKER OF INFLAMMATION IN PATIENTS WITH HIDRADENITIS SUPPURATIVA   Renuncio-Garc\u00eda, M\u00f3nica1; Gonz\u00e1lez-L\u00f3pez, Elena1; Ocejo-Vinyals, J. Gonzalo1; Blanco, Ricardo2; Hern\u00e1ndez, Jos\u00e9 Luis3; Gonz\u00e1lez-L\u00f3pez, Marcos Antonio4.  1Servicio de Inmunolog\u00eda. Hospital Universitario Marqu\u00e9s de Valdecilla, Santander; 2Servicio de Reumatolog\u00eda. Hospital Universitario Marqu\u00e9s de Valdecilla. Universidad de Cantabria (UNICAN), Santander; 3Servicio de Medicina Interna. Hospital Universitario Marqu\u00e9s de Valdecilla. Universidad de Cantabria (UNICAN), Santander; 4Servicio de Dermatolog\u00eda. Hospital Universitario Marqu\u00e9s de Valdecilla. Universidad de Cantabria (UNICAN), Santander.  Introduction Hidradenitis suppurativa (HS) is a chronic inflammatory disorder characterized by nodular lesions, abscesses and fistulae that affects skin regions. It has been described that high levels of TNF\u03b1 in skin lesions as well as IL-17 in serum of HS patients correlate with disease severity, together with an inflammatory profile and a predominance of Th1 and Th17 lymphocytes.  Angiopoietin-like protein 2 (ANGPTL2) signaling functions in angiogenesis and tissue repair, whereas an excess of ANGPTL2 signaling has been associated with chronic inflammation and subsequent pathological irreversible tissue remodeling. Since ANGPTL2 is involved in tissue homeostasis by inflammation and regeneration, the aim of this study is to evaluate if ANGPTL2 serum levels could be involved in HS pathogenesis.  Methods This was a cross-sectional study including 94 patients with HS and 60 controls, recruited from our Dermatology outpatient clinic at the Marqu\u00e9s de Valdecilla University Hospital (Santander, Spain). Patients were all \u226518 years and fulfilled the diagnostic criteria for HS. The control group was recruited among hospital medical staff and subjects with non-inflammatory cutaneous disorders. Determination of ANGPTL2 serum was carried out by ELISA by following manufacturer\u2019s instructions Statistical analysis was performed using Graph Pad Prism software 6.0 version. Comparisons were based in U-Mann-Whitney test    \n  \nResults Differences between HS patients and controls ANGPTL2 levels were statistically significant (p<0.0001). Medians and interquartile ranges of controls and patients were calculated: 0.37 (0.0925-0.9200); 42.79 (26.99-53.69), respectively (Figure 1).  Conclusion The precise inflammatory mechanism underlying HS is still not fully elucidated. High serum levels of ANGPTL2 have been associated with inflammatory processes and autoimmune diseases. Here we demonstrated that ANGPTL2 elevation in HS patients could serve as a biomarker that would indicate an alteration of tissue homeostasis. Further and larger studies are needed in order to know the exact role of this protein.    \n                \n \n  \nP-067  ANALYSIS OF THE EXPRESSION OF FOUR POTENTIAL ASTHMA TRIGGERS IN LUNG TISSUES OF ASTHMATIC PATIENTS  Cremades-Jimeno, Luc\u00eda1; L\u00f3pez-Ramos, Mar\u00eda1; Baos, Selene1; Mah\u00edllo-Fern\u00e1ndez, Ignacio2; Sastre, Joaqu\u00edn3; C\u00e1rdaba, Blanca4.  1Departamento de Inmunolog\u00eda, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz-UAM, Madrid; 2Unidad de Bioestad\u00edstica y Epidemiolog\u00eda, Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid; 3Departamento de Alergia, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz / CIBER de Enfermedades Respiratorias, CIBERES, Madrid; 4Departamento de Inmunolog\u00eda, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz-UAM / CIBER de Enfermedades Respiratorias, CIBERES, Madrid.  Background Asthma is a chronic inflammatory disease, with high heterogeneity, making its management difficult sometimes. Besides, treatments are symptomatic and needed for long periods. We previously defined and theoretically prioritize, using systems biology, a group of potential biomarkers with the ability to differentiate asthma phenotypes in peripheral blood samples; and identified potential triggers: AKT1, MAPK13, STAT1 and TLR4.  Objective Analyze the expression of the theoretically defined asthma triggers in lung samples of asthmatic patients with the aim of find new possible therapeutic targets. Methods Lung tissue samples from 10 healthy controls (HC) and 19 asthmatic patients were obtained from the CIBERES (CIBER of respiratory diseases) biobank. After mechanic homogenization of tissue samples, RNA was extracted trough TRIzol method and gene expression was analyzed trough RT-qPCR. Differential gene expression was analyzed with InStat program; and a study of their sensitivity and specificity to discriminate groups was performed through ROC curve analysis.   Results All genes showed a lower expression in the asthma group compared to HC, with statistically significant differences for MAPK13, STAT1 and TLR4. ROC curve analysis showed the best AUC values for TLR4 and MAPK13.Then, we analyzed separately the expression in patients with asthma only (n=9), and observed that all genes showed statistically significant differences with the HC group, while only MAPK13 and TLR4 were significantly different in the asthmatic patients presenting other respiratory diseases (n=10). The best AUC values were found for the discrimination between the HC and the patients with asthma only. Finally, the comparison between both asthma subgroups showed differences in the expression of the four genes, without statistical significance, and the higher AUC value for MAPK13.  Conclusion  \n  \nAKT1, MAPK13, STAT1 and TLR4 gene expression in lung tissue is differential between patients with asthma and healthy subjects, opening new possibilities in the search of asthma treatments.                                                     \n  \nP-068  TRANSVERSAL STUDY OF NK-CELL SUBSETS AND T-CELL ACTIVATION PATTERNS IN ALCOHOL USE DISORDER PATIENTS ACCORDING TO LIVER FIBROSIS DEGREE   Zurera Egea, Coral1; Hern\u00e1ndez Rubio, Anna2; Teniente Serra, Aina2; Fuster, Daniel2; Mart\u00ednez C\u00e1ceres, Eva2; Muga, Roberto2; Zuluaga, Paola2.  1Fundaci\u00f3 Institut d\u2019Investigaci\u00f3 en Ci\u00e8ncies de la Salut Germans Trias i Pujol (IGTP), Badalona; 2Hospital Universitari Germans Trias i Pujol, Badalona.  Introduction: Cellular immunity in alcohol-related liver diseases (ARLD) is currently being characterized. CD8+T-cell activation is known to be detrimental enhancing liver damage, whereas Natural Killer (NK)-cells and NKT-cells play an important role in ARLD development having subsets with opposing roles. Here, we aimed to evaluate the phenotype of NK and NKT-cells and the T-cell activation profile in patients with alcohol use disorder (AUD) according to their liver fibrosis degree.  Methods: Patients were admitted to treatment of severe AUD (2019-2021). Advanced liver fibrosis (ALF) was defined when: FIB-4 score >2.67 (n=19), or Forns score >6.9 (n=21). Patients with HCV-infection, HIV-infection and history of liver cirrhosis were excluded. We analyzed NK-cell subsets (CD3-CD56+CD16+, CD3-CD56+CD16-, CD3-CD56-CD16+), NKT-cells (CD3+CD56+), and the activation status of CD4+, CD8+ and regulatory T-cells (Tregs) according to HLA-DR expression.  Results: 79 patients (51 years, 71% males), with a mean AUD duration of 18\u00b111 years and a daily alcohol consumption of 155\u00b177gr/day, were included. CD3-CD56+CD16-NK-cells in ALF patients were significantly lower (4.8\u00b13.3; 4.9\u00b13.4) compared to non-ALF patients (7.8\u00b16.2; 7.7\u00b16.2) according to Forns and FIB-4, respectively. CD3-CD16+CD56+NK-cells were significantly higher in ALF patients (87\u00b111) compared to non-ALF patients (80\u00b116) according to Forns. No significant differences were observed in CD3-CD56-CD16+NK-cells and NKT-cells. ALF patients also presented increased HLA-DR+-expressing Tregs (38\u00b111.6; 39.2\u00b111.5) and CD8+ (16\u00b18.3; 15.6\u00b18.8) compared to Tregs (32.7\u00b19.4; 32.5\u00b19.3) and CD8+ (12\u00b19.1; 12.2\u00b19) in non-ALF patients according to Forns and FIB-4, respectively. HLA-DR+CD4+cells were higher in ALF patients (5.1\u00b13.1) than in non-ALF patients (3.9\u00b13) according to FIB-4 (p<0.05) (Fig.1).  Conclusions: Severe AUD patients with ALF presented an increased NK cytotoxic phenotype  \n  \nconcomitant with a decreased cytokine-secreting phenotype, possibly as a compensating mechanism of liver fibrosis. Meanwhile, the increased activation pattern observed in some T-cell subsets of ALF patients could be a mechanism that favors the development and maintenance of liver fibrosis.  \n                     \n \n  \nP-069  ROLE OF JNK KINASES IN CHRONIC INTESTINAL INFLAMMATION AND ITS RELATIONSHIP WITH EPITHELIAL MALIGNANCY   Rivas Pardo, Benigno; Mart\u00edn Adrados, Beatriz; Solsona Garc\u00eda, Adela; G\u00f3mez Del Moral, Manuel; Cubero, Francisco Javier; Mart\u00ednez Naves, Eduardo.  Facultad de Medicina, UCM, Madrid.  Introduction The c-Jun N-terminal kinases (JNKs) are conserved proteins which regulate a wide range of cellular responses, including cell proliferation, differentiation or survival. Hyperactivation of the JNK signaling pathway is observed in many inflammatory diseases, such as colitis, and this increased activation of JNK frequently results in pathology via the regulation of the transcription of numerous inflammation-related genes. The general objective of this work is to identify specific mechanisms of the JNK signaling pathway involved in injury-derived chronic inflammation.  Methods Mice with conditional deletion of Jnk1 and Jnk2 in the intestinal epithelial cells (JNK\u0394IEC) were generated by crossing Jnk1/2flox/flox mice with VillinCre-transgenic mice. We then analyzed samples of small and large intestine using histological techniques and RNAseq. Moreover, we analyzed the phenotype of intraepithelial lymphocytes by flow cytometry. Results 10 weeks old JNK\u0394IEC mice develop spontaneous mild inflammation in the duodenum and colon. Preliminary data shows that in both small intestine and colon may be a reduction of T\u03b1\u03b2 lymphocytes and an increase of T\u03b3\u03b4 and iNKTs in JNK\u0394IEC mice compared with controls. 52 weeks old JNK\u0394IEC mice present aberrant architecture and epithelial-dysplasia together with cellular infiltrates in the duodenum. At this age we observed significant changes in the intestinal transcriptome. Interestingly, we found a dramatic downregulation of the complement pathway in colon samples, while this is highly enriched in duodenum samples compared with controls. Moreover, we found that 72 weeks old JNK\u0394IEC mice develop numerous tumors in the duodenum. Conclusions Jnk1 and Jnk2 deletion in intestinal epithelial cells is associated with a deregulation of the immune system that produces spontaneous intestinal inflammation in young JNK\u0394IEC mice, which may be the cause of the progression to epithelial-dysplasia and the tumors observed in the duodenum of older mice. The complement system might be a key factor in this process.    \n  \n \n                   \n \n  \nP-070  INCREASED MYELOIDE-DERIVED SUPRESSOR CELLS IN PATIENTS WITH RECURRENT MISCARRIAGE AND RECURRENT IMPLANTATION FAILURE  Subhi-Issa Marin, Nabil1; De La Fuente Mu\u00f1oz, Eduardo2; Gil Laborda, Raquel1; Suarez, Lydia Pilar3; Ochoa Grull\u00f3n, Juliana3; Calvo, Marta3; Crist\u00f3bal, Ignacio3; Fern\u00e1ndez Arquero, Miguel3; S\u00e1nchez Ram\u00f3n, Silvia1.  1Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica del Hospital Cl\u00ednico San Carlos, Madrid; 2Hospital Clinico San Carlos, Madrid; 3Hospital Cl\u00ednico San Carlos, Madrid.   Recurrent miscarriage (RM) and recurrent implantation failure (RIF) are two distinct disorders that can be associated with baseline pro-inflammatory state. Different surrogate inflammatory biomarkers have been associated with these disorders, including expanded cytotoxic NK cells, increased pro inflammatory cytokines or reduced regulatory T cells (TReg) in a subgroup of these patients. Myeloid-derived supressor cells (MDSCs) are a heterogeneous population of leukocytes, characterized by their ability to modulate immune responses. The immunosuppressive function of MDSC in cancer has been well established, while a controversial role in chronic inflammatory diseases has been reported. Typically, there are two major groups of MDSCs in humans: polymorphonuclear MDSCs (PMN-MDSCs) and monocytic MDSCs (M-MDSCs). Freshly collected blood samples were analyzed by multiparametric flow cytometry using a BD FACS CANTO II. Peripheral blood M-MDSCs were characterized based on HLA-DR, CD14, CD33 and CD45 expression. A group of healthy non-pregnant women up to 45 years old with two or more children (proven fertility) and no spontaneous miscarriage was used as control group (CS).  In this study, we evaluated 65 women, 33 that fulfilled RM criteria and 32 with RIF. In addition, a group of 28 non-pregnant fertile women was included as a control group. We characterized MDSCs as CD14+CD33+CD45+HLA-DR-/LOW, according to previous reports. We observed a significant expansion of peripheral blood MDSCs in RM group (7,9 [6,75-10,55]; p= 0.002) and RIF (8,6 [6,15-12,15]; p=0.003) compared to CS group (6,35 [4,78-7,6]). We performed ROC curve analysis to evaluate the predictive power. The area under the curve was 0.72. We established an optimal cut-off level of 7.65% for both groups, with a sensitivity of 58.5% and a specificity of 77.8%. MDSCs might be a good predictor for RM and RIF patients and with other biomarkers may classify a subgroup of patients with pro-inflammatory profile that can benefit from personalized therapies.    \n  \nP-071  EVALUATION OF BASAL \u201cEX VIVO\u201d INFLAMMASOME ACTIVATION IN PERIPHERAL BLOOD MONOCYTES SUBSETS FROM HEALTHY DONORS BY FLOW CYTOMETRY   S\u00e1nchez Rodr\u00edguez, Carlos; Ot\u00e1lora Alcaraz, Almudena; Salgado Cecilia, M\u00aa Gema; Moya Quiles, Rosa; Gali\u00e1n Mejias, Jose Antonio; Muro, Manuel; Mart\u00ednez Banaclocha, Helios.  HCUVA, Murcia.  Introduction Human peripheral blood monocytes are classified in three subsets namely classical (CD14++CD16\u2212), intermediate (CD14++CD16+), and non-classical (CD14+CD16+) . CD16 (+) monocytes have an inflammatory function and are expanded in inflammatory conditions. Inflammasomes are cytosolic multiprotein complexes composed by a NLR, the adaptor protein ASC and caspase-1 that proteolytically cleave pro-inflammatory cytokines like IL-1\u03b2 and IL-18. In the present work we investigate \u201cex vivo\u201d the activation of the inflammasome by human monocyte subsets in basal conditions measuring ASC protein oligomerization and caspase-1 activation by flow cytometry.  Methods Human PBMCs obtained from 18 healthy donors were stained with anti-CD3, CD56, CD19, HLA-DR, CD14 and CD16 fluorescent monoclonal antibodies to isolate CD14++CD16-, CD14++CD16+ and CD14+CD16+ monocytes by cell sorting. 1x105cells of each subset were cultured in RPMI media 10% FBS during 18 hours. CD14++CD16- were also cultured in the presence of LPS (200ng/ml) during 18h as positive control for inflammasome activation. Cells were then stained with FAM FLICA caspase-1 kit (Bio-Rad) following manufacturer instructions, fixed, permeabilized, stained with anti-ASC-PE antibody and adquired in a FACS Lyric flow cytometer to measure intracellular ASC aggregates and active caspase-1 as markers of inflammasome activation. Statistical analysis was performed using prism software v5.  Results We found a significantly higher percentage of CD14++CD16+ and CD14+CD16+ monocytes forming intracellular ASC aggregates (Figures 1a-c) and with intracellular active caspase-1 (Figures 1b-c) compared to CD14++CD16- monocytes after 18 hours of cell culture in resting conditions, suggesting a higher basal inflammasome activation in CD16+ monocytes subsets.  Conclusions In the present work we report an increased basal \u201cex vivo\u201d activation of inflammasome by  \n  \nCD14++CD16+ and CD14+CD16+  monocytes compared to CD14++CD16- monocytes. This result needs further investigation to identify the mechanism of inflammasome activation in monocytes subsets and whether inflammasome activation in CD16+ monocytes could be involved in the development of inflammatory diseases.                                                  \n  \nP-072  PLASMATIC DETERMINATION OF CYTOKINE INDUCTION TO ASSESS THE INFLAMMATORY RESPONSE AGAINST VIRAL ANTIGENS  Lopez Martinez, Rocio; Garc\u00eda Torre, Alejandra; Rioseras, Beatriz; Bueno Garc\u00eda, Eva; Alonso, Sara; Moro Garc\u00eda, Marco Antonio; Alonso Arias, Rebeca.  Hospital Universitario Central de Asturias, Oviedo.  During the SARS-CoV-2 pandemic, the \u201ccytokine storm\u201d phenomenon has been widely described in severe cases of COVID-19, being established as the main biomarker of severity. This fact makes relevant to be able to predict those individuals who are going to develop an exaggerated innate response to viral antigens. We developed a protocol to measure the intrinsic capacity of cytokine production against viral antigens in whole blood cultures. Thirty-nine patients who had overcome COVID-19 (mean time after infection= 5.5 months) without requiring hospitalization (mean age=67.9, N=14), requiring hospitalization on the ward (mean age=71.7, N=13) or requiring ICU admission (mean age=66.8, N=12) was studied to evaluate the test and to compare their ability to produce proinflammatory cytokines. Peripheral blood samples anticoagulated with heparin were cultured for 18 hours both without stimulation and stimulated with R848, an agonist to TLR7 and TLR8. After incubation, plasma was obtained and the inflammatory cytokine profile was measured using the kit cytokine 9-Plex ProcartaPlex Panel (ThermoFisher) and LuminexxMAPtechnology. This kit includes the cytokines IL-1\u03b2, IL-2, IL-6, IL-8, IL-10, IFN-\u03b1, IFN-\u03b2, IFN-\u03b3 and TNF-\u03b1. Cytokine levels were undetectable or very low in unstimulated cultures. Only IL-8 was detected in all patients, and TNF-\u03b1, IL-6 and IL-1\u03b2 were at very low levels in more than half patients. R848 induced the production of all cytokines in all patients and a significant increase in those in which it was already detected without stimulation. IL-8, IL-1\u03b2, IL-6 and TNF-\u03b1 reached the highest levels. When individuals who had different degrees of SARS-CoV-2 severity were compared, we found that those admitted to ICU produced higher levels of IL-2, IL-10 and TNF-\u03b1 (p<0.05). We conclude that whole blood cultures stimulated with R848 are a useful system to evaluate response to viral antigens and it may predict individuals with a higher risk of exaggerated inflammatory response.       \n  \nP-073  EFFECTOR AND REGULATORY CD4+ T CELL SUBSETS IN NEWBORNS WITH LEUKEMOID REACTION   Segura Guerrero, Marina1; Andreu Matillas, Valero2; Maroto, Cristina1; Berman Riu, Maria2; L\u00f3pez, Antonio1; Pol Pol, Elisabet1; Salinas, Jose Antonio1; Figuerola, Joan1; Pons De Ves, Jaime1; Juli\u00e0 Benique, Maria Rosa1.  1Hospital Universitario Son Espases. Instituto de Investigaci\u00f3n Sanitaria de las Islas Baleares (IdISBa), Palma de Mallorca; 2Instituto de Investigaci\u00f3n Sanitaria de las Islas Baleares (IdISBa), Palma de Mallorca.  Introduction: Neonatal leukemoid reaction (LR) is a rare disease that reaches 17% incidence among preterm neonates with high morbidity and mortality. Its etiology is unknown although it has been related to an excessive inflammatory response. Perinatal immune system is tightly regulated to avoid an allogenic response and an excessive reaction against new antigens. Different subsets of effector and regulatory lymphocytes are involved in these regulatory mechanisms. The role of T regulatory (Treg) and T CD4+ T helper effector (Th) cell subsets has not been evaluated in LR.  Aim: To study the contribution of different peripheral lymphocyte subsets in preterm neonates with leukemoid reaction (LR): n=8, compared to healthy preterm neonates (PT): n=12, healthy full-term neonates (T): n=20 and healthy adults (HA): (n=10).  Methods: 2 ml of peripheral whole blood were collected. In LR and their paired controls (PT) two samples were taken, at the disease\u2019s debut and one week later.  Cell surface markers were analysed by flow cytometry using BD FACSLyric, data evaluation was done with the BD FACSuite Software (Becton Dickinson). We quantified: Treg (CD4+CD25+CD127-), Th: CD4+CD45RA-CXCR5- and circulating follicular Th (cTfh): CD4+ CD45RA-CXCR5+, expressing CXCR3 (Th1/cTfh1), CCR6 (Th17/cTfh17), CXCR3 and CCR6 (Th17.1/cTfh17.1) and CXCR3-/CCR6- (Th2/cTfh2).  Results: The contribution of Treg was found in the order PT>T>HA, as has already been reported, without differences between LR and PT. The main finding was that we detected a statistically significant reduction of TH17 percentages in PT (7.2\u00b16) and T (5.5\u00b13.8) compared to HA group (17.86\u00b14.1): p<0.01 and p<0.001, respectively, that was not significant in LR (8.8\u00b14.9). The remaining cell subsets did not show relevant results (Figure1).  Conclusions:  Th17 CD4+ effector cells are increased in LR newborns. Functional studies will  \n  \ndiscern whether they have a role in their inflammatory response and could be targets of specific biological therapies.     \n                     \n \n  \nP-074  DEFICIENCIA DE LA CONTRIBUCION DE LA POBLACI\u00d3N DE MONOCITOS CD16+ CD14-/+ EN EL DIAGN\u00d3STICO DE PACIENTES EN LOS QUE COEXISTE UN PROCESO INFLAMATORIO Y TUMORAL.  Ballester Gonz\u00e1lez, Rub\u00e9n; Rodr\u00edguez Mart\u00edn, Eulalia; Rodr\u00edguez Ramos, Rafael; Iturrieta Zuazo, Ignacio Maria; Mart\u00edn Moro, Fernando; Piris Villaespesa, Miguel; Villar Guimerans, Luisa Maria; Rold\u00e1n Santiago, Ernesto.  Hospital Universitario Ram\u00f3n y Cajal, Madrid.  A trav\u00e9s de un caso cl\u00ednico, se expone el reto diagn\u00f3stico que acompa\u00f1a a las entidades que cursan con expansi\u00f3n de monocitos, dada la dificultad de distinguir, mediante las tres t\u00e9cnicas diagn\u00f3sticas habituales (citolog\u00eda, citometr\u00eda de flujo e histolog\u00eda) procesos/patolog\u00edas tan dispares como las monocitosis reactivas, la leucemia mielomonoc\u00edtica cr\u00f3nica (LMMC) o las leucemias mieloides agudas (LMA) con componente monoc\u00edtico. En un intento de esclarecer este problema, recientemente se describi\u00f3 la pr\u00e1ctica desaparici\u00f3n de monocitos CD16+ en la LMMC como un excelente biomarcador. Sin embargo, la coexistencia de un proceso inflamatorio/infeccioso, caracterizado por un aumento de la poblaci\u00f3n de monocitos CD16+ invalida parcialmente la utilidad del mismo. El caso se centra en una mujer con una insuficiencia respiratoria aguda que debuta con monocitosis, objetiv\u00e1ndose en el frotis un alto porcentaje de promonocitos, sin rasgos displ\u00e1sicos en ninguna de las tres series. Con la sospecha inicial de LMMC, se realiz\u00f3 el estudio inmunofenot\u00edpico por citometr\u00eda en sangre perif\u00e9rica, detect\u00e1ndose una marcada expansi\u00f3n de monocitos maduros no cl\u00e1sicos (CD14-/dim CD16+; 24% respecto a monocitos totales) e intermedios (CD14+ CD16+; 41%), sin evidente expresi\u00f3n aberrante de ant\u00edgenos y no detect\u00e1ndose formas inmaduras de monocitos (figura A). Con estos datos contradictorios, se realiz\u00f3 el estudio en m\u00e9dula \u00f3sea, obteni\u00e9ndose resultados muy dispares en las tres t\u00e9cnicas diagn\u00f3sticas antes referidas, hasta el punto que se propusieron hasta tres posibilidades diagn\u00f3sticas distintas: LMA, LMMC (figura B) y proceso reactivo. El caso se resolvi\u00f3 gracias a los resultados de la biolog\u00eda molecular, que detect\u00f3 el gen NPM1 mutado lo que decant\u00f3 la balanza hacia un proceso agudo.  Estos hallazgos demuestran que la elecci\u00f3n de este biomarcador para el diagn\u00f3stico diferencial de estos procesos no es completamente fiable y abre la posibilidad de que distintas t\u00e9cnicas denominen al mismo monocito de diferente forma.    \n  \n                                   \n \n  \nP-075  S\u00cdNDROME AUTOINFLAMATORIO CON MUTACI\u00d3N EN LOS GENES PSTPIP1 Y WAS: RETO DIAGN\u00d3STICO EN PACIENTE CON ESPONDILOARTROPAT\u00cdA REFRACTARIA A M\u00daLTIPLES TERAPIAS BIOL\u00d3GICAS.   D\u00edaz Luna, Mercedes; Alba Cano, Trinidad; Balastegui Mart\u00edn, H\u00e9ctor; Garc\u00eda Mart\u00ednez, Elena; Rodr\u00edguez Sainz, Carmen; Fern\u00e1ndez-Cruz P\u00e9rez, Eduardo; Di Natale, Marisa.  Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid.  Nuestro objetivo es presentar el caso de una paciente mujer de 40 a\u00f1os referida a nuestra Unidad de Inmunolog\u00eda Cl\u00ednica por cuadro de infecciones respiratorias recurrentes, espondiloartropat\u00eda axial HLA-B27+, brotes recurrentes de herpes z\u00f3ster y artropat\u00eda psori\u00e1sica. Asociaba picos febriles, astenia y artromialgias con limitaci\u00f3n para actividades b\u00e1sicas de la vida diaria. A su llegada a consultas, la paciente ya hab\u00eda recibido tratamiento con Adalimumab, Etanercept, Golimumab y Ustekinumab y gammaglobulina intravenosa, sin mejor\u00eda cl\u00ednica. En el estudio inmunol\u00f3gico inicial, \u00fanicamente se detect\u00f3 un ANA positivo (1/80) de patr\u00f3n homog\u00e9neo e hipocomplementemia C3 (68.3mg/dL). Se realiz\u00f3 estudio gen\u00e9tico mediante la secuenciaci\u00f3n de nueva generaci\u00f3n (NGS) utilizando un panel de 200 genes asociados a inmunodeficiencias.   Dicho an\u00e1lisis gen\u00e9tico revel\u00f3 dos variantes heterocigotas en el gen PSTPIP1 (p.Arg405Cys) y el gen WAS (p.His180Asn) respectivamente. Ambas mutaciones implican interpretaciones conflictivas en cuanto a patogenicidad seg\u00fan las bases de datos gen\u00f3micas revisadas. La primera de ellas sugiere una alteraci\u00f3n en la interacci\u00f3n de dicha prote\u00edna con el citoesqueleto y otras mol\u00e9culas de sus v\u00edas de actuaci\u00f3n, como la IL-1\u03b2, cuya producci\u00f3n tambi\u00e9n es regulada por la interacci\u00f3n de esta prote\u00edna con la pirina. Tambi\u00e9n se encontr\u00f3 evidencia de expresi\u00f3n reducida de la prote\u00edna WASP en asociaci\u00f3n con la segunda mutaci\u00f3n descrita.  En relaci\u00f3n con la sospecha de posible enfermedad autoinflamatoria con desregulaci\u00f3n de producci\u00f3n de la IL-1\u03b2, se inici\u00f3 tratamiento con Anakinra. La paciente mostr\u00f3 buena tolerancia inicial con mejor\u00eda del cuadro cl\u00ednico permiti\u00e9ndole reincorporarse a sus actividades y mantuvo el tratamiento durante 3 meses, con reaparici\u00f3n progresiva de la sintomatolog\u00eda. Como conclusi\u00f3n, en estos casos complejos el estudio gen\u00e9tico puede brindar luz en cuanto a las v\u00edas moleculares alteradas, lo que puede brindar una opci\u00f3n terap\u00e9utica eficiente como en el caso descrito.      \n  \nP-076  REFERENCE RANGES OF INFLAMMATORY CYTOKINES IN HEALTHY POPULATION  \u00c1lvarez Romero, Paula; Molina Alcaide, Juan Eduardo; Trujillo Aguilera, Antonio; Navas Romo, Ana Mar\u00eda; Bernardo Serrano, Raquel; Costa Anzola, Antonio; Jurado Roger, Aurora.  Hospital Universitario Reina Sof\u00eda, C\u00f3rdoba.  Background: Inflammatory cytokines are signalling molecules involved in the immune system homeostasis, but also in many pathological processes. Due to their diagnostic, prognostic and predictive values, determining their serum concentration has become a routine practice in specialised laboratories, despite the heterogeneity in quantitation methods. The aim of this study was to determine inflammatory cytokine levels by flow cytometry in a healthy population according to age in order to stablish normal ranges.   Materials and methods:  Samples were obtained from 152 healthy volunteers, who were stratified into 3 or 6 groups of age. Those with chronic diseases, immunological alterations, infections, cancer or metabolic syndrome or under immunomodulation drugs treatment were excluded, except when they were >70 y.o. Circulating IL-1\u03b2, IL-6, IL-8, IL-10, IL-12p70, TNF-\u03b1, IFN-\u03b3, MCP-1 and IP-10 were measured in 1:4 diluted serum samples using Cytometry Bead Array (CBA) on a BD FacsCanto II and analysed with FCAP Array.    Results: IL-1\u03b2, IL-6, IL-10, IL-12p70, TNF-\u03b1 and IFN-\u03b3 were undetectable. Results did not show significant differences considering gender, allergy or smoke habits. Correlation analyses revealed a decreased in IL-8 (r=-0.44) and an increased in IP-10 levels (r=0.37) with age (p<0.05). In addition, MCP-1 slightly increased with weight (p<0.05; r=0.16). IL-8, MCP-1 and IP-10 levels were affected by diabetes, hypertension, hypercholesterolemia and cardiopathy (p<0.05).       \n  \n    Cytokine  Group 1 \n(19-29 y.o.)  Group 2 \n(30-39 \ny.o.) Group 3 \n(40-49 \ny.o.) Group 4 \n(50-59 \ny.o.) Group 5 \n(60-69 \ny.o.) Group 6 \n(>70 y.o.)  IL-8 0.00-\n2587.92  0.00-\n643.38  0.00-\n798.08  1.69-\n211.63  0.00-\n447.39  0.00-10.37  MCP-1 0.00-259.48 7.40-395.38 8.33-263.83 7.63-371.05 14.15-427.84 11.35-83.97 IP-10 21.35 -\n218.93  22.09 -\n397.89  11.01 -\n215.24  67.27 -\n200.97  55.16 -\n584.00  83.35 -\n1339.49   Cytokine  Group A (<40 y.o.)  Group B (40 -59 y.o.)  Group C (>60 y.o.)  IL-8 0.00-2319.76  0.00-616.66  0.00-447.39  MCP -1 4.07-320.64  7.86-345.91  11.35 -427.84  IP-10 21.76 -371.76  16.85 -210.60  55.16 -1339.49     Conclusion:  In conclusion, inflammatory cytokine levels in healthy individuals change with age and the presence of chronic diseases.                              \n  \nP-122  CHARACTERIZATION OF HLA-DR IMMUNOPEPTIDOME PRESENTED BY DENDRITIC CELLS PULSED WITH THE BREAST CANCER TUMORAL CELL LINE MCF-7 LYSATES   L\u00e1zaro, Gonzalo1; Aran, Andrea1; Molina, Elisa1; Carrascal, Montserrat2; Cedano, Juan Antonio1; Cort\u00e9s, Javier3; Mart\u00ed, Merc\u00e81.  1Institut de Biotecnologia i Biomedicina, Universitat Aut\u00f2noma de Barcelona, Bellaterra (Cerdanyola del Vall\u00e8s); 2Biological and Environmental Proteomics, Institute of Biomedical Research of Barcelona, Spanish National Research Council, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IIBB-CSIC/ IDIBAPS),, Barcelona; 3International Breast Cancer Center (IBCC), Barcelona.  The characterization of tumor antigens that drive the immune response has great potential as a tool to develop new treatments, especially antigen-derived therapies. Despite the importance of cytotoxic T cells, the CD4+ T response has gained interest due to its major contribution in the maintenance and orchestration of the anti-tumor immune response. Moreover, due to the epithelial etiology of carcinomas, the presentation of peptides by HLA-II is mediated by antigen presenting cells, mainly dendritic cells (DCs). Therefore, we have performed the characterization of the peptides presented by different HLA-DR molecules of monocyte-derived DCs (moDCs) from eight donors. Six moDCs samples were pulsed with protein extracts from the breast cancer cell line MCF-7 and two samples of non-pulsed moDCs were used as controls. The objectives of this study were: (i) to determine whether there are differences between the peptidome presented by pulsed and non-pulsed moDCs, both at peptide and protein levels; (ii) to determine the percentage of peptide and protein overlap between moDCs with different HLA-DR alleles; (iii) to evaluate the influence of the allele combination on antigenic presentation. The results showed that: (i) the pulse displaces part of the proteins of the moDCs ligandome, since the non-pulsed samples share most of the proteins with the rest of the pulsed moDCs, but not the other way around; (ii) there is a positive correlation between the abundance of an allele in the samples studied and the level of peptide and protein overlap presented by them but not with the sample size; (iii) the immunopeptidome of the pulsed moDCs is modified by different HLA-DR alleles. In conclusion, the HLA-DR allele combinatorics has some influence on the immunopeptidome presented by moDCs, which should be considered to better design personalized antigen-directed therapies.       \n  \nP-124  COMPARATIVE ANALYSIS AND CHARACTERIZATION OF TCR REPERTOIRES IN BREAST CANCER TIL  Aran, Andrea1; Molina, Elisa1; Abanc\u00f3, Ferran1; Marco Molina, Vicente2; P\u00e9rez, Jos\u00e93; Cort\u00e9s, Javier3; Mart\u00ed, Merc\u00e81.  1Institut de Biotecnologia i Biomedicina - Universitat Aut\u00f2noma de Barcelona, Bellaterra; 2Hospital Quir\u00f3nsalud Barcelona, Barcelona; 3International Breast Cancer Center, Barcelona.  The characterization of T cell receptors (TCR) expressed by tumor-infiltrating lymphocytes (TIL) is gaining interest since TCR can be used as a tool of immunotherapy but also as a biomarker. Thus, it is necessary to understand the TCR features and their differences in the CD4+ and CD8+ infiltrating subsets. Biopsy fragments from 7 breast cancer patients were cultured as explants to analyze the TCR in the initial biopsy-derived T cells. Later, expanded cells were sorted by their CD4 and CD8 expression. TCR HTS was performed to analyze the clonality, the sequence overlapping and different properties of the TRA and TRB CDR3, as well as to find motifs in the TRB sequences. Significant differences in the biochemical properties of the TRB CDR3 amino acid sequences were found, i.e., TRB CDR3 sequences presented shorter N(D)Nnt regions in the CD8+ set and more positively charged sequences in the CD4+ set. We also found a higher diversity in the CD8+ compared to the CD4+ TIL subsets \u2013 both in the TRA and TRB sequences \u2013 and a higher sequence overlap, as well as a higher number of motifs, shared between biopsies in the CD4+ subset. Overall, this data indicates different characteristics of the TIL's TCR in each subset independently of the biopsy. Interestingly, the CDR3 sequences of the CD4+ cells show a higher similarity between biopsies than that of the CD8+ cells, suggesting that these are more restricted in the tumor environment.                 \n  \nP-125   MELANOMA SPHEROIDS AND MEMORY-LIKE NK CELLS: OPTIMIZATION OF AN IN VITRO ASSAY TO EVALUATE TUMOUR-IMMUNE CELL SYNAPSIS   Carreira Santos, Sof\u00eda1; Lavado Fern\u00e1ndez, Elena1; S\u00e1nchez Hern\u00e1ndez, Eva1; Dur\u00e1n Fl\u00f3rez, Esther2; Tarazona, Raquel1; Casado, Javier G.1; L\u00f3pez Sejas, Nelson1.  1Immunology Unit, Department of Physiology, University of Extremadura, C\u00e1ceres; 2Anatomy and Comparative Pathological Anatomy, Department of Animal Medicine, Faculty of Veterinary Medicine, University of Extremadura, C\u00e1ceres.  NK cells are a key component of the innate immune system, essential not only in host defence against virus-infected cells, but also in tumour immune surveillance. Their function is regulated by a balance of activating and inhibitory signals. The in vitro stimulation of NK cells using cytokine cocktails (IL-12/15/18) induces a memory-like phenotype. These cytokine-activated memory-like (CIML) NK cells are strongly cytotoxic and have a longer half-life, which makes them ideal for immunotherapy. Although NK cell cytotoxicity can be studied through monolayer cultures, 3D cultures have turned into a state-of-the-art model for studying molecular interactions between immune and tumour cells.  The purpose of this study was to establish a protocol to obtain memory-like NK cells and to characterize them in terms of phenotype and function. Moreover, we aimed to develop a 3D culture method of melanoma cell lines to evaluate NK cell-tumour interactions. Briefly, NK cells were isolated from peripheral blood and analysed through flow cytometry to identify phenotypic and functional differences between control and CIML NK cells at different time points of culture.  Significant differences were found in the expression of activating and inhibitory receptors, as well as in intracellular perforin and granzyme. Moreover, functional differences were also observed in terms of TNF-\u03b1/INF-\u03b3 expression and degranulation against target cell lines.  Regarding, 3D cultures of tumour cells, spheroids from the melanoma cell line MaMel56 were established and co-cultured at day 7 with in vitro-expanded NK cells and monitored with different microscopy techniques. After 24h of co-culture, several changes in spheroid morphology could be observed. In conclusion, the obtention of highly cytotoxic and longer-lived NK cells, together with the optimization of a co-culture method using tumour spheroids, could give a better understanding for modelling the crosstalk between tumour and immune cells and may help for the development of new immunotherapies.    \n  \nP-126  ORAL SQUAMOUS CARCINOMA INDUCES IMMUNOSUPRESSIVE MONOCYTES  Pel\u00e1ez Prestel, H\u00e9ctor; Ochaita Aguado, Andrea; S\u00e1nchez Trincado, Jos\u00e9 Luis; Lafuente, Esther M.; Reche, Pedro A.  Laboratory of Immunomedicine, Department of Immunology, Ophtalmology and ORL, School of Medicine, Complutense University of Madrid, Ave. Complutense s/n, 28040, Madrid, Spain, Madrid.  Introduction  Oral squamous carcinoma (OSC) is one of the top 10 cancers in prevalence and mortality. The tumor microenvironment is highly important in OSC, where tumor-associated macrophages (TAMs) are the most abundant cell type. Most of these TAMs derive from circulating monocytes and differentiate in situ. TAMs can be M2-like macrophages possessing pro-tumoral functions, enabling immunosuppression, vasculogenesis, tumor progression and metastasis, but can also be M1 macrophages, which have been related to anti-tumoral effects and better prognosis.  Objectives Study the effect of OSC cells (OSCCs) on monocytes differentiation. Materials and Methods We have used the H413 and TR146 OSCC lines and its supernatant for co-culture assays with primary monocytes from healthy donors\u2019 peripheral blood during different times (16 hours or 5 days). Also, we have co-cultured conditioned-monocytes with allogeneic total T cells. The complement-mediated phagocytic capacity of those monocytes was also tested using opsonized labelled sheep red blood cells. Cell markers and cytokine production were studied by flow cytometry and ELISA.  Results OSCCs induce early activation of monocytes, as pro-inflammatory cytokines (TNF\u03b1, IL-6, IL-12, IL-1\u03b2) are increased. However, at longer times, OSCCs imprint an immunosuppressive phenotype on monocytes related to M2 macrophages, judged by the lower expression of HLA-DR, CD86, CD11c and increase of PD-L1, IDO and IL-10. In addition, supernatant-conditioned monocytes were unable to activate allogeneic T cells, indicated by the expression of IFN\u03b3 and Tbet. Finally, the phagocytic ability of these monocytes was decrease when they were co-culture with OSCCs. Conclusion Our data indicate that OSCCs promote the differentiation of immunosuppressive monocytes into an M2-like phenotype, which may facilitate tumor progression.     \n  \nP-127  LEUCEMIA LINFOBLASTICA B CD2+ CON TRANSDIFERENCIACI\u00d3N A ESTIRPE MONOC\u00cdTICA: CARACTER\u00cdSTICAS DE PROLIFERACI\u00d3N Y APOPTOSIS DE SUS DIFERENTES SUBPOBLACIONES   Ballester Gonz\u00e1lez, Rub\u00e9n; Rodr\u00edguez Mart\u00edn, Elulalia; Mart\u00edn Moro, Fernando; Quintero Calca\u00f1o, Victor Manuel; Veiga Gonz\u00e1lez, Jos\u00e9 Luis; Villar, Luisa Mar\u00eda; Rold\u00e1n Santiago, Ernesto.  Hospital Universitario Ram\u00f3n y Cajal, Madrid.  En las Leucemias Linfoblasticas Agudas B (LLA-B) el cambio de linaje de los precursores B aberrantes hacia linaje mieloide durante el tratamiento ocurre en raras ocasiones y puede provocar dudas sobre el diagn\u00f3stico inicial y la continuaci\u00f3n del tratamiento. Recientemente se ha descrito un subgrupo de pacientes cuyos blastos al diagn\u00f3stico expresan total o parcialmente el ant\u00edgeno CD2, y tras inicio del tratamiento presentan mayor probabilidad de transdiferenciaci\u00f3n hacia c\u00e9lulas de estirpe monocitoide. Se expone a continuaci\u00f3n un caso cl\u00ednico. Paciente pedi\u00e1trico diagnosticado de LLA-B com\u00fan en aspirado de m\u00e9dula \u00f3sea (MO) (95% de blastos linfoides), con expresi\u00f3n aberrante del ant\u00edgeno CD2. Se inici\u00f3 quimioterapia seg\u00fan la gu\u00eda Pethema en rama de riesgo intermedio. En d\u00eda +15 tras tratamiento, se realiza estudio de control, objetiv\u00e1ndose un 28% de precursores aberrantes, con clara diferenciaci\u00f3n de una fracci\u00f3n de linfoblastos originales hacia c\u00e9lulas monocitoides, pudi\u00e9ndose establecer hasta 3 poblaciones claramente diferenciadas. Se realiz\u00f3 un cultivo celular con el aspirado de MO del paciente en el d\u00eda +15 post-tratamiento, determin\u00e1ndose a d\u00edas +2 y +5 del cultivo el porcentaje de cada poblaci\u00f3n, viabilidad y capacidad de proliferaci\u00f3n. Los resultados demostraron mayor capacidad de proliferaci\u00f3n en las c\u00e9lulas con diferenciaci\u00f3n monocitoide. Adem\u00e1s, tras 5 d\u00edas de cultivo se apreci\u00f3 un notable incremento de mortalidad en la fracci\u00f3n de blastos linfoides, mientras que las subpoblaciones con diferenciaci\u00f3n monoc\u00edtica permanec\u00edan viables en su pr\u00e1ctica totalidad.  En el d\u00eda +30 post-tratamiento, no se detectaron blastos aberrantes de ning\u00fan tipo de linaje. Este caso demuestra que una evidente transdiferenciaci\u00f3n del blasto linfoide CD2+ original no cambia el diagn\u00f3stico ni su tratamiento, los pacientes consiguen respuestas completas aunque m\u00e1s lentamente. El estudio in vitro revela que durante el tratamiento, las c\u00e9lulas con clara diferenciaci\u00f3n monocitoide mostraron una mayor capacidad proliferativa y supervivencia, explicando el comportamiento de las diferentes poblaciones.   \n  \n                                    \n \n  \nP-128  STUDY OF THE THERAPEUTIC APPLICATIONS OF BACTERIORUBERIN AND ITS DERIVATIVES AGAINST CANCER.  Baeza-Morales, Andr\u00e9s; Medina-Garc\u00eda, Miguel; Pascual-Garc\u00eda, Sandra; Mart\u00ednez-Peinado, Pascual; L\u00f3pez-Ja\u00e9n, Ana Belen; Sempere-Ortells, Jos\u00e9 Miguel.  Universidad de Alicante, Dpto. de Biotecnolog\u00eda, San Vicente del Rapeig (Alicante).  Because high levels of ROS are generated during the early stages of tumour development, the cancer cells with the highest antioxidant capacity will be those that will initially determine the tumour phenotype. However, given that throughout tumour development the concentrations of ROS that will be reached will usually be higher than those reached in normal cells, cancer cells, in order to avoid ending up experiencing selective pressure with respect to normal cells, increase their antioxidant molecules. On the basis of this premise, it has been suggested, on the one hand, that cancer cells may be more sensitive than normal cells to increases in ROS levels. Furthemore, with regard to the use of carotenoids as antioxidant substances, it should be noted that their use on tumour cells with high levels of ROS may end up oxidising these molecules, in such a way that when the amount of oxidised antioxidant exceeds certain levels, a pro-oxidant effect of these molecules predominates. This is why it is currently thought that carotenoids could act selectively against tumour cells, showing prooxidant activity on them and, in turn, protecting normal cells from oxidative stress due to their antioxidant activity under physiological conditions. On the other hand, we also assume that many other mechanisms have been described by which carotenoids suppress the onset and progression of cancer. Finally, it is important to mention that bacteriorruberin, the subject of this project, is a carotenoid pigment with a much higher antioxidant capacity than conventional pigments and whose biomedical applications are still largely unexplored. All this suggests that this compound could have a greater anti-tumour capacity than conventional pigments. Preliminary data from the research group suggest that bacteriorruberin could increase cell death and decrease the rate of proliferation in the K562 tumour cell line.             \n  \nP-129  IMPORTANCIA DE LOS RECEPTORES KIR Y SUS LIGANDOS COMO FACTOR PRON\u00d3STICO TRAS TRATAMIENTO CONVENCIONAL EN PACIENTES CON C\u00c1NCER DE OVARIO   Manzanares Mart\u00edn, B\u00e1rbara; Alvarez Romero, Paula; Costa Anzola, Antonio; Navas Romo, Ana; Solana Lara, Rafael; Gonz\u00e1lez Fern\u00e1ndez, Rafael.  HRU Reina Sof\u00eda, C\u00f3rdoba.  El tumor de ovario es el de mayor mortalidad a nivel ginecol\u00f3gico. Su abordaje terapeutico convencional con cirug\u00eda y quimioterapia no ofrece buenos resultados por lo que nuevas terapias est\u00e1n siendo analizadas. En este sentido, nuestro grupo trabaja en un proyecto en etapa experimental precl\u00ednica que emplea linfocitos TCAR multidianas. Los receptores KIR regulan en parte la funci\u00f3n de las c\u00e9lulas NK y linfocitos T en la respuesta antitumoral. Sin embargo, se desconoce si su amplio polimorfismo podr\u00eda intervenir en el curso de estas pacientes tras los tratamiento cl\u00e1sicos.  Objetivo: Analizar los polimorfismos KIR/HLA en estas pacientes para establecer posibles biomarcadores pron\u00f3stico tras tratamiento convencional y de indicaci\u00f3n de tratamiento precoz con nuevas terapias.  Pacientes y m\u00e9todos. Se han incluido pacientes con c\u00e1ncer de ovario intervenidas en los \u00faltimos 5 a\u00f1os, analizando tiempo hasta recaida y supervivencia. Se aislar\u00e1 ADN conservado en parafina y se analizar\u00e1n los genes KIR (Genotipaje KIR de Innotrain Diagnostik) y sus ligandos HLA (Lifecodes HLA-A,B SSO Typing Kit y Lifecodes HLA-C eRES SSO Typing Kit, Immucor) Resultados: Se estudia la influencia de las combinaciones KIR/HLA en los pacientes que han sido estratificadas seg\u00fan su diferente respuesta a los tratamientos convencionales. Se presentar\u00e1 la influencia de forma independiente de 2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DL1, 3DL2, 3DL3 y 3DS1, 2DP1 y 3DP1 y las variantes de KIRDL5, KIR2DS4 y KIR3DP1. Tambi\u00e9n los datos referentes al an\u00e1lisis de los diferentes haplotipos y semihaplotipos centrom\u00e9ricos y telom\u00e9ricos con diferente potencial inhibidor o activador. Se incluye tambi\u00e9n los resultados de los ligandos HLA (Bw4 y del dimorfismo de HLA-C). Entre los alotipos Bw4, se consideran HLA-A*24:02, A*32:01 y A*23:01, pero no HLA-A*25:01. Los resultados previos no muestran diferencias entre las pacientes incluidas sin tener en cuenta las variables estudiadas y el grupo control       \n  \nP-130  LA V\u00cdA HLA-G/ILT2 MODULA LA FUNCI\u00d3N EFECTORA DE LOS LINFOCITOS T CD8 EN C\u00c1NCER G\u00c1STRICO  Vaquero Yuste, Christian1; Molina Alejandre, Marta1; Ju\u00e1rez Mart\u00edn-Delgado, Ignacio1; Su\u00e1rez Trujillo, Fabio1; Guti\u00e9rrez Calvo, Alberto2; L\u00f3pez Garc\u00eda, Adela2; Lasa Unzue, Inmaculada2; G\u00f3mez Sanz, Remedios2; Fern\u00e1ndez-Cruz P\u00e9rez, Eduardo3; Rodr\u00edguez-S\u00e1inz, Carmen3; Arnaiz Villena, Antonio1; Mart\u00edn Villa, Jos\u00e9 Manuel1.  1Dpto. de Inmunolog\u00eda, Oftalmolog\u00eda Y ORL. Facultad de Medicina. Universidad Complutense de Madrid, Madrid; 2Hospital Universitario Pr\u00edncipe de Asturias, Alcal\u00e1 de Henares; 3Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, Madrid.  Introducci\u00f3n: Las terapias actuales con inhibidores de puntos del control del sistema inmunitario (ICI; PD1/PDL1), han supuesto un gran avance en el tratamiento del c\u00e1ncer g\u00e1strico. Sin embargo, no todos los pacientes pueden beneficiarse, lo que lleva a la necesidad de buscar nuevas dianas. HLA-G es una mol\u00e9cula HLA no cl\u00e1sica, capaz de inducir tolerancia a trav\u00e9s de su receptor ILT2 en c\u00e9lulas T, lo que podr\u00eda establecer HLA-G como una nueva diana para ICI.  Objetivos: Estudiar el fenotipo y funci\u00f3n de los linfocitos ILT2+, modulados por HLA-G, en c\u00e1ncer g\u00e1strico.  MyM: Se aislaron PBMCs de 16 pacientes y 9 controles. Se realizaron ensayos de activaci\u00f3n con \u03b1CD3/CD28/CD2 y de proliferaci\u00f3n con CFSE en presencia o ausencia de HLA-G, mediante citometr\u00eda de flujo con anticuerpos \u03b1CD8, CD3, PD1, ILT2 e IFNy.  Reultados: Encontramos un aumento de la expresi\u00f3n de ILT2 en linfocitos CD8+ de pacientes (38,7%) con respecto a los controles (15,1%, p=0,002). Parte de la poblaci\u00f3n ILT2+ era PD1-, lo que indica una regulaci\u00f3n independiente. El 21,9% de los linfocitos CD8+ ILT2+ producen IFNy en comparaci\u00f3n con los CD8+ ILT2- (7,9%, p<0,0001). Cocultivando PBMCs en presencia de HLA-G, las c\u00e9lulas CD8+ILT2+ producen una cantidad significativamente menor de IFNy en comparaci\u00f3n con los cocultivos sin HLA-G (p=0,018). En estos cocultivos tambi\u00e9n se observa una reducci\u00f3n de la proliferaci\u00f3n de c\u00e9lulas ILT2+ en presencia de HLA-G, ya sea de membrana o soluble. Conclusiones: Existe un aumento significativo en la frecuencia de c\u00e9lulas CD8+ ILT2+ en PBMCs de pacientes con c\u00e1ncer g\u00e1strico. Adem\u00e1s, las c\u00e9lulas ILT2+ tienen una mayor capacidad de producir IFNy tras la activaci\u00f3n mediada por el TCR. HLA-G es capaz de bloquear la activaci\u00f3n y proliferaci\u00f3n, de los linfocitos de estos pacientes. La v\u00eda HLA-G/ILT2  \n  \npuede convertirse en una nueva v\u00eda para el tratamiento del c\u00e1ncer g\u00e1strico.    \n           \n \n  \nP-131  CROSS-REACTIVITY STUDY BETWEEN OLE E 7 AND PRU P 3 NSLTPS  \u00c1lvarez Romero, Paula; Aguado \u00c1lvarez, Roc\u00edo; Navas Romo, Ana Mar\u00eda; Blanco Toledano, Nadine; Ruiz Le\u00f3n, Berta; Moreno Aguilar, Carmen; Jurado Roger, Aurora.  Hospital Universitario Reina Sof\u00eda, C\u00f3rdoba.  Background: Non-specific Lipid Transfer Proteins (nsLTPs) are small proteins thoroughly represented in plants and responsible for severe forms of allergy. Pru p 3 is a common primary sensitizer in southern Europe, while Ole e 7 is a very powerful sensitizer particularly in Andalusian area, where the existence of co-sensitization to both of them is usually described. The aim of this study was to identify a possible cross-reactivity between Pru p 3 and Ole e 7 underlying this co-sensitization.    Materials and methods: We measured specific IgE (sIgE) to Ole e 7 and Pru p 3 by ImmunoCAP 250 (sIgE>0.35 kUI/L positive cut-off) in sera samples of 9 patients, who were classified into: Ole e 7-monosensitized (MONOLE; n=3), Pru p 3-monosensitized (MONPRU; n=3) and bisensitized (BI; n=3). Basophil Activation Test (BAT) was performed using Ole e 7 and Pru p 3 recombinant proteins at 10 \u03bcg/ml.  For epitope mapping, MALDI-TOF was performed after protein digestion with trypsin and separately incubation with a serum mix from each group.  Results: As expected, BI patients presented a positive BAT to both allergens, while MONPRU basophils only degranulated with Pru p 3. Surprisingly, BAT of MONOLE patients was positive to both nsLTPs. The epitope mapping identified one Pru p 3 peptide, \u201cISASTNCATVK\u201d, able to be recognized by the three groups of mixed sera, including MONOLE. Likewise, the digestion of Ole e 7 provided one peptide \u201cKSALALVGNKV\u201d also recognized by all the groups. No linear sequence homology was detected between the above peptides.   Conclusion: A possible cross-reactivity between different epitopes from Ole e 7 and Pru p 3 could be the underlying cause of the co-sensitization observed in the south Mediterranean. The epitope sequence disparity suggests two distinct pathways of sensitization, in which Pru p 3 or Ole e 7 could act as primary sensitizers.        \n  \nP-132  SYSTEMIC MASTOCYTOSIS. A RETROSPECTIVE EVALUATION OF CASES IN OUR CENTER    Gallardo Garc\u00eda, Alberto; L\u00f3pez P\u00e9rez, Juan; Garc\u00eda Cuesta, Daniel; Mora L\u00f3pez, Francisco; De La Varga Mart\u00ednez, Raquel.  Hospital Universitario Puerta del Mar, C\u00e1diz.  Introduction Mastocytosis is a heterogeneous group of diseases defined by an unusual accumulation of pathological and clonal mastocytes in various tissues. Systemic mastocytosis (SM) is normally diagnosed based on bone marrow (BM) histopathology and there are major and minor diagnostic criteria.  Objectives To determine the diagnostic efficiency of the study of the D816V mutation in C-KIT, study of aberrant mast cells by flow cytometry (FCM) and serum tryptase levels in a cohort of patients with suspected SM, as well as to describe the characteristics of the cohort. Methods The cohort consisted of 34 patients from the province of C\u00e1diz with suspected SM from January 2020 to February 2022. Tests results that form part of diagnostic criteria, clinical characteristics, study of hymenoptera venom allergy and other data of analytical interest were collected.  Results Of the 34 patients, 11 (32.4%), were diagnosed with SM. Sensitivity and specificity values of the 3 tests analysed are shown in table 1. Both serum tryptase levels and the percentage of aberrant mastocytes in BM are higher in patients diagnosed with SM. In addition, 8 out of 11 patients with SM (73%) had a history of cutaneous mastocytosis (CM). There are two cases (18%) with sensitivity to hymenoptera venom. Table 1.    Sensitivity (%)  Specificity (%)  C-KIT mutation  90.9 91.3 Aberrant mastocytes FCM  100 89.5 Serum tryptase >20 ng/ml  90.9 69.5  Conclusion The evaluated tests have a high sensibility for the diagnosis of SM in our cohort of patients. According to the bibliography, more than the 70% of the SM cases have a history of CM. SM is underdiagnosed in cases of allergic reactions caused by hymenoptera venom and its diagnosis in  \n  \nour cohort would help to take appropriate preventive measures in case of such reactions.     \n  \nP-133  THERAPEUTIC EFFICACY OF ENDOVENOUS LIVE TUBERCULOSIS VACCINES AGAINST ESTABLISHED EXPERIMENTAL ASTHMA BY SYSTEMIC DESENSITIZATION  Calvo, Silvia; Taranc\u00f3n, Raquel; Uranga, Santiago; G\u00f3mez, Ana Bel\u00e9n; Mart\u00edn, Carlos; Aguil\u00f3, Nacho.  Universidad de Zaragoza, Zaragoza.  Asthma is one of the most common pulmonary diseases in the world, and its incidence continues increasing, generating a huge economic burden in public health. Asthma is often associated with an exacerbated type 2 inflammation. Allergen-specific Th2 lymphocytes produce cytokines which are responsible of some of the clinical symptoms. Thus, therapies targeting asthma-associated type 2 responses have demonstrated to be highly promising.  MTBVAC is a novel live attenuated tuberculosis vaccine currently under clinical evaluation as tuberculosis vaccine. Intradermal MTBVAC has been widely tested in preclinical (mice to non-human primates) and clinical (phase I and II) trials, and it is expected to start efficacy trials in newborns during 2022. Due to its Th1 response-promoting activity, the pulmonary administration of the MTBVAC has been shown to have strong therapeutic efficacy.  Here, considering the systemic character of endovenous administration of vaccines, we explore this route with MTBVAC to study how its mechanism against allergies works. Results show that the endovenous administration of MTBVAC is capable of desensitizing (reduction of antigen specific Th2 cytokines) in spleen, also in absence of stablished symptoms, such as eosinophilia. In addition, MTBVAC produces IFN\u03b3, which is not necessary for reducing eosinophils in BAL and lung. According to efficacy studies, MTBVAC has a long-term protection against asthma, as therapeutic effect is maintained six months post vaccination. Our data showed strong therapeutic efficacy of MTBVAC endovenous administration in a scenario of established disease.                  \n  \nP-134  SPECIFIC IGE ALLERGIC ADJUSTED CUT-OFFS IN THE DIAGNOSIS AND INDICATION OF ALLERGENIC IMMUNOTHERAPY Bernardo Serrano, Raquel; Manzanares, B\u00e1rbara; Gonz\u00e1lez, Rafael; Moreno, Carmen; Jurado, Aurora.  Hospital Universitario Reina Sof\u00eda, C\u00f3rdoba.  Background. Specific IgE (sIgE) quantification plays a crucial role in the diagnosis of allergy. Given the heterogeneity observed between techniques, standardized cut-offs must be established to improve the accuracy of the diagnosis and the administered treatment. Since the importance of Olive and Grass pollens throughout the Mediterranean area, the objective of this study was to establish an effective and efficient sIgE cut-off supporting the diagnosis and the indication of allergen immunotherapy (AIT).  Material and methods. The clinical history of 1172 patients previously diagnosed with seasonal rhino-conjunctivitis and with the suspicion of allergy to olive and/or grass was retrospectively reviewed, including data of symptoms, sIgE to the whole extract and to main allergenic components (Ole e 1, Ole e 7, Ole e 9 and Phl p 1+5). ROC curves were performed considering final diagnosis and AIT as primary outcomes to obtain the best cut-offs.  Results. At univariate ROC analysis, sIgE to Lolium and sIgE to Olea showed the best AUC (0.957; 95% CI 0.945-0.968 and 0.950; 95% CI 0.936-0.963, respectively). Thus, sIgE to Lolium of 1.79 kU/l (sensitivity 91.60%) was appropriated to discard and of 5.62 kU/l (specificity 92.27%) was appropriated to confirm grass allergy, whereas 8.83 kU/l was optimal for the indication of AIT (AUC 0.872; 95% CI 0.849-0.896). Furthermore, sIgE to Olea of 2.41 kU/l (sensitivity 91.52%) and of 6.49 kU/l (specificity 91.75%) were appropriated to discard or confirm olive allergy, respectively. Considering the indication of AIT, Ole e 1 showed the best AUC (0.86; 95% CI 0.83-0.88) with a sIgE cut-off of 14.05 kU/l (AUC 0.86; 95% CI 0.83-0.88).  Conclusions. Results show differences between the standard cut-off (0.35 kU/L) and those obtained by us. These calculated cut-offs would allow shortening the gap between sensitization and clinical diagnosis of seasonal allergic rhinitis and the indication of AIT.     \n  \nSesi\u00f3n Poster. Inmunoterapia (I). Pantalla 5   P-077  GENERACI\u00d3N DE LINFOCITOS INFILTRANTES DE TUMOR CD3+/PD1+ PARA TERAPIA CELULAR ADOPTIVA EN C\u00c1NCER DE MAMA AVANZADO O TRIPLE NEGATIVO.  Gonz\u00e1lez, E. Azucena1; Espa\u00f1ol-Rego, Marta1; Heredia, Libertad1; De Guzman, Catherine2; Olesti, Eulalia3; Calvo, Gonzalo3; Chic, Nuria4; Juan, Manel5; Prat, Aleix6; Pascal, Mariona7.  1Immunology department. Hospital Cl\u00ednic, Barcelona. Institut d'investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona; 2Immunology Department. Hospital Cl\u00ednic, Barcelona; 3Advanced Therapies Unit. Hospital Cl\u00ednic, Barcelona; 4Medical Oncology Department. Hospital Cl\u00ednic.Translational Genomics and Targeted Therpeutics in Solid Tumors Group (IDIBAPS), Barcelona; 5Immunology Department. Hospital Cl\u00ednic. Institut d'investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS) University of Barcelona, Barcelona; 6Medical Oncology Department.Hospital Clinic. Translation Genomics and Targeted Therapeutics in Solid Tumpors Group (IDIBAPS). University of Barcelona, Barcelona; 7Immunology Department. Hospital Cl\u00ednic. Translational Genomics and Targated Therapeutics in Solid Tumors Group) IDIBAPS). University of Barcelona., Barcelona.  El c\u00e1ncer de mama es el segundo tipo tumoral m\u00e1s frecuente en Espa\u00f1a, con m\u00e1s de 32.000 nuevos casos al a\u00f1o, siendo la primera causa de muerte relacionada con c\u00e1ncer en mujeres (Globocan 2018), lo que pone de manifiesto la necesidad de encontrar alternativas terap\u00e9uticas m\u00e1s eficaces. La terapia celular adoptiva (TCA), que consiste en aislar c\u00e9lulas del sistema inmunitario del propio paciente y manipularlas en el laboratorio para su posterior infusi\u00f3n, ha logrado resultados esperanzadores en algunos tumores avanzados politratados (especialmente melanoma) present\u00e1ndose como una terapia prometedora en estos pacientes, ya sea en monoterapia como en combinaci\u00f3n con otros tipos de inmunoterapia (como los checkpoint inhibitrs). Sin embargo, a d\u00eda de hoy, pocos datos existen de esta terapia en pacientes con c\u00e1ncer de mama avanzado/metast\u00e1sico. Nuestro objetivo es determinar la factibilidad de seleccionar TILs PD1+ y su posterior expansi\u00f3n para  producir TCA a partir de biopsias de pacientes con c\u00e1ncer de mama avanzado. Hasta la fecha, se han conseguido aislar y expandir TILs en un 76% de las muestras tumorales de mama procesadas (22 de 29). Adem\u00e1s, se han llevado a cabo tres expansiones celulares completas en un biorreactor celular (Xuri Cell Expansion System) bajo condiciones GMP, consiguiendo en todas ellas un producto final de m\u00e1s de 1x109 TILs (mediana 15x109 TILs) con m\u00e1s de un 90% de CD3+.     \n  \nP-078  IMMUNOMODULATORY AND ANTIOXIDANT CAPACITY OF BACTERIORRUBERIN ON MESENCHYMAL STEM CELLS AND PERIPHERAL BLOOD MONONUCLEAR CELLS.    Medina Garc\u00eda, Miguel; Baeza Morales, Andr\u00e9s; Martinez Peinado, Pascual; Pascual Garc\u00eda, Sandra; L\u00f3pez Ja\u00e9n, Ana Bel\u00e9n; Sempere Ortells, Jose Miguel.  Universidad de Alicante, Alicante.  The immunomodulatory and toxic effects of various pigments have been observed in different studies and how they can affect different cells of the immune system and mesenchymal cells (MSCs), with promising results. Because of this, MSCs have been proposed as a therapy for various autoimmune diseases. However, there is no study at present that focuses on the use of bacterioruberin as an immunomodulatory or therapeutic agent and what its effect on these cell populations might be. In the present study, physiological response studies have been carried out in MSC and in different cell populations of the immune system, with the aim of determining the antioxidant and immunomodulatory capacity of bacterioruberin. For this purpose, both MSC and peripheral blood mononuclear cells were cultured with different concentrations of our pigment of interest. To observe the direct effect of bacterioruberin on the different cell groups, measurements of various factors were made at different incubation times, such as cell division and proliferation, apoptosis, or modulation of regulatory T lymphocytes. In addition, to observe the immunomodulatory capacity, we intend to co-culture peripheral blood mononuclear cells with MSCs, with the goal of being able to test this possible immunomodulatory effect in cell lines of autoimmune diseases, such as rheumatoid arthritis or lupus erythematosus. The results obtained in the first phase of the study show that the use of the pigment in the different cell cultures together with peripheral blood mononuclear cells does not induce apoptosis at any of the concentrations used, which are between 150 \u00b5l/ml and 1.25 \u00b5l/ml.                 \n  \nP-079  THE ACTIVATION OF TLRS BY THEIR LIGANDS POLARIZES MACROPHAGES TOWARDS M1 AND ACTIVATES ITS CYTOCIDAL FUNCTION AGAINST GLIOBLASTOMA STEM CELLS IN IN VITRO GLIOBLASTOMA MODELS  Fraga-Lodeiro, Mar\u00eda; San-Miguel, Teresa; Mu\u00f1oz-Hidalgo, Lisandra; Gozalbo, Daniel; Cerd\u00e1-Nicol\u00e1s, Miguel; L\u00f3pez-Gin\u00e9s, Concha; Gil, Mar\u00eda Luisa; Monle\u00f3n, Daniel; Cabrera-Pastor, Andrea; Meg\u00edas, Javier.  Universidad de Valencia, Valencia.  Glioblastoma (GBM) is the most frequent and most malignant primary brain tumor. The median survival rate of treated patients will not exceed two years, so new and more effective therapies should be investigated. GBM stem cells (GSC) have been linked to resistance to treatments, therefore one of the most promising lines of research against GBM is based on inducing the differentiation of GSC into mature GBM cells, which are more susceptible to treatments. Recently, the induction of GSC differentiation through Toll-like Receptors (TLR) signaling has been studied.  In the present work, two in vitro models have been developed for the study of GSCs: one of glioblastoma cells enriched in GSC and a co-culture of GSC and macrophages, a cell type highly relevant in the tumor microenvironment. In these models we studied the effect of TLR activation by three of their ligands (Pam3CSK4, LPS and imiquimod) on: GSC differentiation, cell viability and macrophage phenotype polarization towards M1 (inflammatory) or M2 (protumoral). Our results show that Pam3CSK4 and LPS ligands reduced the percentage of GSC and increased the proportion of mature cells in both models, making the cells more vulnerable to treatment with temozolomide (main chemotherapeutic drug used against this tumor). In addition, both ligands induced the differentiation of macrophages to their M1 phenotype with antitumor function, which reduced the viability of glioblastoma cells, especially in the presence of temozolomide. Imiquimod was shown to have a role in the differentiation and elimination of glioblastoma cells by decreasing cell viability in the presence of temozolomide in the in vitro glioblastoma model and reducing the percentage of GSC and mature cells in the co-culture model. These findings enhance TLR ligands as potential drugs in immunotherapy against GBM.  Trabajo realizado en el marco del Proyecto VLC-Biocl\u00ednic AP-2021-001, LIGAM1.          \n  \nP-080  EVALUATION OF A CHEMILUMINESCENT IMMUNOASSAY FOR THERAPEUTIC DRUG MONITORING OF INFLIXIMAB    Morandeira Rego, Francisco1; Garc\u00eda Serrano, Lydia1; Padull\u00e8s Zamora, N\u00faria2; Santacana Juncosa, Eug\u00e8nia2; Pol Pol, Elisabet3; Segura Guerrero, Marina3; Juli\u00e0 Benique, Maria Rosa3.  1Department of Immunology, Hospital de Bellvitge, L'Hospitalet de Llobregat; 2Department of Pharmacy, Hospital de Bellvitge, L'Hospitalet de Llobregat; 3Department of Immunology, Hospital Universitari Son Espases, Institut d\u2019Investigaci\u00f3 Sanit\u00e0ria Illes Balears (IdISBa), Palma.  Introduction Therapeutic drug monitoring of Infliximab (IFX) is useful for optimizing therapy of inflammatory diseases. ELISA is the most commonly used technique to measure IFX through levels, nevertheless, it is time-consuming and requires analysis of multiple samples at once to reduce costs. The chemiluminescent analyzer i-Track10 is a fully automated random acces system that could be a good alternative to ELISA.  Objective To evaluate the performance of the CLIA analyzer i-Track10 (Theradiag) to measure Infliximab concentration in serum by comparing it with the ELISA kit Promonitor (Grifols).  Methods 117 serum samples: 65 from Hospital Son Espases, 52 from Hospital de Bellvitge, were obtained from patients treated with IFX (mean age: 45\u00b115 years, 66% men) and analyzed by ELISA and CLIA. Diagnoses are shown in table 1. Results were compared using Pearson\u2019s correlation and Passing-Bablock regression.  Results 2 out of the 117 pair of results were excluded from the statistic analysis because its diferences were considered outliers. The values of the 115 remaining samples showed a Pearson\u2019s correlation of r=0.97. Passing-Bablock regression showed this equation: y=1.03x + 0.67 The analysis did not show a proportional difference (slope: 1.026; 95% CI: 0.977-1.075) but it showed a constant difference given that the 95% confidence interval (CI) of the intercept did not contain 0 (intercept: 0.678; 95% CI: 0.037-1.312).       \n  \n Diagnosis  Frequency  Crohn\u2019s disease  50.4%  Ulcerative colitis  31.3%  Ankylosing spondylitis  4.3%  Crohn+ rheumatoid arthritis  1.7%  Ulcerative colitis+arthritis  1.7%  Rheumatoid arthritis  0.9%  Crohn+ spondylitis 0.9% Ulcerative colitis+ spondylitis  0.9%  Other diagnoses  7.7%   Table 1  Conclusions There is a strong correlation between the results of Promonitor and i-Track10, but even though the values are very similar, according to Passing-Bablock regression the 2 methods are not interchangeable. The substitution of the ELISA method for the CLIA method would involve a period of adaptation to the new values.    \n            \n \n  \nP-081  EVALUATION OF A CHEMILUMINESCENT IMMUNOASSAY FOR THERAPEUTIC DRUG MONITORING OF ADALIMUMAB   Garc\u00eda Serrano, Lydia1; Morandeira Rego, Francisco1; Padull\u00e8s Zamora, N\u00faria2; Santacana Juncosa, Eug\u00e8nia2; Pol Pol, Elisabet3; Segura Guerrero, Marina3; Juli\u00e0 Benique, Maria Rosa3.  1Department of Immunology, Hospital de Bellvitge, L'Hospitalet de Llobregat; 2Department of Pharmacy, Hospital de Bellvitge, L'Hospitalet de Llobregat; 3Department of Immunology, Hospital Universitari Son Espases, Institut d\u2019Investigaci\u00f3 Sanit\u00e0ria Illes Balears (IdISBa), Palma.  Introduction Therapeutic drug monitoring of Adalimumab (ADL) is useful for optimizing therapy of inflammatory diseases. ELISA is the most commonly used technique to measure ADL through levels, nevertheless, it is time-consuming and requires analysis of multiple samples at once to reduce costs. The chemiluminescent immunoassay (CLIA) analyzer i-Track10 is a fully automated random acces system that could be a good alternative to ELISA.  Objective To evaluate the performance of the CLIA analyzer i-Track10 (Theradiag) to measure Adalimumab concentration in serum by comparing it with the ELISA kit Promonitor (Grifols).   Methods 71 serum samples: 26 from Hospital Son Espases, 45 from Hospital de Bellvitge, were obtained from patients treated with ADL (mean age: 46\u00b116 years, 56% women) and analyzed by ELISA and CLIA. Diagnoses are shown in table 1. Results were compared using Pearson\u2019s correlation and Passing-Bablock regression.  Results 3 out of the 71 pair of results were excluded from the statistic analysis because its diferences were considered outliers. The values of the 68 remaining samples showed a Pearson\u2019s correlation of r=0.98. Passing-Bablock regression showed this equation: y=0.89x + 0.4. The analysis did not show a constant difference (intercept: 0.405; 95% CI: -0.1861-0.9961), but it showed a proportional difference given that the 95% confidence interval (CI) of the slope did not contain 1 (slope: 0.889; 95% CI: 0.843-0.935).      \n  \n Diagnosis  Frequency  Crohn\u2019s disease  59.2%  Ulcerative colitis  14.1%  Rheumatoid arthritis  9.9%  Psoriasis  4.2%  Hidradenitis  4.2%  Ankylosing spondylitis  1.4%  Other diagnoses 7.0%  Table 1  Conclusions There is a strong correlation between the results of Promonitor and i-Track10, but even though the values are very similar, according to Passing-Bablock regression the 2 methods are not interchangeable. The substitution of the ELISA method for the CLIA method would involve a period of adaptation to the new values.    \n \n  \nP-083  STUDY OF THE EFFICACY OF INTRAVENOUS BCG IN A METASTATIC LUNG ADENOCARCINOMA MOUSE MODEL.  Guerrero Perales, Claudia; Moreo, Eduardo; Uranga, Santiago; G\u00f3mez, Ana Bel\u00e9n; Mart\u00edn, Carlos; Aguil\u00f3, Nacho.  Universidad de Zaragoza, Zaragoza.  Bacillus Calmette-Gu\u00e9rin (BCG) is a live attenuated mycobacterium vaccine and it is at present the only tuberculosis vaccine used in humans. Since more than four decades ago, intravesical BCG represents a gold standard therapy for high-risk non-muscular invasive bladder cancer. Recently, systemic delivery of BCG has recently been reported to drive profound changes in bone marrow (BM) myelopoiesis providing a more efficient capacity of response against a subsequent tuberculosis infection. However, i.v. BCG has never been studied in the context of orthotopic lung tumors. Here a metastatic lung adenocarcinoma mouse model was generated to study the antitumoral response of intravenous (i.v.) BCG.  Mice inoculated with i.v. BCG prior to tumor cells inoculation showed higher survival compared to non-treated mice. However, i.v. BCG delivery after tumor challenge did not provide any therapeutic advantage, suggesting that tumor might be influencing i.v. BCG efficacy. A congenic BM transplant mouse model suggested the ability of i.v. BCG to re-educate haematopoietic progenitors to overcome tumor influence. Moreover, prior administration of i.v. BCG avoided myeloid-derived supressor cells (MDSCs) accumulation in lungs of tumor-bearing mice, in contrast to i.v. BCG after tumor challenge leading to an immunosuppresive ambience. Finally, therapeutic combination of i.v. BCG with gemcitabine, which reduce MDSCs at low doses, futher increased mouse survival compared to gemcitabine in monotherapy.  As a result, combination of i.v. BCG with chemotherapy could represent an attractive therapeutic approach for advanced lung cancer.             \n  \nP-084  LA ADICI\u00d3N DE C\u00c9LULAS TRONCALES MESENQUIMALES EX VIVO DISMINUYE LA EXPRESI\u00d3N DE MARCADORES DE DEGRADACI\u00d3N DE LA MATRIZ EXTRACELULAR Y DE LINFOCITOS T NA\u00cfVE  Pascual Garc\u00eda, Sandra; Pujalte Satorre, Carolina; Mart\u00ednez Peinado, Pascual; L\u00f3pez Ja\u00e9n, Ana Bel\u00e9n; Baeza Morales, Andr\u00e9s; Medina Garc\u00eda, Miguel; Sempere Ortells, Jos\u00e9 Miguel.  Universidad de Alicante, San Vicente del Raspeig.  Las c\u00e9lulas troncales mesenquimales (MSC) son c\u00e9lulas multipotentes que, debido a la liberaci\u00f3n de factores solubles o al contacto directo con otras c\u00e9lulas, presentan una gran capacidad inmunomoduladora e inmunosupresora. Esto las ha convertido en una potencial herramienta terap\u00e9utica para diversas enfermedades inflamatorias. El objetivo del presente estudio es analizar la expresi\u00f3n de marcadores de degradaci\u00f3n de la matriz extracelular, metaloproteinasa de matriz (MMP) 9, y de linfocitos T na\u00efve, CD45RA, en c\u00e9lulas mononucleares de sangre perif\u00e9rica (PBMC) tras el cocultivo con MSC derivadas de tejido adiposo. Las PBMC se aislaron de muestras de sangre anticoagulada de voluntarios sanos (n=5) mediante centrifugaci\u00f3n en gradiente de densidad. Posteriormente, se realiz\u00f3 un cocultivo con MSC:PBMC (104:105 c\u00e9lulas) en medio RPMI-1640 suplementado con 10% suero de ternera fetal, 1% antibi\u00f3ticos y 1% glutamina. Las c\u00e9lulas fueron estimuladas con 20 ng/ml PMA y se incubaron durante 24h a 37\u00baC y 5% CO2. Se a\u00f1adi\u00f3 a las PBMC, 3 \u03bcg/ml brefeldina A y se volvieron a incubar durante 3h. Finalmente, se fijaron, se permeabilizaron y se marcaron con los anticuerpos anti-MMP-9-Alexa Fluor-488 y anti-CD45RA-PE. El an\u00e1lisis se realiz\u00f3 con el cit\u00f3metro de flujo EPICS XL. Las PBMC mostraron una expresi\u00f3n de MMP-9 y de CD45RA en torno al 70-80%, tanto en condiciones sin estimular como estimuladas. La adici\u00f3n de MSC a las PBMC produjo una disminuci\u00f3n en la expresi\u00f3n de MMP-9 tanto en condiciones controles, como estimuladas (p<0,05). El cocultivo de ambas poblaciones celulares caus\u00f3 una ligera disminuci\u00f3n de CD45RA en las PBMC en condiciones sin estimular y estimuladas. En conclusi\u00f3n, estos resultados muestran que las MSC producen una disminuci\u00f3n en la expresi\u00f3n de MMP-9 y de CD45RA, confirmando su papel antiinflamatorio e inmunosupresor, lo que abrir\u00eda la posibilidad a utilizarlas como terapia celular frente a enfermedades autoinmunes, como la artritis reumatoide.       \n  \nP-085  EFICACIA DE ANAKINRA EN UNA PACIENTE CON PERICARDITIS RECURRENTE REFRACTARIA   Moncayo Mu\u00f1oz, Ana Paulina; D\u00edaz Luna, Mar\u00eda De Las Mercedes; Mej\u00eda, Mar\u00eda Alejandra; Fernandez-Cruz, Eduardo; Carbone, Javier.  Hospital General Universitario Gregorio Mara\u00f1on, Madrid.  Introducci\u00f3n La pericarditis refractaria se asocia con una importante afectaci\u00f3n de la calidad de vida de los pacientes y a riesgos de complicaciones graves. Describimos una paciente con pericarditis de larga evoluci\u00f3n tratada con Anakinra por esta indicaci\u00f3n.   M\u00e9todos Recogida de datos de la historia cl\u00ednica personal electr\u00f3nica. Seguimiento prospectivo. Datos obtenidos en visitas cl\u00ednicas protocolizadas realizadas.    Resultados Mujer de 34 a\u00f1os que en 2016 present\u00f3 el primer episodio de pericarditis. Como antecedentes refiere una picadura de garrapata en 2008 con serolog\u00eda positiva frente a Borrelia Burgdorferi, present\u00f3 eritema migrans recibiendo tratamiento con Tetraciclina. Los estudios de autoinmunidad fueron negativos. RMN cardiaca en 2019 presenta datos de lesi\u00f3n peric\u00e1rdica leve y fibrosis incipiente. Ha tenido entre 3-4 episodios por a\u00f1o de pericarditis consistentes en dolor retroesternal de moderada-grave intensidad, disnea que exacerba con las actividades f\u00edsicas, limitaci\u00f3n de tareas de vida diaria, sue\u00f1o no reparador por el dolor. El tratamiento inicial fue: AAS, colchicina, ciclos de glucocortioides a altas dosis con reducci\u00f3n gradual de dosis, hidroxicloroquina, y azatioprina; sin cambios a nivel cl\u00ednico ni radiol\u00f3gico de la pericarditis.  La paciente fue remitida a nuestro servicio en 2020, presentaba hipogamaglobulinemia leve con d\u00e9ficit de subclases IgG3 y consumo de complemento C3 y C4, tambi\u00e9n se realiz\u00f3 un panel de secuenciaci\u00f3n gen\u00e9tica siendo negativo. Inici\u00f3 el tratamiento con Anakinra 100 mg SC autoadministrados diarios en mayo del 2020 con respuesta cl\u00ednica favorable, refer\u00eda dolor tor\u00e1cico leve, deambulaci\u00f3n sin limitaciones y sue\u00f1o reparador durante 6 meses. No hubo complicaciones infecciosas.   Conclusi\u00f3n En un caso de pericarditis recurrente se observa respuesta favorable inicial frente al uso de Anakinra sin complicaciones aparentes, siendo esta una opci\u00f3n para mantener una aceptable  \n  \ncalidad de vida en una paciente previamente muy sintom\u00e1tica y largamente tratada con otras opciones de terapia convencionales.                                                      \n  \nP-086  OVERCOMING T CELL DYSFUNCTION IN THE TUMOR MICROENVIRONMENT'S ACIDIC PH TO ENHANCE ADOPTIVE T CELL TRANSFER IMMUNOTHERAPY  Navarro Negredo, Flor1; Casares, Noelia2; Martin-Otal, Celia2; Lasarte-Cia, Aritz2; Covo, Angela3; Gorraiz, Marta2; Sarrion, Patricia2; Llopiz, Diana2; Reparaz, David2; Varo, Nerea4; Rodriguez-Madoz, Juan Roberto2; Prosper, Felipe2; Hervas-Stubbs, Sandra2; Lozano, Teresa2; Lasarte, Juan Jose2.  1Centro de Investigaci\u00f3n Medica Aplicada (CIMA), Pamplona; 2CIMA, Pamplona; 3Universidad de Navarra, Pamplona; 4Cl\u00ednica Universitaria de Navarra, Pamplona.  The high metabolic activity and insufficient perfusion of tumors leads to the acidification of the tumor microenvironment (TME). The acidified intracellular pH (pHi) of tumor infiltrating T cells resuls in inhibited T cell function and anti-tumor activity. We found that pharmacological inhibition of the acid loader chloride/bicarbonate anion exchanger 2 (Ae2) with 4,4\u2019-diisothiocyanatostilbene-2,2\u2019-disulfonicacid (DIDS) alkalinized the pHi of CD4+ and CD8+ T cells and enhanced their function upon TCR activation in vitro, especially under acid pH conditions. In vivo, DIDS administration delayed B16OVA tumor growth in immunocompetent mice as monotherapy or when combined with adoptive T cell transfer immunotherapy using OVA-specific T cells. Notably, the genetic silencing of Ae2 in OVA-specific T cells alkalinized the pHi of CD4+ and CD8+ T cells and improved their function in vitro as well as their anti-tumor activity in vivo. B16OVA-challenged mice treated with Ae2 KO OVA-specific T cells had significantly better overall survival than those treated with control T cells. Similarly, genetic modification of OVA-specific T cells to overexpress the voltage gated hydrogen channel 1 (Hv1), a selective H+ extruder that prevents T cell acidification, significantly improved T cell function in vitro, even at acid pH conditions. B16OVA tumor growth was significantly delayed when mice were given adoptive T cell transfer immunotherapy of Hv1-overexpressing OVA-specific T cells indicating that the overexpression of Hv1 results in a better anti-tumor T cell response. Hv1 overexpression also improved the anti-tumor activity of chimeric antigen receptor (CAR) T cells specific for Glypican 3 (GPC3) in mice bearing PM299L-GPC3 hepatocellular carcinoma tumors. Our results demonstrate that preventing intracellular acidification by regulating the expression of acidifier ion channels such as Ae2 or alkalinizer channels like Hv1 in tumor-specific lymphocytes enhances their antitumor response by making them more resistant to the acidic TME.      \n  \n                                \n \n  \nP-087  LIPOSOMES CONJUGATED WITH THE 9 KDA ISOFORM OF GRANULYSIN POTENTIATES ITS CYTOTOXICITY AGAINST TUMOR CELLS   Soler, Ruth1; Guerrero, Patricia1; Marco, Joaqu\u00edn1; Ib\u00e1\u00f1ez, Raquel1; Marzo, Isabel1; Mart\u00ednez, Luis2; Anel, Alberto1.  1Universidad de Zaragoza, Zaragoza; 2Hospital Cl\u00ednico Universitario Lozano Blesa, Zaragoza.  9 kDa granulysin (GRNLY) is a human cytolytic protein secreted by cytotoxic T lymphocyte CTL and NK cells of the immune system whose demonstrated physiological function is the elimination of bacteria and parasites. In previous studies of our group it was demonstrated the anti-tumoral capacity of recombinant granulysin, both in vitro and in vivo. In the present work we have developed lipid nanoparticles whose surface can bind recombinant granulysin through the formation of a complex of coordination between the histidine tail of the protein and Ni2+ provided by a chelating lipid in the liposome composition and termed them LUV-GRNLY, for granulysin-bound large unilamellar vesicles. The objective of this formulation is to increase granulysin concentration at the site of contact with the target cell and to increase the cytotoxicity of the administered dose. The results obtained indicate that recombinant granulysin binds to the surface of the liposome with high efficiency and that its cytotoxicity is significantly increased in association with liposomes. In addition, we also demonstrate that the main mechanism of death induced by both granulysin and LUV-GRNLY is apoptosis. Jurkat-shBak cells are resistant to GRNLY and also to LUV-GRNLY, showing that LUV-GRNLY uses the mitochondrial apopototic pathway to induce cell death. On the other hand, we show that LUV-GRNLY induces the expression of the pro-apoptotic members of the Bcl-2 family Bim and especially Puma, although it also induced the expression of anti-apoptotic Bcl-XL.                   \n  \nP-088  INFLAMMATORY RESPONSE IN BLADDER FIBROBLASTS INDUCED BY BACILLUS CALMETTE-GU\u00c9RIN-IMMUNOTHERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER  Garc\u00eda Mart\u00ednez, V\u00edctor Manuel1; Ib\u00e1\u00f1ez Fern\u00e1ndez, Ismael2; Suarez Cabrera, Cristian2; Munera Maravilla, Ester2; Pinto Nunes, Sandra3; Due\u00f1as, Marta2; L\u00f3pez Santalla, Mercedes4; Juli\u00e1n, Esther5; De La Rosa, Federico6; G\u00f3mez Del Ca\u00f1izo, Carmen6; Rodr\u00edguez Izquierdo, Marta6; Guerrero Ramos, F\u00e9lix6; Castellano, Daniel7; Paramio Gonz\u00e1lez, Jes\u00fas Mar\u00eda2.  1Molecular and Traslational Oncology Division, Biomedical Innovation Unit, CIEMAT; Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer;  Institute of Biomedical Research, University Hospital '12 de Octubre', Madrid; 2Molecular and Traslational Oncology Division, Biomedical Innovation Unit, CIEMAT; Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer; Institute of Biomedical Research, University Hospital '12 de Octubre', Madrid; 3Molecular and Traslational Oncology Division, Biomedical Innovation Unit, CIEMAT; Institute of Biomedical Research, University Hospital '12 de Octubre'; Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Porto; 4Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, CIEMAT; Centre for Biomedical Network Research on Rare Diseases (CIBER-ER) and Advanced Therapy Unit, Health Research Institute-Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Universidad Aut\u00f3noma de Madrid (IIS-FJD, UAM), Madrid; 5Department of Genetics and Microbiology, Autonomous University of Barcelona, Barcelona; 6Urology Department, University Hospital '12 de Octubre', Madrid; 7Division of Medical Oncology, University Hospital '12 de Octubre', Madrid.  Transurethral instillations of Mycobacterium bovis bacillus Calmette-Gu\u00e9rin (BCG) has been used for decades as immunotherapy for the treatment of high risk non-muscle invasive bladder cancer (NMIBC) patients. While relatively effective, 43% of BCG-treated patients will recur within 5 years and we do not know why. BCG-induced innate and adaptive responses are key for the desired anti-cancer immunity. But how these two are generated and connected is still not well understood. Fibroblast exert important immunological roles in many tissues. But their role in the BCG-treatment scenario is not known. Here we show that repeated instillations of BCG in healthy mice induce formation of lymphoid aggregates reminiscent of early granuloma structures, formed by leukocytes and fibroblasts. Furthermore, these fibroblasts appear activated as determined by flow cytometry. In vitro studies using mouse primary bladder resident fibroblasts (BFs) show that these cells respond directly to the attenuated pathogen. We also observed a similar inflammatory response against BCG in cancer-associated fibroblasts. We performed RNAseq analysis in FACS-sorted BFs, finding that BFs upregulate genes that control leukocyte migration. Specifically, we found that BFs and no other cell types, present a robust increased the expression of Ccl2, Cxcl1 and Cxcl2, among other chemotactic factors. Transwell experiments show that BCG-treated BFs attract monocytes and neutrophils. Besides, instillation of BCG in Ccr2-KO mice shows reduced inflammation in the bladder, which further supports  \n  \nthe importance of the CCR2/CCL2 axis to mount an adequate organ response against BCG. Finally, statistical analysis suggests that the presence of fibroblasts in the tumour tissue is detrimental for the efficacy of BCG therapy. In summary, we found that BFs directly respond to BCG and acquire an inflammatory phenotype likely controlling immune cell recruitment. Association of high expression of fibroblast markers with poor prognosis suggests that fibroblast actions may reduce efficacy of BCG-induced immunotherapy.                                               \n  \nP-090  ARTIFICIAL INTELLIGENCE-DRIVEN, DECENTRALIZED PRODUCTION FOR ADVANCED THERAPIES IN THE HOSPITAL   Navarro Vel\u00e1zquez, Sergio1; Cofan Pujol, Montserrat1; Pascal Capdevila, Mariona1; Hort, Simon2; Espa\u00f1ol Rego, Marta1; Gonz\u00e1lez Navarro, Europa Azucena1; Ortiz De Landazuri Pascal, I\u00f1aki1; Juan Otero, Manel1.  1Hospital Cl\u00ednic de Barcelona, Immunology Service \u2013 Immunotherapy Section, Barcelona; 2Fraunhofer-Institut f\u00fcr Produktionstechnologie IPT, Aachen.  Artificial intelligence (AI) is a very broad concept and encompasses many disciplines that have emerged with the advancement of computing and data science. We could define AI as any technique that allows a computer to mimic human intelligence. But within AI we have different disciplines that support it. One of them and the most important is Machine learning, it is a discipline within AI that includes those techniques that allow machines to improve tasks with experience. And within machine learning we would have its main base, which is deep learning, which is a system based on neural networks that allow any machine to train itself to perform a task. Artificial intelligence has many potential applications, such as business, commerce, transport or health services. In the health system, the appearance of a large amount of data has allowed us to improve and implement systems for diagnosis, prognosis, treatments, etc. These factors have created the need to improve the multidisciplinary relationship between the world of engineering and the world of health, allowing the creation of collaborative consortiums at different levels to improve the quality of life of patients. Faced with these needs, the AIDPATH (Artificial Intelligence-driven, Decentralized Production for Advanced Therapies in the Hospital) EU consortium was born. Its principal aim is to facilitate and improve the next generation of personalized medicine with genetically engineered T-lymphocytes, modified to express a synthetic chimeric antigen-specific receptor (CART), in EU hospitals. AIDPATH will use AI technology to integrate patient-specific data and biomarkers into CART therapy and optimize manufacturing, scheduling and resource planning to reduce costs and hospital resource utilization. Our task in the consortium is the recruitment of CART manufacturing, patient follow-up and resource management data to improve the AI system.        \n  \nP-091  ASSESSMENT OF MESENCHYMAL STEM/STROMAL CELL-BASED THERAPY IN K/BXN SERUM TRANSFER-INDUCED ARTHRITIS  Lopez Santalla, Mercedes1; Conde, Carmen2; Rodriguez Trillo, Angela2; Bueren Roncero, Juan Antonio1; Garin Ferreira, Marina Inmaculada1.  1Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energ\u00e9ticas Medioambientales y Tecnol\u00f3gicas (CIEMAT), Centre for Biomedical Network Research on Rare Diseases (CIBER-ER) and Advanced Therapy Unit, Health Research Institute-Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Universidad Aut\u00f3noma de Madrid (IIS-FJD, UAM), Madrid; 2Laboratorio de Reumatolog\u00eda. Experimental y Observacional, Instituto de Investigaci\u00f3n Sanitaria de Santiago (IDIS), Hospital Cl\u00ednico Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago de Compostela.  Rheumatoid arthritis (RA) is an autoimmune disease characterized by systemic and chronic inflammation in synovial tissues together with cartilage/bone destruction. Despite the advances in understanding the aetiology and mechanisms of RA and the existence of numerous anti-rheumatic drugs, significant number of individuals with RA do not respond or are intolerant to current treatments. Mesenchymal stem cells (MSCs) have emerged as a very promising treatment for different autoimmune and inflammatory diseases such as rheumatoid arthritis (RA) due to their immunosuppressive properties. Collagen-induced arthritis (CIA) mouse model is the most commonly used model in preclinical studies in MSC-based therapy. However, due to its low incidence, the mouse strain restriction and the prolonged induction phase, alternative experimental models of RA have been developed.  In this study, we evaluated whether the K/BxN serum transfer-induced arthritis (STIA) could be used as an alternative model to study the MSC-based therapy. Surprisingly, our data suggest that allogeneic adipose-derived MSC therapy was unable to modulate the course of systemic joint inflammation in arthritic mice despite the various experimental conditions and protocols tested.  These results suggest that the discrepancies in the efficacy of MSC-based therapy among the arthritic models may be based on the differences in the pathogenesis of inflammation according to the different immune statuses and monocytic/macrophage balance in the inflamed mice among the different preclinical models of arthritis. These observations could help to identify those RA patients most likely to respond to MSC-based therapy that will clearly accelerate the clinical translation of MSC.          \n  \nP-092  IMPROVED FUNCTIONALITY OF GENETICALLY ENGINEERED HUMAN MESENCHYMAL STEM/STROMAL CELLS EXPRESSING CXCR4 AND IL10 IN EXPERIMENTAL COLITIS  Lopez Santalla, Mercedes; Ya\u00f1ez, Rosa Maria; Hernando Rodriguez, Miriam; Bueren Roncero, Juan Antonio; Garin Ferreira, Marina Inmaculada.  Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energ\u00e9ticas Medioambientales y Tecnol\u00f3gicas (CIEMAT), Centre for Biomedical Network Research on Rare Diseases (CIBER-ER) and Advanced Therapy Unit, Health Research Institute-Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Universidad Aut\u00f3noma de Madrid (IIS-FJD, UAM), Madrid.  Mesenchymal stem/stromal cell (MSCs)-based therapy represents a potential alternative treatment for immune-mediated disorders due to their immunomodulatory and regenerative properties. In this context, preclinical data from animal models and clinical trials have demonstrated that MSC therapy is safe, although a significant heterogeneity exists in terms of therapeutic efficacy in the clinic. Inflammatory bowel diseases (IBD) consist on a chronic inflammation of intestinal mucosa, thus, the reported heterogeneity in the therapeutic efficacy of MSC-based therapy may be due to a limited trafficking of infused MSCs to the damaged intestinal tissue. To improve the efficacy of MSC-based therapy, we tested genetically engineered adipose-derived MSCs carrying the CXCR4 to enhance their trafficking to inflamed tissues. Additionally, interleukin 10 gene was used to improve the anti-inflammatory potential of the MSCs. The therapeutic efficacy of CXCR4/IL10-expressing MSCs was analysed using the dextran suphate sodium (DSS)-induced colitis model. A single dose of CXCR4/IL10-expressing MSCs reduced the disease activity index, total body weight losses and the incidence of colitis together with increased survival compared to unmodified MSCs suggesting that CXCR4/IL10-expressing MSCs represent a promising and more efficacious therapeutic approach for the treatment of inflammatory bowel diseases.                 \n  \nP-094  IN SILICO LYNCH SYNDROME-RELATED NEOANTIGENS PREDICTION AND VALIDATION FOR A DENDRITIC-CELL BASED CANCER PREVENTION VACCINE  Bay\u00f3 Llorens, Cristina1; Castellano, Giancarlo1; Oca\u00f1a, Teresa2; Moreira, Leticia2; Rivero-Sanchez, Liseth2; Carballal, Sabela2; S\u00e1nchez, Ariadna2; Moreira, Rebeca2; Jung, Gerhad3; Otriz, Oswaldo2; Castells, Antoni2; Pellis\u00e9, Maria2; Juan, Manel4; Ben\u00edtez-Ribas, Daniel4; Balaguer, Francesc2.  1Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS); Hospital Cl\u00ednic de Barcelona, Barcelona; 2Gastroenterology Department, Hospital Cl\u00ednic de Barcelona, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD), Barcelona; 3Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS) Gastroenterology Departmentt, HCB, CIBEREHD, University of Barcelona, Barcelona; 4Immunology Department, Immunotherapy section, Hospital Cl\u00ednic de Barcelona, Barcelona.  Introduction:  Lynch syndrome (LS), caused by germline mutations on DNA mismatch-repair genes (MMR) predisposes individuals to colorectal and endometrial cancer (CRC, EC) amongst other tumors. Although CCR prevention methods are effective, no preventive strategies exist for the majority of LS-related tumors. Ex-vivo generated and tumor-antigen-loaded dendritic cell (DC) vaccines have mainly been used in advanced cancers therapy; however their full therapeutic potential would likely be as a preventive approach in high-risk cancer patients. LS is a paradigmatic model for its limited and predictive mutational spectrum in repetitive DNA sequences termed microsatellites (MS). We have identified the main frame-shift derived neopeptides (FSDN) that are shared among cancers from LS patients to develop a cancer preventive DC-based neoepitope vaccine. Methods:  Selection of LS-related coding MS and FSDN published in literature and in public databases (Seltar Database; The Cancer Genome Atlas, TCGA). Application of neoepitope prediction pipelines to prioritize FSDN with high coverage on the most frequent HLA-I and HLA-II haplotypes (pVACbind; pVACtools v2.0.1). Validation of the selected FSDN in colorectal adenomas (CrAD), EC and CRC samples from LS patients and non-LS MS instability (MSI) tumors through mutational signature analysis, HLA-typing and neoantigens prediction (pVACseq). Results:  98 FSDN restricted to HLA-I and HLA-II were prioritized. Validation analysis determined that selected FSDN A) virtually bind up to 36 HLA-II and 60 HLA-I alleles, B) Have sequence similarity to known pathogens and no significant self-similarity, C) Are virtually presented in CrAD, EC and CRC LS samples, and C) 29 FSDN-deriving mutations in coding-MS have high  \n  \npresence in non-LS MSI-h tumors. Conclusions:  Our predicted neoepitope set has an optimal coverage among LS patients in terms of HLA alleles, associated cancers and prevalence and is highly represented in non-LS MSI tumors. In vitro immunogenicity studies are ongoing to consolidate an optimal FSDN set.  \n  \nP-095  EXTINCTION CATASTROPHE  OF ANTIVIRAL DRUGS MOLNIPIRAVIR ( MK-4482), REMDESIVIR   AND 4 -FLUOR URIDINE (4FIU)  ACTING AS A NUCLEOSIDE ANALOGUES AGAINST PANDEMIC HUMAN CORONAVIRUSES.   L\u00f3pez Corbal\u00e1n, Juan Carlos1; Segu\u00ed Ripoll, Jose Miguel2; Lopez Penabad, Luis2.  1Subdelegacion del Gobierno en Alicante, Alicante; 2Hospital San Juan Alicante, Alicante.  Error catastrophe could be defined as a cumulative loss of genetic information in alineage of organisms due to high mutation rates. The process leading to viral extinctionthrough the accumulation of errors is known as lethal mutagenesis. Error catastropheoccurs when the mutation rate exceeds an error threshold. Viruses and bacteria haveevolved to mainto maintain a characteristic error rate. RNA viruses have very high mutation rates and replicate near the error threshold for the maintenance of genetic information . .Error catastrophe occurs when the mutation rate exceeds an error threshold. Viruses and bacteria haveevolved to maintain a characteristic error rate. RNA viruses have very high mutation ratesand replicate near the error threshold for themaintenance of genetic information Molnupiravir (a prodrugof \u03b2-D-N4-hydroxycytidine) has been recently approved for the treatment of SARS-CoV-2 infection.  Its triphosphate derivative can be incorporated into viral RNA and extended by the coronavirus RNApolymerase. Incorrect base pairing and inefficient extension by the polymerase promote mutagenesisby increasing the G\u2192A and C\u2192U transition frequencies. Molnupiravir is the isopropylester prodrug of the ribonucleoside analogue \u03b2-D-N4-hydroxycytidine (NHC). NHC is abroad-spectrum antiviral compound that inhibits the replicationof multiple viruses in cell culture (e.g., Chikungunya virus, Venezuela equine encephalitis virus, respiratory syncytial virus, hepatitis C virus, norovirus, influenza A and B viruses, Ebola virus, and human coronaviruses) (3). The triphosphorylated derivative of NHC is a substrate for viral RNA polymerases andinterferes with viral replication. In cell culture assays, molnupiravir was found to be a potent inhibitor of SARS-CoV-2replication with an EC50 in the submicromolar range.  Nucleotide analogues  Remdesivir, Molnipiravir   and Paxlovid (Ritonavir +Nirmatrelvir)    remains as the only drugs approved by regulatory agencies to treat COVID-19.  A new drug  such as 4-FIU also  an analogue of Uracil;  have a \u201cterminal chain effect\u201d that must be carefully studied.       \n  \nP-096  RECRUITMENT OF CCR2+ MONOCYTES IS NOT ESSENTIAL FOR THE BENEFICIAL EFFECT OF MESENCHYMAL STEM/STROMAL CELL-BASED THERAPY IN EXPERIMENTAL COLITIS  Lopez Santalla, Mercedes; Martin Rey, Miguel Angel; Bueren Roncero, Juan Antonio; Garin, Marina Inmaculada.  Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energ\u00e9ticas Medioambientales y Tecnol\u00f3gicas (CIEMAT), Centre for Biomedical Network Research on Rare Diseases (CIBER-ER) and Advanced Therapy Unit, Health Research Institute-Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Universidad Aut\u00f3noma de Madrid (IIS-FJD, UAM)), Madrid.  Inflammatory bowel diseases (IBD) are characterized by persistent and relapsing inflammatory processes of the intestinal mucosa related to genetic background, environmental factors and commensal microbiota. In spite of recent advances in clinical treatments leading to decrease inflammation, significant numbers of IBD patients experienced severe side effects or loss of response to current treatments. Thus, new effective alternatives are highly needed. In this sense, mesenchymal stem/stromal cells (MSCs) have emerged as a new therapeutic strategy for IBD thanks to their immunomodulatory and regenerative properties. Although numerous immune responses and mechanisms of action of MSCs have been described, nowadays the precise mechanisms remain to be fully defined. We have previously reported a transient increase in Ly6C++ monocyte populations in peripheral blood following the infusion of MSCs in a model of collagen-induced arthritis.  Additionally, an increase of regulatory IL10-expressing macrophages were also observed in the draining lymph nodes that paralleled to a decline in the clinical score of arthritis. Based on these data, in this study, we evaluated whether the CCR2-mediated trafficking of myeloid populations is involved in the beneficial effects of MSC-based therapy using an experimental model of colitis induced by treatment with dextran sulphate sodium (DSS). In contrast to our initial hypothesis and previously reported studies, a single dose of allogeneic adipose-derived MSCs infused in DSS-induced colitic CCR2-deficient mice was as effective as in WT mice. These results suggest that the CCR2-mediated trafficking of immune cells is not involved in the mechanism of action mediated by MSC-based therapy at least in DSS-induced colitis.           \n  \nP-098  C\u00c9LULAS EDA CAR-T FRENTE AL MICROAMBIENTE TUMORAL COMO ALTERNATIVA AL TRATAMIENTO DE TUMORES S\u00d3LIDOS  Mart\u00edn-Otal, Celia1; Lasarte, Aritz1; Serrano, Diego1; Casares, Noelia1; Navarro, Flor1; S\u00e1nchez, In\u00e9s1; Gorraiz, Marta1; Sarri\u00f3n, Patricia1; De-Andrea, Carlos2; Echeveste, Jos\u00e92; Calvo, Alfonso1; Rodriguez-Madoz, Juan Roberto1; San Miguel, Jes\u00fas2; Pr\u00f3sper, Felipe1; Herv\u00e1s-Stubbs, Sandra1; Lasarte, Juan Jos\u00e91; Lozano, Teresa1.  1CIMA-Universidad de Navarra, Pamplona; 2Cl\u00ednica Universidad de Navarra, Pamplona.  El microambiente tumoral (TME) de los tumores s\u00f3lidos constituye una importante barrera que dificulta la eficacia antitumoral de las c\u00e9lulas CAR-T. La generaci\u00f3n de CAR espec\u00edficos de ant\u00edgenos del TME podr\u00eda considerarse una alternativa para superar esta limitaci\u00f3n y mejorar as\u00ed su eficacia. Dentro del TME destaca la funci\u00f3n de la matriz extracelular en la progresi\u00f3n e invasi\u00f3n tumoral. Uno de los componentes principales de esta matriz es la fibronectina. Hemos generado un CAR espec\u00edfico para el splicing alternativo EDA de la fibronectina, que se encuentra altamente expresado en muchos tipos de tumores (hepatocarcinoma, colangiocarcinoma o c\u00e1ncer de p\u00e1ncreas) y sin embargo, no se detecta expresi\u00f3n en tejidos sanos. Las c\u00e9lulas EDA CAR-T fueron capaces de reconocer y eliminar c\u00e9lulas tumorales que expresan EDA en la membrana. Interesantemente, la transferencia adoptiva de c\u00e9lulas EDA CAR-T retras\u00f3 el crecimiento tumoral en el modelo de teratocarcinoma F9, donde la expresi\u00f3n de EDA est\u00e1 asociada al endotelio del tumor y no a la propia c\u00e9lula tumoral. El efecto anti-tumoral observado en este modelo se acompa\u00f1\u00f3 de una reducci\u00f3n significativa de la vasculatura tumoral. Sorprendentemente, la versi\u00f3n humana de EDA CAR, incluyendo los endodominios humanos 41BB y CD3\u03b6, ejerci\u00f3 actividad antitumoral en el modelo de hepatocarcinoma humano PLC implantado en ratones NSG, que expresa altamente EDA en la matriz extracelular y la vasculatura endotelial. Las c\u00e9lulas EDA CAR-T exhibieron un tropismo por los tumores que expresaban EDA y no se observ\u00f3 toxicidad en ratones con tumor ni en ratones sanos tras la terapia. Estos resultados sugieren que la terapia celular adoptiva basada en c\u00e9lulas CAR-T dirigidas a la variante espec\u00edfica de tumor EDA de la fibronectina es factible y ofrece una opci\u00f3n terap\u00e9utica ampliamente aplicable a diferentes tipos de c\u00e1ncer.    \n  \n                                \n \n  \nP-099  POTENTIAL USE OF TREG CELLS OBTAINED FROM PEDIATRIC THYMIC TISSUE (THYTREG) AS ALLOGENEIC CELL THERAPY FOR EXACERBATED IMMUNE RESPONSES   C\u00f3zar Fern\u00e1ndez, Beatriz1; Bernaldo De Quir\u00f3s Plaza, Esther1; Fern\u00e1ndez Castillo, Marta1; L\u00f3pez Esteban, Roc\u00edo1; Gil Jaurena, Juan Miguel2; Pardo, Carlos2; Pita, Ana2; P\u00e9rez Caballero, Ram\u00f3n2; Vicario Moreno, Jos\u00e9 Luis3; Moreno Hidalgo, Miguel \u00c1ngel3; Pion, Marjorie4; Correa Rocha, Rafael1; Mart\u00ednez Bonet, Marta1.  1Laboratorio de Inmuno-Regulaci\u00f3n. Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, Madrid; 2Secci\u00f3n de Cirug\u00eda Cardiaca Infantil. Hospital Materno Infantil Gregorio Mara\u00f1\u00f3n, Madrid; 3Histocompatibilidad. Centro de Transfusi\u00f3n de la Comunidad de Madrid, Madrid; 4Grupo de Inmuno-Regulaci\u00f3n Avanzada. Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, Madrid.  Due to its immunomodulatory potential, regulatory T cell (Treg) therapies have acquired great interest in the treatment of diseases where restoring immune homeostasis is crucial. Until now, autologous Treg cell therapy has proven its safety, but employing blood as the source of Treg presents limitations regarding recovery and quality. Our group has developed a protocol to produce massive amounts of GMP Treg derived from thymic tissue (thyTreg) that could overcome the main obstacles found in the current Treg therapies. We are employing thyTreg cells with success in a clinical trial as autologous cell therapy in heart transplanted children. Given the large amounts of thyTreg obtained from a single thymus, the main objective is to evaluate the possibility of the allogeneic use of thyTreg, in terms of immunogenicity and functionality.  ThyTreg obtained in our laboratory exhibit high viability (>90%) and purity (>80% CD25+FoxP3+ expression) and does not overexpress immunogenicity markers. Moreover, in vitro co-culture models of thyTreg with allogeneic peripheral blood mononuclear cells (alloPBMC) from healthy donors have been performed to i) determine if thyTreg trigger an immunogenic response on alloPBMC, and ii) evaluate the capacity of thyTreg to suppress the alloPBMC proliferation. Although HLA disparity in the co-cultures between thyTreg and alloPBMC was high (13 of the 21 typed pairs had HLA <4/12 concordance), thyTreg did not induce the expression of activation markers nor the proliferation or the production of pro-inflammatory cytokines (IFN-g) by alloPBMCs, even when alloPBMC were pre-stimulated (mirroring an exacerbated immune response). Moreover, thyTreg greatly inhibit allogeneic CD4 and CD8 T cells proliferation.  The results suggest that thyTreg are not immunogenic and can exert their suppressive function in an allogeneic context, indicating their possible off-the-shelf use as treatment for transplant  \n  \nrejection, graft-versus-host disease, autoimmune diseases, or the cytokine release syndrome characteristic of severe COVID-19 patients.                                  \n  \nSesi\u00f3n Poster. Inmunoterapia (II). Pantalla 6  P-100  INFLUENCE OF MULTIPLE SCLEROSIS INFLAMMATORY CONTEXT IN THE DEVELOPMENT OF A TOLEROGENIC DENDRITIC CELL THERAPY   Fondelli, Federico1; Mansilla Lopez, Mar\u00eda Jos\u00e91; Godoy, Gerard2; Presas Rodriguez, Silvia3; Selles Rius, Ares4; Ramo Tello, Cristina3; Ballestar, Esteban2; Martinez Caceres, Eva3.  1Institut German Trias i Pujol, Barcelona; 2Institut Joseph Carreras, Barcelona; 3Hospital German Trias i Pujol, Barcelona; 4IMIDomics, Barcelona.  Introduction:  Multiple Sclerosis (MS) is a chronic inflammatory disease affecting the central nervous system where autoreactive lymphocytes induce demyelination and neurodegeneration. Current treatments reduce inflammation but can\u2019t cure the disease. In this context, antigen-specific immunotherapies represent a potentially curative approach, able to re-educate immunity toward homeostasis. Our group developed an autologous tolerogenic dendritic cell product (VitD3-TolDCs) produced from peripheral blood monocytes in presence of Vitamin D3, which showed safety/tolerability in a Phase I clinical trial in patients with MS and for which we are starting a Phase II trial. However, given MS systemic inflammation, monocytes could present a proinflammatory phenotype in comparison to Healthy Donors (HD), leading to less-than-ideal VitD3-TolDCs. Thus, to translate this therapy to the clinic, we aim to compare the phenotype and functionality of monocytes and VitD3-TolDCs from MS patients and HD, in order to identify pathways that could be modulated to produce stronger 2nd generation VitD3-TolDCs. Methods:  We analyzed via flow cytometry and methylation microarrays monocyte samples from active, na\u00efve MS patients and HD (n=15vs15). Then, we evaluated the capability of VitD3-TolDCs generated from MS-derived monocytes to induce allogeneic PBMCs proliferation in Mixed Lymphocyte Reactions in comparison to HD (n=7vs7). Results:  Flow Cytometry of MS monocytes show an increase in the intermediate subset and increased expression of inflammation markers, while methylation arrays show wide methylation changes in MS and enrichment of specific transcription factors binding motifs in unmethylated genes involved in immune activation and response. Finally, VitD3-tolDCs from MS patients resulted less able to suppress allogenic proliferation (mean suppression 0.63 (HD) vs 0.35 (MS)). Conclusions:   \n  \nMS monocytes present a proinflammatory phenotype in comparison to HD and when used to produce VitD3-tolDCs they generate less powerful tolerogenic cells. Given this proinflammatory signature, we propose that VitD3-tolDCs potency could be boosted by modulating the identified pathways.                                                 \n  \nP-101  A QUASI-MONOCLONAL APPROACH TO STUDY ATHEROPROTECTION BY A12 ANTIBODY.  Raposo Guti\u00e9rrez, Irene1; Lorenzo Mart\u00edn, Cristina2; Rodr\u00edguez Ramiro, Almudena1.  1Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC)., Madrid; 2Colegio Base, Madrid.  Atherosclerosis is the main underlying cause of cardiovascular diseases, the leading cause of death worldwide, and can remain asymptomatic for long periods of time. Thus, there is a critical need for new therapeutic and diagnostic avenues in this area. Both the innate and adaptive arms of the immune response are important in atherosclerosis. However, our knowledge on the antigenic triggers of the adaptive immune response in atherosclerosis is very limited. Recently, our lab has identified the self-protein ALDH4A1 as a novel atherosclerosis antigen targeted by the atheroprotective antibody A12, revealing ALDH4A1 and A12 as potential therapeutic targets. To study the molecular mechanisms underlying the atheroprotective role of the A12 antibody we have developed a quasi-monoclonal mouse model that will allow both isotype switching and somatic hypermutation of the A12 antibody in vivo. We used a cassette that harbors a prerearranged Ig\u03ba VJ segment, a human Ig\u03ba constant (hukappa) region (for tracing purposes), a P2A cleavage site and a prerearranged IgH VDJ segment and inserted it into the Igh endogenous locus (IghA12/+mice). We have generated 3 independent founders. To characterize IghA12/+ mice we first performed FACS analysis of peripheral blood samples from IghA12/+ founders and their offspring and found a subset (3-7% of B cells) of hukappa positive cells, confirming the presence of the transgenic construct. In addition, the proportion of peripheral B cells was reduced in IghA12/+ mice compared to control Igh+/+ littermates. FACS analysis of the bone marrow showed a severe reduction of hukappa+ immature B cells, strongly suggesting that hukappa+ cells are subject to strong, yet incomplete, negative selection. Together IghA12/+ model provides additional evidence that A12 recognizes a self-antigen and provides a valuable tool to study A12 function in atherosclerosis.                         \n  \nP-102  CORRELATIVE BIOLOGICAL STUDIES RELATED TO THE RESPONSE, PEAK AND PERSISTENCE OF ARI0002H, AN ACADEMIC BCMA-DIRECTED-CAR-T CELL FOR PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)   Espa\u00f1ol Rego, Marta1; Oliver-Cald\u00e9s, Aina1; Zabaleta, Aintzane2; Inog\u00e9s, Susana2; L\u00f3pez-D\u00edaz De Cerio, Ascensi\u00f3n2; Gonz\u00e1lez-Calle, Ver\u00f3nica3; Caba\u00f1as, Valent\u00edn4; Martin-Antonio, Beatriz5; P\u00e9rez-Amill, Lorena1; Reguera, Juan Luis6; Rodr\u00edguez-Madoz, Juan Roberto2; Rodr\u00edguez-Otero, Paula2; Ben\u00edtez-Ribas, Daniel1; Lozano, Miquel1; Cid, Joan1; Mena, Mari Pau1; Lasa, Marta2; Rodr\u00edguez-Lobato, Luis Gerardo1; Gonz\u00e1lez, Azucena1; Rosi\u00f1ol, Laura1; Moraleda, Jos\u00e9 Mar\u00eda4; Pr\u00f3sper, Felipe2; Urbano-Ispizua, \u00c1lvaro1; Mateos, Maria Victoria3; Juan, Manel1; Paiva, Bruno2; Pascal, Mariona1; Fern\u00e1ndez De Larrea, Carlos1.  1Hospital Clinic de Barcelona. IDIBAPS. Universidad de Barcelona, Barcelona; 2Cl\u00ednica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona; 3Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigacion del Cancer (IBMCC-USAL, CSIC),, Salamanca; 4Hospital Clinico Universitario Virgen de la Arrixaca, Murcia; 5Instituto de Investigaci\u00f3n Sanitaria - Fundacion Jimenez Diaz, Madrid; 6Hospital Universitario Virgen del Rocio, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), Universidad de Sevilla, Sevilla.  Background ARI0002h is an academic humanized anti-BCMA CAR T-cell, evaluated in CARTBCMA-HCB-01 clinical trial against RRMM.  Here, we present the correlative biological studies performed related to disease response.  Methods ARI0002h manufacturing data were analyzed, including the percentage of CAR expression in the final product (FP) by flow cytometry (FC). Peripheral blood (PB) samples were collected at inclusion and sequentially after infusion. T-cell subpopulations were analyzed in apheresis, FP, and PB samples at day +28. ARI0002h persistence was evaluated in PB after infusion by qPCR. Plasmatic soluble BCMA (sBCMA) and human anti-human antibodies (HAHAs) were determined prior to infusion, at day +28 and +100, and after a booster dose (starting 4 months post first infusion).  Results Thirty-three apheresis collections were transduced, with a median manufacturing time of 11 days (range 9-14). The mean CAR expression in FP was 56% (SD \u00b125). A higher CD4/CD8 ratio in the apheresis (but not in the FP) was correlated with the achievement of stringent complete response (sCR) (p=0.003). T-cell subpopulations in the FP did not correlate with response. A significant increase of exhaustion markers was observed between the FP and at day +28 PB paired samples.  \n  \nARI0002h cells showed a maximum PB expansion at day +14. Median persistence of ARI0002h cells in PB was 5 months without correlation with RRMM response.  85% of eligible patients received a booster dose, with a subsequent CART-cell expansion in 50% patients. All patients showed a deep decrease of sBCMA after CAR T-cell infusion.  HAHAs were detected in only 4% and 11% patients at day +100 and +6 months, respectively.  Conclusion ARI0002h manufacturing is fast and feasible. The peak of CAR T-cell expansion occurs 14 days after the infusion, and also in some patients after the booster dose.  Responses obtained are deep and construct immunogenicity seems to be low.                                           \n  \nP-103  DASATINIB-INDUCED SPLEEN CONTRACTION LEADS TO TRANSIENT LYMPHOCYTOSIS  Marcos Jim\u00e9nez, Ana1; Claudino Carvoeiro, Daniela2; Mu\u00f1oz Calleja, Cecilia1; V. Stein, Jens2.  1Hospital Universitario La Princesa, Madrid; 2Universidad de Friburgo, Friburgo.  Dasatinib is a tyrosine kinase inhibitor (TKI) approved for the treatment of Philadelphia-positive chronic myeloid leukemia (CML) and acute lymphoblastic leukemia. Although effective and well tolerated, patients usually exhibit a transient lymphocytosis 2 hours after the oral intake that resolves spontaneously around 4 hours later. Despite this lymphocytosis has been associated to better response to treatment, the underlying mechanism has remained elusive to date. Following the hypothesis that dasatinib could interfere with lymphocyte recirculation to and from secondary lymphoid organs (SLO), we used a murine model to investigate the effect of this drug on lymphocyte homing and egress. We did not observe any effects on lymphocyte homing to lymph nodes and spleen. In contrast, dasatinib induced a significant lymphocyte egress from the spleen, which was independent of the canonical sphingosine-1-phosphate-mediated egress signaling. Dasatinib also resulted in a significant reduction of spleen size, while preserving its microarchitecture, and was able to promote myosin light chain phosphorylation in splenic stromal cells, supporting a dasatinib-induced spleen contractility. Accordingly, pharmacological inhibition of the contraction-promoting factor ROCK partially reversed dasatinib-induced lymphocytosis and egress in vivo. Interestingly, we have uncovered the reduction of spleen size in CML patients immediately after dasatinib intake, as measured by ultrasound. This reduction paralleled the increase of lymphocytes in peripheral blood and was proportional to dasatinib plasma levels. In conclusion, our results suggest that dasatinib triggers the contraction of splenic stromal cells, leading to a mechanical egress of lymphocytes from the spleen to peripheral blood, likely contributing to the lymphocytosis associated to its intake. Thus, we have described a novel effect of dasatinib, which opens up new potential clinical applications for this drug.              \n  \nP-104  CARACTERIZACI\u00d3N FENOT\u00cdPICA Y FUNCIONAL DE LINFOCITOS T MEMORIA PRODUCTORES DE IFN-\u0393 ESPEC\u00cdFICOS DE SARS-COV-2, PROVENIENTES DE DONANTES CONVALECIENTES DE COVID-19  Gil, Rub\u00e9n1; Ostiz Urroz, Ainhoa1; Zalba, Saioa2; Bandr\u00e9s, Eva3; Tamayo, Ibai4; Rojas, Elvira1; Redondo, Margarita2; Zabalza, Amaya2; Ram\u00edrez, Natalia1.  1Grupo de Investigaci\u00f3n en Oncohematolog\u00eda, Hospital Universitario de Navarra (HUN), Universidad P\u00fablica de Navarra (UPNA), Instituto de Investigacion Sanitaria de Navarra (IdiSNA) Navarrabiomed, Pamplona; 2Departamento de Hematolog\u00eda y Hemoterapia, HUN, IdiSNA, Pamplona; 3Servicio de Inmunolog\u00eda, HUN, IdiSNA, Pamplona; 4Unidad de Metodolog\u00eda, Navarrabiomed, HUN, UPNA, IdiSNA, Pamplona, Pamplona.  Introducci\u00f3n La pandemia de la COVID-19 ha sido responsable de millones de fallecimientos en todo el mundo. Ello ha motivado la b\u00fasqueda de tratamientos para pacientes hospitalizados por infecci\u00f3n por SARS-CoV-2. Con el objetivo de validar su utilizaci\u00f3n como Inmunoterapia Adoptiva en pacientes con neumon\u00eda asociada a SARS-CoV-2, se analiz\u00f3 el fenotipo y la funcionalidad de los linfocitos T memoria espec\u00edficos de SARS-CoV-2 (LT-SC2), existentes en sujetos convalecientes de una infecci\u00f3n moderada.  Material y M\u00e9todos Se reclutaron 12 donantes convalecientes de infecci\u00f3n por SARS-CoV-2. La identificaci\u00f3n, cuantificaci\u00f3n y an\u00e1lisis fenot\u00edpico de los LT-SC2 se realiz\u00f3 mediante ensayos de secreci\u00f3n de IFN-\u03b3 y tinci\u00f3n de citoquinas intracelulares tras estimulaci\u00f3n con p\u00e9ptidos espec\u00edficos. Posteriormente, se realiz\u00f3 una expansi\u00f3n policlonal in vitro de LT-SC2, seguida de su selecci\u00f3n inmunomagn\u00e9tica a d\u00eda 14. Con estas c\u00e9lulas se desarrollaron ensayos de liberaci\u00f3n de calce\u00edna y de diluci\u00f3n de CFSE para determinar su potencial citot\u00f3xico y proliferativo. Resultados El 75% de los sujetos se consideraron aptos, y presentaron una frecuencia media de 0.019\u00b10.010%, con predominio de CD3+CD4+IFN-\u03b3+ frente a CD3+CD8+IFN-\u03b3+. Estos LT-SC2 mostraron mayormente fenotipo TEM, con mayor expresi\u00f3n de CD8+Granzima B+ y CD8+Perforina, frecuencia destacable de CD4+PD-1+, y ausencia de FasL y marcadores de activaci\u00f3n (CD38, Ki-67; Figura 1A). La expansi\u00f3n provoc\u00f3 un aumento de CD3+CD45+IFN-\u03b3+ hasta 4.16\u00b12.37%. Tras su selecci\u00f3n, la pureza alcanz\u00f3 75.5\u00b111.0% CD3+CD45+IFN-\u03b3+, con recuperaci\u00f3n de 65.9\u00b122.7%. Estas c\u00e9lulas mostraron in vitro capacidad citot\u00f3xica dependiente de la frecuencia relativa de CD8+ y de la proporci\u00f3n diana:efectora (Figura 1B); as\u00ed como potencial proliferativo al diluirse el CFSE tras ser co-cultivadas con feeders pulsados con p\u00e9ptidos espec\u00edficos (Figura 1C).   \n  \nConclusiones Realizada su caracterizaci\u00f3n fenot\u00edpica, y demostrada su capacidad funcional in vitro, los LT-SC2 provenientes de individuos convalecientes por infecci\u00f3n por SARS-CoV-2 podr\u00edan utilizarse como producto de Inmunoterapia Adoptiva para tratar pacientes graves por COVID-19.                                                  \n  \nP-105  METASTATIC MELANOMA (MM) PATIENTS WITH STABLE DISEASE DISPLAY REDUCED MO-MDSCS LEVELS IN PERIPHERAL BLOOD  Iglesias Escudero, Maria1; Kronenberg, Katharina2; Riquelme, Paloma2; Mart\u00ednez C\u00e1ceres, Eva Mar\u00eda1; Hutchinson, James A.2.  1Hospital German Trias i Pujol, Badalona; 2Hospital Universitario Clinico de Regensburg, Regensburg.  Introduction: Myeloid-derived suppressor cells (MDSCs) are increased in late-stage tumors promoting metastasis by exerting their immunosuppressive functions. Recently, treatment with anti-PD1 and/or anti-CTLA-4 has improved the prognosis of metastatic melanoma (MM). In this regard, the immune effect of cancer immunotherapy on MDSCs is poorly understood. The aim of this study was to examine Mo-MDSCs frequencies in peripheral blood in relation with clinical outcomes in MM patients under immunotherapy.  Material and methods: Peripheral blood from 38 MM patients included in a clinical trial authorised by the Ethics Committee of the University of Regensburg was collected before administration of the first dose of Nivolumab and/or Ipilimumab. Patients were classified according to the iRECIST criteria into complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). Samples were acquired with a NaviosTM cytometer. Mo-MDSCs were defined as CD14+ CD33+ CD11b+ CD15- HLA-DR-/low lin- cells.  Results: We found no association between Mo-MDSCs levels and checkpoint blockade adverse events (hepatitis and colitis), sex, presence of IgG anti-CMV and stage of the disease. On the contrary, we observed that Mo-MDSCs frequencies in patients with stable disease (n=7, median 50.92 IQR 49.63-71.49) were lower compared to those who progress (n=15, median 77.95 IQR 67.24-83.39) (p=0.026) and those who have partial response (n=11, median 78.98 IQR 66.84-80.35) (p= 0.0185).  Conclusion: Further studies are required to understand the immune response to immunotherapy and if MDSCs could serve as a biomarker to predict prognosis in MM patients under immunotherapy treatment.         \n  \nP-106  SERUM MASS SPECTROMETRY: AN ALTERNATIVE TECHNIQUE TO ANALYZE DISEASE RESPONSE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH ANTI-BCMA CAR T-CELL THERAPY  Ortiz De Landazuri, I\u00f1aki1; Oliver-Cald\u00e9s, Aina1; Espa\u00f1ol-Rego, Marta1; Contreras, Mar\u00eda Teresa2; Zabaleta, Aintzane3; Agull\u00f3, Cristina2; Puig, Noem\u00ed2; Caba\u00f1as, Valent\u00edn4; Gonz\u00e1lez-Calle, Ver\u00f3nica2; Jim\u00e9nez, Raquel1; Inog\u00e9s, Susana3; Rodr\u00edguez-Otero, Paula3; Mart\u00edn-Antonio, Beatriz5; Reguera, Jos\u00e9 Luis6; L\u00f3pez-D\u00edaz De Cerio, Ascensi\u00f3n3; Ben\u00edtez-Ribas, Daniel1; Rodr\u00edguez-Lobato, Luis Gerardo1; Gonz\u00e1lez-Navarro, Europa Azucena1; Rosi\u00f1ol, Laura1; Yag\u00fce, Jordi1; Moraleda, Jos\u00e9 M.4; Urbano-Ispizua, \u00c1lvaro1; Mateos, Mar\u00eda Victoria2; Juan, Manel1; Paiva, Bruno3; Pascal, Mariona1; Fern\u00e1ndez De Larrea, Carlos1.  1Hospital Cl\u00ednic de Barcelona, Barcelona; 2Hospital Universitario de Salamanca, Salamanca; 3Cl\u00ednica Universidad de Navarra, Pamplona; 4Hospital Cl\u00ednico Universitario Virgen de la Arrixaca, Murcia; 5Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid; 6Hospital Universitario Virgen del Roc\u00edo, Sevilla.  Background: ARI0002h is an academic BCMA-directed CAR T-cell, effective against relapsed/refractory multiple myeloma (RRMM). Here, we explore EXENT Quantitative Immunoprecipitation Mass Spectrometry (QIP-MS) as an alternative monitoring technique to serum Immunofixation (IFE) or to next generation flow cytometry (NGF) bone marrow (BM) in RRMM patients, and able to identify interferences. Methods: Thirty-three RRMM patients with measurable disease were treated with ARI0002h. The M-protein (MP) was analyzed in serum by QIP-MS at three time points: before ARI0002h infusion, and 28 and 100 days post-infusion. The presence of disease was also investigated by IFE and NGF at 28 and 100 days post-infusion. Results: Concordant and discordant results between QIP-MS and IFE (A), or QIP-MS and NGF (B) are summarized in Table 1. Interferences due to daratumumab and tocilizumab were successfully detected. Before ARI0002h, daratumumab was identified in 10 patients (30.3%) and persisted at day +100 in 5 of them (15.2%). Tocilizumab was detected at day +28 in 15 (71.4%) patients out of the 21 receiving it, persisting at day +100 in 3 of them (14.3%). Regarding to clinical outcome, the achievement of QIP-MS(-) at day +100 post ARI0002h, was associated with a prolonged overall survival (OS) (Fig. 1).  Conclusions: In this study, serum QIP-MS allowed the identification of the MP in all cases with high sensitivity.  \n  \nQIP-MS was also able to differentiate between the MP and t-mAb, allowing a correct labeling of treatment response. In our cohort, QIP-MS provided valuable information of patient\u00b4s clinical outcome in terms of OS.  Table 1.                  A) +28d ARI0002h  +100d ARI0002h          \nQIP-MS(-)   \nQIP-MS(+)    \nQIP-MS(-)   \nQIP-MS(+)      IFE(+)  1* 15 0 10     IFE(-) 8 6 14 6     * False positive (daratumumab interference).                                    B) +28d ARI0002h  +100d ARI0002h         \nQIP-MS(-)   \nQIP-MS(+)    \nQIP-MS(-)   \nQIP-MS(+)      NGF(+)  0 1 0 2     NGF( -) 7 17 13 14     NGF(NE)  2 6 1 2     NE: Not evaluable             \n  \n                            \n \n  \nP-107  PRE-CLINICAL DEVELOPMENT OF AN ACADEMIC FRATRICIDE-RESISTANT ANTI-CD7 CAR T-CELL THERAPY FOR T-CELL HEMATOLOGIC MALIGNANCIES   Ortiz De Landazuri, I\u00f1aki1; Altuna, Ane2; Ben\u00edtez-Ribas, Daniel1; Vilella, Ram\u00f3n1; Urbano-Ispizua, \u00c1lvaro1; Juan, Manel1; Uribe-Herranz, Mireia2.  1Hospital Cl\u00ednic de Barcelona, Barcelona; 2Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona.  Background: T-cells modified to express a CD7-directed chimeric antigen receptor (CAR T-cell) are showing effective results against T-cell malignancies. However, disrupting CD7 membrane expression in CAR T-cells is required to prevent fratricide. Our objective is the development of a lentiviral vector that allows the co-expression of a CD7trap, to avoid CD7 membrane trafficking, and an effective anti-CD7 CAR (CARCD7).  Methods: Three anti-CD7 antibody-secreting hybridoma (named as A, B and C) were sequenced to obtain their corresponding single chain variable fragments (scFv). Each scFv was fused to an intracytoplasmic retention domain to obtain CD7trap constructs. The most effective CD7trap was fused to each CARCD7 candidate. The expansion and CAR expression capacity of T-cells modified with the resulting constructs were evaluated. Their anti-tumor effect was analyzed in co-cultures against Jurkat-GFP and MOLT4-GFP cell lines at different effector-target rates. IFN\u03b3, TNF\u03b1 and granzyme-B levels were measured from the co-culture supernatants by ELISA.  Results: The percentage of membrane CD7 decrease from A, B and C-derived CD7traps was 50-90%, 40% and 10-40%; respectively. Thus, A-derived CD7trap (trap) was fused to B- or C-derived anti-CD7 CARs, obtaining CARCD7B-trap and CARCD7C-trap, respectively. T-cells modified with CARCD7B-trap showed a population doubling of 3.5, while this value reached 4.5 and 5 for CARCD7C-trap and untransduced control T-cells, respectively. The CAR expression was 10% for CARCD7B-trap and 30% for CARCD7C-trap. However, CARCD7B-trap eliminated the 90-100% of Jurkat-GFP and the 80-90% of MOLT4-GFP target cells, while the CARCD7C-trap was ineffective. These data agreed with ELISA results.  Conclusions: We have developed a CD7trap, derived from A scFv, that avoids CD7 trafficking to the  \n  \nmembrane and prevents fratricide.  CARCD7B-trap seemed to be the best candidate for future approaches to develop an anti-CD7 CAR T-cell therapy against T-cell malignancies due to its anti-tumor capacity and fratricide resistance.                                                  \n  \nP-108  PRE-TCR-SPECIFIC CAR-PT\u0391 T CELLS AS A NOVEL IMMUNOTHERAPY FOR T-ALL  Bay\u00f3n-Calder\u00f3n, F\u00e1tima; Fuentes, Patricia; Cela Rodr\u00edguez, Carmela; Alcain, Juan; Toribio, Mar\u00eda L.; Gonz\u00e1lez-Garc\u00eda, Sara.  CBMSO, Madrid.  Introduction: T-ALL is an aggressive haematological malignancy mostly affecting children. Still, high rates of relapse with ineffective options for refractory disease and poor clinical outcomes are associated with T-ALL. Therefore, there is an urgent need for developing novel, effective and safe therapies to improve life expectancy of T-ALL patients. T-cells engineered to express chimeric antigen receptors (CARs) against tumours have emerged as a powerful tool against refractory haematopoietic malignancies. However, CAR-T therapy for T-ALL has been puzzling due to the shared antigen expression between malignant and healthy T-cells, which can lead to CAR T-cell fratricide and T-cell aplasia, resulting in impaired anti-tumour efficacy and life-threatening immunodeficiency. Therefore, identification of antigens exclusively expressed in T-ALL blasts is critical for CAR-T cell development against T-ALL. Objective: We aimed at developing and preclinically validating a CAR-T immunotherapy, based on a surface antigen specifically expressed on distinct T-ALL subgroups, the pre-TCR complex. As we showed that the pre-TCR is involved in human T-ALL pathogenesis and progression, our anti-pre-TCR strategy may represent a specific, safe and efficacious CAR-T immunotherapy for T-ALL treatment. Results: Taking advantage of a mAb developed in our lab against the pT\u03b1-chain of the human pre-TCR, we produced a second-generation CAR-pT\u03b1 (CD28TM-CD28IC-CD3\u03b6IC). After validating its specificity, cytotoxic potential and pro-inflammatory cytokines production by CARpT\u03b1 primary T-cells was confirmed in in vitro functional assays. The efficacy of this novel immunotherapy was also validated in vivo in preclinical assays, showing that administration of CAR-pT\u03b1 T-cells hampers tumour progression of both pre-TCR+ T-ALL cell lines and patient-derived leukaemias, resulting in increased overall mice survival. Moreover, CAR-pT\u03b1 T-cells persisted in vivo for long periods in the infused animals. Collectively, we provide proof of concept that our CAR-T therapy against the pre-TCR can be an effective strategy for the treatment of a significant number of T-ALL patients.        \n  \n P-109  DEVELOPMENT OF GENE-MODIFIED T-CELLS TO EXPRESS SPECIFIC T-CELL RECEPTORS (TTCR) FOR THE RECOGNITION OF INTRACELLULAR TUMOR ANTIGENS PRESENTED ON CLASS II MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULES.  Casanovas Albert\u00ed, Berta1; Gonz\u00e1lez Navarro, Europa Azucena2; Hern\u00e1ndez Jim\u00e9nez, Enrique1; Bartol\u00f3 Ibars, Ariadna1; Betriu, Sergi1; Pascal, Mariona2; Juan, Manel2.  1Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Hospital Cl\u00ednic de Barcelona, Barcelona; 2Immunology Department, Centre de Diagn\u00f2stic Biom\u00e8dic (CDB), Hospital Cl\u00ednic de Barcelona, Barcelona.  Natural transgenic T-cell receptors (tTCR) represent an emergent type of cell therapy against cancer, recognizing peptides expressed both on the intracellular and extracellular level. The capacity to recognize intracellular antigens constitutes a significant advantage in comparison to chimeric antigen receptor (CAR) therapy that can only recognize extracellular surface proteins, which are difficult to define as Tumor Associated Antigens (TAA), especially on solid tumors. However, it must be taken into consideration that TCR therapies against TAAs could potentially generate off-tumor on-target toxicity. In order to prevent this risk, this work is focused on New York Esophageal Squamous cell carcinoma Origin 1 (NY-ESO-1), from the cancer/testis antigen family, expressed on several types of tumors but not relevantly on healthy tissues besides testicles. Several tTCR clinical trials targeting NY-ESO-1 have been performed, but all of them are focused on peptide presentation to class I HLA (Human Leukocyte Antigen) molecules. However, we focus our work on TCR recognizing peptides presented on class II HLA, although collaborating with other T-cells focused against class I HLA. By developing a TCR that is able to recognize NY-ESO-1 presented on HLA-II, we are looking for a TCR against a NY-ESO-1 peptide presented by the allele HLA-DRB3*02:02 (DR52b), expressed approximately by half of the Caucasian population in a similar way to HLA-A*02:01 (the most frequent allele of the class I HLA), for which many more studies have been performed. Other studies determined that stimulation of T-cells from patients with NY-ESO-1 peptides triggers a CD4+ T-cell-specific immune response, restricted to HLA-DR52b and with a preserved TCR repertoire. It remains important to develop research enabling the generation of new TCR therapies that can recognize intracellular antigens presented by HLA-II, that can be useful to a high percentage of population and that can be applicable to several types of tumors.        \n  \nP-110  SYNAPSE TOPOLOGY AND DOWNMODULATION EVENTS DETERMINE THE FUNCTIONAL OUTCOME OF ANTI-CD19 T CELL-REDIRECTING STRATEGIES  Ramirez Fernandez, Angel1; Aguilar Sope\u00f1a, Oscar2; Diez Alonso, Laura1; Segura Tudela, Alejandro1; Arroyo Rodenas, Javier1; Dominguez Alonso, Carmen1; Roda Navarro, Pedro2; Alvarez Vallina, Luis1; Blanco, Belen1.  1Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid; 2Department of Immunology, Ophthalmology and ENT, School of Medicine, Universidad Complutense, Madrid.  Immunotherapeutic approaches focused on the redirection of T cell activity toward tumor cells are actively being investigated. Strategies based on the endogenous secretion of T cell redirecting bispecific antibodies by engineered T lymphocytes (STAb-T) are emerging as alternative or complementary approaches to those based on chimeric antigen receptors (CAR-T). The anti-tumor efficacy of bispecific anti-CD19 x anti-CD3 (CD19xCD3) T cell engager (BiTE)-secreting STAb-T cells has been demonstrated in several mouse models of B cell acute leukemia. Here, we have investigated the spatial topology and downstream signaling of the artificial immunological synapses (IS) that are formed by CAR-T or STAb-T cells. Upon interaction with CD19-positive target cells, STAb-T cells form IS with structure and signal transduction which more closely resemble those of physiological cognate IS, compared to IS formed by CAR-T cells expressing a second-generation CAR bearing the same CD19-single-chain variable fragment. Importantly, while CD3 is maintained at detectable levels on the surface of STAb-T cells, indicating sustained activation mediated by the secreted BiTE, the anti-CD19 CAR was rapidly downmodulated, which correlated with a more transient downstream signaling. Furthermore, CAR-T cells, but not STAb-T cells, provoked an acute loss of CD19 in target cells. Such differences might represent advantages of the STAb-T strategy over the CAR-T approach and should be carefully considered in order to develop more effective and safer treatments for hematological malignancies.              \n  \nP-111  DEVELOPMENT OF A NOVEL IMMUNOTHERAPY BASED ON NANOBODIES TARGETING FUNGAL GLUCANOSYLTRANSFERASES FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS AND CRYPTOCOCCOSIS   Redrado, Sergio1; Dolader, Elena1; Mac\u00edas, Javier2; Domingo, Mar\u00eda Pilar1; Esteban, Patricia1; Arias, Maykel3; Ram\u00edrez, Ariel3; Hurtado, Ram\u00f3n2; Pardo, Juli\u00e1n3; G\u00e1lvez, Eva Mar\u00eda1.  1ICB-CSIC, Zaragoza; 2IIS Arag\u00f3n CIBA, Zaragoza; 3CIBA, Zaragoza.  The incidence of opportunistic fungal infections has significantly increased over the last two decades due to a growing number of immunocompromised patients, being Aspergillus spp and Cryptococcus spp the main responsible for these infections and the cause of greatest number of deaths. Elevated mortality rates mainly due to late non-specific diagnosis and emerging antifungal resistance highlight the importance of finding new therapeutic alternatives. Here we have developed a new nanobody (Nb3) targeting a \u03b2-1,3-glucanosyltransferase, Gel4, a key fungal enzyme involved in cell wall remodeling that has been previously shown to be essential for fungal survival. We have found out that Nb3 is able to cross the fungal cell wall reaching its target, Gel4, located at the cell membrane, exerting fungistatic in vitro activity against several strains from Aspergillus fumigatus and Cryptococcus neorformans including azole-resistant strains. In addition, using in vivo mouse models of Aspergillus and Cryptococcus infections we show that therapeutic administration of Nb3 in infected animals is highly effective and significantly increases animal survival, correlating with a reduction of fungal burden in lung and brain. Importantly, in vivo biodistribution analysis shows that Nb3 is able to cross the blood-brain barrier reaching the brain which is the main organ affected during Cryptococcus infections. Our results present a novel class of compounds to treat lethal fungal infections and provide the basis to further develop other immunotherapy treatments based on Nb3 (i.e. Nb3-based CAR cells) to effectively treat invasive fungal infections. Nb3 and related treatments present a safe and efficient alternative to overcome increasing antifungal drug resistance and reduce morbidity and mortality of a high number of patients at risk of these infections including cancer, UCI and transplantation.            \n  \nP-112  CART CELL DETECTION: COMPARISON, PROS AND CONS OF THE TWO MOST COMMONLY USED TECHNIQUES.   Valdivieso Shephard, Juan1; Matas P\u00e9rez, Elisabet1; L\u00f3pez Granados, Eduardo2; Garc\u00eda Bujalance, Silvia3; Mirones Aguilar, Isabel4; Gonz\u00e1lez Mart\u00ednez, Berta5; P\u00e9rez-Mart\u00ednez, Antonio5; Mart\u00ednez Feito, Ana6; S\u00e1nchez Zapardiel, Elena7.  1Department of Immunology, La Paz University Hospital, Madrid, Spain., Madrid; 2Department of Immunology, La Paz University Hospital, Madrid, Spain. La Paz Institute of Biomedical Research, Group 22, Madrid, Spain. Center for Biomedical Network Research on Rare Diseases (CIBERER U767), Madrid, Spain., Madrid; 3Department of Microbiology, La Paz University Hospital, Madrid, Spain., Madrid; 4Translational Research Unit in Paediatric Haemato-Oncology, Hematopoietic Stem Cell Transplantation and Cell Therapy, La Paz University Hospital, Madrid, Spain., Madrid; 5Translational Research Unit in Paediatric Haemato-Oncology, Hematopoietic Stem Cell Transplantation and Cell Therapy, La Paz University Hospital, Madrid, Spain. Department of Paediatric Haemato-Oncology, La Paz University Hospital, Madrid, Spain., Madrid; 6Department of Immunology, La Paz University Hospital, Madrid, Spain. La Paz Institute of Biomedical Research, Group 19, Madrid, Spain., Madrid; 7Department of Immunology, La Paz University Hospital, Madrid, Spain. La Paz Institute of Biomedical Research, Group 22, Madrid, Spain., Madrid.  The genetic modification of autologous T lymphocytes to express a chimeric membrane protein directed against a specific cell antigen, currently known as CAR-T cell therapy, is revolutionizing the treatment of many hematologic malignancies and is expected to be approved for so many more, as solid tumors or autoimmune diseases.  We present a comparison between the two most used flow cytometry techniques for CAR-T cell therapy monitorization and characterization.  The first one (protocol A) is based on the use of anti-mouse IgG-Fab antibody, which binds the chimeric portion of the CAR-T construction. The second one (protocol B) consists in a human CD19 extracellular domain and a mutated human IgG1-Fc region that constitutes a biotinylated antigen-based fusion protein, which can be detected by an anti-biotin antibody conjugated to a fluorochrome. Viral load(copies/\nL) was determined by qPCR in peripheral blood.  We analyzed a negative control, 3 infusion products(IP) and 5 peripheral blood(PB) from infused patients(median days post-infusion 12 IQR 9-16). As expected, in both protocols median %CD3+CART+ was higher in the IP compared to PB, nevertheless protocol B showed higher %CD3+CART+ for both sample types (protocol A, IP 8.33 IQR 4.17-9.95 vs PB 0.77 IQR 0.50-1.09; protocol B, IP 18.28 IQR 15.98-19.15 vs PB 7.85 IQR 0.15-88.17). Negative control rendered higher background when using protocol A vs B (2.19 vs 0.20 %CD3+CART+). Interestingly, peripheral blood samples with viral load under 104 copies/\nL  \n  \nshowed a %CD3+CART+ below the background.  In conclusion, protocol B was selected for a more sensitive follow-up of CAR-T therapy by flow cytometry in our laboratory. Despite this is just a modest observation, the wide range of options and the rapid implementation of new therapies makes it clear that it is necessary the standardization across the health care system, in order to magnify the evidence, which may help us to understand and improve patient outcomes.                                               \n  \nP-113  A NEW CAR-T ANTI-IL13R\u03912 AS AN OPTION FOR TREATING GLIOBLASTOMA  Vazquez, Mario1; Ortiz De Land\u00e1zuri Pascal, I\u00f1aki1; Altuna, Ane1; Barcia, Carlos2; Engel, Pablo3; Morales, Andr\u00e9s4; Juan, Manel5; Calder\u00f3n, Hugo5; Uribe, Mireia1.  1IDIBAPS, Barcelona; 2Universidad Aut\u00f3noma de Barcelona, Cerdanyola del Vall\u00e8s; 3Universitat de Barcelona, Barcelona; 4Hospital Sant Joan de D\u00e9u, Barcelona; 5Hospital Cl\u00ednic de Barcelona, Barcelona.  Background: Gliomas are the most common type of primary neoplasms in the central nervous system, being glioblastoma (GBM) the most frequent and malignant form.  With the current treatment, only 7% of patients survive more than 5 years. New therapeutical approaches based on immunotherapy have shown promising results, particularly CAR-T cells directed against the Interleukin 13 receptor alpha2 (IL13R\u03b12), a marker that has been described to be overexpressed in GBM. Methods: (A) After obtaining several anti-IL13Ra hybridomas, to determine our single chain variable fragment sequence from these hybridoma cells, we amplified and sequenced their DNA sequences by PCR and via Sanger method, respectively. (B) Cloning determined sequences into plasmid expression vectors to generate lentiviral vectors for the different CAR constructs. (C) Gene engineering by transduction of donor human T-cells to assess proliferation upon CD3/CD28 stimulation and CAR surface expression (D) Testing of our CAR-T cytotoxic capacity and specificity against cell lines with different IL13Ra2 expression using the XCelligence Real Time Analyzer\u00ae. Results:  A total of 3 different donors were used to assess CAR expression and proliferation, obtaining proliferation results within the accepted range and proper CAR surface expression after 9 days of expansion. These same 3 donors were used to assess cytotoxic capacity, CAR-T cells showed a good killing capacity when confronted with U87MG cell line. When confronted against different cell lines that do not express the IL13Ra2, CAR-T cells did not show any cytotoxic effect. Conclusions: Our engineered CAR T cells demonstrated to have a good T cell proliferation fitness and CAR surface expression. Our CAR-T cells demonstrated a promising and specific cytotoxic capacity against a IL13R\u03b12 glioblastoma-derived cell line.           \n  \nP-115  CLINICAL DEVELOPMENT OF TRANSPOSON-BASED CAR T THERAPY FOR LYMPHOMA TREATMENT.   Calvi\u00f1o-Sampedro, Cristina1; D\u00edez, Bego\u00f1a2; Fern\u00e1ndez-Garc\u00eda, Mar\u00eda2; Hernando, Miriam2; \u00c1lvarez, Lara2; Lozano, Mluz2; Rodriguez-Diaz, Saray3; Martinez-Turrillas, Rebeca3; Jauregui, Patricia1; Iglesias, Elena3; San Martin-Uriz, Patxi3; Ceballos, Candela4; L\u00f3pez-Corral, Luc\u00eda5; Navarro, Almudena5; Alfonso, Ana1; Rif\u00f3n, Jose1; Serrano, Juana6; Llamas, Pilar6; Viguria, Mar\u00eda Cruz4; Redondo, Margarita4; Juan, Manel7; S\u00e1nchez-Salinas, Andr\u00e9s8; S\u00e1nchez-Guijo, Ferm\u00edn5; Rodr\u00edguez-Madoz, Juan R3; Inog\u00e9s Sancho, Susana9; L\u00f3pez-D\u00edaz De Cerio, Ascensi\u00f3n9; Y\u00e1\u00f1ez, Rosa M10; Bueren, Juan A10; Pr\u00f3sper, Felipe11.  1Hematology and Cell Therapy Department, Cl\u00ednica Universidad de Navarra, IdiSNA, Pamplona; 2Hematopoietic Innovative Therapies Division, Centro de Investigaciones Energ\u00e9ticas Medioambientales y Tecnol\u00f3gicas/Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIEMAT/CIBERER), Unidad Mixta de Terapias Avanzadas, IIS Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid; 3Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, CIBERONC, Pamplona; 4Servicio de Hematolog\u00eda, Hospital Universitario de Navarra, IdiSNA, Pamplona; 5Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USALCSIC), Salamanca; 6Division of Hematology and Hemotherapy, IIS Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid; 7Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Department of Immunology and Cell Immunotherapy Platform HSJD-HCB. UB, Hospital Cl\u00ednic de Barcelona, Barcelona; 8Deparment of Hematology, Stem Cell Transplant and Cell Therapy Unit, IMIB-Arrixaca, Virgen de la Arrixaca University Hospital, University of Murcia, Murcia; 9Hematology and Cell Therapy Department and Immunology and Inmunotherapy Department. Cl\u00ednica Universidad de Navarra, IdiSNA., Pamplona; 10Innovative Therapies Division, Centro de Investigaciones Energ\u00e9ticas Medioambientales y Tecnol\u00f3gicas/Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIEMAT/CIBERER), Unidad Mixta de Terapias Avanzadas, IIS Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid; 11Hematology and Cell Therapy Department, Cl\u00ednica Universidad de Navarra, IdiSNA. Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, CIBERONC., Pamplona.  In the TranspoCART project we have developed an innovative CAR T cell product (TranspoCART19 cells) based on a viral vector-free gene-transfer strategy using the Sleeping Beauty (SB) transposon system, that presents high transduction efficiencies with a safe integration profile and a significantly reduced production cost compared to conventional protocols based on viral vectors. For TranspoCART19 cell generation, T cells are engineered with SB minicircles carrying a second generation CAR construct targeting CD19 with a 41BB\nE endodomain and a truncated human epidermal growth factor receptor (EGFRt) as a safety switch. Our optimized manufacturing protocol showed transduction efficiency ranged between 30 and 70% in both healthy donors and patients\u2019 samples, with great expansion rates (between 15.2x and 26x), compatible with clinical applications. Extensive in vitro characterization of TranspoCART19 cells showed an enriched stem-cell memory/central memory phenotype, no signs of cell exhaustion and high level of specific cytotoxicity activity against tumoral cell lines and primary tumor cells expressing CD19. Dilution of SB minicircle  \n  \nand transposase protein during cell manufacturing process was confirmed, with no detectable levels of both components at the end of the expansion period. In vivo antitumoral efficacy of TranspoCART19 cells was evaluated using xenograft mice model using immunodeficient NSG mice. Animals treated with TranspoCART19 cells showed improved survival compared to untreated mice, similar to the one observed in mice treated with lentivirus-produced CAR T cells. Biodistribution and toxicity studies showed that TranspoCART19 cells administration is safe. Moreover, in vivo functionality of the safety switch with EGFRt was demonstrated with the complete depletion of TranspoCART19 cells after cetuximab administration. Finally, scale-up GMP manufacturing was validated in two independent GMP facilities, demonstrating that our protocol is highly efficient and reproducible. These encouraging results will support our clinical trial with TranspoCART19 cells for the treatment of lymphoma.                                       \n  \nP-116  SEMLIKI FOREST VIRUS-BASED VACCINES ENCODING CAR ANTIGENS TO FOSTER THE ACTIVATION, EXPANSION AND ANTITUMOR EFFICACY OF CAR-T CELLS  Rodriguez, M. Luis; Capozzi, Roberto; Covo, Angela; Conde, Enrique; Vercher, Enric; Manche\u00f1o, Uxua; Elizalde, Edurne; Lasarte, Juan J.; Smerdou, Cristian; Hervas-Stubbs, Sandra.  Centro De Investigaci\u00f3n Medica Aplicada, Pamplona.  Chimeric antigen receptor (CAR) T (CAR-T) cells represents a revolutionary treatment for hematological tumors but this success has not been extrapolated to solid tumors. The activation and expansion of transferred cells in vivo is key for the success of CAR-T therapy, with both phenomena being highly dependent on the recognition of the target antigen (Ag). In the case of solid tumors, target Ag recognition occurs exclusively in the tumor, but the immunosuppressive microenvironment prevents the efficient activation and expansion of CAR-T cells. Furthermore, CAR-T cells require a relatively high level of Ag expression to be adequately activated and this makes their activation inefficient when tumor cells express low Ag levels. We believe that the promotion of CAR-T-cell activation through off-tumor recognition of the target Ag may substantially improve the efficacy of CAR-T therapy in solid tumors. This may be safely achieved using vaccines able to deliver the target Ag. To test our hypothesis, we chose a CAR tumor Ag with low surface density expression, such as gp75 expressed in B16 melanoma cells. In an immunocompetent mouse model we studied the role of a Semliki Forest virus (SFV)-based vaccine encoding a mutant gp75 protein (gp75mut), which exhibits enhanced surface expression, to foster the antitumor efficacy of CAR-T cells. We demonstrate that SFVgp75mut vectors increased the activation and expansion of cognate CAR-T cells in vitro. Moreover, intratumoral (IT) administration of SFVgp75mut vaccine strongly increased the number of gp75CAR-T cells within the tumor. More importantly, SFVgp75mut in combination with gp75CAR-T cells delayed tumor growth and enhanced overall survival. Interestingly, the CAR-T/SFVgp75mut combination also exerted antitumoral effect on distal, non-SFVgp75mut-treated tumors. Our data show that the administration of SFV-based vaccines increase the therapeutic efficacy of CAR-T therapy in solid tumors, with the local administration of these vaccines being even able to exert abscopal effects          \n  \nP-117  GALECTIN-1 AS A NOVEL MODULATOR OF REGULATORY T CELL FUNCTION IN TREG CELL-BASED THERAPY IN CHRONIC COLITIS      Fern\u00e1ndez P\u00e9rez, Raquel; S\u00e1nchez, Rebeca; Aberquilla, Omaira; Mart\u00edn Rey, Miguel A.; Bueren, Juan A.; Garin, Marina I.  CIEMAT / IIS-F Jim\u00e9nez D\u00edaz, Madrid.  Cell therapy with regulatory T cells (Tregs) is under intense development thanks to their potential to maintain peripheral tolerance and their capacity to modulate unwanted immune responses. Galectin-1 (Gal-1) is a \u03b2-galactoside-binding protein that has broad anti-inflammatory and pro-resolving activities by targeting glycoproteins expressed by immune cells. We have previously demonstrated that Gal-1 is expressed by regulatory T cells and contributes to their immunosuppressive function in vitro. In this study, we analyzed the ability of galectin-1 deficient CD4+CD25+Foxp3 Tregs (Lgals1-/- Tregs) to suppress gastrointestinal immune responses using a T-cell transfer model of experimental colitis to study their functionality in vivo. Lgals1-/-Tregs showed reduced immunomodulatory capacity compared to wild type Tregs, as suggested by the increase number of Lgals1-/- Tregs required to modulate intestinal inflammation induced by na\u00efve CD4+ T cells into Rag-1-/- mice. In addition, long-term survival of colitic mice treated with Lgals1-/- Tregs was compromised with respect to colitic mice treated with wild type Tregs mainly due to a systemic decline in Lgals1-/- Tregs, which paralleled to an increase in Th17 T cells frequencies in colon lamina propria and in spleen. These results indicate that galectin-1 is a key effector molecule in Tregs that is also required for long-term protection in chronic colitis. In summary, an adequate expression of galectin-1 should be analyzed in future cell therapy protocols with Tregs in inflammatory bowel disease.                    \n  \nP-118  A PHASE I/II STUDY TO EVALUATE A POINT-OF-CARE MANUFACTURED ANTI-CD19 CAR T IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)   Alserawan, Leticia1; Betriu, Sergi2; Espa\u00f1ol-Rego, Marta2; De Guzman, Catherine1; Guijarro, Carla1; Cabez\u00f3n, Raquel1; Egri, Natalia2; Ortiz De Landazuri, I\u00f1aki2; Cid, Joan3; Ben\u00edtez-Ribas, Daniel2; Lozano, Miquel3; Pascal, Mariona2; Van Muyden, Anna4; Juan, Manel5; Delgado, Julio6.  1Department of Immunology (CDB) Hospital Cl\u00ednic de Barcelona, Barcelona; 2Department of Immunology (CDB) Hospital Cl\u00ednic de Barcelona, IDIBAPS, Barcelona; 3Hemotherapy and Hemostasis Department (ICMHO) Hospital Cl\u00ednic de Barcelona, IDIBAPS, Barcelona; 4Cellpoint B.V., The Netherlands, Oegstgeest; 5Department of Immunology (CDB) Hospital Cl\u00ednic de Barcelona, IDIBAPS, Universitat de  Barcelona, Barcelona; 6Department of Hematology (ICMHO) Hospital Cl\u00ednic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona.  Introduction CLL/SLL are similar types of B-cell non-Hodgkin lymphoma (NHL) usually with an indolent course and today incurable. Patients who develop relapsed/refractory disease and become resistant have a poor prognosis and new therapeutic strategies are needed. Adoptive cell therapy with T-cells expressing chimeric antigen receptors (CAR) targeting CD19 is a well-established approach for the treatment of B-cell malignancies. Despite there are anti-CD19 CAR T-cell products currently available, none has been approved for CLL/SLL yet.  We present a clinical trial with a new CART-CD19 product for CLL/SLL (BCN-CP01), a follow-on product of CARTCD19-ARI0001 developed by our institution. Both have the same CAR design but differ in manufacturing process. BCN-CP01 is manufactured with the Cocoon\u00ae bioreactor (Lonza), a closed automated instrument suitable for decentralized, point-of-care manufacturing, optimized towards fresh administration with a short vein-to-vein time (1 week).  Methods  The study is a multicenter, non-randomized, open-label study with a Dose escalation phase (Phase I) and Dose expansion phase (Phase II). The main objective of phase I is to evaluate safety, preliminary efficacy and to establish the recommended phase II-dose of BCN-CP01. Dose escalation will follow the Bayesian Optimal interval (BOIN) design, based on the occurrence of dose-limiting toxicities evaluated during a 28-day period. Three dose levels are evaluated in 15 patients: low, medium and high. The primary objective of phase II is to evaluate efficacy, measured by the objective response rate (ORR). Secondary objectives include further  \n  \nassessment of the safety profile and efficacy endpoints such as duration of response, PFS, OS, as well as the feasibility of point-of-care BCN-CP01 manufacturing with Cocoon\u00ae from patient-derived starting material.  Conclusion Recruiment of patients on-track and awaiting clinical results. Cocoon manufacturing successful with a 7 day vein-to-vein time, offering a fast alternative process for CAR-T manufacturing. (Sponsored by CellPoint, a Galapagos Company; Euplagia-1/CP0101-CLL, EU registration number 2021-003815-25).                                           \n  \nP-119  STUDY OF TCR DIVERSITY IN BREAST CANCER PATIENTS TREATED WITH ACTIVE IMMUNOTHERAPY   Hato Alvaro, Laura; L\u00f3pez, Ascensi\u00f3n; Herv\u00e1s, Sandra; Conde, Enrique; Mejias, Luis; Santisteban, Marta; Inog\u00e9s, Susana.  Cl\u00ednica Universidad de Navarra, Pamplona.  Introduction Breast cancer is the most common oncology disease in women. Lack of therapeutic efficacy in some subtypes makes it necessary to develop new strategies. We design a clinical trial to evaluate the clinical efficacy of the combination of standard treatment with monocyte-derived dendritic cells vaccines (DCV) preloaded with autologous tumour lysate in patients with BC without HER2 overexpression. T lymphocytes mediate the cellular immune response and their function is an essential component in the humoral immune response. T cells recognize the antigen through their surface receptor (TCR) and this is a powerful tool to rapidly expand and activate functional properties of the specific clon of T cells that has recognized the antigen. The study of the TCR repertoire could be a useful tool to detect specific activation of the immune system after treatment with DCV.  Objectives To determine whether DCV induces changes in the TCR repertoire that may indicate activation of a specific response by flow cytometry and sequencing, and to compare both techniques.  Methods Peripheral blood mononuclear cells were collected from 12 patients before and after treatment and TCR diversity was evaluated by flow cytometry and next generation sequencing. Various diversity index were calculated to determine the diversity/clonality of the samples.  Results Baseline samples from patients with very good clinical response (VGCR) (pT4/5 with Miller&Payne classification; pN0) showed greater TCR diversity that no-VGCR. Moreover, the change in diversity indices for both flow cytometry and sequencing suggests that there is a decrease in diversity and an increase in clonality of T cells.  Conclusion Our data provide strong support that vaccines induce an oligoclonal expansion of T cell. Since  \n  \nthe results of both techniques are similar, it can be concluded that cytometry, which is a simpler technique available in most laboratories, is a useful tool for studying the TCR repertoire.                                                     \n  \nP-120  AIDPATH: AI METHODS FOR PRODUCTION SCHEDULING AND RESOURCE MANAGEMENT  Navarro Vel\u00e1zquez, Sergio1; Csan\u00e1d Cs\u00e1ji, Bal\u00e1zs2; Kis, Tam\u00e1s2; Kis, Kriszti\u00e1n2; Juan Otero, Manel1.  1Hospital Cl\u00ednic de Barcelona, Barcelona; 2Sztaki (Sz\u00e1m\u00edt\u00e1stechnikai \u00c9s Automatiz\u00e1l\u00e1si Kutat\u00f3int\u00e9zet), Budapest.  The EU consortium AIDPATH is dedicated to enable and to augment the next-generation of personalised medicine with gene-engineered immune cells at EU hospitals through the use of AI technology. The exemplary embodiment of gene-engineered immune cells in AIDPATH will be T cells, modified to express a synthetic chimeric antigen receptor (CAR-T), which are already a revolutionary novel treatment in haematology and oncology. AIDPATH will apply AI technology to integrate personnel, hospital sites, materials and patient-specific data to optimise production scheduling and resource planning, to reduce costs and to ensure the effective utilisation of hospital resources. In the case of resource management for personalized CAR T-cell therapies, tasks are the medical procedures which have a strict order of precedence. The resources are the medical equipment that is used for a given procedure and the medical staff, doctors and nurses, who perform these procedures. We have determined several possible optimization objectives for the CAR T-cell therapy, such as minimizing the number of protocol deviations or the number of patients who drop out from the therapy. The main feature of the resource management software will be to generate a close-to-optimal patient and medical staff schedule every time a new schedule is needed. As the high-level overview of the resource management, the simulation model highly relies on real life datasets about ongoing CAR-T therapies. These datasets are used for building, fine-tuning, and validating the simulation model, in order to best describe the real process. During later stages of the project, a reinforcement learning (RL) based resource management strategy will be developed, which will be trained on the simulation model of the hospital environment.              \n  \nP-275  INFECTIOUS BURSAL DISEASE VIRUS AS A POTENTIAL ONCOLYTIC VIROTHERAPY AGAINST GLIOBLASTOMA AND OTHER CANCER CELL TUMOR MODELS  Tur Planells, Vicent1; Bykov, Yonina2; Palac\u00edn Aliana, Irina3; Garc\u00eda Romero, Noemi3; Dawodu, Gloria2; Ayuso Sacido, \u00c1ngel3; Rodr\u00edguez, Jos\u00e9 F4; Rodr\u00edguez, Dolores4; Garc\u00eda Sastre, Adolfo2; Cuadrado Casta\u00f1o, Sara2; Nistal Vill\u00e1n, Estanislao5.  1Universidad CEU San Pablo, Madrid; 2Department of Microbiology, Icahn School of Medicine at Mount Sinai, Nueva York; 3Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Madrid; 4Molecular and Celular Biology Department, Centro Nacional de Biotecnolog\u00eda-CSIC, Madrid; 5Microbiology Section, Department Pharmacological and Health Sciences, Facultad de Farmacia, Universidad CEU San Pablo, Madrid.  Glioblastoma is considered the most aggressive type of central nervous system (CNS) cancer. Current therapies such as temozolomide (TMZ) do not offer a life expectancy greater than 15 months, while other cancers such as colon carcinoma still do not have a consolidated therapy. The use of oncolytic viruses (OVs) is an immune-related therapeutic strategy based on the selective destruction of cancer cells lacking or with limited anti-viral innate immune mechanisms, leaving non-tumoral cells as barrier controlling virus growth without cell damage. In this work, we propose the potential use of infectious bursitis disease virus (IBDV) as a novel virotherapy. IBDV is a bird pathogen causing the Gumboro disease and is not pathogenic in humans. We have tested and compared the oncolytic effect of IBDV with the reference Newcastle disease virus (NDV) in several tumor models in vitro and in vivo. Results indicate a potential oncolytic activity of IBDV in several cancer types such as glioblastoma (CT-2A and GL261), melanoma (B16-F10), colon carcinoma (CT26) and B cell lymphoma (A20). In all cell lines tested, IBDV has the ability to infect, replicate and kill cancer cells as well as stimulate pro-inflammatory cytokines that may potentially trigger the activation of the immune system against both, the virus and the tumor. Finally, we have used Flow Cytometry to study in more detail the innate and adaptative immune responses of Glioblastoma after IBDV infection in vivo, characterizing the immune profile within the Tumor Microenvironment (TME).          \n  \nSesi\u00f3n Poster. Autoinmunidad (I). Pantalla 1  P-135  A DIFFERENT CONSULTATION WITH THE CLINICAL IMMUNOLOGIST: SUSPICION OF HETEROPHILIC ANTIBODIES AS A CAUSE OF FALSE POSITIVE IN AN IMMUNOASSAY  Iturrieta Zuazo, Ignacio; Caja Guayerbas, Laura; Veiga Gonz\u00e1lez, Jos\u00e9 Luis; Menacho Rom\u00e1n, Miriam; Carrasco Sayalero, Angela.  Hospital Universitario Ram\u00f3n y Cajal, Madrid.  The case of consultation referred from the oncology service is described, in which a 38-year-old patient with a history of stage IIA embryonal testicular carcinoma in remission and sarcoidosis, was requested to be evaluated due to suspicion of a false-positive serum beta-human chorionic gonadotropin (BhCG) determination. BhCG is a sensitive and specific marker for tumors of germ cell origin. Thus, treatment of recurrent testicular carcinoma is often initiated on the basis of rising BhCG levels, even in the absence of clinical, radiological, or histological evidence of a relapse. Several causes for false-positive serum hCG levels have been reported in the literature and Heterophilic antibodies are mentioned as the most frequent. Heterophile antibodies can be IgG, IgM, and IgA isotypes that are poorly defined and react with a wide spectrum of antigens. These antibodies may develop after infections or contact with animal tissues or constituents. They may bind the animal antibodies used in an immunoassay and thus produce erroneous results. Such interference has been increasingly recognized as a diagnostic problem.  To study its possible presence, we carry out different analyzes in collaboration with the Clinical Biochemistry service: heterophile antibody assays based on erythrocyte agglutination, Indirect immunofluorescence assays for detection of autoantibodies AMA, ASMA,  LKM, or APCA in rat tissues and use of commercial blocking solutions. Finally, the presence of heterophile antibodies was confirmed as a cause of false positives by incubating the serum samples with solutions composed of immunoglobulins and other antigens that allow the fixing of heterophile antibodies.  Thus, it is important to note that although the frequency of heterophilic antibody interference is not very significant, recently reported cases to have a large magnitude of interference, affecting the clinical interpretation of test results. Therefore, the multidisciplinary management of these patients in reference centers is essential.   \n  \nP-136  CHARACTERIZATION AND CLINICAL ASSOCIATION OF AUTOANTIBODIES AGAINST PERILIPIN 1 IN PATIENTS WITH ACQUIRED GENERALIZED LIPODYSTROPHY Corvillo, Fernando1; Abel, Brent S.2; L\u00f3pez Lera, Alberto1; Ceccarini, Giovanni3; Magno, Silvia3; Santini, Ferruccio3; Ara\u00fajo Vilar, David4; Brown, Rebecca J.2; Nozal, Pilar5; L\u00f3pez Trascasa, Margarita6.  1Hospital La Paz Institute for Health Research (IdiPAZ); Center for Biomedical Network Research on Rare Diseases, Madrid; 2National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda; 3Obesity and Lipodystrophy Center at the Endocrinology Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa; 4UETeM-Molecular Pathology Group. Department of Psychiatry, Radiology, Public Health, Nursing and Medicine, IDIS-CIMUS, University of Santiago de Compostela, Santiago de Compostela; 5Immunology Unit, La Paz University Hospital; Hospital La Paz Institute for Health Research (IdiPAZ); Center for Biomedical Network Research on Rare Diseases, Madrid; 6Departamento de Medicina, Universidad Aut\u00f3noma de Madrid; Hospital La Paz Institute for Health Research (IdiPAZ), Madrid.  Introduction: Acquired generalized lipodystrophy (AGL) is a rare condition characterized by massive loss of adipose tissue through the body, causing severe metabolic complications. Autoimmune destruction of adipocytes is strongly suspected based on the frequent association of AGL with autoimmune disorders. In 2018 autoantibodies against Perilipin 1 (PLIN1) were identified in three patients with autoimmune-associated AGL. However, the pathogenic mechanism and clinical impact of anti-PLIN1 remain unsolved. Objective: To characterize anti-PLIN1 autoantibodies and assess its clinical association in patients with AGL. Results: The prevalence of anti-PLIN1 autoantibodies in an AGL cohort of 40 patients was 50% (20/40). Among positive patients, ten had the autoimmune variety and ten had panniculitis-associated AGL. The IgG isotype was predominant although some IgM antibodies were detected. Epitope mapping studies did not identify a single, major epitope. Instead, autoantibodies typically bound to several different peptides, among which the central (233-405) domain was detected in all antibody positive patients, both for IgG and IgM autoantibodies. In-depth epitope mapping indicated that anti-PLIN1 autoantibodies predominantly recognize the ABHD5 binding site (383-405). Autoantibodies dose-dependently blocked the binding of PLIN1 to ABHD5 and caused a dislocation of ABHD5 towards cytosol, leading to an increase in lipolysis and lipase activities. Finally, anti-PLIN1 titers significantly correlated with the amount of fat loss, metabolic control impairment, and severity of the liver injury.  Conclusions: Our data strongly support that anti-PLIN1 autoantibodies are a diagnostic biomarker and a cause of lipodystrophy in patients with AGL.   \n  \nP-138  EVALUATION OF INDIRECT IMMUNOFLUORESCENT ASSAYS FOR LGI-1 ANTIBODY DETECTION IN PATIENTS WITH LGI1-ASSOCIATED ENCEPHALITIS   Mu\u00f1oz S\u00e1nchez, Guillermo; Planaguma, Jesus; Couso, Rocio; Ortiz De Landazuri, I\u00f1aki; Anton, Mari Carmen; Romera, Maria Antonia; Naranjo, Laura; Martinez Hernandez, Eugenia; Graus, Francesc; Dalmau, Josep; Ruiz Garc\u00eda, Raquel.  Hospital Clinic de Barcelona, Barcelona.  LGI1 autoantibodies are probably the most common cause of autoimmune limbic encephalitis and the second most common cause of autoimmune encephalitis. Detection of antibodies to neuronal surface proteins and synaptic receptors is important to establish a definitive diagnosis of autoimmune encephalitis. Herein, we assess the clinical performance of two antigen-specific indirect immunofluorescent assays (IIFA) for LGI-1 antibody detection in serum and CSF: 1) commercial IIFA with cells transfected with a GPI-LGI1 construct and 2) in-house IIFA with HEK293 cells co-transfected with LGI1 and ADAM23 constructs. We also evaluated whether CSF or serum is the most suitable sample to detect LGI1 antibodies by IIFA and Indirect Immuno Histochemistry (IIHC), employed as screening assay.  We retrospectively examined 70 patients with serum and CSF paired samples and a positive IIHC for LGI1 classic staining pattern in at least one of the two samples. From the 70 analyzed sera, 69 (98.5%) were positive by IIHQ, 66/70 (94.3%) were positive by commercial IIFA and 58/70 (82.8%) were positive by in-house IIFA assay. Regarding CSF samples analysis, 68/70 (97.1%) resulted positive by IIHC, 58/70 (82.8%) were positive by commercial IIFA while 70/70 (100%) CSF resulted positive when tested by in-house IIFA. All patients were positive for LGI-1 antibodies in CSF. The only way to detect all patients by antigen-specific test was by testing CSF by in-house IIFA (LGI-1 co-transfected with ADAM23). As screening method, the sensitivity of IHC (gold standard method) was similar when comparing sera (69/70) and CSF (68/70) testing.               \n  \nP-139  RHEUMATOID ARTHRITIS ASSOCIATED INTERSTITIAL LUNG DISEASE: THE ROLE OF NON-CRITERIA AUTOANTIBODIES  P\u00e9rez-Isidro, Albert1; Castellanos-Moreira, Raul2; Sarmiento-Monroy, Juan Camilo2; De Moner, Noem\u00ed1; Grundhuber, Maresa3; Vi\u00f1as, Odette1; Sanmart\u00ed, Raimon2; Ruiz-Ortiz, Est\u00edbaliz1.  1Immunology Department, Hospital Cl\u00ednic de Barcelona, Barcelona; 2Rheumatology Department, Hospital Cl\u00ednic de Barcelona, Barcelona; 3Thermo Fisher Scientific, Phadia GmbH, Freiburg.  Introduction Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic joint inflammation. RA-associated interstitial lung disease (ILD) is the most frequent and severe extra-articular manifestation and is associated with an increase of mortality. Rheumatoid Factor (RF-IgM) and anti-citrullinated peptide antibodies (ACPA-IgG) are important diagnostic tools included in the classification criteria (ACR/EULAR 2010). However, new biomarkers are still needed, to diagnose and predict patient\u2019s disease subsets and prognosis. The aim of this study was to analyse the prevalence and the association with RA-ILD of non-criteria isotypes of RF, ACPA and anti-hnRNP-A2/B1 (RA33) in Hospital-Cl\u00ednic Arthritis-Unit RA cohort.  Methods This cross-sectional study included 229 patients with definite RA (ACR/EULAR 2010 criteria). ILD was diagnosed after clinical suspicion and confirmed by high resolution computed tomography. Serum samples from all RA patients and 50 healthy controls were tested for IgM/IgG/IgA of RF, ACPA (CCP2 antigen) and RA33 using EliA Platform. Cut-offs values were established with 95%-specificity for healthy controls.  Results ILD was confirmed in 57 patients (RA-ILD). IgA isotype for ACPA (OR: 2.1 [1.1-4.0]), IgA-RF (OR: 2.8 [1.2-6.5]), as well as IgG-RF (OR: 2.8 [1.5-5.3]) were associated with ILD in RA. Combinations of non-criteria autoantibodies showed a wide sensitivity (70.2% - 36.8%) and specificity (84.3% - 50.0%) range for ILD in RA. Particularly, IgA-ACPA + IgA-RF + IgG-RF showed 52.6% sensitivity and 74.4% specificity.  Conclusions This study confirms the association of IgA-ACPA antibodies with RA-ILD, but no association with IgG-ACPA was observed. Moreover, both IgA-RF and IgG-RF are associated with RA- \n  \nILD. The results of the present study support the role of mucosal immunity in the development of ILD in patients with RA. Combinations of non-criteria autoantibodies could be useful to identify RA-ILD patients. More prospective studies to confirm the non-criteria autoantibodies predictive value for RA-ILD stratification are warranted.                                                \n  \nP-140  LA ACTIVIDAD DESMIELINIZANTE EN LOS PACIENTES CON EM SE ASOCIA A LA PRESENCIA DE LINFOCITOS EN EL SISTEMA NERVIOSO CENTRAL.   Mu\u00f1oz Mor\u00f3n, \u00darsula1; Sebal Neira, Cristina1; Escudero Lirola, Esther1; Esiri, Margaret2; Tzartos, John3; Sloan, Carolyn2; S\u00e1daba Argaiz, Maria Cruz1.  1Universidad San Pablo Ceu, Madrid; 2Neurpathology Department. John Radcliffe Hospital. Oxford, Oxford; 3Eginition Hospital Athens, Atenas.  Introducci\u00f3n: Los linfocitos B pueden jugar un papel fundamental en el desarrollo de la esclerosis m\u00faltiple (EM). Nosotros nos planteamos analizar la relaci\u00f3n entre el n\u00famero de linfocitos B y la actividad de las lesiones. M\u00e9todos: 71 necropsias obtenidas de pacientes con EM (n=14). An\u00e1lisis inmunohistoqu\u00edmico utilizando los anticuerpos anti-CD68 (actividad de la lesi\u00f3n), anti-CD79 (linfocitos B), anti-CD138 (c\u00e9lulas plasm\u00e1ticas y anti-IgG y anti-IgM. Resultados: El n\u00famero de linfocitos B era mayor en los espacios perivasculares de las lesiones agudas (2,32\n0,99) y activas (1,09\u00b10,31) que en las cr\u00f3nicas inactivas (C.I, 0,21\n0,06) y la sustancia blanca aparentemente normal (NAWM) (0,04\n0,020). En las meninges tambi\u00e9n se observ\u00f3 un incremento de linfocitos B en las agudas (19,63\n10,49) en comparaci\u00f3n con las lesiones C.I (2,16\n0,58) y NAWM (2,55\n2,49). Sin embargo, la proporci\u00f3n de c\u00e9lulas plasm\u00e1ticas era mayor en los espacios perivasculares de las lesiones cr\u00f3nicas activas (0,54\n0,16) y las lesiones C.I (0,50\n0,020) que en las lesiones agudas (0,13\n0,05) y la NAWM (0,02\n0,01). Las lesiones con dep\u00f3sitos de IgG ten\u00edan mayor n\u00famero de linfocitos en el espacio perivascular que las que no presentaban (1,24\n0,35 vs 0,36\n0,57) y tambi\u00e9n en el par\u00e9nquima (0,45\n0,13 vs 0,06\n0,05). Por el contrario, en las lesiones que hab\u00eda dep\u00f3sitos de IgM se observ\u00f3 un mayor n\u00famero de c\u00e9lulas plasm\u00e1ticas en el espacio perivascular (0,78\n0,21 vs 0,13\n0,04) y meninges (6,76\n2,28 vs 2,28\n0,093) en comparaci\u00f3n con las que no ten\u00edan. Conclusiones: La actividad desmielinizante aguda est\u00e1 relacionada con el n\u00famero de linfocitos B y la cr\u00f3nica con las c\u00e9lulas plasm\u00e1ticas. Es necesario el desarrollo de nuevos f\u00e1rmacos para regular a estas c\u00e9lulas residentes en el sistema nervioso central.              \n  \nP-141  ANTIPHOSPHOLIPID ANTIBODIES ARE CO-STARS IN COVID-19 THROMBOSIS, NOT MERE STONE GUESTS  Gil Etayo, Francisco Javier1; Garcinu\u00f1o, Sara2; Lalueza, Antonio1; D\u00edaz Sim\u00f3n, Raquel1; Perez Rivilla, Alfredo1; Pleguezuelo, Daniel1; Paz Artal, Estela1; Serrano, Antonio1.  1Hospital Universitario 12 de Octubre, Madrid; 2Instituto de Investigaci\u00f3n Biom\u00e9dica i+12, Madrid.  Background: Patients with COVID-19 present thrombophilia reminiscent of the antiphospholipid syndrome (APS), a disease characterized by vascular thrombosis, or gestational morbidity in carriers of antiphospholipid antibodies (aPL). The relationship between aPL-presence and the appearance of thrombi as well as the transience of aPL in COVID-19 has been extensively studied but with small patient samples and contradictory results. Methods: A group of 360 COVID-19 patients were recruited in the first 24 hours after diagnosis and followed-up for 6 months. Sidney\u00b4s Classic aPL (anti-cardiolipin or anti-B2GP1 IgG/M), as well as anti-phosphatidylserine/prothrombin IgG/M, anti-B2GPI IgA and anti-SARS-CoV-2 IgG antibodies were evaluated at diagnosis and >12 weeks later. A reference control group was created with 143 healthy volunteers of the same age-range distribution. Results: Prevalence of aPL in COVID-19 patients did not show significant differences with that observed in reference population, however COVID-19 patients positive for criteria aPL or IgA anti-B2GP1 had a higher incidence of thrombosis in the first weeks after infection (OR: 2.33, 1.03\u20135.29, p=0.043 and 3.71, 1.71\u20138.05, p=0.001).  Thrombosis non-aPL-associated occurred earlier after hospital admission (median 4 days, IQR: 3-7), however the aPL-associated appears later (median: 17 days, IQR:6-28, p=0.016). A strong agreement in aPL positivity at diagnosis and >12 weeks was observed for classic aPL and anti-B2GPI IgA (Weighted kappa: 0.92). COVID-19 did not seem to induce aPL de novo, since anti-SARS-CoV-2 antibodies levels increased during convalescence, aPL hardly changed.  Conclusions: In COVID-19 thrombosis at least two different mechanism could co-exist, an early immune-dysregulation-mediated thrombosis after infection and belated-aPL-mediated thrombosis, with SARS-CoV-2 behaving as a second hit. The presence of aPL in COVID-19 patients is not associated with the infection, they were pre-formed. The 27% of aPL carriers could develop thrombotic events, once infected of SARS-CoV-2.         \n  \nP-142  USO DE LIKELIHOOD RATIO EN LA INTERPRETACI\u00d3N DE LOS RESULTADOS DE ANTICUERPOS ANTI-RACH PARA EL DIAGN\u00d3STICO DE MIASTENIA GRAVIS.  Cantenys Molina, Sergi; Schiaffino Garc\u00eda-Villanova, Mar\u00eda Teresa; Alba Cano, Trinidad; Di Natale, Marisa; S\u00e1nchez-Mateos Rubio, Paloma.  Hospital General Universitario Gregorio Mara\u00f1\u00f3n, MADRID.  Introducci\u00f3n: Los anticuerpos anti-receptor de acetilcolina (anti-RACh) son criterio diagn\u00f3stico de Miastenia Gravis (MG). La t\u00e9cnica RIA es el gold standard para su detecci\u00f3n pero requiere equipamiento y personal cualificado. Una alternativa es el ELISA, pero presenta una menor especificidad. Nuestro objetivo es valorar si la raz\u00f3n de verosimilitud (likelihood ratio, LR) puede mejorar la interpretaci\u00f3n del ELISA de anticuerpos anti-RACh para el diagn\u00f3stico de MG.  Metodolog\u00eda: Se analizaron 666 peticiones de anticuerpos anti-RACh recibidas durante los a\u00f1os 2019-2022 (abril), que se categorizaron en pacientes (n=526) o controles (n=140) en funci\u00f3n de si ten\u00edan diagn\u00f3stico cl\u00ednico de MG. Se calcul\u00f3 la curva ROC, puntos de corte y el LR utilizando el programa estad\u00edstico GraphPad Prism v9.  Resultados: La sensibilidad y especificidad obtenida para el punto de corte establecido por el kit (0,45 nmol/L) fue 81% y 74%, respectivamente. El percentil 95% de los controles fue 0,69 nmol/L, muy similar al punto de corte de la zona gris establecida por el laboratorio previamente (0,45-0,68 nmol/L). El \u00e1rea bajo la curva fue 0,85 (IC95% 0,80-0,89). El LR por intervalos fue: LR=0,26 (Ac.Anti-RACh<0,45 nmol/L), LR=0,79 (Ac.Anti-RACh = 0,45-0,68 nmol/L), LR=1,25 (Ac.Anti-RACh = 0,68-1 nmol/L) y LR=102,75 (Ac.Anti-RACh>1 nmol/L). Conclusi\u00f3n: El uso del LR para informar resultados de tests de anticuerpos ha sido propuesto como un m\u00e9todo v\u00e1lido para transformar datos num\u00e9ricos en informaci\u00f3n cl\u00ednica. Nuestros resultados reflejan que el LR se aproxima m\u00e1s a la realidad de la pr\u00e1ctica cl\u00ednica que la interpretaci\u00f3n de los resultados mediante un punto de corte para los anticuerpos anti-RACh medidos por ELISA.           \n  \nP-143  ANTICUERPOS ANTI-TH/TO: CLAVES PARA AFRONTAR RESULTADOS DESCONCERTANTES.    L\u00f3pez Brull, \u00c1ngel; Vegas S\u00e1nchez, Maria Del Carmen; Casado Navarro, Natalia; D\u00e1vila Rosales, Marian; Mart\u00ednez-Becerra, Mar\u00eda Jos\u00e9.  Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid.  Los anticuerpos anti-Th/To son marcadores de esclerosis sist\u00e9mica (ES) con afectaci\u00f3n pulmonar. Se han descrito discrepancias entre t\u00e9cnicas comercializadas debido a la diferente representaci\u00f3n antig\u00e9nica [hPop (Euroimmun) y Rpp25 (DTEK)].  Analizar nuestra serie de muestras positivas para anti-Th/To comparando los ensayos comerciales disponibles. Revisi\u00f3n retrospectiva de pacientes anti-Th/To positivo por al menos un inmunoblot disponible (SCL10D24-DTEK, lectura subjetiva y EurolineSSc-Euroimmun, sistema de lectura  EuroblotOne)  desde 01/2020-04/2022. Se recopilaron datos cl\u00ednicos y la presencia de otros anticuerpos, dividi\u00e9ndolos en criterioES, no criterioES y otras especificidades asociadas a EAI sist\u00e9micas. Se recogi\u00f3 el resultado de inmunofluorescencia indirecta (IFI). Obtuvimos 71 muestras positivas por alguna de las dos t\u00e9cnicas (65 pacientes).  \nedad 57 a\u00f1os (21-86), 66%mujeres.  En 34/65 pacientes se estudiaron los dos inmunoblots. De estos, 8 tuvieron positivo en ambos, el resto discordantes (Tabla1). En la asociaci\u00f3n con otros anticuerpos de ES, lo m\u00e1s frecuente fue la coexistencia con anticuerpos no criterio ES (18/28). En todos los grupos asociados (criterioES, no criterioES y otras especificidades) lo m\u00e1s frecuente fue encontrar anti-Th/To a t\u00edtulo d\u00e9bil (9/10, 12/18 y 4/4, respectivamente). Un 66% de anti-Th/To aislados presentaban patr\u00f3n AC-8, un 41% en no aislados. La menor frecuencia de patr\u00f3n AC-8 se dio en los positivos d\u00e9biles de ambos grupos (Imagen 1). Dispon\u00edamos de informaci\u00f3n cl\u00ednica en 38/65 pacientes. De estos, 15/38 ten\u00edan ES (60% monoespec\u00edficos Th/To): 8 positivos por Euroimmun (38% s\u00f3lo realizado blot Euroimmun), 6 por DTEK y 1 positivo por ambos blots. 7/15 presentaban positividad d\u00e9bil. Las positividades solapadas hPop+ Rpp25+ son infrecuentes. Los casos de ES se dan en ambas especificidades, lo que enfatiza la importancia de abordar la b\u00fasqueda de anti-Th/To con los dos inmunoblots.    \n  \n                 \n                  \nTabla1      DTEK      ND NEG + ++ +++ Euroimmun  ND           NEG     3 2 7 + 25 10     2 ++ 4 2   1   +++ 2 2     5  \n  \nP-144  ASSOCIATION OF IL10 AND IL17 RECEPTOR EXPRESSION IN B-CELL SUBPOPULATIONS WITH CELL ACTIVATION, ANTI-CPP LEVELS, AND CLINICAL DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS  Morales N\u00fa\u00f1ez, Jose Javier1; Mu\u00f1oz Valle, Jos\u00e9 Francisco1; Garc\u00eda Chagoll\u00e1n, Mariel1; Cerpa Cruz, Sergio2; Mart\u00ednez Bonilla, Gloria Esther2; Medina Rosales, Vianey Montserrat1; D\u00edaz P\u00e9rez, Saul Alberto1; Hern\u00e1ndez Bello, Jorge1.  1Universidad de Guadalajara - Centro Universitario de Ciencias de la Salud, Guadalajara; 2Servicio de Reumatolog\u00eda del Hospital Civil de Guadalajara \u201cFray Antonio Alcalde, Guadalajara.  Background: The pathogenesis of rheumatoid arthritis (RA) depends on cytokine deregulation and autoantibody secretion; B cells play a predominant role in both processes. Some studies suggest that IL-10 and IL-17, as well as their receptors, can be key molecules in the activation and differentiation of B cell subpopulations of, which can be altered in autoimmune and inflammatory pathologies such as RA and contribute to the inflammatory process, production of autoantibodies and clinical disease activity. Objective: To determine the association of IL-10 and IL-17 receptor expression in B cell subpopulations with cell activation, autoantibody levels, and clinical disease activity in patients with RA. Methods: 87 RA patients classified according to the DAS28 index and 25 control subjects (CS) were included. Flow cytometry was used to determine peripheral B cell subpopulations' frequencies (%), CD69, IL-10R, and IL-17R markers. Erythrocyte sedimentation rate (ESR) was measured by the Westergren method. Anti-CCPs were measured by an ELISA test. Results: Total B cells did not differ between patients and CS (p>0.05). Memory B cells were decreased (p=0.0013), and mature B cells increased (p=0.0186) in RA compared to CS. A higher percentage of total B cells in patients were activated (CD69+, p=0.0026) than in CS, patients with high activity showing the highest activation (p=0.0373). IL-10R and IL-17R receptors were expressed more in plasmablasts (p<0.0001), but their expression does not differ by clinical activity (p>0.05). IL-17R is expressed more in B cells than IL-10R (p<0.0001). Conclusions: IL-10R and IL17RA may be associated with the differentiation of B cells due to their high expression in plasmablasts. In AR, B cells are more activated, and memory B cells are probably a cellular subpopulation involved in the pathogenesis of RA. Keywords: Rheumatoid arthritis, B cell, IL-10R, IL-17R, DAS28   \n  \n                                    \n \n  \nP-145  FROM ALLO- TO AUTOANTIBODIES AGAINST BILE CANALICULI   Arrese Mu\u00f1oz, Iria; Sanz Martinez, Maria Teresa; Vi\u00f1as Gimenez, Laura.  Hospital Universitari Vall d'Hebron, Barcelona.  Cholestatic liver injury can be caused by primary (genetic) or secondary (e.g. alcohol) defects of bile canaliculi proteins such as membrane proteins, tight junction proteins (TJ) and/or hepatic transporters of bile salt. The bile salt export pump protein (BSEP) is in the canalicular membrane of the hepatocyte and its deficiency due to congenital mutations leads to progressive familial intrahepatic cholestasis (PFIC). Curative treatment is a liver transplant. However, some patients relapse as a result of blocking alloantibodies against the native BSEP of the donor organ.  We included 4 patients, 3 pediatric liver transplanted patients due to PFIC disease and one adult male with alcoholic cirrhosis. All of them presented a bile canaliculi pattern by Indirect Immunofluorescence Assay (IFA) on rat liver sections (Fig.1A). We confirmed anti-BSEP specificity by western blot (WB) in the 3 pediatric patients (Fig.1B). During follow up, one clinically recovered patient presented a negative seroconversion of the anti-BSEP alloantibodies by IFA and WB (Fig.1B). Next, we performed WB with extracted proteins of 3 human healthy tissues (liver, stomach and thyroid). Immunoblotting with the serum of the alcoholic cirrhotic patient revealed two specific bands, one of 55kDa in the stomach and one of 30kDa in the liver and stomach (Fig.1C).  In conclusion, the IFA pattern in bile canaliculi is caused by alloantibodies against BSEP. Moreover, in patients clinically recovered is possible to observe a negative seroconversion.  However, BSEP is not the only specificity for this pattern. We have presented an alcoholic cirrhotic patient with this pattern as a result of de novo autoantibody formation against other proteins of the canaliculi. Molecular weight of the WB bands and the location in more than one tissue (liver and stomach) suggested that the specificity of the autoantibodies anti-canaliculi in this patient could be a TJ protein. However, further studies are needed.     \n  \n \n  \nP-146  COMPARATIVA ENTRE UN ELISA DE RUTINA Y UNA T\u00c9CNICA POINT-OF-CARE PARA LA DETERMINACI\u00d3N DE NIVELES DE F\u00c1RMACO Y ANTICUERPOS ANTI-F\u00c1RMACO.   L\u00f3pez Brull, \u00c1ngel; Pe\u00f1a Blanque, Virginia; Vegas S\u00e1nchez, Maria Del Carmen; Sancho Cadenas, Elena; Mart\u00ednez-Becerra, Mar\u00eda Jos\u00e9.  Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid.   Las t\u00e9cnicas point-of-care (POC) permiten monitorizar niveles de anti-TNF y anticuerpos anti-f\u00e1rmaco de manera r\u00e1pida.  Comparar las concentraciones de infliximab(IFX), adalimumab(ADA) y anticuerpos anti-f\u00e1rmaco obtenidas por ELISA y POC.  Estudio prospectivo en el que se analizaron muestras de rutina por ELISA (Promonitor-Grifols) y POC (Quantum Blue-B\u00fchlmann) entre 11/2021 y 04/2022. En muestras con f\u00e1rmaco indetectable se estudiaron anticuerpos anti-f\u00e1rmaco por ambas t\u00e9cnicas. Se valor\u00f3 la correlaci\u00f3n global y en 4 grupos de concentraci\u00f3n de f\u00e1rmaco (0-4,99ug/ml, 5-9,99ug/ml, 10-14,99ug/ml y \u226515ug/ml). Para la comparativa se utiliz\u00f3 \u00edndice de correlaci\u00f3n intraclase (ICC)(f\u00e1rmaco) y kappa cohen (anticuerpos).  Se estudiaron 280 muestras (180 IFX y 100 ADA). En IFX [\nedad 45(rango 12-85), 46,7%mujeres]: niveles medios IFX-ELISA 7.77(\u00b19.96) y POC 13.86(\u00b122.37). En ADA [\n48(4-81), 48,5%mujeres]: niveles medios de ADA-ELISA 8.33 (\u00b16.24) y POC 9.78 (\u00b17.18). Globalmente obtuvimos un ICC=0,66(IC95% 0,57-0,73) para IFX y 0,84(IC95% 0,77-0,89) para ADA. En la comparativa por rangos observamos que la correlaci\u00f3n es buena para valores inferiores a 5ug/ml para IFX y ADA (ICC=0,75 y 0,80, respectivamente), pero no para concentraciones superiores (Tabla 1). Los anticuerpos se valoraron en 44 muestras (31 IFX, 13 ADA): \u00edndice Kappa=0,73(IC95% 0,50-0,97) y 0,57(IC95% 0,03-1) respectivamente.  En anti-IFX la sensibilidad del POC fue 71.43%(IC95% 45-88), con 2/4 resultados POC negativo y ELISA positivo en niveles>150 UA/ml.  La utilidad del POC radica en la posibilidad de identificar de manera r\u00e1pida concentraciones <5 ug/mL. Sin embargo, su correlaci\u00f3n con ELISA se pierde para concentraciones altas.  \n  \nEn el estudio de anticuerpos llama la atenci\u00f3n la limitada sensibilidad del POC que obliga a confirmar todos los resultados por ELISA.              Tabla 1. ICC y \n para IFX y ADA por rangos.                                          IFX   ADA  Rangos \n(ug/ml)  Muestras  ICC(IC95%)    Muestras  ICC(IC 95%)  0-4,99 93 0,74(0,65 -0,83)    26 0,8(0,6-0,9) 5-9,99 44 0,21(0 -0,47)    45 0,31(0,02 -0,55)  10-14,99  15 0(0-0,43)    13 0,14(0, -0,55)  \u226515 28 0,20(0 -0,53)    16 0,61(0,19 -0,84)   \n  \nP-147  ANTIBODY RE-FORMATTING, ASSISTED BY PHAGE DISPLAY, A NOVEL METHODOLOGY FOR DEVELOPING A HIGH-AFFINITY FAB AGAINST GLUTEN.   Garc\u00eda Calvo, Eduardo Rafael1; Garc\u00eda Garc\u00eda, Aina1; Rodr\u00edguez G\u00f3mez, Santiago1; Takkinen, Kristiina2; Mart\u00edn De Santos, Rosario1; Garc\u00eda Lacarra, Teresa1.  1Facultad de Veterinaria Univ.Complutense de Madrid, Madrid; 2VTT-Technical Research Center of Finland, Espoo.  Gluten-related disorders refer to a group of heterogeneous conditions related to the consumption of gluten proteins (found in wheat, rye, and barley) by sensitized persons. These disorders are classified by their etiopathology in three main groups: allergic, autoimmune, and non-allergic and non-autoimmune diseases.  Celiac disease is the best known and most prevalent condition. Although many pharmacological approaches have been tried to settle a therapy (anti-inflammatory drugs, monoclonal antibodies, intestinal permeability modulators\u2026), a gluten-free diet is still the most effective. Epidemiological evidence suggests that most individuals with celiac disease can tolerate the ingestion of 20 ppm of gluten, so this is the limit used in most countries to label a product as \u201cgluten-free\u201d. The main objective of this work is to develop new antibody-based tools (in Fab format) for gluten traceability, enabling food safety assurance for all intolerant patients.  A new strategy for developing new Fabs has been implemented for the first time for this application: merging chains of different origins, a semisynthetic heavy chain, and an immune light chain. A pre-existing dAb (selected from a semi-synthetic human VH3-23 based library) was transformed into a subset of IgGs heavy chains that were cloned into a celiac patient-derived light chain immune repertoire, resulting in a novel Fab library. Then, phage-displayed Fabs were screened against gliadin to select the best gluten binding candidates. Once the most suitable candidate was found, it was expressed and purified from an E.coli bio-factory as soluble molecules. In addition, structural and antigen-antibody interactions in silico analysis were performed.  The generated functional molecules will be the main reactant to develop new gluten immunodetection systems. Furthermore, this protein evolution methodology is proven to be efficient for antibody re-formatting and led to an affinity and stability increase of pre-existing molecules.       \n  \nP-148  THE UNEXPECTED ROLE OF MACROPHAGES AND AUTOIMMUNITY IN THE HOMEOSTASIS OF RED BLOOD CELLS  Fernandez Arias, Clemente1; Fernandez Arias, Cristina2.  1Centro de Investigaciones Biol\u00f3gicas (CIB)-CSIC, Madrid; 2Instituto de Medicina Molecular, Lisboa.  The number of red blood cells (RBCs) in circulation emerges from an exquisite balance between cell production and destruction. RBC production is regulated by erythropoietin, a hormone secreted by kidney fibroblasts in response to the levels of oxygen in the body. The destruction of senescent RBCs relies on hepatic and splenic macrophages. Mammalian RBCs are devoid of cytoplasmic structures (including the nucleus and the mitochondria), which hinders their ability to undergo apoptosis. Instead, they use two membrane molecules to control phagocytosis.  Phosphatidylserine acts as an \u201ceat-me\u201d signal and promotes RBC destruction by macrophages. On the other hand, CD47 (a universal marker of self in mammals) conveys \u201cdon\u2019t-eat-me\u201d signals that inhibit the phagocytosis of the RBC. The profile of membrane signals determines the fate of RBCs when they pass through the liver and the spleen. According to this model of RBC destruction, widely accepted in the literature, the behavior of macrophages would be determined by \u201ceat-me\u201d and \u201cdon\u2019t-eat-me\u201d signals on the membrane of passing RBCs. Therefore, macrophages would be passive agents of RBC homeostasis. In this talk, we argue that this approach is overly simplistic and misses key aspects of the biology of RBCs. We suggest that macrophages actively regulate RBC lifespan depending on the levels of erythropoietin, allowing the organism to adjust the number of cells in response to internal or external perturbations (e.g. hemorrhages or infections). Moreover, macrophages can trigger autoimmune responses that result in the production of auto-antibodies against circulating RBCs. This would be a physiological mechanism intended to rapidly remove RBCs from the blood when they are no longer needed. The frequent detection of anti-RBC antibodies in the serum under normal conditions (and with no clinical manifestation) would respond to this new role of macrophages and autoimmunity in RBC homeostasis.             \n  \nP-149  ENSAYOS PARA ANTI-MI2, \u00bfSON INTERCAMBIABLES?   Jim\u00e9nez De Las Pozas, Yesenia; Vegas S\u00e1nchez, M Carmen; Casado Navarro, Natalia; D\u00e1vila Rosales, Marian; Mart\u00ednez Becerra, Mar\u00eda Jos\u00e9.  H.U. Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid.  Anti-Mi2 son marcadores espec\u00edficos de dermatomiositis. Para su identificaci\u00f3n existen diferentes ensayos comercializados.  El objetivo fue evaluar el comportamiento de las principales t\u00e9cnicas disponibles para la detecci\u00f3n de anti-Mi2.   Se revisaron retrospectivamente las muestras anti-Mi2 positivo por ELiA(Thermo\u2013Positivo>7 U/mL) entre 01/2013-05/2022 y se compararon con los resultados obtenidos por inmunoblot-Euroimmun\u00ae (BlotA) (MYO7G-Lectura automatizada EuroblotOne) e inmunoblot-Dtek\u00ae (BlotB)(PMS12D-24). Se registr\u00f3 patr\u00f3n de fluorescencia Hep2, otros anticuerpos asociados a EAIs y datos cl\u00ednicos. Para evaluar la especificidad de BlotA, en una segunda fase se analizaron retrospectivamente las muestras detectadas en rutina como positivas para anti-Mi2 alfa y/o beta entre 01/2020-05/2022. De 1997 muestras analizadas por ELiA, el 4.9% fueron positivas (98muestras/40pacientes) edad\n=45a\u00f1os(5-88), 75%mujeres, niveles\n=174,54[7.4-2520U/mL]. En el 40% de los pacientes se observ\u00f3 reactividad para al menos otro anticuerpo. En 23 muestras se realizaron ambos blot:  \u2022 18/23 coincidieron: 13 positivas (10/13 perfil\u03b1+\u03b2 en BlotA) y 5 negativas.  \u2022 En 5/23 se obtuvo un resultado discordante: 3/5BlotA+/BlotB- (\n=28U/mL) y 2/5BlotA-/BlotB+ (\n=77U/mL). En las que s\u00f3lo se hab\u00eda estudiado un blot:  \u2022 BlotA: 6/10 fueron positivos (2/6perfil\u03b1+\u03b2)  (\nNegativo:136.9U/mL/\nPositivo:193.3U/mL, p=0.5303) \u2022 BlotB: 9/17 positivos (\nNegativo:25.5U/mL/\nPositivo:133.6U/mL p=0.0325). En un segundo paso analizamos 1259 determinaciones realizadas por BlotA. El 93% fue negativo para anti-Mi2\u03b1 y anti-Mi2\u03b2. De las 88 positivas: 6 fueron positivas para \u03b1+\u03b2 (5/6ELiA Positivo), 16 fueron positivas aisladas para anti-Mi2\u03b1 y 66 para anti-Mi2\u03b2. De las aisladas, 4/69  \n  \ndeterminadas por ELiA fueron positivas, especificidad Mi2\u03b1=8% y Mi2\u03b2=5%.  Comparando las dos series observamos que el perfil \u03b1 y \u03b2 de BlotA cambia cuali y cuantitativamente cuando es positivo por todas las t\u00e9cnicas versus positivos aislados (Figura1).  La probabilidad de confirmar anti-Mi2 por inmunoblot depende del fabricante empleado. Esta limitaci\u00f3n en BlotA se observa incluso en pacientes con niveles altos. Describimos adem\u00e1s inespecificidades del BlotA, donde el perfil \u03b1+\u03b2 es el m\u00e1s especifico. Estos resultados implican una variable capacidad diagn\u00f3stica.    \n                       \n \n  \nP-150  PERFILES DE ALTERACI\u00d3N HEP\u00c1TICA EN PACIENTES CON AUTOANTICUERPOS ANTINUCLEARES ASOCIADOS A COLANGITIS BILIAR PRIMARIA   Aguilar Criado, Marta; Lucas Blanco, \u00c1ngela; S\u00e1nchez Redondo, David; Rodr\u00edguez L\u00f3pez, Ana; Valencia Pereira, Roc\u00edo; Narv\u00e1ez Rodriguez, Isidoro; Vargas P\u00e9rez, Mar\u00eda Luisa.  Hospital Universitario de Badajoz, Badajoz.  Introducci\u00f3n Los anticuerpos antinucleares (ANA), anti-SP100 y anti-GP210, y antimitocondriales (AMA), son claves junto con la elevaci\u00f3n de fosfatasa alcalina (FA) en el diagn\u00f3stico de colangitis biliar primaria (CBP).  \u00daltimamente la elevaci\u00f3n de gamma-glutamil transferasa (GGT) est\u00e1 siendo considerada.  Objetivo Evaluar la asociaci\u00f3n entre anti-SP100 y/o anti-GP210 con o sin AMA con diferentes perfiles de alteraci\u00f3n colest\u00e1sica y diagn\u00f3stico de CBP.  M\u00e9todos Estudio observacional retrospectivo de 289 pacientes anti-sp100/anti-GP210+ (2008-2021). ANA y AMA (M2) fueron detectados mediante inmunofluorescencia indirecta en c\u00e9lulas Hep2000 y triple tejido de rata respectivamente (A. Menarini Diagnostics) y confirmados por Line-dot (Euroline Autoimmune liver disease, Euroimmun).  Se recopil\u00f3 de la historia cl\u00ednica: alteraci\u00f3n de FA, GGT y diagn\u00f3stico.  Resultados Del grupo estudiado 36,84% presentaban ANA y AMA y 64,56% s\u00f3lo anti-SP100/GP210. 34,6% fue diagnosticado de CBP.  En AMA+ se observ\u00f3 con m\u00e1s frecuencia la alteraci\u00f3n enzim\u00e1tica de FA y GGT que en AMA-, as\u00ed como m\u00e1s CBP (p-valor <0.05). De 105 pacientes AMA+, 68 (64,76%) presentaron alteraci\u00f3n de GGT y FA, 3 (2,85%) de FA aislada y 11 (10,47%) de GGT. La presencia de CBP fue mayor en elevaci\u00f3n enzim\u00e1tica conjunta (85,29%) respecto a FA aislada (66.6%) o GGT (27.27%).  En AMA- (184 casos) la distribuci\u00f3n fue diferente: 48 (26,08%) elevaron FA y GGT, 10 (5.43%) FA y 43 (23.36%) GGT.  Adem\u00e1s, la elevaci\u00f3n de dos enzimas colest\u00e1sicas no asoci\u00f3  \n  \nm\u00e1s CBP (50%) que s\u00f3lo FA (40%). En alteraci\u00f3n GGT aislada hubo un 7.5% de CBP.  Conclusiones En pacientes con anti-SP100 y/o anti-GP210, un AMA+ aumenta la frecuencia de alteraci\u00f3n enzim\u00e1tica y el diagn\u00f3stico de CBP. Adem\u00e1s, en este grupo la elevaci\u00f3n de GGT aumenta la probabilidad diagn\u00f3stica respecto a FA aislada. En AMA- la alteraci\u00f3n de GGT no incrementa la probabilidad de CBP respecto a FA aislada en nuestra muestra y tiempo de estudio.                                             \n  \nP-151  EFFECTS OF BAMBI DEFICIENCY IN THE DEVELOPMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS.  P\u00e9rez, Paula1; Ruso, Fulgencio1; Casado, Victoria1; Cappitelli, Vincenzo1; Merino, Jes\u00fas2; Merino P\u00e9rez, Ram\u00f3n3.  1Inhibitec-Anticuerpos S.L., Santander; 2Universidad de Cantabria, Santander; 3Instituto de Biomedicina y Biotecnolog\u00eda de Cantabria, Santander.  Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies and immune complexes deposition in various organs. Follicular CD4+ T cells play a crucial role in this autoimmune syndrome by activating autoreactive germinal center B cells. The transforming growth factor \u03b2 (TGB\u03b2) inhibitor BAMBI (Bone Morphogenetic Protein and Activin Membrane-Bound Inhibitor) is known to control the differentiation of CD4+ T lymphocytes into either tolerogenic Tregs or pathogenic Th17 cells. BAMBI absence in mutant mice or its pharmacological inhibition with the B101.37 monoclonal antibody promotes an increase in Treg differentiation and activity and at the same time, a reduction in Th17 cell differentiation, resulting in the inhibition of autoimmune disease development.  Based on these findings, in the present study we have analysed the effects of BAMBI deficiency in the development of SLE. We have employed the chronic graft-versus-host disease lupus model induced after the transference of 40-60 \u00d7 106 lymphocytes from B6 or B6-BAMBI-KO mice into either Bm12 or Bm12-BAMBI-KO recipients. As reported previously, Bm12 mice receiving lymphocytes from B6 mice produce high levels of circulating IgG anti-DNA and anti-nucleosomal autoantibodies and exhibit linear glomerular IgG deposits in their kidneys. In contrast, both Bm12 mice injected with allogeneic B6-BAMBI-KO lymphocytes and Bm12-BAMBI-KO recipients receiving lymphocytes from B6 donors do not produce significant levels of circulating autoantibodies. Taken together, these results indicate that the absence of BAMBI in either donor or recipient lymphocytes protects mice against the development of SLE.               \n  \nP-152  EL EFECTO DE LAS C\u00c9LULAS DECIDUALES ESTROMALES HUMANAS EN LA MIGRACI\u00d3N DE C\u00c9LULAS T ACTIVADAS CXCR3+ (TH1, TC1). PAPEL EN LA TOLERANCIA INMUNOL\u00d3GICA MATERNO-FETAL   Llorca Colomina, Tatiana1; Ruiz Maga\u00f1a, Mar\u00eda Jos\u00e91; Rodr\u00edguez Do\u00f1a, Luc\u00eda1; M\u00e9ndez Malag\u00f3n, Cristina1; Mart\u00ednez Aguilar, Roc\u00edo2; Abad\u00eda Molina, Ana Clara3; Ruiz Ruiz, Carmen3; Garc\u00eda Olivares, Enrique3.  1Centro de Investigaci\u00f3n Biom\u00e9dica, Granada; 2Departamento de Ginecolog\u00eda y Obstreticia, Universidad de Edimburgo, Edimburgo; 3Departamento de Bioqu\u00edmica y Biolog\u00eda Molecular III e Inmunolog\u00eda, Granada.  Las c\u00e9lulas deciduales estromales (DSC) juegan un papel clave en la tolerancia inmunol\u00f3gica materno-fetal. En modelo murino se ha observado que las DSC inhiben la expresi\u00f3n de quimiocinas que atraen c\u00e9lulas Th1 y Tc1, de actividad abort\u00edgena. No obstante, no hay estudios equivalentes en humanos. Por ello, el objetivo del trabajo es determinar la expresi\u00f3n de quimiocinas en DSC humanas no decidualizadas (preDSC) y DSC decidualizadas (dDSC), as\u00ed como estudiar su actividad quimiot\u00e1ctica sobre c\u00e9lulas T activadas.   Las l\u00edneas de DSC se decidualizan con AMPc y progesterona y se recogen medios condicionados (MC) del sobrenadante del cultivo de preDSC y dDSC. Se compara, mediante RT-PCR, la expresi\u00f3n de CXCL9, CXCL10 y CXCL11. Adem\u00e1s, se estudia la migraci\u00f3n, en C\u00e1maras Transwell, de linfocitos de sangre perif\u00e9rica activados con PHA+anti-CD28+IL-2, en contacto con MC. Se emplean membranas de di\u00e1lisis MWCO 6-8kD para caracterizar mol\u00e9culas implicadas en la migraci\u00f3n.  Los resultados indican que preDSC y dDSC no expresan CXCL9 y la expresi\u00f3n de CXCL10 y CXCL11 disminuye significativamente con la decidualizaci\u00f3n. Los MC de preDSC incrementan significativamente la migraci\u00f3n de c\u00e9lulas T activadas, pero esta se inhibe significativamente con los MC de dDSC. La di\u00e1lisis aboli\u00f3 el efecto inhibitorio de la migraci\u00f3n del MC de dDSC.   Concluimos que la decidualizaci\u00f3n inhibe la expresi\u00f3n en DSC de quimiocinas que atraen c\u00e9lulas Th1 y Tc1. Adem\u00e1s, este proceso induce la secreci\u00f3n de factores inhibidores de la migraci\u00f3n. As\u00ed se evita la llegada de c\u00e9lulas T abort\u00edgenas a la decidua.          \n  \nP-153  THE IMMUNOMODULATORY FUNCTION OF ENDOGENOUS GALECTIN-1 IN DSS-INDUCED COLITIS   Fern\u00e1ndez P\u00e9rez, Raquel1; L\u00f3pez Santalla, Mercedes1; S\u00e1nchez Dominguez, Rebeca1; Aberquilla, Omaira1; Gutierrez Ca\u00f1as, Irene2; Juarranz, Jasmina2; Bueren, Juan1; Garin, Marina I.1.  1CIEMAT / IIS-F Jim\u00e9nez D\u00edaz, Madrid; 2Universidad Complutense de Madrid, Madrid.  Galectin-1 is a member of a family of carbohydrate-binding proteins, the so-called lectins, with high affinity for \u03b2-galactosides. Galectin-1 is widely expressed in many tissues and has immunomodulatory activity over different immune cell subsets that has been associated to induction of apoptosis in the target cells. Although, the immunosuppressive function of recombinant galectin-1 has been reported in many studies, the role of endogenous galectin-1 remains to be fully defined. In this study, galectin-1 deficient mice (Lgals1-/- mice) were used to investigate the in vivo function of galectin-1 in experimental colitis. Lgals1-/- mice showed enhanced susceptibility to experimental colitis with respect to WT mice as shown by the increased body weight losses and higher DAI compared to colitic WT mice. An increased plasticity of Th17 cells towards Th1 profile in DSS-induced colitic Lgals1-/- mice were determined. Strikingly, the exacerbated intestinal inflammatory responses in colitic Lgals1-/- mice was accompanied with increased frequencies of regulatory T cells in cLP. In addition, our results show that in the absence of endogenous galectin-1 an enhanced conversion of Foxp3+CD4+ Treg cells into pathogenic T-Bet-expressing Foxp3+CD4+ T cells was determined. Adoptive transfer of wild-type Foxp3+CD4+ regulatory T cells into Lgals1-/- mice during DSS-induced colitis reduces the severity of the disease, achieving a similar intestinal inflammation as to colitic WT mice. Altogether, our results highlight the relevance of the expression of endogenous galectin-1 to prevent the development of aberrant pathogenic Treg cells during the course of an intestinal inflammatory response.               \n  \nP-154  CHARACTERIZATION OF INTERSTITIAL LUNG DISEASE PRESENT IN P-SELECTIN KO MICE (LUPUS-LIKE SYNDROME) AND PSGL-1 KO MICE (SCLERODERMA-LIKE SYNDROME)  San Antonio Sanchez, M\u00aa Esther1; Sanchez Abad, Ines1; Gonzalez Sanchez, Elena1; Mu\u00f1oz Calleja, Antonio1; Vicente Rabaneda, Esther2; Garcia Perez, Javier3; Casta\u00f1eda, Santos2; Urzainqui Mayayo, Ana1.  1Servicio de Inmunolog\u00eda, Hospital Universitario \"La Princesa\", Madrid; 2Servicio de Reumatologia, Hospital Universitario \"La Princesa\", Madrid; 3Servicio de Neumolog\u00eda, Hospital Universitario \"La Princesa\", Madrid.  Systemic lupus erythematosus (SLE) and Systemic sclerosis (SSc) are multiorganic autoimmune diseases with significant mortality and morbidity. One of most severe clinical manifestation in both diseases is interstitial lung disease (ILD), a parenchymal lung disorder with a pattern of inflammation and fibrosis. The interaction of P-Selectin glycoprotein ligand-1 (PSGL-1)/P-selectin plays an important role in immune system homeostasis. Indeed, the absence of PSGL-1 develop SSc-like syndrome and P-Selectin absence develop SLE-like syndrome in mice.  C57BL/6 WT, PSGL-1 KO and P-Selectin KO mice (n=8/group), aged 12-24 month, were used in this study. Bronchoalveolar lavage (BAL) and lungs were obtained and analyzed by flow cytometry to characterize the ILD present in these animals.  P-selectin and PSGL-1 KO mice presented an increase number of CD45(+) cells in BAL, including alveolar and interstitial macrophages, eosinophils and granulocytes, with respect to WT mice. Also, lung analyse in P-Selectin KO mice showed increased number of eosinophils, granulocytes, T cells and B cells compared to WT, coinciding with PSGL-1 KO mice. Secondly the study of CD45(-) population revealed a higher total number of cells in BAL and lung of PSGL-1 KO mice. Further analyses showed increased CD31(+) cells in lung and increased CD90(+) cells in BAL. However, P-Selectin KO mice just showed increased number of cells in CD45(-) population of BAL compared to WT. The study of apoptosis in lymphoid and non-lymphoid populations showed a higher number of apoptotic CD45(+) and CD45(-) cells in both P-Selectin and PSGL-1 KO mice in lung tissue. Regarding BAL, PSGL-1 KO but not P-Selectin KO mice, showed increased number of apoptotic CD45(+) cells.  These results indicate that P-Selectin KO-ILD and PSGL-1 KO-ILD show a similar lung  \n  \ninfiltration pattern regarding CD45(+) population although B cells were only increased in P-Selectin KO mice. Moreover, high level of apoptotic cells was found in both groups.                                                   \n  \nP-155  EVOLUCI\u00d3N DEL LINFOGRAMA DUODENAL EN PACIENTES CELIACOS ADULTOS TRAS RETIRAR EL GLUTEN DE LA DIETA   Garc\u00eda-Hoz Jim\u00e9nez, Carlota; Pariente Rodriguez, Roberto; Crespo P\u00e9rez, Laura; Roy Ari\u00f1o, Garbi\u00f1e.  Hospital Universitario Ram\u00f3n y Cajal, Madrid.  Introducci\u00f3n: La enteropat\u00eda celiaca (EC) se caracteriza por cambios en las subpobaciones de linfocitos intraepiteliales (LIE), su determinaci\u00f3n mediante citometr\u00eda de flujo (CMF) es el linfograma duodenal. Nuestro grupo ha establecido los puntos de corte que definen un linfograma celiaco: %LIE TCR\n+ >14% y %LIE sCD3- <4%. Objetivo: Conocer c\u00f3mo evoluciona el linfograma en pacientes adultos con EC activa (ECA) al iniciar dieta sin gluten (DSG). Pacientes y M\u00e9todos: Estudio retrospectivo sobre una cohorte de 59 pacientes ECA. Disponemos de los resultados de anatom\u00eda patol\u00f3gica y linfograma antes y despu\u00e9s de la retirada de gluten de la dieta (tiempo mediano de DSG 24 meses), y de las determinaciones de anticuerpos anti-trasglutaminasa (AcTG2). Como grupo control se incluyeron 410 pacientes a los que se descart\u00f3 EC (ver tabla). Resultados: Tras la DSG el 90% de los pacientes mantiene un %LIE TCR\n superior al 14% y el 56% mantiene un %LIE sCD3- inferior al 4% sin poder establecer una relaci\u00f3n clara con el grado de atrofia vellositaria. El 52,4% mantienen el linfograma celiaco completo, un 45,6% linfogramas parciales y solo el 6,8% presenta un linfograma no celiaco. CONCLUSIONES: La mayor\u00eda de los pacientes mantienen alteraciones en el linfograma a pesar de una correcta adherencia a la DSG, con negativizaci\u00f3n de AcTG2 y recuperaci\u00f3n de la integridad de la mucosa (ver tabla). El linfograma celiaco constituye un marcador de EC, tanto en el estad\u00edo inflamatorio como tras tratamiento cuando se ha revertido la inflamaci\u00f3n y la lesi\u00f3n histol\u00f3gica.            \n  \n \nQ1: cuartil 1, Q3: Cuartil 3                                        Control  ECA DSG %IEL mediana  \nQ1/Q3  8,1 \n Q1:5,1/Q3:11,2  18,2 \n Q1:14,3/Q3:23,7  10,5 \nQ1:6,8/Q3:14,8  %TCR\n + mediana  \n Q1/Q3  4,9 \nQ1:2,5/Q3:9,4  21,2 \nQ1:16,2/Q3:31,1  27,3 \nQ1:20,5/Q3:34,4  %sCD3 - mediana  \n Q1/Q3  14,4 \nQ1:8,6/Q3:24,2  0,8 \nQ1:0,4/Q3:1,4  3,2 \nQ1:1,2/Q3:6,7  Pacientes con AcTG + \n(%) 0 91,5 3,4 Pacientes con atrofia \nvellositaria grado MIII \n(%) 0,5 100 18,6  \n  \nP-156  PSGL-1/P-SELECTIN AXIS IN THE HOMEOSTASIS OF MONOCYTES FROM HEALTHY DONORS, LUPUS AND SCLERODERMA PATIENTS.  Mu\u00f1oz Callejas, Antonio1; Castillo Serrulla, Pablo1; San Antonio, Esther1; Vicente Rabaneda, Esther2; Garc\u00eda P\u00e9rez, Javier3; Casta\u00f1eda, Santos2; Urzainqui, Ana1.  1Servicio de Inmunolog\u00eda Hospital Universitario de La Princesa, Madrid; 2Servicio de Reumatolog\u00eda Hospital Universitario de La Princesa, Madrid; 3Servicio de Neumolog\u00eda Hospital Universitario de La Princesa, Madrid.  Background: PSGL-1, a transmembrane protein found in all leukocytes, is involved in the immune system homeostasis regulation through interaction with P-selectin. One of the pathways  activated after P-selectin/PSGL-1 interaction is AKT-mTOR, a signaling pathway implicated in autophagy. P-selectin and PSGL-1 KO mice develop autoimmune syndromes similar to lupus and scleroderma, respectively. Interestingly, these autoimmune diseases have alterations in autophagy that prevent the correct elimination of cell fragments, thus contributing to their pathogenesis. Objectives: 1- To study the basal levels of autophagy (LC3B-II expression), pAKT and p-mTOR in monocytes from HD, lupus and scleroderma patients. 2- To determine whether PSGL-1/P-selectin interaction regulates the expression of LC3B-II, pAKT and p-mTOR in monocytes from HD, lupus and scleroderma patients. Materials and Methods: Human monocytes were isolated from healthy donors (HD), lupus and scleroderma patients. After incubation with BSA or BSA+P-selectin in rolling-like conditions (shaking at 60 rpm) for 15 min, cells were left to adhere at 37\u00baC for 1 hour. Other cells were incubated without rolling in BSA at 37\u00baC for 1 hour. The measurement of LC3B-II, pAKT and p-mTOR values was performed by flow cytometry. Results: Circulating monocytes from lupus and scleroderma patients show increased LC3B-II and pAKT levels compared to HD. In addition, scleroderma patients present higher p-mTOR expression than HD.  PSGL-1/P-selectin interaction in rolling-like conditions induces a decrease in LC3B-II levels in monocytes from HD and scleroderma patients, with respect to rolling on BSA. Moreover, PSGL-1/P-selectin interaction reduces pAKT values in HD and lupus patients. P-selectin interaction also reduces p-mTOR level in lupus patients but not in HD.  \n  \nConclusions: Lupus and scleroderma patients show alterations in the levels of LC3B-II, pAKT and p-mTOR. PSGL-1/P-selectin interaction reduces LC3B-II and pAKT expression in monocytes from HD. However, monocytes from lupus and scleroderma patients have altered the response to P-selectin engagement.                                               \n  \nP-157  PHENOTYPE CLUSTERS OF ANTI-MDA5 POSITIVE DERMATOMYOSITIS PATIENTS IN ASTURIAS   Rioseras De Bustos, Beatriz; Ayala Soriano, Say; Arias Guill\u00e9n, Miguel; Colunga Arg\u00fcelles, Dolores; De Dios Vel\u00e1zquez, Alvaro; Caminal Montero, Luis; Coto Hern\u00e1ndez, Rub\u00e9n; Fern\u00e1ndez Vega, Iv\u00e1n; Crespo Villoria, Lara; Mozo Avellaned, Lourdes.  Hospital Universitario Central de Asturias (HUCA), Oviedo.  Anti-Melanoma Differentiation-Associated gene 5 (MDA5) is a Dermatomyositis (DM) specific antibody (Ab) initially described in amyopathic patients with rapidly progressive interstitial lung disease (RP-ILD). Its widespread determination by commercial methods has allowed the description of other clinical associations. In 2020, by applying a decisional algorithm, a French multicenter study of 83 anti-MDA5 DM patients established three well differentiated phenotype clusters: a RP-ILD cluster (15/83, 18.1%), a rheumatoid cluster (46/83, 55.4%) and a vasculopathic cluster (22/83, 26.5%). The RP-ILD cluster showed a high mortality rate while the rheumatoid cluster had an overall better outcome. This study applies the proposed algorithm to a cohort of anti-MDA5 Asturian DM patients.  We reviewed relevant clinical information of 10 anti-MDA5 positive DM patients detected between 2008 and 2022 in the Immunology Department of the Hospital Universitario Central de Asturias (HUCA) which is the reference center for the autoimmune serologic diagnosis in the autonomous region of Asturias, Spain. In all patients, the presence of anti-MDA5 was confirmed by two commercial immunoblots.  Six patients were female (60%) and the age at DM diagnosis was 44-77 years. All the patients exhibited dermatologic manifestations; 7 patients showed respiratory symptoms, 6 of them suffering from ILD; 6 patients had muscle involvement; 8 developed rheumatologic manifestations and 4 of them presented Raynaud phenomenon. By applying the decisional algorithm, 2 of the studied patients would be grouped in the RP-ILD cluster (20%), 5 fit in the rheumatoid cluster (50%) and 3 could be included in the vasculopathic cluster (30%). Two patients died, both belonging to the RP-IDL cluster.  These results show that the Asturian anti-MDA5 DM cohort reproduces the phenotype cluster distribution observed in the French cohort, with most of the patients in the rheumatoid cluster.      \n  \nSesi\u00f3n Poster. Autoinmunidad (II). Pantalla 2  P-159  ACETATE CORRELATES WITH OPTIMAL RESPONSE TO OCRELIZUMAB IN LOW INFLAMMATORY PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS PATIENTS.  Fern\u00e1ndez-Velasco, Jos\u00e9 Ignacio1; Monreal, Enric1; Kuhle, Jens2; Meca-Lallana, Virginia3; Meca-Lallana, Jos\u00e94; Izquierdo, Guillermo5; Oreja-Guevara, Celia6; Gasc\u00f3n-Gim\u00e9nez, Francisco7; Sainz De La Maza, Susana1; Walo-Delgado, Paulette1; Lapuente-Suanzes, Paloma1; Maceski, Aleksandra2; Rodr\u00edguez-Mart\u00edn, Eulalia1; Rold\u00e1n, Ernesto1; Villarrubia, Noelia1; Saiz, Albert8; Blanco, Yolanda9; Diaz-Perez, Carolina10; Valero L\u00f3pez, Gabriel11; Diaz Diaz, Judit12; Aladro, Yolanda13; Brieva, Luis14; \u00cd\u00f1iguez, Cristina15; Gonz\u00e1lez-Su\u00e1rez, In\u00e9s16; Rodr\u00edguez De Antonio, Luis A Rodr\u00edguez De Antonio17; Garc\u00eda-Dom\u00ednguez, Jos\u00e9 M18; Sabin, Julia19; Llufriu, Sara9; Garc\u00eda-Calvo, Estefan\u00eda20; Machuca, Andr\u00e9s20; Luque-Garcia, Jose L20; Masjuan, Jaime1; Costa-Frossard, Lucienne1; Villar Guimerans, Luisa Mar\u00eda1.  1Hospital Universitario Ram\u00f3n y Cajal, Madrid; 2Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine, and Clinical Research, University Hospital Basel, University of Basel Basel, Basel; 3Hospital Universitario La Princesa, Madrid; 4Hospital Universitario Virgen de la Arrixaca, Madrid; 5Hospital Vithas Nisa, Sevilla; 6Hospital Cl\u00ednico San Carlos, Madrid; 7Hospital Cl\u00ednico Universitario, Valencia; 8Hospital Clinic, Barcelona; 9Center of Neuroimmunology, Neurology Department, Cl\u00ednic of Barcelona Hospital, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), and Institut de Neuroci\u00e8ncies, Universitat de Barcelona, Barcelona; 10Neurology Department, La Princesa University Hospital, Madrid; 11Multiple Sclerosis and Clinical Neuroimmunology unit, Virgen de la Arrixaca University Hospital, Murcia; 12Neurology Department, Cl\u00ednico San Carlos Hospital, IdISSC, Madrid; 13Hospital de Getafe, Madrid; 14Hospital Arnau de Vilanova, Lleida; 15Hospital Cl\u00ednico Universitario Lozano Blesa, Zaragoza; 16Hospital \u00c1lvaro Cunqueiro, Vigo; 17Hospital Universitario de Fuenlabrada, Madrid; 18Hospital Universitario Gregorio Mara\u00f1\u00f3n, Madrid; 19Hospital Universitario Puerta de Hierro de Majadahonda, Madrid; 20Universidad Complutense de Madrid, Madrid.  Background: Short-chain fatty acids (SCFA) are compounds derived from gut microbiota metabolism that have a role in gut-brain axis and have been related to multiple sclerosis (MS) etiopathogenesis.  Objective: To ascertain the role of plasma SCFA levels in the response to ocrelizumab in primary-progressive multiple sclerosis (PPMS) patients.  Methods: Multicentre prospective study including 69 patients with PPMS who initiated ocrelizumab treatment, classified according to baseline presence [Gd+, n=16] or absence [Gd-, n=53] of gadolinium-enhancing lesions in brain MRI. Serum SCFA and immunoglobulin levels were measured at baseline and 6 months after ocrelizumab initiation by liquid chromatography-mass spectrometry and nephelometry, respectively.  \n  \n Results: Ten (62.5%) Gd+ and 41 (77.4%) Gd- patients reached an optimal response (NEDA) defined as no disability progression or new MRI lesions after 1 year of ocrelizumab treatment. NEDA status associated, only in low-inflammatory Gd- patients, with an increase of plasma acetate levels 6 months after the first ocrelizumab dose (p=0.0013) and this correlates with an elevation in serum IgA levels (p=0.006) and IgA/IgG ratio (p=0.0011). No differences were found in Gd+ groups.  Conclusions: NEDA associated in Gd- patients with increased plasma acetate levels, thus strongly suggesting an association between gut microbiota and response to ocrelizumab in low-inflammatory PPMS patients. Future studies will further demonstrate the correlation between microbiota composition and response to ocrelizumab in these patients.                                      \n  \nP-160  NORMALIZACI\u00d3N DE ANTICUERPOS ANTITRANSGLUTAMINASA EN PACIENTES CON D\u00c9FICIT DE IGA Y ENFERMEDAD CEL\u00cdACA: EXPERIENCIA DE UN CENTRO  Gonz\u00e1lez Torbay, Andrea; Matas P\u00e9rez, Elisabet; Cuesta Mart\u00edn De La C\u00e1mara, Ricardo; Miguel Berenguel, Laura; Gianelli, Carla; C\u00e1mara Hij\u00f3n, Carmen; Rodr\u00edguez Pena, Rebeca; L\u00f3pez Granados, Eduardo; S\u00e1nchez Zapardiel, Elena; Nozal Aranda, Pilar.  Hospital Universitario La Paz, Madrid.  Introducci\u00f3n y Objetivos La enfermedad cel\u00edaca (EC) es una enteropat\u00eda autoinmune frecuente, desencadenada por el consumo de gluten en individuos con predisposici\u00f3n gen\u00e9tica a la misma. Los pacientes con d\u00e9ficit de IgA tienen mayor riesgo, en comparaci\u00f3n con poblaci\u00f3n sana, de desarrollar patolog\u00edas autoinmunes como la EC. El objetivo de este estudio es determinar si hay diferencias significativas en el tiempo de persistencia de anticuerpos antitransglutaminasa IgG (TGG) o IgA (TGA) en pacientes cel\u00edacos con o sin deficiencia de IgA, respectivamente, desde el inicio de una dieta sin gluten (DSG).  M\u00e9todos Se realiz\u00f3 un estudio retrospectivo mediante la revisi\u00f3n de historias cl\u00ednicas de los 1342 pacientes con deficiencia de IgA seguidos en la Unidad de Inmunolog\u00eda del Hospital Universitario La Paz: desde 2009, 78 de ellos se han diagnosticado de EC, de los cuales 36 han tenido un seguimiento regular y fueron seleccionados para este estudio. Se eligieron 36 pacientes cel\u00edacos de edades similares sin deficiencia de IgA como grupo control. Se realiz\u00f3 un an\u00e1lisis de supervivencia utilizando el test de Mantel-Coz para comparar el tiempo de normalizaci\u00f3n de los t\u00edtulos de anticuerpos antitransglutaminasa desde el inicio de DSG en ambos grupos.  Resultados Se encontraron diferencias significativas entre ambos grupos: la mediana de tiempo necesario para aclarar TGG en pacientes con EC y deficiencia de IgA fue de 19.47 meses, mientras que la necesaria para aclarar TGA en pacientes con solo EC fue de 9.45 meses (P=0,0002)  Conclusiones Los pacientes con EC y deficiencia de IgA tardan m\u00e1s tiempo en alcanzar valores normales de anticuerpos antitranglutaminasa desde el inicio de DG que los cel\u00edacos que no presentan deficiencia de IgA.  \n  \nP-161  EXPRESI\u00d3N DE RECEPTORES DE BAFF Y APRIL EN PACIENTES CON LUPUS ERITEMATOSO SIST\u00c9MICO    Ortiz Aljaro, Pilar1; Montes, Marco Antonio1; Garc\u00eda Lozano, Jos\u00e9 Ra\u00fal1; Lucena Soto, Jos\u00e9 Manuel1; Garc\u00eda Hern\u00e1ndez, Francisco2; Gonz\u00e1lez, Mar\u00eda Francisca1.  1Servicio de Inmunolog\u00eda. Hospital Universitario Virgen del Roc\u00edo, Sevilla; 2Servicio de Medicina Interna. Hospital Universitario Virgen del Roc\u00edo, Sevilla.  Los desajustes en los mecanismos de control de las c\u00e9lulas B autorreactivas son importantes en la etiopatogenia del lupus eritematoso sist\u00e9mico (LES). BAFF (B cell activating factor belonging to the TNF family) es una citocina miembro de la familia TNF, clave en la regulaci\u00f3n de la homeostasis de los linfocitos B, ya que controla el n\u00famero total de c\u00e9lulas B perif\u00e9ricas mediante la interacci\u00f3n con sus receptores. APRIL (A proliferation-inducing ligand) es una citocina relacionada con BAFF con la que comparte dos receptores, TACI y BCMA, mientras que, un tercero, BAFF-R, es exclusivo de BAFF. Estos receptores se expresan en la superficie de linfocitos B dependiendo de su grado de maduraci\u00f3n y pueden encontrase en otros tipos celulares, como BCMA que se expresa en c\u00e9lulas plasm\u00e1ticas. Con el objetivo de mejorar el conocimiento de la implicaci\u00f3n del sistema BAFF/APRIL y sus receptores en el desarrollo del LES reclutamos una cohorte de mujeres entre 18 y 60 a\u00f1os compuesta por 42 pacientes (18 con nefritis y 24 sin nefritis) y 26 controles sanos de las que se obtuvo muestra de sangre total y se determinaron, a trav\u00e9s de citometr\u00eda de flujo, los porcentajes de expresi\u00f3n de BAFF-R y TACI con respecto a los linfocitos CD19+ y porcentaje de expresi\u00f3n de BCMA respecto a los linfocitos CD19+/CD27+/CD38+ (c\u00e9lulas plasm\u00e1ticas), junto a sus intensidades de fluorescencia media (MFI). Como resultado, no encontramos diferencias en los porcentajes de expresi\u00f3n entre pacientes y controles (94,5% vs. 94,8% en BAFF-R; 27,0% vs. 31,1% en TACI y 3,9% vs. 3,6% en BCMA respectivamente, P>0.05). Tampoco encontramos diferencias significativas en las MFI, ni al comparar estas variables entre los grupos de pacientes con y sin nefritis. En conclusi\u00f3n, nuestros resultados sugieren que la expresi\u00f3n de receptores tanto BAFF como APRIL no estar\u00edan implicados en la fisiopatogenia del LES.             \n  \nP-162  DETECTION OF M2-TYPE ANTI-MITOCHONDRIAL ANTIBODIES SUBTYPES IN THE DIAGNOSIS OF PRIMARY BILIARY CHOLANGITIS IN PATIENTS WITH DISCORDANT RESULTS  Arnaldos P\u00e9rez, Cristina; Bolos, Uma; P\u00e9rez Isidro, Albert; Rodr\u00edguez Tajes, Sergio; Londo\u00f1o, Mar\u00eda Carlota; Vi\u00f1as, Odette; Ruiz Ortiz, Est\u00edbaliz.  Hospital Cl\u00ednic de Barcelona, Barcelona.  Introduction: Primary biliary cholangitis (PBC) is a chronic autoimmune liver disorder characterized by inflammation of intrahepatic bile ducts and ultimately cirrhosis. M2-type anti-mitochondrial antibodies (M2-AMA) are specific and, together with biochemical cholestasis, are sufficient for diagnosis, without the need for liver biopsy. M2-AMA recognise mainly the E2 subunits of the 2-oxo-acid dehydrogenase complex: PDC-E2, OGDC-E2 and BOADC-E2, being PDC-E2 the dominant subunit. The aim of this study is to determine if the use of E2 subunits separately (sep-E2), by Dot-Blot, can improve M2-AMA detection in cases with low positive or discordant results between methods without sep-E2. Material and methods: Patients with suspicion of PBC were routinely evaluated with indirect immunofluorescence on Rat-Triple-Tissue, ELISA and Dot-Blot assay to detect M2-AMA. None of those methods included sep-E2 as autoantigens. Patients with low positive or discordant results between techniques without sep-E2 (n=24) were analyzed on sep-E2 by Dot-blot. All of them had showed reactivity in the routine Dot-blot assay against a fusion protein formed by the immunogenic domains of the three E2 subunits mentioned, but had a negative result for native M2 antigen with E2-PDH as main component. In addition, clearly positive patients (n=2) in these three assays as controls were also analyzed on sep-E2. Results: Dot-Blot (sep-E2) positive M2-AMA results were as follows: native-PDC (6/24; 25%), PDC-E2 (6/24; 25%), OGDC-E2 (2/24; 8.33%) y BCOADC-E2 (17/24; 70.83%). Isolated reactivity was only observed against PDC-E2 (4/6; 66.67%) and BCOADC-E2 (13/17; 76.47%). In the remaining positive cases OGDC-E2 and BCOADC-E2 were observed in combination with PDC (native o recombinant). Conclusions: The use of sep-E2 subunits for M2-AMA detection in patients with low levels or discordant results between techniques can better support the diagnosis of CBP, being BCOADC M2-AMA the main responsible in our cohort. Therefore, biopsy could be avoided in some cases.      \n  \nP-163  AUTOANTIBODIES DETECTION BY MULTIPARAMETRIC ASSAY IN PATIENTS WITH SYSTEMIC AUTOIMMUNE DISEASES  Vi\u00f1as, Odette1; P\u00e9rez-Isidro, Albert1; Adao Abe, Collin-Dexter2; Mart\u00ednez, Maria Jos\u00e91; De Moner, Noem\u00ed1; Fern\u00e1ndez Alonso, Irene3; G\u00f3mez-Puerta, Jos\u00e9 Alfredo2; Espinosa, Gerard4; Ruiz-Ortiz, Est\u00edbaliz1.  1Servei d'Immunologia CDB Hospital Cl\u00ednic de Barcelona IDIBAPS, Barcelona; 2Servei de Reumatologia Hospital Cl\u00ednic de Barcelona IDIBAPS, Barcelona; 3Unidad de Autoinmunidad; Werfen Spain & Portugal, Barcelona; 4Autoimmune Disease Department Hospital Cl\u00ednic de Barcelona, Barcelona.  Introduction Systemic autoimmune diseases (SAID) are a heterogeneous group of diseases characterized by an immune response against self-antigens. Autoantibodies (Abs) are a hallmark of most of the SAID being some of them part of the classificatory criteria. In the last years, multiparametric technologies for Abs detection have been proposed to improve the accuracy of the immunological diagnosis of SAID. Particle-based multi-analyte technology (PMAT-Aptiva) is a multiplexed system based on the coupling of different antigens to paramagnetic particles with unique signatures. It allows us to obtain results from different Abs simultaneously.  The aim of this study was to evaluate the CTD-Essential (PMAT-Aptiva) diagnostic performance in a cohort of patients with SAID from the Hospital Cl\u00ednic.  Patients and Methods Study cohort includes patients with Systemic Sclerosis (n=99), Systemic Lupus Erythematosus (n=63), Sj\u00f6gren Syndrome (n=39), Mixed Connective Tissue Disease (n=12), anti-Synthetase Syndrome (n=5), other SAID (n=32) and other patients without SAID (n=70). Anti-dsDNA, -Sm, -Ribo-P, -Ro/SSA, -La/SSB, -Ro52, -U1-RNP, -Jo1, -Cenp-B, -Scl70, -DFS70 Abs were measured by the classical method employed by our laboratory (EIA, CIA, FEIA or Immunoblot) and PMAT-Aptiva.  Results A good correlation (Cohen kappa >0.7) was observed for all Abs, except for anti-Sm (CIA results) and Jo1 (Immunoblot results). CIA results for anti-Jo1 Abs show good correlation. Using PMAT-technology, positive-likelihood ratio for each biomarker ranges from 1.93 to >50.00 being the best (>10) for anti-Sm, -Ribo-P, -Jo1 and -Cenp-B. Specificities range between 72.9%-100% for all biomarkers whereas sensitivities range between 43.2%-80.0% excluding anti-Sm (15.9%), -Ribo-P (15.9%) and -Ro52 (33.9%) Abs.  \n  \n Conclusions In relation to anti-Sm and -Jo1 Abs, the difference observed can be explained due to the different nature of the antigen used for each method. However, multiparametric Abs testing using PMAT-Aptiva is a good option for Abs detection and to improve SAID diagnosis, showing a good sensitivity and specificity.                                              \n  \nP-164  ASOCIACI\u00d3N ENTRE BIOMARCADORES \u201cNO CRITERIO\u201d Y COMPONENTES DEL COMPLEMENTO EN PACIENTES CON S\u00cdNDROME CORONARIO AGUDO Y S\u00cdNDROME ANTIFOSFOL\u00cdPIDO SUBYACENTE.  Veiga Gonz\u00e1lez, Jos\u00e9 Luis1; Rodr\u00edguez Ramos, Rafael1; Pariente Ror\u00edguez, Roberto1; Tejeda-Velarde, Amalia2; Nieto Ga\u00f1\u00e1n, Israel1; Villalobos-S\u00e1nchez, Lourdes1; Carrasco Sayalero, \u00c1ngela1.  1Hospital Ram\u00f3n y Cajal, Madrid; 2Hospital Universitario de Salamanca, Salamanca.  Antecedentes y Objetivos El s\u00edndrome antifosfol\u00edpido (SAF) es una enfermedad autoinmune sist\u00e9mica definida por la aparici\u00f3n de abortos recurrentes y trombosis en presencia de anticuerpos antifosfol\u00edpidos.  Investigaciones recientes muestran el papel del perfil inmunol\u00f3gico en el infarto agudo de miocardio (IAM) en pacientes con APS. En este ensayo comparamos dos grupos (pacientes de APS con SCA frente a control) para comprobar la contribuci\u00f3n de estos anticuerpos. M\u00e9todos Para comparar ambos grupos de pacientes estudiamos los siguientes par\u00e1metros: Citocinas (IL-1\u03b2, IL-17, TNF-\u03b1 e IL-6) analizadas con Luminex\u00ae Multiplex Assays. Componentes del complemento e inmunoglobulinas analizadas por nefelometr\u00eda. Autoanticuerpos analizados por ELIA y ELISA. Resultados Se observaron diferencias estad\u00edsticamente significativas, en los valores de ACA IgA, IL-6, IL-17, MPO, PR3 y antiCCP. As\u00ed como en las determinaciones de C3, C4, PCR y VSG.  No se encontr\u00f3  diferencias   estad\u00edsticas  en los niveles de inmunoglobulinas. Conclusi\u00f3n Nuestro estudio  confirma la existencia de alteraciones en el perfil inmunol\u00f3gico (autoanticuerpos \u201cno criterio\u201d y componentes del complemento) en los pacientes con SAF que sufren SCA Se deben seguir haciendo estudios que confirmen estos resultados, as\u00ed como recomendar la determinaci\u00f3n de un perfil inmunol\u00f3gico en pacientes con predisposici\u00f3n de sufrir con SCA dada su relevancia cl\u00ednica y terap\u00e9utica.           \n  \nP-165  SAFO NO CRITERIO, \u00bfREALMENTE NO CRITERIO?  Vega Romero, Elena; Jim\u00e9nez De Las Pozas, Yesenia; D\u00e1vila Rosales, Mariam Alexandra; Casado Navarro, Natalia; Mart\u00ednez Becerra, Mar\u00eda Jos\u00e9; Vegas S\u00e1nchez, Mar\u00eda Del Carmen; Llamas Sillero, Pilar; Guzm\u00e1n L\u00f3pez, Karina.  H.U. Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid.  Las nuevas t\u00e9cnicas de laboratorio para anticuerpos antifosfol\u00edpido (AAF) y el concepto de morbilidad obst\u00e9trica \u201cno criterio\u201d se\u00f1alan la necesidad de revisar los criterios de clasificaci\u00f3n del S\u00edndrome antifosfol\u00edpido obst\u00e9trico (SAFO).  Valorar si la ampliaci\u00f3n del panel de AAF y de los criterios de morbilidad obst\u00e9trica permite clasificar como SAFO a mujeres hasta ahora fuera de esta clasificaci\u00f3n y analizar la eficacia del tratamiento. Estudio retrospectivo y descriptivo que incluy\u00f3 mujeres <45 a\u00f1os, remitidas a la consulta de hematolog\u00eda e inmunolog\u00eda de la gestaci\u00f3n de nuestro centro (2020-2021) en las que no exist\u00eda otra causa que justificara morbilidad obst\u00e9trica. Se les realiz\u00f3 estudio de AAF cl\u00e1sicos por triple t\u00e9cnica: ELISA-QUANTALite\u00ae (Inova Diagnostics), CLIA-BIO FLASH\u00ae (Inova Diagnostics) y ELiA-ImmunoCap\u00ae (Thermo Fisher Scientific); y de AAF \u201cno cl\u00e1sicos\u201d: aPS/PT IgG/IgM ELISA-QUANTALite\u00ae (Inova Diagnostics), EliA-Cardiolipin IgA\u00ae y EliA-\u03b22GlycoproteinI IgA\u00ae (Thermo Fisher Scientific).  La morbilidad obst\u00e9trica \u201cno criterio\u201d se defini\u00f3 seg\u00fan Arachchillage 2015. Se analiz\u00f3 la variable \u201cembarazo a t\u00e9rmino\u201d y su relaci\u00f3n con el tratamiento. 73 de las 278 pacientes cumplieron criterios de inclusi\u00f3n  (Figura 1). La aplicaci\u00f3n de la triple t\u00e9cnica para AAF cl\u00e1sicos permiti\u00f3 incluir a un 69.23% de las pacientes en criterios de S\u00eddney respecto al 30.77% clasificadas utilizando una sola t\u00e9cnica. 13.70% de las pacientes presentaban \u00fanicamente AAF \u201dno cl\u00e1sicos\u201d (presentes en un 38.36% del total).  En un 67.12% se identific\u00f3 morbilidad obst\u00e9trica \u201cno criterio\u201d. No se encontraron diferencias entre las pacientes SAFO \u201ccriterio\u201d y SAFO \u201cno criterio\u201d respecto a la variable \u201cembarazo a t\u00e9rmino\u201d (p=1), ni entre los tratamientos recibidos.  El uso de diferentes ensayos para la detecci\u00f3n de AAF cl\u00e1sicos permiti\u00f3 reclasificar como SAFO a un grupo de mujeres susceptibles de tratamiento. Esto y la consideraci\u00f3n de la morbilidad obst\u00e9trica \u201cno criterio\u201d podr\u00eda aportar beneficio cl\u00ednico a un subgrupo de pacientes actualmente no contemplado.     \n  \n                                \n \n  \nP-166  RECUPERACI\u00d3N DE PACIENTES CON SOSPECHA DE COLANGITIS BILIAR PRIMARIA PERDIDOS POR EL SISTEMA DE SALUD.  Arenas Caro, Pedro Pablo1; Monz\u00f3n Casado, David1; Requejo Olaizola, Pedro Mikel1; Espinosa Ros, Eduardo1; Aragon Irusquieta, Larraitz1; Rey Rey, Mercedes1; De Juan Ech\u00e1varri, Mar\u00eda Dolores1; Guti\u00e9rrez Larra\u00f1aga, Mar\u00eda1; Fern\u00e1ndez, Beatriz2; Stampa, Jon2; Prada Inurrategui, \u00c1lvaro1.  1Hospital Universitario Donostia. Inmunolog\u00eda., Donostia; 2Hospital Universitario Donostia. Aparato Digestivo., Donostia.  Introducci\u00f3n. La Colangitis Biliar Primaria (CBP) es una enfermedad autoinmune caracterizada por la destrucci\u00f3n de los canal\u00edculos biliares intrahep\u00e1ticos, lo que produce colestasis y da\u00f1o hep\u00e1tico. Se estima una prevalencia en Espa\u00f1a de 19,5/100000 habitantes y una incidencia de 1,7/100000 habitantes. La identificaci\u00f3n de estos pacientes es importante para un correcto seguimiento y tratamiento. Al tratarse de una enfermedad infrecuente, la sospecha de CBP es baja, existiendo el riesgo de \u201cperder\u201d pacientes en el transcurso de la atenci\u00f3n sanitaria. El objetivo de este estudio es identificar, seg\u00fan la literatura, los pacientes con CBP que se han perdido por el sistema de salud en el \u00e1rea de Gipuzkoa.  Materiales y m\u00e9todos. Estudio retrospectivo de bases de datos de resultados anal\u00edticos de inmunolog\u00eda y bioqu\u00edmica, y revisi\u00f3n de historias m\u00e9dicas de los sistemas inform\u00e1ticos del \u00c1rea de Salud de Gipuzkoa, entre el 01/01/2019 y el 31/12/2021. El diagn\u00f3stico de CBP se basa en un t\u00edtulo de anticuerpos anti-mitocondriales (AMA) \u2265 1/80, elevaci\u00f3n cr\u00f3nica de la fosfatasa alcalina (FA) y ausencia de otras patolog\u00edas hep\u00e1ticas. Los pacientes fueron identificados como \u201cperdidos por el sistema\u201d en ausencia de diagn\u00f3stico m\u00e9dico y/o seguimiento y tratamiento m\u00e9dico espec\u00edficos.  Resultados. Pacientes con FA y AMA positivos: 178 Pacientes diagnosticados de CBP, HAI, s\u00edndromes overlap o patolog\u00edas relacionadas: 164 (92,1%) Pacientes perdidos por el sistema: 14 (7,9%)   Conclusiones. Un 7,9% de los pacientes que cumpl\u00edan con los criterios diagn\u00f3sticos de CBP han sido perdidos por el sistema.   \n  \nEstos pacientes no se est\u00e1n beneficiando de tratamientos espec\u00edficos efectivos (principalmente \u00e1cido ursodesoxic\u00f3lico) para modificar la progresi\u00f3n a cirrosis y complicaciones asociadas. El screening de AMA con t\u00edtulo \u2265 1/80 junto con elevaci\u00f3n cr\u00f3nica de FA se muestra como criterio eficaz para el diagn\u00f3stico de CBP. Junto con la historia cl\u00ednica, permite detectar \u201cp\u00e9rdidas de pacientes\u201d por el sistema de salud.                      \n  \nP-167 ANTI-OJ ANTIBODY NOT DETECTED BY COMMERCIAL LINE IMMUNOASSAY Baucells De La Pe\u00f1a, Andr\u00e9s1; Mart\u00ednez Mart\u00ednez, Laura2; \u00c1lvaro Gargallo, Yolanda2; Molt\u00f3 Lacosta, Elisabeth2; Calahorro Aguilar, Ver\u00f3nica2; Mill\u00e1n Arciniegas, Ana Milena2; Lobo Prat, David2; Ju\u00e1rez Rubio, C\u00e1ndido2; Castellv\u00ed Barranco, Iv\u00e1n2; Castillo Villegas, Diego2; Mariscal Rodriguez, Ana\u00eds2.  1Corporaci\u00f3 Sanitaria Parc Taul\u00ed, Sabadell; 2Hospital de Sant Pau, Barcelona.  Introduction:  The anti-synthetase syndrome (ASS) is a rare autoimmune disease defined by antibodies directed against an aminoacyl tRNA synthetase along with clinical features that can include interstitial lung disease (ILD), myositis, Raynaud\u2019s phenomenon, arthritis, unexplained fever, and mechanic\u2019s hands. The anti-synthetase antibodies are particularly useful in the identification of patients with ILD, since many times the distinctive muscle weakness is not present.     Clinical case:  We report a 65 years old male who debuted in February 2021 with a low exertion dyspnoea, with cough without expectoration that required oxigenotherapy. Radiography was performed showing bilateral infiltrates in the lungs, and it was evaluated as a bilateral pneumonia, highly suspicious of infection by SARS-COV-2. The result of the PCR was negative and the CT scan showed findings consistent with bilateral organized pneumonia.  Treatment with 80 mg prednisone was started but despite that, due to increased O2 requirements, he was transferred to the ICU where he required invasive ventilation. In the differential diagnosis of organized pneumonia, antinuclear antibodies (ANA) and commercial myositis profile were tested.    Results: The ANA testing revealed a 1:640 cytoplasmic dense fine speckled (AC-19) pattern that strongly suggested an anti-synthetase antibody. But the myositis profile turned out to be negative. Because the clinical suspicion matched the ANA pattern, an RNA immunoprecipitation was performed and we observed a pattern compatible with anti-synthetase antibody. Then, we performed a protein immunoprecipitation-western blot. The result revealed that it was an anti-OJ antibody that recognizes conformational epitopes.      \n  \nConclusion: In the case of a negative myositis immunoblot with high clinical suspicion for anti-synthetase syndrome and ANA pattern that supports it, the diagnosis should not be discarded.  In these cases, it is recommended to perform an extended analysis including RNA and protein immunoprecipitations.                                                \n  \nP-168  COMPARACI\u00d3N DE TRES T\u00c9CNICAS PARA LA DETERMINACI\u00d3N DE ANTICUERPOS ANTI-DSDNA   Ruiz B\u00e1\u00f1ez, Judit; Escuder Azuara, Elsa; Creus Izquierdo, Mireia; Rodr\u00edguez Villasante, Marta; G\u00f3mez N\u00fa\u00f1ez, Ana; Mart\u00ednez \u00c1balos, Mar\u00eda Jos\u00e9; Castro Garc\u00eda, Elisa; Egu\u00eda N\u00fa\u00f1ez, Jorge; Villegas Mart\u00edn, Eduardo.  Laboratori de Refer\u00e8ncia de Catalunya, El Prat de Llobregat.   Introducci\u00f3n  Los anticuerpos anti-\u00e1cido desoxirribonucleico de cadena doble (anti-dsDNA por sus siglas en ingl\u00e9s) se asocian principalmente a lupus eritematoso sist\u00e9mico (LES), siendo de utilidad para el diagn\u00f3stico y el seguimiento. No obstante, si existe una alta sospecha cl\u00ednica, el LES no debe descartarse ante un valor negativo de anticuerpos anti-dsDNA, ya que existen otros criterios diagn\u00f3sticos.  Objetivo  Comparar los resultados de tres t\u00e9cnicas para la determinaci\u00f3n de anticuerpos anti-dsDNA: inmunoensayo multiplex (BioPlex 2200, Bio-Rad), inmunoblot (EUROBlotOne, Euroinmmun) e inmunofluorescencia indirecta (IFI) sobre Crithidia luciliae (Sprinter, Euroinmmun).  Material y M\u00e9todos  Se analizaron un total de 214 muestras s\u00e9ricas por estas tres t\u00e9cnicas. En el caso del inmunoensayo multiplex, se consideraron positivas aquellas muestras con un valor >10 IU/mL siguiendo las indicaciones del fabricante.  Resultados  Todas las muestras negativas por multiplex (\u226410 IU/mL) fueron tambi\u00e9n negativas por los otros dos m\u00e9todos con la excepci\u00f3n de una muestra que fue positiva por IFI y otra que fue positiva por inmunoblot. De los resultados positivos por multiplex con valores entre 11 y 20 IU/mL, el 22,99 % se confirmaron por IFI sobre Crithidia, el 10,34 % por inmunoblot y el 6,90 % por ambas t\u00e9cnicas.   El porcentaje de resultados concordantes entre multiplex e IFI aument\u00f3 hasta el 33,33 % en el rango de 21-30 IU/mL, hasta el 59,57 % para valores entre 31-90 IU/mL y hasta el 80,95 % en resultados >90 IU/mL.  Conclusi\u00f3n  La diferencia de sensibilidad y especificidad entre los distintos m\u00e9todos hace necesaria la realizaci\u00f3n de al menos dos t\u00e9cnicas para confirmar los resultados positivos. La t\u00e9cnica por  \n  \nmultiplex demuestra una alta sensibilidad, pero es necesaria la confirmaci\u00f3n por IFI, mucho m\u00e1s espec\u00edfica, para descartar los falsos positivos. El uso de una tercera t\u00e9cnica, como podr\u00eda ser el inmunoblot, podr\u00eda ser de utilidad en casos con resultados dudosos o discrepantes.                                                     \n  \nP-169  DISCREPANT RESULTS BETWEEN DSDNA ANTIBODY ASSAYS FOR DIAGNOSIS AND FOLLOW UP OF SLE  Trujillo Aguilera, Antonio; Bernardo Serrano, Raquel; Navas Romo, Ana; Aguado \u00c1lvarez, Roc\u00edo; \u00c1lvarez Romero, Paula; Cantis\u00e1n Boh\u00f3rquez, Sara; Jurado Roger, Aurora.  Hospital Universitario Reina Sof\u00eda, C\u00f3rdoba.  Introduction There are a variety of tests to identify anti-dsDNA autoantibodies, but EliA and Crithidia immune-fluorescence test (CLIFT) are the most commonly used. Due to their differences in specificity and sensitivity, it is frequent to obtain discrepant results between them. Despite the high sensitivity of EliA, CLIFT is still considered the gold standard for high avidity anti-dsDNA antibodies in SLE. This study aimed to outline the relevance of EliA in discrepant cases after 4-6 years of follow-up. Materials and methods ANA screening by indirect immunofluorescence was performed in 6954 samples and EliA anti-dsDNA antibodies were tested for those showing a related pattern. 1024 samples were classified as positive (anti-dsDNA >10 UI/ml) and CLIFT was only performed in 417 of them belonging to 225 patients. The diagnosis, evolution and clinical relevance of both tests were studied in patients with discrepant results. Results Among 225, 89 of patients were CLIFT and EliA positive and 127 were discrepant (EliA positive and CLIFT negative). 44 discordant patients were SLE diagnosed, 10 of them were new diagnoses and 34 were active flares in already diagnosed patients. Quantitative results for anti-dsDNA in each group are shown in Table 1. Our results shown that 52% of positive sera for EliA and negative CLIFT belonged to SLE patients. Discrepant samples of SLE patients showed moderate titers (15-50 UI/ml), 10% of discrepant results belonged to individuals who were diagnosed between 4 months and 4 years after testing and 78% of SLE discrepant patients were already diagnosed. Conclusions Positive EliA with negative CLIFT cases and with no adhesion to EULAR/ACR 2019 criteria, should be followed up. Moreover, CLIFT can display negative results in patients suffering a flare that is detected by EliA, reinforcing the importance of quantitative assays as monitoring      \n  \nP-170  LABORATORY DIAGNOSTIC APPROACH TO SUSPECTED AUTOIMMUNE ENCEPHALITIS IN A REGIONAL REFERRAL HOSPITAL: IS THE COST-BENEFIT RATIO BALANCED  Trujillo Aguilera, Antonio; Aguado \u00c1lvarez, Roc\u00edo; Navas Romo, Ana Mar\u00eda; \u00c1lvarez Romero, Paula; Cantis\u00e1n, Sara; Jurado Roger, Aurora.  Hospital Reina Sof\u00eda de C\u00f3rdoba, Instituto Maimonides de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba (IMIBIC)/Universidad de C\u00f3rdoba., C\u00f3rdoba.  Autoimmune encephalitis (AE) comprises a group of immune-mediated inflammatory disorders involving central nervous system. In past years, the number of autoantibodies targeting neuronal surface or synaptic antigens has increased. We aimed to evaluate the performance of the diagnostic approach to AE in a regional referral hospital. Materials and methods  469 samples from 415patients admitted to Neurology with clinical suspicion of AE or compatible symptoms between 2019 and 2022 were revised. These samples of serum, cerebrospinal fluid (CSF) or pairs sera-CSF were tested using a commercial biochip by Euroimmun. This kit detects autoantibodies by indirect immunofluorescence assay (IIFA) using human-embryonic-kidney cells transfected to express NMDAR, GAD65, LGI1, CASPR2, AMPAR1-2 and GABABR. Results 9 (2.17%) patients showed a positive result: 5 (1.2%) were positive against NMDAR, 3 (0.72%) were anti-CASPR2, and 1 (0.24%) was anti-GABABR. Nevertheless, the initial suspicion of AE was maintained in some patients despite a negative result. Discussion  We obtained similar ranges to published data (2.62-5.3%), but the incidence in our population was fewer than expected (0.35/100.000 person-years compared to 0.8-1/100.000 in published data). The presence of antibodies against antigens not included in the kit, or posible false-negative results, have been reported for anti-GABAR, LGl1 and AMPAR. The low number of tests requested and positive cases ratio, due to a non-restrictive patient selection, would be higher if suspicion were nearer to proposed guidelines. However, it could miss non-typical presentations, meaning the delay of the treatment onset. \u2006  Conclusions It is advisable to carry out a fine selection of patients to be tested under the recommended guidelines.  In high suspicion of AE with negative result of the test, the study should be repeted in reference laboratories with different techniques.  \n  \nThe efficiency of the early treatment and the severe course without therapy offsets the potential cost of non-selected cases.                                                     \n  \nP-171  LONGITUDINAL FOLLOW UP OF ILCS IN PERIPHERAL BLOOD OF CLADRIBINE-TREATED MS PATIENTS   Zurera Egea, Coral1; Fondelli, Federico1; Teniente Serra, Aina2; Presas Rodr\u00edguez, Silvia2; Mansilla, Maria Jos\u00e91; Willemyns, Jana1; Ramo Tello, Cristina2; Mart\u00ednez C\u00e1ceres, Eva2.  1Fundaci\u00f3 Institut d\u2019investigaci\u00f3 en Ci\u00e8ncies de la Salut Germans Trias i Pujol (IGTP), Badalona; 2Hospital Universitari Germans Trias i Pujol, Badalona.  Introduction: Multiple Sclerosis (MS) is a disease characterized by the autoimmune response against the myelin of the central nervous system in which various cell types are involved. Cladribine is an oral MS treatment reported to induce a decrease in both CD4+ and CD8+T-cells, B-cells and Natural Killer cells. Alterations on the myeloid lineage such as in Dendritic Cells have not been observed after cladribine treatment. Innate lymphoid cells (ILCs) are lymphocytes that lack the expression of an antigen-specific cell receptor. These represent a very small subset in peripheral blood and are divided in three immunoregulatory subsets; ILC1, ILC2 and ILC3, that mimic Th1, Th2 and Th17 CD4+ T-cell subsets, respectively. ILCs are involved in the pathogenesis of some autoimmune diseases. Considering their potential involvement in MS pathogenesis and the lack of data regarding the effect of cladribine on ILCs, we aimed to evaluate the long-term effects of cladribine on ILCs in a 3-year follow-up study. Methods: 11 MS patients were included. Samples were obtained at Baseline, 3, 6, 12, 18, 24 and 30 months after initial treatment. We performed flow cytometry analyses on samples obtained after bulk-lysis of 15ml of whole blood. Samples were acquired through FACSFortessa (BDBiosciences) and analysed through FlowJo Software. Statistical analyses and graphs were performed through SPSS and GraphPad softwares. Results: No significant differences were observed in the main three ILC subsets throughout the follow-up. However, the C-kit+CD161-ILC2 subset was significantly increased after 12 months (Fig.1a). Also, NCR+CD161-ILC3 cells increased throughout time and significantly decreased at the 12-month timepoint (Fig.1b). Finally, CD161 expression in ILC2s significantly increased throughout time. (Fig.1c). Conclusions: Results indicate that cladribine treatment induces changes in several ILC subsets, that could be possibly related with its therapeutical effect. An increased sample size might unravel other subset differences masked due to interindividual variability.   \n  \n                         \n \n  \nP-172  DETERMINACI\u00d3N DE ANTICUERPOS ANTI-FIBRILARINA POR LINEDOT   Lucas Blanco, \u00c1ngela; Aguilar Criado, Marta; D\u00edaz Lozano, Azahara; Alcal\u00e1 Pe\u00f1a, Mar\u00eda Inmaculada; Vargas P\u00e9rez, Maria Luisa.  Servicio de Inmunolog\u00eda. Hospital universitario de Badajoz, Badajoz.  Indtroduci\u00f3n:  Los anticuerpos antifibrilarina/U3snRNP (AFA), espec\u00edficos de la esclerosis sist\u00e9mica (ES), presentan patr\u00f3n de inmunofluorescencia indirecta (IFI) AC-9 sobre c\u00e9lulas hep-2. La confirmaci\u00f3n de los mismos debe realizarse por otras t\u00e9cnicas como linedot o ELISA. Nuestro objetivo es comprobar la correlaci\u00f3n, en nuestro medio, de patr\u00f3n AC-9, antifibrilarina, y desarrollo de ES.   Material  M\u00e9todos:   Estudio retrospectivo de pacientes con patr\u00f3n AC-09 (IFI en c\u00e9lulas Hep-2000) a los que se realiz\u00f3 linedot espec\u00edfico de esclerosis (Euroimmun \u00a9) (periodo de estudio 2018-2021).  Se revisaron sus historias cl\u00ednicas en base a los criterios clasificatorios de ACR/EULAR 2013.  Resultados:   Un total de 26 pacientes fueron analizados: 15 AFA+ (11 mujeres, 4 hombres. Mediana edad 57 a\u00f1os) y 11 AFA- (6 mujeres, 5 hombres. Mediana de edad 60 a\u00f1os).   Entre los pacientes AFA+, dos casos presentaban ES definida (>9 puntos), 8 presentaban alg\u00fan \u00edtem sin llegar a reunir criterios clasificatorios (fen\u00f3meno de Raynaud, edema de manos y/o enfermedad pulmonar intersticial), 5 pacientes no presentaban ning\u00fan criterio. En total 10 (66%) presentaban diagn\u00f3stico/criterios clasificatorios.   Entre los AFA- se detect\u00f3 un paciente con ES definida. El resto (90%) no presentaba ning\u00fan criterio.   De un total de 11 casos con diagn\u00f3stico/s\u00edntomas compatibles, 10 (90%) son AFA+. De los 15 casos sin ning\u00fan criterio, 5(33%) son AFA+.  Seg\u00fan nuestros datos, para pacientes con ES/s\u00edntomas de inicio, la sensibilidad de los AFA ser\u00eda del 91%  Conclusiones:   Aunque la detecci\u00f3n del patr\u00f3n AC-9 no es frecuente, podr\u00eda orientar hacia la detecci\u00f3n de anticuerpos antifibrilarina por m\u00e9todo espec\u00edfico como el linedot. La presencia de AFA en nuestro estudio se asocia a esclerosis sist\u00e9mica definida o a s\u00edntomas de inicio. Seg\u00fan la literatura, dada la especificidad de este anticuerpo, el seguimiento de los pacientes AFA+ (con o sin s\u00edntomas) podr\u00eda ser aconsejable para un diagn\u00f3stico y tratamiento precoz de ES.    \n  \nP-173  INMUNOCROMATOGRAF\u00cdA ES TAN EFICAZ COMO ELISA PARA LA DETERMINACI\u00d3N DE F\u00c1RMACOS ANTI-TNF\u0391 EN SANGRE   Bermejo Olivera, Francisco Javier; Garc\u00eda Jim\u00e9nez, Sandra; Gil Etayo, Francisco Javier; Serrano Blanco, Manuel; Cabrera Marante, Oscar; Pleguezuelo Garrote, Daniel Enrique; Garcinu\u00f1o Serrano, Sara; Paz Artal, Estela; Serrano Hern\u00e1ndez, Antonio.  Hospital Universitario 12 de Octubre, Madrid.  Introducci\u00f3n: Los f\u00e1rmacos anti-TNF\u03b1 son una de las principales l\u00edneas de tratamiento para enfermedades autoinmunes sist\u00e9micas, como la artritis reumatoide y las enfermedades inflamatorias intestinales. La monitorizaci\u00f3n de los niveles de f\u00e1rmaco en sangre permite la individualizaci\u00f3n de la posolog\u00eda ya que tiene buena correlaci\u00f3n el grado de respuesta cl\u00ednica. La t\u00e9cnica m\u00e1s utilizada para medir concentraci\u00f3n de f\u00e1rmaco es el ELISA debido a su gran sensibilidad. La inmunocromatograf\u00eda es una metodolog\u00eda muy r\u00e1pida que permite obtener resultados en minutos, posibilitando una r\u00e1pida modificaci\u00f3n de la actitud terap\u00e9utica adaptada a las necesidades reales del paciente. La equivalencia de los resultados obtenidos por inmunocromatograf\u00eda con los aportados por otros inmunoensayos m\u00e1s lentos no es suficientemente conocida.    Objetivo: Evaluar la correlaci\u00f3n entre las concentraciones sangu\u00edneas de f\u00e1rmacos determinadas por ELISA e inmunocromatograf\u00eda. Material y M\u00e9todos: Se estudiaron 87 muestras de pacientes en tratamiento con Infliximab y 83 con Adalimumab respectivamente. Los niveles de cada f\u00e1rmaco se evaluaron mediante ELISA (Promonitor, Grifols) e inmunocromatograf\u00eda (QuantumBlue, B\u00fchlmann).  Resultado: En la comparativa entre ambas t\u00e9cnicas se obtuvo una fuerte concordancia para Infliximab (\u00cdndice Kappa: 0.86) y Adalimumab (\u00edndice Kappa: 0.74). Adem\u00e1s, se observ\u00f3 una correlaci\u00f3n fuerte de los valores obtenidos por ambas t\u00e9cnicas tanto para Infliximab (r=0.81, p<0.0001) y muy fuerte para Adalimumab (r=0.91, p<0.0001). Conclusi\u00f3n: La inmunocromatograf\u00eda es una t\u00e9cnica que ha llegado a su madurez y actualmente proporciona resultados comparables a ELISA en un tiempo mucho m\u00e1s corto lo que posibilita realizar intervenciones terap\u00e9uticas r\u00e1pidas que redundan en beneficio del paciente.             \n  \nP-174   A CASE OF TRANSVERSE MYELITIS WITH MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODIES AND COVID-19 INFECTION.   Pacho De Lucas, Mar\u00eda Ar\u00e1nzazu; Maruri Machado, Natalia.  Laboratorio de Inmunolog\u00eda. Hospital Universitario Cruces, Baracaldo.  Introduction The inflammatory demyelinating diseases of the central nervous system has expanded with the identification of glial autoantibodies against aquaporin-4 (AQP4-IgG) and myelin oligodendrocyte glycoprotein (MOG-IgG). MOG-IgG antibodies have been established as a biomarker for MOG-antibody-associated disease (MOGAD). In this disease, myelitis is the second most common presentation in adults, followed by optic neuritis. MOG-IgG-associated myelitis features help to distinguish MOGAD from both multiple sclerosis and neuromyelitis optica spectrum disorder. It has long been known that viruses contribute to the production of autoimmune antibodies. Acute transversal myelitis has been reported in patients with COVID-19.  Objectives To report a case of a patient with dysuria and subsequent anuria, fever, and weakness in the lower extremities, presenting antibodies to MOG and with COVID-19.  Material and Methods MOG-IgG antibodies were determined using a cell-based assay: BIOCHIP KIT of EUROIMMUN AG (L\u00fcbeck, Germany) with employs human HEK293 cells expressing aquaporin-4 and MOG. Cerebrospinal fluid analysis and serological tests were performed. Information regarding patient\u00b4s image data, functional tests and other tests were available in the electronic medical history.  Results We present a 51-year-old male patient with dysuria of four days of evolution and anuria, fever of up to 39 \u00baC, lumbar pain and weakness in the lower extremities, and testing positive for COVID-19. Laboratory results showed positivity for autoantibodies against MOG at serum dilution of 1/400. Immunosuppressive therapy significantly improved patient\u00b4s condition.   \n  \n Conclusions The availability of a quick and simple test for the determination of MOG antibodies provides the clinician with additional information for the diagnosis and treatment of MOGAD. This case adds to the growing literature describing a possible relationship between this autoimmune disease and COVID-19.                                              \n  \nP-175  COMPARATIVE ANALYSIS OF TRANSGLUTAMINASE IGA AUTOANTIBODIES DETECTED BY QUANTA-FLASH\u00ae VERSUS APTIVA\u00ae IN THE DIAGNOSE OF CELIAC DISEASE  \u00c1lvarez Romero, Paula; Trujillo Aguilera, Antonio; Molina Alcaide, Juan Eduardo; Aguado \u00c1lvarez, Roc\u00edo; Cantis\u00e1n Boh\u00f3rquez, Sara; Jurado Roger, Aurora.  Hospital Universitario Reina Sof\u00eda, C\u00f3rdoba.  Background: Celiac disease (CD) is a chronic enteropathy mediated by immune mechanisms and triggered by the exposure to diet gluten in genetically susceptible individuals, resulting in an atrophy of the small bowel mucosa and a malabsorption syndrome. The identification of sera autoantibodies (IgA) against tissular transglutaminase (tTG) is critical for its diagnosis, supported by other clinical, genetic and histologic findings. The aim of this study was to compare two semi-quantitative methods detecting serum tTG IgA: the recent launched Aptiva\u00ae (Werfen, Inova Diagnostics, Inc.) and the previous established QUANTA-Flash\u00ae (Werfen, Inova Diagnostics, Inc.). Materials and methods: A total of 172 serum samples were routinely and duplicate tested for tTG IgA autoantibodies in patients with the suspicion of or having being diagnosed with CD, using QUANTA-Flash\u00ae and Aptiva\u00ae. According to the manufacturer, the positivity threshold for QUANTA-Flash\u00ae was 20 CU (Chemiluminescent Units), with a grey zone ranging from 20 to 30 CU; and 5 FLU (Fluorescent Light Units) for Aptiva\u00ae. Anti-endomysium antibody detection was performed as confirmatory test. Results: Both methods equally identified 166 negative and 5 positive values. Exceptionally, one value was detected in the grey zone only by QUANTA-Flash\u00ae. This value belonged to a patient who exhibited uncertain CD symptomatology. The positive tTG samples also presented positive anti-endomysium autoantibodies, and all of them belonged to patients diagnosed with CD. The correlation analysis showed a Pearson coefficient of 0.976 (p<0.01). The difference between values obtained by each method was calculated and then analysed by Student T test, with no significant differences found (p=0.13), suggesting an adequate concordance. Conclusion: Anti-transglutaminase autoantibody detection by QUANTA-Flash\u00ae and Aptiva\u00ae was highly reproducible. However, Aptiva system is able to simultaneously detect anti-tTG IgA antibodies, anti-deaminated gliadin peptide IgA antibodies and total IgA quantification in a single reaction thanks to the multi-analyte technology.  \n  \nP-176  PACIENTE CON LUPUS ERITEMATOSO SIST\u00c9MICO Y PRESENCIA DE ANTICUERPOS ANTI MI-2 Requejo Olaizola, Pedro Mikel; Espinosa Ros, Eduardo; Arenas Caro, Pedro Pablo; Rey Rey, Mercedes; Monz\u00f3n Casado, David; Arag\u00f3n Iruskieta, Larraitz; De Juan Echavarri, Mar\u00eda Dolores; Prada I\u00f1urrategui, \u00c1lvaro.  HUD Donostia, San Sebasti\u00e1n (Guip\u00fazcoa).  Introducci\u00f3n: El LES es una enfermedad autoinmune sist\u00e9mica en la que multitud de \u00f3rganos se ven da\u00f1ados por el dep\u00f3sito de inmunocomplejos. Para su diagn\u00f3stico se deben cumplir los criterios diagn\u00f3sticos del EULAR/Colegio Americano de Reumatolog\u00eda que combinan diferentes manifestaciones cl\u00ednicas y criterios anal\u00edticos (ANAs e hipocomplementemia). Sin embargo, existen otros autoanticuerpos muy raramente asociados a LES como anti-Mi2, espec\u00edfico de miopat\u00eda inflamatoria. Objetivo: Presentamos el caso de una mujer de 35 a\u00f1os sin antecedentes m\u00e9dicos de inter\u00e9s ingresada en Medicina Interna tras cuadro de astenia severa. Asocia r\u00e1pida p\u00e9rdida ponderal, febr\u00edcula, v\u00e9rtigos, aftas orales, erupciones cut\u00e1neas sim\u00e9tricas en extremidades y espalda. En la exploraci\u00f3n llama la atenci\u00f3n la dificultad para subir escaleras. En la anal\u00edtica sangu\u00ednea destacan trombopenia y linfopenia junto con test de Coombs directo positivo en ausencia de anemia hemol\u00edtica. Materiales y m\u00e9todos: An\u00e1lisis de ANAs y otras especificidades mediante IFI e IB por el Servicio de Inmunolog\u00eda tras valoraci\u00f3n cl\u00ednica en planta.        \n  \nResultados: AUTOINMUNIDAD  Nucleares anticuerpos (ANA) (IFI)  Positivo a t\u00edtulo 1/1280. Patr\u00f3n homog\u00e9neo  DNA doble cadena, Ac (IFI)  Positivo  DNA doble cadena, Ac 6.356,70 Ant\u00edgeno nuclear extra\u00edble (ENA), Ac  Positivo  Ant\u00edgeno nuclear extra\u00edble ENA, Ac (IB)  Nucleosomas, Ac  Positivo++  DFS70, Ac  Positivo++  Histona, Ac  Positivo++  Ro-52, Ac  Positivo+++  SS-A, Ac  Positivo+++  Miopat\u00edas Inflamatorias, Ac (IB)  Mi-2 alfa, Ac  Positivo+++  Ku, Ac  Positivo+++  Resto de especificidades negativas  Conclusiones: Existen muy pocos casos descritos en la literatura de pacientes diagnosticados de LES con presencia de anticuerpos anti-Mi-2, espec\u00edficos de miopat\u00eda inflamatoria. Resulta llamativa la combinaci\u00f3n de manifestaciones cl\u00ednicas y anticuerpos espec\u00edficos de ambas entidades (LES y miopat\u00eda) simult\u00e1neamente.         \n  \nP-177  COMPARATIVA ENTRE LA PCR-SSO Y LA PCR EN TIEMPO REAL EN EL ESTUDIO GEN\u00c9TICO DE LA ENFERMEDAD CEL\u00cdACA  Mora D\u00edaz, Sergio; Jim\u00e9nez Portillo, Ana Luc\u00eda; Bravo Gonz\u00e1lez, Maikel; Marco De La Calle, Francisco Manuel; Fusi Velarde, Cinthia Mavel.  Hospital General Universitario Dr. Balmis, Alicante.  La enfermedad cel\u00edaca es una patolog\u00eda cr\u00f3nica autoinmune de afectaci\u00f3n enteral causada por el gluten (presente en trigo, centeno y cebada) y prolaminas, que afecta a 1 de cada 100 personas a nivel mundial. La celiaqu\u00eda se caracteriza por el desarrollo de una respuesta inmunitaria contra el intestino delgado que da\u00f1a las vellosidades intestinales, produciendo inflamaci\u00f3n y malabsorci\u00f3n. Aunque los s\u00edntomas cl\u00ednicos son heterog\u00e9neos dependiendo de los pacientes, los m\u00e1s comunes son la diarrea, dolor y distensi\u00f3n abdominales. La enfermedad es una enfermedad polig\u00e9nica que muestra una fuerte asociaci\u00f3n gen\u00e9tica con genes localizados en la regi\u00f3n HLA (Human leukocyte Antigen) del cromosoma 6p21, desarroll\u00e1ndose en personas gen\u00e9ticamente susceptibles. Las mol\u00e9culas HLA implicadas en el reconocimiento del gluten y presentaci\u00f3n a los linfocitos T CD4+ son heterod\u00edmeros formados por una subunidad \u03b1 y una \u03b2 codificadas por los genes HLA-DQA1 y HLA-DQB1, respectivamente. La gran mayor\u00eda de los pacientes cel\u00edacos (90%-96%) presentan el heterod\u00edmero HLA-DQ2 (isoforma DQ2.5) y los restantes el HLA-DQ8. Adem\u00e1s, hay un efecto de dosis en los genes HLA-DQB1*02 y HLA-DQB1*03, siendo recomendable su informaci\u00f3n. Para determinar los heterod\u00edmeros implicados en la enfermedad se pueden genotipar los genes HLA-DQA1 y HLA-DQB1, o bien determinar los alelos espec\u00edficos que los codifican. Se compararon los genotipos HLA-DQA1*03/05 y HLA-DQB1*02/03:02 determinados en 200 muestras mediante PCR-SSO (single specific oligonucleotid) y PCR en tiempo real. Se observ\u00f3 una correlaci\u00f3n cercana al 100% en la determinaci\u00f3n de los genotipos anteriores mediante ambas t\u00e9cnicas. La PCR en tiempo real ofrece resultados en menor tiempo que la PCR-SSO.               \n  \nP-178  REFERENCE VALUES OF ANTI-MYELOPEROXISASE AND ANTI-SERINE PROTEIN 3 ANTIBODIES  Barba Naveiro, Uxia; Batllori Tragant, Marta; Poyatos Cant\u00f3n, Elisabet.  Hospital Sant Joan de D\u00e9u, Esplugues de Llobregat.  Introduction Antineutrophil cytoplasmic autoantibodies (ANCA) against myeloperoxidase (MPO) and serineprotease3 (PR3) are useful in the diagnosis of small vessel vasculitis. Their early detection is crucial due to the rapid progression of the pathology.  Objective Review of reference values for anti-MPO and anti-PR3.  Material and Methods Establishment of anti-MPO and anti-PR3 reference values in 40 presumably healthy individuals (age:0.58-86 years, 60%men) by non-parametric test. Retrospective review of 66 patients (age:59.2 (9-91) years, 61%women). We analised anti-MPO and anti-PR3 by chemiluminescence (AcuStar. Werfen) over 10 years. Demographic and clinical variables were collected. Sensitivity (Se), specificity (Sp) and AUC were calculated by ROC curves, the risk (OR) of vasculitis by logistic regression and the difference of antibodies by Student's t-test in different diseases using Stata 14.0.  Results With the manufacturer's cut-off (19.9IU/mL), 16.7% had anti-PR3 (46% vasculitis, 55% gastric disorders, 27% rheumatic), 13.6% anti-MPO (44% vasculitis, 56% bronchial alteration and 22 % rheumatoid arthritis (RA)) and 4.5% (n:3) anti-MPO+anti-PR3 (1. Vasculitis and RA, 2. neurological and gastric disorders, 3. rheumatological disorders). For vasculitis, anti-PR3 showed Se:42%, Sp:85%, AUC: 0.56 and anti-MPO Se:42%, Sp:85%, AUC:0.58 and OR:4(p:0.043). The cut-off obtained in our healthy population presented: anti-PR3 <3.2IU/mL (Se:58%, Sp:43%, OR:4.8(p:0.020)) and anti-MPO <4.1IU/mL(Se:58% and Sp:36%). The optimal Se-Sp cut-off presented: anti-PR3<12.7IU/mL(Se:42%, Sp:83%, OR:4(p:0.031)) and anti-MPO<9.2IU/mL(Se:58%, Sp:74%). Anti-PR3 and anti-MPO showed differences in vasculitis (p:0.025 and p<0.001, respectively) and anti-MPO in RA (p:0.004) and bronchial alteration (p:0.002).   \n  \nConclusions -We suggest to decrease the anti-PR3 cut-off (12.7IU/mL) and to maintain the anti-MPO cutoff (19.9IU/mL). Both cut-offs obtained in our healthy population have low diagnostic performance. Lower anti-PR3 cut-off(12.7IU/mL) supposes a significant increase in the vasculitis diagnostic capacity with similar Se-Sp. Lower anti-MPO cut-off (9.2IU/mL) decreases Sp and loses the diagnostic capacity. -Anti-PR3 and anti-MPO increases significantly in vasculitis and anti-MPO in RA and bronchial alteration.                                           \n  \nP-179  EVALUACION DE LA DEMANDA DE ANTICUERPOS ANTINUCLEARES EN EL LABORATORIO DE INMUNOLOG\u00cdA DE UN HOSPITAL TERCIARIO   Espinosa Ros, Eduardo; Arenas Caro, Pedro; Requejo Olaizola, Pedro; Rey Rey, Mercedes; Monzon Casado, David; Arag\u00f3n Iruskieta, Larraitz; De Juan Echavarri, Maria Dolores; Prada I\u00f1urrategui, Alvaro.  Hospital Universitario de Donosti, Donosti.  Introducci\u00f3n: Una gesti\u00f3n apropiada del an\u00e1lisis de los anticuerpos antinucleares (ANAs) es necesaria ya que suponen importantes cargas de trabajo en el laboratorio de inmunolog\u00eda, un aumento del coste en el sistema de salud, influyen en la seguridad del paciente y tienen un impacto negativo en la eficiencia de los facultativos. Objetivo: Evaluar la demanda de ANAs en el laboratorio de Inmunolog\u00eda de un hospital terciario durante dos meses, provenientes de atenci\u00f3n especializada y primaria en el \u00e1rea sanitaria de Gipuzkoa. Otro objetivo es evaluar el porcentaje de resultados positivos. Materiales y m\u00e9todos: An\u00e1lisis retrospectivo de ANAs solicitados desde atenci\u00f3n primaria y especializada. Se eval\u00faan los resultados totales y en % sobre el total de las solicitudes de las 10 especialidades m\u00e1s demandantes. Se eval\u00faa el porcentaje de resultados positivos.    Resultados: En dos meses se analizaron 4324 sueros, fueron positivos 1442 (33%).     1. Resultados del TOP 10 de especialidades con m\u00e1s solicitudes y % sobre el total solicitados.   Total  %  AP 1939  44,8 Digestivo  525 12,14  Reumatolog\u00eda  416 9,6 Neurolog\u00eda  206 4,75 Cr\u00f3nicos  168 3,9 Hematolog\u00eda  140 3,23 Neumolog\u00eda  113 2,6 MI 109 2,5 Nefrolog\u00eda  101 2,33 Dermatolog\u00eda  101 2,33      \n  \n 2.-  TOP 10 por porcentaje de resultados positivos.     Total  Positivos  % Reumatolog\u00eda  416 273 65,6 Nefrolog\u00eda  101 41 40 Digestivo  525 186 35,4 Hematolog\u00eda  140 48 34,2 Cr\u00f3nico 168 57 33,9 Dermatolog\u00eda  101 34 33,5 Neumolog\u00eda  113 37 32,7 AP 1939  523 26,56  MI 109 27 24,7 Neurolog\u00eda  206 50 24,27  Media      35,08   Conclusiones: 1.- El \u00e1rea de AP presenta una solicitud de ANAs excesiva (44.8% del total), con un porcentaje de positivos muy bajo (26.56%). MI y Neurolog\u00eda tienen porcentajes positivos inferiores a la media. 2.- En la especialidad de AP son necesarias medidas de adecuaci\u00f3n de la demanda para disminuir costes y mejorar la eficiencia del sistema.                             \n  \nP-180  ANTICUERPOS ANTI-BETA-2-GLICOPROTE\u00cdNA I DE ISOTIPO IGA EN PACIENTE CON LIVEDO RETICULARIS D\u00edaz Alberola, Irene1; Carrasco Pardo, Esther2; Cabo Zabala, Laura2; Escobar Sevilla, Joaqu\u00edn1; J\u00e1imez G\u00e1miz, Laura1.  1Hospital Universitario Virgen de las Nieves, Granada; 2Hospital Universitario de Torrec\u00e1rdenas, Almer\u00eda.  Mujer, 74 a\u00f1os, derivada para estudio de livedo reticularis de a\u00f1o de evoluci\u00f3n. Tambi\u00e9n disestesias y parestesias en manos. Niega artromialgias, xerostom\u00eda, xeroftalm\u00eda, aftosis, fen\u00f3meno Raynaud. AP: HTA, insuficiencia venosa, no abortos o trombosis. Tratamiento: Aspirina, Losartan, Atenolol, HCTZ.  Exploraci\u00f3n: livedo reticularis severa, rizartrosis del pulgar, acrocianosis, pulsos sim\u00e9tricos, pobreza capilar en capilaroscopia. Laboratorio: hemograma, coagulaci\u00f3n, Coombs directo, crioglobulinas, complemento, factor reumatoide, Ac anti-p\u00e9ptido c\u00edclico citrulinado, inmunoglobulinas, proteinograma y PCR normales. Hematuria y leucocituria. IFI Hep-2 patr\u00f3n nuclear homog\u00e9neo (AC-1) > 1/320, Ac anti-DNAdc 51 U/mL [0-15] confirmados por IFI Crithidia. Anticoagulante l\u00fapico negativo, Ac anti-beta-2-Glicoprote\u00edna I IgM 10 U/mL [0-10], anti-beta-2-Glicoprote\u00edna I IgG 1,9 U/mL [0-10], anti-beta-2-Glicoprote\u00edna I IgA 29 U/mL [0-10], anti-cardiolipina IgM 5.5 MPL/mL [0-40], anti-cardiolipina IgG 1.3 GPL/mL [0-20], anti-cardiolipina IgA 7 APL/mL [0-20]. A las 12 semanas, confirma positividad anti-beta-2-Glicoprote\u00edna I IgA 33 U/mL. El s\u00edndrome antifosfol\u00edpido (SAF) es un trastorno autoinmune sist\u00e9mico caracterizado por fen\u00f3menos tromb\u00f3ticos y/o morbilidad gestacional en pacientes con anticuerpos antifosfol\u00edpidos (aPL) altos y mantenidos, concretamente anticoagulante l\u00fapico, y los isotipos IgG e IgM anti-beta-2-Glicoprote\u00edna I y anti-cardiolipina. Puede darse como cuadro primario o asociado a otras enfermedades autoinmunes, principalmente lupus eritematoso sist\u00e9mico (LES). Para su diagn\u00f3stico se emplean los criterios de Sydney, sin embargo, han sido sujeto de debate por la existencia de pacientes con cl\u00ednica de SAF y \u2018\u2019aPL criterio\u2019\u2019 negativos, o pacientes con manifestaciones \"extracriterio\", destacando livedo reticularis, trombocitopenia, enfermedades valvulares card\u00edacas o nefropat\u00eda. La presentaci\u00f3n de livedo reticularis en la paciente y positividad anti-beta-2-glicoprote\u00edna I IgA reflejan SAF seronegativo, y ANA y Ac anti-DNAdc positivos sugieren SAF asociado a LES que a\u00fan no cumple criterios, planteando inicio con hidroxicloroquina. El tratamiento con aspirina podr\u00eda estar enmascarando fen\u00f3menos  \n  \ntromb\u00f3ticos, siendo imprescindible el seguimiento de la paciente, recalcando la importancia de aPL \u2018\u2019no criterio\u2019\u2019 en la patogenia del SAF.   \n                      \n \n  \nSesi\u00f3n Poster. Inmunogen\u00e9tica. Pantalla 3   P-182  ESTUDIO DE LOS GENES HLA-C Y KIR EN PACIENTES CON ABORTO RECURRENTE  Gil Laborda, Raquel; Rodriguez De Frias, Edgar; Subhi-Issa, Nabil; Ochoa Grullon, Juliana; Guzman Fulgencio, Maria; Nu\u00f1ez Beltran, Maria; Fernandez Arquero, Miguel; Sanchez Ramon, Silvia.  Hospital Clinico San carlos, Madrid.  Fundamento y objetivos: Durante el embarazo en el ser humano, la decidua est\u00e1 en su mayor\u00eda poblada por linfocitos NK los cuales expresan receptores de tipo inmunoglobulina (KIR) que reconocen a sus ligandos HLA-C de las c\u00e9lulas del trofoblasto. El objetivo de este trabajo fue analizar las frecuencias de fenotipos KIR de mujeres est\u00e9riles (E) o con abortos recurrentes (AR) y su ligando HLA-C expresado por el feto, para evaluar si existe una susceptibilidad gen\u00e9tica en comparaci\u00f3n con controles f\u00e9rtiles.  M\u00e9todos del estudio: Se estudiaron las frecuencias de los genes KIR y HLA-C de 50 mujeres de AR y 96 de E; los genes HLA-C se analizaron en las parejas de cada grupo; total 119 donantes. Las frecuencias se compararon con los datos de los controles; 33 donantes. Resultados:   HLA-C1 aparec\u00eda con mayor frecuencia en el grupo control en comparaci\u00f3n con el grupo AR   y mujeres est\u00e9riles (0, 504, 0,.193; respectivamente), adem\u00e1s las mujeres control ten\u00edan una frecuencia de C1C1 combinada con KIR AA m\u00e1s alta que el resto de grupos. Al contrario, las mujeres del E   y AR, ten\u00edan mayor frecuencia de C2C2 en comparaci\u00f3n con el grupo control (mirar esta frecuencia tiene que ser menos de 1 5, .120, 5,647, respectivamente), adem\u00e1s, las mujeres del grupo AR con un KIR AA tuvieron mayor frecuencia de C2C2 (centrom\u00e9rico: P<0,05, telom\u00e9rico: P<0,05). La frecuencia KIR BB present\u00f3 mayor frecuencia de C1C1 en mujeres controles en comparaci\u00f3n con grupo de esterilidad (centrom\u00e9rico no significativo, telom\u00e9rico: P<0,05).  Conclusiones: Sugiere susceptibilidad a desarrollar aborto cuando aumenta la frecuencia de C2C2, as\u00ed como protecci\u00f3n frente a \u00e9ste cuando C1C1 est\u00e1 aumentado. Las combinaciones C1C1/AA y C1C1/BB podr\u00edan favorecer el embarazo natural, mientras que C2C2/AA tiene efecto directo en la inhibici\u00f3n de las c\u00e9lulas NK y la generaci\u00f3n de abortos.        \n  \nP-183  RETOS EN EL DIAGN\u00d3STICO GEN\u00c9TICO EN EL ESPECTRO DE PATOLOG\u00cdAS QUE CURSAN CON ELEVACI\u00d3N DE LA IGE Y MANIFESTACIONES AL\u00c9RGICAS  Balastegui Mart\u00edn, H\u00e9ctor; Garc\u00eda Mart\u00ednez, Elena; Di Natale, Marisa; Seoane Reula, Elena; Fern\u00e1ndez-Cruz P\u00e9rez, Eduardo; Rodr\u00edguez Sainz, Carmen.  Hospital Universitario Gregorio Mara\u00f1\u00f3n, Madrid.  Introducci\u00f3n La elevaci\u00f3n de IgE se observa en el contexto de numerosas enfermedades: desde asma y atopia hasta ser una primera manifestaci\u00f3n de inmunodeficiencias primarias complejas. Presentamos 4 pacientes con fenotipo cl\u00ednico semejante cuyo an\u00e1lisis gen\u00e9tico result\u00f3 crucial en el pron\u00f3stico y el manejo de los mismos. Materiales y M\u00e9todos Se aisl\u00f3 DNA gen\u00f3mico a partir de sangre de los pacientes y se procedi\u00f3 a la construcci\u00f3n de una librer\u00eda enriquecida en 200 genes relacionados al Sistema Inmune. Resultados Caso 1: Var\u00f3n de 1 a\u00f1o con antecedentes de asma, placas eritematosas cong\u00e9nitas e infecciones respiratorias. Asociaba fenotipo facial caracter\u00edstico con incremento de IgE. Se detect\u00f3 una deleci\u00f3n de 6 amino\u00e1cidos inframe en el dominio linker de la prote\u00edna  STAT3 compatible con diagn\u00f3stico molecular de S\u00edndrome HiperIgE. Caso 2: Var\u00f3n de 7 a\u00f1os con dermatitis at\u00f3pica grave, asma bronquial y elevaci\u00f3n de IgE. El an\u00e1lisis gen\u00e9tico detecta 2 mutaciones en el gen NLRP12 (p.Leu859Ile y p.Ala523Gly) y una mutaci\u00f3n en NLRP3 (p. Arg556Ter) que podr\u00edan estar en relaci\u00f3n a la desregulaci\u00f3n inmune del paciente. Caso 3: Ni\u00f1o de 8 a\u00f1os con m\u00faltiples otitis medias agudas y neumon\u00edas con elevaci\u00f3n persistente de la IgE donde se detecta mutaci\u00f3n en SPINK5 (p.Glu748Gly) en heterocigosis. Caso 4: Ni\u00f1o de 2 a\u00f1os con elevaci\u00f3n de la IgE, m\u00faltiples alergias alimentarias, infecciones de repetici\u00f3n y dermatitis at\u00f3pica grave. Se detecta mutaci\u00f3n en CASP10. Se hipotetiza el compromiso en la apoptosis de la v\u00eda extr\u00ednseca y  de c\u00e9lulas plasm\u00e1ticas aberrantes secretoras de IgE. Conclusiones La elevaci\u00f3n de la IgE y presencia de eccemas puede ser una manifestaci\u00f3n presente en patolog\u00edas con s\u00edntomas solapantes. La detecci\u00f3n de variantes en genes relacionados con el Sistema Inmune puede ayudar a predecir el curso de la enfermedad mediante la monitorizaci\u00f3n exhaustiva de s\u00edntomas o par\u00e1metros de laboratorio.    \n  \nP-184  NATURAL KILLER RECEPTOR VARIANTS ROLE IN THE EVOLUTION OF MYELODYSPLASTIC SYNDROMES PATIENTS   Closa, Laia1; Estrada, Natalia2; Xicoy, Blanca2; Zamora, Lurdes2; Herrero, Maria J1; Vidal, Francisco3; Caro Oleas, Jose Luis4.  1Histocompatibility and Immunogenetics Laboratory, Banc de Sang i Teixits, Barcelona; 2Department of hematology, Institut Catal\u00e0 d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Badalona; 3Congenital Coagulopathy Laboratory, Banc de Sang i Teixits, Barcelona; 4Department of Immunology, Hospital Cl\u00ednic, Barcelona.  Myelodysplastic Syndromes (MDS), a complex group of haematological malignancies, are characterized by ineffective haematopoiesis, bone marrow dysplasia, cytopenia and risk of progression to secondary Acute Myeloid Leukemia (sAML).  The aim of this retrospective study was to decipher the role in disease development and evolution of activating and inhibitory KIR genes as well as the activating NKG2D receptor, all them present in NK cells, and also their respective ligands, HLA-A, -B, -C, -G, -F, MICA and MICB. For this purpose, 89 DNA samples from MDS patients from Institut Catal\u00e0 d\u2019Oncologia (ICO) Badalona were collected and their immune target genes were studied by Next Generation Sequencing with an in-house designed gene panel. As controls, 445 healthy donors for KIR-HLA class I and 96 for non-classic HLA and NKG2D genes were analysed. Moreover, 76 AML de novo DNA samples were compared with sAML. In the first 5 years, 18 patients (20.22%) developed sAML in an average of 37.8 months (range= 3.48-60 months). The presence of the KIR2DL3/HLA-C1 pair was associated with the onset of the disease [(n=70/89, 78.65%) vs (n=283/445, 63.59%), p-value=0.0089]. Moreover, genes KIR2DL2 and KIR2DS2 were found to present a protective role of sAML and AML de novo [(n=8/18, 44.4%) and (n=35/76, 46.05%) vs (n=266/445, 59.77%), p-value=0.1 and p-value=0.02]. Furthermore, MICA129met, which enhances a stronger biding with NKG2D activating receptor, was statistically associated with protection against MDS [(n=37/89, 41.57%) vs (n=57/96, 59.38%), p-value=0.01]. No differences were found between MDS patients who underwent to sAML and AML de novo. Finally, presenting a high number (4 or more) activating KIR genes appeared to be a protective factor against sAML progression [(HighAct= 3/40, 7.5% vs LowAct=15/49, 30.61%), p-value = 0.005]. In summary, our results showed that activating NK receptor genotypes might protect against MDS, as well as the progression from MDS to sAML.       \n  \nP-185  HLA-DQA1*05 EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL EN TRATAMIENTO CON F\u00c1RMACOS ANTI-TNF   Rub\u00e9n L\u00f3pez Blanco, Rub\u00e9n; M\u00e9ndez, Isabel Mar\u00eda; Recio, Rafael; Rodr\u00edguez, Antonio; Caballero, Abelardo; Tor\u00edo, Alberto.  Hospital Regional Universitario de M\u00e1laga, M\u00e1laga.  Introducci\u00f3n: La mitad de los pacientes con enfermedad inflamatoria intestinal (EII) presentan p\u00e9rdida de respuesta al tratamiento con f\u00e1rmacos anti-TNF. Estudios recientes han demostrado una relaci\u00f3n entre la presencia del alelo HLA-DQA1*05 con un aumento de la inmunogenicidad asociada a los f\u00e1rmacos anti-TNF en la EII medida por medio de la aparici\u00f3n de anticuerpos contra el f\u00e1rmaco (Sazonovs et al. Gastroenterology, 2020).  El objetivo de nuestro estudio es evaluar si la presencia del alelo HLA-DQA1*05 se asocia al desarrollo de anticuerpos contra los f\u00e1rmacos biol\u00f3gicos en pacientes con EII en una serie de pacientes de nuestro hospital.   M\u00e9todos: Estudio de cohortes retrospectivo de pacientes con EII tratados con f\u00e1rmacos anti-TNF a los que se les hab\u00eda realizado determinaci\u00f3n de niveles del f\u00e1rmaco. La determinaci\u00f3n de anticuerpos anti-f\u00e1rmaco por Elisa (positivo >10 AU/mL) se realiza \u00fanicamente en pacientes con niveles del f\u00e1rmaco menores de 0,5 \u00b5g/mL. Se incluyeron en el estudio un total de 259 pacientes en los que se realiz\u00f3 el tipaje HLA-DQA1 por t\u00e9cnica de PCR-SSOP con kits comerciales de la casa One Lambda.  Resultados: El 42,1% de los pacientes estudiados eran portadores del alelo HLA-DQA1*05. \u00danicamente en 28 pacientes se detect\u00f3 la presencia de anticuerpos anti-f\u00e1rmaco (10,8%), siendo 16 de ellos portadores del alelo HLA-DQA1*05 (53,3%). De los 28 pacientes con anticuerpos positivos, 9 de ellos estaban tratados con adalimumab y 19 con infliximab. Aunque en los pacientes con anticuerpos anti-f\u00e1rmaco es m\u00e1s frecuente la presencia del alelo DQA1*05, esta diferencia no alcanza significaci\u00f3n estad\u00edstica (p=0.08).   Conclusi\u00f3n: No podemos confirmar los estudios previos que asocian la presencia del alelo HLA-DQA1*05 con la aparici\u00f3n de anticuerpos. Sin embargo, nuestros resultados muestran una tendencia que podr\u00eda llegar a la significaci\u00f3n con un n\u00famero mayor de pacientes.     \n  \nP-186  HETEROGENEIDAD GEN\u00c9TICO-CL\u00cdNICA EN EL ANGIOEDEMA HEREDITARIO: EXPERIENCIA EN EL LABORATORIO DE INMUNOGEN\u00c9TICA Y REVISI\u00d3N DE CASOS.    Garc\u00eda Mart\u00ednez, Elena; Balastegui Mart\u00edn, H\u00e9ctor; Di Natale, Marisa; Gil Herrera, Juana; Fern\u00e1ndez-Cruz, Eduardo; Baeza, Maria Luisa; Rodr\u00edguez-Sainz, Carmen.  Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid.  Introducci\u00f3n Mutaciones en el gen SERPING1, que codifica para la prote\u00edna C1-Inhibidor (C1-INH), se asocian al desarrollo de Angioedema hereditario (AEH) de tipo I si hay deficiencia cuantitativa, y de tipo II si se produce una alteraci\u00f3n funcional con niveles normales. El AEH es una patolog\u00eda con herencia dominante de baja prevalencia y potencialmente grave que se manifiesta cl\u00ednicamente con edemas cut\u00e1neos y en mucosas, destacando como mecanismo molecular el aumento de bradicinina y la alteraci\u00f3n de prote\u00ednas reguladoras asociadas como C1-INH. Variantes en otros genes que afectan a estas v\u00edas se relacionan con AEH-nC1INH (AEH con C1-INH normal).  Serie de casos Caso-1: Identificaci\u00f3n de variante en heterocigosis en ex\u00f3n 8 de SERPING1:p.Pro475Leu, no descrita previamente, en tres generaciones de familia con niveles reducidos de C1-INH (AEH-I) y cl\u00ednica similar asociada, solo con tratamiento sintom\u00e1tico. Caso-2: Variante en heterocigosis en SERPING1: p.pro498ser, ya descrita, en familia con AEH-I (aparici\u00f3n de novo en progenitor) y mal control de la cl\u00ednica, en tratamiento mantenido. Caso-3: Identificaci\u00f3n de dos variantes complejas monoal\u00e9licas en SERPING1: p.Glu451_Thr452insAlaAlaGly y p.Gly453delinsAspArg en familia con AEH-II, penetrancia completa pero expresi\u00f3n cl\u00ednica muy variable. Caso-4: Paciente sin antecedentes familiares con diagn\u00f3stico de AEH-I y sintomatolog\u00eda intestinal. Variante monoal\u00e9lica en ex\u00f3n 5 de SERPING1:p.Leu287His, no descrita previamente.  Caso-5: Paciente con antecedentes de carcinoma de col\u00f3n y mama, en seguimiento por Inmunolog\u00eda por hipogammaglobulinemia IgM, disminuci\u00f3n c\u00e9lulas IgM de memoria y escasa producci\u00f3n t\u00edmica. Mutaci\u00f3n monoal\u00e9lica en SERPING1:p.Arg537Gln considerada como probable patog\u00e9nica. Sin antecedentes familiares ni cl\u00ednica actual sugestiva de angioedema.  Caso-6: Tres familias no relacionadas con variante en FXII:p.Thr328Lys y AEH-III: una familia con clara asociaci\u00f3n a estr\u00f3genos (embarazos) y otras dos con d\u00e9bil/sin asociaci\u00f3n.      \n  \nConclusi\u00f3n El diagn\u00f3stico molecular de AEH se ve dificultado por la heterogeneidad al\u00e9lica de los genes implicados y un amplio espectro de manifestaciones cl\u00ednicas asociadas.                                                     \n  \nP-187  SEQUENCING OF TWO NEW HLA-B ALLELES, B*44:517 AND B*45:01:01:09, IDENTIFIED IN TWO HAEMATOLOGICAL PATIENTS.    Planelles Silvestre, Mar\u00eda Dolores1; Balas P\u00e9rez, Antonio2; Rodr\u00edguez Cebri\u00e1, Manuel1; Montoro, Juan3; G\u00f3mez Segu\u00ed, In\u00e9s3; Luis Hidalgo, Mar1; Castro, Emma1; Larrea, Luis1; Arbona, Cristina1; Vicario, Jos\u00e9 Luis2.  1Centro de Transfusi\u00f3n de la Comunidad Valenciana, Valencia; 2Centro de Transfusion de Madrid, Madrid; 3Hospital Universitario y Politecnico La Fe, Valencia.  Introduction The usual HLA typing protocol for patients with an indication for hematopoietic stem cell transplantation includes high-resolution typing of at least the HLA-A, -B, -C, -DRB1 and -DQB1 loci. Currently, HLA typing by Next Generation Sequencing (NGS) is the one with the highest level of resolution. Objective Molecular characterisation of two novel HLA-B alleles by NGS. Material and Methods The new allele HLA-B*44:517 was identified in a patient diagnosed of acute myelogenous leukemia. Family samples were not available to confirm the new allele, therefore verification was performed with a second patient\u2019s sample obtained from epithelial buccal cells.The new HLA-B*45:01:01:09 allele was identified in a patient diagnosed with myelodysplastic syndrome with excess blasts (MDS-EB1) and in his daughter. The NGS procedure was performed using commercially available reagents (NGSgo\u00ae-MX6-1, GenDX) and a MiniSeq platform (Illumina\u2122). Data were analysed using the NGSengine\u00ae Software (GenDX) and the 3.43.1 version of the IPD-IMGT/HLA Database.  Results The new HLA-B*44:517 differs from its most closely related B*44:02:01:01 allele by one nucleotide substitution at genomic position 1704 G>A, codon 229 GAG>AAG, within exon 4. The nucleotide change results in a substitution at amino acid 229E>K. Complete HLA typing was: A*01:01:01,*02:01:01; B*37:01:01,*44:517; C*05:01:01,*06:02:01; DRB1*10:01,*13:01:01; DQB1*05:01:01,*06:03:01; DPB1*04:01:01,*14:01:01. NGS sequencing of the MDS patient\u00b4s sample for HLA-B locus provided a B*14:02:01:01, B*45:01var assignment. The daughter\u00b4s sample gave a B*45:01var, B*51:01:01:01 assignment. The new HLA-B*45:01:01:09 allele showed a 10 base pairs deletion within intron 2, positions 677-686, when compared with its closest allele B*45:01:01:01. Family haplotype analysis demonstrated that this allele is included in the haplotype:  \n  \nA*02:01:01~C*16:01:01:01~B*45:01:01:09~DRB1*10:01~DQB1*05:01:01~DPB1*02:01:02. The new HLA-B alleles were officially named as B*44:517 and B*45:01:01:09 by the WHO Nomenclature Committee for Factors of the HLA System in May 2021. Conclusions NGS technology is revealing greater polymorphism in the HLA system and facilitates the detection of new alleles.                                               \n  \nP-188  CHARACTERISATION OF TWO NEW HLA ALLELES, HLA-A*68:02:01:14 AND -DPB1*1153:01, IDENTIFIED IN TWO SPANISH BONE MARROW DONORS BY NEXT GENERATION SEQUENCING.   Planelles Silvestre, Mar\u00eda Dolores1; Balas P\u00e9rez, Antonio2; Rodr\u00edguez Cebri\u00e1, Manuel1; Luis Hidalgo, Mar1; Larrea, Luis1; Roig, Roberto1; Callao, Virginia3; Ortiz De Salazar, Mar\u00eda Isabel4; Arbona, Cristina1; Vicario, Jos\u00e9 Luis2.  1Centro de Transfusi\u00f3n de la Comunidad Valenciana, Valencia; 2Centro de Transfusion de Madrid, Madrid; 3Centro de Transfusi\u00f3n de Castell\u00f3n, Castell\u00f3n; 4Centro de Transfusi\u00f3n de Alicante, Alicante.  Introduction In order to optimize the Spanish registry of bone marrow donors, in recent years an effort has been made to type new donors to loci HLA-A, -B, -C, -DRB1 \u2013DQB1 and -DPB1 by Next Generation Sequencing (NGS). Objective Molecular and serological characterisation of two novel HLA alleles: A*68:02:01:04 and DPB1*1153:01. Material and Methods The new alleles were identified in two Spanish voluntary bone marrow donors. The NGS procedure was performed using commercially available reagents (NGSgo\u00ae-MX6-1, GenDX) and a MiniSeq platform (Illumina\u2122). Data were analysed using the NGSengine\u00ae Software (GenDX). Serologic typing analysis of cell including the new A*68:02:01:14 was performed using monoclonal and polyclonal serological commercial trays (Innotrain). Results and Discussion The new HLA-A*68:02:01:04 has a nucleotide mismatch, T>C, in the position -102 in the 5\u2019UT region of the A*68:02:01:01 allele. Sample showed the following typing: A*01:01:01,*68:02:01:14; B*14:02:01,*57:01:01; C*07:01:01,*08:02:01; DRB1*01:02:01,*07:01:01; DQB1*03:03:02,*05:01:01; DPB1*04:01:01,*04:02:01. Nucleotide position -102 is placed within the enhancer B region which has been involved in the expression level of HLA class I molecules. In order to determine a possible weak serological reaction pattern for the A*68 molecule, serologic typing analysis of cell was performed, but similar result was obtained to that for a wild type A68 molecule. This suggests that the point mutation observed does not has any effect on the expression of the HLA class I molecules. The new HLA-DPB1*1153:01 differs from its most closely related DPB1*04:02:01:02 allele by one nucleotide substitution at genomic position 9784 A>G, codon 222 AAG>GAG, within exon 4. This nucleotide change results in a substitution at amino acid 222K>E. Complete HLA typing was: A*25:01:01,*30:02:01; B*15:01:01,*18:01:01; C*03:03:01,*05:01:01;  \n  \nDRB1*01:01:01,*15:01:01; DQB1*05:01:01,*06:02:01; DPB1*04:01:01,*1153:01. The new HLA alleles were officially named as A*68:02:01:14 (HWS10061027), and DPB1*1153:01 (HWS10060569), by the WHO Nomenclature Committee for Factors of the HLA System in January 2021 and October 2020, respectively.                                                  \n  \nP-189  SEARCH PROGNOSIS ALGORITHM TO DETERMINE SIRE PROBABILITY IN CORD BLOOD UNITS FROM VALENCIAN COMMUNITY (SPAIN) DEPENDING ON HLA-A, -B AND -DRB1 FREQUENCIES  Selma-Soriano, Estela; Planelles, Dolores; Luis-Hidalgo, Mar; Castro, Emma; Larrea, Luis; Arbona, Cristina; Boix, Francisco.  Centro de Transfusiones de la Comunitat Valenciana, Valencia.  Background The development of different search algorithms for the prognosis of finding an adult unrelated donor (URD) is of great importance for transplant teams. These search tools provide the probability, according to patient\u2019s ethnicity as well as frequency of HLA genotype, of finding a match. Aim We aimed to determine the HLA genotype frequency from cord blood units (CBU) with low cellularity to stratify them as good, fair or poor prognosis groups. Methods We used the Search Prognosis Application to have genotype frequency and prognosis from 577 low-cellularity CBU collected from 1999 to 2011 from Valencian Community. CBU were categorized into 3 groups: good (likely to have 6/6 match), fair (likely to have a 5/6 match) and poor (unlikely to have a 6/6 and may not have a 5/6 match) for each ethnicity group. Data were analyzed using Chi-Square tests. P-values <0.05 were considered significant. Results Out of all CBU, 66.72% (N=385) had a good prognosis, 31.54% (N=182) had a fair prognosis and 1.73% (N=10) showed a poor prognosis. The Asian Pacific Islander (API) group showed the highest percentage of poor prognosis (N=161, 27.9%), whereas Hispanic (HIS) group showed the lowest percentage of poor prognosis (N=12, 2.08%).  Table 1. Prognosis Search from 577 CBU from Valencian Community with low cellularity    Good  Fair Poor  P-value  CAU  66.90%  28.08%  5.03%  0.0046  HIS 33.62%  64.30%  2.08%  <0.0001  API 7.45%  64.64%  27.90%  <0.0001  AFA  6.76%  84.06%  9.19%  <0.0001  CAU: White; HIS: Hispanic; API: Asian Pacific Islander; AFA: African American    \n  \nConclusions The probability to find a match, for each ethnicity group, using the Search Prognosis Application could help cord blood banks to optimize typing and selection strategies of their stored CBU suitable for allogeneic stem cell transplantation. We conclude that from our stored CBU, Caucasian will have the highest likelihood to find a 6/6 match.     \n                                \n \n  \nP-190  ESTUDIO DEL POLIMORFISMO GEN\u00c9TICO DE KIR3DL2 EN S\u00cdNDROME DE S\u00c9ZARY Y MICOSIS FUNGOIDE AVANZADA.   Santos L\u00f3pez, Adri\u00e1n1; Mart\u00edn, Paloma1; Navarro, Bel\u00e9n1; Zapata, Irma1; Ortiz, Pablo2; Vilches, Carlos1; G\u00f3mez Lozano, Natalia1.  1Instituto de Investigaci\u00f3n Sanitaria Puerta De Hierro-Majadahonda, Majadahonda; 2Hospital Universitario 12 de Octubre, Madrid.  KIR3DL2 es un receptor con caracter\u00edsticas estructurales y funcionales \u00fanicas dentro de su familia, los receptores KIR. Se expresa t\u00edpicamente en c\u00e9lulas NK y en poblaciones minoritarias de c\u00e9lulas T. Adem\u00e1s, la expresi\u00f3n de este receptor en c\u00e9lulas tumorales T CD4+ es una caracter\u00edstica molecular de algunos linfomas cut\u00e1neos de c\u00e9lulas T como el s\u00edndrome de S\u00e9zary (SS) y la micosis fungoide en estadios avanzados (MFa), sin embargo, se desconoce su papel en la etiopatogenia de estas enfermedades. Existen muy pocos datos sobre la diversidad gen\u00e9tica de KIR3DL2 en SS/MFa, y nuestro objetivo es estudiar su posible implicaci\u00f3n en estas patolog\u00edas. Para ello, hemos realizado un estudio de frecuencias al\u00e9licas y de SNPs del gen en una cohorte de 37 individuos diagnosticados de SS/MFa procedentes de los Hospitales Universitarios Puerta de Hierro-Majadahonda y 12 de Octubre y en una serie de 40 individuos control de la misma \u00e1rea geogr\u00e1fica. Los resultados muestran que determinados alelos de KIR3DL2 tienden a estar sobrerrepresentados en los pacientes con SS/MFa respecto a los controles. Estos alelos comparten un polimorfismo en la regi\u00f3n que codifica para el dominio ITIM (immunoreceptor tyrosine-based inhibition motifs) de este receptor, cuya presencia aumenta en tres veces el riesgo de padecer SS/MFa (OR: 3.3, IC95%: 1.27-8.59). Adem\u00e1s, hemos analizado la expresi\u00f3n al\u00e9lica de este polimorfismo de KIR3DL2 en muestras de sangre y en biopsias parafinadas de piel de MF en estadios tempranos, en SS/MFa y en controles. Con ello, hemos querido estudiar la asociaci\u00f3n de los diferentes patrones de expresi\u00f3n al\u00e9lica de KIR3DL2 con el curso cl\u00ednico de estas enfermedades. En conclusi\u00f3n, nuestro estudio muestra que la variabilidad gen\u00e9tica de KIR3DL2 es un factor de riesgo asociado al desarrollo de SS/MFa. Estudios posteriores permitir\u00e1n esclarecer el mecanismo de acci\u00f3n del polimorfismo gen\u00e9tico de KIR3DL2 en este grupo de linfomas.          \n  \nP-191  GENERACI\u00d3N DE MATERIAL AUDIOVISUAL PARA LA ENSE\u00d1ANZA DE LA INMUNOGEN\u00c9TICA EN GRADOS DE CIENCIAS B\u00c1SICAS Y DE LA SALUD  Meg\u00edas, Javier; San-Miguel, Teresa; Mu\u00f1oz-Hidalgo, Lisandra; Y\u00e1\u00f1ez, Alberto; Calabuig-Fari\u00f1as, Silvia; Montoliu, Carmina; Monle\u00f3n, Daniel; Morales, Jos\u00e9 Manuel; Boix-Ferrero, Javier; Bono Tapp, Cristina; Mauricio Avi\u00f1\u00f3, Mar\u00eda Dolores; Serna, Eva; L\u00f3pez-Gin\u00e9s, Concha; Gil, Mar\u00eda Luisa.  Universidad de Valencia, Valencia.  Como resultado de una colaboraci\u00f3n entre los Departamentos de Patolog\u00eda, Microbiolog\u00eda y Fisiolog\u00eda de la Universidad de Valencia, se han producido dos v\u00eddeos que introducen al alumnado de los Grados en Ciencias Biol\u00f3gicas, Medicina, Odontolog\u00eda y Podolog\u00eda a la inmunogen\u00e9tica.  Los v\u00eddeos son breves, a modo de p\u00edldora educativa, y llevan por t\u00edtulo: \u201cDescripci\u00f3n, estructura y diversidad de las inmunoglobulinas\u201d el primero, con una duraci\u00f3n aproximada de cuatro minutos, y \u201cGeneraci\u00f3n de diversidad de anticuerpos en los linfocitos B\u201d, el segundo, de seis minutos y medio de duraci\u00f3n. La tem\u00e1tica de estos v\u00eddeos, centrada en la inmunogen\u00e9tica humana, y el enfoque particular que se ha dado a su contenido, hace que sean de gran utilidad es asignaturas como: Inmunolog\u00eda, Gen\u00e9tica M\u00e9dica/Humana, Biolog\u00eda celular y Fisiolog\u00eda, ya que integra conocimientos de estas cuatro disciplinas en diferente medida:  A.  Inmunolog\u00eda: descripci\u00f3n de las inmunoglobulinas, mecanismos de producci\u00f3n de diversidad de inmunoglobulinas, afinidad en la uni\u00f3n ant\u00edgeno-anticuerpo.  B. Gen\u00e9tica m\u00e9dica/humana: loci de las cadenas de inmunoglobulinas humanas, recombinaci\u00f3n VDJ, hipermutaci\u00f3n som\u00e1tica, exclusi\u00f3n al\u00e9lica. C. Biolog\u00eda celular: caracter\u00edsticas de los linfocitos B, control de la expresi\u00f3n g\u00e9nica por modificaciones de la secuencia de ADN. D. Fisiolog\u00eda: tejidos hematopoy\u00e9ticos y sus tipos celulares, linfopoyesis. Para alcanzar una mayor difusi\u00f3n entre el alumnado de la Universidad de Valencia, los v\u00eddeos se ofrecen en espa\u00f1ol, ingl\u00e9s y valenciano y se acompa\u00f1an de una encuesta de evaluaci\u00f3n de realizaci\u00f3n voluntaria. La formaci\u00f3n de equipos de trabajo multidisciplinares en innovaci\u00f3n docente nos obliga a seguir innovando, a aprender y a esforzarnos por aportar algo m\u00e1s a la docencia. En este caso, los v\u00eddeos de inmunogen\u00e9tica, realizados por docentes de diferentes \u00e1reas permiten una difusi\u00f3n del conocimiento a un gran n\u00famero de alumnos de diferentes grados.     \n  \n Trabajo realizado en el marco de la convocatoria NOU-PID, UV-SFPIE_PID-1639302 de la Universitat de Val\u00e8ncia.                                                    \n  \nP-192  SINGULAR EVOLUTION OF MAJOR HISTOCOMPATIBILITY COMPLEX (MHC)-G AND \u2013C, AND NK RECEPTORS IN OLD WORLD AND NEW WORLD PRIMATES  Suarez Trujillo, Fabio; Palacio Gr\u00fcber, Jos\u00e9; Vaquero Yuste, Christian; Molina Alejandre, Marta; Mart\u00edn Villa, Jos\u00e9 Manuel; Arnaiz Villena, Antonio; Ju\u00e1rez, Ignacio.  Universidad Complutense de Madrid, Madrid.  Major Histocompatibility Complex (MHC)-G and -C molecules bear ligands to natural killer immunoglobulin receptors (KIR). MHC-G evolution in primates shows some anomalies. In New World monkeys MHC-G molecules show a high polymorphism and most likely are classical antigen presenters; they also cluster closer to MHC-E in a relatedness dendrogram. Their genes lack intron 2 deletion, which is typical of all other primates in regard to MHC-G. Medium-sized Eurasian-African monkeys (Cercopithecinae) show stop codons in exon 3: only MHC-G isoforms without exon 3 are possible. Big apes such as the orangutan, gorilla, and chimpanzee as well as human beings show limited HLA-G polymorphism. HLA-C has not been found in medium-size Eurasian-African monkeys, but we have found MHC-C DNA sequences in more evolutionary ancient New World monkeys. Taking into account that the KIR inhibitory receptors signal is dominated by MHC-C in human beings, this suggests that both MHC-C molecules and their ligands within natural killer lymphocyte KIR also exist in the most evolutionary ancient apes (New World monkeys were present on Earth before 40 million years ago), as KIR receptors also appeared before 130 million years ago in evolution. Indeed, KIR receptor genes have recently been found in a New World monkey.                      \n  \nP-193  TWO NEW HLA-C ALLELES, HLA-C*14:02:36 AND \u2013C*15:236, IDENTIFIED BY NEXT GENERATION SEQUENCING IN THE SPANISH POPULATION.    Balas P\u00e9rez, Antonio1; Planelles Silvestre, Mar\u00eda Dolores2; Rodr\u00edguez Cebri\u00e1, Manuel2; Granell, Rosa2; Mochol\u00ed, Carmen2; Vicario, Jos\u00e9 Luis1.  1Centro de Transfusi\u00f3n de Madrid, Madrid; 2Centro de Transfusi\u00f3n de la Comunidad Valenciana, Valencia.  Introduction Mismatching for HLA-C between patients and unrelated donors generally leads to higher risk of graft-versus-host disease and mortality after hematopoietic stem cell transplantation (HSCT), so an effort has been made recently adding HLA-C typing to registered donors.  Objective Molecular characterization of two novel HLA-C alleles by Next Generation Sequencing (NGS) technology. Material and Methods The new allele HLA-C*14:02:36 was identified in a Spanish voluntary bone marrow donor. HLA-C*15:236 was identified in a patient diagnosed of chronic myeloid leukemia; this new allele was confirmed in a second sample of DNA obtained from epithelial buccal cells. The NGS procedure was performed using commercially available reagents (NGSgo\u00ae-MX6-1, GenDX) and a MiniSeq platform (Illumina\u2122). Data were analyzed using the NGSengine\u00ae Software (GenDX). Results The new HLA-C*14:02:36 has one synonymous nucleotide change from C*14:02:01:01 at nucleotide position 2570 G > A, codon 325 GCG>GCA, within exon 6, which does not lead to any amino acid change (325A>A). The complete HLA typing of this sample was: A*02:01:01, --; B*07:02:01, *51:01:01; C*07:02:01, *14:02:36; DRB1*09:01:02G, *15:01P; DQB1*03:03:02:02, *06:02; DPB1*04:01P, *04:02P. The new HLA-C*15:236 differs from its most closely related C*15:04:01:01 allele by one nucleotide substitution, position 67 T>A, within exon 1, codon -2 TGG>AGG. The nucleotide change results in a substitution at amino acid residue -2 W>R. HLA typing of this sample was: A*24:02:01,--; B*45:01:01, *51:01:01, C*15:236,*16:01:01:01; DRB1*10:01, *13:02:01; DQB1*05:01:01, *06:04; DPB1*14:01:01, *17:01:01:01. The new HLA-C alleles were officially named as C*14:02:36 and C*15:236 by the WHO Nomenclature Committee for Factors of the HLA System in March 2020 and May 2021, respectively.   \n  \nConclusions HLA-C is now routinely typed both in patients with an indication for HSCT and in unrelated donors, which is allowing the detection of an increasingly growing number of alleles in this locus until now considered the least diverse of class I.  \n  \nP-194  TWO NEW HLA-B ALLELES, HLA-B*35:510 AND \u2013B*55:01:24, IDENTIFIED IN TWO SPANISH BONE MARROW DONORS BY NEXT GENERATION SEQUENCING.  Balas P\u00e9rez, Antonio1; Planelles Silvestre, Mar\u00eda Dolores2; Rodr\u00edguez Cebri\u00e1, Manuel2; Mart\u00ednez, Francisco2; Laguarda, Encarna2; Vicario, Jos\u00e9 Luis1.  1Centro de Transfusion de Madrid, Madrid; 2Centro de Transfusion de la Comunidad Valenciana, Valencia.  Introduction The application of NGS to routine HLA typing of donors from the Spanish voluntary marrow donor registry is allowing the detection of a large number of new HLA alleles.  Objective Molecular characterisation of two novel HLA-B alleles by Next Generation Sequencing (NGS) technology.  Material and Methods The new alleles HLA-B*35:510 and HLA-B*55:01:24 were identified in two Spanish voluntary bone marrow donors. The NGS procedure was performed using commercially available reagents (NGSgo\u00ae-MX6-1, GenDX, Utrecht, The Netherlands) and a MiniSeq platform (Illumina\u2122, San Diego, California). Data were analysed using the NGSengine\u00ae Software (GenDX) and the 3.38 (HLA-B*55:01:24) and 3.41 (HLA-B*35:510) versions of the IPD-IMGT/HLA Database.  Results The new HLA-B*35:510 differs from its most closely related B*35:03:01:01 allele by one nucleotide substitution at genomic position 968 G>A, codon 175 GGG>AGG within exon 3, resulting in coding change, Glycine 175 is replaced by Arginine. Complete HLA typing for this sample was the following: A*29:01:01,*68:01:02; B*07:05:01,*35:510; C*04:01:01,*15:05:02; DRB1*10:01:01,*11:02:01; DQB1*03:01:01,*05:01:01; DPB1*04:01:01,*13:01:01. The new HLA-B*55:01:24 has one synonymous nucleotide change from B*55:01:01:01 at nucleotide position 449 C > T, codon 83 GGC>GGT, within exon 2, which does not lead to any amino acid change (83G>G). The complete HLA typing of this sample was: A*29:02:01,*68:01:02; B*35:02:01, *55:01:24; C*03:03:01, *04:01:01; DRB1*11:01:01, *11:04:01; DQB1*03:01P,-; DPB1*04:01:01, -.  The names B*35:510 (HWS10061167) and B*55:01:24 (HWS10059043) have been officially  \n  \nassigned by the WHO Nomenclature Committee for Factors of the HLA System in February 2021 and March 2020, respectively.  Conclusions Due to the extreme polymorphism of the HLA system, NGS typing is the suitable procedure for a complete and reliable HLA typing.                                              \n  \nP-195  A NEW HLA-C ALLELE, C*12:358, DETECTED IN THE COURSE OF THE SPANISH EXTERNAL PROFICIENCY TESTING FOR HISTOCOMPATIBILITY & IMMUNOGENETICS (GECLID-SEI) PROGRAMME.   Planelles Silvestre, Mar\u00eda Dolores1; Balas P\u00e9rez, Antonio2; De Juan Ech\u00e1varri, Mar\u00eda Dolores3; Muro Amador, Manuel4; Palau, Eduard5; Mart\u00edn Alonso, Carmen6.  1Centro de Transfusi\u00f3n de la Comunidad Valenciana, Valencia; 2Centro de Transfusi\u00f3n de la Comunidad Madrid, Madrid; 3Hospital Universitario de Donostia, San Sebasti\u00e1n; 4Hospital Universitario Virgen de la Arrixaca, Murcia; 5Hospital Cl\u00ednic Universitari de Barcelona, Barcelona; 6Centro de Hemoterapia y Hemodonaci\u00f3n de Castilla y Le\u00f3n, Valladolid.  Introduction A new HLA allele, C*12:358, has been identified by Next Generation Sequencing (NGS) typing in the course of one of the HLA typing schemes within the Spanish External Proficiency Testing (EPT) for Histocompatibility & Immunogenetics (GECLID-SEI) Programme (https://www.geclid.es/ ). Objective Disambiguation of an HLA-C*12 typing. Material and Methods HLA-C low resolution typing of the EPT sample HLA21-5.06r2 by polymerase chain reaction-sequence specific oligonucleotide (PCR-SSO) method (Lifecodes HLA-C eRES SSO test, Immucor) reported inconclusive typing result with a suggestive C*04, C*06:76/*12 ambiguous assignment, with the most likely C*12 allele being C*12:03. Real time PCR typing using Olerup SSP\u00ae reagents (QType test, Olerup SSP AB) reported unambiguous C*04,*12 result, but the C*12 most probably assignment was *12:04. Confirmatory typing by NGS was performed by one laboratory (from the EPT Steering Commitee) using commercially available reagents (GenDX) and a MiniSeq platform (Illumina). Data were analyzed using the NGSengine Software (GenDX) and the 3.45.1 version of the IPD-IMGT/HLA Database. Results HLA-C sequencing gave a C*04:01:01, C*12:03:01:01var assignment after complete genomic HLA-C analysis in a single phase. The new allele showed one nucleotide difference from C*12:03:01:02 in exon 2, genomic position 435 (T>C) codon 78 (CTG>CCG), resulting in a coding change, 78L>78P. This new HLA-C allele was officially named as C*12:358 (HWS10063929) by the WHO Nomenclature Committee for Factors of the HLA System in November 2021. EPT-assigned typing of sample including C*12:358 allele was the following: A*03,*26; B*35,*38; C*04:01:01,*12:358; DRB1*04,*11; DRB3*02, DRB4*01; DQA1*03,*05; DQB1*03,*03; DPA1*01,-.  \n  \nConclusions The application of NGS to HLA typing is revealing that the HLA-C locus is almost as polymorphic as the HLA-A locus (7393 alleles vs 7452, respectively, in the latest release of the IPD-IMGT/HLA Database) and its diversity is very close to that of the HLA-B, the most polymorphic locus with 8849 alleles officially recognised as of June 2022.                                         \n \n  \nP-196  NGS AND FLOW CYTOMETRY IN RICHTER'S SYNDROME CLASSIFICATION  L\u00f3pez P\u00e9rez, Juan; Gallardo Garc\u00eda, Alberto; Garc\u00eda Cuesta, Daniel; De La Varga Mart\u00ednez, Raquel.  Hospital Universitario Puerta del Mar, C\u00e1diz.  Introduction: A 59-year-old man diagnosed with long-standing B-CLL had lymphocytosis, consisting of lymphocytes of different sizes and morphological appearance. In addition, the medulogram revealed 58% of blasts of lymphoid habitus with Burkitt morphology. The study was therefore extended to include a possible Richter's syndrome. Objective: To examine and classify Richter's syndrome by means of flow cytometry analysis (FCM) and genetic study. Material and Methods: The patient's peripheral blood was evaluated by FCM and the usage of the Euroflow LST tube, ALOT, BCP-ALL and B-CLPD tube 2. Bone marrow sample was used for genetic study by NGS sequencing and FISH, and also for an immunohistochemical analysis. Results: The FCM study revealed an infiltration of clonal B-lymphoid blasts with surface expression of immunoglobulin kappa light chain with SSC/FSC+high CD45+low CD19+ CD20+ CD5- Kappa+ CD10+ CD38+ CD23- CD200- CD79b+ phenotype, representing 41% of the lymphoid population. In addition, a clone with a B-CLL phenotype (CD19+ CD20+low CD23+ CD5+ kappa+low) was observed, representing 7% of the lymphoid population. Immunohistochemistry revealed an infiltration by a B lymphoproliferative process compatible with Burkitt's lymphoma. The genetic study showed three mutations in the TP53 gene by NGS (c.314G>A, c.313G>C, c.701A>G), previously described in patients with Burkitt's lymphoma. The FISH study was negative for MYC rearrangement. Conclusions: The study was suggestive of B-CLL in progression to leukaemic Burkitt's lymphoma by both flow cytometry and immunohistochemistry analysis. Richter syndrome affects 2-10% of patients with B-CLL and consists of transformation to a fast-growing lymphoma, most commonly to DLBCL (90%) and Hodgkin lymphoma. Although rarely, it may also progress to dendritic cell/histiocytic sarcoma, lymphoblastic lymphoma or other lymphomas (<1%). We therefore present a rare case of a patient diagnosed with long-progressing B-CLL who transformed into leukaemic Burkitt's lymphoma (LLAB-IV).     \n  \nP-197  VARIANTES MISSENSE EN HETEROCIGOSIS EN LOS GENES ELANE Y FPR1 ASOCIADAS A LA BIOLOG\u00cdA DE LOS NEUTR\u00d3FILOS EN PACIENTE CON INFECCIONES DE REPETICI\u00d3N  Alba Cano, Trinidad1; Mu\u00f1oz G\u00f3mez, Sara1; D\u00edaz Luna, Mar\u00eda De Las Mercedes1; Balastegui, H\u00e9ctor1; Garc\u00eda Mart\u00ednez, Elena1; Zambrano Ibarra, Gabriela2; Seoane Reula, Mar\u00eda Elena2; Fern\u00e1ndez-Cruz P\u00e9rez, Eduardo1; Rodr\u00edguez Sainz, Carmen1.  1Servicio de Inmunolog\u00eda Cl\u00ednica-Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid; 2Inmuno-Alergia Infantil-Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid.  Paciente y M\u00e9todo:  Ni\u00f1a de 13 a\u00f1os en seguimiento por posible inmunodeficiencia primaria asociada a la aparici\u00f3n de abscesos axilares, infecci\u00f3n por Mycobacterium tuberculosis y 4 episodios de neumon\u00eda que han requerido hospitalizaci\u00f3n. Otros aspectos cl\u00ednicos relevantes son: broncoespasmos de repetici\u00f3n, dermatitis at\u00f3pica, asimetr\u00eda de miembros y alteraciones ortop\u00e9dicas y taquicardia supraventricular intervenida. El estudio gen\u00e9tico de secuenciaci\u00f3n del ADN gen\u00f3mico, extra\u00eddo de sangre perif\u00e9rica, se ha llevado a cabo por secuenciaci\u00f3n masiva de segunda generaci\u00f3n (NGS, Next Generation Sequencing) a trav\u00e9s de un panel de 200 genes asociados con inmunodeficiencias. Resultados: Los resultados de la secuenciaci\u00f3n han permitido identificar dos variantes missense en heterocigosis: una en el gen ELANE (ENSP00000263621.1:p.Gly125Ala) que codifica la elastasa, una ser\u00edn proteasa que se encuentra en los gr\u00e1nulos de los neutr\u00f3filos y monocitos; y otra en el gen FPR1 (ENSP00000302707.3:p.Ile147Thr) que codifica el receptor de p\u00e9ptidos formilados tipo 1 que se localiza en las c\u00e9lulas fagoc\u00edticas y que interviene en la activaci\u00f3n y migraci\u00f3n de los neutr\u00f3filos. Ninguna de las variantes ha sido descrita en las bases de datos internacionales de mutaciones del genoma humano o de variantes con significaci\u00f3n cl\u00ednica. Sin embrago, otro cambio en el gen ELANE (p.Gly125Trp) que afecta al mismo cod\u00f3n que la variante que presenta nuestra paciente se ha asociado a neutropenia c\u00edclica con herencia autos\u00f3mica dominante. Conclusi\u00f3n: Aunque el diagn\u00f3stico gen\u00e9tico no es definitivo debido a la falta de evidencia sobre las variantes encontradas en esta paciente, ambas alteraciones en los genes ELANE y FPR1 est\u00e1n asociadas a defectos en la correcta funcionalidad de los neutr\u00f3filos pudiendo explicar el fenotipo de la paciente y la susceptibilidad a la infecci\u00f3n.     \n  \nP-198  THE ORIGIN OF MAPUCHE AMERINDIANS (CHILE) ACCORDING TO THEIR HLA PROFILE  Palacio Gr\u00fcber, Jos\u00e9; Suarez Trujillo, Fabio; Vaquero Yuste, Christian; Molina Alejandre, Marta; Heras Garc\u00eda, Alba; Mart\u00edn Villa, Jos\u00e9 Manuel; Arnaiz Villena, Antonio; Ju\u00e1rez, Ignacio.  Universidad Complutense de Madrid, Madrid.  The peopling of the Americas is thought to have occurred from Siberia through Beringia. However, the oldest human activity is found in southernmost South America (Monte Verde, Chile), a Mapuche Amerindian area. We decided to compare the Mapuche HLA features with other North and South American Amerindians and other worldwide populations, particularly Pacific populations, since some authors have put forward a southern Pacific route for the peopling of southern South America. One hundred and ten unrelated and healthy Mapuche volunteers from an area close to Concepcion (Chile) were genetically analysed using a SSO (single specific oligonucleotide) standard Luminex HLA-typing technique. Allele and haplotype frequencies, genetic distances between populations, neighbour-joining (NJ) dendrograms and correspondence analyses were computed using ARLEQUIN, DISPAN and VISTA software. Results show how Mapuche Amerindians are genetically close to other Andean Amerindians populations (Quechuans, Aymaras) and also to North American Amerindian populations (Lakota-Sioux, Tarahumaras). This general phenomenon of lack of correlation between geography and genetics supports the idea that all Amerindians came to America in approximately the same time, and from the same genetic background. The peopling of the Americas through Beringia is supported by the present Mapuche HLA data.                     \n  \nP-199  ESTUDIO GEN\u00c9TICO EN EL D\u00c9FICIT SELECTIVO DE IGA Y ENFERMEDAD CEL\u00cdACA   Cruz Quevedo, Mileydis1; Bodas Pinedo, Andr\u00e9s2; Vecino L\u00f3pez, Raquel2; Barrio Merino, Alfonso3; Fern\u00e1ndez-De-La-Madrid Yag\u00fce, Mar\u00eda Eugenia1; Ochoa Grull\u00f3n, Juliana2; Guzm\u00e1n Fulgencio, Mar\u00eda2; S\u00e1nchez Ram\u00f3n, Silvia2; Fern\u00e1ndez Arquero, Miguel2.  1Universidad Complutense de Madrid, Madrid; 2Hospital Cl\u00ednico San Carlos, Madrid; 3Hospital Fundaci\u00f3n Alcorc\u00f3n, Madrid.  Introducci\u00f3n: Se ha planteado una posible predisposici\u00f3n gen\u00e9tica entre el d\u00e9ficit selectivo de IgA (DsIgA) y la enfermedad cel\u00edaca (EC) por sus prevalencias entre sujetos de una misma familia o en un mismo individuo (10-15%).  Objetivo: Estudiar los haplotipos HLA clase II compartidos entre enfermedad cel\u00edaca y d\u00e9ficit selectivo de IgA y su implicaci\u00f3n entre ambas patolog\u00edas.  M\u00e9todos: Se realiz\u00f3 un estudio multic\u00e9ntrico descriptivo transversal en pacientes de los servicios de Inmunolog\u00eda y/o Gastroenterolog\u00eda del Hospital Cl\u00ednico San Carlos de Madrid y Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n, entre noviembre del 2021 y junio del 2022. Se estudiaron los genes HLA-DRB1, DQA1 y DQB1 mediante la tecnolog\u00eda Luminex. Resultados: La muestra estuvo conformada por 213 pacientes, distribuidos en tres grupos: 50 pacientes con DsIgA, 149 con EC y 14 con EC asociada a DsIgA. Los resultados se compararon con una poblaci\u00f3n sana (n=85) de origen y caracter\u00edsticas similares. En pacientes con DsIgA se demostr\u00f3 una asociaci\u00f3n estad\u00edsticamente significativa con el haplotipo HLA-DRB1*01:01-DQA1*01:01-DQB1*05:01 (68%; OR=13,99) y su homocigosis (12%; OR=7,13). En el estudio de los pacientes cel\u00edacos, se encontr\u00f3 una asociaci\u00f3n estad\u00edsticamente significativa con el haplotipo DRB1*03:01-DQA1*05:01-DQB1*02:01 (62,4%; OR=11,78) y los heterocigotos DRB1*03:01-DQA1*05:01-DQB1*02:01 / DRB1*01:01-DQA1*01:01-DQB1*05:01 se encuentran aumentados (OR= 4,23). En el estudio de los pacientes afectados de EC y DsIgA   se encontr\u00f3 el haplotipo DRB1*03:01-DQA1*05:01-DQB1*02:01: (50,0%; OR=13,17), y el DRB1*01:01-DQA1*01:01-DQB1*05:01: (37,5%; OR=7,32).  Conclusiones: Existe una inmunogen\u00e9tica compartida entre EC y DsIgA.            \n  \nP-200  IDENTIFICATION OF THE NOVEL HLA-C*08:243 ALLELE IN A SPANISH BONE MARROW DONOR  Renuncio Garc\u00eda, M\u00f3nica1; Gonz\u00e1lez L\u00f3pez, Elena1; Roa Bautista, Adriel1; Guti\u00e9rrez Larra\u00f1aga, Mar\u00eda1; Balas, Antonio2; Arroyo, Jos\u00e9 Luis3; Ocejo-Vinyals, J. Gonzalo1.  1Servicio de Inmunolog\u00eda. Hospital Universitario Universitario Marqu\u00e9s de Valdecilla, Santander; 2Histocompatibilidad, Centro de Transfusi\u00f3n de Madrid, Madrid; 3Banco de Sangre y Tejidos de Cantabria, Santander.  We report here the novel HLA-C*08:243 allele found in a Spanish bone marrow donor. Routine HLA typing by Next Generation Sequencing (NGS), detected a variant HLA-C*08 allele, closely related to the partially defined and unconfirmed HLA-C*08:51 allele. The NGS procedure was performed using commercially available reagents (GenDX, Utrecht, The Netherlands) and an iSeq100 platform (Illumina, San Diego, California). Data were analyzed using the NGSengine Software (GenDX) and the 3.45.1 version of the IPD-IMGT/ HLA Database (1). The new allele showed one nucleotide difference from C*08:51 in exon 3, genomic position 915 (G > T), codon 156 (CGG > CTG), producing an amino acid replacement 156R>L. Two additional mismatches can be found when compared to the most frequent C*08 subtype in Caucasians, C*08:02, at nucleotide positions 959 (T>C) and 977 (A>G), giving an additional change at codon 171Y>H (Figure 1). Amino acid positions 156 and 171 are placed at the H2 \n-helix domain of the HLA class I molecule, and are part of the antigen binding pockets F and A respectively (2). Therefore, C*08:243 would show relevant mismatches, from a functional point of view, compared to the most common C*08:02 allele. Complete HLA typing for this sample was the following: A*11:01:01,23:01:01:01; B*14:02:01:01,51:01:01; C*08:243,14:02P; DRB1*01:02:01,12:01P; DQB1*03:01:01:05,05:01P; DPB1*03:01:01,04:01:01. According to this, a tentative haplotype A*11:01:01~C*08:243~B*14:02:01~DRB1*01:02:01~DQB1*05:01P could be defined for this new HLA-C allele. The name C*08:243 has been officially assigned by the WHO Nomenclature Committee for Factors of the HLA System in March 2022. This follows the agreed policy that, subject to the conditions stated in the most recent Nomenclature Report (3) names will be assigned to new sequences as they are identified. Lists of such new names will be published in the following WHO Nomenclature Report.     \n  \n                              \n \n  \nP-201  CHARACTERISATION OF A NOVEL HLA-B ALLELE, B*45:29, BY FULL-LENGTH PCR-NGS-BASED SEQUENCING IN A PATIENT WITH SICKLE CELL ANAEMIA DISEASE AND RELATED DONORS.  Planelles Silvestre, Mar\u00eda Dolores1; Boix Giner, Francisco1; Rodr\u00edguez Cebri\u00e1, Manuel1; Luis Hidalgo, Mar1; Argiles, Bienvenida2; Mart\u00ednez Reig, Francsico1; Granell, Rosa1; Laguarda, Encarna1; Mochol\u00ed, Carmen1; Castro, Emma1; Larrea, Luis1; Arbona, Cristina1.  1Centro de Transfusi\u00f3n de la Comunidad Valenciana, Valencia; 2HOSPITAL INFANTIL LA FE, Valencia.  Introduction Polymorphism is a defining feature of the HLA system, with HLA-B being the most polymorphic locus, currently with 8.849 alleles identified to date. Objective Molecular characterisation of a novel HLA-B allele. Material and Methods The new allele B*45:29 was identified in a haematological patient, his father, and his identical sibling, of Moroccan origin, by Next Generation Sequencing (NGS) using commercially available reagents (NGSgo\u00ae-MX6-1, GenDX, Utrecht, The Netherlands) and a MiniSeq platform (Illumina\u2122, San Diego, California). Data were analysed using the NGSengine\u00ae Software (GenDX) and the 3.45.1 version of the IPD-IMGT/HLA Database. Confirmatory typing was carried out by polymerase chain reaction-sequence specific oligonucleotide (PCR-SSO) method (Lifecodes\u00ae HLA-B SSO test, Immucor) reporting inconclusive typing results. A suggestive B*45:02/03,*14, type for the patient and his sister; and a B*45,*50:14, with the most likely B*45 allele being B*45:01, in the case of the father. Results NGS sequencing of the patient and sister\u2019s samples for HLA-B locus provided a B*14:02:01:01, B*45:02var assignment after completing full-length genomic HLA-B analysis in a single phase. Furthermore, the father\u00b4s sample gave yet a B*45:02var, B*50:01:01:01 assignment.  The new allele showed one single nucleotide difference from its closest allele B*45:02 in exon 3, genomic position 792 (T>A), cDNA 419, codon 116 (TTC>TAC), resulting in an amino acid change, 116F>116Y (Figure 1). Family haplotype analysis demonstrated that this new HLA-B allele is included in the haplotype: A*29:02:01:01~C*16:01:01:01~B*45:29~DRB1*13:02:01~DQB1*05:01~DPB1*02:01:19:01. This new HLA-B allele was officially named B*45:29 (HWS10060520) by the WHO Nomenclature Committee for Factors of the HLA System in February 2022.    \n  \nConclusions NGS technology allows simultaneous sequencing of multiple loci for HLA typing and facilitates the detection of new alleles, thus benefiting the process of selecting compatible donors for haematopoietic stem cell transplantation.  \n                                       \n \n  \nP-202  CONSERVED RESIDUES OF CLASS I MHC IN ALL VERTEBRATES ARE NOT PRESENT IN SONGBIRDS (PASSERIFORMES): FUNCTIONAL, STRUCTURAL AND EVOLUTIONARY CONSEQUENCES  Arnaiz Villena, Antonio; Palacio Gr\u00fcber, Jos\u00e9; Vaquero Yuste, Christian; Molina Alejandre, Marta; Heras Garc\u00eda, Alba; S\u00e1nchez Orta, Alejandro; Suarez Trujillo, Fabio; Ju\u00e1rez, Ignacio.  Universidad Complutense de Madrid, Madrid.  Birds are considered dinosaurs that passed the 65 million years ago bottleneck. Songbirds (Passeriformes) included about half extant bird species (about 5000) and are general the most air-thriving bird species, particularly in conjunction with their small size. Mayor Histocompatibility Complex (MHC) molecules stimulate immune responses against microbes and its class I molecules has seven conserved residues in all vertebrates from jawed-fishes, 300 million years ago, to humans, including chickens. All wild songbird species tested by us (n=18) and others (n= 2) differ in \u03b11 domain residue 10 and \u03b12 residue 96 from all other vertebrates. Amplification, cloning and sequencing were performed by standard methods. Sequences alignment were done by using PAUP and MEGA programs software. Crystallographic studies were performed by using mammal and bird MHC molecules from MPID database and other sources and showed that these changes did not significantly vary the MHC class I molecule stability in songbirds. Further \u03b11 and \u03b12 domain comparisons by simple Composition Distances and Bayesian Inference showed that songbirds overall MHC class I molecules are phylogenetically more separated from mammal and other birds molecules. In addition MHC class I introns from Passeriformes (songbirds) were found to be longer than humans, chicken introns having the shortest ones. These small mainly air-borne dinosaurs (Passeriformes) have undergone a different evolutionary pathway, regarding to MHC, than all other tested vertebrates and more terrestrial birds. This may have been originated by an altogether different dinosaurs linage origin or to adaptation to more aerial than terrestrial environment or other unknown cause. In any case, the specific changes observed in this work for class I molecules in songbirds have reached an entropic, stable solution similar to that reached by other vertebrates.             \n  \nP-203  NARCOLEPSIA Y ENFERMEDADES AUTOINMUNES  Fern\u00e1ndez De Lamadrid Yag\u00fce, Mar\u00eda Eugenia1; Ameyugo Fern\u00e1ndez, Elena2; Cruz Quevedo, Mileydis1; Ochoa Grull\u00f3n, Juliana3; Guzm\u00e1n Fulgencio, Mar\u00eda4; Mart\u00ednez Orozco, Francisco Javier2; S\u00e1nchez Ram\u00f3n, Silvia5; Fern\u00e1ndez- Arquero, Miguel6.  1Dpto de Inmunologia oftalmolog\u00eda y ORL. Facultad de Medicina Universidad Complutense de Madrid., Madrid; 2Neurofisiolog\u00eda Cl\u00ednica. Hospital Cl\u00ednico San Carlos., Madrid; 3Hospital San Carlos, Madrid; 4Dpto de Inmunologia oftalmolog\u00eda y ORL. Facultad de Medicina Universidad Complutense de Madrid, Madrid; 5Servicio de Inmunolog\u00eda del Hospital Cl\u00ednico San Carlos, Madrid; 6Dpto de Inmunologia oftalmolog\u00eda y ORL. Facultad de Medicina Universidad Complutense de Madrid.Servicio de Inmunolog\u00eda del Hospital Cl\u00ednico San Carlos, Madrid.  Introducci\u00f3n: La narcolepsia es un trastorno neurol\u00f3gico cr\u00f3nico poco frecuente en el que se produce una desregulaci\u00f3n del ciclo vigilia-sue\u00f1o. No ha sido muy estudiada su relaci\u00f3n con otras enfermedades autoinmunes, sin embargo, se ha reportado comorbilidad con enfermedades inmunomediadas.  Objetivo: Estudiar la relaci\u00f3n existente entre la narcolepsia y su comorbilidad con otras enfermedades autoinmunes.  M\u00e9todos: Se realiz\u00f3 un estudio descriptivo transversal y observacional en pacientes pertenecientes del Cl\u00ednico San Carlos, en el per\u00edodo 2018-2020. La poblaci\u00f3n de estudio consisti\u00f3 en una cohorte de 109 pacientes con narcolepsia y otras enfermedades inmunomediadas. Para su estudio se dividi\u00f3 la muestra en tres grupos: grupo A pacientes con narcolepsia (n= 87; 79,8%), grupo B pacientes con narcolepsia y una enfermedad autoinmune asociada (n=15; 13,76%) y grupo C pacientes con narcolepsia y dos enfermedades autoinmunes asociadas (n=6; 5,5%).  Resultados: Se encontr\u00f3 que la edad de comienzo de la enfermedad era menor en aquellos pacientes que con una manifestaci\u00f3n m\u00e1s agresiva: Cateplej\u00eda y Enfermedad autoinmune . En cuanto al sexo, se observ\u00f3 predominio del sexo masculino en pacientes con narcolepsia sin otra patolog\u00eda (3:1) y del sexo femenino cuando esta se asocia a autoinmunidad (3:1).    Conclusiones: 1. la narcolepsia presenta una comorbilidad con la enfermedad autoinmune 2. Las formas m\u00e1s agresivas de la enfermedad est\u00e1n asociadas cuando existe enfermedad autoinmune 3.  El sexo masculino en pacientes con narcolepsia sin otra patolog\u00eda (3:1) y el sexo femenino se asocia a autoinmunidad (3:1)        \n  \nSesi\u00f3n Poster. Trasplante. Pantalla 4  P-204  ESTADO INMUNOL\u00d3GICO DE PACIENTES CON ENFERMEDAD RENAL CR\u00d3NICA (ERC) INFECTADOS POR SARS-COV-2 SOMETIDOS A HEMODI\u00c1LISIS (HD).  Gonz\u00e1lez Cuadrado, Cecilia1; Chivite Lacaba, Marta1; Caro Espada, Paula Jara2; Almendro V\u00e1zquez, Patricia2; Utrero Rico, Alberto3; Yuste Lozano, Claudia2; Guti\u00e9rrez Sol\u00eds, Elena2; Morales Ruiz, Enrique2; Laguna Goya, Rocio2; Paz Artal, Estela2.  1Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica Hospital 12 de Octubre, Madrid; 2Hospital Universitario 12 de Octubre, Madrid; 3Icahn School of Medicine at Mount Sinai, Nueva York.  Introducci\u00f3n: Se ha observado que los pacientes con ERC en HD infectados por SARS-CoV-2 experimentaban un empeoramiento de los s\u00edntomas, con reaparici\u00f3n de la fiebre y mal estar general, tras las sesiones de HD. Objetivos: Evaluar cambios en el sistema inmunol\u00f3gico asociados al deterioro cl\u00ednico durante la sesi\u00f3n de HD en pacientes con COVID-19. Metodolog\u00eda: Estudiamos 14 pacientes en HD, 9 con COVID-19 confirmada por RT-PCR y 5 no infectados. En sangre perif\u00e9rica en el momento pre y post-di\u00e1lisis se cuantific\u00f3 IL2, IL7, IL6, IL10, IL17A, GM-CSF, IL1\u03b2, IL21, IFN\u03b3, IL8, CCL3 y TNF\u03b1, subpoblaciones linfocitarias (CD4/CD8 MC, CD4/CD8MP, CD19, CD56) y de monocitos cl\u00e1sicos (CD14+CD16-), intermedios (CD14+CD16+) y no cl\u00e1sicos (CD14-CD16+), y marcadores de activaci\u00f3n (HLA-DR, CD86) y migraci\u00f3n (CCR2, CCR5). Aislamos c\u00e9lulas CD14+ que fueron estimuladas con LPS overnight y se cuantific\u00f3 en el sobrenadante: GM-CSF, IL18, IL1\u03b2, IL1Ra, IL6, IL8, CXCL10, CCL2, CCL3, IL10 y TNF\u03b1. Resultados: Los pacientes en HD infectados vs. no infectados, presentaron en pre-di\u00e1lisis: (1) mayores niveles s\u00e9ricos de las citoquinas pro-inflamatorias IL6, TNF\u03b1 e IL8; (2) linfopenia T CD4 y CD8; (3) mayor porcentaje de monocitos intermedios y menor de no-cl\u00e1sicos; (4) menor expresi\u00f3n en membrana de CCR2, HLA-DR y CD86 en monocitos; (5) mayor producci\u00f3n de GM-CSF, IL6, IL1\u03b2, IL1Ra, CCL3, CCL2 y TNF\u03b1 por monocitos estimulados con LPS. Entre la pre- y la post-di\u00e1lisis (fold change), los monocitos estimulados con LPS aumentaron la secreci\u00f3n de GM-CSF, IL6, IL1\u03b2, IL8, CCL2 y CCL3 en pacientes que desarrollaban deterioro cl\u00ednico post-HD en relaci\u00f3n con los pacientes sin COVID-19 (p<0.05 para CCL3 e IL6) o con pacientes sin empeoramiento (p<0.05 para todas las citoquinas).  Conclusiones: El deterioro cl\u00ednico en pacientes con ERC infectados por SARS-CoV-2 tras la sesi\u00f3n de HD se acompa\u00f1a de activaci\u00f3n de monocitos y secreci\u00f3n de citoquinas pro-inflamatorias.    \n  \nP-205  MONITORIZACION DE EXPRESI\u00d3N G\u00c9NICA DEL SISTEMA BAFF (BAFF/APRIL/R-BAFF/TACI/BCMA) Y ANTICUERPOS ANTI-DSA EN TRASPLANTE RENAL. META-ANALISIS DE ESTUDIOS TRANSCRIPTOMICOS DEL \u00cdNDICE CADI EN GEO  Alfaro, Rafael1; Jimenez-Coll, Victor1; Sanchez-Rodriguez, Carlos1; Gonzalez-Lopez, Rosana1; Llorente, Santiago2; Galian, Jose Antonio1; Martinez-Banaclocha, Helios1; Botella, Carmen1; Moya-Quiles, Maria Rosa1; De La Pe\u00f1a, Jesus3; Minguela, Alfredo1; Legaz, Isabel1; Muro, Manuel4.  1Servicio de Inmunologia. Hospital Clinico Universitario Virgen de la Arrixaca. IMIB, Murcia; 2Servicio de Nefrologia. Hospital Clinico Universitario Virgen de la Arrixaca. IMIB, Murcia; 3Servicio de Anatomia Patologica. Hospital Clinico Universitario Virgen de la Arrixaca. IMIB, Murcia; 4Servicio de Inmunolog\u00eda. Hospital Clinico Universitario Virgen de la Arrixaca, Murcia.  La se\u00f1alizaci\u00f3n del sistema del factor activador de c\u00e9lulas B (BAFF) es fundamental para la homeostasis de las c\u00e9lulas B, las funciones efectoras y el mantenimiento de la tolerancia en el trasplante, pero no se ha estudiado en los receptores de trasplante renal (KTR). El objetivo era analizar los cambios en la expresi\u00f3n del sistema BAFF en KTR con/sin rechazo agudo (AR/NAR). La expresi\u00f3n del sistema BAFF se analiz\u00f3 por qPCR en 40 KTRs. Se identific\u00f3 tambi\u00e9n un metan\u00e1lisis de la expresi\u00f3n del sistema BAFF y el da\u00f1o renal histol\u00f3gico mediante el \u00cdndice de da\u00f1o cr\u00f3nico del aloinjerto (CADI) y se realiz\u00f3 a partir de la base de datos GEO. La expresi\u00f3n del ligando inductor de proliferaci\u00f3n (APRIL) aument\u00f3 a los tres y seis meses despu\u00e9s del trasplante renal (p=0,014 y p<0,001). La expresi\u00f3n del ant\u00edgeno de maduraci\u00f3n de c\u00e9lulas B (BCMA) aument\u00f3 a los seis meses despu\u00e9s del KT (p=0,038). La expresi\u00f3n de BAFF se mantuvo estable en NAR-KTR, pero aument\u00f3 en CADI con respecto al grupo No-CADI al a\u00f1o (p=0,008). La expresi\u00f3n de BCMA aument\u00f3 en el grupo CADI en uno (p = 0,001) y seis a\u00f1os despu\u00e9s del trasplante renal (p=0,024). El gen Interactor del modulador de calcio y activador transmembrana (TACI) se elev\u00f3 significativamente en receptores renales con DSA (p=0,034) a los tres meses. Los KTRs con DSA aumentan significativamente el receptor del factor activador de c\u00e9lulas B (R-BAFF; p=0,021) y TACI (p=0,018) entre pre-trasplante y tres meses despu\u00e9s del implante. Los cambios en la expresi\u00f3n del sistema BAFF aumentan durante el post-trasplante renal en el desarrollo de AR y da\u00f1o cr\u00f3nico del aloinjerto y podr\u00edan ser una herramienta patol\u00f3gica importante para detectar y prevenir el resultado del injerto renal.         \n  \nP-206  INFLUENCE OF HLA-DPB1 MISMATCH ON ALLOGENEIC MATCHED RELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION     Ni\u00f1o Ram\u00edrez, Jairo Eduardo; Alcoceba Sanchez, Miguel; Bastos Boente, Miguel; De La Torre, Igor; L\u00f3pez Corral, Luc\u00eda; P\u00e9rez L\u00f3pez, Estefan\u00eda; Cabrero, Monica; Cabero Martinez, Almudena; Caballero Barrig\u00f3n, Dolores; Gonz\u00e1lez, Marcos; Garc\u00eda Sanz, Ram\u00f3n; Tejeda Velarde, Amalia.  Hospital Universitario de Salamanca, Salamanca.  Background: HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the first curative option for some hematological disorders. Acute graft-versus-host disease (aGVHD) remains the leading cause of morbidity and mortality, even in HLA 10/10 identical sibling pairs. However, the occurrence of chromosomal crossing-over can cause disparities that affect HLA-DPB1 locus. Until recently, DPB1 locus was not included in studies to identify donor/recipient (D/R) compatibility. Therefore, the influence of DPB1 mismatch in allo-HSCT evolution is still unclear. Objective: We aimed to assess the frequency of disparities in HLA-DPB1 and its association with the outcome of related HLA-identical allo-HSCT. Material and methods: 131 Donor/Receptor (D/R) HLA-identical 10/10 (A, B, C, DRB1 and DQB1) sibling pairs from the University Hospital of Salamanca were retrospectively DPB1 typed by PCR-SSOP LIFECODES\u00ae. DPB1 mismatch status was classified as permissive or non-permissive according to T cell epitope algorithm V2.0 (IPD-IMGT/HLA). Statistical analyses were performed using IBM\u00ae SPSS 26 software. Results: Of 131 D/R pairs, 11 (8.4%) were DPB1 mismatch (8 single mismatch and 3 double allelic mismatch). Of these, six (4.6%) were permissive and five (3.8%) were non-permissive. In non-permissive group, four (3.1%) pairs showed predicted immunogenicity in the Graft-versus-Host (GvH) direction and one in the Host-versus-Graft (HvG) direction. Three patients with GvH mismatch presented aGVHD, while the only patient with HvG mismatch presented graft failure. Non-permissive disparity augmented the risk of aGVHD development in univariate (80% vs. 68.3%, p=0.024) and multivariate analysis [HR: 3.5; 95%CI 1.08-11.42]. Conclusion: In our centre, the frequency of DPB1 mismatch in related HLA-identical allo-HSCT is 8.4%, although the frequency of DPB1 non-permissive discrepancy is lower (3.8%). Our data suggest that non-permissive DPB1 disparities could increase the risk of aGVHD development after allo-HSCT even in related HLA 10/10 identical sibling pairs.     \n  \nP-207  EL EFECTO A LARGO PLAZO DE LA TERAPIA CON GAMMAGLOBULINA IV EN TRASPLANTE DE \u00d3RGANO S\u00d3LIDO CON INFECCI\u00d3N E HIPOGAMMAGLOBULINEMIA   Sarmiento, Elizabeth1; Mont\u00e1nchez, Judith1; Ezzahouri, Ikram1; Mej\u00eda, Mar\u00eda1; Zatarain, Eduardo2; Sousa, Iago2; Ortiz, Carlos2; Carbone, Javier3.  1Servicio de inmunolog\u00eda. Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid; 2Servicio de Cardiolog\u00eda. Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid; 3Servicio de Inmunolog\u00eda. Servicio de Cardiolog\u00eda. Hospital Gregorio Mara\u00f1\u00f3n. Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n. Universidad Complutense de Madrid, Madrid.  Introducci\u00f3n. Las infecciones, el rechazo y el c\u00e1ncer siguen siendo barreras a largo plazo para buenos resultados tras el trasplante de \u00f3rgano s\u00f3lido. Las gammaglobulinas IV est\u00e1n indicadas en pacientes inmunosuprimidos con infecciones graves que tienen hipogammaglobulinemia. La hip\u00f3tesis de este estudio es que el uso de GGIV puede impactar positivamente no s\u00f3lo en el desarrollo de infecciones sino en otras complicaciones post trasplante. Material y M\u00e9todos. Estudio prospectivo de seguimiento ampliado tras la \u00faltima visita de un ensayo de GGIV para terapia de infecci\u00f3n grave en presencia de hipogammaglobulinemia IgG < 600 mg/dL. El protocolo administrado consisti\u00f3 en 2 dosis de 15 gramos (intervalo 7-15 d\u00edas) y otras 3 de 20 gramos (intervalo 15-30 d\u00edas). De 22 pacientes incluidos en un centro en el ensayo aleatorizado, 9 fueron aleatorizados a GGIV y 13 a terapia antimicrobiana convencional. Durante un seguimiento m\u00ednimo de 2 y m\u00e1ximo de 7 a\u00f1os, adicional tras la \u00faltima visita de ensayo se recogieron prospectivamente: eventos de infecci\u00f3n, rechazo, c\u00e1ncer y muerte y un evento compuesto por la presencia de al menos uno de los anteriores. Resultados. La tasa de eventos de infecci\u00f3n, rechazo, c\u00e1ncer y muerte en los pacientes tratados con GGIV versus los no tratados con GGIV fue como sigue, respectivamente: 22 vs 84.6% (p=0.011), 11.1 vs 30.7% (p=0.279), 11.1 vs 15.38% (p=0.774), 11.1 vs 30.7% (p=0.279). La variable de resultado compuesta la desarrollaron un 44.4% de pacientes que usaron GGIV vs un 84.6% de pacientes no tratados con GGIV (p=0.047). Conclusiones. El uso de GGIV en pacientes que desarrollan infecciones e hipogammaglobulinemia IgG moderada tras el trasplante de \u00f3rgano s\u00f3lido se asocia con menor prevalencia de distintas complicaciones y no solo con la disminuci\u00f3n de infecciones. Es posible que haga falta redefinir el punto de corte de indicaci\u00f3n de GGIV en trasplantados.           \n  \nP-208  EFFECTIVE DESENSITIZATION APPROACH IN A CARRIER OF VENTRICULAR ASSIST DEVICE AS A STRATEGY TO URGENT CARDIAC TRANSPLANT.  Mej\u00eda Gonz\u00e1lez, Mar\u00eda Alejandra1; Samiento Marchese, Elizabeth2; Zatarain, Eduardo3; Sousa, Iago3; Vicario Moreno, Jos\u00e9 Luis4; Anaya, Fernando5; Carbone Campoverde, Javier A.1.  1Servicio de Inmunolog\u00eda. Hospital General Universitario Gregorio Mara\u00f1\u00f3n., Madrid; 2Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n., Madrid; 3Servicio de Cardiolog\u00eda. Hospital General Universitario Gregorio Mara\u00f1\u00f3n., Madrid; 4Centro de Transfusi\u00f3n de la Comunidad de Madrid, Madrid; 5Servicio de Nefrolog\u00eda. Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid.  The risk of Antibody Mediated Rejection and allograft loss in sensitized patients is increased due to preformed donor specific antibodies (DSA) detected before transplantation. One in seven heart transplant candidates are sensitized. Ventricular assist devices (VADs) are increasingly being used as a bridge to transplantation and have been implicated as a risk factor for allosensitization to human leukocyte antigens (HLA). Our aim is to describe the evolution of a 27-year-old heart recipient patient after been treated with a desensitization protocol. His personal history included acute lymphocytic leukaemia in childhood with chemotherapy-induced cardiotoxicity that progressed to terminal heart failure and hepatitis C virus infection. At age 27, required VDA implantation as bridge to transplant, due to the need for prolonged pre-transplant HCV treatment. Complement-dependent cytotoxicity (CDC), panel reactive antibody (PRA) levels and Luminex antibody profiles were followed and, after two months of the implantation of the VDA, anti-HLA class I antibodies were detected (A2,A9,A23,A24,A28,A68,A69,B17,B57,B58) with high titres (MFI 3000-11000, PRA 75%). Elimination of circulating anti-HLA antibody was viewed as a critical strategy to successfully allow transplant. He received plasmapheresis along with IVIG (400 mg/kg) on days 1, 3 and 5. On day 7, after the MFI value decreased to 1000 \u2013 3000, the patient was placed on the emergency 0 transplant list. A dose of Rituximab (375mg/m2sc) was added, as well as 3 more cycles of plasmapheresis and IVIG on alternate days, with subsequent complete negativization of cytotoxic antibodies, at which time the heart transplant could be performed with an induction protocol that included thymoglobulin instead of basiliximab. After transplantation, anti-HLA antibodies have remained persistently negative and, five years after the transplant, he has not presented graft vascular disease or rejection episodes. Desensitization protocol was safe.   \n  \n In high sensitized patients, desensitization may allow transplantation in well selected candidates for this intervention.                                                    \n  \n P-209  RELEVANCE OF THE BW4 AND BW6 EPITOPES DETERMINATION IN THE MANAGEMENT OF HYPERIMMUNIZED PATIENTS IN RENAL TRANSPLANT: ABOUT A CLINICAL CASE.   Barrera Aguilera, Mar\u00eda Del Carmen; V\u00edlchez Guti\u00e9rrez, Jos\u00e9 Ram\u00f3n; D\u00edaz Alberola, Irene; L\u00f3pez Nevot, Miguel \u00c1ngel.  Hospital Universitario Virgen de las Nieves, Granada.  The presence of anti-HLA Donor Specific Antibodies (DSA) and their specificities are determined by routine pre-transplant check-ups for all the potential recipients by solid phase techniques (LABScreen\u2122, One Lambda), allowing to know in advanced the concrete specificity of these anti-HLA DSA. In this case, the compatibility between a donor and a potential hyperimmunized recipient was thoroughly analyzed, in the context of a dead donor renal transplant virtual cross-match. HLA typing was done by two different low-resolution molecular techniques: real time PCR (qPCR) with commercial LinkSeq\u2122 panels (One Lambda) as well as with SSP-PCR commercial Fluogene\u00ae panels (Inno-Train). The obtained result in both cases was the same: A*02,*11; B*13,*27; C*02,*06; DRB1*01, 15; DQB1*05, 06. After an exhaustive analysis of hyperimmunized recipients in the virtual cross-match (vPRA > 95%), a recipient with a 99% vPRA was selected. This recipient presented anti-HLA DSA against HLA-B*27:08 allele (MFI ~ 2400), but not against HLA-B*27:05 (MFI ~ 195). Not having a higher resolution HLA typing from the donor, Bw4 and Bw6 epitopes were of great importance to face this dilemma, as in the B*27 allelic group all the alleles share the Bw4 epitope, with the exception of B*27:08, which presents Bw6 specificity. Both of the HLA typing molecular techniques that were used do have specific probes to determine Bw4 and Bw6 individually, revealing this way that the potential donor was homozygous for Bw4. Thus, the presence of B*27:08 in the donor typing was excluded, and the transplant was carried through with no immunological complications. Subsequently, donor high resolution typing was performed with SSO-PCR (Immucor), confirming that the allele in the donor was indeed B*27:05, dismissing this way the presence of HLA DSA in the recipient. In summary, the independently determination of the Bw4/Bw6 epitopes allow to perform the transplant, without higher resolution HLA typing techniques.     \n  \n  \n                           \n \n  \n P-210  IMPACTO DEL GENOTIPO KIR E INCOMPATIBILIDAES KIR-LIGANDO EN LA EVOLUCI\u00d3N DE LOS TPH CON DONANTE HAPLOID\u00c9NTICO  Manzanares Mart\u00edn, B\u00e1rbara; Trujillo Aguilera, Antonio; Bernardo Serrano, Raquel; Molina Alcaide, Juan; Jurado Roger, Aurora; Gonz\u00e1lez Fern\u00e1ndez, Rafael.  HRU Reina Sof\u00eda, C\u00f3rdoba.  El trasplante de progenitores hematopoy\u00e9ticos (TPH) es un tratamiento curativo disponible para diferentes neoplasias de origen hematol\u00f3gico. El donante haploid\u00e9ntico es una opci\u00f3n v\u00e1lida, por su disponibilidad r\u00e1pida y econ\u00f3mica y por sus resultados equiparables al donante no relacionado. La presencia de determinadas combinaciones KIR y de las incompatibilidades KIR/ligando han sido descritas como variables a tener en cuenta para la elecci\u00f3n del mejor donante. Sin embargo, existe controversia para determinar que influencia tienen cada una de ellas. Objetivos: Determinar si el genotipo y semihaplotipos KIR en el donante y la incompatibilidad KIR/ligando tiene importancia en la evoluci\u00f3n de los TPH sin depleci\u00f3n de c\u00e9lulas T con donante haploid\u00e9ntico Pacientes y m\u00e9todos: An\u00e1lisis retrospectivo de TPH haploid\u00e9ntico entre 2013-2021. Se han analizado los genes KIR (Genotipaje KIR de Innotrain Diagnostik) en el donante y sus ligandos HLA (Lifecodes HLA-A,B SSO Typing Kit y Lifecodes HLA-C eRES SSO Typing Kit, Immucor) en donante y receptor. Se estudia su influencia en la supervivencia global (SG), supervivencia libre de evento (SLE), probabilidad de reca\u00edda (PR) y EICH. Resultados: la mitad de los pacientes fueron trasplantados por una LMA, sigui\u00e9ndoles LLA y linfoma. El 21% de los donantes presentaban AA y el 79% Bx. En los pacientes con neoplasias mieloides la presencia de Bx se asocia con una disminuci\u00f3n significativa de la PR en comparaci\u00f3n con AA. Esta significaci\u00f3n se pierde cuando no se dividieron a los pacientes por su patolog\u00eda previa, aunque segu\u00eda observ\u00e1ndose cierta tendencia a favor de Bx. Los semihaplotipos CENB y TELB se asociaron a una PR significativamente menor tanto en la serie global como en el subgrupo mieloide. La SG fue mayor en el grupo con 2 o m\u00e1s semiaplotipos B. La incompatibilidad KIR-ligando no influy\u00f3 ni en la SG, SLE, PR ni EICH.            \n  \n P-211  FORMAS SOLUBLES DEL SISTEMA BAFF/BLYS Y AN\u00c1LISIS DE CORRELACI\u00d3N DE ANTICUERPOS ANTI-DSA EN LA MONITORIZACI\u00d3N Y EVOLUCI\u00d3N DEL TRASPLANTE RENAL   Alfaro, Rafael; Llorente, Santiago; Martinez, Pedro; Jimenez-Coll, Victor; Gonzalez-Lopez, Rosana; Sanchez-Rodriguez, Carlos; Martinez-Banaclocha, Helios; Galian, Jose Antonio; Botella, Carmen; Moya-Quiles, Maria Rosa; Minguela, Alfredo; Legaz, Isabel; Muro, Manuel.  Servicio de Inmuniologia. Hospital Clinico Universitario Virgen de la Arrixaca, Murcia;   Objetivo. El sistema BAFF juega un papel fundamental en la homeostasis y tolerancia de las c\u00e9lulas B, aunque no ha sido ampliamente probado en trasplante con resultados dudosos. El objetivo principal fue estudiar las formas solubles de BAFF y su correlaci\u00f3n con el rechazo agudo (AR) y los anticuerpos espec\u00edficos del donante (DSA).  M\u00e9todos. Se analizaron los niveles s\u00e9ricos de BAFF, APRIL y formas solubles de sus receptores en receptores renales (RR) con y sin aparici\u00f3n de rechazo agudo (RA/NAR). Todas las mol\u00e9culas se evaluaron antes y despu\u00e9s del trasplante. Resultados. sTACI mostr\u00f3 una correlaci\u00f3n significativa con los niveles de BAFF y sR-BAFF, y sBCMA tambi\u00e9n mostr\u00f3 una correlaci\u00f3n positiva con los niveles de sAPRIL. Tambi\u00e9n se encontr\u00f3 un aumento significativo en los niveles de sAPRIL en pacientes con RA, y el an\u00e1lisis de las curvas ROC mostr\u00f3 un AUC=0,724, siendo una concentraci\u00f3n de 6,05 ng/ml (sensibilidad=66,7%; especificidad=73,3%) el mejor punto de corte para predecir AR. En la din\u00e1mica posterior al trasplante de los niveles de sAPRIL en la cohorte longitudinal, observamos una disminuci\u00f3n significativa a los tres y seis meses posteriores al trasplante en comparaci\u00f3n con el estado previo al trasplante. Tambi\u00e9n observamos que los receptores con niveles altos de sAPRIL pretrasplante generaron anticuerpos antes que estos pacientes con niveles m\u00e1s bajos de sAPRIL, aunque su postrasplante a largo plazo no fue diferente.  Conclusi\u00f3n. Nuestros resultados muestran que los niveles s\u00e9ricos elevados de APRIL pueden ser \u00fatiles como biomarcador para el diagn\u00f3stico de AR, aunque el estudio longitudinal muestra que no es \u00fatil como biomarcador pron\u00f3stico.            \n  \n P-212  A COMPARATIVE STUDY OF CELL CULTURE CONDITIONS DURING CONVERSION FROM PRIMED TO NAIVE HUMAN PLURIPOTENT STEM CELLS   Romayor, Irene1; Herrera, Lara1; Bur\u00f3n, Mar\u00eda1; Martin-Inaraja, Myriam1; Prieto, Laura1; Etxaniz, Jone1; Ingl\u00e9s-Ferr\u00e1ndiz, Marta1; Pineda, Jose Ram\u00f3n2; Eguizabal, Cristina1.  1Instituto de Investigaci\u00f3n Sanitaria Biocruces Bizkaia, Barakaldo; 2Universidad del Pa\u00eds Vasco (UPV/EHU), Leioa.  The successful reprograming of human somatic cells into induced pluripotent stem cells (hiPSCs) represented a turning point in the stem cell research field owing to their ability to differentiate into any cell type and lack of ethical issues. In the mouse, PSCs are thought to exist in a naive state, the cell culture equivalent of the immature, pre-implantation embryo whereas in humans, PSCs are in a primed state, which is more committed pluripotent state than naive state. Recent studies have focused on capturing a similar cell state in human, since their earlier development stage and lack of cell-of-origin epigenetic memory make the better candidates for further re-differentiation and use in disease modelling, regenerative medicine and drug discovery. In this study, we described and evaluated the successful establishment and maintenance of primed hiPSC and human embryonic stem cell (hESC) lines with three different naive conversion media both feeder and feeder-free conditions. In addition, we compared the directed differentiation capacity of primed and naive cells in the three germ layers. We characterized these different cell states with commonly used pluripotent and lineage specific markers, and showed that, in general, naive culture medium 1 (in both feeder and feeder-free system) confers greater hiPSCs and hESCs viability and highest naive pluripotency markers expression. This medium also allows for better differentiation of cells toward endoderm. In conclusion, we developed a cell culture differentiating protocol with the aim of future potential applications in cell therapies.                   \n  \n P-213  AN\u00c1LISIS DE REPRODUCTIBILIDAD DE PCR DIGITAL EN LA DETERMINACI\u00d3N DE QUIMERISMO HEMATOPOY\u00c9TICO  Mu\u00f1oz Garc\u00eda, Raquel; Ortiz Aljaro, Pilar; Garc\u00eda Lozano, Jose Ra\u00fal; Gonz\u00e1lez Escribano, Maria Francisca.  Hospital Universitario Virgen del Roc\u00edo, Sevilla.  Introducci\u00f3n:  La cuantificaci\u00f3n de ADN de donante y receptor (an\u00e1lisis del quimerismo hematopoy\u00e9tico) se usa para monitorizar pacientes sometidos a trasplante alog\u00e9nico de progenitores hematopoy\u00e9ticos (aloTPH). Una de las metodolog\u00edas m\u00e1s utilizada es el estudio de marcadores INDELs mediante PCR en tiempo real (qPCR). La PCR digital (dPCR) ha demostrado mayor precisi\u00f3n y menor susceptibilidad a inhibidores de la PCR, no necesitando curvas de calibraci\u00f3n. Sin embargo, es una t\u00e9cnica larga y laboriosa. Actualmente se han desarrollado nuevos equipos que favorecen el uso de esta t\u00e9cnica.  Objetivo: Comparar la precisi\u00f3n en los estudios de quimerismos de qPCR y dPCR realizada con el equipo \u201cQuantStudio\u2122 Absolute Q\u2122 Digital PCR\u201d de Thermo Fisher. Materiales y m\u00e9todos:  Se analizaron muestras post-trasplante de 3 pacientes varones sometidos a aloTPH de una mujer. Se estudi\u00f3 el marcador SRY (ChrY) mediante qPCR y dPCR. Se realizaron 5 repeticiones independientes con cada t\u00e9cnica. Para comparar las desviaciones est\u00e1ndar de ambos m\u00e9todos se us\u00f3 el test de ANOVA (an\u00e1lisis de varianzas). Resultados:  En la Tabla 1 se muestran los resultados de la media (\u00b5) y desviaci\u00f3n est\u00e1ndar (\u03c3) obtenidos por qPCR y dPCR. En las tres muestras, la \u03c3 fue estad\u00edsticamente m\u00e1s peque\u00f1a en los estudios de dPCR en comparaci\u00f3n con la qPCR (p<0.05).             \n  \n  \n  dPCR  qPCR  ANOVA   \n  \u00b5   \u03c3   \u00b5   \u03c3   p-valor  Paciente 1  0,135  0,186  0,176  0,021  <0,01  Paciente 2  0,357  0,368  0,765  0,039  <0,01  Paciente 3  0,723  0,270  1,15 0,078  0,03  Tabla 1. Media y desviaci\u00f3n est\u00e1ndar de 5 determinaciones realizadas por ambos m\u00e9todos de PCR en cada paciente. p-valor del Test Anova comparando los dos m\u00e9todos para cada paciente.  \u00b5: media; \u03c3: desviaci\u00f3n est\u00e1ndar  En la Figura 1 se representa un gr\u00e1fico de los resultados.  Conclusiones: Los resultados obtenidos por dPCR en los estudios de quimerismos hematopoy\u00e9ticos son m\u00e1s exactos y reproducibles que mediante qPCR.    \n     \n \n  \nP-214  IMMUNOTHERAPY BASED IN QPCR ANALYSIS IN INTESTINAL TRANSPLANT RECIPIENTS AND CANDIDATES   Lasa Lazaro, Maria1; Ramos Boluda, Esther2; Serradilla, Javier2; Andr\u00e9s, Ane Miren2; Serrano, Pilar2; Hern\u00e1ndez Oliveros, Francisco2; Paz Artal, Estela1; Talayero, Paloma1.  1Hospital Universitario 12 de Octubre, Madrid; 2Hospital Universitario La Paz, Madrid.  Introduction  Inflammatory bowel disease (IBD) in intestinal transplantation (ITx) recipients and candidates is a common complication due to the immunosuppression or the underlying disease. Conventional treatment uses to be effective, but in some patients the inflammation is refractory. Aim To determine the intestinal cytokine expression in order to establish the optimal therapy in ITx recipients and candidates with persistent enteritis. Methods Two multivisceral recipients with episodes of ulcerative enteritis refractory to conventional treatment were studied, as well as, two ITx candidates with intestinal failure and inflammatory colitis and enteropathy, respectively. Mucosal biopsies were taken from affected and healthy areas. Expression of cytokine genes which are targeted by approved drugs (IL1B, IL6, IL12p70, IL17A, IL23 and TNF) was determined by qPCR. Results ITx recipients (P1 and P2): both patients (13 and 14 years old males) developed in the late posttransplant ulcerative ileitis and ulcerative colitis respectively. They were treated with metilprednisolone and infliximab without endoscopic improvement. Graft cytokine expression of healthy and inflamed area was performed, showing a significant increase of IL6 (Figure1A/1B); Tocilizumab was administered, getting clinical resolution in two months. ITx candidates: P3 (5 years old male) suffered from trichohepatoenteric syndrome with ulcerative colitis. He was tread with corticosteroids without improvement. Intestinal cytokine expression objectified elevated IL1 and IL6 levels. After Tocilizumab treatment, healing of the colitis was observed (Figure1C). Enteropathy in P4 (1 year old male) was derived from an autoinflammatory disorder associated to MVK mutation. He was treated with Infliximab with only transient improvement. Intestinal cytokine expression showed elevated IL1, IL6 and TNF levels (Figure1D). He was then treated with Anakinra without clinical improvement, changing for Adalimumab achieving clinical  \n  \nresolution. Conclusions In the context of mucosal inflammation, intestinal cytokine expression analysis by qPCR is a useful and affordable tool to guide the treatment in a personalized way.                                                 \n  \nP-215  DETECTION OF NON-HLA ANTIBODIES IN KIDNEY TRANSPLANT PATIENTS WITH GRAFT DYSFUNCTION  Caro Oleas, Jose Luis1; Reinoso, Johanna2; Larque, Ana Bel\u00e9n3; Torres, Juan4; Dig\u00f3n, Montse4; Manch\u00f3n, Alexandra4; Revuelta, Ignacio5; Cucchiari, David5; Oppenheimer, Federico5; Diekmann, Fritz5; Palou, Eduard4.  1Servicio Inmunolog\u00eda. Hospital Cl\u00ednic de Barcelona, Barcelona; 2Servicio Nefrolog\u00eda. Hospital Cl\u00ednic de Barcelona, Barcelona; 3Servicio de Anatom\u00eda Patol\u00f3gica. Hospital Cl\u00ednic de Barcelona, Barcelona; 4Servicio de Inmunolog\u00eda. Hospital Cl\u00ednic de Barcelona, Barcelona; 5Servicio de Nefrolog\u00eda. Hospital Cl\u00ednic de Barcelona, Barcelona.  Introduction: No donor-specific anti-HLA antibodies (DSAs) are detected in some patients with suspicion of antibody-mediated rejection (ABMR) in renal biopsies performed for renal function impairment. Non-HLA antibodies directed against self- or allo-antigens present pre-transplantation or produced de novo post-transplantation could play a relevant role. Objective: To study the presence of non-HLA antibodies in pre- and post-transplant sera, coincident with biopsy, of kidney transplant patients with impaired renal function. Materials and Methods: 22 kidney transplant recipients from 2014 to 2019 with renal graft function impairment were included. The mean time from transplantation of biopsies was 137 \u00b1 275 days. The presence of anti-HLA DSA antibodies was ruled out by Single Antigen Luminex assay (Immucor). The study of non-HLA antibodies was performed with version 1 (32 antigens) and version 2 (60 antigens) of the Lifecodes Non-HLA Antibody kit (Immucor). Results: In 17 patients the biopsy was reported with findings compatible with ABMR with positive C4d (10 patients) or negative C4d (7 patients), while in 5 patients there were no signs of ABMR (3 without morphological data of rejection, 2 with cellular rejection). All patients, except 3, still have a functioning graft. In 20/22 (91%) of the patients some non-HLA antibodies were detected, both in the pre-transplant and in the post-transplant samples. In some patients, non-HLA antibodies against only one antigen were detected, whereas other patients had antibodies against up to 11 different non-HLA antigens. There was no difference between patients with or without non-HLA antibodies and the diagnosis of ABMR. Conclusions: Prospective studies and a larger cohort are needed to confirm or not the usefulness of such determination and the pathological role that these non-HLA antibodies may play, although in this small group of patients we do not find any clinical relevance.         \n  \nP-216  EXPRESI\u00d3N DE MIRNAS Y EFICACIA DIAGN\u00d3STICA DE MIR-150-5P COMO POTENCIAL BIOMARCADOR DE RECHAZO EN TRASPLANTE RENAL , PREDICCI\u00d3N COMPUTACIONAL Y MODELO DE INTERACCI\u00d3N CON MBD6   Alfaro, Rafael1; Legaz, Isabel2; Jimenez-Coll, Victor2; Gonzalez-Lopez, Rosana2; Sanchez-Rodriguez, Carlos2; Martinez-Banaclocha, Helios2; Galian, Jose Antonio2; Botella, Carmen2; Moya-Quiles, Maria Rosa2; Boix, Francisco2; De La Pe\u00f1a, Jesus3; Minguela, Alfredo2; Llorente, Santiago4; Muro, Manuel5.  1Hospital Clinico Universitario Virgen de la Arrixaca- IMIB, Murcia; 2Servicio de Inmunologia. Hospital Clinico Universitario Virgen de la Arrixaca- IMIB, Murcia; 3Servicio de Anatomia Patologica. Hospital Clinico Universitario Virgen de la Arrixaca- IMIB, Murcia; 4Servicio de Nefrologia. Hospital Clinico Universitario Virgen de la Arrixaca- IMIB, Murcia; 5Servicio de Inmunolog\u00eda. Hospital Clinico Universitario Virgen de la Arrixaca, Murcia.  Antecedentes: La biopsia de aloinjerto renal se considera el est\u00e1ndar de oro para el rechazo, pero es invasivo y podr\u00eda ser indeterminado. Varias publicaciones apuntan al papel de los miARN expresi\u00f3n al sugerir su implicaci\u00f3n en la aceptaci\u00f3n o rechazo del trasplante de \u00f3rganos. Este estudio tuvo como objetivo analizar microRNAs involucrados en la diferenciaci\u00f3n y activaci\u00f3n de B y Linfocitos T de leucocitos de sangre perif\u00e9rica de pacientes trasplantados de ri\u00f1\u00f3n (KT) para ser utilizados como biomarcadores de rechazo renal agudo (RA). M\u00e9todos: Un total de 15 pacientes KT con y sin agudo rechazo (AR/NAR) fueron analizados y cuantificados por miRNA PCR array. Un total de 84 miARN relacionados con la diferenciaci\u00f3n y activaci\u00f3n de linfocitos B y T. Las funciones y Se analizaron las v\u00edas biol\u00f3gicas para predecir los objetivos potenciales de los miARN expresados diferencialmente. Resultados: Se incrementaron seis miRNA en el grupo AR (miR-191-5p, miR-223-3p, miR-346, miR-423-5p, miR-574-3p y miR-181d) y miR-150-5p aumentaron en el grupo NAR. Los estudios in silico mostraron un total de 2603 genes diana para el aumento de miARN en AR, mientras que para la disminuci\u00f3n de miARN, un total de Se encontraron 1107 genes de potencial diana. Conclusiones: Nuestros resultados muestran que KT con AR muestra una disminuci\u00f3n en la expresi\u00f3n de miR-150-5p en comparaci\u00f3n con NAR, lo que sugiere que la disminuci\u00f3n en miR-150-5p podr\u00eda estar relacionado con un aumento de MBD6 cuya desregulaci\u00f3n podr\u00eda tener consecuencias cl\u00ednicas y evitar el rechazo.          \n  \nP-217  IDENTIFICATION AND CHARACTERIZATION OF THE NOVEL HLA-B*49:78 ALLELE WITH LEADER SEQUENCE MODIFICATIONS  Tejeda Velarde, Amalia1; Ni\u00f1o Ram\u00edrez, Jairo Eduardo1; Balas, Antonio2; Terradillos, Pilar1; Balanzategui, Ana1; Vicente Parra, Ariadna1; Jim\u00e9nez, Isabel1; Bastos, Miguel1; Alcoceba, Miguel1; Garc\u00eda Sanz, Ram\u00f3n1.  1Hospital Universitario de Salamanca, Salamanca; 2Centro de Transfusi\u00f3n de la Comunidad de Madrid, Madrid.  Introduction: Allogeneic-Hematopoietic Stem Cell Transplantation (a-HSCT) is a curative treatment for several malignant and non-malignant diseases. HLA mismatches lead to higher risk of Graft-versus-host disease (GVHD) and mortality after a-HSCT. Nowadays, the degree of HLA compatibility is evaluated according to polymorphisms present within the peptide binding region. However, HLA-B leader sequence can influence a-HSCT outcome depending on the dimorphism (Methionine or Threonine) at position -21. Here, we describe a novel HLA-B allele (HLA-B*49:78) which is included in HLA-B*49:01P group, but does not have the same leader sequence as B*49:01:01:01. Material and methods: HLA-B*49:78 allele was identified in a female bone marrow donor by next-generation sequencing (NGS).  Results: HLA sequencing gave a B*44:03:01 and B*49var assignment after complete genomic HLA-B analysis in a single phase. The HLA-B*49var showed six nucleotide differences from B*49:01:01:01: three in coding regions and the other three in non-coding regions. Coding regions substitutions were all detected in exon 1, while substitutions in non-coding regions were found in 5\u2019UTR and intron 1. First change in exon 1 was located in genomic position 5 (G>T), codon -23 (CGG>CTG) producing an amino acid modification Leucine -23 to Arginine. Next change was placed in genomic position 11 (C>T), codon -21 (ACG>ATG) causing another amino acid change Methionine -21 to Threonine and the modification of the leader sequence genotype. Last variation in exon 1 was a synonymous substitution for the amino acid Alanine located in genomic position 15 (A>T), codon -20 (GCA>GCG). The three single nucleotide changes identified in non-coding regions, where located in genomic positions -61 (T>G), -18 (A>G) and 89 (C>G). Conclusions: HLA-B*49:78 and HLA-B*49:01:01:01 have the same amino acid composition at peptide binding region, but does not share the same leader sequence. This change could influence a-HSCT outcome depending on patient\u2019s HLA-B matching and HLA-B leader variant.      \n  \nP-218  COMPARISON OF NEXT-GENERATION SEQUENCING AND SHORT-TANDEM REPEATS TO MONITOR CHIMERISM ANALYSIS  Ni\u00f1o, Jairo; Arn\u00e9s-Moreta, Estrella; Balanzategui, Ana; Corral, Roc\u00edo; Ant\u00f3n, Alicia; Navarro-Bail\u00f3n, Almudena; Garc\u00eda-\u00c1lvarez, Mar\u00eda; Maldonado, Rebeca; Bastos-Boente, Miguel; De La Torre, Igor; Medina, Alejandro; Jim\u00e9nez, Cristina; Sarasquete, Mar\u00eda Eugenia; Chill\u00f3n, M. Carmen; Hern\u00e1ndez-Ruano, Montserrat; Lucas, Sandra; S\u00e1nchez, Ana Isabel; S\u00e1nchez-Villares, Inmaculada; Gonz\u00e1lez-Calle, Ver\u00f3nica; Tejeda-Velarde, Amalia; Garc\u00eda-Sanz, Ram\u00f3n; Alcoceba, Miguel.  Hospital Universitario de Salamanca, Salamanca.  Introduction: Chimerism analysis is of great clinical utility to monitor engraftment and to predict relapse after allogeneic hematopoietic stem cell transplantation. More sensitive techniques such as next-generation sequencing (NGS) possible allow anticipating relapse in cases than the gold-standard short tandem repeats (STR) could not. Aim: To compare the limit of detection (LOD) and the quantification ability of NGS using AlloSeq HCT kit (CareDx) and STRs with PowerPlex 16HS kit (Promega) in clinical samples and artificial mixtures. Methods: LOD accuracy was evaluated by 8 artificial mixtures (50% to 0.38%). Intra- and inter-experiment reproducibility was evaluated by duplicate samples (n=3). Informativeness was assessed in 21 donor-recipient pairs (D/R). Quantification correlation of both techniques was performed on 62 clinical samples from 19 patients applying a Bland and Altman analysis. Results: The analysis of artificial mixtures showed better LOD in NGS (0,4%) than in STR (2%). There was an excellent correlation of the quantification between both techniques, with Bland and Altman analysis showing a small bias (-0,0252, Figure 1A). Informativeness was better for NGS than for STR in 21 D/R (100% vs. 95%). Reproducibility was similar for both techniques (SD \n0,74% NGS vs. \n0,42% STRs). A mixed chimerism was detected only by NGS in 14/64 samples (Figure 1B), all below the LOD of STR. This allows to detect increasing recipient cells by NGS in 2/19 patients with complete chimerism by STRs, at a median of 21 days prior to relapse. Regarding technical features, both techniques use the same quantity of DNA (10ng), but NGS is more time-consuming and expensive than STR. Conclusions: NGS technology allows a reliable quantification of chimerism with better LOD and Informativeness than STR. However, it requires to collect higher number of samples, and time to results and costs are higher. Disclosure: Work partially supported by Diagnostica Longwood and CareDx. CB16/12/00233      \n  \n \n                                   \n \n  \nP-219  OPTIMIZATION OF FLOW CYTOMETRY-BASED METHOD FOR THE DETECTION OF BOTH CYTOTOXICITY AND IGG BINDING FOR HLA ANTIBODY CROSSMATCH ASSAY  Lorca Arce, Daniel; Exp\u00f3sito, Nuria; Palou, Eduard; Caro, Jose Luis; Serra, Carles; Torres Canizales, Juan.  Secci\u00f3n de Inmunolog\u00eda del Trasplante, Servicio de Inmunolog\u00eda, Hospital Cl\u00ednic de Barcelona, Barcelona.  Background: Detection of preformed complement-binding donor-specific HLA-antibodies (DSAs) before transplantation is an important factor to prevent organ rejection. The complement-dependent cytotoxicity (CDC) assay is the conventional technique for detecting DSAs. However, it has several limitations such as low sensitivity, being a long-time technique, and its observer-dependent interpretation.  Aim: Develop a technique able to detect the presence of DSAs and their CDC ability by a flow cytometry-based procedure.   Method: Donor cells were incubated with HLA-sensitized recipient sera using 96-well plates. Then, cells were washed 3 times and incubated with rabbit complement. Afterward, lymphocyte populations were labeled with anti-CD3 and anti-CD19 fluorochrome-conjugated antibodies, FITC-conjugated goat F(ab)2 anti-human IgG and 7-actinomycin D (7-AAD).  IgG binding was reflected by flow cytometry through the mean fluorescence intensity (MFI) and cytotoxicity was calculated as percentage of 7AAD-positive cells within T or B cells.  Results: Successive experiments have established that the optimum protocol conditions  required for the crossmatch were as follows: 1) Incubation (30 minutes) of 100000 donor cells in 25 \u03bcL with 50 \u03bcL of recipient serum. 2) Incubation (30 minutes) with 100 \u03bcL of complement. 3) Incubation (30 minutes) with a titrated mix of monoclonal antibodies and 7AAD. 4) Analysis by flow cytometry. Tests were performed with sera from HLA-sensitized patients, demonstrating that the technique is able to detect the cytotoxic capacity of IgG anti-HLA class I and/or II antibodies, as well as to discriminate them from IgM antibodies. (Figure 1)  Conclusion: We describe the optimization of a flow cytometry-based procedure for the determination of both cytotoxicity and IgG HLA antibodies binding to donor-derived lymphocytes, without the need of magnetic separation of T and B lymphocytes and lowering the  \n  \ntime spent in relation to the conventional CDC technique. This procedure could improve pre-transplant risk assessment and progress organ allocation efficiency.    \n   \n \n  \nP-220  ESTUDIO DE LA DEFICIENCIA DE FORMACI\u00d3N DE ANTICUERPOS EN PERIODO DE LISTA DE ESPERA DE TRASPLANTE CARDIACO   Sarmiento, Elizabeth; Mej\u00eda, Mar\u00eda; Zatarain, Eduardo; Gonzalez, Omar; Carbone, Javier.  Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid.  Introducci\u00f3n. En la \u00faltima actualizaci\u00f3n de indicaciones de gammaglobulinas intravenosas (GGIV) de la EMA (Enero 2019) se estableci\u00f3 como criterio el fallo de formaci\u00f3n de anticuerpos frente a ant\u00edgenos polisac\u00e1ridos definido como aumento menor a 2 veces sobre el nivel basal tras vacuna de neumococo. En los primeros 6 meses post-trasplante cardiaco (TC) esta vacuna no se suele indicar por lo que no se puede utilizar esta definici\u00f3n ante infecciones graves. La hip\u00f3tesis de este trabajo es que existen pacientes con fallo de formaci\u00f3n de anticuerpos en el periodo pre-TC y que estos pacientes podr\u00edan ser considerados como candidatos a GGIV si acontecen eventos infecciosos graves en el post-TC. Material y M\u00e9todos. Estudio prospectivo de cuantificaci\u00f3n de anticuerpos anti-polisac\u00e1rido de neumococo pre y post vacuna de 23 serotipos de polisac\u00e1rido de neumococo mientras el paciente esta en lista de espera para TC. El nivel post-vacunal se realiz\u00f3 2-3 semanas tras vacuna. Se utiliz\u00f3 un ELISA de 23 serotipos de polisac\u00e1rido de neumococo coincidentes con los 23 de la vacuna de neumococo (Binding Site, Birmingham, UK).   Resultados. Durante el estudio se hizo la evaluaci\u00f3n pre y post-vacunal en 16 pacientes. En 6 de los 16 (37.5%) pacientes se pudo demostrar un fallo de formaci\u00f3n de anticuerpos frente a polisac\u00e1rido de neumococo tras 1 dosis de vacuna. El 66,6% de estos pacientes desarrollaron infecciones graves post-TC mientras que un 20% de pacientes sin deficiencia de formaci\u00f3n de anticuerpos las tuvieron (p=0.062). Conclusiones. Un importante porcentaje de pacientes con patolog\u00eda cardiaca terminal y en lista de espera para TC muestran datos de fallo de formaci\u00f3n de anticuerpos frente a ant\u00edgenos polisac\u00e1ridos. Si estos pacientes desarrollan infecciones graves post-TC podr\u00edan evaluarse como candidatos a terapia con GGIV utilizando los criterios de indicaci\u00f3n de la EMA.              \n  \nP-221  PREDICCI\u00d3N COMPUTACIONAL DE BIOMARCADORES, V\u00cdAS Y NUEVOS F\u00c1RMACOS DIANA EN LA PATOGENIA DE ENFERMEDADES DE BASE INMUNITARIA CON RESPECTO A RECHAZO DEL TRASPLANTE RENAL.   Alfaro, Rafael1; Martinez-Banaclocha, Helios1; Llorente, Santiago2; Jimenez-Coll, Victor1; Galian, Jose Antonio1; Botella, Carmen1; Moya-Quiles, Maria Rosa1; Minguela, Alfredo1; Legaz, Isabel1; Muro, Manuel1.  1Servicio de Inmunologia. Hospital Clinico Universitario Virgen de la Arrixaca, Murcia; 2Servicio de Nefrologia. Hospital Clinico Universitario Virgen de la Arrixaca, Murcia.  Diagn\u00f3stico de rechazo en trasplantados renales (TR) es realizado por biopsia, pero la evoluci\u00f3n de ciencias \u00f3micas y bioinform\u00e1ticas ha contribuido al avance en predicci\u00f3n de biomarcadores, v\u00edas y nuevos f\u00e1rmacos diana que permitan un diagn\u00f3stico preciso y menos invasivo. El objetivo era buscar genes diferencialmente expresados (DEG) en pacientes con/sin rechazo mediado por anticuerpos (AMR) y encontrar leucocitos infiltrantes en el injertoinvolucrados en AMR, nuevos f\u00e1rmacos diana, interacciones prote\u00edna-prote\u00edna (PPI) y conocer su an\u00e1lisis funcional y biol\u00f3gicocon herramientas bioinform\u00e1ticas. Cuatro bases de datos GEO de biopsias renales se analizaron con/sin AMR. Nuestros resultados muestran los DEG y las poblaciones de leucocitos infiltrantes en el injerto presentaban un aumento en la expresi\u00f3n de genes relacionados con diferentes etapas de la activaci\u00f3n inmunitaria, presentaci\u00f3n antig\u00e9nica, ADCC o migraci\u00f3n de leucocitos durante AMR. La importancia de las v\u00edas de respuesta IRF/STAT1 al IFN en el control de la expresi\u00f3n de genes relacionados con AMR se postularon como posibles dianas terap\u00e9uticas y biomarcadores AMR. Estos procesos biol\u00f3gicos correlacionados mostraron la infiltraci\u00f3n de c\u00e9lulas NK y monocitos hacia el aloinjerto, adem\u00e1s del aumento en la maduraci\u00f3n de las c\u00e9lulas dendr\u00edticas, juega un papel central en la mediaci\u00f3n del da\u00f1o sufrido por el injerto en AMR. Enfoques computacionales para la b\u00fasqueda de nuevos usos terap\u00e9uticos de diana aprobada. Los medicamentos tambi\u00e9n mostraron que imatinib te\u00f3ricamente podr\u00eda ser \u00fatil en TR para la prevenci\u00f3n y/o tratamiento de AMR. Nuestros resultados sugieren la importancia de las v\u00edas IRF/STAT1 en AMR. C\u00e9lulas NK y monocitos tienen un papel esencial en el da\u00f1o del injerto durante rechazo, eimatinib mejora los resultados del TR. Nuestros resultados tendr\u00e1n que ser validados para el uso potencial de genes sobreexpresados como biomarcadores de rechazo que pueden usarse como marcadores diagn\u00f3sticos y pron\u00f3sticos y como dianas terap\u00e9uticas para evitar el rechazo.         \n  \nP-222  MUERTES POR SEPSIS E INSUFICIENCIA HEP\u00c1TICA EN PACIENTES CON CIRROSIS ALCOH\u00d3LICA Y TRASPLANTADOS DE H\u00cdGADO. INFLUENCIA DE LOS RECEPTORES KIR.  Morales, Raquel; Collados-Ros, Aurelia; Bolarin, Jose Miguel; Muro-Perez, Manuel; Minguela, Alfredo; Luna, Aurelio; Muro, Manuel; Legaz, Isabel.  Servicio de Inmunologia. Hospital Clinico Universitario Virgen de la Arrixaca-IMIB, Murcia.  Los mecanismos cl\u00ednicos y moleculares implicados en la causa y el momento de la muerte y la supervivencia de los pacientes con cirrosis alcoh\u00f3lica (CA) sometidos a trasplante hep\u00e1tico (TH) no se conocen del todo. Este estudio tuvo como objetivo determinar, en pacientes con CA sometidos a TH, la influencia de las caracter\u00edsticas sociodemogr\u00e1ficas, cl\u00ednicas y gen\u00e9ticas de los genes KIR, principales causas/tiempo de muerte y supervivencia. Se analizaron un total de 122 pacientes CA fallecidos hasta tres a\u00f1os despu\u00e9s del TH. El ADN gen\u00f3mico se extrajo de sangre perif\u00e9rica y el genotipado KIR se realiz\u00f3 mediante PCR-SSO con tecnolog\u00eda Luminex\u00ae. Se observ\u00f3 un 53,3% de muerte no s\u00fabita. La sepsis fue la principal causa de muerte s\u00fabita con mayor porcentaje (21,3%) de mortalidad, seguida del fracaso del injerto (FG) y el fallo multiorg\u00e1nico (15,6%) a los diez a\u00f1os. La mortalidad por FG de los pacientes con AC sin encefalopat\u00eda parece estar influenciada por la presencia de KIR3DL1+ (P=0,045). Adem\u00e1s, KIR2DS1+/S1+ (P=0,011) o KIR3DL1+ (P=0,012) parecen influir en la supervivencia de los pacientes con GF a los tres a\u00f1os. En conclusi\u00f3n, nuestros resultados muestran la vulnerabilidad del paciente AC sometido a TH en funci\u00f3n de las caracter\u00edsticas de los genes KIR. La estrecha vigilancia m\u00e9dica, y la b\u00fasqueda de biomarcadores que predigan una causa y momento concretos de la muerte, son fundamentales para mejorar, controlar y adaptar los tratamientos m\u00e9dicos para prolongar la supervivencia del paciente.                  \n  \nP-223  CAUSAS DE MUERTE Y SUPERVIVENCIA EN PACIENTES CON CIRROSIS ALCOH\u00d3LICA SOMETIDOS A TRASPLANTE HEP\u00c1TICO: INFLUENCIA DE VARIABLES CL\u00cdNICAS, VULNERABILIDAD INMUNITARIA Y COMPLICACIONES EN EVOLUCION POST-TRASPLANTE.   Bolarin, Jose Miguel1; Collados-Ros, Aurelia1; Perez-Carceles, Maria Dolores1; Luna, Aurelio1; Minguela, Alfredo2; Muro, Manuel3; Legaz, Isabel1.  1Departamento Medicina Legal. Facultad de Medicina. Universidad de Murcia-IMIB, Murcia; 2Servicio de Inmunologia. Hospital Clinico Universitario Virgen de la Arrixaca-IMIB, Murcia; 3Servicio de Inmunolog\u00eda. Hospital Clinico Universitario Virgen de la Arrixaca, Murcia.  Los mecanismos cl\u00ednicos y moleculares involucrados en la causa y el momento de la muerte de los receptores con cirrosis alcoh\u00f3lica (CA) y trasplante hep\u00e1tico (TH) no se conocen por completo. En los casos de muerte s\u00fabita, la pr\u00e1ctica de la autopsia judicial es obligatoria para determinar la causa y circunstancias de la muerte. Los datos de la autopsia m\u00e9dico-legal son fundamentales para ayudar a las autoridades sanitarias a orientar las futuras actuaciones de salud p\u00fablica y evaluar la eficacia de sistemas sanitarios y adoptar las medidas preventivas para mejorar y adaptar los tratamientos para aumentar la supervivencia de estos pacientes. Nuestro estudio tuvo como objetivo determinar las diferentes causas cl\u00ednicas y sociodemogr\u00e1ficas que influyen en las diferentes causas de muerte y supervivencia del receptor CA y TH. Se analizaron 122 receptores CA y TH en diferentes momentos postrasplante. Se analizaron las complicaciones pre- y postrasplante sobre la causa de muerte y sobrevida, y las causas y tiempo en que ocurri\u00f3 la muerte. Se observ\u00f3 53,3% de muerte no s\u00fabita. Gran parte de las muertes de pacientes CA y TH se debe a muerte no s\u00fabita, sepsis y fallo del injerto (FG), siendo similares en ambos sexos. En las muertes no s\u00fabitas, no existen diferencias significativas entre tasas de muerte relacionadas o no relacionadas con TH. La sepsis fue la principal causa con mayor porcentaje (21,3%) de mortalidad seguida de FG (18,9%) y fallo multiorg\u00e1nico (15,6%) a diez a\u00f1os. Adem\u00e1s, nuestros resultados muestran c\u00f3mo las complicaciones cl\u00ednicas pre-trasplante, como infecciones virales y encefalopat\u00eda, influyen en la edad a la que se produce el fallo multiorg\u00e1nico del trasplantado. Conclusion: El fallo multiorg\u00e1nico es la primera causa de muerte s\u00fabita, con mayor mortalidad durante el primer a\u00f1o post-trasplante, seguida de sepsis y FG, mostrando vulnerabilidad del paciente CA dentro y fuera del hospital.       \n  \nP-224  UTILIDAD DEL TIPAJE HLA DE MEDIA/ALTA RESOLUCI\u00d3N EN EL TRASPLANTE RENAL   Vilches Moreno, Miriam; Jurado Orozco, Alicia; Gonz\u00e1lez Escribano, Mar\u00eda Francisca.  Hospital Universitario Virgen del Roc\u00edo, Sevilla.  La respuesta inmunitaria frente a ant\u00edgenos HLA representa la principal barrera al trasplante de \u00f3rganos s\u00f3lidos. Peque\u00f1os cambios en la secuencia de ADN de una mol\u00e9cula HLA pueden inducir la producci\u00f3n de anticuerpos donante espec\u00edficos. En la mayor\u00eda de centros se realiza tipificaci\u00f3n HLA de baja resoluci\u00f3n para diferentes loci HLA, generalmente HLA-A, B, C DRB1 y DQB1. Presentamos tres casos de seguimiento de DSA postrasplante renal en los que los pacientes se sensibilizaron contra ant\u00edgenos HLA del mismo grupo al\u00e9lico de baja resoluci\u00f3n que los suyos propios. La tipificaci\u00f3n HLA se realiz\u00f3 utilizando PCR-SSOr (LabtypeTM SSO) y el estudio de anticuerpos se realiz\u00f3 con mediante screening y single antigen en plataforma Luminex (lifecodes\u00ae LSA y lifeScreen deluxe). Los tipajes de baja resoluci\u00f3n de los pacientes eran los siguientes: paciente 1 (A*03,30; B*49,52; DRB1*03,15), paciente 2 (A*11,29; B*38,44; DRB1*01,11) y paciente 3 (A*02,03; B*07,35; DRB1*04,11). En el paciente 1 se detectaron anticuerpos frente a HLA-A*03:01P, en el paciente 2 frente a HLA-B*44:02P/B*44:03P y en el paciente 3 frente a HLA-B*35:01P. Al re-analizar el tipaje HLA de estos pacientes, el A*03 del paciente 1 era del grupo A*03:02P, el B*44 del paciente 2, B*44:04P y el B*35 del paciente 3, B*35:02P. Por tanto, peque\u00f1as diferencias en las secuencias de prote\u00ednas pueden desencadenar sensibilizaci\u00f3n. Estos resultados demuestran que, al menos en algunos pacientes, es necesario realizar tipaje HLA con intermedia o alta resoluci\u00f3n y la necesidad de contar con este nivel de resoluci\u00f3n en los tipajes de los donantes para realizar el seguimiento postrasplante. Asimismo, la sensibilizaci\u00f3n frente a mol\u00e9culas del mismo grupo al\u00e9lico que las suyas propias dificultar\u00e1 las posibilidades de acceso a un posible retrasplante si se utilizan sistemas de tipaje de baja resoluci\u00f3n.    \n  \nP-225  DETECTION OF POSSIBLE FALSE ANTI-HLA ANTIBODIES AGAINST SELF ANTIGENS USING SINGLE ANTIGEN LUMINEX TECHNOLOGY  Arnaldos P\u00e9rez, Cristina1; Dig\u00f3n, Montse1; Manch\u00f3n, Alexandra1; Torres, Juan1; Gonz\u00e1lez, Elena2; San Segundo, David2; Palou, Eduard1; Caro, Jos\u00e9 Luis1.  1Hospital Cl\u00ednic de Barcelona, Barcelona; 2Hospital Marqu\u00e9s de Valdecilla, Santander.  Introduction: The accurate identification of anti-HLA antibodies is crucial in the context of transplantation since false positive results can decrease the chance of finding a suitable donor and undergo patients to unnecessary immunosupression. The aim of this study was to determine the prevalence of these false HLA autoantibodies in a cohort from recipients on kidney transplant waiting list. Materials and methods: We analyzed the records from a total of 5570 Single Antigen (SAB) results performed from 2019 to 2020. First, results with calculated panel-reactive antibody \u2260 0 (n= 2560) were selected. Then, patients with at least two determinations in this period (n=1147) were filtered and finally those patients having a high-resolution HLA typing for class I and/or class II were analyzed in detail and the presence of a null allele in the recipient was discarded. The positivity criteria in the SAB were the recommended by the manufacturer (Immucor).  Results: None out of 253 patients showed anti-HLA class I antibodies against self allele beads. For class II, we detected potential auto-HLA antibodies in 14 out of 159 patients (10.7%): 6 DQ, 3 DRB3, 1 DRB4, 3 DPB1 and 1 DRB1. Median Fluorescence Intensity (MFI) was similar among each couple of sera except in one case. The MFI range was between 813 and 22423. We check the highest positive sera of each patient with the SAB kit from the other manufacturer (One Lambda) and in all cases except one the results were negative against these specific alleles. Conclusions: The detection of false anti-HLA class II autoantibodies is not uncommon, whereas we did not detect any case in class I. In order to confirm that these antibodies are recognizing cryptic or denatured antigens, these positive results should be verified by the use of a cellular crossmatch and/or a different SAB kit.            \n  \nP-226  PRESENCIA DE FALSOS POSITIVOS POR ANTICUERPOS ANTI-HLA NATURALES EN ENSAYOS DE FASE SOLIDA   Garc\u00eda-Soid\u00e1n Gonz\u00e1lez, Ana1; Veiga Gonz\u00e1lez, Jose Luis1; Iturrieta Zuazo, Ignacio1; Nieto Ga\u00f1an, Israel2; Casta\u00f1er Alabau, Jose Luis1.  1Hospital Universitario Ram\u00f3n y Cajal, Madrid; 2Hospital Universitario Ramon Y Cajal, Madrid.  Introduccion Los ensayos en fase s\u00f3lida para el estudio de anticuerpos anti-HLA son importantes en estudios pre y post-trasplante de receptores renales. No obstante, por su alta sensibilidad y la presencia de ant\u00edgenos HLA en diversos grados de desnaturalizaci\u00f3n, da lugar a la detecci\u00f3n de falsos positivos as\u00ed como anticuerpos anti-HLA no patog\u00e9nicos. Objetivo Discriminaci\u00f3n de anticuerpos anti-HLA patog\u00e9nicos de no patog\u00e9nicos. Materiales y Metodos Se realizan estudios de screening, especificidades de anticuerpos anti-HLA y estudio de anticuerpos fijadores de complemento mediante ensayos Luminex por bead arrays (Labscreen Mixed, Labscreen Single Antigen (SA) Clase I y II y C1qscreen, One Lambda, INC) en sueros de paciente en lista de espera de trasplante renal. Resultados El estudio de screening result\u00f3 negativo y el estudio de SA positivo para todos los beads con DR y varios con DQ. Se realizaron pruebas cruzadas por CDC y citometr\u00eda de flujo frente a dianas celulares contra las que los sueros problema presentaban elevadas MFI. El ensayo C1q result\u00f3 negativo en los sueros pre-trasplante. Lo anterior sugiere la presencia de anticuerpos anti-HLA frente a ep\u00edtopos ocultos (neoep\u00edtopos) que quedar\u00edan expuestos en las mol\u00e9culas de HLA desnaturalizadas presentes en los beads de SA. Tras el trasplante, con inmunosupresi\u00f3n est\u00e1ndar, el seguimiento de anticuerpos revel\u00f3 un importante descenso de las MFI de los anticuerpos anti-HLA detectados anteriormente y la aparici\u00f3n de anticuerpos anti-HLA frente a incompatibilidades del injerto. Hallazgos que se confirman por ensayo C1q. Conclusion Los ensayos de SA, por su alta sensibilidad y presencia de mol\u00e9culas HLA desnaturalizadas en los beads, pueden dar lugar a falsos positivos lo que dificulta su correcta interpretaci\u00f3n. Es recomendable el uso de t\u00e9cnicas complementarias (ensayo C1q, pruebas cruzadas con dianas celulares), para confirmar la patogenicidad de los anticuerpos anti-HLA detectados por SA  \n  \nP-227  NEED TO USE OF THE SINGLE ANTIGEN KIT IN POST-TRANSPLANT FOLLOW-UP OF B*45 AND DRB1*12 DONORS   Abad Molina, Cristina1; Vilches Moreno, Miriam2; Magriz Tasc\u00f3n, Irene3; Callejo Del Pozo, Mar\u00eda Paz1; Coca Rojo, Armando1; Pascual N\u00fa\u00f1ez, Pilar1.  1Hospital Cl\u00ednico Universitario de Valladolid, Valladolid; 2Hospital Universitario Puerta del Mar, C\u00e1diz; 3Hospital Juan Ram\u00f3n Jim\u00e9nez, Huelva.  According to the Banff classification, the presence of donor-specific anti-HLA antibodies (DSA) is one of the diagnostic criteria for humoral rejection and the correct detection of anti-HLA antibodies is essential, as it is used in clinical practice to assess the risks of rejection and graft loss. Solid phase assays with the Luminex platform for the study of anti-HLA antibodies have become the \"gold standard\" technique and have been incorporated into the routine of all histocompatibility laboratories, allowing their study in a simple way. The usual practice is to use the screening kit and if it is completely negative, the non-detection of DSA is reported.  However, it may happen that there are HLA antigens that are under represented in the screening beads and for their detection it is necessary to use the single antigen kit. We present two renal transplant recipients in a follow-up study of DSA in which patients were sensitized to donor HLA antigens. The antibody study was performed with the single antigen and screening kit on the Luminex platform (lifecodes\u00ae LSA and lifeScreen deluxe). Here we identified the presence of anti-B45 antibodies by single antigen and not by screening kit in a transplanted patient whose donor was B*45, as well as the presence of anti-DR12 antibodies in the other patient whose donor was DRB1*12. These antibodies are detected with median fluorescence intensity (MFI) of around 5,000. Currently, the patient with anti-B45 antibodies shows deterioration of renal function with increased creatinine and the patient with anti-DR12 antibodies remains stable. It is very important to report these cases to avoid errors in the diagnosis and consequent treatment that the patient may receive, so we recommend always using the single antigen kit when we are evaluating the presence of DSA with B*45 and DRB1*12 donors.             \n  \nP-228  LIVER TRANSPLANT RECIPIENTS WITH ALTERED ELASTOGRAPHY DISPLAY A MORE PROINFLAMMATORY IMMUNE PROFILE.   Guti\u00e9rrez Larra\u00f1aga, Mar\u00eda1; Corberos Del Caz, Marina2; Fern\u00e1ndez Rodr\u00edguez, Andrea2; Gonz\u00e1lez L\u00f3pez, Elena2; Renuncio Garc\u00eda, M\u00f3nica2; Roa Bautista, Adriel2; F\u00e1brega, Emilio2; Crespo, Javier2; San Segundo Arribas, David3; L\u00f3pez Hoyos, Marcos4.  1IDIVAL, Santander; 2Hospital Universitario Marqu\u00e9s de Valdecilla, Santander; 3Hospital Universitario Marqu\u00e9s de Valdecilla, IDIVAL, Santander; 4Hospital Universitario Marqu\u00e9s de Valdecilla, IDIVAL, Universidad de Cantabria, Santander.  Introduction: Non Alcoholic Fatty Liver Disease (NAFLD) involves hepatic alterations ranging from simple hepatic steatosis to Non Alcoholic Steatohepatitis (NASH), potentially leading to cirrhosis and hepatocellular carcinoma. NAFLD has been positioned as one of the main indications for liver transplantation in the last decade and, more recently, it has also been identified as a post-transplant complication. Transplant recipients might have enhanced risk for NASH due to, first, the proinflammatory response caused by the ischemia-reperfusion injury and the allogenic stimuli and, second, the use of immunosuppressive treatments which might predispose to metabolic syndrome, a well-known risk factor for NAFLD. The main objective of this work was to determine the immune cellular landscape of hepatic transplant recipients with altered Fibroscan values in comparison with healthy subjects. Methods: We studied a cohort of 36 hepatic transplant recipients and 7 healthy subjects similar in age and gender proportions. A Fibroscan test was performed to all patients and controls in order to look for hepatic fibrosis and steatosis, both characteristics of NASH. Multiparametric flow cytometry was conducted to assess a wide variety of immune cellular components. Mann Whitney U test was used to explore differences between groups. Results: No significant differences were found in the main cellular components such as B cells, T cells (CD4+ or CD8+), NK cells or NKT cells. However, in transplant recipients with altered liver elastography CD4 subset of cells showed a more effector phenotype in transplant recipients, and a more proinflammatory profile with decreased Th2 (CCR6-CXCR3-CD294+) and increased Th17 (CCR6+CXCR3-) and Th1-Th17 mixed phenotype (CCR6+ CXCR3+). In addition, transplant recipients showed significantly lower proportion of unswitched B cells (CD27+IgD+).  Conclusion: Liver transplant recipients with altered Fibroscan values show a more effector and  \n  \nproinflammatory helper T cell phenotype than healthy controls despite immunosuppression. This might be associated to NASH development.    \n \n  \nP-229  OPTIMIZED NGS-BASED HLA TYPING FOR THE DETECTION OF HLA LOSS RELAPSE  Vera Santiesteban, Elsie1; Mantec\u00f3n Ferrer, S\u00edlvia1; Caro Mart\u00ednez, Josefa1; Mongay Berdet, Laura1; Alonso Garc\u00eda, Laura2; Mussetti, Alberto3; Canelo Vilaseca, Marta4; Nogu\u00e9s G\u00e1lvez, Nuria5; Rudilla Salvador, Francesc6; Herrero Mata, Mar\u00eda Jos\u00e91; G\u00f3mez Massa, Elena1.  1Laboratori d'Histocompatibilitat i Immunogen\u00e8tica (Banc de Sang i Teixits), Barcelona; 2Servei de Pediatria oncol\u00f2gica i Hematologia Pedi\u00e0trica, Hospital Infantil Vall d\u2019Hebron, Barcelona, Barcelona; 3Servei d\u2019Hematologia Cl\u00ednica, Institut Catal\u00e0 d'Oncologia-Hospitalet, Hospitalet de Llobregat; 4Servei d\u2019Hematologia, ICO-Badalona, Hospital Universitari Germans Trias i Pujol, Badalona; 5Laboratori d\u2019Immunohematologia, Banc de Sang i Teixits, Barcelona; 6Laboratori d\u2019Immunohematologia, Banc de Sang i Teixits, Barcelona, Barcelona.  HLA loss relapse (HLA-LR) consists on genomic loss of mismatched HLA molecules in re-emerging leukemic cells. Prospective HLA-LR detection would require a sensitive and cost-effective technique implemented in routine laboratories. HLA-KMR\u00ae (GenDx) is the unique commercial kit specifically designed to detect HLA-LR. Although it has advantages intrinsic to the qPCR technique (high sensitivity and fast), allele and gene HLA coverage is limited. Assessing HLA-LR by analysing chimerism plus Next-generation sequencing (NGS)-based HLA typing not only could overcome this limitation but also involves high-throughput and flexibility (adjusting deep coverage according to the required sensitivity). The aim of this study is to optimize our NGS-based HLA typing strategy to detect HLA loss. For this purpose, we assessed the behavior of this technique with artificial chimerism curves and the noise level and pattern among HLA genes. Then, some conditions of current NGS protocol were modified (such as increasing the deep coverage of these specific samples) in order to increase the sensitivity to detect low-represented alleles. Analysing 6 artificial chimerim curves with the routine procedure, we observed that the capacity of detection of the low-represented allele varied among HLA genes being limited in class I genes due to the high noise level (Figure 1A). The alternative conditions in NGS protocol improved the discrimination between the low-represented allele signal and the noise (Figure 1B). With the optimized conditions, the obtained sensitivity in all class I and II HLA genes was comparable to HLA-KMR\u00ae kit based on qPCR (Figure 1C).  Finally, samples from patients with classical and HLA-LR were used as validation samples for our optimized HLA loss detection strategy.   In conclusion, optimized HLA typing NGS strategy is a useful tool for HLA-LR detection considering its high sensitivity and complete HLA gene and allele coverage.     \n  \n                       \n \n  \nSesi\u00f3n Poster. Inmunidad frente a las infecciones. Pantalla 5  P-230  TH SUBSETS PLAY A KEY ROLE IN THE PROGNOSIS OF COVID-19 PROGRESSION   Gil Etayo, Francisco Javier1; Su\u00e1rez Fern\u00e1ndez, Patricia2; Garcinu\u00f1o, Sara2; Arroyo S\u00e1nchez, Daniel1; Cabrera Marante, Oscar1; Mancebo, Eshter1; Lalueza, Antonio1; Allende, Luis M1; Pleguezuelo, Daniel1; Paz Artal, Estela1; Serrano, Antonio1.  1Hospital Unviersitario 12 de Octubre, Madrid; 2Instituto de Investigaci\u00f3n Biom\u00e9dica, i+12, Madrid.  Background The coordination of the immune response by  T-helper subsets is determinant in the evolution of infectious diseases. This fact is well known in HIV or Mycobacterium leprae/tuberculosis. This work has been aimed to evaluate the T-helper responses in the early infection in COVID-19 patients and to classify them according to disease evolution based on infection severity. Methods A randomized unicenter prospective study 184 COVID-19 patients diagnosed in the Hospital Universitario 12 de Octubre (Madrid). In the first 24 hours after diagnosis, T-helper subsets and the serum cytokine profile were evaluated by flow cytometry and Luminex, respectively and were followed-up until discharge/death. Patients were classified according the severity of the disease during the follow-up: 1) Asymptomatic 2) Symptomatic without hospital requirements 4) Hospitalized with mild-moderate disease 4) Severe patients who developed ADRS. Results COVID-19 patients showed lymphopenia, including proportions of Th1, Th2 and Th17 than healthy controls. Hospitalized patients (groups 3 and 4) presented a marked proinflammatory cytokine prolife related to their non-hospitalized counterparts (groups 1 and 2). Non-hospitalized patients showed a potent and robust Th1 immune response, whereas hospitalized patients, especially the severe ones exhibited hyper activated Th2 and Th17 responses. The multivariable analysis of every parameter associated with bad prognosis showed that early Th1 immunity behaved as an independent protective factor for the development of severe forms of the disease (OR: 0,11, IC 95%: 0,02-0,6, AUC: 0,874). The evaluation of the subsets showed that Th1 immunity is necessary to control in an efficient manner the infection, even avoiding the appearance of symptoms. Conclusions A predominant Th1 immunity in the acute phase of COVID-19 could be used as a tool to  \n  \nidentify patients with low risk for unfavorable prognosis. This finding is important for designing prophylactic and therapeutic strategies in which cellular immunity should be enhanced against antibody-based immunity.                                                    \n  \n P-231  A MACHINE LEARNING MODEL TO ASSOCIATE CELLULAR SUBSETS AND CLINICAL MARKERS WITH COVID-19 SEVERITY IN INFECTED INDIVIDUALS ATTENDING THEIR INGRESSION INTO THE EMERGENCY SERVICE   Gil Manso, Sergio1; Herrero Quevedo, Diego2; Rivera Araque, Mar\u00eda2; Ru\u00edz Calvo, Andr\u00e9s2; Yuste Ramos, Pablo2; G\u00f3mez, Vanessa2; Carbonell, Diego3; Miguens Blanco, Iria4; Bernaldo De Quir\u00f3s Plaza, Esther5; Mart\u00ednez Bonet, Marta5; Kennedy Batalla, Rebeca5; Gallego Valle, Jorge1; Bl\u00e1zquez L\u00f3pez, Elena6; L\u00f3pez Esteban, Roc\u00edo5; Correa Rocha, Rafael5; Pion, Marjorie1.  1Grupo de Inmuno-Regulaci\u00f3n Avanzanda, IiSGM, HGUGM, Madrid; 2Teor\u00eda de la Se\u00f1al y Comunicaciones, UC3M, Legan\u00e9s; 3Servicio de Hematolog\u00eda, HGUGM, Madrid; 4Servicio de Urgencias, HGUGM, Madrid; 5Laboratorio de Inmuno-Regulaci\u00f3n, IiSGM, HGUGM, Madrid; 6Servicio de Hepatolog\u00eda y Gastroenterolog\u00eda, IiSGM, HGUGM, Madrid.  SARS-CoV-2 was a novel coronavirus emerging in December 2019, responsible of the coronavirus disease 19 (COVID-19). Since December 2019, more than 511 million infection cases and 6.24 million deaths have been reported globally, the more significant pandemic in recent history, saturating healthcare systems worldwide. Because of its broad symptoms leading to organs\u2019 failure and lack of knowledge regarding the infection curse of this novel coronavirus, most patients went to the emergency services. Therefore, there is a need to stratify COVID-19 patients who need hospitalization or be treated in the intensive care unit. For that purpose, we performed a 4-flow cytometry panel distinguishing a high spectrum of T-, B- and innate cell subsets in 75 individuals on the day of their ingression into the emergency service. At the same time, their demographic and clinical characteristics were collected. Then, they were classified a posteriori for their infection severity, according to the WHO Severity Score. We developed a machine learning model that allowed us to automatically predict the Severity Score of each patient with a blood sample on their first day at the emergency service. Besides, this mathematical model allowed us to identify some immune populations highly correlated to the severity; for example, the percentage of regulatory T cells expressing the CD38 marker had a positive correlation regarding the severity, whereas the absolute number of plasmacytoid dendritic cells, NK 16+ 56- and NK 16+ 56- HLA-DR+ had a negative correlation. Therefore, this model allows us to predict the severity of the infection in individuals at the beginning of the SARS-CoV-2 infection regarding specific immune populations and clinical markers. Those results could allow us to identify individuals who will have more severe COVID- to better optimize healthcare resources.      \n  \nP-232  PROFILAXIS INFECCIOSA CON VACUNAS POLIBACTERIANAS SUBLINGUALES EN PACIENTES CON ENFERMEDADES AUTOINMUNES SIST\u00c9MICAS E IMUNOSUPRESI\u00d3N FARMACOL\u00d3GICA ACTIVA  La Fuente Mu\u00f1oz, Eduardo1; P\u00e9rez Sancristobal, In\u00e9s2; \u00c1lvarez Hern\u00e1ndez, Paula2; Mart\u00ednez, Cristina2; Morado, Inmaculada2; Freites, Dalifer2; Candelas, Gloria2; Ochoa Grull\u00f3n, Juliana1; Fern\u00e1ndez Arquero, Miguel1; S\u00e1nchez-Ram\u00f3n, Silvia1.  1Hospital Cl\u00ednico San Carlos Servicio Inmunolog\u00eda Cl\u00ednica, Madrid; 2Hospital Cl\u00ednico San Carlos Servicio Reumatolog\u00eda, Madrid.  Las infecciones en pacientes con enfermedades reum\u00e1ticas autoinmunes sist\u00e9micas (EAs), se relacionan con disfunci\u00f3n inmunol\u00f3gica, actividad de la enfermedad e inmunosupresi\u00f3n. Los f\u00e1rmacos modificadores de la enfermedad (FAMEs) sint\u00e9ticos y biol\u00f3gicos, han mejorado el pron\u00f3stico estas. Se ha evidenciado que las vacunas polibacterianas sublinguales disminuyen la tasa de infecciones recurrentes del tracto urinario (ITU) y del tracto respiratorio (ITR), mejorando la morbimortalidad.  Se realiz\u00f3 un estudio observacional de pacientes con ERAs que hab\u00edan recibido dichas vacunas entre 2014 \u2013 2018. A partir de 2018 y hasta 2021, se analiz\u00f3 la incidencia de ITU e ITR y se compar\u00f3 con incidencia anual previa a la administraci\u00f3n y tras el a\u00f1o postvacuna.  Se observ\u00f3 un aumento del n\u00famero de infecciones entre los a\u00f1os 2018 a 2021, comparado con el a\u00f1o postvacuna, para ITU (1,53\u00b12,17 vs 0,63\u00b11,13; p=0,005) y para ITR (1,63\u00b12,32 vs 0,67\u00b10,92; p=0,003).  Al categorizar por n\u00famero de infecciones, observamos que a pesar del aumento del n\u00famero medio de ITU e ITR, aproximadamente la mitad de los pacientes no tuvieron infecci\u00f3n en el periodo 2018-2021 (51,2% ITU y 43,5% ITR).  La comparaci\u00f3n con el a\u00f1o previo a la vacuna, a pesar del aumento del n\u00famero de infecciones durante el periodo 2018-2021 respecto al postvacunal, el n\u00famero de episodios de ITR segu\u00eda siendo menor (1,61\u00b12,26 vs 2,76\u00b1 2,57; p= 0,002), al igual que el n\u00famero de ITU (1,56\u00b12,12 vs 2,69\u00b13,07; p= 0,010).  El efecto de las vacunas polibacteranas sublinguales se mantuvo hasta 3 a\u00f1os, con disminuci\u00f3n significativa de infecciones con respecto al a\u00f1o previo a la vacuna, lo que sugiere que estas vacunas podr\u00edan tener beneficio a largo plazo. El n\u00famero de infecciones respiratorias y urinarias aument\u00f3 durante los a\u00f1os que no estuvo disponible la administraci\u00f3n de la vacuna. Sin embargo, se observ\u00f3 ausencia de infecciones en la mitad de los pacientes.        \n  \nP-233  IL11 AND WNT5A DYSREGULATION SIGNALING BY SARS-COV-2 ACCESSORY PROTEINS ARE INVOLVED IN INFLAMMATORY AND PRO-FIBROTIC DISEASES  Dies L\u00f3pez-Ayll\u00f3n, Blanca1; Garc\u00eda Garc\u00eda, Tr\u00e1nsito2; Mendoza, Laura1; De Lucas Rius, Ana1; Fern\u00e1ndez Rodr\u00edguez, Ra\u00fal2; Redondo, Natalia1; Pedrucci, Federica1; Zaldivar L\u00f3pez, Sara2; Jim\u00e9nez Mar\u00edn, \u00c1ngeles2; Garrido, Juan J2; Montoya Gonz\u00e1lez, Mar\u00eda1.  1Molecular Biomedicine Department, Margarita Salas Center for Biological Research (CIB-CSIC), MADRID; 2Immunogenomics and Molecular Pathogenesis BIO365 Group, Department of Genetics, University of C\u00f3rdoba. Immunogenomics and Molecular Pathogenesis GA14 Group, Maim\u00f3nides Biomedical Research Institute of C\u00f3rdoba (IMIBIC), C\u00d3RDOBA.  SARS-CoV-2, the cause of the COVID-19 pandemic, possesses eleven accessory proteins encoded in its genome. Their roles during infection are still not completely understood and several of them have been mutating into the different variants of the virus. WNT5A dysregulation signaling has been implicated in the development of various pathological conditions in humans such as inflammation and fibrosis. Interleukin-6 (IL6) family members induce WNT5A expression in various cell types, highlighting a critical role for WNT5A in immune responses. Expression of Interleukin-11 (IL11), a member of IL6 cytokine family, correlates with the extent of fibrosis and its signaling induced fibroblast activation via TGF\u03b2. In this study, A549 were transduced with lentivirus expressing individual viral accessory proteins ORF6, ORF8, ORF9b or ORF9c from SARS-CoV-2 (Wuhan-Hu-1 isolate) and their interaction with cellular responses were analyzed. Firstly, transcriptomic analysis revealed that both WNT5A and IL11 were significantly up-regulated in all transduced cells. Some IL11 signaling-related genes, such as STAT3 or TGF\u03b2, were differentially expressed. IPA software analysis showed that both WNT5A and IL11 were involved in pulmonary fibrosis idiopathic disease. Subsequently, bioinformatics and functional assays revealed that these four accessory proteins were implicated in both inflammatory and fibrotic responses. While overexpression of ORF8 and ORF9c appear to trigger a STAT3-dependent cellular response mediated by IL11, ORF6 and ORF9b seem to provoke a cell profibrotic response mediated by TGFb through WNT5A. Our results suggest that ORF6, ORF8, ORF9b and ORF9c could be involved in inflammatory and fibrotic responses in SARS-CoV-2 infection. Thus, these accessory proteins could be targeted by new therapies for COVID-19 disease.          \n  \nP-234  DIN\u00c1MICA DE LA RESPUESTA INMUNE ADAPTATIVA EN LA INFECCI\u00d3N NATURAL POR SARS-COV-2    Almendro V\u00e1zquez, Patricia1; Laguna Goya, Roc\u00edo2; Ruiz Ruig\u00f3mez, Mar\u00eda2; Utrero Rico, Alberto3; Lalueza, Antonio2; Maestro De La Calle, Guillermo2; Delgado, Pilar4; P\u00e9rez Ordo\u00f1o, Luis2; Muro, Eva2; Vila, Juan2; Zamarr\u00f3n, Isabel2; Moreno Batanero, Miguel1; Chivite Lacaba, Marta1; Gil Etayo, Francisco Javier1; Mart\u00edn Higuera, Carmen2; Mel\u00e9ndez Carmona, Mar\u00eda \u00c1ngeles2; Lumbreras, Carlos2; Arellano, Irene4; Alarc\u00f3n, Balbino4; Allende, Luis Miguel2; Aguado, Jose Mar\u00eda2; Paz Artal, Estela2.  1Instituto de Investigaci\u00f3n Hospital 12 de Octubre, Madrid; 2Hospital 12 de Octubre, Madrid; 3Icahn School of Medicine at Mount Sinai, Nueva York; 4Centro de Biologia Molecular Severo Ochoa, Consejo Superior de Investigaciones Cientificas (CSIC), Madrid.  El objetivo del estudio fue comprender c\u00f3mo se desarrolla la respuesta inmune adaptativa en la infecci\u00f3n natural por SARS-CoV-2, su relaci\u00f3n con los diferentes niveles de gravedad y su mantenimiento a largo plazo.  Se analiz\u00f3 longitudinalmente la respuesta celular (IFN-\u03b3 y/o IL-2) mediante FluoroSpot (spot forming unit (sfu)/106 PBMC) frente a la esp\u00edcula (S), membrana y nucleoc\u00e1pside del SARS-CoV-2 y la respuesta de anticuerpos anti-S y su actividad neutralizante en dos cohortes: 88 pacientes con infecci\u00f3n aguda clasificados en leves (seguimiento ambulatorio, n=32), moderados (ingreso corto sin complicaciones, n=34) y graves (UCI, ventilaci\u00f3n mec\u00e1nica y/o exitus, n=22); y 234 pacientes recuperados de COVID-19.  La enfermedad leve se caracteriz\u00f3 por el r\u00e1pido desarrollo de c\u00e9lulas T altamente funcionales, alcanzando su pico 15 d\u00edas tras el inicio de s\u00edntomas (DPSO), seguido de una coordinada respuesta humoral. Los pacientes moderados iniciaron m\u00e1s tempranamente la producci\u00f3n de anticuerpos y alcanzaron la m\u00e1xima respuesta T aproximadamente 21DPSO. Los pacientes graves, sin embargo, no mostraron c\u00e9lulas T espec\u00edficas dentro de los 21DPSO y produjeron altos niveles de anticuerpos desde el principio. En un an\u00e1lisis multivariante, la respuesta celular espec\u00edfica para S1 medida en urgencias permaneci\u00f3 como factor protector frente a COVID-19 grave, independientemente del sexo y la edad (OR por incremento de 100 IFN-\u03b3-sfu/106 PBMC: 0.47, p<0.05).  Entre los pacientes recuperados, el 97% y el 99% manten\u00edan, respectivamente, respuesta celular (IL-2 predominante) y humoral 4-7 meses tras la infecci\u00f3n, observ\u00e1ndose una disminuci\u00f3n progresiva \u00fanicamente de anticuerpos y actividad neutralizante.   \n  \nEstos resultados sugieren que los pacientes sin una pronta respuesta T progresan a formas graves de COVID-19, mientras que una respuesta celular temprana y coordinada con la producci\u00f3n de anticuerpos contiene la infecci\u00f3n y favorece cuadros leves. La medici\u00f3n de ambas ramas de la inmunidad adaptativa proporciona informaci\u00f3n sobre el pron\u00f3stico y la protecci\u00f3n frente a COVID-19.     \n              \n \n  \nP-235  SARS-COV-2 SEROPREVALENCE AND HAEMATOLOGICAL FEATURES IN BLOOD DONORS  Mart\u00edn, M Carmen; Gonzalez, M Isabel; Holgado, Nuria; Jimenez, Ana; Ortega, Nuria; Parrado, Alba; Page, Isabel; Perez, Maria; Blanco-Peris, Lydia.  Centro de Hemoterapia y Hemodonaci\u00f3n de Castilla y Le\u00f3n, Valladolid.  Background: The vast majority of COVID-19 cases both symptomatic and asymptomatic develop immunity after COVID-19 contagion. Whether lasting differences exist between infection and vaccination boosted immunity is yet to be known. The aim of this study was to determine how long total anti-SARS-CoV2 antibodies due to past infection persist in peripheral blood and whether sex, age or haematological features can influence their lasting. Material and Methods: A series of 2421 donations either of SARS-CoV-2 convalescent plasma or whole blood from 1107 repeat donors from January 2020 to March 2021 was analysed. An automated chemiluminescence immunoassay for total antibodies recognizing the nucleocapsid protein of SARS-CoV-2 in human serum and plasma was performed. Sex, age, blood group, blood cell counts and percentages and immunoglobulin concentrations were extracted from electronic recordings. Blood donation is allowed after a minimum of one-month post symptom\u2019s relapse. Donors were 69.7% males and their average age was 46. The 250 donors who had later donations after a positive one underwent further analysis. Both qualitative (positivity) and quantitative (rise or decline of optical density regarding consecutive donations) outcomes were evaluated. Results and discussion: In 97.6% of donors with follow-up, anti-SARS-CoV-2 protein N total antibodies remained positive at the end of a follow-up period of 12.4 weeks median time (1-46, SD=9.65) after the first positive determination. The blood group was not related to antibody waning. Lower lymphocyte counts and higher neutrophils would help predict future waning or decay of antibodies. Most recovered donors maintain their total anti-SARS-CoV-2 N protein antibodies for at least 16 weeks (at least one month must have been awaited from infection resolution to blood donation). The 10 individuals that could be followed up longer than 40 weeks (approximately 44 weeks after symptom\u2019s relapse) were all still positive.   \n  \n                   \n \n  \nP-236  SINGLE-CELL PROFILING OF SUCCESSFULLY-TREATED HIV-INFECTED SUBJECTS WITH INVERTED CD4/CD8 RATIO   Garrido-Rodr\u00edguez, Vanesa1; Bulnes-Ramos, \u00c1ngel1; Olivas-Mart\u00ednez, Israel1; Pozo-Balado, Mar\u00eda Del Mar1; Vilad\u00e9s, Consuelo2; Rull, Anna2; Vidal, Francesc2; Pacheco, Yolanda1.  1Laboratorio de Inmunolog\u00eda, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo/CSIC/Universidad de Sevilla, Sevilla; 2Hospital Universitari Joan XXIII, IISPV, Universitat Rovira i Virgili, Tarragona.  Most HIV-infected subjects fail to normalize the CD4/CD8 ratio after successful antiretroviral therapy (ART), showing higher risk of clinical progression and death. We characterized the immune profile of chronic HIV-infected subjects according to their CD4/CD8 ratio. We analysed samples from 25 HIV-infected patients achieving 500 CD4 T-cell counts after 3 years under ART (RIS-BioBank), grouped according to their CD4/CD8 ratio into LOW (<0.8) and HIGH (>1.2) groups. PBMCs were deeply phenotyped using Maxpar Direct Immune Profiling Assay (Fluidigm) by mass cytometry (CyTOF). Dimensionality reduction (tSNE) analysis was performed in FCS Express 7 and statistical analysis was performed using Mann-Whitney U test (SPSS). A total of 100,000 cells and 32 markers were used to generate a representative t-SNE map of the immune system of HIV-infected patients with LOW (N=13) and HIGH (N=12) CD4/CD8 ratio (Figure 1). No differences were found regarding CD4 T-cells maturational subsets distribution, but a trend to higher Th1 frequency was observed in the LOW group (5.0[3.8-5.4] vs. 3.8[3.2-4.6], p=0.079). Moreover, the LOW group showed lower frequency of na\u00efve CD8 T-cells (41.0[28.8-50.5] vs. 55.3[46.0-77.0], p=0.014) while a higher frequency of the effector memory phenotype (6.5[3.2-10.8] vs. 3.0[1.5-9.4], p=0.055). Interestingly, higher frequencies of dendritic cells (DCs) (15.2[10.2-18.4] vs. 10.3[8.0-13.3], p=0.026), myeloid-derived suppressor cells (MDSCs) (41.2[25.9-53.0] vs. 32.3[16.7-42.8], p=0.042) and CD4+CD8+ double positive cells (2.2[1.9-3.1] vs. 1.5[0.7-2.1], p=0.007), as well as a trend of higher frequencies of mucosal associated invariant T/invariant NKT (MAIT/iNKT) lymphocytes (1.2[1.0-2.2] vs. 0.7[0.5-2.2], p=0.074) were found in the LOW group. Total monocytes, B and NK lymphocytes and their maturational subsets showed no differences between groups. Our results suggest that the distribution of certain populations is altered in HIV-infected subjects keeping an inverted CD4/CD8 ratio despite successful ART. This feature could be contributing to their immune dysfunction and clinical progression.   \n  \n         \n \n  \nP-237  DIFFERENTIAL PATTERN OF IFN\u0393 AND IL-2 SECRETION BY T-CELLS IN CHRONIC HIV-INFECTED SUBJECTS KEEPING INVERTED CD4/CD8 RATIO      Garrido-Rodr\u00edguez, Vanesa1; Olivas-Mart\u00ednez, Israel1; Bulnes-Ramos, \u00c1ngel1; Pozo-Balado, Mar\u00eda Del Mar1; Vilad\u00e9s, Consuelo2; Rull, Anna3; Vidal, Francesc3; Pacheco, Yolanda1.  1Laboratorio de Inmunolog\u00eda, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo/CSIC/Universidad de Sevilla, Sevilla; 2Hospital Universitari Joan XXIII, IISPV, Universitat Rovira i Virgili, Sevilla; 3Hospital Universitari Joan XXIII, IISPV, Universitat Rovira i Virgili, Tarragona.  Most HIV-infected subjects fail to normalize the CD4/CD8 ratio after successful antiretroviral therapy (ART), showing higher risk of clinical progression and death. We explored antigen-specific T-cell responses in patients depending on the CD4/CD8 ratio. Samples from patients achieving 500 CD4 T-cell counts after 3 years under ART (RIS-BioBank) were classified according to their CD4/CD8 ratio into LOW (<0.8; N=18) and HIGH (>1.2; N=22) groups. PBMCs were stimulated by CEFTA (CD4-specific), CEF (CD8-specific) and Gag (HIV-specific) peptide pools by ELISPOT assay. Positive response was considered when Spots Forming Units (SFUs)>50 after subtracting SFUs from the negative control (unstimulated PBMCs). Comparisons between pie charts were made using a Permutation test (SPICE), while those between SFUs were made using a U Mann-Whitney\u2019s test (SPSS). The frequencies of patients responding to one or several stimuli in both IFN\u03b3 and IL-2 secretion were different between study groups (p<0.0001; Figure). The proportion of patients responding to 3 stimuli was higher in LOW regarding both, IFN\u03b3 (56% vs. 43%) and IL-2 (50% vs. 27%) secretion. Interestingly, none of the LOW patients, but 14% of the HIGH, were absolute non-responders regarding IFN\u03b3. Regarding individual stimulus, the simultaneous secretion of IFN\u03b3+IL2 was similar between groups. Among responders, no differences were observed regarding IFN\u03b3 secretion in response to any stimuli, however, a trend to lower IL-2 production was found in LOW patients after CEF stimulation (148[94-810] vs. 1004[220-1640] SFUs, p=0.083). Regarding the total cytokine secretion per well, no differences were found in the spot volume of IFN\u03b3, although a significant lower IL-2 spot volume was found in LOW patients after CEFTA stimulation (30144[10594-44419] vs. 84223[15266-127141], p=0.028). Our results show a differential pattern of T-cell cytokine secretion in chronic patients maintaining an inverted CD4/CD8 ratio despite successful ART, which could be reflecting an immune dysfunction and ultimately, affecting their clinical progression.    \n  \n \n              \n \n  \nP-238  INDIVIDUALS WITH POST-COVID SYNDROME SHOW REDUCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY AND EBV REACTIVATION, REGARDLESS OF WHETHER THEY WERE HOSPITALIZED OR NOT DURING COVID-19   Gal\u00e1n, Miguel1; Vig\u00f3n, Lorena1; Nasarre-De-Letosa, Laura1; Garc\u00eda-P\u00e9rez, Javier2; Mateos, Elena1; Ar\u00e1nzazu Murciano-Ant\u00f3n, Mar\u00eda3; Torres, Montserrat1; Rodr\u00edguez-Mora, Sara1; Dom\u00ednguez-Mateos, Susana3; Alcam\u00ed, Jos\u00e92; L\u00f3pez-Huertas, Mar\u00eda Rosa1; P\u00e9rez-Olmeda, Mayte4; Coiras, Mayte1.  1Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Majadahonda, Spain, Madrid; 2AIDS Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Majadahonda, Spain, Madrid; 3Family Medicine, Centro de Salud Doctor Pedro La\u00edn Entralgo, Alcorc\u00f3n, Spain., Madrid; 4Serology Laboratory, National Center of Microbiology, Instituto de Salud Carlos III, Majadahonda, Spain, Madrid.  Introduction: About 10% of individuals with SARS-CoV-2 infection suffer from Post-COVID syndrome. It is currently unknown why some individuals recover completely from COVID-19 whereas others not. The main objective of our study was to evaluate the effectiveness of the humoral immune response in individuals with Post-COVID syndrome, in comparison with individuals who completely recovered after COVID-19. Methods: Individuals with Post-COVID were subdivided according to the COVID-19 severity in non-hospitalized (NH-PostCOVID, n=30) and hospitalized (H-PostCOVID, n=9). 20 individuals recovered completely for mild COVID-19 (Recovered) were also recruited as controls. PBMCs B cell subpopulations were analyzed by flow cytometry. Anti-SARS-CoV-2 IgG titers were analysed by ELISA and their neutralizing capability was measured using pseudotyped SARS-CoV-2. ADCC was analysed using rituximab-coated Raji cells as target. Herpesvirus reactivation (EBV, CMV) was analysed in blood by qPCR. Results: 1) 86.6%, 88.9% and 55.50% participants were female in NH-PostCOVID, H-PostCOVID, and Recovered cohorts, respectively. Median age at diagnosis was 42 (IQR 37-46), 48 (IQR 44-54), and 45 years (IQR 28-57), respectively. 2) Levels of tissue-like memory B cells were reduced 3.0-fold in NH-PostCOVID and 5.5-fold in H-PostCOVID groups, in comparison with Recovered. 3) No significant differences were found in anti-SARS-CoV-2 IgG titers and their neutralizing capacity between all groups. 4) ADCC was decreased 1.6-fold in NH-PostCOVID, in comparison with Recovered. 5) reactivation of CMV was not detected in any participant, but EBV was reactivated in 33.3% of NH-PostCOVID participants and 44.4% of H-PostCOVID participants, in comparison with 5% of Recovered individuals. Conclusion: Individuals with Post-COVID syndrome showed normal levels of neutralizing antibodies but ADCC was impaired, regardless of whether they were or not hospitalized during  \n  \nCOVID-19. This may indicate that there is a reduced immune response and an impairment in viral clearance in these individuals, which would contribute to the EBV reactivation observed in these individuals.  \n  \nP-239  LA RESPUESTA INMUNE IGM FRENTE A L\u00cdPIDOS DE LA ENVOLTURA DEL SARS-COV-2 ES FUNDAMENTAL EN LA DEFENSA FRENTE AL VIRUS.     Pi\u00e9drola Pedraza, Ignacio1; Mu\u00f1oz Mor\u00f3n, \u00darsula1; S\u00e1nchez-Vera G\u00f3mez-Trelles, Isabel1; Escudero Lirola, Esther1; Mart\u00ednez L\u00f3pez, Sara1; S\u00e1nchez Lorenzo, Ana1; Gradillas Nicolas, Ana1; Barbas Arribas, Coral1; Varona Arche, Jos\u00e9 Felipe2; Ruiz Fern\u00e1ndez, Andr\u00e9s2; Castellano, Jos\u00e9 Mar\u00eda2; S\u00e1daba Argaiz, Maria Cruz1.  1Universidad San Pablo Ceu, Madrid; 2Hospital Universitario HM Madrrid, Madrid.  Antecedentes: la pandemia de Covid-19 ha supuesto una crisis de salud mundial. La progresi\u00f3n de la enfermedad es heterog\u00e9nea, algunos de los pacientes son asintom\u00e1ticos, otros desarrollan formas leves o graves. Esta \u00faltima est\u00e1 relacionada con el trastorno metab\u00f3lico de los l\u00edpidos y la coagulopat\u00eda intravascular diseminada, asociada a la presencia de anticuerpos contra los l\u00edpidos (aPL). Nuestro objetivo fue establecer la relaci\u00f3n entre el perfil lip\u00eddico, la presencia de aPL y la progresi\u00f3n de la enfermedad. M\u00e9todos. Se analizaron muestras de suero de pacientes con COVID-19 con buena (n=40) y mala (n=40) evoluci\u00f3n y grupo control (n=40). El perfil de l\u00edpidos se analiz\u00f3 mediante UHPLC-ESI-QTOF-MS. Se identificaron m\u00e1s de 200 fosfol\u00edpidos y glucol\u00edpidos. Se utiliz\u00f3 un ensayo ELISA de alta sensibilidad desarrollado en nuestro laboratorio para analizar IgG e IgM frente a fosfatidilcolina (PC), fosfatidiletanolamina, fosfatidilinositol, fosfatidilinositol, fosfatidilserina, esfingomielina, sulf\u00e1tidos y cardiolipina. Resultados: observamos que los pacientes con Covid-19 mostraron niveles elevados de lisofosfatidilcolina en comparaci\u00f3n con el grupo control. Por el contrario, los pacientes con Covid-19 con mala evoluci\u00f3n mostraron niveles de fosfatidilinositol m\u00e1s bajos que aquellos con buena evoluci\u00f3n. En esta l\u00ednea, los pacientes con Covid-19 de buena (0,440\u00b10,038) y mala (0,420\u00b10,034; p<0,0001) evoluci\u00f3n ten\u00edan niveles mayores de IgM frente a fosfatidilcolina que el grupo control (0,218\u00b10,029; p<0,0001). Adem\u00e1s, los pacientes con Covid-19 de buena evoluci\u00f3n mostraron niveles s\u00e9ricos de IgM frente al fosfatidilinositol superiores (0,233\u00b10,026; p<0,0001) que los pacientes de mala evoluci\u00f3n (0,128\u00b10,026) y el grupo control (0,103\u00b10,028; p<0,0001). Conclusiones. La respuesta inmune humoral est\u00e1 relacionada con el perfil lip\u00eddico en Covid19. La IgM a la fosfatidilcolina y al fosfatidilinositol es una respuesta inmune principal frente a SARS-CoV-2. Son necesarios estudios futuros para definir el papel de los mismos en la fisiopatolog\u00eda de la enfermedad y/o como biomarcadores.   \n  \n P-240  EVALUACI\u00d3N DE LA RESPUESTA T-ESPEC\u00cdFICA FRENTE AL CITOMEGALOVIRUS POR CITOMETR\u00cdA DE FLUJO EN LA SELECCI\u00d3N DE POSIBLES DONANTES PARA INFUSI\u00d3N DE LINFOCITOS   Cuesta Mart\u00edn De La C\u00e1mara, Ricardo; Gonz\u00e1lez Torbay, Andrea; Matas P\u00e9rez, Elisabeth; Miguel Berenguel, Laura; Rodr\u00edguez Pena, Rebeca; Mart\u00ednez Fe\u00edto, Ana; L\u00f3pez Granados, Eduardo; S\u00e1nchez Zapardiel, Elena.  Hospital Universitario La Paz, Madrid.  Una de las principales complicaciones post-trasplante de progenitores hematopoy\u00e9ticos (TPH) son las infecciones virales, siendo la de citomegalovirus (CMV) una de las m\u00e1s frecuentes. Presentamos el caso de un var\u00f3n diagnosticado con 2 a\u00f1os de enfermedad granulomatosa cr\u00f3nica (variante en NCF2) que, a los cuatro meses de recibir un TPH alog\u00e9nico de donante no emparentado (marzo 2021), sufre una ventriculoencefalitis por CMV. Recibe antivirales, inmunoglobulinas (Ig) intratecales anti-CMV e intravenosas y una \u00fanica infusi\u00f3n con linfocitos T citot\u00f3xicos (CTLs) anti-CMV. Las cargas virales en sangre y l\u00edquido cefalorraqu\u00eddeo (LCR) disminuyen; aunque, tras su aumento en LCR a los 3 meses, se decide realizar una infusi\u00f3n de linfocitos de donante (DLI) emparentado (padre, madre o hermano), distinta fuente de las que recibe del donante TPH (CMV-negativo). Mediante citometr\u00eda de flujo se estudi\u00f3 la producci\u00f3n intracelular de interfer\u00f3n-gamma (IFNg) en respuesta a CMV, estimulando in vitro PBMCs con p\u00e9ptidos espec\u00edficos (CMV-PT, Miltenyi Biotec) y con Dynabeads CD3/28 (Gibco), adem\u00e1s del control sin est\u00edmulo. Tras 6 horas de incubaci\u00f3n, se marc\u00f3 la superficie celular (7-AAD, CD45-KO, CD3-ECD, CD4-APC-AF750 y CD8-APC-AF700, BC), se permeabiliz\u00f3 (IntraPrep Permeabilization, BC) y se marc\u00f3 intracelularmente (IFNg-PB, BC). El nivel de competencia se calcul\u00f3 restando el porcentaje CD3+IFNg+ del control negativo al del est\u00edmulo CMV. Cut-off >0.10% CD3+IFNg+. Los tres familiares presentaban serolog\u00eda IgG-positiva para el CMV, con diferente respuesta T espec\u00edfica: 0,66%, 0,58% y 1,61% CD3+IFNg+ en el padre, la madre y el hermano, respectivamente. Con estos resultados se realizaron 5 DLIs del hermano. Actualmente las cargas se mantienen indetectables, con cl\u00ednica estable. Las DLIs tras evaluaci\u00f3n de  la respuesta T espec\u00edfica al virus constituyen una alternativa en caso de no disponibilidad de CTLs espec\u00edficos de CMV que puede contribuir al manejo del tratamiento de la infecci\u00f3n en el contexto del post-TPH.       \n  \nP-241  CD64 EXPRESSION ON NEUTROPHILS AS A BIOMARKER FOR SPONTANEOUS BACTERIAL PERITONITIS  Gonz\u00e1lez L\u00f3pez, Elena1; Renuncio Garc\u00eda, M\u00f3nica1; Guti\u00e9rrez Larra\u00f1aga, Mar\u00eda1; Roa Bautista, Adriel1; Castro Hern\u00e1ndez, Carolina1; Mikhalkovich, Dzmitry1; Mota P\u00e9rez, Nerea1; Comins Boo, Alejandra1; Irure Ventura, Juan1; Odriozola, Aitor2; San Segundo Arribas, David1; Fortea, Ignacio2; L\u00f3pez Hoyos, Marcos1.  1Servicio de Inmunolog\u00eda, Hospital Universitario Marqu\u00e9s de Valdecilla, Santander; 2Servicio de Digestivo, Hospital Universitario Marqu\u00e9s de Valdecilla, Santander.  Introduction The innate immune system is responsible for generating the first response against foreign agents. During bacterial infections, type II interferon induces CD64 expression on neutrophils (CD64Neu). The assessment of CD64Neu by flow cytometry in both peripheral blood and other biological fluids has been validated for bacterial infections. Ascites can be caused by several complications as spontaneous bacterial peritonitis (SBP) in patients with cirrhosis. For its diagnosis, manual counting of polymorphonuclear cells in ascitic fluid is essential. The rapid identification of a possible bacterial infection in this type of patient would be useful for therapeutic intervention. We aimed to validate the expression of CD64Neu in ascitic fluid and assess its potential usefulness in the identification of SBP. Materials and methods The expression of CD64 on neutrophils of 41 ascitic fluid samples, recruited from November 2021 to May 2022 in the Immunology Laboratory at Marqu\u00e9s de Valdecilla University Hospital, was analysed by flow cytometry. Results A total of 8 out of 41 (13.8%) samples were diagnosed as SPB (SPB+ group). The median of CD64Neu MFI was significantly increased in SPB+ group (2838.2 MFI [1756.5-5230.0] vs 1155.3 MFI [658.8-2096.1], p= 0.048). In order to assess the risk of SPB, a binary logistic regression analysis was conducted with those parameters involved in SPB risk. The increase of CD64Neu was independently associated with SPB risk (p=0.042). The area under the curve of the model was 0.902 with 75% sensitivity and 97% specificity. Conclusion The CD64Neu determined by flow cytometry could help in diagnosis of SPB. The role of CD64Neu by flow cytometry in the assessment of SPB should be validated in larger studies to confirm our results.    \n  \nP-242  CORRELATION OF IMMUNE CELL COUNTING BASED ON FLOW CYTOMETRY IN ASCITIC FLUID SAMPLES WITH THE GOLD STANDARD FOR THE DIAGNOSIS OF SPONTANEOUS BACTERIAL PERITONITIS.   Renuncio-Garc\u00eda, M\u00f3nica1; Gonz\u00e1lez-L\u00f3pez, Elena1; Guti\u00e9rrez-Larra\u00f1aga, Mar\u00eda1; Roa-Bautista, Adriel1; Castro-Hern\u00e1ndez, Carolina1; Mikhalkovich, Dzmitry1; Mota-P\u00e9rez, Nerea1; Comins-Boo, Alejandra1; Irure-Ventura, Juan1; Odriozola, Aitor2; San Segundo, David1; Fortea, Jos\u00e9 Ignacio2; L\u00f3pez Hoyos, Marcos1.  1Servicio de Inmunolog\u00eda. Hospital Universitario Marqu\u00e9s de Valdecilla, Santander; 2Servicio de Digestivo. Hospital Universitario Marqu\u00e9s de Valdecilla, Santander.  Introduction Spontaneous bacterial peritonitis (SBP) is defined as the infection of ascitic fluid without the existence of a secondary intra-abdominal infectious focus. A polymorphonuclear count (PMN) \u2265 250/uL confirms the diagnosis irrespective of a positive culture result. The gold standard (GS) for PMN count is based on light microscopy. However, the higher sensitivity of flow cytometry (FC) opens new opportunities to clinical diagnosis. The aim was to evaluate the PMN count by flow cytometry and the potential role for clinical purposes.  Methods The study includes 154 ascitic fluids from 94 patients with ascites of any etiology. The PMN cell count was performed both with an optical microscope in a Neubauer chamber and by FC. Final SBP diagnosis was assigned based on clinical records. For clinical assessment, those ascitic fluids of the same hospital income were excluded.  Results A high-positive correlation between both methods was observed (r=0.939). Different cut-off points were calculated for SBP diagnosis and finally, 4 different groups were defined: 2 with concordant results: both Negative (NN) (n=81) or Positive (PP) (n=7) results and 2 with discordant results: GS Positive and FC Negative (n=1) and GS Negative and FC Positive (n=11) (NP group) (Figure1). The median (IQR) of hospital stay was significantly increased in PP compared with NN group (p=0.011) 11(10-20) vs 9 (6-13) whereas in NP group the median was 9 (7-14).    Conclusion The PMN cell count in ascitic fluid by FC is highly correlated with the GS method based in optical microscopy. The higher sensitivity of FC could allow the identification of intermediate  \n  \nclinical phenotypes with longer hospital stay.    \n                               \n \n  \nP-244  EFFECT OF LATENT CMV INFECTION AND AGING ON CD4 AND CD8 T-CELL FUNCTIONALITY   Hassouneh, Fakhri1; Goldeck, David2; Pera, Alejandra1; Van Heemst, Diana3; Slagboom, P Eline4; Pawelec, Graham5; Solana, Rafael1.  1GC01-Immunology and Allergy Group, Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Cordoba; 2Department of Internal Medicine II, Centre for Medical Research, University of T\u00fc-bingen, T\u00fcbingen; 3Section Gerontology and Geriatrics, Department of Internal Medicine, Leiden Univer-sity Medical Center, Leiden; 4Molecular Epidemiology, Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden; 5Department of Immunology, University of T\u00fcbingen, T\u00fcbingen.  Memory T cells undergo replicative senescence upon prolonged proliferation by chronic antigen stimulation. In humans, senescent T cells are marked in part by loss of CD28 expression and acquired expression of CD57. However, these senescent T cells can still produce large quantities of pro-inflammatory cytokines and cytotoxic mediators. CMV infection also induces the expansion of CD57+ T-cells, but whether this has a beneficial, detrimental, or neutral role for immunity is still debated. The increased functionality of CD57+ T-cells can be considered useful, but a growing body of evidence suggests that these cells may have pathogenic potential in conditions like chronic kidney rejection, cancer, atherosclerosis, and myocardial infarction, underscoring the detrimental roles of these cells in various chronic inflammatory responses. We have demonstrated that CMV-seropositivity is associated with the expansion of polyfunctional CD57+ T-cells in young and middle-aged individuals in response to different stimuli. Here, we expand our results on the effects of age and CMV infection on T-cell functionality in a cohort of healthy middle-aged and older individuals stratified by CMV serostatus. Specifically, we studied the polyfunctional responses (degranulation, IFN-\u03b3 and TNF-\u03b1 production) of CD4+ and CD8+ T-cells according to CD57 expression in response to Staphylococcal Enterotoxin B (SEB). Results showed that CD57+ T-cells were mainly expanded in CMV-seropositive individuals and clearly demonstrate that in the absence of CMV, age has no effect on the size or polyfunctionality of both the CD4 and CD8 T-cell responses to SEB. The study shows that CD57+ T-cells are more polyfunctional than CD57\u2212 T-cells in any age group. Our results also show that CMV, but not aging, has a significant role in the expansion CD57+ T-cells. This data could be of clinical importance because CMV infection can be treated, and the expansion of such cytotoxic proinflammatory cells could potentially be prevented.        \n  \nP-245   SPECIFIC CELLULAR RESPONSE AGAINST THREE DIFFERENT MODELS OF VIRAL ANTIGENS IN ELDERLY IMMUNOCOMPETENT INDIVIDUALS  Rioseras De Bustos, Beatriz; Garc\u00eda Torre, Alejandra; Bueno Garc\u00eda, Eva; L\u00f3pez Mart\u00ednez, Roc\u00edo; Campo Ramos, Rainer; Moro Garc\u00eda, Marco Antonio; Alonso Arias, Rebeca.  Hospital Universitario Central de Asturias, Oviedo.  T-lymphocytes have a crucial role controlling viral infections. CMV chronic infection, seasonal H1N1 influenza and the novel SARS-COV2 infection represent three distinct models of inducing viral immune memory. The aim of this work was to characterise the specific cellular responses against these three different viruses in 59 individuals aged over 60 years. They had overcome SARS-CoV-2 infection asymptomatically or with very mild symptoms. We characterized T subpopulations by flow cytometry. Specific memory T-lymphocytes against these three viruses were measured by IFN-\u0263 released by ELISpot. Responses to chronic CMV infection among CMV seropositive individuals showed negative correlation with na\u00efve CD8+ and with na\u00efve and the less differentiated effector memory EM1 CD4+ T-lymphocytes. Positive correlation was only observed with the highly differentiated subpopulation EMRA CD4+ (p.value<0.05). On the contrary, Influenza responses among individuals recently vaccinated, but with probable numerous encounters with the virus throughout life, correlated negatively with highly differentiated EM3 CD4+ and EMRA CD8+ and positively with EM1 CD4+ (p.value<0.05). Similarly, responses against the new and unique infection with SARS-COV-2 showed negative correlation with EMRA CD8+ and positive correlation with na\u00efve CD8+ (p.value<0.05). In fact, the ability to develop specific cellular responses against influenza and SARS-CoV2 in the influenza vaccinated group correlated positively. There was no significant correlation between the responses against SARS-CoV-2 and CMV virus although SARS-CoV2 responses were lower in CMV seropositive than in CMV seronegative patients. Our results suggest that specific cellular response against novel pathogens resembles the memory response enhanced by repeated but not chronic virus encounters. Both may be favoured by a more na\u00efve T-lymphocyte phenotype comparing with the immunosenescence induced by chronic CMV infection. Moreover, subpopulation distribution and antigen-specificity of T-lymphocyte subpopulations could be good biomarkers of the immunocompetent status in elderly individuals, reflecting their ability to generate specific memory responses against new pathogens.       \n  \nP-246  ANALYSIS OF ANTIGEN-SPECIFIC CELLULAR AND HUMORAL IMMUNE RESPONSE IN COVID-19 PATIENTS.   Egri, Natalia1; Martinez, Robert2; Oliv\u00e9, Victoria3; Hern\u00e1dez-Rodriguez, Jos\u00e94; Castro, Pedro5; Prieto, Sergio6; L\u00f3pez-Soto, Alfonso7; Vega, Gamaliel3; De Guzman, Catherine8; Heredia, Libertad8; Castellet Segura, Ana9; Fern\u00e1ndez, M. Dolores10; De Moner, Noemi8; Torradeflot, Mar\u00eda8; Ball\u00fas, Judit11; Vazquez, Mario2; Mu\u00f1oz-Sanchez, Guillermo8; Pascal, Mariona8; Calder\u00f3n, Hugo8; Gonz\u00e1lez-Navarro, Europa Azucena8; Juan, Manel8.  1Servicio de Inmunologia, Hospital Clinic, Barcelona; 2Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Barcelona; 3Salud Laboral, Hospital Clinic, Barcelona; 4Unidad de vasculitis y enfermedades autoinflamatorias. Hospital Clinic, Barcelona; 5Unidad de cuidados intensivos. Hospital Clinic., Barcelona; 6Unidad de vasculitis y enfermedades autoinflamatorias. Hospital Clinic., Barcelona; 7Servicio de Medicina Interna, Unida de geriatria. Hospital Clinic, Barcelona; 8Servicio de Inmunologia. Hospital Clinic., Barcelona; 9Salud laboral. Hospital clinic., Barcelona; 10Servicio de Inmunologia. Hospital Clinic, Barcelona; 11Servicio de Inmunologia, Barcelona.  Background The cellular and humoral immune responses are essential towards COVID-19 recovery and protection against SARS-CoV-2 reinfection. To this day, the evaluation of the immune protection to SARS-CoV-2 has mainly been focused on the detection of antibodies; However a large body of evidence suggest T lymphocytes have a greater role to resolve an established infection.  Objective Compare the magnitude of the cellular and humoral immune response in 252 convalescent COVID-19 from mild to severe patients.  Methods 252 individuals with COVID-19 (200 mild, 20 moderate and 32 severe COVID-19) were enrolled in the study. The study inclusion criteria included individuals age \u226518 years diagnosed by SARS-CoV-2 positive real-time reverse transcriptase PCR (RT-PCR) tests from nasopharyngeal swabs. Blood samples were collected two weeks after the first RT-PCR positive test.  The IgG, IgA and IgM were assessed by an in-house Luminex-based assay. The N- and S-reactive T cells were evaluated by in-house ELISpot and CoVITEST assay.  Results SARS-CoV-2-specific T cells were identified in 100% of mild COVID-19, 95% of moderate COVID-19 and 84.3%% in severe COVID-19. On the other hand, anti-SARS-CoV-2 immunoglobulins were identified in 95% of mild COVID-19, 90% of moderate COVID-19 and  \n  \n87.5% of severe COVID-19. We observed a strong SARS-CoV-2-specific T cell responses in mild COVID individuals compared to moderate and severe COVID-19.  Conclusion  We show that the T-cell responses, unlike antibodies, are detected in practically all patients with COVID-19. Reinforcing the need of assessing cellular immunity, especially in vulnerable patients, instead of the humoral response.                                         \n  \nP-247  CHANGES IN T-CELL DIFFERENTIATION PATTERNS AFTER ALCOHOL RELAPSE IN ALCOHOL USE DISORDER (AUD) PATIENTS  Zurera Egea, Coral1; Hern\u00e1ndez Rubio, Anna2; Teniente Serra, Aina2; Fuster, Daniel2; Mart\u00ednez C\u00e1ceres, Eva2; Muga, Roberto2; Zuluaga, Paola2.  1Fundaci\u00f3 Institut d\u2019investigaci\u00f3 en Ci\u00e8ncies de la Salut Germans Trias i Pujol (IGTP), Badalona; 2Hospital Universitari Germans Trias i Pujol, Badalona.  Introduction: Alcohol has a main immunosuppressive role conferring increased risk of infections or decreased vaccines effect in alcohol use disorder (AUD) patients.  CD4+T-cells exert three main types of responses depending on the insult: Th1, Th2 and Th17. However, cellular differentiation is dynamic and can polarize towards a specific response. Here, we aim to evaluate the differences in CD4+T-cell differentiation in AUD patients that need a second hospital admission for treatment after alcohol relapse.  Methods: Patients were initially admitted to treatment between 2013 and 2017 in Germans Trias I Pujol Hospital. Readmission occurred between 2014 and 2021. HCV-positivity, HIV-positivity and liver cirrhosis were exclusion criteria. T-cells Immunophenotyping defined four cellular differentiation profiles according to CCR7/CD45RA expression: na\u00efve, central memory (TCM), effector memory (TEM) and terminally differentiated effector memory. Memory subsets were subdivided into Th1, Th2 and Th17 according to CXCR3/CCR6 expression. T-cell activation was measured according to HLA-DR/CD38 expression. Paired analyses were performed to compare these subsets between both time-points.  Results: 27 patients (46-y at first admission, 82% males) were included. AUD duration was 17,4\u00b19 and 17,5\u00b18 years and daily alcohol consumption was 186\u00b1112 and 157\u00b166 gr/day at the first admission and readmission, respectively. No differences were observed regarding activation markers. However, we observed significantly increased TCMTh2/TCMTh17 (1,49\u00b11,97 VS 0,9\u00b10,28), TEMTh2/TEMTh17 (1,64\u00b12,17 VS 0,83\u00b10,59), total-Th2/total-Th17 (1,51\u00b11,98 VS 0,88\u00b10,31) and TEMTh1/TEMTh17 (4,89\u00b15,11 VS 3,32\u00b12,89) ratios in the readmission compared to the initial admission. We observed a tendency to increase of TCMTh1/TCMTh17 (1,63\u00b12,01 VS 1,03\u00b10,53) and total-Th1/total-Th17 (2,18\u00b12,5 VS 1,49\u00b10,94) ratios in the readmission compared to the initial admission. Fig1  Conclusion: In AUD patients with alcohol relapse there is a change in the phenotype of CD4+T-cells observed in the increase of Th1 and Th2 phenotypes proportional to a Th17 decrease. These immune-related effects could explain the increased  \n  \nsusceptibility to infections of AUD patients.    \n               \n \n  \nP-248  POTENTIAL IMMUNOLOGICAL BIOMARKERS OF COVID-19 DISEASE PROGRESSION  Bernardo Serrano, Raquel1; Costa Anzola, Antonio1; Molina Alcaide, Juan1; \u00c1lvarez Romero, Paula1; Trujillo Aguilera, Antonio1; Martin, Manuel2; Jurado Roger, Aurora1.  1Departamento de Inmunolog\u00eda y Alergia, Hospital Universitario Reina Sof\u00eda, C\u00f3rdoba; 2Instituto Universitario de Biomarcadores de Patolog\u00edas Metab\u00f3licas de la Universidad de Extremadura, C\u00e1ceres.   Background: Although the majority of Covid-19 disease clinical manifestations range from asymptomatic to mild respiratory infection, several patients undergo severe pneumonia requiring advanced medical support. A reliable prediction of the infection clinical course could be critical to improve outcome success by enabling an early therapy implementation in patients with high risk of progression towards severe disease and death. We aimed to find immune biomarkers capable of foreseeing the evolution of SARS-CoV-2 infection. Material and methods. A total of 1008 patients hospitalized with SARS-CoV-2 positive PCR were included. Levels of peripheral-blood lymphocytes and serum inflammatory cytokines were measured at the moment of hospital admission and compared according to infection severity (graded 1-3 following local-guidelines), intensive care requirement and decease. Lymphocyte subsets were identified by BD Multitest\u2122, whereas circulating IL-1\u03b2, IL-6, IL-8, IL-10, IL-12p70, TNF-\u03b1, IFN-\u03b3, MCP-1 and IP-10 (pg/mL) were measured by Cytometry Bead Array on a BD FacsCantoII cytometer according to manufacturer instructions. Results. In critical patients (group 3), IL-8, IL-6, IL-10 and IP-10 levels were higher (p<0.005), whereas T-cell populations were significantly lower (p<0.005) compared to patients with less severe disease (groups 1 and 2). Similarly, counts of helper and cytotoxic T-cells and NK cells were decreased in patients requiring ICU admission (p<0.005) and levels of IL-8, IL-6 and IL-10 were increased (p<0.005). Interestingly, patients displaying the triad of risk factors (age>65, T-cell lymphopenia and high-level of IL-6 and IL-8 proinflammatory cytokines) at hospital admission exhibited almost 60-times more risk of fatal outcome in contrast to patients without any risk feature (p<0.001).  Conclusions. T-lymphocyte populations (including CD4+ and CD8+) and levels of proinflammatory cytokines, mainly IL-6 and IL-8, measured at the moment of admission could be useful biomarkers to predict Covid-19 outcome addressing a rapid intervention to patients.  \n  \nP-249 THE MIGRATORY PROFILE OF DIFFERENT IMMUNE CELLS DEFINES TWO GROUPS OF POST-COVID-19 PATIENTS P\u00e9rez-C\u00f3zar, Francisco1; Cuesta-Sancho, Sara2; Cal-Sabater, Paloma2; Rybakowska, Paulina1; Landeira, Alicia2; Arribas, Elisa2; Fiz-L\u00f3pez, Aida2; Garc\u00eda-Blesa, Antonio2; Hern\u00e1ndez, Juan2; Guti\u00e9rrez, Sara3; Teller\u00eda, Pablo3; Novoa, Cristina3; Rojo Rello, Silvia4; De Prado, \u00c1ngel2; P\u00e9rez, C\u00e1ndido2; Sedano, Rosa3; Dom\u00ednguez-Gil, Marta5; Pe\u00f1arrubia, Mar\u00eda Jes\u00fas6; Pieren, Daan Kj7; Garrote, Jos\u00e9 A.2; Arranz, Eduardo2; Eiros, Jos\u00e9 Mar\u00eda5; Tamayo, Eduardo8; Ordu\u00f1a, Antonio4; Fuentes, Manuel9; Van Els, C\u00e9cile Acm7; Due\u00f1as, Carlos3; Mara\u00f1\u00f3n, Concepci\u00f3n1; Bernardo, David2.  1Pfizer-University of Granada-Junta de Andaluc\u00eda Centre for Genomics and Oncological Research (GENYO), Granada; 2Mucosal Immunology Lab, Unit of Excellence Institute of Biology and Molecular Genetics (IBGM), University of Valladolid and CSIC, Valladolid; 3Internal Medicine Department, Hospital Cl\u00ednico Universitario de Valladolid, Valladolid; 4Microbiology Unit, Hospital Cl\u00ednico Universitario de Valladolid, Valladolid; 5Microbiology Department, Hospital Universitario Rio Hortega, Valladolid; 6Department of Hematology, Hospital Cl\u00ednico Universitario de Valladolid, Valladolid; 7Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven; 8Research Unit, Hospital Cl\u00ednico Universitario de Valladolid, Valladolid; 9Cancer Research Center (University of Salamanca-CSIC), Campus Miguel de Unamuno, Valladolid.  Introduction: SARS-CoV-2 infection causes a mild to severe respiratory disease (COVID-19) in humans with a mortality rate of 2%. Clinical symptoms following resolution of the infection are known as long-COVID. The symptoms and clinical manifestations are clinically heterogeneous and suggest involvement of multi-organs/systems. The diagnostic criteria are mainly based on the narrative of the patients and general recurrent symptoms include fatigue, dyspnoea, joint pain, etc. Here, we study the immunological changes in a cohort of convalescent COVID-19 patients in order to characterize their potential relationship with persistent syndrome or acute disease severity. Methods: We collected peripheral blood samples from patients who recovered from COVID-19, 3 months after they were discharged from hospital (n = 83). Immune phenotyping was performed using a 40-plex mass cytometry panel on PBMC, and cytokine levels were quantified in the plasma by Luminex. Results were compared to 17 pre-pandemic healthy donors and 25 post-influenza individuals.  \n  \nResults: Several cytokines and immune cell subsets were altered in post-COVID patients, compared to both post-influenza individuals and pre-pandemic healthy donors, revealing a post-COVID-specific immune signature. Furthermore, immune cells of post-COVID patients showed a differential migratory phenotype. Using a logistic regression model, we were able to classify all individuals according to their diagnosis with good accuracy. Machine learning unsupervised algorithm K-means revealed four clusters of individuals when combining cytokine and mass cytometry data. Two of these clusters corresponded to post-COVID patients (figure 1), which did not correlate with post-COVID symptoms or acute severity but seemed to differ in age of individuals. Conclusions: Our results showed immune abnormalities, both in cells and cytokines levels, in post-COVID patients three months after hospital discharge. We were able to divide post-COVID individuals into two groups through machine learning models. The immune alterations observed were independent of acute or post-syndrome symptoms.  \n        \n \n  \nP-250  SARS-COV-2 ORF7A AND ORF7B DIFFERENTIALLY CONTROL IMMUNE RESPONSES, CELLULAR METABOLISM AND CELL ADHESION  Garc\u00eda-Garc\u00eda, Tr\u00e1nsito1; Fernandez-Rodriguez, Ra\u00fal1; Redondo, Natalia2; De Lucas-Rius, Ana2; Zald\u00edvar-L\u00f3pez, Sara1; Dies L\u00f3pez-Ayll\u00f3n, Blanca2; Su\u00e1rez-C\u00e1rdenas, Jose Manuel1; Jim\u00e9nez-Mar\u00edn, Angeles1; Montoya Gonz\u00e1lez, Maria2; Garrido, Juan J1.  1Immunogenomics and Molecular Pathogenesis BIO365 Group, Department of Genetics, University of C\u00f3rdoba. Maim\u00f3nides Biomedical Research Institute of C\u00f3rdoba (IMIBIC), GA-14 Research Group., C\u00f3rdoba; 2Molecular Biomedicine Department, Centro de Investigaciones Biol\u00f3gicas Margarita Salas (CIB), CSIC, Madrid.  The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic that is a serious global health problem. There is an urgent need to better understand the molecular mechanisms governing SARS-CoV-2 pathogenesis, as this will have implications for the design of better treatments and vaccines. SARS-CoV-2 possesses eleven accessory proteins encoded in its genome and some of them have been involved in facilitating infection and pathogenesis by their interaction with cellular components. Among these proteins, accessory protein ORF7a and ORF7b functions have not been fully comprehended. In this study, A549 human epithelial cells were transduced to express ORF7a and ORF7b, respectively, to explore more in depth the role of each accessory protein in the pathological manifestation leading to COVID-19. Using transcriptomic combined with bioinformatic analysis and functional assays we showed that individually expressed ORF7a and ORF7b are sufficient to alter lung cells creating conditions more favorable for SARS-CoV-2. Overexpression of ORF7a or ORF7b induce alteration of metabolic cascades via UGT1A9, PTGS2 and CYP1A1; interferon responses via OASL, IFIT1 and IFIT2; inflammation via IL-8, IL-11 and CXCL1 and cell adhesion via ICAM-1, ZO-1 and gamma-catenin. Thus, in light of these results, it is plausible to speculate that ORF7a and ORF7b could be targeted by new therapies or used as future biomarkers in this pandemic.                 \n  \nP-251  IMMUNE CELL POPULATION AND CYTOKINE PROFILING SUGGEST AGE-DEPENDENT DIFFERENCES IN THE RESPONSE TO SARS-COV-2 INFECTION   Aragon, Larraitz1; Iribarren-L\u00f3pez, Andrea2; Iparraguirre, Leire2; Saiz-Calderon, Nagore1; Agudo, Julia1; G\u00e1lvez, M\u00ba Isabel1; Cipitria, M\u00ba Carmen1; Alberro, Ainhoa2; Prada, Alvaro1; Otaegui, David2.  1Hospital Universitario de Donostia, San Sebasti\u00e1n; 2IIS Biodonostia, San Sebasti\u00e1n.  Introduction Coronavirus disease 2019 (COVID-19) is an infectious disease produced by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Epidemiological studies have shown that older patients are at higher risk of developing severe COVID-19. To further understand the relation between host age-related factors, immunosenescence/exhaustion of the immune system and the response to the virus, we characterized immune cells and cytokine responses in COVID-19 patients and healthy controls (HCs) of different age ranges.  Materials and Methods Immune cell populations were analyzed in blood samples of 58 COVID-19 patients and 40 HCs. Circulating cytokines in serum were evaluated in the same individuals and 29 extra patients. Five multicolor flow cytometry panels were used to analyze the lymphocyte populations.  Cytokines were measured with the BD-CBA Human Inflammatory Cytokines Kit. A FACS Canto II flow cytometer was used.  Results COVID-19 patients exhibited lower T lymphocytes, but increased B cells. Patients also present a higher proportion of Th2 and Th17 subtypes and a decrease in Tregs. Besides, exhausted (PD1+) cells are higher in patients than in HCs. A significant reduction in TNF and IL-1\u03b2 levels in patients was reported. The analysis per age ranges showed that the greatest number of significant differences between patients and HCs was found in the youngest age range (30-39 years). In this group, among other changes, IL-8, Th and na\u00efve Th cells are decreased while Th2 cells are increased in COVID-19 patients. On the contrary, there are some variables, which are more affected in older patients (60-69 years) \u2013 increased IL-12, IL-10 and IL-6 and decreased total lymphocytes.  Conclusions Our findings suggest that there are age-dependent differences in the immunological response to SARS-CoV-2 infection. Further studies are needed to know whether these differences are the  \n  \ncause or consequence of the increased severity of the SARS-CoV-2 infection in older individuals.                                                     \n  \nP-252  ELDERLY PEOPLE RESPOND TO SARS-COV-2-VACCINATION BUT REQUIRE MORE IMMUNIZATIONS THAN YOUNG DONORS TO GENERATE IMMUNOLOGICAL MEMORY AND DO NOT REACH THE LEVELS ACQUIRED AFTER INFECTION  Bueno Garc\u00eda, Eva1; Garc\u00eda Torre, Alejandra1; Tudela Gal\u00e1n, Nerea2; Del Reguero Mu\u00f1iz, Carolina2; Rioseras De Bustos, Beatriz1; L\u00f3pez Mart\u00ednez, Roc\u00edo1; Moro Garc\u00eda, Marco Antonio1; Alonso Arias, Rebeca1.  1Hospital Universitario Central del Principado de Asturias (HUCA) / Instituto de Investigaci\u00f3n Sanitaria de Asturias (ISPA), Oviedo; 2Centro de Salud El Cristo, Oviedo.  Taking advantage of the COVID-19 pandemic and the vaccination campaign against SARS-CoV-2, we have taken this vaccination program as a model to study the development of immunological memory against new antigens. To study the ability of elderly people to respond to neoantigens, we analysed the immunological memory of 35 elderly donors (ED; age: 75.5, IR:6) and 57 young donors (YD; age: 50, IR:34) a month after receiving the second dose RNA-based SARS-CoV-2 vaccine, and 34 elderly patients who were studied six months after their recovering from SARS-CoV-2 infection in 2020 (EP; age: 71.5, IR:16). In 25 ED we also studied the immunological memory a month after receiving the third dose of the SARS-CoV-2 vaccine. Specific memory T-lymphocytes to SARS-CoV-2 were quantified using IFN-\n-Enzyme-Linked ImmunoSpot Assay (ELISpot) after their stimulation with viral peptide pools (S1, S2, N). We found IFN-\nproducing T-lymphocytes in 28/35 and 56/57 patients in ED and YD, respectively. The median number of specific IFN-\nproducing T-lymphocytes was 116 (IR:340) and 252 (IR:292) cells/106PBMC, respectively (p<0.05). ED had also less specific IFN-\nproducing T-lymphocytes than EP (median: 526, IR:797) (p<0.001). Although no significative differences were found between the number of specific memory T-lymphocytes in ED after the third dose of the vaccine (median: 168, IR:290) and YD after the second one, levels were still lower than in EP (p<0.01). We compared ED individuals with higher and lower cellular immune responses and we observed a higher percentage of na\u00efve B-lymphocytes and higher absolute number of Th2 and follicular helper memory CD4+ T-lymphocytes in those with higher cellular memory (p<0.05). Our results suggest that, despite their aged immune system, elderly people can respond to SARS-CoV-2-vaccination, although they require more immunizations than young donors to generate the same level of immunological memory and their responses are lower than the ones generated after SARS-CoV-2 infection.    \n  \nP-253  CHARACTERIZING THE HUMORAL RESPONSE AGAINST SARS-COV-2 INFECTION IN RELATION TO BIOCHEMICAL AND THYMIC FUNCTION-RELATED PARAMETERS    Olivas-Mart\u00ednez, Israel1; Genebat, Miguel2; Bulnes-Ramos, \u00c1ngel1; Pozo-Balado, M\u00aa Del Mar1; Garrido-Rodr\u00edguez, Vanesa1; Calder\u00f3n, Alba2; Lozano, Carmen3; \u00c1lvarez-R\u00edos, Ana Isabel3; Leal, Manuel4; Pacheco, Yolanda Mar\u00eda1.  1Instituto de Biomedicina de Sevilla (IBiS), Sevilla; 2Hospital de F\u00e1tima, Sevilla; 3Hospital Virgen del Roc\u00edo, Sevilla; 4Hospital Viamed-Santa \u00c1ngela, Sevilla.  SARS-CoV-2 infection shows variable humoral responses and outcomes. We aimed to analyze predictive factors of humoral response and potential relationships with biochemical and immune parameters, including thymic function.  During the first wave of COVID-19 pandemic, unvaccinated SARS-CoV-2-infected subjects were recruited, including moderate-severe symptomatology, with hospital admission and different grades of pneumonia (MS, n=50) and mild-asymptomatic without hospital admission (MA, n=20). Different biochemical markers were measured at diagnosis in all hospital admitted subjects and in seven MA. One month after, blood samples were obtained from all subjects for biochemical analysis, and determination of leukocyte populations and thymic function-related parameters (\u03b4/\u03b2 TRECs ratio, PBMCs\u2019 relative\u2013telomere-length_RTL and thymosin levels). IgG-antibodies (Ab) against trimeric SARS-CoV-2 Spike protein were quantified by chemiluminescence at this point.  Our cohort was 56 [46-64] years-old, 41.4% females and had 790 [384-1700] anti-S Ab levels. A significantly higher level of specific Ab was observed in MS respect to MA (1260[674-1923] vs. 287[68-614], p<0.0001) (Figure 1A), not being affected by age or comorbidities. Among MS patients, those with higher Ab levels spent more days at hospital (Figure 1B). Globally, Ab response positively correlated with ferritin, CRP, creatinine and LDH (the last association being kept in MS), but negatively with protein levels at diagnosis (Figure 1C). In multivariable analysis, only LDH independently predicted Ab levels (beta coefficient=5.13 [2.29-7.97 95%CI], p=0.001). Ab levels negatively correlated with IgM (also inside MA group) whereas positively with \n2-microglobulin and transferrin soluble receptor values one month after diagnosis (both also inside MS group) (Figure 1D). No associations were found with leukocyte subpopulations or thymic-function related parameters. However, MA showed significantly higher levels of thymosin than MS (Figure 1E).   \n  \nInflammation and damage-related levels, especially LDH, at diagnosis seem to impact the humoral response against SARS-CoV-2 infection. A potential role of thymic function in infection\u2019s severity deserves study.     \n                           \n \n  \nP-254  CLOSE LONGITUDINAL IMMUNE-MONITORING ALLOWS THE IDENTIFICATION OF IMMUNE PROFILES ASSOCIATED WITH THE SEVERITY OF INFECTION BY SARS-COV-2  Fuentes Herrero, Blanca1; Oliva Ariza, Guillermo1; Carbonell, Cristina2; Lecrevisse, Quentin1; P\u00e9rez Pons, Alba1; Torres Valle, Alba1; Pozo, Julio1; Mart\u00edn Oterino, Jose \u00c1ngel2; Gonz\u00e1lez L\u00f3pez, \u00d3scar1; L\u00f3pez Bern\u00fas, Amparo2; Bernal Ribes, Marta1; Belhassen Garc\u00eda, Moncef2; P\u00e9rez Escurza, Oihane1; P\u00e9rez Andr\u00e9s, Mart\u00edn1; Vazquez, Lourdes2; Hern\u00e1ndez P\u00e9rez, Guillermo2; Garc\u00eda Palomo, Francisco Javier1; Leoz, Pilar1; Costa Alba, Pilar2; P\u00e9rez Losada, Elena2; Yeguas, Ana2; Santos S\u00e1nchez, Miryam1; Garc\u00eda Bl\u00e1zquez, Marta2; Mor\u00e1n Plata, F. Javier1; Damasceno, Daniela1; Botafogo, Vitor1; Mu\u00f1oz Garc\u00eda, Noem\u00ed1; Fluxa, Rafael3; Contreras Sanfeliciano, Teresa2; Almeida, Julia1; Marcos, Miguel2; Orfao, Alberto1.  1Centro de Investigaci\u00f3n del C\u00e1ncer, Salamanca; 2Hospital Universitario de Salamanca, Salamanca; 3Cytognos SL, Salamanca.  Introduction. COVID-19 pandemic has resulted in high morbidity and mortality. Although most cases are mild/asymptomatic, 20% develop severe forms. Still, the relationship between the (variable) response of the immune system and the clinical heterogeneity of the disease remains to be fully elucidated. Objective. To analyse in blood the kinetics of leukocyte populations and anti-SARS-CoV-2 antibodies, and their relationship with disease severity, through close monitoring along the infection. Material and Methods. A total of 802 samples from 345 patients (median 56y, from 20-99y) were analysed, including 28 cases (n=161 samples) studied every 24h-48h during the acute phase. The distribution of cell populations was analysed by flow-cytometry; in all cases, plasma levels of anti-virus N-protein antibodies were determined by ELISA. Results were relativised from the day of symptom onset (d0) and adjusted by age with healthy donors (n=960). Results. Eosinopenia, lymphopenia (mainly T-lymphocytes - all subpopulations) and neutrophilia were evident early (d+2), followed by an increase in plasma cells (d+10-d+15), returning to normal from d+50 onwards (Fig.1A); most patients had detectable plasma antibodies (IgM, IgG and IgA) from d0. Eosinopenia, lymphopenia and neutrophilia were more pronounced in more severe patients, with a later recovery, while the plasma cell peak was higher (albeit later) vs. milder patients (Fig.1B). Also, increased levels of specific IgG and IgA were found in more severe cases. Conclusions. There are unique immunological profiles of each leukocyte population, particularly during the acute phase of infection, that follow different patterns depending on severity, with more severe patients showing a greater increase/decrease in affected populations and antibody levels, but with a delay in reaching peak or returning to normal. Precise  \n  \nknowledge of the kinetics of the immune response and the profiles associated with severity will contribute to a more accurate prognostic assessment in COVID-19 patients.  \n                               \n \n  \nP-256  IRON METABOLISM IN CHRONIC HIV: IMPAIRED HEPCIDIN-SOLUBLE TRANSFERRIN RECEPTOR AXIS    Garrido-Rodr\u00edguez, Vanesa1; \u00c1lvarez-R\u00edos, Ana Isabel2; Olivas-Mart\u00ednez, Israel1; Pozo-Balado, Mar\u00eda Del Mar1; Bulnez-Ramos, \u00c1ngel1; Leal, Manuel3; Pacheco, Yolanda1.  1Laboratorio de Inmunolog\u00eda, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo/CSIC/Universidad de Sevilla, Sevilla; 2Servicio de Bioqu\u00edmica, Hospital Universitario Virgen del Roc\u00edo, Sevilla; 3Hogar Residencia de la Santa Caridad/Servicio de Medicina Interna, Hospital Viamed Santa \u00c1ngela de la Cruz, Sevilla.  Chronic HIV-infected subjects under effective antiretroviral treatment (ART) exhibit an immune dysfunction leading to comorbidities. Since iron metabolism plays an essential role in immune cell function, its regulation may be relevant in this context. We included 92 asymptomatic chronic HIV-infected subjects under suppressive treatment (HIV), 25 age-matched non-HIV healthy donors (<65 years-old; Young, Y) and 25 non-HIV elderly subjects (>65 years-old; Elderly, E). For partial analysis, 84 patients with iron deficiency and ferritin<50 ng/mL were also included (Ferropenic, F). Traditional biomarkers of iron metabolism, as well as soluble transferrin receptor (sTfR), hepcidin, and inflammatory markers were determined in plasma. Compared to both healthy (Young and Elderly) controls, HIV subjects exhibited decreased iron (Y, 100[60-116]; HIV, 31[24-42]; E, 81[49-119] \u03bcg/dL), transferrin saturation (Y, 26[16-29]; HIV, 11[8-15]; E, 26[15-37] %) and sTfR (Y, 3.1[2.7-4.1]; HIV, 2.0[1.5-2.6]; E, 3.9[3.0-5.2] mg/L), although increased ferritin (Y, 72[25-142]; HIV, 119[61-183] ng/mL), but similar hepcidin levels (Figure 1A and B). As expected, ferropenic subjects showed the lowest levels of hepcidin (HIV, 9.4[6.1-14.4]; F, 1.9[1.6-3.0] ng/mL). Interestingly, HIV showed altered relationships between iron parameters and their regulators unlike young, elderly or even the ferropenic group (Figure 1C). Specifically, associations between sTfR and iron or transferrin saturation index were negative in healthy and ferropenic groups, while positive in HIV. Moreover, the expected negative correlation between hepcidin and sTfR, observed in healthy and ferropenic groups, was absent in HIV. Interestingly, the HIV inflammatory profile differed from the Elderly one (with an inflammaging-related profile), showing high levels of homocysteine (HIV, 3.2[2.4-4.3] vs. Y, 1.8[1.6-2.2] mg/L, p<0.0001) and \u03b22-microglobulin (HIV, 2.1[1.9-2.5] vs. Y, 1.8[1.6-2.3] mg/L, p=0.018) compared to young. Chronic HIV-infected patients under ART exhibit an imbalanced regulation of iron metabolism-related components, including hepcidin and sTfR, suggesting a complex functional iron deficiency that could contribute to their persisting immune dysfunction.  \n  \n \n                       \n \n  \nP-258  CMV IN AORTIC STENOSIS  Alvarez Heredia, Pablo1; Dominguez Del Castillo, Jose Joaquin2; Reina Alfonso, Ester Irene1; Gutierrez Gonzalez, Carmen1; Lopez Romero, Rosalia2; Mu\u00f1oz Carvajal, Ignacio2; Pera Rojas, Alejandra1.  1IMIBIC, Cordoba; 2Hospital Reina Sofia, Cordoba.  Immunosenescence is not always a consequence of chronological ageing, but it can also be accelerated by persistent antigens inducing chronic stimulation of the immune system. Regarding this, our group has demonstrated that the expansion of proatherogenic and proinflammatory CD28null T cells is driven by cytomegalovirus (CMV) and not an effect of age. In the past years, CMV latent infection has also been associated with several autoimmune conditions, and an increased risk of cardiovascular death (up to 20%). Recent studies suggest that aortic stenosis (AS) is an active inflammatory atherosclerotic-like process. Furthermore, the expansion of peripheral CD28null T cells has been observed in AS patients, suggesting that CMV could have a role in the degeneration of the aortic valve. Thus, we performed a detailed phenotypical/functional characterization of peripheral and valvular immune cells from AS patients, and healthy volunteers (HD) by multiparametric flow cytometry. This analysis included the identification of valve infiltrating CMV-specific T cells and their response to CMV peptides. CMV-associated pro-atherosclerotic and highly cytotoxic T cells were increased in peripheral blood and valvular tissue in AS patients compared with HD. Furthermore, we found CMV-specific T cells (tetramer positive) infiltrating the aortic valve tissue in AS patients. This was further corroborated by valvular T cell response to CMV peptides. Our results show for the first time an association of ASwith CMV chronic infection supporting its role in the calcification of the aortic valve. This will be mediated, partly, by CMV-specific T cells and other CMV-driven proinflammatory cells. Moreover, we successfully developed a novel protocol for the characterization of immune cells implicated in cardiovascular disease immunopathology.  Funding: This research was funded by Instituto de Salud Carlos III Ministerio de Salud, grants PI19/00075 (to Pera A.) and FI20/00194 (to Alvarez-Heredia P.).          \n  \nP-259  IMMUNE RESPONSE OF MRNA COVID-19 VACCINES IN ELDERLY ADULTS AND PATIENTS WITH LYMPHOID MALIGNANCIES.  Hern\u00e1ndez V\u00e1zquez, Juan1; De La Cal Sabater, Paloma1; Arribas, Elisa1; Fiz Lopez, Aida1; Perez Segurado, Candido1; Martin Mu\u00f1oz, Alvaro2; Gutierrez, Sara3; Telleria, Pablo3; Novoa, Cristina3; Rojo, Silvia4; De Prado, Angel1; Garcia Blesa, Antonio1; Sedano, Rosa3; Martinez Garcia, Ana Maria4; Garcinu\u00f1o Perez, Sonsoles4; Dominguez Gil, Marta4; Hernan Garcia, Cristina5; Guerra, Maria Mercedes5; Mu\u00f1oz Sanchez, Eduardo6; Barrag\u00e1n, Cristina6; Diez Morales, Soraya6; Cassazza, Oriana6; Ramos Pollo, Daniel6; Santamarta Solla, Natalia6; Alvarez Manzanares, Paula M6; De La Fuente Graciani, Ignacio7; Perez Gonzalez, Sonia7; Bravo, Sara7; Garcia Alonso, Cristina7; Tesedo Nieto, Angel8; Lopez Moreno, Elisabet Carmen8; Cabrera Sanz, Maria Esther8; Borge Olmedo, Sara8; De Paula Ortiz, Miguel8; Castellanos Asenjo, Alberto8; Gay Alonso, Jenifer9; Garrote, Jose A1; Arranz, Eduardo1; Eiros, Jose Maria10; Rescalvo Santiago, Fernando8; Quevedo Villegas, Carolina8; Tamayo, Eduardo11; Ordu\u00f1a, Antonio4; Due\u00f1as, Carlos3; Pe\u00f1arrubia, Maria Jesus7; Bernardo Ordiz, David1; Cuesta Sancho, Sara1.  1Mucosal Immunology Lab, Unit of Excellence Institute of Biology and Molecular Genetics (IBGM), University of Valladolid and CSIC, Valladolid, Spain., Valladolid; 2Flow Cytometry facility. Unit of Excellence Institute of Biology and Molecular Genetics (IBGM), University of Valladolid-CSIC, Spain., Valladolid; 3Internal Medicine Department, Hospital Cl\u00ednico Universitario de Valladolid, Valladolid, Spain., Valladolid; 4Microbiology and Inmunology Unit, Hospital Cl\u00ednico Universitario de Valladolid, Valladolid, Spain., Valladolid; 5Servicio de Medicina Preventiva, Hospital Cl\u00ednico Universitario de Valladolid, Valladolid, Spain., Valladolid; 6Unidad de Cuidados Paliativos del Hospital Universitario Rio Hortega, Valladolid, Spain., Valladolid; 7Department of Hematology, Hospital Cl\u00ednico Universitario de Valladolid, Valladolid, Spain., Valladolid; 8Servicio de Prevenci\u00f3n de Riesgos Laborales, Hospital Cl\u00ednico Universitario de Valladolid, Valladolid, Spain., Valladolid; 9Residencia y Centro de D\u00eda ORPEA Valladolid, Valladolid, Spain., Valladolid; 10Microbiology Department,  Hospital Universitario Rio Hortega, Valladolid, Spain., Valladolid; 11Unidad Investigaci\u00f3n, Hospital Cl\u00ednico Universitario de Valladolid, Valladolid, Spain., Valladolid.  COVID-19 affects the population unequally with a higher impact on aged and immunosuppressed people. Hence, we characterized the immune response triggered by mRNA vaccines in 25 healthy adults (under 70); 28 institutionalized elderlies (over 70 years); and 48 oncohematologic patients untreated or treated with B-cells antiproliferative drugs (lenalidomide, ibrutinib and rituximab). Humoral and cellular memory towards SARS-CoV-2 was determined before and after vaccination, together with the phenotype of peripheral blood mononuclear cells by spectral cytometry (40-plex spectral cytometry panel) and the plasma cytokine profile (13-plex panel). While healthy adults and institutionalized elderlies developed a serologic response, that was much lower in the hematooncologic cohorts (untreated: <70%; lenalidomide-treated: <90%; ibrutinib-treated: 60%; rituximab-treated: <10% response). Nevertheless, all cohorts (excluding patients treated with ibrutinib) developed a T-cell mediated immune response. T-SNE analysis of the spectral cytometry characterization revealed that all cohorts grouped independently of each other (Figure 1). Indeed, while healthy adults, together with untreated and  \n  \nrituximab patients changed their immune profile following vaccination, elderly adults and patients treated with lenalidomide or ibrutinib were not affected. Moreover, Post/Pre vaccination ratio for every immune subset was revealed that untreated hematologic patients had a significant increase in monocytes, NK, CD4+ and CD4+CD8+ T-cells and T regs coupled with a decrease on ILCs. On the other hand, elderly adults had an increase in NK, and CD8+ T-cells. In addition, the NK subset was reduced on rituximab patients. Cytokine analysis showed significant increased CXCL10 levels in older adults and untreated patients, as well as increased CCL2 in patients treated with rituximab and elderly prior to immunization. No differences were nevertheless observed due vaccination. In summary, here we have shown that these cohorts, especially oncohematologic patients treated with ibrutinib, display a reduced immune response to mRNA COVID vaccines, suggesting that they may be less protected against infection.  \n                \n \n  \nP-260  LA INFECCI\u00d3N POR SARS-COV-2 AUMENTA EL RIESGO CARDIOVASCULAR ASOCIADO A CMV  Reina Alfonso, Ester Irene1; \u00c1lvarez Heredia, Pablo1; Dom\u00ednguez Del Castillo, Jos\u00e9 Joaqu\u00edn2; Guti\u00e9rrez Gonz\u00e1lez, Carmen Mar\u00eda1; \u00c1lvarez Romero, Paula2; Navas Romo, Ana Mar\u00eda2; Jurado Roger, Aurora2; Molina Alcaide, Juan Eduardo2; Pera Rojas, Alejandra1.  1Instituto Maim\u00f3nides de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba, C\u00f3rdoba; 2Hospital Universitario Reina Sof\u00eda, C\u00f3rdoba.  La severidad de la infecci\u00f3n por SARS-CoV-2 aumenta con la edad asoci\u00e1ndose a inmunosenescencia. El citomegalovirus (CMV) induce inmunosenescencia acelerada acompa\u00f1ada de una expansi\u00f3n de c\u00e9lulas T CD28null proinflamatorias y aterog\u00e9nicas. Adem\u00e1s, la seropositividad a CMV se asocia con un aumento del riesgo de muerte por enfermedad cardiovascular (ECV). La infecci\u00f3n por SARS-CoV-2 tambi\u00e9n se asocia a ECV. Las c\u00e9lulas T CD28null expresan CD57 y CX3CR1, y son capaces de infiltrar la vasculatura atra\u00eddas por la fractalkina producida por c\u00e9lulas endoteliales vasculares en respuesta a inflamaci\u00f3n. As\u00ed, realizamos un an\u00e1lisis de la frecuencia de c\u00e9lulas T CD28nullCD57+CX3CR1+ como marcador de riesgo cardiovascular en pacientes COVID-19 leves/asintom\u00e1ticos a los 3-6 meses y al a\u00f1o post-infecci\u00f3n; pacientes con ECV; y controles sanos (CS), estratificados seg\u00fan seropositividad a CMV. Observamos un aumento de estas c\u00e9lulas en pacientes COVID-19 comparados con CS, solo en individuos CMV-seropositivos. Esta expansi\u00f3n se observ\u00f3 incluso un a\u00f1o despu\u00e9s de la infecci\u00f3n por SARS-CoV-2, siendo la frecuencia de estas c\u00e9lulas proaterog\u00e9nicas similar a pacientes con ECV. Nuestros resultados sugieren que, tras infecci\u00f3n leve/asintom\u00e1tica por SARS-CoV-2, se acelera el riesgo cardiovascular asociado a CMV. Este efecto se observ\u00f3 en individuos 20 a\u00f1os (edad media) m\u00e1s j\u00f3venes que pacientes con ECV, alertando de un aumento del riesgo potencial de desarrollar eventos cardiovasculares a edades m\u00e1s tempranas. Dada la elevada prevalencia mundial de infecci\u00f3n por CMV y SARS-CoV-2, esto puede suponer un grave problema de salud mundial en un futuro pr\u00f3ximo. Financiaci\u00f3n: Proyecto PI1900075, Proyectos I+D+i de Investigaci\u00f3n en Salud 2019, Instituto de Salud Carlos III (Pera, A.); proyecto PE-COVID-0053-2020, Subvenciones para la financiaci\u00f3n de la I+D+i biom\u00e9dica y en ciencias de la salud en Andaluc\u00eda 2021, co-financiado por la Unci\u00f3n Europea, Consejer\u00eda de Salud y Familias de la Junta de Andaluc\u00eda (Pera, A. y Juan Molina); contrato PFIS FI20/00194 (\u00c1lvarez-Heredia, P.)      \n  \nSesi\u00f3n Poster. Vacunas. Pantalla 6  P-261  IMPLICATIONS OF THE PREVIOUS SARS-COV-2 INFECTION IN THE CELLULAR AND HUMORAL RESPONSES BEFORE AND AFTER THE MRNA-1273 BOOSTER DOSE IN TWO-DOSE BNT162B2 VACCINATION SCHEDULE  Lozano-Rodr\u00edguez, Roberto1; Avenda\u00f1o-Ortiz, Jos\u00e92; Terr\u00f3n-Arcos, Ver\u00f3nica1; Montalb\u00e1n-Hern\u00e1ndez, Karla1; Casalvilla-Due\u00f1as, Jos\u00e9 Carlos1; Berg\u00f3n, Marta1; Del Fresno, Carlos1; L\u00f3pez-Collazo, Eduardo1.  1Instituto de Investigaci\u00f3n Hospital Universitario La Paz (IdiPAZ), Madrid; 2Instituto de Investigaci\u00f3n Hospital Ram\u00f3n y Cajal, Madrid.  We have assessed both humoral and cellular immune responses induced by the vaccination schedule of two-dose BNT162b2 (Pfizer mRNA vaccine) plus booster mRNA-1273 (Moderna mRNA vaccine) in a longitudinal cohort of na\u00efve and recovered individuals from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Regarding the humoral response, we have observed a disparate pattern in the increment of the plasmatic anti-Spike IgA and IgG antibodies levels after the first and second doses between na\u00efve and recovered individuals that were abolished both along the time and after the boost vaccination. In addition, after the boost dose, both individuals reached similar anti-Spike IgA antibodies as after the second dose and comparable anti-Spike IgG antibodies levels as recovered individuals after the first dose. In relation to the cellular response, we have evaluated the SARS-CoV-2 Spike-specific T lymphocyte proliferation capacity before and after the boost dose using 15-mer peptides of Spike protein with 11 overlapped amino acids of the wild type (WT), delta (B.1.617.2) and Omicron (B.1.1.529) variants. We have discerned a robust T cell proliferation, especially in CD4+ T cells, after the boost dose against all spike peptide pools used. Furthermore, when we broke down between na\u00efve and recovered individuals, both responded in a similar way against WT, delta and Omicron peptide pools after the boost dose with non-significant differences between them in the T CD4+ cell proliferation. Our data indicate that in both na\u00efve and COVID-19-recovered individuals, both humoral and cellular responses balance between them after the third dose, losing the differential pattern observed with the two-dose typical schedule of vaccination.      \n  \n                             \n \n  \nP-263  AN\u00c1LISIS LONGITUDINAL DE LA INMUNIDAD ADAPTATIVA TRAS 2 Y 3 DOSIS DE LAS VACUNAS DE ARNM ANTI-SARS-COV-2 EN INDIVIDUOS NA\u00cfVE Y RECUPERADOS DE COVID-19   Almendro V\u00e1zquez, Patricia1; Chivite Lacaba, Marta1; Utrero Rico, Alberto2; Gonz\u00e1lez Cuadrado, Cecilia1; Laguna Goya, Roc\u00edo3; Moreno Batanero, Miguel1; S\u00e1nchez Paz, Laura4; Luczkowiak, Joanna1; Labiod, Nuria1; Folgueira, Mar\u00eda Dolores3; Delgado, Rafael3; Paz Artal, Estela3.  1Instituto de Investigaci\u00f3n Hospital 12 de Octubre, Madrid; 2Icahn School of Medicine at Mount Sinai, Nueva York; 3Hospital 12 de Octubre, Madrid; 4Hospital Infanta Leonor, Madrid.  En este estudio caracterizamos longitudinalmente, a lo largo de 12 meses, la respuesta de c\u00e9lulas T mediante FluoroSpot (spot forming unit(sfu)/106 PBMC), IgG y anticuerpos neutralizantes (Nabs) inducidos por la vacunaci\u00f3n BNT162b2 de dos dosis m\u00e1s una tercera de mRNA-1273 en sujetos sanos: 17 con COVID-19 previo a la vacunaci\u00f3n (recuperados) y 60 na\u00efve.   La respuesta m\u00e1xima de c\u00e9lulas T e IgG inducida por dos dosis fue similar en ambos grupos y se alcanz\u00f3 a los 15 d\u00edas de la segunda dosis. Sin embargo, la neutralizaci\u00f3n fue menor en los na\u00efve. Tras el pico, la respuesta T se mantuvo estable 3-6 meses, mientras que los niveles de IgG y Nabs disminuyeron progresivamente. En comparaci\u00f3n con los individuos na\u00efve, los recuperados mantuvieron niveles significativamente superiores de c\u00e9lulas T, IgG y Nabs 1-6 meses tras la vacunaci\u00f3n. La tercera dosis potenci\u00f3 la neutralizaci\u00f3n \u00fanicamente en los na\u00efve, mientras que la potenciaci\u00f3n de la respuesta T fue superior en recuperados.    Durante los 12 meses de seguimiento se reportaron 17 infecciones por SARS-CoV-2, asintom\u00e1ticas o leves, todas en individuos na\u00efve: cinco (8,3%) 3-5 meses tras la segunda dosis y doce (21,8%) 15-30 d\u00edas tras la tercera (ola \u00d3micron). Esta exposici\u00f3n al virus potenci\u00f3 la respuesta adaptativa e indujo el desarrollo de c\u00e9lulas T frente a la nucleoc\u00e1pside y la membrana. Finalmente, un an\u00e1lisis de clusters demostr\u00f3 que el desarrollo de una robusta respuesta T y neutralizante a los 15 d\u00edas de la segunda dosis se asocia con protecci\u00f3n frente a infecci\u00f3n tras la vacunaci\u00f3n. En conclusi\u00f3n, la respuesta celular se mantiene tras la vacunaci\u00f3n y la tercera dosis fue especialmente \u00fatil para incrementar la neutralizaci\u00f3n en individuos na\u00efve. Haber sufrido COVID-19 previamente y el perfil de protecci\u00f3n detectado con c\u00e9lulas T y Nabs elevados podr\u00edan tenerse en cuenta para personalizar pr\u00f3ximas estrategias de vacunaci\u00f3n.      \n  \n                                  \n \n  \nP-264  AVIDITY STUDY OF THE HUMORAL RESPONSE AFTER ONE AND TWO DOSES OF MRNA COVID-19 VACCINES   Barrios Del Pino, Yvelise1; Placer D\u00edaz, M Jos\u00e91; \u00c1lava Cruz, Cristina2; Franco Maside, Andr\u00e9s1; Matheu Delgado, V\u00edctos2.  1Laboratorio de Inmunolog\u00eda.  Hospital Universitario de Canarias, San Crist\u00f3bal de La Laguna. Tenerife; 2Servicio de Alergolog\u00eda Hospital Universitario de Canarias, San Cristobal de La Laguna;   Introduction.  mRNA vaccines induce good immunogenicity and excellent effectiveness in real-world population. However, a detailed profile of immunological properties of the humoral response achieved after one or two doses of the vaccine is needed to guide recomendations about vaccine schedule in the future.   Methods.  After informed consent was obtained, serum samples from 30 vaccinated and  healthy HCW were studied 3 weeks after first and second dose. Avidity index was determined by their antibody-antigen binding resistance to 8 M urea. Serum samples were prediluted to give an OD at 450 nm readout of between 1.0 and 1.5 (ELISA) and were added to plates coated with RBD antigen (Euroimmun, L\u00fcbeck, GE). Plates were then washed with either PBS-T (1% BSA\u20130.05% Tween in PBS) or 8 M urea in PBS-T, before incubation with the conjugate. Samples were developed and the avidity index was calculated as the percentage of the OD of urea-treated samples/OD of PBS-T-treated samples. The study was approved by Ethics Committee of Hospital Universitario de Canarias (CHUC_2021_04).   Results.  The mRNA vaccines used were Pfizer (n=27) and Moderna (n=3). After 1D, avidity index was 8,7+/-4,0% vs 11,2+/-5,7% in the female (f): male (m) participants. Avidity index after 2D was 27,4+/-16,3% vs 28,7+/-19,1% (f:m). The avidity index results comparing the two mRNA vaccines administered were as follows: 9,0+/-4,5% (1D) to 23,9+/-14,1% (2D) for the Pfizer group and 13,2+/-4,4% (1D) to 56+/-13,3% (2D) in the Moderna group. A summary with these results is provided in figure 1.      \n  \nDiscussion.  Avidity is used to describe the total strenght of the interaction exhibited by the Ab-Ag binding. As expected, there is a generalised increase in the avidity index after the second dose of the vaccine, a biological expression of the humoral immunological improvement achieved after two doses of these mRNA vaccines in these healthy HCW.     \n                              \n \n  \nP-265  RESPUESTA IMMUNE Y SEGURIDAD DE LA VACUNA MRNA-1273 CONTRA SARS-COV-2 EN PACIENTES CON MIASTENIA GRAVIS.   Lynton Pons, Elionor1; Reyes Leiva, David1; Bravo G\u00f3mez, Andrea Carolina1; Gallardo, Eduard2; Albert Jar\u00e9s, Daniel1; L\u00f3pez-Contreras, Joaqu\u00edn1; Pl\u00e0 Junc\u00e0, Francesc2; Cort\u00e9s Vicente, Elena1; Moga Naranjo, Esther1.  1Hospital de la Santa Creu i Sant Pau, Barcelona; 2Institut de recerca de l'Hospital de la Santa Creu i Sant Pau, Barcelona.  La Miastenia Gravis (MG) es una enfermedad autoinmune que, en el 85% de los casos, cursa con anticuerpos anti-receptor de acetilcolina, causando debilidad muscular. La fluctuaci\u00f3n de los s\u00edntomas es caracter\u00edstica de la MG aunque diferentes factores como las infecciones pueden inducir exacerbaciones de la enfermedad. La pandemia causada por el SARS-CoV-2 ha propiciado el desarrollo de vacunas basadas en la tecnolog\u00eda del ARN mensajero (ARNm). En el contexto de la necesidad de una vacunaci\u00f3n masiva de la poblaci\u00f3n, se abri\u00f3 el debate sobre su efectividad en pacientes con enfermedades autoinmunes tratados con inmunosupresores y la seguridad de estas vacunas para los pacientes con MG.  En este estudio longitudinal se evalu\u00f3 la eficacia y seguridad de la vacuna mRNA-1273 en un grupo de 100 pacientes con MG tratados con diferentes terapias inmunosupresoras. Los pacientes recibieron dos dosis de la vacuna en concordancia con el protocolo de administraci\u00f3n del Hospital de la Santa Creu i Sant Pau (Barcelona). Se recogieron muestras de los pacientes antes de la primera y despu\u00e9s de la segunda dosis, determinando la respuesta inmune humoral y celular en ambos tiempos. Igualmente, se reportaron los cambios cl\u00ednicos mediante la puntuaci\u00f3n MG-ADL (Myasthenia Gravis activities of daily life score) antes de la primera dosis y tambi\u00e9n despu\u00e9s de la primera y de la segunda dosis. Despu\u00e9s de la segunda dosis, el 88.77% de los pacientes presentaron anticuerpos IgG anti-spike y el 73.47% mostraron un test de liberaci\u00f3n de interfer\u00f3n-gamma positivo, sin asociaci\u00f3n con empeoramiento sintom\u00e1tico de relevancia cl\u00ednica. Los pacientes con terapia combinada (prednisona con otro inmunosupresor) reportaron menores niveles estad\u00edsticamente significativos de seroconversi\u00f3n y de respuesta celular T.  En conclusi\u00f3n, la vacuna mRNA-1273 es segura en pacientes con MG y no afecta negativamente al curso de la enfermedad, logrando adem\u00e1s niveles altos de respuesta inmune humoral y celular.         \n  \nP-266  RESPUESTAS CELULAR Y HUMORAL A LA VACUNA MRNA-1273 FRENTE AL SARS-COV-2 EN PACIENTES ONCOL\u00d3GICOS   Mohamed Mohamed, Kauzar; Alonso Arenilla, Barbara; Benitez Fuentes, Javier David; De Luna Aguilar, Alicia; Jim\u00e9nez Garc\u00eda, Carlos; Guevara Hoyer, Kissy; Garc\u00eda Bravo, Laura; Rodr\u00edguez De La Pe\u00f1a, Antonia; Jim\u00e9nez Ortega, Alejandro Francisco; Mayol Hornero, Elsa; Pereiro Rodr\u00edguez, Alejandro; Perez Segura, Pedro; S\u00e1nchez-Ram\u00f3n, Silvia.  Hospital Cl\u00ednico San Carlos, Madrid.  Objetivos El objetivo del estudio fue evaluar las respuestas celular y humoral en pacientes con c\u00e1ncer s\u00f3lido vacunados con mRNA-1273 frente al SARS-CoV-2. Material y m\u00e9todo Se determin\u00f3 la producci\u00f3n basal de interfer\u00f3n-gamma (IFN-\u03b3) y de anticuerpos frente a la subunidad S1 del SARS-CoV-2 y dos meses despu\u00e9s de la segunda y tercera dosis de la vacuna mRNA-1273 en 36 pacientes oncol\u00f3gicos. Adem\u00e1s, se evaluaron los linfocitos T exhaustos mediante citometr\u00eda de flujo en una selecci\u00f3n de pacientes oncol\u00f3gicos y controles sanos. Resultados Se obtuvieron resultados basales positivos de inmunidad celular en 13 de 36 (36.1%) pacientes oncol\u00f3gicos y en 33 de los 36 (91,7%) tras la segunda dosis, observ\u00e1ndose diferencias significativas con los niveles basales (p&lt;0.001). Tras la tercera dosis, se observ\u00f3 un comportamiento dual: 24 pacientes (66.7%) mostraron una respuesta celular parcial tras la segunda dosis que se increment\u00f3 tras la tercera dosis vacunal (p=0.002); mientras que 11 pacientes (30,5%) presentaron una respuesta celular \u00f3ptima tras la segunda dosis y una marcada reducci\u00f3n en los niveles de INF-\u03b3 tras la tercera dosis (p=0.010). La seroconversi\u00f3n ocurri\u00f3 en todos los pacientes tras la segunda dosis vacunal. Los pacientes que presentaron una bajada en la respuesta celular tras la tercera dosis vacunal mostraron una elevada expresi\u00f3n de linfocitos T exhaustos CD8 + CD57hiPD1hi y CD8+CD57 medPD1hi en comparaci\u00f3n con los pacientes oncol\u00f3gicos que aumentaron su respuesta celular y los controles sanos. Conclusiones Estos resultados muestran que la vacunaci\u00f3n frente al SARS-CoV-2 con dos dosis resulta beneficiosa en todos los pacientes oncol\u00f3gicos. Una dosis adicional puede ser \u00fatil en los respondedores parciales mientras que los que presentan una respuesta m\u00e1xima puede presentar linfocitos T exhaustos por exposici\u00f3n antig\u00e9nica repetitiva. Nuestros datos podr\u00edan respaldar la relevancia de las pruebas inmunol\u00f3gicas para evaluar la necesidad de dosis de refuerzo.   \n  \nP-267  MAINTENANCE OF A GOOD ANTI-S ANTIBODY TITER AFTER THE COVID-19 VACCINE. EIGHT-MONTH FOLLOW-UP STUDY IN A HOME FOR THE ELDERLY.    Pozo Balado, Mar\u00eda Del Mar1; Bulnes Ramos, \u00c1ngel1; Olivas Fern\u00e1ndez, Israel1; Garrido Rodr\u00edguez, Vanesa1; Lozano, Carmen2; \u00c1lvarez R\u00edos, Ana Isabel2; S\u00e1nchez S\u00e1nchez, Berta2; Lara, Jos\u00e9 Manuel2; Maldonado Calzado, Isabel2; S\u00e1nchez Bejarano, Encarnaci\u00f3n2; Santamar\u00eda, Juan3; Bernal, Rafael3; Gonz\u00e1lez Escribano, Mar\u00eda Francisca2; Leal Noval, Manuel4; Pacheco, Yolada M.1.  1Instituto de Biomedicina de Sevilla (HUVR), Sevilla; 2Hospital Universitario Virgen del Roc\u00edo (HUVR)), Sevilla; 3Residencia Hogar de la Santa Caridad, Sevilla; 4Hospital Viamed Santa \u00c1ngela de la Cruz/Residencia Hogar de la Santa Caridad, Sevilla.  Neutralizing anti-S antibody levels are highly predictive of clinical protection against symptomatic Covid-19.  We aimed to characterize immune predictors for the maintenance of a good anti-S antibody titer and to determine the primary antibody cut-off (after the two-dose vaccine protocol) that guarantees such maintenance along time.  Residents and health workers from the \u201cSanta Caridad Elderly Home\u201d without previous Covid-19, receiving two doses of BNT162b2 vaccine were recruited (n=143). Blood was collected one (T1), four (T4) and eight (T8) months after second-dose. IgG-antibodies against trimeric SARS-CoV-2 Spike protein were quantified by chemiluminescence (LIAISON\u00aeSARS-CoV-2 TrimericS IgG, Diasorin). Seroconversion was \u226533.8 BAU/mL and good response (GR) was\u2265520 BAU/mL (1:80 median neutralization titer). Inflammatory markers and immune cellular subsets were determined by standard procedures. Telomere relative length (TRL) and ratio \u03b4/\u03b2 TRECs were quantified on PBMC by digital PCR and serum \u03b11-thymosin levels by ELISA. Cut-off antibody values at T1 to maintain GR at T4 and T8 were obtained from ROC curves using Youden index. Our cohort was 64 [46-77] years-old (with 49.7% people over 65) and 66.9% men. All participants seroconverted at T1, showing most of them GR (86.5%) (Fig.1A). GR rate decayed while NR rate increased along time. At T4, subjects with GR significantly differed from those with NR or PR regarding immune parameters measured at T1 (Fig.1B). Thus, subjects maintaining GR were younger and had higher anti-S antibody titers as well as higher levels of T-and B-cells and \u03b4/\u03b2 TRECs ratios but lower levels of NK cells, homocysteine, beta-2-microglobuline, CRP and d-dimers. Cut-offs of 1645 BAU/mL (AUC 0.914(0.864-0.965); 87.5% Sensitivity and 81.4% Specificity; PPV=91.8, NPV=72.3) and 1995 BAU/mL (AUC  \n  \n0.912(0.848-0.975); 100% Sensitivity and 79.4% Specificity; PPV=100%, NPV=74.1%), were obtained for T4 and T8, respectively.  Our model could help to develop personalized strategies of vaccination based on the duration of humoral responses.    \n                \n \n  \nP-268  PRODUCTION OF NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 AFTER CORONAVAC IMMUNIZATION IN YOUNG INDIVIDUALS WITH AND WITHOUT PRIOR COVID-19  Morales N\u00fa\u00f1ez, Jos\u00e9 Javier; P\u00e9rez D\u00edaz, Sa\u00fal Alberto; Mu\u00f1oz Valle, Jos\u00e9 Francisco; Machado Sulbaran, Andrea Carolina; Mora Mora, Jes\u00fas Carlos; Hern\u00e1ndez Bello, Jorge.  Universidad de Guadalajara - Centro Universitario de Ciencias de la Salud, Guadalajara.  Background: Neutralizing antibody levels can determine the effectiveness of a vaccine. CoronaVac is a vaccine against SARS-CoV-2 with an efficacy of 50.7% and higher effectiveness against severe diseases. However, breakthrough infections leading to severe disease and death in adults vaccinated with CoronaVac have been reported. Thus, it is essential to clear the immunological mechanisms induced by this vaccine.  Objective: To determine the production dynamics of neutralizing antibodies against SARS-CoV-2 and side effects in response to immunization with the CoronaVac vaccine.  Methods: We included 112 individuals immunized with CoronaVac, with COVID-19 (n=37), and without prior COVID-19 (n=75). The presence of IgG and IgM antibodies against protein S was determined by lateral flow assays and the presence of neutralizing antibodies and their inhibitory capacity by a competitive ELISA.  Results: After the first dose of CoronaVac, there was an increase in neutralizing antibodies in individuals with and without prior COVID-19 (p <0.001); however, a higher inhibitory capacity was observed in individuals with prior COVID-19 (p = 0.0168). For the group without prior COVID-19, after the second dose, antibody values were optimized (p <0.0001), and all generated neutralizing antibodies. Based on the complete scheme, there was no difference between the groups (p<0.05). The most frequent side effects of the first and second vaccine doses were headache, asthenia, myalgia, and irritability, without significant difference by groups (p > 0.05).  Conclusions: Two doses of the CoronaVac vaccine efficiently stimulate the neutralizing antibody production in individuals with and without a history of COVID-19.  However, in individuals with prior COVID-19 infection, it induces a faster production of antibodies and since the first dose induces an optimal inhibitory capacity. This vaccine did not induce severe side effects in any study group. Keywords: CoronaVac, neutralizing antibodies, vaccine, SARS-CoV-2    \n  \n                    \n \n  \nP-269  EFFICACY AND SAFETY OF MRNA SARS-COV-2 VACCINATION IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: SINGLE CENTRE EXPERIENCE.  Boigues-Pons, Marc1; Huguet, Maria2; Iglesias Escudero, Mar\u00eda3; Mart\u00ednez-C\u00e1ceres, Eva1; Morgades, Mireia2; Felip, Eudald4; Ferr\u00e0, Christelle2; Quirant, Bibiana1.  1Division of Immunology, LCMN, Germans Trias i Pujol University Hospital and Research Institute, Barcelona, Spain.; Departament of Cellular Biology, Physiology and Immunology, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain., Badalona; 2Hematology Department, Institut Catal\u00e0 d\u2019Oncologia de Badalona, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Badalona. Universitat Auton\u00f2ma de Barcelona, Spain., Badalona; 3Division of Immunology, LCMN, Germans Trias i Pujol University Hospital and Research Institute. FOCIS Center of Excellence- UAB, Barcelona; 4Universitat de Vic \u2013 Universitat Central de Catalunya, Spain., Badalona.  Background Hematopoietic stem cell transplantation (HCST) recipients present high risk of severe SARS- CoV-2 infection and have been considered for priority vaccination. However, as they usually remain immunosuppressed for months after HSCT, vaccine efficacy might be compromised. First reports on serological response after vaccination in hematological patients confirm the lower antibody response rate, compared to the general population (&gt;90%). The characterization of the humoral and cellular response of transplanted patients could help to design more efficacious vaccination programs.  Methods SARS-CoV-2 vaccination with mRNA1273 vaccine (Moderna) was prospectively evaluated in haematological patients after HSCT and serological response was assessed after complete vaccination. In patients without specific anti-SARS-CoV-2 antibodies, we reassessed humoral and cellular response after receiving a third booster.  Results Eighty-seven patients (56 auto-HSCT and 31 allo-HSCT) received the complete vaccination regimen with two doses between March and May 2021. At 2-4 months, 86% of patients presented seroconversion. Median antibody response rate was higher for the allo-HSCT group (2578 UI/mL) compared to auto-HSCT group (1675.5 UI/mL). Twelve patients presented a persistent negative serological status after vaccination. We found an association between negative serological response and low B-lymphocyte count (&lt;113.5 cells/uL), low IgG (&lt;700 mg/dL) and treatment with anti-CD20 antibodies in the last year before vaccination. 11/12 patients without seroconversion received a third dose of the vaccine after  \n  \nwhich 5/11 patients achieved seroconversion and 6/11 presented cellular response. At 6 months follow-up, no cases of COVID-19 infection have been reported in this series.  Conclusions Seroconversion rate after mRNA SARS-CoV-2 vaccination in HSCT recipients is elevated although lower than in the general population (&gt;90%). Anti-CD20 therapy, low B-lymphocyte count and hypogammaglobulinemia are associated with no serological response after vaccination. Specific cellular and humoral response monitoring after SARS-CoV-2 vaccination is indicated to identify booster dose candidates.  \n  \nP-270  HUMORAL AND CELLULAR RESPONSES TO BNT162B2 VACCINATION AFTER HAPLOIDENTICAL ALLOGENIC BONE MARROW TRANSPLANT IN A PATIENT WITH SEZARY SYNDROME    L\u00f3pez G\u00f3mez, Ana1; Ju\u00e1rez, Ignacio1; Rossi, Nineth1; Horndler, Lydia2; Gonz\u00e1lez Garc\u00eda, Raquel3; Martinez-Quiles, Narcisa3; Alarc\u00f3n S\u00e1nchez, Balbino4; G\u00f3mez Del Moral, Manuel5; Mart\u00ednez-Naves, Eduardo3; Regueiro, Jos\u00e9 Ram\u00f3n3.  1Departamento de Inmunolog\u00eda, Oftalmolog\u00eda y ORL, Facultad de Medicina, Universidad Complutense de Madrid., Madrid; 2Centro de Biolog\u00eda Molecular Severo Ochoa CBMSO, Madrid; 3Departamento de Inmunolog\u00eda, Oftalmolog\u00eda y ORL, Facultad de Medicina, Universidad Complutense de Madrid, Madrid; 4Centro de Biolog\u00eda Molecular Severo Ochoa, CBMSO, Madrid; 5Departamento de Biolog\u00eda Celular, Facultad de Medicina, Universidad Complutense de Madrid, Madrid.  We studied the response to three doses of BNT162b2 vaccine (Pfizer-BioNTech, September 2021 to January 2022) in a 63-year-old male with Sezary syndrome after receiving an haploidentical allogenic bone marrow transplant, when under cyclosporine and mycophenolate treatment.  We analyzed serum and PBMC from the patient to determine the humoral and cellular response to vaccines.  Anti-Spike SARS-CoV-2 IgG antibody isotypes were quantified by flow cytometry (FCM) of Jurkat cells transfected with Spike and EGFR. Total IgG and IgG1 were detected, particularly after the first and third dose. The sera neutralized SARS-CoV-2 ACE2-RBD binding with similar kinetics to IgG levels, as determined by a competitive ELISA assay.  The cellular response was analyzed by FCM in PBMC as IFN\u03b3 production in CD8 and CD4 T-cells after 7 days expansion and restimulation with SARS-CoV-2-specific Spike protein peptides. We observed a high production of IFN\u03b3 (5.11% in CD4 and 0.34% in CD8 T-cells) after the third dose that weaned in the next two months (0.73% in CD4 and 0.086% in CD8 T-cells).  These data suggest that three doses of BNT162b2 can induce strong SARS-CoV-2-neutralizing cellular and humoral responses in patients with an haploidentical allogenic bone marrow transplant and immunosuppression, but further vaccines may be required to maintain protection.     \n  \n   \n \n  \n P-271  VACUNAS QUE (QUIZ\u00c1S) DEBERIAN ADMINISTRARSE EN LOS CENTROS DE VACUNACI\u00d3N INTERNACIONAL.  L\u00f3pez Corbal\u00e1n, Juan Carlos1; Segu\u00ed Ripoll, Jos\u00e9 Miguel2.  1Subdelegacion del Gobierno, Alicante; 2Hospital San Juan Alicante, Alicante.   En los centros de Vacunacion Interncional de l Minsiterio de sanidad se   dan las recomendaciones de viaje, profilaxis conra enfermedades  tropicales , fundamentalmente malaria  y se recomiendan y administran determinadas vacunas: Vacuna anti hepatitis A ( RNA virus, dos dosis espaciadas 2-3 semanas). para personal de riesgo, generalmente  joven ( menos de 45 a\u00f1os) que viajan a zona end\u00e9mica. Vacunas contra la Encefalitis  japonesa ; 3 dosis, 0,7 y 28 dias. Vacuna contra la febre amarilla ( cepa 17 D del flavivirus atenuado en pases en c\u00e9lulas de huevo. Vacuna oral contra Fiebre tifoidea, oral, administrada, tres dias alternativos. Vacuna  intramuscular contra Fiebre tifoidea, una sola dosis. Vacunacion  T\u00e9tanos . Normalmente a prescripcion facultativa segun  el estado inmunol\u00f3gicvo del  viajero. Vacuna Encefalitis Europea ( garrapatas  del g\u00e9nero ixodes).Tres dosis, 0,7 y 28 d\u00edas.  Quiz\u00e1s sepodr\u00eda  ampliar la lista de vacunas a: Vacuna contra el \u00c9bola . Ervebo y Zabdeno + Mvabea; el Zabdeno es (Ad26.ZEBOV-GP), suspensi\u00f3n inyectable del adenovirus 26 (si, el mismo virus vector que usa el instituto Gamaleya para la vacuna \"Spuknik\" contra el SARs CoV 29). A las 8 semanas se administra   la Mvabea.Vacunaci\u00f3n de refuerzo con Zabdeno (personas que hayan recibido previamente la pauta de primovacunaci\u00f3n de 2 dosis con Zabdeno y Mvabea) Las personas que hayan completado previamente la pauta de primovacunaci\u00f3n de 2 dosis, pueden recibir una dosis de refuerzo de Zabdeno. Hay otra vacuna ,Erbevo,con una proteina del virus Ebola. Vacuna contra el dengue.  Hay una vacuna EMA/688282/2021 EMEA/H/C/004171 llamada Dengvaxia (vacuna tetravalente contra el dengue), es atenuada y se prescribe para personas de entre 6 y 45 a\u00f1os que han padecido una infecci\u00f3n previa por el virus del dengue, por que la segunda vez que se pasa la enfermedad es mucho m\u00e1s grave.       \n  \nP-272  THYMIC FUNCTION AND THE HUMORAL RESPONSE TO THREE DOSES OF COVID-19 VACCINATION IN KIDNEY TRASPLANT RECIPIENTS   Bulnes-Ramos, Angel1; Pozo-Balado, Mar\u00eda Del Mar1; Bernal-Blanco, Gabriel2; Su\u00e1rez-Benjumea, Alejandro2; Garrido-Rodr\u00edguez, Vanesa1; \u00c1lvarez-R\u00edos, Ana Isabel2; Lozano, Carmen2; Gonz\u00e1lez-Corvillo, Carmen2; Su\u00f1er-Poblet, Marta2; Olivas-Mart\u00ednez, Israel1; Gonz\u00e1lez-Escribano, Mar\u00eda Francisca2; Gonz\u00e1lez-Roncero, Francisco Manuel2; S\u00e1nchez-S\u00e1nchez, Berta2; Maldonado-Calzado, Isabel2; Lara-Ru\u00edz, Jos\u00e9 Manuel2; Pacheco-L\u00f3pez, Yolanda-Mar\u00eda1.  1Instituto De Biomedicina De Sevilla, Sevilla; 2Hospital Universitario Virgen del Roc\u00edo, Sevilla.  Kidney transplant recipients (KTR) achieve lower seroprotection rates than the general population after two-doses of COVID-19 mRNA vaccine. To analyse humoral response to the third dose of COVID-19 vaccine in KTR and potential predictive factors including thymic function.  Methods: KTR receiving three doses of mRNA-1273 vaccine and healthy controls (HD) receiving two doses of BNT162b2 vaccine were included. Humoral response to vaccine, as SARS-CoV-2 Trimeric-S-IgG antibodies (BAU/mL) was analysed before vaccination (T0), 3-4 weeks after the first dose (T1), one and four months after the second dose (T2 and T3, respectively) and one month after the third dose (T4). Seroconversion was defined as BAU/mL\u226533.8. Immune cellular subsets, kidney function-related parameters, inflammatory status, thymic output and thymosin-\u03b11 (T\n1) were measured at T0. Seventy-four KTR were included (T1 and T2) and 54 KTR remained at T3 and T4. Sixteen HD were included. KTR showed a lower seroconversion rate than HD after two doses of vaccine (44.3% vs. 100%, p<0.001), improving after the third dose (64.8%). After the full vaccination schedule, baseline immunosuppression therapy, kidney function, inflammatory status and age were negatively related to the response in KTR while higher counts of lymphocytes, T-CD3, T-CD4, B-Cells, T\n1 plasma concentration and thymic output were related to a better humoral response (Figure 1). T\n1 was independently associated to seroconversion (OR (95%CI): 1.1(1.0,1.2), p=0.037) whereas a trend to independent association was observed with baseline blood concentration of mycophenolate (OR (95%CI): 0.3(0.1,1.0); p=0.059). Antibody titers at T4 were independently associated with age (\u03b2I (95%CI): -132(-239.2-25.7), p=0.017) and baseline mycophenolate blood level (\u03b2I (95%CI): -705(-1392.5-18.3), p=0.045) and \u03b22-microglobuline (\u03b2I (95%CI): 656(90.4-1222), p=0.025). Immune cellular subsets, thymic function, inflammatory status, immunosuppression therapy and age before vaccination could be relevant for the design of future trials aiming to optimize the COVID-19 vaccination protocol with mRNA vaccines in KTR.   \n  \n          \n \n  \nP-274  RESPUESTA HUMORAL A VACUNAS EN PACIENTES CON INMUNODEFICIENCIAS. COMPARACI\u00d3N DE VACUNAS FRENTE A SARS-COV-2, DIFTERIA, T\u00c9TANOS Y PNEUMOCOCO  D\u00edaz Lozano, Azahara; Lucas Blanco, \u00c1ngela; Aguilar Criado, Marta; Sobieschi, Oana Irina; Mart\u00edn Cordero, Mar\u00eda Paloma; Melero Ru\u00edz, Josefa; Vargas P\u00e9rez, Mar\u00eda Luisa.  Hospital Universitario de Badajoz, Badajoz.  Objetivos:  Valorar la respuesta humoral a vacunas frente SARS-CoV-2 en comparaci\u00f3n con la respuesta a otras vacunas en pacientes de la consulta de inmunodeficiencias mediante un  estudio observacional retrospectivo descriptivo. Materiales y m\u00e9todos:  Han sido estudiados 129 pacientes, divididos en 6 grupos diagn\u00f3sticos: D\u00e9ficit de IgA (1), D\u00e9ficit de IgA y subclases de IgG (2), Disminuci\u00f3n de IgG y subclases (3), Hipogammaglobulinemia (4), Hipogammaglobulinemia secundaria a Rituximab (5) e Inmunodeficiencia Combinada Variable (IDCV) (6). Todos han sido vacunados con Ditanrix frente a ant\u00edgenos proteicos de Difteria y T\u00e9tanos, Pneumovax\u00ae23 y/o Prevenar-13\u00ae frente a Pneumococo y entre 1 y 4 dosis de las vacunas: Comirnaty y/o COVID-19 Vaccine Moderna de ARNm, y/o COVID-19 Vaccine AstraZeneca suspension inyectable (multidosis) de ADN frente a SARS-CoV-2. El estudio serol\u00f3gico de respuesta para las vacunas de Difteria, T\u00e9tanos y Pneumococo fue realizado a los 28 d\u00edas tras la administraci\u00f3n, mientras que para el SARS-CoV-2 se realiz\u00f3 entre 10 y 180 d\u00edas tras la vacunaci\u00f3n. Para el diagn\u00f3stico serol\u00f3gico se utilizaron kits de cuantificaci\u00f3n de IgG espec\u00edfica en cada caso. Resultados: Los pacientes pertenecientes a los grupos 1-4 presentaron una adecuada respuesta humoral tras la administraci\u00f3n de vacunas conjugadas, proteicas, y SARS-CoV-2. En cambio, los pacientes de los grupos 5 y 6 presentan respuesta humoral nula o insuficiente ante vacunas conjugadas o proteicas en el 70-75% de los casos, sin embargo, tras la vacunaci\u00f3n con ARNm y/o ADN frente a SARS-CoV-2, el 70-75% de los pacientes han desarrollado una respuesta adecuada. Conclusiones: Gran parte de los pacientes que no responden a vacunas conjugadas o proteicas, han respondido adecuadamente a vacunas frente a SARS-CoV-2 (de ARNm y/o ADN). Esto podr\u00eda ser debido al tipo de vacuna, lo que sugerir\u00eda una posible nueva v\u00eda de inmunizaci\u00f3n para este tipo de pacientes.  ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}